{"f2e236f0458f86706985c627ef88d40c8f037492": [["A peptide-based enzyme-linked immunosorbent assay (ELISA) can be used for retrospective serosurveillance of severe acute respiratory syndrome (SARS) by helping identify undetected chains of disease transmission.", [["acute respiratory syndrome", "DISEASE", 115, 141], ["SARS", "DISEASE", 143, 147], ["enzyme", "PROTEIN", 16, 22], ["A peptide-based enzyme-linked immunosorbent assay", "TEST", 0, 49], ["severe acute respiratory syndrome", "PROBLEM", 108, 141], ["disease transmission", "PROBLEM", 190, 210], ["severe", "OBSERVATION_MODIFIER", 108, 114], ["acute", "OBSERVATION_MODIFIER", 115, 120], ["respiratory syndrome", "OBSERVATION", 121, 141], ["chains", "OBSERVATION_MODIFIER", 180, 186], ["disease", "OBSERVATION", 190, 197]]], ["The assay was developed by epitope mapping, using synthetic peptides from the spike, membrane, and nucleocapsid protein sequences of SARS-associated coronavirus.", [["membrane", "ANATOMY", 85, 93], ["SARS", "DISEASE", 133, 137], ["membrane", "CELLULAR_COMPONENT", 85, 93], ["SARS-associated coronavirus", "ORGANISM", 133, 160], ["nucleocapsid protein sequences", "PROTEIN", 99, 129], ["The assay", "TEST", 0, 9], ["epitope mapping", "TREATMENT", 27, 42], ["synthetic peptides", "TREATMENT", 50, 68], ["nucleocapsid protein sequences", "TEST", 99, 129], ["SARS", "PROBLEM", 133, 137], ["coronavirus", "PROBLEM", 149, 160]]], ["The new peptide ELISA consistently detected seroconversion by week 2 of onset of fever, and seropositivity remained through day 100.", [["fever", "DISEASE", 81, 86], ["The new peptide ELISA", "TEST", 0, 21], ["fever", "PROBLEM", 81, 86], ["seropositivity", "PROBLEM", 92, 106], ["fever", "OBSERVATION", 81, 86]]], ["Specificity was 100% on normal blood donor samples, on serum samples associated with infection by other pathogens, and on an interference panel.", [["blood", "ANATOMY", 31, 36], ["samples", "ANATOMY", 43, 50], ["serum samples", "ANATOMY", 55, 68], ["infection", "DISEASE", 85, 94], ["blood donor samples", "ORGANISM_SUBSTANCE", 31, 50], ["serum samples", "ORGANISM_SUBSTANCE", 55, 68], ["Specificity", "TEST", 0, 11], ["serum samples", "TEST", 55, 68], ["infection", "PROBLEM", 85, 94], ["other pathogens", "PROBLEM", 98, 113], ["an interference panel", "TEST", 122, 143], ["infection", "OBSERVATION", 85, 94]]], ["The peptide-based test has advantages of safety, standardization, and automation over previous immunoassays for SARS.", [["SARS", "DISEASE", 112, 116], ["The peptide-based test", "TEST", 0, 22], ["standardization", "TEST", 49, 64], ["automation", "TEST", 70, 80], ["previous immunoassays", "TEST", 86, 107], ["SARS", "PROBLEM", 112, 116]]], ["The assay was used for a retrospective survey of healthy healthcare workers in Taiwan who treated SARS patients.", [["SARS", "DISEASE", 98, 102], ["patients", "ORGANISM", 103, 111], ["patients", "SPECIES", 103, 111]]], ["Asymptomatic seroconversions were detected in two hospitals that had nosocomial disease.", [["nosocomial disease", "DISEASE", 69, 87], ["Asymptomatic seroconversions", "PROBLEM", 0, 28], ["nosocomial disease", "PROBLEM", 69, 87], ["seroconversions", "OBSERVATION", 13, 28], ["nosocomial disease", "OBSERVATION", 69, 87]]], ["R etrospective surveillance for infection is an important means to screen for and interrupt undetected chains of disease transmission.", [["infection", "DISEASE", 32, 41], ["R etrospective surveillance", "TEST", 0, 27], ["infection", "PROBLEM", 32, 41], ["disease transmission", "PROBLEM", 113, 133], ["infection", "OBSERVATION", 32, 41], ["disease", "OBSERVATION", 113, 120]]], ["Such surveillance may be key to tracking the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) because mild and asymptomatic cases of SARS-CoV infection that do not meet the World Health Organization's case definition (1) have been identified by immunoassays (2) (3) (4) , and SARS-CoV-like viruses have been isolated from wild mammals (5) .", [["acute respiratory syndrome-associated coronavirus", "DISEASE", 52, 101], ["SARS", "DISEASE", 103, 107], ["SARS-CoV infection", "DISEASE", 152, 170], ["SARS-CoV", "ORGANISM", 103, 111], ["SARS-CoV", "ORGANISM", 152, 160], ["SARS-CoV-like viruses", "ORGANISM", 295, 316], ["SARS-CoV", "SPECIES", 103, 111], ["SARS-CoV", "SPECIES", 152, 160], ["SARS-CoV", "SPECIES", 295, 303], ["the severe acute respiratory syndrome", "PROBLEM", 41, 78], ["coronavirus", "PROBLEM", 90, 101], ["mild and asymptomatic cases", "PROBLEM", 121, 148], ["SARS", "PROBLEM", 152, 156], ["CoV infection", "PROBLEM", 157, 170], ["immunoassays", "TEST", 264, 276], ["SARS", "PROBLEM", 295, 299], ["CoV-like viruses", "PROBLEM", 300, 316], ["severe", "OBSERVATION_MODIFIER", 45, 51], ["acute", "OBSERVATION_MODIFIER", 52, 57], ["respiratory syndrome", "OBSERVATION", 58, 78], ["coronavirus", "OBSERVATION", 90, 101], ["mild", "OBSERVATION_MODIFIER", 121, 125], ["infection", "OBSERVATION", 161, 170], ["viruses", "OBSERVATION", 309, 316]]], ["SARS-CoV may have persisted over the summer in previously affected areas in such difficult-to-recognize reservoirs (6) .", [["SARS", "DISEASE", 0, 4], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["SARS-CoV", "SPECIES", 0, 8], ["SARS", "PROBLEM", 0, 4], ["CoV", "PROBLEM", 5, 8]]], ["The reemergence of SARS in the city of Guangzhou of the Guangdong Province of China in December 2003 and January 2004 (7) is evidence that an unknown reservoir exists and signals the need for continued surveillance with laboratory testing.", [["SARS", "DISEASE", 19, 23], ["SARS", "PROBLEM", 19, 23], ["continued surveillance", "TEST", 192, 214], ["laboratory testing", "TEST", 220, 238], ["SARS", "OBSERVATION", 19, 23]]]], "fba3484c3e6d586d8c9dc67153fea9a345609f0a": [["public, and the environment from exposure to infectious microorganisms handled in the laboratory [14] .", [["infectious microorganisms", "PROBLEM", 45, 70], ["infectious", "OBSERVATION_MODIFIER", 45, 55]]], ["Containment is achieved through a combination of good microbiological work practices, use of appropriate safety equipment, and proper laboratory facility design and operation.", [["operation", "TREATMENT", 165, 174]]], ["The field of biosafety, including the regulations and guidelines that make up the current regulatory environment, is based on the principles of risk assessment and risk mitigation.", [["risk assessment", "TEST", 144, 159]]], ["These principles allow research to be performed with infectious microorganisms for the benefit of society and the environment, with a focus on protecting laboratory workers, the public, and the environment from the risks associated with release of infectious agents from the laboratory setting [14] .Development of National Guidelines: Work at the United States Army Medical ResearchInstitute of Infectious Diseases in Fort Detrick, Maryland, laid the groundwork for future development of national biosafety guidelines [14] , beginning with the publication by the Centers for Disease Control and Prevention (CDC) of the Classification of Etiologic Agents on the Basis of Hazard in 1974 [15] . a.", [["Infectious Diseases", "DISEASE", 396, 415], ["a.", "SPECIES", 693, 695], ["infectious microorganisms", "PROBLEM", 53, 78], ["infectious agents", "TREATMENT", 248, 265], ["Disease Control", "TREATMENT", 576, 591]]], ["Classification of Etiologic Agents on the Basis of Hazard: This document represents one of the first uses of the concept of multiple levels of containment, each corresponding with increased work practice, engineering, and facility design controls developed to mitigate risks associated with handling specific categories of infectious microorganisms.", [["infectious microorganisms", "PROBLEM", 323, 348], ["multiple", "OBSERVATION_MODIFIER", 124, 132], ["containment", "OBSERVATION", 143, 154], ["infectious", "OBSERVATION", 323, 333]]], ["Microorganisms with similar modes of transmission and which cause diseases with similar levels of severity in healthy, adult humans are placed in the same category in Classification of Etiologic Agents on the Basis of Hazard [15] .", [["humans", "ORGANISM", 125, 131], ["humans", "SPECIES", 125, 131], ["humans", "SPECIES", 125, 131], ["Microorganisms", "PROBLEM", 0, 14], ["diseases", "PROBLEM", 66, 74], ["severity", "OBSERVATION_MODIFIER", 98, 106]]], ["The Classification of Etiologic Agents on the Basis of Hazard describes four containment levels that serve as the basis for the biosafety levels in use today, biosafety levels one through 4 (BSL-1-BSL-4), as described in the CDC and National Institutes of Health (NIH) publication Biosafety in Microbiological and Biomedical Laboratories (BMBL) [14] .", [["the biosafety levels", "TEST", 124, 144], ["biosafety levels", "TEST", 159, 175], ["BSL", "TEST", 191, 194]]], ["The Classification of Etiologic Agents on the Basis of Hazard also establishes a fifth classification of nonindigenous animal pathogens for which entry into the United States is restricted by the US Department of Agriculture (USDA) [15] .", [["nonindigenous animal pathogens", "PROBLEM", 105, 135]]], ["This fifth classification of infectious agents serves as a foundation for the groups of infectious agents that are currently regulated under the USDA's Animal and Plant Health Inspection Service (APHIS) veterinary services (VS) and plant protection and quarantine (PPQ) permitting processes [14] . b.", [["PPQ", "CHEMICAL", 265, 268], ["infectious agents", "TREATMENT", 29, 46], ["infectious agents", "TREATMENT", 88, 105], ["plant protection", "TREATMENT", 232, 248], ["quarantine (PPQ)", "TREATMENT", 253, 269], ["infectious", "OBSERVATION", 29, 39], ["infectious", "OBSERVATION", 88, 98]]], ["The NIH Guidelines for Research Involving Recombinant DNA (rDNA) Molecules:Development of National Guidelines: Work at the United States Army Medical ResearchAs a result of the emergence of recombinant methods for generating novel DNA molecules, the NIH developed the NIH Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines), first published in 1976 [16] .", [["DNA", "CELLULAR_COMPONENT", 54, 57], ["rDNA", "CELLULAR_COMPONENT", 59, 63], ["DNA", "CELLULAR_COMPONENT", 231, 234], ["DNA", "CELLULAR_COMPONENT", 318, 321], ["DNA molecules", "PROTEIN", 231, 244], ["recombinant methods", "TREATMENT", 190, 209], ["generating novel DNA molecules", "PROBLEM", 214, 244], ["Research Involving Recombinant DNA Molecules", "TREATMENT", 287, 331]]], ["The NIH Guidelines use the model developed by the CDC in Classification of Etiologic Agents on the Basis of Hazard to describe four ascending levels of work practice, equipment, and facility design safeguards corresponding to four levels of physical containment tailored to the potential hazard associated with the type of microorganism in use with emerging rDNA technology.", [["rDNA", "CELLULAR_COMPONENT", 358, 362], ["physical containment", "TREATMENT", 241, 261]]], ["Specific physical containment levels are described for work with rDNA materials in organisms within laboratories (biosafety levels one through four; BL1-BL4), plants (plant biosafety levels one through four; BL1P-BL4P), and animals (animal biosafety levels one through four; BL1N-BL4N) are described in NIH Guidelines Appendix G, P, and Q, respectively [16] .", [["Specific physical containment levels", "TEST", 0, 36], ["rDNA materials", "PROBLEM", 65, 79], ["biosafety levels", "TEST", 114, 130], ["BL1", "TEST", 149, 152], ["plant biosafety levels", "TEST", 167, 189], ["BL1P", "TEST", 208, 212], ["animal biosafety levels", "TEST", 233, 256], ["BL1N", "TEST", 275, 279], ["Appendix G", "TEST", 318, 328], ["P", "TEST", 330, 331]]], ["For clarity, readers should note that biosafety levels are abbreviated as \"BSL\" in the BMBL and as \"BL\" in the NIH Guidelines.", [["BMBL", "CANCER", 87, 91], ["biosafety levels", "TEST", 38, 54]]], ["The NIH Monograph contains detailed recommendations for good microbiological work practices, personal hygiene, personal protective equipment (PPE), disinfection and disposal of laboratory wastes, containment equipment (e.g., biological safety cabinets), and facility design, all of which are designed to ensure containment of research involving rDNA [17] .", [["rDNA", "CELLULAR_COMPONENT", 345, 349], ["rDNA", "DNA", 345, 349], ["personal protective equipment", "TREATMENT", 111, 140], ["disinfection", "TREATMENT", 148, 160], ["laboratory wastes", "TREATMENT", 177, 194], ["containment equipment", "TREATMENT", 196, 217]]], ["While the scope of the original version of the NIH Guidelines was limited to rDNA molecules constructed using recombinant techniques, advances in synthetic biology resulted in addition of synthetic nucleic acid molecules to the scope of the NIH Guidelines.", [["nucleic acid", "CHEMICAL", 198, 210], ["rDNA molecules", "DNA", 77, 91], ["rDNA molecules", "TREATMENT", 77, 91], ["recombinant techniques", "TREATMENT", 110, 132], ["synthetic nucleic acid molecules", "TREATMENT", 188, 220]]], ["These changes, along with the addition of \"Synthetic Nucleic Acid Molecules\" to the title of the document, became effective on March 5, 2013. c.", [["\"Synthetic Nucleic Acid Molecules", "PROBLEM", 42, 75]]], ["Biosafety in Microbiological and Biomedical Laboratories: The first edition of the joint CDC/NIH guidance document BMBL was published in 1984 [14] and supplemented the information contained in the Classification of Etiologic Agents on the Basis of Hazard and the NIH Monograph with summary statements containing specific guidance for work with infectious microorganisms known to have caused LAIs.", [["LAIs", "DISEASE", 391, 395], ["LAIs", "PATHOLOGICAL_FORMATION", 391, 395], ["infectious microorganisms", "PROBLEM", 344, 369], ["joint", "ANATOMY", 83, 88]]], ["The BMBL has been updated several times and is currently in its fifth edition [14] 3.", [["BMBL", "CHEMICAL", 4, 8], ["BMBL", "CANCER", 4, 8], ["BMBL", "PROTEIN", 4, 8]]], ["Development of Federal Regulations a.", [["Federal Regulations", "OBSERVATION", 15, 34]]], ["The Bloodborne Pathogen Standard: The Occupational Safety and Health Administration (OSHA) bloodborne pathogen standard (BBP) was published in 1991 and describes regulatory requirements in 29 CFR \u00a71910.1030 to protect employees from exposure to infectious microorganisms that can be transmitted via blood, body fluids, and other potentially infectious materials (OPIM) [18] .", [["blood", "ANATOMY", 299, 304], ["body fluids", "ANATOMY", 306, 317], ["blood", "ORGANISM_SUBSTANCE", 299, 304], ["body", "ORGANISM_SUBDIVISION", 306, 310], ["infectious microorganisms", "PROBLEM", 245, 270], ["blood, body fluids", "TEST", 299, 317], ["infectious", "OBSERVATION", 341, 351]]], ["In November of 2000, the Needlestick Safety and Prevention Act was passed, requiring revision of the OSHA BBP to include language specifying the evaluation and use of sharps with engineered sharps injury protection (SESIPs) [19] . b.", [["sharps injury", "DISEASE", 190, 203], ["the Needlestick Safety", "TREATMENT", 21, 43], ["revision", "TREATMENT", 85, 93], ["the OSHA BBP", "TREATMENT", 97, 109], ["the evaluation", "TEST", 141, 155]]], ["Development of the Federal Select Agent Program (FSAP): Prior to the mid-1980s, aside from facility inspections and permits required by USDA APHIS for transfer of regulated agricultural infectious agents, there were no regulations requiring registration, licensing, or reporting of transfer of human and zoonotic pathogens within the United States [20] .", [["human", "ORGANISM", 294, 299], ["human", "SPECIES", 294, 299], ["human", "SPECIES", 294, 299]]], ["Enacted in 1996, the Antiterrorism and Effective Death Penalty Act required the Department of Health and Human Services (HHS) to identify biological agents that have the potential to pose a severe threat to public health and safety and to regulate their transfer, resulting in the designation of certain biological agents and toxins as \"select agents\" [21] ( Table 1 ).", [["Death", "DISEASE", 49, 54], ["Human", "ORGANISM", 105, 110], ["Human", "SPECIES", 105, 110], ["biological agents", "TREATMENT", 138, 155], ["toxins", "TREATMENT", 326, 332]]], ["In 2001, the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act (USA PATRIOT Act) established penalties for unauthorized possession and or transfer of select agents and toxins and established criteria for restricting access [21, 23] .", [["select agents", "TREATMENT", 214, 227]]], ["In 2002, the Public Health Security and Bioterrorism Preparedness and Response Act (Bioterrorism Response Act) required promulgation of additional regulations to expand control of possession and transfer of biological agents and toxins that have the potential to pose a severe threat to public health and safety and biological agents and toxins that have the potential to pose a severe threat to animal or plant health or to animal or plant products by creating the HHS CDC Select Agent Program and the USDA APHIS Select Agent Program [21, 24] .", [["promulgation", "TREATMENT", 120, 132], ["additional regulations", "TREATMENT", 136, 158], ["biological agents", "TREATMENT", 207, 224], ["toxins", "TREATMENT", 229, 235], ["biological agents", "TREATMENT", 316, 333], ["toxins", "TREATMENT", 338, 344]]], ["As a result, in 2002, the CDC Division of Select Agents and Toxins and USDA APHIS established the joint FSAP as an interagency program to regulate safety and security practices of individuals and institutions in possession of select agents and toxins [21] .", [["Select Agents", "TREATMENT", 42, 55], ["Toxins", "TREATMENT", 60, 66], ["joint", "ANATOMY", 98, 103]]], ["The BMBL contains valuable guidance for researchers working with biological hazards, including information on risk assessment for biological agents, guiding principles of laboratory biosafety and biosecurity, and agent summary statements for many pathogens used in research laboratories.", [["risk assessment", "TEST", 110, 125], ["biological agents", "TREATMENT", 130, 147], ["laboratory biosafety", "TEST", 171, 191], ["biosecurity", "TREATMENT", 196, 207], ["many pathogens", "PROBLEM", 242, 256]]], ["The BMBL describes sets of work practices, safety equipment, and facility design features that together can be used to mitigate risks associated with research involving human pathogens posing increasing levels of risk to human health on potential exposure [14] .", [["human", "ORGANISM", 169, 174], ["human", "ORGANISM", 221, 226], ["human", "SPECIES", 169, 174], ["human", "SPECIES", 221, 226], ["human", "SPECIES", 169, 174], ["human", "SPECIES", 221, 226], ["human pathogens", "PROBLEM", 169, 184]]], ["Agent summary statements describing the routes of infection, infectious dose, recommendations for safe work in research laboratories, and any specialized occupational health or regulatory issues are provided for a variety of pathogens that may be used in biological research.", [["infection", "DISEASE", 50, 59], ["infection", "PROBLEM", 50, 59], ["pathogens", "PROBLEM", 225, 234], ["infection", "OBSERVATION", 50, 59]]], ["While agent summaries are provided for a variety of bacterial, fungal, parasitic, rickettsial, and viral agents, it is important for investigators to realize that failure to list a particular biological agent in the BMBL does not indicate that there are no risks associated with the agent in question [14] .", [["rickettsial", "DISEASE", 82, 93], ["bacterial, fungal, parasitic, rickettsial", "PROBLEM", 52, 93], ["viral agents", "TREATMENT", 99, 111]]], ["In particular, the fifth edition of the BMBL was revised to include additional information regarding occupational health and immunizations for personnel working with biological agents, decontamination and sterilization methods, requirements for agriculture pathogen safety (BSL-3 (Ag)), and updated information on safe work practices for biological toxins [14] .", [["Ag", "CHEMICAL", 281, 283], ["immunizations", "TREATMENT", 125, 138], ["biological agents", "TREATMENT", 166, 183], ["decontamination", "TREATMENT", 185, 200], ["sterilization methods", "TREATMENT", 205, 226]]], ["[16] (NIH Guidelines), which provide guidance for proper review, oversight, and containment for procedures involving the construction and/ or use of recombinant nucleic acid molecules, synthetic nucleic acid molecules, and cells, organisms, and viruses containing these molecules (Section I-A) [16] .CDC and USDA FSAPa.", [["cells", "ANATOMY", 223, 228], ["nucleic acid", "CHEMICAL", 161, 173], ["nucleic acid", "CHEMICAL", 195, 207], ["cells", "CELL", 223, 228], ["recombinant nucleic acid molecules", "PROTEIN", 149, 183], ["synthetic nucleic acid molecules", "PROTEIN", 185, 217], ["procedures", "TREATMENT", 96, 106], ["the construction", "TREATMENT", 117, 133], ["recombinant nucleic acid molecules", "TEST", 149, 183], ["synthetic nucleic acid molecules", "TEST", 185, 217], ["cells", "PROBLEM", 223, 228], ["organisms", "PROBLEM", 230, 239]]], ["The CDC is tasked with developing regulations to apply to all entities that possess, use, transfer, or store infectious agents and toxins that \"have the potential to pose a severe threat to public health and safety\" [22] , while USDA APHIS is tasked with regulation of infectious agents and toxin that \"have the potential to pose a severe threat to plant health or plant products\" [26] and those that \"have the potential to pose a severe threat to animal health, or animal products\" [27] .", [["infectious agents", "TREATMENT", 269, 286], ["toxin", "PROBLEM", 291, 296]]], ["Certain select agents and toxins that pose a severe threat to both human and animal health and animal products are designated as overlap select agents and are subject to regulation by both APHIS and CDC [22, 26, 27] .", [["human", "ORGANISM", 67, 72], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 67, 72], ["Certain select agents", "TREATMENT", 0, 21], ["toxins", "TREATMENT", 26, 32], ["a severe threat", "PROBLEM", 43, 58], ["animal products", "TREATMENT", 95, 110]]], ["Import of etiological agents, hosts, and/or vectors of human disease into the United States requires an approved permit under the CDC Etiologic Agent Import Permit Program (IPP) (42 CFR \u00a771.54).", [["human disease", "DISEASE", 55, 68], ["human", "ORGANISM", 55, 60], ["human", "SPECIES", 55, 60], ["human", "SPECIES", 55, 60]]], ["Under the regulation, etiologic agents include microorganisms and microbial toxins that can cause disease in humans, and the importation of bats, arthropods, snails, and nonhuman primate trophies.", [["humans", "ORGANISM", 109, 115], ["nonhuman", "ORGANISM", 170, 178], ["primate", "ORGANISM", 179, 186], ["humans", "SPECIES", 109, 115], ["humans", "SPECIES", 109, 115], ["etiologic agents", "TREATMENT", 22, 38], ["microorganisms", "PROBLEM", 47, 61], ["microbial toxins", "TREATMENT", 66, 82], ["disease in humans", "PROBLEM", 98, 115], ["nonhuman primate trophies", "TREATMENT", 170, 195]]], ["USDA APHIS also regulates the importation and/or interstate transfer of organisms that may be infectious to animals (including poultry) and animal vectors that have been intentionally infected with organisms or are known to be infected with or have been exposed to any contagious, infectious, or communicable disease of animals or poultry (9 CFR \u00a7122.1 (d) and (e)).", [["organisms", "PROBLEM", 72, 81], ["animal vectors", "TREATMENT", 140, 154], ["organisms", "PROBLEM", 198, 207], ["communicable disease of animals", "PROBLEM", 296, 327], ["CFR", "TEST", 342, 345], ["may be", "UNCERTAINTY", 87, 93], ["infectious", "OBSERVATION", 94, 104], ["infectious", "OBSERVATION", 281, 291]]], ["Permits for importation of plant pathogens must be approved by the USDA APHIS PPQ division ( [28, 29] .", [["plant pathogens", "PROBLEM", 27, 42]]], ["In research with biological materials, shipments that are known or reasonably suspected to contain pathogens, cultures of pathogens, patient specimens, biological products derived from living organisms, and that are known or reasonably believed to contain pathogens, genetically modified organisms, patient specimens, and/or shipments that contain dry ice are subject to regulation under the IATA DGR and/or the DOT FHMR [28, 29] .8.Department of Labor OSHA a.", [["specimens", "ANATOMY", 141, 150], ["specimens", "ANATOMY", 307, 316], ["patient", "ORGANISM", 133, 140], ["patient", "ORGANISM", 299, 306], ["patient", "SPECIES", 133, 140], ["patient", "SPECIES", 299, 306], ["biological materials", "TREATMENT", 17, 37], ["pathogens", "PROBLEM", 99, 108], ["cultures", "TEST", 110, 118], ["pathogens", "PROBLEM", 122, 131], ["patient specimens", "TEST", 133, 150], ["biological products", "TREATMENT", 152, 171], ["living organisms", "PROBLEM", 185, 201], ["pathogens", "PROBLEM", 256, 265], ["patient specimens", "TEST", 299, 316], ["shipments", "TREATMENT", 325, 334], ["dry ice", "TREATMENT", 348, 355], ["the DOT FHMR", "TEST", 408, 420]]], ["The General Duty Clause: OSHA is responsible for promulgating general workplace safety regulations.", [["Duty Clause", "OBSERVATION", 12, 23]]], ["In addition to regulations related to specific workplace hazards, all employers must comply with the OSHA general duty clause, which requires employers to provide employment and a place of employment free from recognized hazards that are likely to cause death or serious physical harm to employees (Section 5 (a)(1)) [30] .", [["death", "DISEASE", 254, 259]]], ["If serious workplace hazards are identified, the employer must implement mitigation measures that can include hazard assessment, exposure monitoring, medical surveillance, engineering and work practice controls, and the use of PPE. b.", [["mitigation measures", "TREATMENT", 73, 92], ["hazard assessment", "TEST", 110, 127], ["exposure monitoring", "TEST", 129, 148], ["medical surveillance", "TEST", 150, 170], ["PPE", "TREATMENT", 227, 230]]], ["The BBP Standard: Compliance with the OSHA BBP Standard is required for \"all occupational exposure to blood or other potentially infectious materials\" (29 CFR \u00a71910.1030a) [18] .", [["blood", "ANATOMY", 102, 107], ["BBP", "CHEMICAL", 4, 7], ["blood", "ORGANISM_SUBSTANCE", 102, 107], ["the OSHA BBP", "TREATMENT", 34, 46]]], ["Bloodborne pathogens are defined in the regulation as \"pathogenic microorganisms that are present in human blood and can cause disease in humans\" [18] .", [["blood", "ANATOMY", 107, 112], ["human", "ORGANISM", 101, 106], ["blood", "ORGANISM_SUBSTANCE", 107, 112], ["humans", "ORGANISM", 138, 144], ["human", "SPECIES", 101, 106], ["humans", "SPECIES", 138, 144], ["human", "SPECIES", 101, 106], ["humans", "SPECIES", 138, 144], ["Bloodborne pathogens", "PROBLEM", 0, 20], ["pathogenic microorganisms", "PROBLEM", 55, 80], ["disease in humans\"", "PROBLEM", 127, 145], ["pathogens", "OBSERVATION", 11, 20]]], ["Bloodborne pathogens include the hepatitis viruses (hepatitis A, B, C, or D) and human immunodeficiency virus (HIV), but many entities choose to expand their interpretation of the regulatory definition to include other common microorganisms that may be used in research by interpreting these agents as falling under the category of OPIM.", [["hepatitis viruses", "DISEASE", 33, 50], ["hepatitis A", "DISEASE", 52, 63], ["human immunodeficiency virus (HIV)", "DISEASE", 81, 115], ["hepatitis viruses", "ORGANISM", 33, 50], ["hepatitis A", "ORGANISM", 52, 63], ["B, C", "ORGANISM", 65, 69], ["D", "GENE_OR_GENE_PRODUCT", 74, 75], ["human immunodeficiency virus", "ORGANISM", 81, 109], ["OPIM", "CANCER", 332, 336], ["human", "SPECIES", 81, 86], ["immunodeficiency virus (HIV", "SPECIES", 87, 114], ["hepatitis viruses", "SPECIES", 33, 50], ["hepatitis A", "SPECIES", 52, 63], ["human immunodeficiency virus", "SPECIES", 81, 109], ["HIV", "SPECIES", 111, 114], ["Bloodborne pathogens", "TEST", 0, 20], ["the hepatitis viruses", "PROBLEM", 29, 50], ["hepatitis A, B, C, or D)", "PROBLEM", 52, 76], ["human immunodeficiency virus", "PROBLEM", 81, 109], ["HIV", "PROBLEM", 111, 114], ["other common microorganisms", "PROBLEM", 213, 240], ["hepatitis viruses", "OBSERVATION", 33, 50]]], ["According to the regulation, OPIM include human body fluids such as semen, vaginal secretions, cerebrospinal, synovial, pleural, pericardial, peritoneal, and/or amniotic fluids as well as saliva in dental procedures [18] .", [["body fluids", "ANATOMY", 48, 59], ["semen", "ANATOMY", 68, 73], ["vaginal secretions", "ANATOMY", 75, 93], ["cerebrospinal", "ANATOMY", 95, 108], ["synovial", "ANATOMY", 110, 118], ["pleural", "ANATOMY", 120, 127], ["pericardial", "ANATOMY", 129, 140], ["peritoneal", "ANATOMY", 142, 152], ["amniotic fluids", "ANATOMY", 161, 176], ["OPIM", "SIMPLE_CHEMICAL", 29, 33], ["human", "ORGANISM", 42, 47], ["body", "ORGANISM_SUBDIVISION", 48, 52], ["semen", "ORGANISM_SUBSTANCE", 68, 73], ["vaginal secretions", "MULTI-TISSUE_STRUCTURE", 75, 93], ["cerebrospinal", "ORGANISM_SUBSTANCE", 95, 108], ["synovial", "TISSUE", 110, 118], ["pleural", "MULTI-TISSUE_STRUCTURE", 120, 127], ["pericardial", "MULTI-TISSUE_STRUCTURE", 129, 140], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 142, 152], ["amniotic fluids", "ORGANISM_SUBSTANCE", 161, 176], ["saliva", "ORGANISM_SUBSTANCE", 188, 194], ["human", "SPECIES", 42, 47], ["human", "SPECIES", 42, 47], ["human body fluids", "TREATMENT", 42, 59], ["vaginal secretions", "PROBLEM", 75, 93], ["cerebrospinal, synovial, pleural, pericardial, peritoneal, and/or amniotic fluids", "PROBLEM", 95, 176], ["vaginal", "ANATOMY", 75, 82], ["secretions", "OBSERVATION", 83, 93], ["cerebrospinal", "ANATOMY", 95, 108], ["synovial", "ANATOMY", 110, 118], ["pleural", "ANATOMY", 120, 127], ["pericardial", "ANATOMY", 129, 140], ["peritoneal", "ANATOMY", 142, 152], ["amniotic fluids", "OBSERVATION", 161, 176]]], ["In addition, unfixed human tissues or organs, HIV-infected cell cultures, culture medium, or other solutions, or blood, organs, or other tissues from animals infected with HIV or hepatitis B virus (HBV) are considered to be OPIM.", [["tissues", "ANATOMY", 27, 34], ["organs", "ANATOMY", 38, 44], ["cell cultures", "ANATOMY", 59, 72], ["blood", "ANATOMY", 113, 118], ["organs", "ANATOMY", 120, 126], ["tissues", "ANATOMY", 137, 144], ["HIV-infected", "DISEASE", 46, 58], ["HIV or hepatitis B", "DISEASE", 172, 190], ["human", "ORGANISM", 21, 26], ["tissues", "TISSUE", 27, 34], ["organs", "ORGAN", 38, 44], ["HIV", "ORGANISM", 46, 49], ["cell cultures", "CELL", 59, 72], ["blood", "ORGANISM_SUBSTANCE", 113, 118], ["organs", "ORGAN", 120, 126], ["tissues", "TISSUE", 137, 144], ["HIV or", "ORGANISM", 172, 178], ["hepatitis B virus", "ORGANISM", 179, 196], ["HBV", "ORGANISM", 198, 201], ["HIV-infected cell cultures", "CELL_LINE", 46, 72], ["human", "SPECIES", 21, 26], ["HIV", "SPECIES", 46, 49], ["HIV", "SPECIES", 172, 175], ["hepatitis B virus", "SPECIES", 179, 196], ["human", "SPECIES", 21, 26], ["HIV", "SPECIES", 46, 49], ["HIV", "SPECIES", 172, 175], ["hepatitis B virus", "SPECIES", 179, 196], ["HBV", "SPECIES", 198, 201], ["unfixed human tissues", "PROBLEM", 13, 34], ["HIV", "PROBLEM", 46, 49], ["infected cell cultures", "TEST", 50, 72], ["culture medium", "TEST", 74, 88], ["other solutions", "PROBLEM", 93, 108], ["blood, organs", "PROBLEM", 113, 126], ["other tissues", "PROBLEM", 131, 144], ["HIV", "PROBLEM", 172, 175], ["hepatitis B virus (HBV", "PROBLEM", 179, 201], ["human tissues", "ANATOMY", 21, 34], ["organs", "ANATOMY", 38, 44], ["infected cell", "OBSERVATION", 50, 63], ["blood", "ANATOMY", 113, 118], ["organs", "ANATOMY", 120, 126]]], ["Other bodily fluids, such as urine or feces, are not considered to be OPIM unless they are visibly contaminated with blood.", [["bodily fluids", "ANATOMY", 6, 19], ["urine", "ANATOMY", 29, 34], ["feces", "ANATOMY", 38, 43], ["blood", "ANATOMY", 117, 122], ["urine", "ORGANISM_SUBSTANCE", 29, 34], ["feces", "ORGANISM_SUBSTANCE", 38, 43], ["blood", "ORGANISM_SUBSTANCE", 117, 122], ["Other bodily fluids", "PROBLEM", 0, 19], ["urine or feces", "PROBLEM", 29, 43], ["fluids", "OBSERVATION", 13, 19]]], ["Many entities choose to include samples from research animals infected with other known human pathogens in their definition of bloodborne pathogens.8.-Individual institutions may choose to interpret the BBP standard to exclude characterized, well-established human cell lines in culture.", [["samples", "ANATOMY", 32, 39], ["cell lines", "ANATOMY", 265, 275], ["bloodborne pathogens", "DISEASE", 127, 147], ["BBP", "CHEMICAL", 203, 206], ["human", "ORGANISM", 88, 93], ["human", "ORGANISM", 259, 264], ["cell lines", "CELL", 265, 275], ["human cell lines", "CELL_LINE", 259, 275], ["human", "SPECIES", 88, 93], ["human", "SPECIES", 259, 264], ["human", "SPECIES", 88, 93], ["human", "SPECIES", 259, 264], ["other known human pathogens", "PROBLEM", 76, 103], ["bloodborne pathogens", "PROBLEM", 127, 147], ["the BBP", "TEST", 199, 206], ["culture", "TEST", 279, 286], ["human cell lines", "OBSERVATION", 259, 275]]], ["However, in an OSHA interpretation letter issued to biological safety professionals of the American Biological Safety Association, even well-characterized and tested human cell lines cannot be tested for every known human pathogen, and as such may be considered to fall under the BBP standard [31] .", [["cell lines", "ANATOMY", 172, 182], ["BBP", "CHEMICAL", 280, 283], ["human", "ORGANISM", 166, 171], ["cell lines", "CELL", 172, 182], ["human", "ORGANISM", 216, 221], ["human cell lines", "CELL_LINE", 166, 182], ["human", "SPECIES", 166, 171], ["human", "SPECIES", 216, 221], ["human", "SPECIES", 166, 171], ["human", "SPECIES", 216, 221], ["human cell lines", "TREATMENT", 166, 182], ["every known human pathogen", "PROBLEM", 204, 230]]], ["Many entities choose to extend the use of universal precautions (in which all human blood and body fluids as well as OPIM are treated as if they are known to be infected with HBV, HIV, or other pathogens) to all use of human cell lines in culture. c.", [["blood", "ANATOMY", 84, 89], ["body fluids", "ANATOMY", 94, 105], ["cell lines", "ANATOMY", 225, 235], ["human", "ORGANISM", 78, 83], ["blood", "ORGANISM_SUBSTANCE", 84, 89], ["body", "ORGANISM_SUBDIVISION", 94, 98], ["fluids", "ORGANISM_SUBSTANCE", 99, 105], ["HBV", "ORGANISM", 175, 178], ["HIV", "ORGANISM", 180, 183], ["human", "ORGANISM", 219, 224], ["cell lines", "CELL", 225, 235], ["human cell lines", "CELL_LINE", 219, 235], ["human", "SPECIES", 78, 83], ["human", "SPECIES", 219, 224], ["human", "SPECIES", 78, 83], ["HBV", "SPECIES", 175, 178], ["HIV", "SPECIES", 180, 183], ["human", "SPECIES", 219, 224], ["universal precautions", "TREATMENT", 42, 63], ["all human blood and body fluids", "TREATMENT", 74, 105], ["HBV", "PROBLEM", 175, 178], ["HIV", "PROBLEM", 180, 183], ["other pathogens", "PROBLEM", 188, 203], ["human cell lines", "TREATMENT", 219, 235], ["culture", "TEST", 239, 246], ["cell lines", "OBSERVATION", 225, 235]]], ["The OSHA PPE Standard -The OSHA PPE standard requires employers to provide and pay for PPE and ensure that it is used whenever employees may be exposed to hazards that may cause injury via absorption, inhalation, or physical contact (29 CFR \u00a71910.132) [32].", [["PPE", "TREATMENT", 87, 90], ["injury", "PROBLEM", 178, 184]]], ["The Federal Insecticide, Fungicide, and Rodenticide Act [33] charges the Environmental Protection Agency (EPA) with regulation of the sale, distribution, and use of antimicrobial pesticides (e.g., sanitizers, disinfectants, and sterilants; 40 CFR \u00a7150-189) [34] .", [["The Federal Insecticide", "TREATMENT", 0, 23], ["Fungicide", "TREATMENT", 25, 34], ["Rodenticide Act", "TREATMENT", 40, 55], ["antimicrobial pesticides", "TREATMENT", 165, 189], ["sanitizers", "TREATMENT", 197, 207], ["disinfectants", "TREATMENT", 209, 222], ["sterilants", "TREATMENT", 228, 238]]], ["Disinfectants and chemical sterilants that are used routinely in hospitals, veterinary clinics, and research laboratories to decontaminate infectious materials and surfaces are registered with the EPA.", [["EPA", "CHEMICAL", 197, 200], ["Disinfectants", "TREATMENT", 0, 13], ["chemical sterilants", "TREATMENT", 18, 37], ["the EPA", "TEST", 193, 200], ["chemical sterilants", "OBSERVATION", 18, 37]]], ["The registration process requires a disinfectant manufacturer to provide safety and, more importantly, efficacy data for inactivation of specific microorganisms to the EPA to receive registration or a license [35] .", [["The registration process", "PROBLEM", 0, 24], ["a disinfectant manufacturer", "TREATMENT", 34, 61], ["specific microorganisms", "PROBLEM", 137, 160]]], ["Use of an EPA-registered disinfectant in accordance with its EPA-approved use instructions as provided on the product label ensures that a registered antimicrobial will be effective against its target microorganisms.", [["EPA", "CHEMICAL", 10, 13], ["EPA", "CHEMICAL", 10, 13], ["EPA", "SIMPLE_CHEMICAL", 10, 13], ["EPA", "SIMPLE_CHEMICAL", 61, 64], ["an EPA", "TREATMENT", 7, 13], ["a registered antimicrobial", "TREATMENT", 137, 163]]], ["Due to the requirement of rigorous efficacy testing as part of the EPA registration process of disinfectants and sterilants, it is the opinion of the author that investigators and institutions should use EPA-registered products in cleaning, sanitizing, disinfection, and decontamination whenever possible.", [["EPA", "CHEMICAL", 204, 207], ["EPA", "CHEMICAL", 204, 207], ["EPA", "SIMPLE_CHEMICAL", 204, 207], ["rigorous efficacy testing", "TEST", 26, 51], ["EPA", "TREATMENT", 204, 207], ["cleaning", "TREATMENT", 231, 239], ["sanitizing", "TREATMENT", 241, 251], ["disinfection", "TREATMENT", 253, 265], ["decontamination", "TREATMENT", 271, 286]]], ["While non-EPA-registered disinfectants such as 70% ethanol can effectively inactivate some microorganisms, standardized efficacy testing and product use instructions similar to those required for registered disinfectants are not available.", [["non-EPA", "CHEMICAL", 6, 13], ["ethanol", "CHEMICAL", 51, 58], ["ethanol", "CHEMICAL", 51, 58], ["non-EPA", "SIMPLE_CHEMICAL", 6, 13], ["ethanol", "SIMPLE_CHEMICAL", 51, 58], ["disinfectants", "TREATMENT", 25, 38], ["some microorganisms", "PROBLEM", 86, 105], ["standardized efficacy testing", "TEST", 107, 136]]], ["Use of EPA-registered disinfectants in accordance with product label instructions provides an institution with assurance that the products in use are effective and increases confidence in inactivation procedures for infectious microorganisms.", [["EPA", "CHEMICAL", 7, 10], ["EPA", "CHEMICAL", 7, 10], ["EPA", "SIMPLE_CHEMICAL", 7, 10], ["EPA", "TREATMENT", 7, 10], ["the products", "TREATMENT", 126, 138], ["inactivation procedures", "TREATMENT", 188, 211], ["infectious microorganisms", "PROBLEM", 216, 241]]], ["Ultimately, it is the opinion of the author that this will lead to a higher level of assurance that the health of the public and the environment are being ensured by preventing a release of pathogens to the environment.Medical/Infectious Waste Handling a.Medical and infectious waste handling regulations are promulgated at the state level.", [["Infectious", "OBSERVATION", 227, 237], ["infectious", "OBSERVATION_MODIFIER", 267, 277]]], ["It is important to note that under no circumstances should medical or infectious waste be disposed of in the normal refuse stream and that a common factor in all medical waste handling regulations is the requirement for decontamination by methods specified in each local or state regulation prior to final disposal of medical waste.The NIH Guidelines: Recombinant and Synthetic Nucleic Acid Oversight1.", [["a common factor", "PROBLEM", 139, 154], ["decontamination", "TREATMENT", 220, 235], ["Recombinant", "TREATMENT", 352, 363], ["Synthetic Nucleic Acid Oversight1", "TREATMENT", 368, 401]]], ["The NIH Guidelines define recombinant and synthetic nucleic acids as follows (Section I-B) [16] .", [["nucleic acids", "CHEMICAL", 52, 65], ["synthetic nucleic acids", "TEST", 42, 65]]], ["Recombinant nucleic acids are molecules that are constructed by joining nucleic acid molecules and that can replicate in a living cell.", [["cell", "ANATOMY", 130, 134], ["nucleic acids", "CHEMICAL", 12, 25], ["nucleic acid", "CHEMICAL", 72, 84], ["cell", "CELL", 130, 134], ["nucleic acid molecules", "PROTEIN", 72, 94], ["Recombinant nucleic acids", "TEST", 0, 25], ["joining nucleic acid molecules", "PROBLEM", 64, 94], ["nucleic acids", "OBSERVATION", 12, 25]]], ["Synthetic nucleic acids are molecules that are synthesized or amplified by chemical or other means, including those that are chemically or otherwise modified, but can still pair with naturally occurring nucleic acids.", [["nucleic acids", "CHEMICAL", 10, 23], ["nucleic acids", "CHEMICAL", 203, 216], ["nucleic acids", "SIMPLE_CHEMICAL", 203, 216], ["Synthetic nucleic acids", "PROBLEM", 0, 23], ["nucleic acids", "TREATMENT", 203, 216], ["nucleic acids", "OBSERVATION", 10, 23]]], ["Any molecules that result from the replication of recombinant or synthetic nucleic acids as defined above also fall under the scope of the NIH Guidelines.", [["nucleic acids", "CHEMICAL", 75, 88], ["Any molecules", "PROBLEM", 0, 13], ["synthetic nucleic acids", "TREATMENT", 65, 88]]], ["While technically not a regulation, any research with recombinant or synthetic nucleic acids that is either performed or sponsored by an institution that receives any support from the NIH must comply with the NIH Guidelines.", [["nucleic acids", "CHEMICAL", 79, 92], ["synthetic nucleic acids", "TEST", 69, 92]]], ["This includes all research with recombinant or synthetic nucleic acids performed at the institution, even if the individual investigator performing the research does not receive NIH support (Section I-C) [16] .", [["nucleic acids", "CHEMICAL", 57, 70], ["synthetic nucleic acids", "TEST", 47, 70], ["NIH support", "TREATMENT", 178, 189]]], ["The NIH Guidelines also apply to any clinical trials or testing of materials containing recombinant or synthetic nucleic acids in humans (Section I-C-1-a-(2)) [16] .", [["nucleic acids", "CHEMICAL", 113, 126], ["humans", "ORGANISM", 130, 136], ["C-1-a-(2)", "SIMPLE_CHEMICAL", 148, 157], ["humans", "SPECIES", 130, 136], ["humans", "SPECIES", 130, 136], ["testing of materials", "TREATMENT", 56, 76], ["synthetic nucleic acids", "TREATMENT", 103, 126]]], ["Failure to comply with the NIH Guidelines could result in suspension, limitation, or termination of NIH funds for the individual noncompliant research project or suspension, limitation, or termination of NIH funds for all recombinant or synthetic nucleic acid research at the institution.", [["nucleic acid", "CHEMICAL", 247, 259], ["Failure", "PROBLEM", 0, 7], ["the NIH Guidelines", "TREATMENT", 23, 41], ["NIH funds", "TREATMENT", 204, 213], ["all recombinant", "TREATMENT", 218, 233]]], ["The NIH also reserves the right to require prior approval by the NIH of any or all projects involving recombinant or synthetic nucleic acids at an institution (Section I-D-1; Section I-D-2) [16] .", [["nucleic acids", "CHEMICAL", 127, 140], ["right", "ANATOMY_MODIFIER", 26, 31]]], ["While entities performing research involving recombinant or synthetic nucleic acids that do not receive funding from the NIH are not required to comply with the NIH Guidelines, many entities choose to voluntarily follow the best practices described in the document [37] .", [["nucleic acids", "CHEMICAL", 70, 83], ["synthetic nucleic acids", "TREATMENT", 60, 83]]], ["The NIH Guidelines describe six general categories of experiments with recombinant or synthetic nucleic acids that fall under the purview of the NIH. a.", [["nucleic acids", "CHEMICAL", 96, 109], ["a.", "SPECIES", 150, 152], ["recombinant", "TREATMENT", 71, 82], ["synthetic nucleic acids", "TREATMENT", 86, 109]]], ["Major Actions: Major actions under the NIH Guidelines involve the deliberate transfer of a drug resistance trait that could compromise the control or treatment of disease in humans, veterinary medicine, or agriculture (Section III-A-1) [16] .", [["humans", "ORGANISM", 174, 180], ["humans", "SPECIES", 174, 180], ["humans", "SPECIES", 174, 180], ["the NIH Guidelines", "TREATMENT", 35, 53], ["a drug resistance trait", "TREATMENT", 89, 112], ["disease in humans", "PROBLEM", 163, 180]]], ["If the drug resistance trait proposed for use in the study would confer resistance to the primary drug available for treatment in the general population and/or in a specific subpopulation (e.g., pregnant women or children), then the experiment must be approved by the NIH director, the NIH Recombinant DNA Advisory Committee (RAC), and the local institutional biosafety committee (IBC) before initiation (Section III-A-1) [16] .The NIH Guidelines: Recombinant and Synthetic Nucleic Acid Oversightb.", [["women", "ORGANISM", 204, 209], ["children", "ORGANISM", 213, 221], ["IBC", "CANCER", 381, 384], ["women", "SPECIES", 204, 209], ["children", "SPECIES", 213, 221], ["the drug resistance trait", "PROBLEM", 3, 28], ["the study", "TEST", 49, 58], ["treatment", "TREATMENT", 117, 126], ["Recombinant", "TREATMENT", 448, 459], ["Synthetic Nucleic Acid Oversightb", "TREATMENT", 464, 497]]], ["Use of Toxin Genes: Experiments that involve deliberate formation of recombinant or synthetic nucleic acid molecules containing genes that encode toxins that are lethal for vertebrates at an LD50 of less than 100 ng per kilogram of body weight must be approved by both the NIH Office of Biotechnology Activities (OBA) and the local IBC before initiation (Section III-B-1) [16] .", [["body", "ANATOMY", 232, 236], ["IBC", "ANATOMY", 332, 335], ["nucleic acid", "CHEMICAL", 94, 106], ["Toxin", "GENE_OR_GENE_PRODUCT", 7, 12], ["body", "ORGANISM_SUBDIVISION", 232, 236], ["IBC", "CANCER", 332, 335], ["recombinant or synthetic nucleic acid molecules", "PROTEIN", 69, 116], ["recombinant or synthetic nucleic acid molecules", "PROBLEM", 69, 116], ["encode toxins", "PROBLEM", 139, 152]]], ["NIH OBA also reserves the right to determine from an investigator's application whether a proposed experiment is equivalent to an experiment previously approved as a major action, as described above.", [["right", "ANATOMY_MODIFIER", 26, 31]]], ["Human Research: Any proposed experiments that involve deliberate transfer of recombinant or synthetic nucleic acid molecules into human research participants (defined in the NIH Guidelines as human gene transfer) [16] must be reviewed by the RAC, the local institutional review board (IRB), and the local IBC prior to enrollment of any research participant (Section III-C) [16] . d.", [["nucleic acid", "CHEMICAL", 102, 114], ["IBC", "DISEASE", 305, 308], ["Human", "ORGANISM", 0, 5], ["human", "ORGANISM", 130, 135], ["human", "ORGANISM", 192, 197], ["IBC", "CANCER", 305, 308], ["Human", "SPECIES", 0, 5], ["human", "SPECIES", 130, 135], ["participants", "SPECIES", 145, 157], ["human", "SPECIES", 192, 197], ["Human", "SPECIES", 0, 5], ["human", "SPECIES", 130, 135], ["human", "SPECIES", 192, 197]]], ["IBC Approval Required Prior to Beginning Work: Often, an investigator's proposed research with recombinant or synthetic nucleic acids will fall under the category of experiments that require IBC approval prior to beginning work as defined in Section III-D of the NIH Guidelines [16] .", [["nucleic acids", "CHEMICAL", 120, 133], ["synthetic nucleic acids", "TREATMENT", 110, 133], ["IBC approval", "TREATMENT", 191, 203]]], ["An investigator is required to submit a registration document to the IBC describing the source of the nucleic acids, the nature of the inserted nucleic acid sequences, the host and vector to be used, whether a foreign gene will be expressed, and the containment level specified by the NIH Guidelines (Section III-D) [16] .", [["IBC", "DISEASE", 69, 72], ["nucleic acids", "CHEMICAL", 102, 115], ["nucleic acid", "CHEMICAL", 144, 156], ["IBC", "CANCER", 69, 72], ["the nucleic acids", "PROBLEM", 98, 115], ["the inserted nucleic acid sequences", "TREATMENT", 131, 166], ["the host and vector", "TREATMENT", 168, 187], ["a foreign gene", "TREATMENT", 208, 222]]], ["Several categories of experiments are captured under this section of the NIH Guidelines: -Experiments using biological agents in risk groups 2-4 or biological agents that require a USDA APHIS permit due to their regulated status as plant or animal pathogens as host-vector systems (Section III-D-1) [16] . -Experiments in which nucleic acids from risk group 2-4 or USDA APHIS-regulated plant or animal pathogens are cloned into nonpathogenic or lower eukaryotic hostvector systems (Section III-D-2) [16] . -Experiments that involve the use of infectious DNA or RNA viruses or replicationdeficient DNA or RNA viruses in combination with helper viruses in in vitro or tissue culture systems (Section III-D-3) [16] . -Experiments involving whole animals in which the animal's genome has been altered by stable insertion of recombinant or synthetic nucleic acid molecules into the germ-line and experiments in which microorganisms that have been modified with recombinant or synthetic nucleic acids are introduced into whole animals (Section III-D-4) [16] . -Experiments involving genetic engineering of plants via introduction of recombinant or synthetic nucleic acid molecules, propagation of such plants, and/ or use of plants with microorganisms or insects containing recombinant or synthetic nucleic acid molecules (Section III-D-5) [16] . -Large-scale experiments, which are defined as any experiment involving more than 10 L of culture (Section III-D-6) [16] .The NIH Guidelines: Recombinant and Synthetic Nucleic Acid Oversight-Experiments involving influenza viruses (Section III-D-7) [16] .", [["tissue culture", "ANATOMY", 666, 680], ["germ-line", "ANATOMY", 877, 886], ["nucleic acids", "CHEMICAL", 328, 341], ["APHIS", "CHEMICAL", 370, 375], ["nucleic acid", "CHEMICAL", 845, 857], ["nucleic acids", "CHEMICAL", 981, 994], ["nucleic acid", "CHEMICAL", 1152, 1164], ["nucleic acid", "CHEMICAL", 1293, 1305], ["influenza viruses", "DISEASE", 1554, 1571], ["DNA", "CELLULAR_COMPONENT", 554, 557], ["DNA", "CELLULAR_COMPONENT", 597, 600], ["germ-line", "CELL", 877, 886], ["infectious DNA", "DNA", 543, 557], ["replicationdeficient DNA", "DNA", 576, 600], ["animal's genome", "DNA", 764, 779], ["recombinant or synthetic nucleic acid molecules", "PROTEIN", 820, 867], ["recombinant or synthetic nucleic acid molecules", "PROTEIN", 1268, 1315], ["biological agents", "TREATMENT", 108, 125], ["biological agents", "TREATMENT", 148, 165], ["a USDA APHIS", "TREATMENT", 179, 191], ["nucleic acids", "TEST", 328, 341], ["animal pathogens", "PROBLEM", 395, 411], ["infectious DNA", "PROBLEM", 543, 557], ["RNA viruses", "PROBLEM", 561, 572], ["replicationdeficient DNA", "PROBLEM", 576, 600], ["RNA viruses", "PROBLEM", 604, 615], ["helper viruses", "PROBLEM", 636, 650], ["tissue culture systems", "TEST", 666, 688], ["recombinant or synthetic nucleic acid molecules", "TREATMENT", 820, 867], ["synthetic nucleic acids", "TREATMENT", 971, 994], ["recombinant or synthetic nucleic acid molecules", "TREATMENT", 1127, 1174], ["such plants", "PROBLEM", 1191, 1202], ["microorganisms", "PROBLEM", 1231, 1245], ["synthetic nucleic acid molecules", "TREATMENT", 1283, 1315], ["Large-scale experiments", "PROBLEM", 1342, 1365], ["culture", "TEST", 1431, 1438], ["Recombinant", "TREATMENT", 1483, 1494], ["Synthetic Nucleic Acid Oversight", "TREATMENT", 1499, 1531], ["influenza viruses", "PROBLEM", 1554, 1571], ["stable", "OBSERVATION_MODIFIER", 800, 806], ["Large", "OBSERVATION_MODIFIER", 1342, 1347], ["-scale", "OBSERVATION_MODIFIER", 1347, 1353]]], ["It should be noted that the NIH Guidelines specifically detail additional work practice, PPE and/ or facility enhancements for work with certain risk group 3 influenza viruses, including strains containing the hemagglutinin segment from human H2N2 influenza strains isolated between 1957 and 1968, certain highly pathogenic avian influenza H5N1 strains, and research with any portion of the reconstructed 1918H1N1 strain (Section III-D-7 and Appendix G-II-C-5, BL-3 enhanced for research involving risk group 3 influenza viruses) [16] . e.", [["influenza viruses", "DISEASE", 158, 175], ["influenza H5N1", "DISEASE", 330, 344], ["influenza viruses", "DISEASE", 511, 528], ["human H2N2 influenza strains", "ORGANISM", 237, 265], ["avian influenza H5N1", "ORGANISM", 324, 344], ["G-II-C-5", "ORGANISM", 451, 459], ["BL-3", "CELL", 461, 465], ["human", "SPECIES", 237, 242], ["H2N2 influenza", "SPECIES", 243, 257], ["avian influenza H5N1", "SPECIES", 324, 344], ["human H2N2 influenza", "SPECIES", 237, 257], ["certain risk group 3 influenza viruses", "PROBLEM", 137, 175], ["strains", "PROBLEM", 187, 194], ["the hemagglutinin segment", "TREATMENT", 206, 231], ["human H2N2 influenza strains", "PROBLEM", 237, 265], ["highly pathogenic avian influenza H5N1 strains", "PROBLEM", 306, 352], ["Section III", "TEST", 422, 433], ["Appendix G", "TEST", 442, 452], ["risk group 3 influenza viruses", "PROBLEM", 498, 528], ["Appendix", "ANATOMY", 442, 450]]], ["Notification of IBC Simultaneously with Initiation of Work: Certain categories of experiments, including those involving the formation of recombinant or synthetic nucleic acid molecules containing no more than two-thirds of the genome of any eukaryotic virus, specific types of low-risk research with whole plants, and experiments that strictly involve generation of transgenic rodents that may be handled and housed appropriately at BL-1, require that the local IBC be notified simultaneously with initiation of experiments by an investigator (Section III-E) [16] . f.", [["IBC", "ANATOMY", 463, 466], ["IBC", "DISEASE", 16, 19], ["nucleic acid", "CHEMICAL", 163, 175], ["rodents", "ORGANISM", 378, 385], ["BL-1", "CELL", 434, 438], ["IBC", "CANCER", 463, 466], ["recombinant or synthetic nucleic acid molecules", "PROTEIN", 138, 185], ["f.", "SPECIES", 567, 569], ["synthetic nucleic acid molecules", "PROBLEM", 153, 185], ["any eukaryotic virus", "PROBLEM", 238, 258], ["whole plants", "TREATMENT", 301, 313], ["transgenic rodents", "TREATMENT", 367, 385], ["eukaryotic virus", "OBSERVATION", 242, 258]]], ["NIH Exempt Research: Finally, certain types of recombinant or synthetic nucleic acid molecules are exempt from the NIH Guidelines [16] : -Those that cannot replicate and that cannot generate nucleic acids that can replicate in any living cell, such as oligonucleotides that do not contain an origin of replication, cannot integrate into DNA, do not result in production of a toxin that is lethal for vertebrates with an LD50 less than 100 ng/kg of body weight, and are not transferred into a human research subject (Section III-F-1) [16] . -Recombinant or synthetic nucleic acids that are not in organisms, cells, or viruses and that have not been manipulated to facilitate penetration of cellular membranes (Section III-F-2) [16] . -Recombinant or synthetic nucleic acids that only consist of the exact nucleic acid sequence from a single source that exists contemporaneously in nature (Section III-F-3) [16] . -Recombinant or synthetic nucleic acids from a prokaryotic host (including any indigenous plasmids or viruses) when only propagated in that same host (or a closely related strain of the same species), or when the nucleic acids are transferred to another host by well-established physiological means (Section III-F-4) [16] . -Recombinant or synthetic nucleic acids from a eukaryotic host (including chloroplasts, mitochondria, or plasmids, but specifically excluding viruses) when propagated only in that same host (or a closely related strain of the same species) (Section III-F-5) [16] . -Recombinant or synthetic nucleic acids consisting entirely of DNA segments from different species that are known to exchange DNA through physiological processes (e.g., known natural exchangers as defined in appendices A-I through A-IV of the NIH Guidelines; Section III-F-6) [16] . -Genomic DNA molecules that have acquired a transposable element as long as the transposable element does not contain any recombinant or synthetic DNA (Section III-F-7) [16] . -Experiments described in Appendix C of the NIH Guidelines, which the NIH director, with advice from the RAC and an opportunity for public comment, has determined not to pose a significant risk to health or the environment (Section III-F-8) [16] .4.The main regulatory mandate of the NIH Guidelines is to provide a framework for the proper assessment of risk, containment, and review and approval of certain classifications of experiments with recombinant and synthetic nucleic acids as defined above [16] . a.", [["cell", "ANATOMY", 238, 242], ["body", "ANATOMY", 448, 452], ["cells", "ANATOMY", 607, 612], ["cellular membranes", "ANATOMY", 689, 707], ["plasmids", "ANATOMY", 1002, 1010], ["chloroplasts", "ANATOMY", 1310, 1322], ["mitochondria", "ANATOMY", 1324, 1336], ["plasmids", "ANATOMY", 1341, 1349], ["nucleic acid", "CHEMICAL", 72, 84], ["nucleic acids", "CHEMICAL", 191, 204], ["nucleic acids", "CHEMICAL", 566, 579], ["nucleic acids", "CHEMICAL", 759, 772], ["nucleic acid", "CHEMICAL", 804, 816], ["nucleic acids", "CHEMICAL", 938, 951], ["nucleic acids", "CHEMICAL", 1125, 1138], ["nucleic acids", "CHEMICAL", 1262, 1275], ["nucleic acids", "CHEMICAL", 1527, 1540], ["nucleic acids", "CHEMICAL", 2430, 2443], ["cell", "CELL", 238, 242], ["DNA", "CELLULAR_COMPONENT", 337, 340], ["body", "ORGANISM_SUBDIVISION", 448, 452], ["human", "ORGANISM", 492, 497], ["cells", "CELL", 607, 612], ["cellular membranes", "CELLULAR_COMPONENT", 689, 707], ["chloroplasts", "CELLULAR_COMPONENT", 1310, 1322], ["mitochondria", "CELLULAR_COMPONENT", 1324, 1336], ["DNA", "CELLULAR_COMPONENT", 1564, 1567], ["DNA", "CELLULAR_COMPONENT", 1627, 1630], ["DNA", "CELLULAR_COMPONENT", 1793, 1796], ["DNA", "CELLULAR_COMPONENT", 1931, 1934], ["nucleic acid sequence", "PROTEIN", 804, 825], ["plasmids", "DNA", 1341, 1349], ["DNA segments", "PROTEIN", 1564, 1576], ["Genomic DNA molecules", "PROTEIN", 1785, 1806], ["transposable element", "DNA", 1828, 1848], ["transposable element", "DNA", 1864, 1884], ["recombinant or synthetic DNA", "DNA", 1906, 1934], ["human", "SPECIES", 492, 497], ["human", "SPECIES", 492, 497], ["a.", "SPECIES", 2468, 2470], ["recombinant or synthetic nucleic acid molecules", "PROBLEM", 47, 94], ["nucleic acids", "TREATMENT", 191, 204], ["oligonucleotides", "TREATMENT", 252, 268], ["a toxin", "PROBLEM", 373, 380], ["Recombinant or synthetic nucleic acids", "PROBLEM", 541, 579], ["organisms", "PROBLEM", 596, 605], ["cells", "PROBLEM", 607, 612], ["viruses", "PROBLEM", 617, 624], ["synthetic nucleic acids", "TEST", 749, 772], ["the exact nucleic acid sequence", "PROBLEM", 794, 825], ["synthetic nucleic acids", "TREATMENT", 928, 951], ["a prokaryotic host", "PROBLEM", 957, 975], ["any indigenous plasmids", "TREATMENT", 987, 1010], ["viruses", "PROBLEM", 1014, 1021], ["the nucleic acids", "TEST", 1121, 1138], ["synthetic nucleic acids", "TREATMENT", 1252, 1275], ["a eukaryotic host", "TREATMENT", 1281, 1298], ["chloroplasts", "TREATMENT", 1310, 1322], ["mitochondria", "TREATMENT", 1324, 1336], ["plasmids", "TREATMENT", 1341, 1349], ["viruses", "PROBLEM", 1378, 1385], ["synthetic nucleic acids", "TREATMENT", 1517, 1540], ["DNA segments", "PROBLEM", 1564, 1576], ["different species", "PROBLEM", 1582, 1599], ["A-IV of the NIH Guidelines", "TREATMENT", 1732, 1758], ["Genomic DNA molecules", "PROBLEM", 1785, 1806], ["a transposable element", "PROBLEM", 1826, 1848], ["the proper assessment", "TEST", 2289, 2310], ["synthetic nucleic acids", "TEST", 2420, 2443], ["cellular membranes", "OBSERVATION", 689, 707], ["viruses", "OBSERVATION", 1014, 1021], ["DNA molecules", "OBSERVATION", 1793, 1806], ["Appendix", "ANATOMY", 1986, 1994], ["main", "OBSERVATION_MODIFIER", 2213, 2217]]], ["Risk Assessment and Containment: The process of risk assessment begins with the investigator's initial assignment of a biosafety level appropriate for the research that will be performed.", [["risk assessment", "TEST", 48, 63]]], ["The NIH Guidelines provide tools to aid the investigator in the initial risk assessment by classifying biological agents into risk groups according to their potential to cause disease in a healthy adult (Appendix B) [16] .", [["the initial risk assessment", "TEST", 60, 87], ["disease", "PROBLEM", 176, 183]]], ["Biological agents are assigned to risk groups 1 through 4, with agents that are not associated with disease in healthy adults assigned to risk group 1, and with each successive risk group 2-4 posing a greater risk to human health.", [["human", "ORGANISM", 217, 222], ["human", "SPECIES", 217, 222], ["human", "SPECIES", 217, 222], ["Biological agents", "TREATMENT", 0, 17], ["agents", "TREATMENT", 64, 70], ["not associated with", "UNCERTAINTY", 80, 99]]], ["Once an initial risk group assignment has been made by the investigator, the NIH Guidelines describe appropriate containment levels for: -In vitro work in the laboratory and work in small animals that are of a size that is conducive to housing in cages that provide containment of biological agents, most often laboratory rodents (Appendix G) [16] , -Work with large animals that are of a size at which caging to provide containment of biological agents is not available and where the room itself provides containment (Appendix N) [16] , -Work with plants (Appendix P) [16] , and -Work with large volumes of biological agents in production facilities (Appendix K) [16] . b.", [["biological agents", "TREATMENT", 281, 298], ["biological agents", "TREATMENT", 436, 453], ["biological agents", "TREATMENT", 608, 625]]], ["Each containment level, defined as a BL, consists of a combination of appropriate microbiological work practices, containment equipment, and facility design features.", [["containment equipment", "TREATMENT", 114, 135]]], ["Each BL, a combination of the above risk-mitigation strategies, is developed to ensure safe research with biological agents that pose a greater risk to human health requiring progressively more complex containment practices and facilities (e.g., BL1 through BL4, BL1N-BLN4, BL1P-BL4P, good large-scale practice (GLSP), BL1-LS-BL3-LS) [16] .", [["human", "ORGANISM", 152, 157], ["BL1P", "PROTEIN", 274, 278], ["human", "SPECIES", 152, 157], ["human", "SPECIES", 152, 157], ["the above risk-mitigation strategies", "TREATMENT", 26, 62], ["biological agents", "TREATMENT", 106, 123], ["BL4", "TEST", 258, 261], ["BL1N", "TEST", 263, 267], ["BLN4", "TEST", 268, 272], ["BL1P", "TEST", 274, 278], ["BL4P", "TEST", 279, 283], ["GLSP", "TEST", 312, 316], ["BL1", "TEST", 319, 322], ["LS", "TEST", 323, 325]]], ["The NIH Guidelines require each institution to establish an IBC, which is responsible for reviewing research with recombinant and synthetic nucleic acids at the institution and ensuring that all such research is performed in compliance with the NIH Guidelines (Section IV-B-2) [16] .", [["nucleic acids", "CHEMICAL", 140, 153], ["IBC", "CANCER", 60, 63], ["an IBC", "TEST", 57, 63], ["recombinant and synthetic nucleic acids", "TREATMENT", 114, 153], ["IBC", "OBSERVATION", 60, 63]]], ["The composition of the IBC is specified in the NIH Guidelines to ensure that the committee includes members with adequate expertise to fully evaluate all research with recombinant and synthetic nucleic acids performed at an institution.", [["IBC", "DISEASE", 23, 26], ["nucleic acids", "CHEMICAL", 194, 207], ["IBC", "CANCER", 23, 26], ["recombinant and synthetic nucleic acids", "TREATMENT", 168, 207], ["IBC", "OBSERVATION", 23, 26]]], ["For example, institutions performing recombinant or synthetic nucleic acid work in plants, animals, or human subjects are required to have at least one plant, animal, or human subject research expert as a committee member (Sections IV-B-4, IV-B-5, and IV-B-6, respectively) [16] .", [["nucleic acid", "CHEMICAL", 62, 74], ["human", "ORGANISM", 103, 108], ["human", "ORGANISM", 170, 175], ["Sections IV-B-4", "ORGANISM", 223, 238], ["IV-B-5", "ORGANISM", 240, 246], ["IV", "PROTEIN", 240, 242], ["B", "PROTEIN", 243, 244], ["IV", "PROTEIN", 252, 254], ["B", "PROTEIN", 255, 256], ["human", "SPECIES", 103, 108], ["human", "SPECIES", 170, 175], ["human", "SPECIES", 103, 108], ["human", "SPECIES", 170, 175], ["synthetic nucleic acid work in plants", "PROBLEM", 52, 89]]], ["Similarly, any institution performing large-scale research or research at BL3 or BL4 must appoint a biological safety officer (BSO) who must serve as a member of the committee (Section IV-B-2(a-(1)) [16] .", [["BSO", "CHEMICAL", 127, 130], ["large", "OBSERVATION_MODIFIER", 38, 43]]], ["The NIH Guidelines also require at least two members of the IBC to be unaffiliated with the institution to represent the interest of the surrounding community (Section IV-B-2(a-(1)) [16] .", [["IBC", "DISEASE", 60, 63], ["IBC", "CANCER", 60, 63]]], ["The specific review of functions of the IBC and the BSO shall be discussed later in this chapter.", [["IBC", "DISEASE", 40, 43], ["BSO", "CHEMICAL", 52, 55], ["BSO", "CHEMICAL", 52, 55], ["IBC", "CANCER", 40, 43], ["BSO", "SIMPLE_CHEMICAL", 52, 55], ["the IBC", "TEST", 36, 43], ["the BSO", "TREATMENT", 48, 55]]], ["The most recent revision of the Federal Select Agent Regulations created a subset of select agents and toxins designated as \"tier one select agents and toxins\" due to the \"greatest risk of deliberate misuse with significant potential for mass casualties or devastating effect to the economy, critical infrastructure, or public confidence, and pose a severe threat to public health and safety\" [40] .", [["select agents", "TREATMENT", 85, 98], ["toxins", "TREATMENT", 103, 109], ["mass casualties", "PROBLEM", 238, 253], ["revision", "OBSERVATION", 16, 24]]], ["Some of the major changes associated with Tier One select agents and toxins are summarized below, but individuals seeking more information regarding Tier One requirements are strongly urged to consult the Resource Manual for the Responsible Official [41] , which contains guidance on compliance with the Select Agent and Toxin Regulations.The Federal Select Agent and Toxin Program-Enhanced Security Plan Requirements for Tier One Select Agents and Toxins: Many of the enhancements required for entities possessing Tier One select agents and toxins are related to increased physical and information security requirements 42 CFR \u00a773.11(f); 7 CFR \u00a7331.11(f); 9 CFR \u00a7121.11(f)) [22, 26, 27] .", [["the major changes", "PROBLEM", 8, 25], ["Toxin Regulations", "TREATMENT", 321, 338], ["Toxin Program", "TREATMENT", 368, 381], ["toxins", "PROBLEM", 542, 548], ["CFR", "TEST", 624, 627], ["CFR", "TEST", 641, 644], ["CFR", "TEST", 659, 662]]], ["The requirement for entities to develop a preaccess suitability assessment program for personnel with access to Tier One select agents and toxins has posed a particular challenge for many entities.", [["a preaccess suitability assessment", "TEST", 40, 74], ["access", "TREATMENT", 102, 108], ["toxins", "TREATMENT", 139, 145]]], ["Entities are also required to develop an ongoing suitability assessment program to ensure that all workers with access to Tier One select agents and toxins continue to meet institution-specific requirements throughout their employment.", [["an ongoing suitability assessment", "TEST", 38, 71], ["toxins", "TREATMENT", 149, 155]]], ["Entities are also required to develop a program to ensure self-and/or peer-reporting of incidents or conditions that could affect an individual's ability to work with or have access to Tier One select agents and toxins. -Enhanced Incident Response Plan Requirements for Tier One Select Agents and Toxins: Entities in possession of Tier One select agents and toxins are required to detail response procedures for failure of intrusion detection systems and a process for notification of federal, state, or local law enforcement agencies of any suspicious or suspected criminal activity at the entity in their mandated incident response plan (42 CFR \u00a773.14(e); 7 CFR \u00a7331.14(e); 9 CFR \u00a7121.14(e)) [22, 26, 27 ].-Occupational Health and Training Enhancements for Tier One Select Agents andToxins: In addition to mandated annual biosafety, security, and incident response training, entities in possession of Tier One select agents and toxins are required to develop annual insider threat awareness training for all personnel with access to Tier One select agents and toxins (42 CFR \u00a773.15(b); 7 CFR \u00a7331.15(b); 9 CFR \u00a7121.15(b)) [22, 26, 27] .", [["toxins", "PROBLEM", 358, 364], ["failure of intrusion detection systems", "PROBLEM", 412, 450], ["CFR", "TEST", 643, 646], ["CFR", "TEST", 660, 663], ["CFR", "TEST", 678, 681], ["toxins", "TEST", 1062, 1068], ["CFR", "TEST", 1073, 1076], ["CFR", "TEST", 1090, 1093], ["CFR", "TEST", 1108, 1111]]], ["Finally, an occupational health program, while strongly recommended for all entities in the opinion of the authors, is required for entities in possession of Tier One select agents and toxins (42 CFR \u00a773.12(d); 7 CFR \u00a7331.12(d); 9 CFR \u00a7121.12(d)) [22, 26, 27] .-Occupational Health and Training Enhancements for Tier One Select Agents andi.", [["toxins", "TEST", 185, 191], ["CFR", "TEST", 196, 199], ["CFR", "TEST", 213, 216], ["CFR", "TEST", 231, 234], ["Training Enhancements", "TREATMENT", 286, 307]]], ["Failure to comply with the regulations will result in potential administrative, civil, and/or criminal penalties for entities and/or individuals (Table 3) [42] .", [["Failure to comply", "PROBLEM", 0, 17]]], ["An approved import permit (IP) must be obtained by an investigator prior to importation of any materials that may be infectious to humans from a foreign country [43] , and approval of an IP may be accompanied by requirements and conditions, including an inspection by the CDC IPP to ensure that: a.", [["humans", "ORGANISM", 131, 137], ["humans", "SPECIES", 131, 137], ["humans", "SPECIES", 131, 137], ["an inspection", "TEST", 251, 264], ["infectious", "OBSERVATION", 117, 127]]], ["The importer has implemented proper biosafety measures, and b.", [["b.", "SPECIES", 60, 62]]], ["The importer ensures that the shipper meets all legal requirements regarding packaging, labeling, and shipment of infectious substances.", [["packaging", "TREATMENT", 77, 86], ["labeling", "TREATMENT", 88, 96], ["infectious", "OBSERVATION_MODIFIER", 114, 124]]], ["In some cases, the IP requires that the CDC approve an additional IP for any subsequent transfer of permitted infectious substances within the United States.The Foreign Quarantine Program was modified in April of 2013 to include the provision thatan approved IP is no longer required for import of a biological select agent listed in 42 CFR Part 73 [22] if the import has been approved by the FSAP under the form two transfer process described in 42 CFR 73.16 (HHS Select Agents) or 9 CFR 121.6 (Overlap Select Agents) [22, 27] .USDA APHIS Biological Products, Organisms and Vectors, and PlantPathogens Permitting Program: Import and Interstate Transfer of Agricultural Pathogens 1.", [["thatan", "CHEMICAL", 243, 249], ["a biological select agent", "TREATMENT", 298, 323], ["CFR", "TEST", 450, 453], ["CFR", "TEST", 485, 488], ["Organisms and Vectors", "TREATMENT", 561, 582], ["Agricultural Pathogens", "PROBLEM", 657, 679], ["infectious", "OBSERVATION", 110, 120], ["Foreign Quarantine", "OBSERVATION", 161, 179]]], ["Import of an animal product as defined by USDA APHIS in 9 CFR \u00a7101 requires an individual to hold an approved US Veterinary Animal Product Permit (9 CFR \u00a7104.1) [44] .USDA APHIS Biological Products, Organisms and Vectors, and PlantAnimal products under this definition include \"vaccines, bacterins, allergens, antibodies, antitoxins, toxoids, immunostimulants, some cytokines, antigenic or immunizing components of live organisms, and diagnostic components, that are of natural or synthetic origin, or that are derived from synthesizing or altering various substances or components of substances such as microorganisms, genes or genetic sequences, carbohydrates, proteins, antigens, allergens, or antibodies\" (9 CFR \u00a7104.2) as well as cell cultures (9 CFR \u00a7104.6) and seed organisms (9 CFR \u00a7104.7) [44] .", [["cell cultures", "ANATOMY", 735, 748], ["carbohydrates", "CHEMICAL", 648, 661], ["bacterins", "SIMPLE_CHEMICAL", 288, 297], ["antitoxins", "SIMPLE_CHEMICAL", 322, 332], ["cell cultures", "CELL", 735, 748], ["antibodies", "PROTEIN", 310, 320], ["antitoxins", "PROTEIN", 322, 332], ["toxoids", "PROTEIN", 334, 341], ["immunostimulants", "PROTEIN", 343, 359], ["cytokines", "PROTEIN", 366, 375], ["antigens", "PROTEIN", 673, 681], ["allergens", "PROTEIN", 683, 692], ["antibodies", "PROTEIN", 697, 707], ["cell cultures", "CELL_LINE", 735, 748], ["Organisms and Vectors", "TREATMENT", 199, 220], ["PlantAnimal products", "TREATMENT", 226, 246], ["\"vaccines", "TREATMENT", 277, 286], ["bacterins", "TREATMENT", 288, 297], ["allergens", "TREATMENT", 299, 308], ["antibodies", "TREATMENT", 310, 320], ["antitoxins", "TREATMENT", 322, 332], ["toxoids", "TREATMENT", 334, 341], ["immunostimulants", "TREATMENT", 343, 359], ["some cytokines", "PROBLEM", 361, 375], ["antigenic", "PROBLEM", 377, 386], ["immunizing components", "TREATMENT", 390, 411], ["live organisms", "PROBLEM", 415, 429], ["altering various substances", "PROBLEM", 540, 567], ["microorganisms", "PROBLEM", 604, 618], ["genetic sequences", "TEST", 629, 646], ["allergens", "PROBLEM", 683, 692], ["antibodies", "TEST", 697, 707], ["CFR", "TEST", 712, 715], ["cell cultures", "TEST", 735, 748], ["CFR", "TEST", 752, 755], ["seed organisms", "TEST", 768, 782], ["CFR", "TEST", 786, 789]]], ["There are several types of permits available for importing animal products, but the most common type required by individual researchers is the US Veterinary Permit to Import Cell Cultures and Their Products (USDA-APHIS VS 16-7) [45] .", [["Cell", "ANATOMY", 174, 178], ["Cell Cultures", "CELL", 174, 187], ["animal products", "TREATMENT", 59, 74], ["Cell Cultures", "TEST", 174, 187], ["APHIS VS", "TEST", 213, 221]]], ["Application for a USDA-APHIS VS 16-7 requires an individual researcher to briefly describe the product, the method of propagation including composition of the medium and the species of animals or cell cultures involved, any inactivation or attenuation of the product, and the proposed plan for evaluation (9 CFR \u00a7104.4) [46] .", [["cell cultures", "ANATOMY", 196, 209], ["cell cultures", "CELL", 196, 209], ["cell cultures", "CELL_LINE", 196, 209], ["composition of the medium", "TREATMENT", 140, 165], ["cell cultures", "TEST", 196, 209], ["evaluation", "TEST", 294, 304], ["CFR", "TEST", 308, 311]]], ["USDA APHIS also regulates the importation and/or interstate transfer of organisms that may be infectious to animals (including poultry), animal vectors that have been intentionally infected with organisms or that are known to be infected with or to have been exposed to any contagious, infectious, or communicable disease of animals or poultry, or animal products and byproducts (9 CFR \u00a7122.1 (d) and (e)) [45] .", [["organisms", "PROBLEM", 72, 81], ["animal vectors", "TREATMENT", 137, 151], ["organisms", "PROBLEM", 195, 204], ["communicable disease of animals", "PROBLEM", 301, 332], ["CFR", "TEST", 382, 385], ["may be", "UNCERTAINTY", 87, 93], ["infectious", "OBSERVATION", 94, 104], ["infectious", "OBSERVATION", 286, 296]]], ["A USDA APHIS VS 16-3 permit for the import or transport of controlled material or organisms or vectors is required and must be issued prior to shipment of organisms or vectors [47] .", [["A USDA APHIS VS", "TEST", 0, 15], ["organisms or vectors", "PROBLEM", 82, 102]]], ["It is important to note that unlike the CDC IP, an approved USDA APHIS VS 16-3 permit is required both for importation of biological products, organisms, or vectors from foreign countries and for transfer of regulated agents from one state, US territory, or the District of Columbia to another (9 CFR \u00a7104.4 (b) (2); 9 CFR \u00a7122.2) [47] .", [["biological products", "TREATMENT", 122, 141], ["organisms", "PROBLEM", 143, 152], ["CFR", "TEST", 297, 300], ["CFR", "TEST", 319, 322]]], ["USDA APHIS also requires investigators to apply for a PPQ Permit prior to importing soil, organisms, soil samples, or plants and plant products (7 CFR \u00a7330) [48] .Dangerous Goods Shipping Regulations: Transport of Biological Agents1.", [["samples", "ANATOMY", 106, 113], ["PPQ", "CHEMICAL", 54, 57], ["a PPQ Permit", "TREATMENT", 52, 64], ["soil samples", "TEST", 101, 113]]], ["IATA DGR and DOT FHMR regulations apply to any package containing dangerous goods that is presented for intrastate, interstate, or international shipment [28, 29] .", [["DOT FHMR regulations", "TREATMENT", 13, 33]]], ["In most situations, investigators or their designees are identified as the shipper of packages containing dangerous goods and as such, are responsible for proper classification of shipped materials, identification (by choosing a proper shipping name), selection of proper packaging materials, compliance with the proper packaging instruction while preparing the package for shipment, proper marking and labeling of packages with appropriate hazard labels, preparation of appropriate shipping documentation, and compliance with any other additional requirements (e.g., obtaining appropriate import and/or export permits) as described elsewhere in this chapter.", [["proper packaging materials", "TREATMENT", 265, 291], ["the proper packaging instruction", "TREATMENT", 309, 341], ["shipment", "TREATMENT", 374, 382]]], ["Under the IATA DGR, this training must be repeated every 24 months to ensure knowledge of the current regulations (IATA 1.5.0.3) [28] , while the DOT FHMR require training to be repeated at least once every three years (49 CFR \u00a7172.704(c)(2)) [29] .", [["this training", "TREATMENT", 20, 33], ["CFR", "TEST", 223, 226]]], ["Since the IATA DGR are the more stringent regulations with regard to training frequency, most institutions and/or employers choose to require that personnel who ship dangerous goods repeat training at least once every two years (24 months).Classification of Dangerous Goods: Dangerous goods are divided into classes accordingto the type of hazard posed by the material.", [["IATA DGR", "DNA", 10, 18], ["Dangerous", "OBSERVATION_MODIFIER", 258, 267]]], ["While the exact list of dangerous goods varies between specific regulations, most dangerous goods associated with biological research will fall into either division 6.2 infectious substances or division 9 miscellaneous dangerous goods. a.", [["a.", "SPECIES", 236, 238]]], ["Division 6.2 Infectious Substances: Any substance known or reasonably expected to contain pathogens such as bacteria, viruses, rickettsiae, parasites, fungi, and/or other agents such as prions that may cause disease in humans or animals is classified as a division 6.2 infectious substance under the IATA DGR (IATA 3.6.2.1.1) and must be packaged and shipped in accordance with the regulations for this division [28] .Classification of Dangerous Goods: Dangerous goods are divided into classes accordingCultures of pathogens must be classified as division 6.2 infectious substances, as well as patient specimens from humans or animals that are known or reasonably expected to contain pathogens.", [["specimens", "ANATOMY", 602, 611], ["rickettsiae", "DISEASE", 127, 138], ["prions", "DISEASE", 186, 192], ["humans", "ORGANISM", 219, 225], ["patient", "ORGANISM", 594, 601], ["humans", "ORGANISM", 617, 623], ["humans", "SPECIES", 219, 225], ["patient", "SPECIES", 594, 601], ["humans", "SPECIES", 617, 623], ["humans", "SPECIES", 219, 225], ["humans", "SPECIES", 617, 623], ["pathogens", "PROBLEM", 90, 99], ["bacteria", "PROBLEM", 108, 116], ["viruses", "PROBLEM", 118, 125], ["rickettsiae", "PROBLEM", 127, 138], ["parasites", "PROBLEM", 140, 149], ["fungi", "PROBLEM", 151, 156], ["disease in humans", "PROBLEM", 208, 225], ["pathogens", "PROBLEM", 515, 524], ["patient specimens", "TEST", 594, 611], ["pathogens", "PROBLEM", 684, 693], ["Dangerous", "OBSERVATION_MODIFIER", 436, 445], ["pathogens", "OBSERVATION", 684, 693]]], ["Infectious substances are further subdivided into either category A or category B substances.", [["Infectious substances", "PROBLEM", 0, 21]]], ["Category A infectious substances include those that are capable of causing permanent disability or life-threatening or fatal disease on exposure in otherwise healthy humans or animals (IATA 3.6.2.2.2.1) [28] .", [["permanent disability", "DISEASE", 75, 95], ["humans", "ORGANISM", 166, 172], ["humans", "SPECIES", 166, 172], ["humans", "SPECIES", 166, 172], ["permanent disability", "PROBLEM", 75, 95], ["fatal disease", "PROBLEM", 119, 132], ["infectious", "OBSERVATION", 11, 21], ["fatal", "OBSERVATION_MODIFIER", 119, 124], ["disease", "OBSERVATION", 125, 132]]], ["Infectious substances that do not meet the criteria for inclusion in category A are classified as category B infectious substances (IATA 3.6.2.2.2.2) [28] . b.", [["Infectious substances", "PROBLEM", 0, 21], ["IATA", "TEST", 132, 136], ["infectious", "OBSERVATION_MODIFIER", 109, 119]]], ["Division 9 Miscellaneous Dangerous Goods: Often biological materials, both those that may be infectious substances and those that do not meet the criteria for classification as an infectious substance, must be shipped below ambient temperatures to preserve viability.", [["an infectious substance", "PROBLEM", 177, 200], ["may be", "UNCERTAINTY", 86, 92], ["infectious", "OBSERVATION", 93, 103], ["infectious", "OBSERVATION", 180, 190]]], ["Any package presented for shipment that contains dry ice (solidified carbon dioxide) must be classified as division 9 miscellaneous dangerous goods (IATA 3.9.2.6) [28] and must be packaged and labeled in accordance with IATA DGR and DOT FHMR for this division [28, 29] .", [["solidified carbon dioxide", "CHEMICAL", 58, 83], ["carbon dioxide", "CHEMICAL", 69, 83], ["carbon dioxide", "SIMPLE_CHEMICAL", 69, 83], ["shipment", "TREATMENT", 26, 34], ["dry ice (solidified carbon dioxide", "TREATMENT", 49, 83]]], ["Nonpathogenic, genetically modified organisms are classified as hazardous materials by the IATA DGR and must be classified as division 9 miscellaneous dangerous goods when shipped by air within the contiguous United States or when shipped by any method internationally and must be packaged and labeled in accordance with DGR (IATA 3.9.2.5.) [28] .", [["Nonpathogenic, genetically modified organisms", "PROBLEM", 0, 45]]], ["However, it should also be noted that nonpathogenic, genetically modified organisms that are shipped by ground within the contiguous United States are not considered to be hazardous materials by the DOT FHMR and therefore are not regulated [29] .", [["nonpathogenic", "PROBLEM", 38, 51], ["genetically modified organisms", "PROBLEM", 53, 83], ["the DOT FHMR", "TEST", 195, 207], ["not considered to be", "UNCERTAINTY", 151, 171], ["hazardous", "OBSERVATION", 172, 181]]], ["Each proper shipping name is associated with a specific United Nations (UN) number, which may be found in Table 4 (IATA 4) [28] .", [["shipping", "OBSERVATION", 12, 20]]], ["Packaging: The regulations provide specific requirements for proper packaging of each type of dangerous good [28] .", [["proper packaging", "TREATMENT", 61, 77]]], ["These requirements are defined in the packing instruction associated with each category of dangerous goods and may have variable maximum net quantity limits that are dependent on the exact transportation mode (e.g., shipment via passenger versus cargo aircraft).", [["the packing instruction", "TREATMENT", 34, 57], ["maximum", "OBSERVATION_MODIFIER", 129, 136], ["net quantity limits", "OBSERVATION", 137, 156]]], ["Specific requirements for use of packaging materials tested and approved to meet UN specifications may apply to each packing instruction, and the number of primary and secondary containers and the presence and type of absorbent materials may also be specified in each packing instruction.", [["packaging materials", "TREATMENT", 33, 52], ["packing instruction", "TREATMENT", 117, 136], ["primary and secondary containers", "TREATMENT", 156, 188], ["absorbent materials", "TREATMENT", 218, 237]]], ["Packing instructions may be found in the IATA DGR (IATA 5) [28] .", [["Packing instructions", "TREATMENT", 0, 20]]], ["Marking and Labeling: All DGR provide instructions regarding the specific type of hazard labels that are required to be attached to each package, including appropriate symbols, minimum dimensions, number of labels per package, and proper placement of markings and labels on each package [28, 29] .", [["proper placement of markings", "TREATMENT", 231, 259], ["markings", "OBSERVATION", 251, 259]]], ["The regulations contain detailed requirements for proper completion of the shipper's declaration and a requirement for retention of these records by both the shipper and the carrier for two years.Special Considerations and Penalties for Violation:a.", [["the shipper's declaration", "TREATMENT", 71, 96]]], ["A technical name is required in addition to the proper shipping name for category A infectious agents in accordance with International Civil Aviation Organization (ICAO) special provision A140 [49] .", [["infectious", "OBSERVATION", 84, 94]]], ["Shipment of category A infectious substances via the US or other international postal systems is prohibited under any circumstances according to the Universal Postal Union (UPU; Article 132.2) [50] , ICAO [49] , and IATA [28] regulations. d.", [["the US", "TEST", 49, 55], ["ICAO", "TEST", 200, 204], ["IATA", "TEST", 216, 220], ["infectious", "OBSERVATION", 23, 33]]], ["In the United States, violation of any hazardous materials regulations may result in a civil penalty of up to $50,000 for each violation, and in some cases, a criminal penalty of up to $500,000 and/or imprisonment for up to five years may apply (49 CFR \u00a7107.329 and \u00a7107.333) [29] .", [["any hazardous materials regulations", "PROBLEM", 35, 70], ["CFR", "TEST", 249, 252], ["hazardous materials", "OBSERVATION", 39, 58]]], ["In cases in which the violation results in serious injury or death, penalties may be doubled [29] .1.Under the BBP standard, any entity where employee(s) may have exposure to BBP must have a written exposure control plan (CFR \u00a71910.1030, c), and this plan must be made accessible to employees [18] .", [["death", "DISEASE", 61, 66], ["BBP", "CHEMICAL", 111, 114], ["BBP", "CHEMICAL", 175, 178], ["serious injury", "PROBLEM", 43, 57], ["death", "PROBLEM", 61, 66], ["serious", "OBSERVATION_MODIFIER", 43, 50], ["injury", "OBSERVATION", 51, 57]]], ["The concept of universal precautions (i.e., treating all blood, body fluids, and in some cases, cultures, as infectious) is critical to compliance with the BBP standard.2.In addition to development of an exposure control plan and adherence to universal precautions, engineering, and work practices controls must be implemented to eliminate or minimize employee exposures (CFR \u00a71910.1030, d, (2)) [18] .", [["blood", "ANATOMY", 57, 62], ["body fluids", "ANATOMY", 64, 75], ["BBP", "CHEMICAL", 156, 159], ["blood", "ORGANISM_SUBSTANCE", 57, 62], ["body", "ORGANISM_SUBDIVISION", 64, 68], ["BBP", "SIMPLE_CHEMICAL", 156, 159], ["universal precautions", "TREATMENT", 15, 36], ["all blood, body fluids", "TREATMENT", 53, 75], ["cultures", "TEST", 96, 104], ["the BBP standard", "TREATMENT", 152, 168], ["an exposure control plan", "TREATMENT", 201, 225], ["universal precautions", "TREATMENT", 243, 264]]], ["Proper handwashing facilities, enforcement of proper handwashing practices following removal of gloves or other PPE, and provision of antiseptic hand sanitizers when handwashing facilities are not immediately available are required.", [["hand", "ANATOMY", 145, 149], ["proper handwashing practices", "TREATMENT", 46, 74], ["removal of gloves", "TREATMENT", 85, 102], ["other PPE", "TREATMENT", 106, 115], ["antiseptic hand sanitizers", "TREATMENT", 134, 160]]], ["Use of sharps in conjunction with BBPs is a highrisk activity, and the BBP standard details proper sharps handling and disposal practices (including use of approved sharps disposal containers) and prohibition of bending, recapping, or removal of contaminated sharps (unless part of a procedure specificrequirement or if no feasible alternative is available) [18] .", [["disposal practices", "TREATMENT", 119, 137], ["sharps disposal containers", "TREATMENT", 165, 191], ["recapping", "TREATMENT", 221, 230], ["removal", "TREATMENT", 235, 242], ["a procedure specificrequirement", "TREATMENT", 282, 313]]], ["Basic good laboratory practices, such as prohibiting mouth pipetting, eating, drinking, smoking, applying cosmetics, or handling contact lenses in work areas, storage of food and drink outside of work areas, and performing laboratory procedures carefully to minimize splashing, spraying, or generation of aerosol droplets of pathogens are also required.", [["mouth", "ANATOMY", 53, 58], ["smoking", "CHEMICAL", 88, 95], ["mouth", "ORGANISM_SUBDIVISION", 53, 58], ["laboratory procedures", "TREATMENT", 223, 244], ["splashing", "TREATMENT", 267, 276], ["spraying", "TREATMENT", 278, 286], ["aerosol droplets", "TREATMENT", 305, 321], ["pathogens", "PROBLEM", 325, 334], ["good", "OBSERVATION_MODIFIER", 6, 10]]], ["Laboratories where work with BBP is performed and potentially contaminated equipment and containers are used for transport of BBP must be appropriately signed and labeled [18] .", [["BBP", "CHEMICAL", 29, 32], ["BBP", "CHEMICAL", 29, 32], ["BBP", "CHEMICAL", 126, 129], ["BBP", "SIMPLE_CHEMICAL", 126, 129], ["BBP", "TEST", 29, 32], ["transport of BBP", "TREATMENT", 113, 129]]], ["Minimum PPE requirements include gloves, gowns or laboratory coats, face shields or masks, and eye protection, as well as mouthpieces, resuscitation bags, or pocket masks or other ventilation devices.", [["eye", "ANATOMY", 95, 98], ["eye", "ORGAN", 95, 98], ["Minimum PPE requirements", "TREATMENT", 0, 24], ["gloves", "TREATMENT", 33, 39], ["laboratory coats", "TREATMENT", 50, 66], ["face shields", "TREATMENT", 68, 80], ["masks", "TREATMENT", 84, 89], ["eye protection", "TREATMENT", 95, 109], ["resuscitation bags", "TREATMENT", 135, 153], ["pocket masks", "TREATMENT", 158, 170], ["other ventilation devices", "TREATMENT", 174, 199], ["eye", "ANATOMY", 95, 98], ["ventilation devices", "OBSERVATION", 180, 199]]], ["The BBP standard also requires employers to ensure that proper PPE is used by employees [18] .", [["BBP", "CHEMICAL", 4, 7]]], ["[51] , respiratory protection (29 CFR 1910 .134) [52] , and hand protection (29 CFR 1910 .138) [53] are of importance for work with biological agents.", [["hand", "ANATOMY", 60, 64], ["hand", "ORGANISM_SUBDIVISION", 60, 64], ["biological agents", "TREATMENT", 132, 149]]], ["In particular, respiratory protection is required for specific work with infectious agents known to be transmitted via respiratory exposure routes (work with animals and manipulations of risk group 3 pathogens and all risk group 4 pathogens).", [["respiratory", "ANATOMY", 15, 26], ["respiratory", "ANATOMY", 119, 130], ["respiratory protection", "TREATMENT", 15, 37], ["infectious agents", "TREATMENT", 73, 90], ["risk group 3 pathogens", "PROBLEM", 187, 209], ["respiratory protection", "OBSERVATION", 15, 37]]], ["The respiratory protection standard includes requirements for medical screening prior to use of specific types of respiratory protection and requirements for proper fit testing of employees (29 CFR \u00a71910.134(e); 29 CFR \u00a71910.134(f), respectively) [52] .Research with Recombinant and Synthetic Nucleic Acids: The IBC1.", [["respiratory", "ANATOMY", 4, 15], ["respiratory", "ANATOMY", 114, 125], ["IBC1", "PROTEIN", 312, 316], ["The respiratory protection", "TREATMENT", 0, 26], ["medical screening", "TEST", 62, 79], ["respiratory protection", "TREATMENT", 114, 136], ["The IBC1", "TREATMENT", 308, 316], ["respiratory protection", "OBSERVATION", 4, 26]]], ["The IBC is responsible for ensuring that all work with recombinant and synthetic nucleic acids at an institution is performed in compliance with the NIH Guidelines.", [["IBC", "DISEASE", 4, 7], ["nucleic acids", "CHEMICAL", 81, 94], ["IBC", "CANCER", 4, 7], ["synthetic nucleic acids", "TREATMENT", 71, 94], ["IBC", "OBSERVATION", 4, 7], ["responsible for", "UNCERTAINTY", 11, 26]]], ["To achieve this function, the IBC reviews proposed research projects and assesses a variety of aspects of the research including: a. assessment of the containment levels required for the research (Section IV-B-2-b-(1)) [16] ; b. assessment of the facilities, procedures, practices, and training of personnel involved in the proposed project (Section IV-B-2-b-(1)) [16] ; c. ensuring that all requirements for any human gene transfer research projects are met (Section IV-B-2-b-(1) and Appendix M) [16] ; d. ensuring that no human research subject is enrolled in a human gene transfer experiment until the NIH RAC has reviewed the research, the project has been approved by both the IBC and IRB of the clinical trial site, and any other regulatory requirements have been met (Section IV-B-2-b-(1)) [16] ; e. ensuring that approval of any human gene transfer experiments chosen for public review by the RAC take into consideration any issues raised and recommendations made as a result of the RAC review and any of the principal investigator's responses to the RAC (Section IV-B-2-b-(1)) [16] ; f. ensuring that the RAC review process has been completed before granting final approval to a project (Section IV-B-2-b-(1)) [16] ; and g. ensuring that the institution complies with all surveillance, data reporting, and adverse event reporting requirements of the NIH Guidelines (Section IV-B-2-b-(1)) [16] .2.The IBC must notify the investigator of the results of its review (Section IV-B-2-b-(2)), is responsible for lowering containment levels for specific experiments (Section IV-B-2-b-(3)) and for setting containment levels for experiments involving animals or plants (Section IV-B-2-b-(4)) [16] .", [["human", "ORGANISM", 413, 418], ["human", "ORGANISM", 524, 529], ["human", "ORGANISM", 564, 569], ["IBC", "CANCER", 682, 685], ["human", "ORGANISM", 837, 842], ["IBC", "CANCER", 1409, 1412], ["human", "SPECIES", 413, 418], ["human", "SPECIES", 524, 529], ["human", "SPECIES", 564, 569], ["human", "SPECIES", 837, 842], ["human", "SPECIES", 413, 418], ["human", "SPECIES", 524, 529], ["human", "SPECIES", 564, 569], ["human", "SPECIES", 837, 842], ["the containment levels", "TEST", 147, 169], ["the research (Section IV", "TREATMENT", 183, 207], ["any other regulatory requirements", "PROBLEM", 726, 759], ["a project (Section IV", "TREATMENT", 1186, 1207], ["all surveillance", "TEST", 1277, 1293], ["the NIH Guidelines", "TREATMENT", 1355, 1373], ["Section IV", "TEST", 1472, 1482], ["lowering containment levels", "PROBLEM", 1514, 1541], ["Section IV", "TEST", 1568, 1578], ["plants (Section IV", "TREATMENT", 1662, 1680], ["Appendix", "ANATOMY", 485, 493]]], ["The IBC must periodically review research conducted at the institution to ensure compliance with the NIH Guidelines, and adopt emergency plans detailing the institution's response to accidental spills and contamination of personnel with recombinant or synthetic nucleic acid materials (Section IV-B-2-b-(6)) [16] .", [["nucleic acid", "CHEMICAL", 262, 274], ["IBC", "CANCER", 4, 7], ["-2-b-(6)) [16]", "SIMPLE_CHEMICAL", 298, 312], ["accidental spills", "PROBLEM", 183, 200], ["recombinant or synthetic nucleic acid materials", "TREATMENT", 237, 284], ["Section IV", "TREATMENT", 286, 296]]], ["Any significant violations of the NIH Guidelines and any significant research-related accidents or illnesses must be reported by the IBC to appropriate institutional officials and NIH OBA within 30 days (Section IV-B-2-b- (7)) [16] .1.A BSO must be appointed by institutions that perform large-scale research or are involved in production activities that use viable organisms containing recombinant or synthetic nucleic acids, or that perform research with recombinant or synthetic nucleic acids at BL3 or BL4 (Sections IV-B-3-a and IV-B-3-b) [16] .", [["accidents", "DISEASE", 86, 95], ["IBC", "DISEASE", 133, 136], ["BSO", "CHEMICAL", 237, 240], ["nucleic acids", "CHEMICAL", 412, 425], ["nucleic acids", "CHEMICAL", 482, 495], ["BSO", "CHEMICAL", 237, 240], ["IBC", "CANCER", 133, 136], ["BSO", "SIMPLE_CHEMICAL", 237, 240], ["BL3", "GENE_OR_GENE_PRODUCT", 499, 502], ["BL3", "PROTEIN", 499, 502], ["BL4", "PROTEIN", 506, 509], ["B", "PROTEIN", 523, 524], ["IV", "PROTEIN", 533, 535], ["B", "PROTEIN", 536, 537], ["illnesses", "PROBLEM", 99, 108], ["A BSO", "TREATMENT", 235, 240], ["viable organisms containing recombinant or synthetic nucleic acids", "PROBLEM", 359, 425], ["synthetic nucleic acids", "TEST", 472, 495], ["IV", "TEST", 520, 522], ["IV", "TEST", 533, 535], ["significant", "OBSERVATION_MODIFIER", 4, 15], ["violations", "OBSERVATION", 16, 26], ["BSO", "OBSERVATION", 237, 240]]], ["The NIH Guidelines further define specific duties for the BSO that must include: a. periodic inspections of laboratories to ensure that laboratory safety standards are followed by investigators and research staff (Section IV-B-3-c- (1)Research with Recombinant and Synthetic Nucleic Acids: The Principal Investigator1.", [["BSO", "CHEMICAL", 58, 61], ["BSO", "CHEMICAL", 58, 61], ["BSO", "SIMPLE_CHEMICAL", 58, 61], ["the BSO", "TREATMENT", 54, 61]]], ["Substantial responsibility lies with the principal investigator (PI) for compliance of his or her research with the requirements of the NIH Guidelines (Section IV-B-7) [16] . a.", [["a.", "SPECIES", 175, 177], ["the NIH Guidelines", "TREATMENT", 132, 150]]], ["General requirements include a responsibility not to initiate research with recombinant or synthetic nucleic acids until appropriate approval is granted as outlined in the NIH Guidelines and ensuring simultaneous notification of the IBC with initiation of experiments described in Section III-E of the NIH Guidelines [16] . b.", [["nucleic acids", "CHEMICAL", 101, 114], ["IBC", "DISEASE", 233, 236], ["IBC", "CANCER", 233, 236], ["synthetic nucleic acids", "TREATMENT", 91, 114]]], ["The PI is responsible for reporting of accidents, exposures or violations of the NIH Guidelines to the appropriate institutional official, in addition to being trained in good microbiological techniques, adhering to institutional emergency plans for response to accidental spills and personnel contamination, and ensuring that all shipping requirements are met in any transfers of recombinant or synthetic nucleic acid molecules.", [["accidents", "DISEASE", 39, 48], ["nucleic acid", "CHEMICAL", 406, 418], ["recombinant or synthetic nucleic acid molecules", "PROTEIN", 381, 428], ["accidental spills", "PROBLEM", 262, 279], ["personnel contamination", "TREATMENT", 284, 307], ["recombinant or synthetic nucleic acid molecules", "PROBLEM", 381, 428]]], ["Specific details regarding information that the PI is required to submit to NIH OBA and the local IBC are detailed in Section IV-B-7-b and Section IV-B-7-c of the NIH Guidelines [16] .Research with Recombinant and Synthetic Nucleic Acids: The Principal Investigatorc.", [["IBC", "ANATOMY", 98, 101], ["IBC", "DISEASE", 98, 101], ["IBC", "CANCER", 98, 101]]], ["Perhaps most importantly, the NIH Guidelines place responsibility for ensuring that all personnel have adequate access to the protocols describing potential biohazards and precautions to be taken, training in the practices and techniques necessary to ensure personnel safety and proper accident response procedures, and information regarding appropriate medical surveillance programs assigned to the protocol such as vaccinations or serum collection with the PI (Section IV-B-7-d) [16] .", [["serum", "ANATOMY", 433, 438], ["serum", "ORGANISM_SUBSTANCE", 433, 438], ["the protocols", "TREATMENT", 122, 135], ["potential biohazards", "TREATMENT", 147, 167], ["precautions", "TREATMENT", 172, 183], ["the protocol", "TREATMENT", 396, 408], ["serum collection", "TEST", 433, 449], ["the PI (Section IV", "TREATMENT", 455, 473]]], ["Under the NIH Guidelines, the PI is also primarily responsible for supervision of the safety performance of the personnel in his or her laboratory and correction of any work errors or conditions that might lead to the release of recombinant or synthetic nucleic acid materials to the environment, including maintaining the integrity of physical containment devices such as biosafety cabinets and any biological containment methods (Section IV-B-7-e) [16] . d.", [["nucleic acid", "CHEMICAL", 254, 266], ["any work errors", "PROBLEM", 165, 180], ["synthetic nucleic acid materials", "TREATMENT", 244, 276], ["physical containment devices", "TREATMENT", 336, 364], ["biosafety cabinets", "TREATMENT", 373, 391], ["any biological containment methods", "TREATMENT", 396, 430]]], ["The PI is also responsible for complying with all applicable reporting requirements including those pertaining to reporting of problems with implementation of containment practices and/or issues associated with human gene transfer experiments (Sections IV-B-7-e-(2) and IV-B-7-e-(5), respectively) [16] .Research with Select Agents and Toxins: The RO1.", [["human", "ORGANISM", 211, 216], ["IV-B-7-e-(5)", "SIMPLE_CHEMICAL", 270, 282], ["human", "SPECIES", 211, 216], ["human", "SPECIES", 211, 216], ["containment practices", "TREATMENT", 159, 180]]], ["Designation of a RO is required as part of an entity's registration with the Select Agent Program. a.", [["a.", "SPECIES", 99, 101]]], ["The RO is required to undergo the same security risk assessment process as all other personnel with access to select agents and must be given the authority and responsibility to act on behalf of the entity regarding all aspects of the Select Agent Program [22, 26, 27] . b.", [["agents", "TREATMENT", 117, 123]]], ["Individual investigators may not communicate with the FSAP.", [["FSAP", "PROTEIN", 54, 58]]], ["The RO is required to be physically present at the registered entity to oversee compliance and to respond to onsite incidents involving select agents and toxins, and must ensure that annual inspections are performed of each laboratory where select agents and toxins are stored or used [22, 26, 27] .", [["toxins", "TREATMENT", 154, 160], ["annual inspections", "TEST", 183, 201]]], ["The placement of this department within the institutional reporting structure may vary, but the department should play a key role in interactions with other institutional compliance bodies.1.It is the opinion of the authors that most compliance issues associated with the NIH Guidelines fall into a category representing failure by investigators to obtain appropriate approval from NIH OBA and/or the IBC prior to beginning work that is covered by the guidelines.", [["IBC", "DISEASE", 401, 404], ["IBC", "CANCER", 401, 404], ["the IBC", "PROBLEM", 397, 404], ["failure", "OBSERVATION", 321, 328]]], ["This can be especially challenging, because a wide variety of products based on recombinant and synthetic nucleic acid materials and/or viral vector-based systems are available for purchase from commercial vendors.", [["nucleic acid", "CHEMICAL", 106, 118], ["a wide variety of products", "TREATMENT", 44, 70], ["recombinant and synthetic nucleic acid materials", "TREATMENT", 80, 128]]], ["Introduction of commercial products involving viral vectors or commercially produced viral particles based on recombinant or synthetic nucleic acids into mammalian cells and/or animals represents research that must be approved by the IBC prior to commencement.2.Transfer of drug resistance traits into microorganisms can be another challenging area of compliance with the NIH Guidelines.", [["mammalian cells", "ANATOMY", 154, 169], ["nucleic acids", "CHEMICAL", 135, 148], ["IBC", "DISEASE", 234, 237], ["mammalian cells", "CELL", 154, 169], ["IBC", "CANCER", 234, 237], ["mammalian cells", "CELL_TYPE", 154, 169], ["commercial products", "TREATMENT", 16, 35], ["viral vectors", "TREATMENT", 46, 59], ["commercially produced viral particles", "PROBLEM", 63, 100], ["synthetic nucleic acids", "TREATMENT", 125, 148], ["mammalian cells", "PROBLEM", 154, 169], ["drug resistance traits", "TREATMENT", 274, 296]]], ["Use of many common antimicrobial resistance markers used in molecular cloning techniques (e.g., kanamycin, puromycin, ampicillin, etc.) do not require preapproval under the major action section of the NIH Guidelines (Section III-A-1) [16] .", [["kanamycin", "CHEMICAL", 96, 105], ["puromycin", "CHEMICAL", 107, 116], ["ampicillin", "CHEMICAL", 118, 128], ["kanamycin", "CHEMICAL", 96, 105], ["puromycin", "CHEMICAL", 107, 116], ["ampicillin", "CHEMICAL", 118, 128], ["kanamycin", "SIMPLE_CHEMICAL", 96, 105], ["puromycin", "SIMPLE_CHEMICAL", 107, 116], ["ampicillin", "SIMPLE_CHEMICAL", 118, 128], ["many common antimicrobial resistance markers", "TREATMENT", 7, 51], ["molecular cloning techniques", "TREATMENT", 60, 88], ["kanamycin", "TREATMENT", 96, 105], ["puromycin", "TREATMENT", 107, 116], ["ampicillin", "TREATMENT", 118, 128]]], ["However, investigators must perform due diligence to ensure that a particular drug resistance trait will not confer resistance to a preferred treatment for use in medicine and/or agriculture.", [["a particular drug resistance trait", "PROBLEM", 65, 99]]], ["Investigators should pay particular attention to specific drugs that are no longer considered to be preferred treatment in most human or animal populations, but are still commonly used in the treatment of special populations (e.g., pregnant women, children, or immunocompromised patients; Section III-A-1-a) [16] .", [["human", "ORGANISM", 128, 133], ["women", "ORGANISM", 241, 246], ["children", "ORGANISM", 248, 256], ["patients", "ORGANISM", 279, 287], ["human", "SPECIES", 128, 133], ["women", "SPECIES", 241, 246], ["children", "SPECIES", 248, 256], ["patients", "SPECIES", 279, 287], ["human", "SPECIES", 128, 133], ["treatment", "TREATMENT", 110, 119]]], ["In general, incidents that involve noncompliance with the guidelines must be reported to NIH OBA within 30 days [54] .", [["OBA", "DISEASE", 93, 96]]], ["This 30-day reporting deadline also applies to accidents or exposures involving low-risk materials (generally BL1).", [["accidents", "DISEASE", 47, 56]]], ["However, in cases of accidents or exposures to higher-risk materials, expedited reporting is required.", [["accidents", "DISEASE", 21, 30]]], ["Accidents or incidents that result in known exposure of personnel to recombinant or synthetic nucleic acids materials handled at BL2 must be reported to NIH OBA immediately [54] .", [["Accidents", "DISEASE", 0, 9], ["nucleic acids", "CHEMICAL", 94, 107], ["synthetic nucleic acids materials", "TREATMENT", 84, 117]]], ["The reporting requirement deadlines for work with recombinant or synthetic nucleic acid materials at BL3 or BL4 are also clearly defined.", [["nucleic acid", "CHEMICAL", 75, 87], ["BL3", "GENE_OR_GENE_PRODUCT", 101, 104], ["BL4", "GENE_OR_GENE_PRODUCT", 108, 111], ["BL4", "PROTEIN", 108, 111], ["work with recombinant or synthetic nucleic acid materials", "PROBLEM", 40, 97]]], ["Accidents, spills, or incidents that result in either a known or a potential personnel exposure must be reported to NIH OBA immediately [54] .1.Possession of Select Agents a.", [["Accidents", "DISEASE", 0, 9], ["Select Agents", "TREATMENT", 158, 171]]], ["Clinical laboratories and research laboratories, particularly those with work that includes screening of samples to identify unknown biological agents, must be aware that the Select Agent Program requires entities that identify a select agent or toxin to notify the FSAP immediately and arrange to either transfer the agent to an entity with a current registration for possession of the select agent or toxin identified or to document destruction of the samples within seven calendar days of identification [22, 26, 27] . b.", [["samples", "ANATOMY", 454, 461], ["Clinical laboratories", "TEST", 0, 21], ["research laboratories", "TEST", 26, 47], ["screening of samples", "TEST", 92, 112], ["toxin", "TREATMENT", 246, 251], ["toxin", "PROBLEM", 403, 408], ["destruction of the samples", "PROBLEM", 435, 461]]], ["Restricted persons -All persons who have received Security Risk Assessment (SRA) approval for access to select agents and toxins are required to notify the RO of any change in personal status that could result in the loss of SRA approval.", [["persons", "ORGANISM", 11, 18], ["persons", "ORGANISM", 24, 31], ["SRA", "PROTEIN", 225, 228], ["persons", "SPECIES", 11, 18], ["persons", "SPECIES", 24, 31], ["SRA approval", "TREATMENT", 225, 237]]], ["This includes any events that would cause an individual to fall into the category of a restricted person [55] . c.", [["person", "SPECIES", 98, 104]]], ["Security Issues -Compliance with the inventory requirements of the Select Agent (SA) regulations can be particularly challenging.", [["the Select Agent (SA) regulations", "TREATMENT", 63, 96]]], ["Inventory discrepancies may result from a variety of situations, including miscounting or misplacement of regulated materials.", [["Inventory discrepancies", "PROBLEM", 0, 23], ["miscounting", "PROBLEM", 75, 86], ["misplacement of regulated materials", "PROBLEM", 90, 125], ["misplacement", "OBSERVATION", 90, 102]]], ["Animals infected with select agents must be accounted for from the time of infection to final carcass destruction.", [["carcass", "ANATOMY", 94, 101], ["infection", "DISEASE", 75, 84], ["carcass destruction", "DISEASE", 94, 113], ["Animals", "ORGANISM", 0, 7], ["carcass", "ORGANISM_SUBDIVISION", 94, 101], ["select agents", "TREATMENT", 22, 35], ["infection", "PROBLEM", 75, 84], ["final carcass destruction", "PROBLEM", 88, 113], ["infected", "OBSERVATION", 8, 16], ["infection", "OBSERVATION", 75, 84], ["destruction", "OBSERVATION", 102, 113]]], ["Documentation of destruction of materials used in in vitro experiments is required as well.", [["destruction of materials", "PROBLEM", 17, 41], ["destruction", "OBSERVATION", 17, 28]]], ["The most recent version of the regulations requires that investigators document information specifying the purpose of use, amount used, and other information each time an inventoried item is accessed [41, 56] . -Access to select agents and toxins must be restricted to personnel who are SRA approved, with additional personnel screening requirements applying to individuals with access to Tier One select agents and toxins [41] .", [["select agents", "TREATMENT", 222, 235], ["toxins", "TREATMENT", 240, 246], ["personnel screening requirements", "TREATMENT", 317, 349], ["access", "TREATMENT", 379, 385]]], ["Any personnel, including both internal employees of the entity and external personnel such as contractors, manufacturer service representatives, etc., who have not received SRA approval and have not completed any additional requirements as part of an entity's registration must be treated as a visitor.", [["SRA approval", "TREATMENT", 173, 185]]], ["Visitors must be escorted at all times by an SRA-approved individual.", [["SRA", "PROTEIN", 45, 48]]], ["This can pose a significant burden on small programs, because the escort is not permitted to have any duties in addition to serving as an escort [41] . -An entity is required to have detailed procedures to detect and respond to breaches in physical and information security and to perform annual drills or exercises to ensure that these procedures are effective [41] .", [["a significant burden on small programs", "PROBLEM", 14, 52], ["detailed procedures", "TEST", 183, 202], ["annual drills or exercises", "TREATMENT", 289, 315], ["significant", "OBSERVATION_MODIFIER", 16, 27], ["burden", "OBSERVATION", 28, 34], ["small", "OBSERVATION_MODIFIER", 38, 43]]], ["It is the opinion of the authors that, while most entities are in compliance with the obvious requirements for physical and information security (e.g., building security and access control measures, firewall protection of information systems, etc.), it is often challenging to deal with the more subtle implications of these security requirements.", [["access control measures", "TREATMENT", 174, 197]]], ["Some examples include failure to collect proximity cards, remove access levels associated with proximity cards, and terminate access to electronic inventory records and other regulated electronic information upon termination of an individual's employment with an entity. d.", [["failure", "PROBLEM", 22, 29], ["an individual's employment", "TREATMENT", 228, 254], ["failure", "OBSERVATION", 22, 29]]], ["Biosafety Issues -The FSAP inspection process is based on compliance with best practices specified in the BMBL and the NIH Guidelines.", [["The FSAP inspection process", "TREATMENT", 18, 45]]], ["During routine, scheduled, and unannounced inspection processes, FSAP inspectors use extensive checklists based on these guidance documents [41] .", [["unannounced inspection processes", "TEST", 31, 63], ["extensive checklists", "TEST", 85, 105]]], ["One common challenge for entities involves the requirement in the most recent edition of the BMBL for annual reverification of ventilation controls under routine operational and failure scenarios to ensure that BSL-3 and BSL-4 facilities are capable of meeting performance standards required for containment of infectious agents. e.", [["BSL-3", "GENE_OR_GENE_PRODUCT", 211, 216], ["annual reverification of ventilation controls", "TREATMENT", 102, 147], ["routine operational and failure scenarios", "TREATMENT", 154, 195], ["BSL", "TEST", 211, 214], ["BSL", "TEST", 221, 224], ["infectious agents", "TREATMENT", 311, 328]]], ["Investigators must be aware that introduction of or selection for drug resistance traits that could confer resistance to agents used to treat diseases caused by select agents or toxins in humans, veterinary medicine, or agriculture requires preapproval from the FSAP [41] .", [["humans", "ORGANISM", 188, 194], ["humans", "SPECIES", 188, 194], ["humans", "SPECIES", 188, 194], ["drug resistance traits", "TREATMENT", 66, 88], ["agents", "TREATMENT", 121, 127], ["diseases", "PROBLEM", 142, 150], ["toxins", "PROBLEM", 178, 184], ["veterinary medicine", "TREATMENT", 196, 215]]], ["If an investigator plans to obtain a strain of a select agent or toxin containing drug resistance traits from another investigator or commercial repository, the entity's RO must be notified well in advance so that the appropriate approvals can be obtained. f.", [["f.", "SPECIES", 257, 259], ["a select agent", "TREATMENT", 47, 61], ["toxin", "TREATMENT", 65, 70], ["drug resistance traits", "TREATMENT", 82, 104]]], ["Release of Select Agents and Toxins -The main regulatory mandate of the FSAP is to prevent the theft, loss, or release of select agents and toxins.", [["FSAP", "CHEMICAL", 72, 76], ["FSAP", "SIMPLE_CHEMICAL", 72, 76], ["Select Agents", "TREATMENT", 11, 24], ["Toxins", "TREATMENT", 29, 35], ["the FSAP", "TREATMENT", 68, 76], ["select agents", "TREATMENT", 122, 135], ["toxins", "PROBLEM", 140, 146]]], ["It can be challenging for entities to determine whether a particular scenario constitutes a release of select agents and toxins that must be reported to the FSAP.", [["a release of select agents", "TREATMENT", 90, 116], ["toxins", "PROBLEM", 121, 127]]], ["Some scenarios that require mandatory reporting include known personnel exposures to select agents and toxins (e.g., failure of respiratory protection, percutaneous injury with contaminated sharps, etc.), a spill outside of a primary containment device, or failure of an engineering control (e.g., failure of ventilation system components resulting in a reversal of airflow in a containment facility, failure of effluent decontamination systems or autoclaves, etc.) [41] . g.", [["respiratory", "ANATOMY", 128, 139], ["percutaneous", "ANATOMY", 152, 164], ["Some scenarios", "PROBLEM", 0, 14], ["toxins", "PROBLEM", 103, 109], ["respiratory protection", "TREATMENT", 128, 150], ["percutaneous injury", "PROBLEM", 152, 171], ["a primary containment device", "TREATMENT", 224, 252], ["an engineering control", "TREATMENT", 268, 290], ["failure of ventilation system components", "PROBLEM", 298, 338], ["a reversal of airflow", "PROBLEM", 352, 373], ["failure of effluent decontamination systems", "PROBLEM", 401, 444], ["autoclaves", "PROBLEM", 448, 458]]], ["Due Diligence Requirements for Research Involving Exempt Quantities of SA Toxins -The most recent version of the Select Agent Regulations requires entities to develop programmatic controls to ensure that investigators working with exempt quantities of select agent toxins are in compliance with the quantity limits that allow work to proceed without registration with the FSAP [57].CDC and USDA APHIS IPPsThe most obvious compliance issue in regard to the CDC and USDA permit programs is failure on the part of an investigator to obtain a permit prior to import of a biological agent controlled under these programs.", [["SA Toxins", "PROBLEM", 71, 80], ["programmatic controls", "TREATMENT", 167, 188], ["agent toxins", "TREATMENT", 259, 271], ["a biological agent", "TREATMENT", 565, 583], ["most obvious", "OBSERVATION_MODIFIER", 409, 421], ["compliance", "OBSERVATION", 422, 432]]], ["These conditions may consist of additional containment practices (e.g., anterooms, primary containment enclosures), specific enhancements to disinfection practices, or facility enhancements required for possession of the biological agent.", [["additional containment practices", "TREATMENT", 32, 64], ["primary containment enclosures", "TREATMENT", 83, 113], ["disinfection practices", "TREATMENT", 141, 163], ["the biological agent", "TREATMENT", 217, 237]]], ["All personnel involved in the preparation of the package and in presentation of the package to the shipper must have had adequate training in compliance with the dangerous goods shipping regulations [28, 29] .", [["the package", "TREATMENT", 45, 56]]], ["In the case of shipment of biological research materials, both the laboratory or research personnel preparing the actual package and any administrative personnel who may present the package to the shipper (e.g., Federal Express, United Parcel Service, etc.) must have appropriate training, and documentation of this training must be maintained by the institution.2.Compliance with all details of the package preparation, package labeling, and paperwork preparation must be observed [28, 29] .", [["this training", "TREATMENT", 311, 324], ["the package preparation", "TREATMENT", 396, 419], ["package labeling", "TREATMENT", 421, 437]]], ["It is common for packages to be returned to the originator or for the shipper to refuse to accept packages that are improperly labeled or presented for shipment with incomplete or improperly completed paperwork.3.Another key area of importance for investigators involves proper classification of biological materials for shipment [28, 29] .", [["area", "OBSERVATION_MODIFIER", 225, 229]]], ["While the designation of category A infectious agents is relatively straightforward, the assignment of a particular sample to either category B or an exempt specimen classification is based on the professional opinion of the individual preparing the package for shipment.", [["infectious", "OBSERVATION", 36, 46]]], ["In the opinion of the authors, the key concept for investigators to consider in classification of biological materials is whether the sample is known or may be reasonably suspected to contain a pathogen.", [["sample", "ANATOMY", 134, 140], ["a pathogen", "PROBLEM", 192, 202], ["pathogen", "OBSERVATION", 194, 202]]], ["For example, it is the opinion of the authors that patient samples obtained from a population in which there is a known outbreak of an infectious disease (animal or human) would be best categorized as category A samples.", [["samples", "ANATOMY", 59, 66], ["infectious disease", "DISEASE", 135, 153], ["patient", "ORGANISM", 51, 58], ["human", "ORGANISM", 165, 170], ["patient", "SPECIES", 51, 58], ["human", "SPECIES", 165, 170], ["human", "SPECIES", 165, 170], ["an infectious disease", "PROBLEM", 132, 153], ["infectious", "OBSERVATION", 135, 145]]], ["Again, in the opinion of the authors, most human and or animal samples may be correctly categorized as category B or exempt, unless the investigator has a reason to suspect that the samples may be infectious.Occupational Safety and Health Administration Bloodborne Pathogen Standard1.", [["samples", "ANATOMY", 63, 70], ["samples", "ANATOMY", 182, 189], ["human", "ORGANISM", 43, 48], ["human", "SPECIES", 43, 48], ["human", "SPECIES", 43, 48], ["infectious", "PROBLEM", 197, 207], ["may be", "UNCERTAINTY", 190, 196], ["infectious", "OBSERVATION", 197, 207]]], ["Specific types of PPE are addressed in the BBP standard, including use of gloves when employees may have hand contact with blood and OPIM, during phlebotomy procedures (except under certain defined situations in the regulation (CFR \u00a71910.1030(3)(ix)(d)), and when handling contaminated items or in contact with contaminated surfaces [18] .", [["hand", "ANATOMY", 105, 109], ["blood", "ANATOMY", 123, 128], ["BBP", "CHEMICAL", 43, 46], ["blood", "ORGANISM_SUBSTANCE", 123, 128], ["PPE", "TREATMENT", 18, 21], ["gloves", "TREATMENT", 74, 80], ["phlebotomy procedures", "TREATMENT", 146, 167], ["PPE", "OBSERVATION", 18, 21]]], ["Masks in combination with eye protection (e.g., goggles, glasses with side shields, or chin-length splash shields) must be worn whenever there is a reasonably anticipated risk of generation of splashes, spray, spatter, or droplets of blood or OPIM (CFR \u00a71910.1030(3)(x)), and protective clothing such as a lab gown, lab coat, or similar dedicated protective apparel is required (CFR \u00a71910.1030(3)(xii)) [18] . b.", [["eye", "ANATOMY", 26, 29], ["blood", "ANATOMY", 234, 239], ["eye", "ORGAN", 26, 29], ["blood", "ORGANISM_SUBSTANCE", 234, 239], ["Masks", "TREATMENT", 0, 5], ["eye protection", "TREATMENT", 26, 40], ["side shields", "TREATMENT", 70, 82], ["chin-length splash shields", "TREATMENT", 87, 113], ["splashes", "PROBLEM", 193, 201], ["spray", "TREATMENT", 203, 208]]], ["The BBP standard also requires that PPE be removed before leaving the work area (CFR \u00a71910.1030(3)(vii)) [18] .", [["BBP", "CHEMICAL", 4, 7], ["BBP", "SIMPLE_CHEMICAL", 4, 7], ["PPE", "TREATMENT", 36, 39]]], ["In the opinion of the authors, proper removal and storage of PPE is a commonly observed compliance issue in research and clinical settings.", [["proper removal", "TREATMENT", 31, 45], ["storage of PPE", "TREATMENT", 50, 64]]], ["In addition to proper removal of PPE, hand hygiene practices are specified in the regulation.", [["hand", "ANATOMY", 38, 42], ["hand", "ORGANISM_SUBDIVISION", 38, 42], ["proper removal of PPE", "TREATMENT", 15, 36], ["hand hygiene practices", "TREATMENT", 38, 60], ["removal", "OBSERVATION_MODIFIER", 22, 29]]], ["It is the responsibility of the employer to provide readily available handwashing facilities or, in areas where this is not feasible, to provide antiseptic hand cleansers or towelettes (BBP \u00a71910.1030, d, (2), (iii and iv)) [18] for employee use.", [["hand", "ANATOMY", 156, 160], ["antiseptic hand cleansers", "TREATMENT", 145, 170]]], ["Similarly, it is the responsibility of the employer to ensure that employees wash hands as soon as possible after removing gloves and other PPE, or in the case of an area where a sink is not readily available, to sanitize hands and follow up with handwashing with soap and water as soon as possible (BBP \u00a71910.1030, d, (2), (iii and v) [18] . c.", [["BBP", "CHEMICAL", 300, 303], ["hands", "ORGANISM_SUBDIVISION", 82, 87], ["gloves", "TREATMENT", 123, 129]]], ["In the opinion of the authors, failure of employers to provide a broad range of sizes and types of appropriate PPE in readily accessible areas can lead to reduced employee compliance with requirements for donning and doffing of PPE (BBP \u00a71910.1030, d, (3), iii) [18] .", [["BBP", "CHEMICAL", 233, 236], ["a broad range of sizes", "TREATMENT", 63, 85], ["appropriate PPE", "TREATMENT", 99, 114]]], ["For example, if gloves are ill fitting, dexterity can be adversely affected.", [["gloves", "TREATMENT", 16, 22]]], ["Likewise, laboratory coats or coverall suits that are too large or too small for an employee can restrict movement and lead to reduced compliance.", [["coverall suits", "TREATMENT", 30, 44]]], ["Providing employees with opportunities to evaluate different types and sizes of PPE (e.g., different types of face shields, safety glasses, gloves, etc.) can lead to increased compliance with PPE requirements.Training and Documentation Challengesa.", [["PPE", "PROBLEM", 80, 83], ["face shields", "TREATMENT", 110, 122], ["safety glasses", "TREATMENT", 124, 138], ["gloves", "TREATMENT", 140, 146], ["PPE requirements", "TREATMENT", 192, 208]]], ["The BBP standard requires annual training for all employees that incorporates a specified list of topics (BBP \u00a71910.1030 (g)(2)) [18] .", [["BBP", "CHEMICAL", 4, 7], ["BBP", "CHEMICAL", 106, 109], ["annual training", "TREATMENT", 26, 41], ["BBP", "TEST", 106, 109]]], ["Ensuring that all employees complete training on an annual schedule can be difficult to manage and enforce. b.", [["an annual schedule", "TREATMENT", 49, 67]]], ["The required Exposure Control Plan must be reviewed and updated annually (BBP \u00a71910.1030(c)(1)(iv)) and must include [18] : -review and addition of new tasks and procedures that may change occupational exposure classifications, and considerations of changes to employee positions that may change the exposure assessments defined in the plan; and -identification and evaluation of new technology and safer medical devices designed to eliminate or minimize occupational exposures. d.", [["procedures", "TREATMENT", 162, 172], ["the exposure assessments", "TEST", 296, 320], ["evaluation", "TEST", 366, 376], ["safer medical devices", "TREATMENT", 399, 420]]], ["SESIP Challenges -Employers are required to provide opportunities for employees directly performing work that may result in exposure to BBP or OPIM to participate in the identification, evaluation, and selection of engineering and work practice controls, including SESIPs (BBP \u00a71910.1030(c)(1)(iv)) [18] .", [["BBP", "CHEMICAL", 136, 139], ["BBP", "CHEMICAL", 136, 139], ["the identification", "TEST", 166, 184], ["evaluation", "TEST", 186, 196]]], ["It is the opinion of the authors that this evaluation process often poses a challenge for personnel involved in laboratory and animal research.", [["this evaluation", "TEST", 38, 53]]], ["Because most SESIPs are engineered specifically for use in clinical applications with human patients, SESIPs are not always available in needle gauges or configurations that lend themselves to research applications.", [["SESIPs", "CANCER", 13, 19], ["human", "ORGANISM", 86, 91], ["patients", "ORGANISM", 92, 100], ["SESIPs", "DNA", 13, 19], ["human", "SPECIES", 86, 91], ["patients", "SPECIES", 92, 100], ["human", "SPECIES", 86, 91], ["SESIPs", "TREATMENT", 102, 108]]], ["In these cases, close communication between safety and research personnel can often result in development of additional work practice controls that mitigate the risks associated with the use of non-safety engineered sharps.", [["non-safety engineered sharps", "TREATMENT", 194, 222]]], ["It should be noted that documentation of the evaluation SESIPs in a particular procedure and specific language providing scientific rationale should be retained for experiments in which research personnel determine that use of SESIPs interferes with the research goal.", [["the evaluation", "TEST", 41, 55], ["a particular procedure", "TREATMENT", 66, 88], ["SESIPs", "TREATMENT", 227, 233]]], ["Personal preference is not an acceptable rationale for noncompliance with the SESIPs provisions of the OSHA BBP standard. -In addition to requiring evaluation and implementation of SESIPs, the OSHA BBP standard also contains provisions for proper disposal of sharps devices (BBP \u00a71910.1030(d)(2)(vii)) [18] .", [["evaluation", "TEST", 148, 158], ["SESIPs", "TREATMENT", 181, 187], ["proper disposal of sharps devices", "TREATMENT", 240, 273]]], ["Disposable, one-time use sharps devices should be disposed of in an approved sharps disposal container immediately after use.", [["sharps devices", "TREATMENT", 25, 39]]], ["Needles should not be recapped, bent, broken, or otherwise handled prior to disposal.", [["Needles", "TREATMENT", 0, 7]]], ["In cases in which there is a procedural requirement for recapping of needles, a one-handed technique or specially designed engineering control (e.g., needle recapping tray) must be used (BBP \u00a71910.1030(d)(2)(vii)(B)) [18] .1.Often, the same institutional resources that are appointed to ensure compliance with guidelines and/or regulations are the most useful resource for investigators.", [["recapping of needles", "TREATMENT", 56, 76], ["a one-handed technique", "TREATMENT", 78, 100], ["engineering control (e.g., needle recapping tray", "TREATMENT", 123, 171]]], ["The personnel responsible for coordination of the IBC activities at a particular institution have a unique understanding of issues that are commonly experienced by investigators.", [["IBC", "DISEASE", 50, 53], ["IBC", "CANCER", 50, 53]]]], "c53ee84efe42f2a1273d654cdb30a2cf5f14ecd0": [["IntroductionOn December 1, 2019, a case of pneumonia of unknown etiology was reported in Wuhan, China, and a novel strain of coronavirus (SARS-CoV-2) associated with the pneumonia case was subsequently isolated on January 7, 2020 1Materials and Methods.", [["pneumonia", "DISEASE", 43, 52], ["coronavirus", "DISEASE", 125, 136], ["SARS", "DISEASE", 138, 142], ["pneumonia", "DISEASE", 170, 179], ["coronavirus", "ORGANISM", 125, 136], ["SARS-CoV-2", "ORGANISM", 138, 148], ["coronavirus", "SPECIES", 125, 136], ["SARS-CoV-2", "SPECIES", 138, 148], ["pneumonia", "PROBLEM", 43, 52], ["coronavirus", "PROBLEM", 125, 136], ["the pneumonia", "PROBLEM", 166, 179], ["pneumonia", "OBSERVATION", 43, 52], ["pneumonia", "OBSERVATION", 170, 179]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted March 30, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["The daily cumulative numbers of confirmed and suspected COVID-19 cases for the period from December 1, 2019 to February 8, 2020 were obtained from the National, Hubei Provincial and Wuhan Municipal Health and Family Planning Commissions.", [["COVID", "TEST", 56, 61]]], ["Due to a concern of under-reporting before January 20, 2020, data in this period were imputed and double-checked manually based on a range of sources, including local government reports, officially published literature and local hospital reports 9 .(which was not certified by peer review)The definitions of confirmed and suspected cases for COVID-19 have been described elsewhere in detail 8 .", [["COVID-19", "DNA", 342, 350], ["COVID", "TEST", 342, 347]]], ["We only used data from confirmed cases in the modelling and included all provinces in mainland China except for Tibet and Xinjiang where only a few confirmed cases were reported.(which was not certified by peer review)Population movement data As the capital city of Hubei Province, Wuhan has more than 11 million residents and is connected to other major cities in China via frequent buses, high-speed trains, and commercial flights.", [["Population movement data", "TEST", 218, 242], ["capital", "OBSERVATION_MODIFIER", 250, 257]]], ["It is the busiest traffic hub of central China.", [["central China", "ANATOMY_MODIFIER", 33, 46]]], ["The daily population movement from and to Wuhan increased dramatically before the Lunar New Year (starting around January 10, 2020), which accelerated the spread of COVID-19 10, 11 .", [["COVID", "TEST", 165, 170], ["movement", "OBSERVATION_MODIFIER", 21, 29]]], ["The daily population movement data into and out of Wuhan by types of transportation (i.e., long-distance bus, train and air) for the period January 10\u221223, 2020 were retrieved from an app-derived real-time location database provided by Baidu Huiyan Company, from which we constructed a travel volume matrix among different provinces.A three-stage piecewise mathematical modelWe established a continuous-time but piecewise Susceptible-Exposed-Infectious-Recovered (SEIR) meta-population model to study the transmission dynamics of COVID-19.", [["a travel volume matrix", "TREATMENT", 283, 305], ["COVID", "TEST", 529, 534], ["Infectious", "OBSERVATION", 441, 451]]], ["We modelled Wuhan city separately because of its heavy disease burden; other cities of Hubei province were modelled together.", [["its heavy disease burden", "PROBLEM", 45, 69], ["heavy", "OBSERVATION_MODIFIER", 49, 54], ["disease", "OBSERVATION", 55, 62]]], ["We divided the epidemic of COVID-19 into three developmental stages and the first two .", [["COVID", "TEST", 27, 32], ["epidemic", "OBSERVATION_MODIFIER", 15, 23]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)A three-stage piecewise mathematical modelThe copyright holder for this preprint this version posted March 30, 2020. . stages were mainly focused on Wuhan, whereas in the last stage we considered epidemics in all provinces.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 244, 264], ["epidemics", "PROBLEM", 398, 407], ["med", "ANATOMY", 105, 108]]], ["Stage 1 commenced on December 1, 2019 when the first COVID-19 case was detected, and ended on January 8, 2020, prior to the mass Lunar New Year population movement.", [["the mass", "PROBLEM", 120, 128], ["mass", "OBSERVATION", 124, 128]]], ["During this period, the disease mainly spread within Wuhan, and inter-provincial movement of infected people was ignored.", [["people", "ORGANISM", 102, 108], ["people", "SPECIES", 102, 108], ["the disease", "PROBLEM", 20, 31], ["disease", "OBSERVATION", 24, 31], ["spread", "OBSERVATION_MODIFIER", 39, 45], ["movement", "OBSERVATION_MODIFIER", 81, 89], ["infected", "OBSERVATION", 93, 101]]], ["The transmission dynamics are described by the following differential equations:A three-stage piecewise mathematical modelwhere \u0730 denotes the population size of Wuhan, \u0735 , \u202b\u0727\u202c , \u202b\u072b\u202c and \u0734 \u0749 denotes the number of susceptible, exposed (incubation), symptomatic and removed individuals, respectively.", [["symptomatic", "PROBLEM", 247, 258], ["size", "OBSERVATION_MODIFIER", 153, 157], ["symptomatic", "OBSERVATION_MODIFIER", 247, 258]]], ["Although \u202b\u072b\"\u202c \" represents infectious individuals in traditional SEIR models, we assumed all exposed individuals were also infectious and used \u202b\u072b\u202c to represent the symptomatic phase.", [["individuals", "ORGANISM", 101, 112], ["infectious individuals", "PROBLEM", 27, 49], ["all exposed individuals", "PROBLEM", 89, 112], ["infectious", "PROBLEM", 123, 133], ["infectious", "OBSERVATION", 27, 37]]], ["As it is not clear how prevalent is asymptomatic infection, we assumed for model simplicity that all exposed individuals move to the symptomatic phase.", [["infection", "DISEASE", 49, 58], ["asymptomatic infection", "PROBLEM", 36, 58], ["asymptomatic", "OBSERVATION_MODIFIER", 36, 48], ["infection", "OBSERVATION", 49, 58]]], ["The infectiousness levels of exposed and symptomatic individuals are represented by the infection forces were detected outside Wuhan during this period, and therefore we still focused on .", [["infection", "DISEASE", 88, 97], ["The infectiousness levels", "TEST", 0, 25], ["symptomatic individuals", "PROBLEM", 41, 64], ["the infection forces", "PROBLEM", 84, 104], ["symptomatic", "OBSERVATION_MODIFIER", 41, 52], ["infection", "OBSERVATION", 88, 97]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)A three-stage piecewise mathematical modelThe copyright holder for this preprint this version posted March 30, 2020. . https://doi.org/10.1101/2020.03.27.20045757 doi: medRxiv preprint Wuhan but added a migration term to reflect outbound human movement:A three-stage piecewise mathematical modeldenotes the emigration rate, measured as the number of emigration Stage 3 commenced from January 23, 2020 when a lockdown was in effect in Wuhan.A three-stage piecewise mathematical modelDue to the strictly enforced travel ban, inter-provincial human movement was significantly reduced.", [["CC", "CHEMICAL", 0, 2], ["human", "ORGANISM", 440, 445], ["human", "ORGANISM", 742, 747], ["human", "SPECIES", 440, 445], ["human", "SPECIES", 742, 747], ["human", "SPECIES", 440, 445], ["human", "SPECIES", 742, 747], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 244, 264], ["a migration term", "TREATMENT", 403, 419], ["the emigration rate", "TEST", 505, 524], ["med", "ANATOMY", 105, 108], ["three-stage", "OBSERVATION_MODIFIER", 457, 468], ["emigration", "OBSERVATION_MODIFIER", 509, 519], ["emigration", "OBSERVATION", 552, 562]]], ["Considering that the tightened control policies reduced the contact frequencies of residents within each province, we added an attenuationA three-stage piecewise mathematical modelto the infection risk from exposed individuals in their incubation period, where \u07d9 is the attenuation coefficient specific to the i-th province.", [["infection", "DISEASE", 187, 196], ["the tightened control policies", "TREATMENT", 17, 47], ["an attenuationA three-stage piecewise", "TREATMENT", 124, 161], ["infection", "OBSERVATION", 187, 196]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted March 30, 2020. . https://doi.org/10.1101/2020.03.27.20045757 doi: medRxiv preprint infection forces.", [["CC", "CHEMICAL", 0, 2], ["infection", "DISEASE", 344, 353], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv preprint infection forces", "PROBLEM", 327, 360], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["infection", "OBSERVATION", 344, 353]]], ["Recovery rate and mortality rate also differ by province, which is reasonable due to the heterogeneity in medical resources.", [["Recovery rate", "TEST", 0, 13], ["mortality rate", "TEST", 18, 32]]], ["The only parameter shared by all provinces is \u07ea , the rate of disease development which depends more on the pathogen than on the population.", [["disease development", "PROBLEM", 62, 81], ["disease", "OBSERVATION", 62, 69]]], ["The 95% confidence interval (95% CI) of the parameter was estimated by independently adding random terms to the initial parameter value during the fitting process.", [["% CI", "TEST", 31, 35], ["the parameter", "TEST", 40, 53]]], ["To assess the goodness-of-fit of the models, we calculated correlation coefficients between simulated and observed data, i.e., between model-predicted cumulative number of infections and the reported cumulativeEstimation and predictionFor Stage 2 in Wuhan, we modify the above calculation considering the population movement:Estimation and predictionFor Stage 3, since some effects dependent on time evolution are taken into account not only in equation (10) for all provinces but also in equation (13) for Wuhan, we .", [["infections", "DISEASE", 172, 182], ["infections", "PROBLEM", 172, 182], ["the above calculation", "TEST", 267, 288], ["Stage 3", "PROBLEM", 354, 361], ["infections", "OBSERVATION", 172, 182]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted March 30, 2020.Estimating the exposed population size in Wuhan in the early epidemic phaseTo retrospectively identify the number of exposed individuals in Wuhan on January 10, we developed a simplified SE model to describe the transmission among the migrating population from Wuhan to the other provinces as follows:\u202b\u202crepresents the proportion of individuals who traveled to the i-th province, and \u0747 is a correction factor for infectivity given that the contacts in transportation vehicles are likely to be much closer than in the general society.", [["CC", "CHEMICAL", 0, 2], ["SE", "DISEASE", 462, 464], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["infectivity", "PROBLEM", 687, 698], ["med", "ANATOMY", 105, 108], ["population", "OBSERVATION_MODIFIER", 298, 308], ["size", "OBSERVATION_MODIFIER", 309, 313]]], ["In this model, we used parameters estimated in Stage 2 for Wuhan and the numbers of exposed individuals in the other provinces at the beginning of Stage 3 to infer the number of exposed individuals on January 10 in Wuhan, i.e. back-estimating in time.\u202b\u202cThe numbers of exposed individuals in the other provinces at the beginning of Stage 3\u202b\u202cwere calculated from the epidemiological data.Ethics Approval.", [["numbers", "OBSERVATION_MODIFIER", 257, 264], ["exposed", "OBSERVATION_MODIFIER", 268, 275], ["individuals", "OBSERVATION_MODIFIER", 276, 287]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted March 30, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["The National Health Commission of China determined that the collection of data from human cases of COVID-19 was part of a continuing public health surveillance of a notifiable infectious disease and was thus exempt from institutional review board approval.Role of the funding sourcesThe funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.", [["infectious disease", "DISEASE", 176, 194], ["human", "ORGANISM", 84, 89], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 84, 89], ["COVID", "TEST", 99, 104], ["a notifiable infectious disease", "PROBLEM", 163, 194], ["the study", "TEST", 298, 307], ["data collection", "TEST", 337, 352], ["data analysis", "TEST", 354, 367], ["data interpretation", "TEST", 369, 388], ["infectious", "OBSERVATION", 176, 186]]], ["The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.ResultsThe stage-specific and overall correlations between model predicted and observed cumulative case numbers were >0.9 for all the provinces with the exception of Wuhan in Stage 1 (Table 1 and in Supplementary Table 1) , which was 0.785.", [["the study", "TEST", 60, 69]]], ["The less satisfactory correlation for the first stage in Wuhan city is likely caused by under-reporting during the early epidemic phase.", [["less", "OBSERVATION_MODIFIER", 4, 8], ["satisfactory", "OBSERVATION", 9, 21]]], ["The results demonstrate that the estimated \u0734 dropped drastically in Stage 2 for Wuhan and the estimated median controlled reproduction number (\u0734 ) was significantly higher in Wuhan in Stage 3 compared to th rest of Hubei.", [["the estimated \u0734", "PROBLEM", 29, 44], ["higher", "OBSERVATION_MODIFIER", 165, 171]]], ["In Stage 3, the infectivity of exposed individuals (\u07da \u0b36 ) was .", [["Stage 3", "OBSERVATION_MODIFIER", 3, 10]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted March 30, 2020. . https://doi.org/10.1101/2020.03.27.20045757 doi: medRxiv preprint significantly higher than that of the infectious individuals for both Wuhan and the rest of Hubei, suggesting that the exposed individuals had become the major source of infection after January 23, 2020.", [["CC", "CHEMICAL", 0, 2], ["infection", "DISEASE", 514, 523], ["individuals", "ORGANISM", 471, 482], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv", "TREATMENT", 327, 334], ["the exposed individuals", "PROBLEM", 459, 482], ["infection", "PROBLEM", 514, 523], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["infectious", "OBSERVATION", 382, 392], ["infection", "OBSERVATION", 514, 523]]], ["The estimated number of exposed individuals on January 10, 2020 in Wuhan is a function of the correction factor \u0747 and the number of infected individuals on January 10, 2020,\u202b\u072b\u202c.", [["number", "OBSERVATION_MODIFIER", 14, 20], ["infected", "OBSERVATION", 132, 140]]], ["As is shown in Table 3 , the number of initial exposed individuals decreases significantly as \u0747 increases, and decreases slightly at a linear trend as \u202b\u072b\u202c increases.", [["exposed", "OBSERVATION_MODIFIER", 47, 54], ["individuals", "OBSERVATION", 55, 66], ["decreases", "OBSERVATION_MODIFIER", 67, 76], ["significantly", "OBSERVATION_MODIFIER", 77, 90], ["increases", "OBSERVATION_MODIFIER", 96, 105], ["decreases", "OBSERVATION_MODIFIER", 111, 120], ["slightly", "OBSERVATION_MODIFIER", 121, 129]]], ["The estimated number of exposed individuals is much greater than the reported infectious individuals on January 17, 2020 (7 days or an incubation period after January 10, 2020) in Wuhan.DiscussionThe respectively) were about equal.", [["exposed individuals", "PROBLEM", 24, 43], ["number", "OBSERVATION_MODIFIER", 14, 20], ["exposed", "OBSERVATION_MODIFIER", 24, 31], ["individuals", "OBSERVATION", 32, 43], ["much", "OBSERVATION_MODIFIER", 47, 51], ["greater", "OBSERVATION_MODIFIER", 52, 59], ["infectious", "OBSERVATION_MODIFIER", 78, 88]]], ["However, in stage 3 the infectivity of exposed individuals was significantly greater than that of the infectious individuals, which was the case for most of the other provinces.", [["greater", "OBSERVATION_MODIFIER", 77, 84], ["infectious", "OBSERVATION", 102, 112]]], ["When symptomatic individuals were isolated .", [["individuals", "ORGANISM", 17, 28], ["symptomatic individuals", "PROBLEM", 5, 28]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted March 30, 2020. . https://doi.org/10.1101/2020.03.27.20045757 doi: medRxiv preprint and treated in time, exposed individuals then became the major source of infection after January 23, 2020.(which was not certified by peer review)We found that the estimated \u0734 value for COVID-19 in Wuhan was significantly higher than those reported for SARS and MERS.", [["CC", "CHEMICAL", 0, 2], ["infection", "DISEASE", 417, 426], ["SARS", "DISEASE", 597, 601], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv preprint", "TREATMENT", 327, 343], ["infection", "PROBLEM", 417, 426], ["COVID", "TEST", 530, 535], ["SARS", "PROBLEM", 597, 601], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["infection", "OBSERVATION", 417, 426]]], ["Since the estimated values are mostly between 2 and 3 for SARS 15 The number of cases in Wuhan in epidemic stages 1 and 2 might be substantially underreported due to various reasons.", [["SARS", "DISEASE", 58, 62], ["the estimated values", "TEST", 6, 26], ["SARS", "PROBLEM", 58, 62]]], ["To address this problem, we designed a method to estimate the epidemic scale in the first two stages.", [["a method", "TREATMENT", 37, 45]]], ["Our numerical results demonstrate a large degree of underreporting with a similar conclusion to a previous study 6 and these exposed individuals likely became a major source of intra-or inter-provincial infection.", [["infection", "DISEASE", 203, 212], ["individuals", "ORGANISM", 133, 144], ["a previous study", "TEST", 96, 112], ["intra-or inter-provincial infection", "PROBLEM", 177, 212], ["large", "OBSERVATION_MODIFIER", 36, 41], ["degree", "OBSERVATION_MODIFIER", 42, 48], ["inter-provincial", "OBSERVATION_MODIFIER", 186, 202], ["infection", "OBSERVATION", 203, 212]]], ["Underreporting of exposed individuals could lead to an underestimation of infectious individuals in stages 1 and 2.", [["exposed individuals", "PROBLEM", 18, 37], ["infectious", "OBSERVATION", 74, 84]]], ["Considering the rapidly increasing number of infectious individuals in Wuhan after January 23, 2020, our .", [["rapidly", "OBSERVATION_MODIFIER", 16, 23], ["increasing", "OBSERVATION_MODIFIER", 24, 34], ["number", "OBSERVATION_MODIFIER", 35, 41], ["infectious", "OBSERVATION_MODIFIER", 45, 55]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted March 30, 2020. . https://doi.org/10.1101/2020.03.27.20045757 doi: medRxiv preprint estimation of the initial exposed number based on the spatio-temporal piecewise structure is necessary and helpful for understanding the true early situations.(which was not certified by peer review)There are several limitations for this study.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["this study", "TEST", 577, 587], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Firstly, individuals with no or only mild symptoms might not seek treatment, and therefore, not be included in the dataset, especially for epidemic stages 1 and 2.", [["mild symptoms", "PROBLEM", 37, 50]]], ["Secondly, we did not include epidemic data from Hong Kong, Macau, Taiwan, and foreign countries.", [["foreign countries", "OBSERVATION", 78, 95]]], ["Spatial and temporal heterogeneity would have been larger if these data were included.", [["Spatial and temporal heterogeneity", "PROBLEM", 0, 34], ["these data", "TEST", 61, 71], ["temporal", "OBSERVATION_MODIFIER", 12, 20], ["heterogeneity", "OBSERVATION", 21, 34], ["larger", "OBSERVATION_MODIFIER", 51, 57]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. .", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["med", "ANATOMY", 105, 108]]]], "1c40aedf4e1de86df6aa09a091b940bef598f819": [["INTRODUCTIONMany components of the vertebrate and arthropod forebrain correspond with regard to their neural arrangements along the rostrocaudal axis and to the connections of higher integrative centres with sensory and motor pathways.", [["forebrain", "ANATOMY", 60, 69], ["neural", "ANATOMY", 102, 108], ["rostrocaudal axis", "ANATOMY", 132, 149], ["arthropod forebrain", "MULTI-TISSUE_STRUCTURE", 50, 69], ["the vertebrate and arthropod forebrain", "PROBLEM", 31, 69], ["vertebrate", "ANATOMY_MODIFIER", 35, 45], ["arthropod forebrain", "ANATOMY", 50, 69], ["rostrocaudal axis", "ANATOMY", 132, 149]]], ["In the ancient lineages from which derive, lampreys and hagfish, both proxies for ancestral vertebrates, the rostral neuropils of the forebrain encode visual and olfactory information relayed to further forebrain centers that integrate these modalities (1, 2) .", [["rostral neuropils", "ANATOMY", 109, 126], ["forebrain", "ANATOMY", 134, 143], ["forebrain centers", "ANATOMY", 203, 220], ["rostral neuropils", "MULTI-TISSUE_STRUCTURE", 109, 126], ["forebrain", "ORGAN", 134, 143], ["ancestral vertebrates", "PROBLEM", 82, 103], ["rostral", "ANATOMY_MODIFIER", 109, 116], ["forebrain", "ANATOMY", 134, 143]]], ["The same arrangements apply to crown arthropods, amongst which Onychophora offer comparable proxies of ancestral neural arrangements (3) .", [["neural", "ANATOMY", 113, 119], ["crown arthropods", "TREATMENT", 31, 47]]], ["In contrast, circuits involved in vestibular reception and integration, and by extension acoustic perception, are located in more caudal territories of the anterior brain that arise in the telencephalon of vertebrates and in the deutocerebrum of arthropods (4, 5) .INTRODUCTIONIt has been postulated that comparable brain organisation in arthropods and vertebrates is an example of genealogical correspondence, traceable to a distant pre-Cambrian ancestor by virtue of the conserved action of suites of homologous developmental control genes along anterior-posterior (AP) and dorso-ventral (DV) axes of the embryonic nervous system (6) (7) (8) (9) (10) (11) (12) (13) .INTRODUCTIONFor example, the Drosophila gene orthodenticle (otd) and its mammalian Otx homologues are required, respectively in the fly and mouse, for rostral brain development (14, 15) .", [["vestibular", "ANATOMY", 34, 44], ["caudal territories", "ANATOMY", 130, 148], ["anterior brain", "ANATOMY", 156, 170], ["telencephalon", "ANATOMY", 189, 202], ["deutocerebrum", "ANATOMY", 229, 242], ["brain", "ANATOMY", 316, 321], ["embryonic nervous system", "ANATOMY", 607, 631], ["rostral brain", "ANATOMY", 820, 833], ["vestibular", "MULTI-TISSUE_STRUCTURE", 34, 44], ["anterior brain", "ORGAN", 156, 170], ["telencephalon", "ORGAN", 189, 202], ["brain", "ORGAN", 316, 321], ["AP", "MULTI-TISSUE_STRUCTURE", 568, 570], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 607, 616], ["nervous system", "ANATOMICAL_SYSTEM", 617, 631], ["orthodenticle", "GENE_OR_GENE_PRODUCT", 714, 727], ["otd", "GENE_OR_GENE_PRODUCT", 729, 732], ["Otx", "GENE_OR_GENE_PRODUCT", 752, 755], ["mouse", "ORGANISM", 809, 814], ["brain", "ORGAN", 828, 833], ["homologous developmental control genes", "DNA", 503, 541], ["Drosophila gene orthodenticle", "DNA", 698, 727], ["otd", "DNA", 729, 732], ["mammalian Otx homologues", "DNA", 742, 766], ["Drosophila", "SPECIES", 698, 708], ["mouse", "SPECIES", 809, 814], ["Drosophila", "SPECIES", 698, 708], ["mouse", "SPECIES", 809, 814], ["extension acoustic perception", "TEST", 79, 108], ["homologous developmental control genes", "PROBLEM", 503, 541], ["the Drosophila gene orthodenticle", "PROBLEM", 694, 727], ["its mammalian Otx homologues", "TREATMENT", 738, 766], ["vestibular reception", "OBSERVATION", 34, 54], ["caudal", "ANATOMY_MODIFIER", 130, 136], ["territories", "ANATOMY_MODIFIER", 137, 148], ["anterior", "ANATOMY_MODIFIER", 156, 164], ["brain", "ANATOMY", 165, 170], ["telencephalon", "ANATOMY_MODIFIER", 189, 202], ["vertebrates", "ANATOMY_MODIFIER", 206, 217], ["anterior", "ANATOMY_MODIFIER", 548, 556], ["posterior", "ANATOMY_MODIFIER", 557, 566], ["dorso-ventral", "ANATOMY_MODIFIER", 576, 589], ["embryonic nervous", "ANATOMY", 607, 624], ["rostral", "ANATOMY_MODIFIER", 820, 827], ["brain", "ANATOMY", 828, 833]]], ["In crossphylum rescue experiments, human OTX2 restores fly brain formation in otd mutant embryos (16, 17) while fly otd can replace Otx1/2 in mouse head and forebrain formation (18, 19) .", [["brain", "ANATOMY", 59, 64], ["embryos", "ANATOMY", 89, 96], ["head", "ANATOMY", 148, 152], ["forebrain", "ANATOMY", 157, 166], ["human", "ORGANISM", 35, 40], ["OTX2", "GENE_OR_GENE_PRODUCT", 41, 45], ["brain", "ORGAN", 59, 64], ["otd mutant", "ORGANISM", 78, 88], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 89, 96], ["otd", "GENE_OR_GENE_PRODUCT", 116, 119], ["Otx1/2", "GENE_OR_GENE_PRODUCT", 132, 138], ["mouse", "ORGANISM", 142, 147], ["head", "ORGANISM_SUBDIVISION", 148, 152], ["forebrain", "ORGAN", 157, 166], ["human OTX2", "PROTEIN", 35, 45], ["Otx1", "PROTEIN", 132, 136], ["human", "SPECIES", 35, 40], ["mouse", "SPECIES", 142, 147], ["human", "SPECIES", 35, 40], ["mouse", "SPECIES", 142, 147], ["crossphylum rescue experiments", "TREATMENT", 3, 33], ["human OTX2", "TREATMENT", 35, 45], ["mutant embryos", "PROBLEM", 82, 96], ["brain", "ANATOMY", 59, 64], ["head", "ANATOMY", 148, 152], ["forebrain", "ANATOMY", 157, 166]]], ["Fly engrailed can replace Engrailed-1 in mouse midbrain-hindbrain boundary (MHB) development (20) .", [["midbrain-hindbrain", "ANATOMY", 47, 65], ["MHB", "ANATOMY", 76, 79], ["Engrailed-1", "GENE_OR_GENE_PRODUCT", 26, 37], ["mouse", "ORGANISM", 41, 46], ["midbrain", "MULTI-TISSUE_STRUCTURE", 47, 55], ["hindbrain boundary", "MULTI-TISSUE_STRUCTURE", 56, 74], ["Engrailed-1", "DNA", 26, 37], ["mouse", "SPECIES", 41, 46], ["mouse", "SPECIES", 41, 46], ["midbrain", "ANATOMY", 47, 55], ["hindbrain", "ANATOMY", 56, 65]]], ["Cross-phyletic studies further revealed corresponding patterns of developmental genetic mechanisms, information processing and pathologies of the vertebrate basal ganglia and the arthropod central complex (9, (21) (22) (23) .", [["basal ganglia", "ANATOMY", 157, 170], ["basal ganglia", "MULTI-TISSUE_STRUCTURE", 157, 170], ["Cross-phyletic studies", "TEST", 0, 22], ["developmental genetic mechanisms", "PROBLEM", 66, 98], ["pathologies of the vertebrate basal ganglia", "PROBLEM", 127, 170], ["vertebrate", "ANATOMY_MODIFIER", 146, 156], ["basal", "ANATOMY_MODIFIER", 157, 162], ["ganglia", "ANATOMY", 163, 170], ["arthropod", "ANATOMY_MODIFIER", 179, 188], ["central", "ANATOMY_MODIFIER", 189, 196]]], ["These similitudes extend to comparisons of the vertebrate hippocampus and arthropod mushroom bodies, centers that support spatial navigation, allocentric memory, and associative learning (10, 24) .INTRODUCTIONEvidence from soft tissue preservation in fossils of stem arthropods, suggests that gross cerebral arrangements typifying the four extant panarthropod lineages originated latest in the early Cambrian, implying that neural ground patterns attributed to the Panarthropoda taxon may be both ancient and extremely stable over geological time (25) .", [["hippocampus", "ANATOMY", 58, 69], ["mushroom bodies", "ANATOMY", 84, 99], ["soft tissue", "ANATOMY", 223, 234], ["stem arthropods", "ANATOMY", 262, 277], ["cerebral", "ANATOMY", 299, 307], ["neural", "ANATOMY", 424, 430], ["hippocampus", "MULTI-TISSUE_STRUCTURE", 58, 69], ["soft tissue", "TISSUE", 223, 234], ["stem arthropods", "CELL", 262, 277], ["cerebral", "ORGAN", 299, 307], ["panarthropod lineages", "CELL_TYPE", 347, 368], ["soft tissue preservation", "TREATMENT", 223, 247], ["gross cerebral arrangements", "PROBLEM", 293, 320], ["the Panarthropoda taxon", "PROBLEM", 461, 484], ["vertebrate", "ANATOMY_MODIFIER", 47, 57], ["hippocampus", "ANATOMY", 58, 69], ["arthropod", "OBSERVATION", 74, 83], ["mushroom bodies", "OBSERVATION", 84, 99], ["spatial navigation", "OBSERVATION", 122, 140], ["soft tissue", "ANATOMY", 223, 234], ["stem arthropods", "OBSERVATION", 262, 277], ["cerebral", "ANATOMY", 299, 307], ["neural ground", "OBSERVATION", 424, 437], ["stable", "OBSERVATION_MODIFIER", 519, 525]]], ["However, in the absence of detailed fossil material, resolving correspondences across phyla has to instead rely on the identification of shared developmental rules and their outcomes (21, 24) .", [["detailed fossil material", "PROBLEM", 27, 51], ["fossil material", "OBSERVATION", 36, 51]]], ["These correspondences are expected to be defined by common gene regulatory (26) and character identity networks (27) that convey positional information and evidence of phenotypic homology, albeit often highly derived (28) .", [["phenotypic homology", "PROBLEM", 168, 187]]], ["Accordingly, it is cell identities, tissues and organs that yield information about common origins and identify corresponding ground patterns across lineages (29) .INTRODUCTIONWe applied this approach using developmental genetics to compare the formation and function of the Drosophila and vertebrate midbrain hindbrain boundary region.", [["cell", "ANATOMY", 19, 23], ["tissues", "ANATOMY", 36, 43], ["organs", "ANATOMY", 48, 54], ["midbrain hindbrain", "ANATOMY", 301, 319], ["cell", "CELL", 19, 23], ["tissues", "TISSUE", 36, 43], ["organs", "ORGAN", 48, 54], ["midbrain hindbrain boundary region", "CELLULAR_COMPONENT", 301, 335], ["Drosophila", "SPECIES", 275, 285], ["Drosophila", "SPECIES", 275, 285], ["this approach", "TREATMENT", 187, 200], ["developmental genetics", "TREATMENT", 207, 229], ["cell identities", "OBSERVATION", 19, 34], ["Drosophila", "ANATOMY_MODIFIER", 275, 285], ["vertebrate", "ANATOMY_MODIFIER", 290, 300], ["midbrain", "ANATOMY", 301, 309], ["hindbrain", "ANATOMY_MODIFIER", 310, 319], ["boundary", "ANATOMY_MODIFIER", 320, 328]]], ["The vertebrate Midbrain-Hindbrain Boundary (MHB) is positioned by adjacent Otx and Gbx activity along the AP axis, and elaborated by regionspecific expression of Engrailed, Wnt, Pax2/5/8, and FGF8mediated organizer activity (30) (31) (32) (33) .", [["MHB", "CELL", 44, 47], ["Otx", "GENE_OR_GENE_PRODUCT", 75, 78], ["Gbx", "GENE_OR_GENE_PRODUCT", 83, 86], ["AP", "GENE_OR_GENE_PRODUCT", 106, 108], ["Engrailed", "GENE_OR_GENE_PRODUCT", 162, 171], ["Wnt", "GENE_OR_GENE_PRODUCT", 173, 176], ["Pax2", "GENE_OR_GENE_PRODUCT", 178, 182], ["5/8", "GENE_OR_GENE_PRODUCT", 183, 186], ["Otx", "PROTEIN", 75, 78], ["Gbx", "PROTEIN", 83, 86], ["Wnt", "PROTEIN", 173, 176], ["Pax2", "PROTEIN", 178, 182], ["5/8", "PROTEIN", 183, 186], ["Pax2", "TEST", 178, 182], ["FGF8mediated organizer activity", "TEST", 192, 223], ["vertebrate", "ANATOMY_MODIFIER", 4, 14], ["Midbrain", "ANATOMY", 15, 23], ["Hindbrain", "ANATOMY", 24, 33], ["Boundary", "ANATOMY_MODIFIER", 34, 42], ["Gbx activity", "OBSERVATION", 83, 95], ["AP axis", "ANATOMY", 106, 113], ["Engrailed", "OBSERVATION_MODIFIER", 162, 171], ["activity", "OBSERVATION_MODIFIER", 215, 223]]], ["In Drosophila, the corresponding boundary (henceforth referred to as the deutocerebral-tritocerebral boundary, DTB) is defined by comparable adjoining expression of otd and unplugged (unpg), homologs of Otx and Gbx, respectively (34) .", [["deutocerebral", "ANATOMY", 73, 86], ["otd", "GENE_OR_GENE_PRODUCT", 165, 168], ["unpg", "GENE_OR_GENE_PRODUCT", 184, 188], ["Otx", "GENE_OR_GENE_PRODUCT", 203, 206], ["Gbx", "GENE_OR_GENE_PRODUCT", 211, 214], ["DTB", "DNA", 111, 114], ["otd", "PROTEIN", 165, 168], ["unpg", "PROTEIN", 184, 188], ["Otx", "PROTEIN", 203, 206], ["Gbx", "PROTEIN", 211, 214], ["Drosophila", "SPECIES", 3, 13], ["Drosophila", "SPECIES", 3, 13], ["Gbx", "TREATMENT", 211, 214]]], ["The observation of these similar expression patterns raises a number of questions: whether they reflect a shared developmental program for the MHB and DTB; what adult brain structures derive from them; and what their function might be.", [["brain structures", "ANATOMY", 167, 183], ["DTB", "CANCER", 151, 154], ["brain structures", "MULTI-TISSUE_STRUCTURE", 167, 183], ["the MHB and DTB", "PROBLEM", 139, 154]]], ["We hypothesized that if the DTB evolutionarily corresponds to the vertebrate MHB, its formation would be mediated by gene regulatory and character identity networks homologous to those driving MHB formation.", [["DTB", "GENE_OR_GENE_PRODUCT", 28, 31], ["MHB", "GENE_OR_GENE_PRODUCT", 77, 80], ["MHB", "GENE_OR_GENE_PRODUCT", 193, 196], ["DTB", "DNA", 28, 31], ["vertebrate MHB", "DNA", 66, 80], ["MHB", "DNA", 193, 196], ["the DTB", "PROBLEM", 24, 31], ["the vertebrate MHB", "PROBLEM", 62, 80]]], ["Furthermore, if true, we expected the DTB to provide circuits mediating behaviours commensurate with those regulated, and constrained, by MHB-derived circuitry.", [["DTB", "PROTEIN", 38, 41], ["MHB", "PROTEIN", 138, 141], ["the DTB", "TEST", 34, 41]]], ["Here we describe experimental evidence verifying that the arthropod DTB indeed shares a ground pattern organization with the vertebrate MHB, including correspondence of neural circuits and their behavioral functions.RESULTSWe focused on phylotypic (35) stage 11-14 embryos to characterize morphological and molecular signatures of the developing Drosophila DTB.", [["neural", "ANATOMY", 169, 175], ["embryos", "ANATOMY", 265, 272], ["DTB", "ANATOMY", 357, 360], ["DTB", "GENE_OR_GENE_PRODUCT", 68, 71], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 265, 272], ["Drosophila", "ORGANISM", 346, 356], ["DTB", "CANCER", 357, 360], ["DTB", "PROTEIN", 68, 71], ["Drosophila", "SPECIES", 346, 356], ["Drosophila", "SPECIES", 346, 356], ["the arthropod DTB", "TEST", 54, 71], ["the vertebrate MHB", "PROBLEM", 121, 139], ["neural circuits", "TREATMENT", 169, 184], ["phylotypic", "TEST", 237, 247], ["the developing Drosophila DTB", "PROBLEM", 331, 360], ["ground pattern", "OBSERVATION", 88, 102], ["neural circuits", "OBSERVATION", 169, 184], ["molecular signatures", "OBSERVATION", 307, 327], ["Drosophila DTB", "OBSERVATION", 346, 360]]], ["In addition to the adjoining otd and unpg expression and function reported earlier (34), we found specific domains of expression of the Pax2/5/8 homologs shaven(sv)/dPax2 and Pox neuro (Poxn), as well as engrailed (en), wingless (wg/dWnt), muscle specific homeobox (msh/dMsx), ventral nervous system defective (vnd/dNkx2), and empty spiracles (ems/dEmx) (Fig. 1A-C and SI Appendix Fig. S1A) .", [["muscle", "ANATOMY", 240, 246], ["ventral nervous system", "ANATOMY", 277, 299], ["spiracles", "ANATOMY", 333, 342], ["otd", "CANCER", 29, 32], ["unpg", "GENE_OR_GENE_PRODUCT", 37, 41], ["Pax2", "GENE_OR_GENE_PRODUCT", 136, 140], ["5/8", "GENE_OR_GENE_PRODUCT", 141, 144], ["shaven(sv)", "GENE_OR_GENE_PRODUCT", 154, 164], ["Pax2", "GENE_OR_GENE_PRODUCT", 166, 170], ["Pox neuro (Poxn)", "GENE_OR_GENE_PRODUCT", 175, 191], ["wingless", "GENE_OR_GENE_PRODUCT", 220, 228], ["wg/dWnt", "GENE_OR_GENE_PRODUCT", 230, 237], ["muscle", "ORGAN", 240, 246], ["homeobox", "GENE_OR_GENE_PRODUCT", 256, 264], ["msh", "GENE_OR_GENE_PRODUCT", 266, 269], ["dMsx", "GENE_OR_GENE_PRODUCT", 270, 274], ["ventral nervous system", "GENE_OR_GENE_PRODUCT", 277, 299], ["Nkx2", "GENE_OR_GENE_PRODUCT", 316, 320], ["spiracles", "ORGAN", 333, 342], ["S1A", "GENE_OR_GENE_PRODUCT", 386, 389], ["Pax2/5/8 homologs", "PROTEIN", 136, 153], ["shaven", "PROTEIN", 154, 160], ["sv", "PROTEIN", 161, 163], ["Pax2", "PROTEIN", 166, 170], ["Pox neuro", "PROTEIN", 175, 184], ["Poxn", "PROTEIN", 186, 190], ["engrailed", "PROTEIN", 204, 213], ["wg", "PROTEIN", 230, 232], ["dWnt", "PROTEIN", 233, 237], ["muscle specific homeobox", "PROTEIN", 240, 264], ["msh", "PROTEIN", 266, 269], ["dMsx", "PROTEIN", 270, 274], ["vnd", "PROTEIN", 311, 314], ["Nkx2", "PROTEIN", 316, 320], ["empty spiracles", "DNA", 327, 342], ["ems", "DNA", 344, 347], ["dEmx", "DNA", 348, 352], ["S1A", "PROTEIN", 386, 389], ["the Pax2", "TEST", 132, 140], ["dPax2", "TREATMENT", 165, 170], ["muscle specific homeobox (msh/dMsx)", "PROBLEM", 240, 275], ["ventral nervous system defective", "PROBLEM", 277, 309], ["empty spiracles", "PROBLEM", 327, 342], ["muscle", "ANATOMY", 240, 246], ["ventral", "ANATOMY_MODIFIER", 277, 284], ["nervous system", "ANATOMY", 285, 299], ["SI Appendix", "ANATOMY", 369, 380]]], ["For axial patterning, we examined the expression and function of the key genes otd + wg (antero-posterior) and msh + vnd (dorsalventral), which revealed essential roles in DTB formation (SI Appendix Fig. S1B) .RESULTSA cardinal feature of the vertebrate MHB is its organizer activity, mainly mediated by the FGF8 effector molecule (30) (31) (32) (33) 36) .", [["DTB", "ANATOMY", 172, 175], ["otd + wg", "GENE_OR_GENE_PRODUCT", 79, 87], ["antero-posterior)", "GENE_OR_GENE_PRODUCT", 89, 106], ["msh + vnd", "GENE_OR_GENE_PRODUCT", 111, 120], ["DTB", "PATHOLOGICAL_FORMATION", 172, 175], ["S1B", "GENE_OR_GENE_PRODUCT", 204, 207], ["MHB", "GENE_OR_GENE_PRODUCT", 254, 257], ["FGF8", "GENE_OR_GENE_PRODUCT", 308, 312], ["otd", "DNA", 79, 82], ["wg", "DNA", 85, 87], ["msh", "DNA", 111, 114], ["vnd", "DNA", 117, 120], ["dorsalventral", "DNA", 122, 135], ["S1B", "PROTEIN", 204, 207], ["vertebrate MHB", "DNA", 243, 257], ["FGF8 effector molecule", "PROTEIN", 308, 330], ["msh + vnd (dorsalventral)", "PROBLEM", 111, 136], ["DTB formation", "PROBLEM", 172, 185], ["the FGF8 effector molecule", "TEST", 304, 330], ["vertebrate MHB", "OBSERVATION", 243, 257], ["organizer activity", "OBSERVATION", 265, 283], ["FGF8", "ANATOMY_MODIFIER", 308, 312]]], ["Previous studies failed to identify a DTB-related function of the FGF8 homolog branchless and its receptor breathless in embryonic brain development of Drosophila (34) .", [["embryonic brain", "ANATOMY", 121, 136], ["DTB", "GENE_OR_GENE_PRODUCT", 38, 41], ["FGF8", "GENE_OR_GENE_PRODUCT", 66, 70], ["embryonic", "MULTI-TISSUE_STRUCTURE", 121, 130], ["brain", "ORGAN", 131, 136], ["DTB", "PROTEIN", 38, 41], ["FGF8 homolog branchless", "PROTEIN", 66, 89], ["Drosophila", "SPECIES", 152, 162], ["Drosophila", "SPECIES", 152, 162], ["Previous studies", "TEST", 0, 16], ["a DTB", "TEST", 36, 41], ["the FGF8 homolog branchless", "PROBLEM", 62, 89], ["its receptor breathless", "PROBLEM", 94, 117], ["embryonic brain", "OBSERVATION", 121, 136]]], ["We now show that a second set of FGF8-like orthologs, thisbe/FGF8-like1 and pyramus/FGF8-like2 (37) , and the FGF8 receptor heartless (htl), are expressed at the DTB (SI Appendix Fig. S2) .", [["FGF8", "GENE_OR_GENE_PRODUCT", 33, 37], ["thisbe", "GENE_OR_GENE_PRODUCT", 54, 60], ["FGF8", "GENE_OR_GENE_PRODUCT", 61, 65], ["like1", "GENE_OR_GENE_PRODUCT", 66, 71], ["pyramus", "GENE_OR_GENE_PRODUCT", 76, 83], ["FGF8-like2 (37)", "GENE_OR_GENE_PRODUCT", 84, 99], ["FGF8", "GENE_OR_GENE_PRODUCT", 110, 114], ["heartless", "GENE_OR_GENE_PRODUCT", 124, 133], ["htl", "GENE_OR_GENE_PRODUCT", 135, 138], ["FGF8", "PROTEIN", 33, 37], ["thisbe", "PROTEIN", 54, 60], ["FGF8", "PROTEIN", 61, 65], ["like1", "DNA", 66, 71], ["pyramus", "DNA", 76, 83], ["FGF8", "DNA", 84, 88], ["like2", "DNA", 89, 94], ["FGF8 receptor heartless", "DNA", 110, 133], ["htl", "DNA", 135, 138], ["S2", "PROTEIN", 184, 186], ["FGF8", "TEST", 33, 37], ["orthologs", "TEST", 43, 52], ["thisbe", "TEST", 54, 60], ["FGF8", "TEST", 61, 65], ["like1", "TEST", 66, 71], ["pyramus", "TEST", 76, 83], ["FGF8", "TEST", 84, 88], ["the FGF8 receptor heartless", "TEST", 106, 133], ["Fig", "OBSERVATION_MODIFIER", 179, 182]]], ["A functional role for FGF8 signalling at the DTB was revealed by altered engrailed expression patterns ( Fig. 2A , arrows) and morphological defects affecting longitudinal connectives ( Fig. 2A, arrowheads) in embryos homozygous for a deficiency, Df(2R)BSC25, uncovering both FGF8-like1 and FGF8-like2 genomic loci, and of a htl null allele.", [["connectives", "ANATOMY", 172, 183], ["embryos", "ANATOMY", 210, 217], ["FGF8", "GENE_OR_GENE_PRODUCT", 22, 26], ["DTB", "CANCER", 45, 48], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 210, 217], ["Df(2R)BSC25", "GENE_OR_GENE_PRODUCT", 247, 258], ["FGF8", "GENE_OR_GENE_PRODUCT", 276, 280], ["like1", "GENE_OR_GENE_PRODUCT", 281, 286], ["FGF8", "GENE_OR_GENE_PRODUCT", 291, 295], ["htl", "GENE_OR_GENE_PRODUCT", 325, 328], ["FGF8", "PROTEIN", 22, 26], ["DTB", "DNA", 45, 48], ["Df(2R)BSC25", "DNA", 247, 258], ["FGF8", "DNA", 276, 280], ["like1", "DNA", 281, 286], ["FGF8", "DNA", 291, 295], ["like2 genomic loci", "DNA", 296, 314], ["htl null allele", "DNA", 325, 340], ["FGF8 signalling", "TEST", 22, 37], ["the DTB", "TEST", 41, 48], ["altered engrailed expression patterns", "PROBLEM", 65, 102], ["morphological defects", "PROBLEM", 127, 148], ["longitudinal connectives", "PROBLEM", 159, 183], ["embryos homozygous", "PROBLEM", 210, 228], ["a deficiency", "PROBLEM", 233, 245], ["BSC25", "TEST", 253, 258], ["FGF8", "TEST", 276, 280], ["FGF8", "TEST", 291, 295], ["genomic loci", "TEST", 302, 314], ["a htl null allele", "PROBLEM", 323, 340], ["engrailed expression", "OBSERVATION", 73, 93], ["morphological defects", "OBSERVATION", 127, 148]]], ["These observations were further substantiated by progressive changes and loss of the DTB expression patterns of unpg and ems in htl null mutant embryos, between embryonic stages 12-16 (Fig. 2B) .", [["embryos", "ANATOMY", 144, 151], ["embryonic", "ANATOMY", 161, 170], ["DTB", "GENE_OR_GENE_PRODUCT", 85, 88], ["unpg", "GENE_OR_GENE_PRODUCT", 112, 116], ["htl", "GENE_OR_GENE_PRODUCT", 128, 131], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 144, 151], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 161, 170], ["DTB", "PROTEIN", 85, 88], ["progressive changes", "PROBLEM", 49, 68], ["loss of the DTB expression patterns", "PROBLEM", 73, 108], ["htl null mutant embryos", "PROBLEM", 128, 151], ["embryonic stages", "TEST", 161, 177], ["progressive", "OBSERVATION_MODIFIER", 49, 60], ["mutant embryos", "OBSERVATION", 137, 151]]], ["These data identify a role of FGF8-like signalling in the maintenance of the embryonic DTB region in Drosophila.", [["embryonic DTB region", "ANATOMY", 77, 97], ["FGF8", "GENE_OR_GENE_PRODUCT", 30, 34], ["embryonic DTB", "MULTI-TISSUE_STRUCTURE", 77, 90], ["FGF8", "PROTEIN", 30, 34], ["embryonic DTB region", "DNA", 77, 97], ["Drosophila", "SPECIES", 101, 111], ["Drosophila", "SPECIES", 101, 111], ["FGF8", "TEST", 30, 34], ["embryonic DTB", "OBSERVATION", 77, 90], ["Drosophila", "ANATOMY_MODIFIER", 101, 111]]], ["In contrast, ectopic expression of the FGF8-like homologue thisbe in ems-specific brain regions did not cause any detectable changes in morphology or molecular signatures of the DTB region (SI Appendix Fig. S3 ).", [["brain", "ANATOMY", 82, 87], ["DTB region", "ANATOMY", 178, 188], ["FGF8", "GENE_OR_GENE_PRODUCT", 39, 43], ["thisbe", "GENE_OR_GENE_PRODUCT", 59, 65], ["brain", "ORGAN", 82, 87], ["FGF8", "PROTEIN", 39, 43], ["thisbe", "DNA", 59, 65], ["ems-specific brain regions", "DNA", 69, 95], ["DTB region", "DNA", 178, 188], ["ectopic expression", "PROBLEM", 13, 31], ["the FGF8", "TEST", 35, 43], ["any detectable changes in morphology", "PROBLEM", 110, 146], ["molecular signatures of the DTB region", "PROBLEM", 150, 188], ["brain", "ANATOMY", 82, 87], ["detectable", "OBSERVATION_MODIFIER", 114, 124], ["changes", "OBSERVATION", 125, 132], ["Appendix Fig", "OBSERVATION", 193, 205]]], ["Despite conserved regulatory interactions between otd/Otx and unpg/Gbx (34) , these data indicate the absence of FGF8-mediated organizer activity in the embryonic DTB.", [["embryonic DTB", "ANATOMY", 153, 166], ["otd", "GENE_OR_GENE_PRODUCT", 50, 53], ["Otx", "GENE_OR_GENE_PRODUCT", 54, 57], ["unpg", "GENE_OR_GENE_PRODUCT", 62, 66], ["Gbx (34)", "GENE_OR_GENE_PRODUCT", 67, 75], ["FGF8", "GENE_OR_GENE_PRODUCT", 113, 117], ["embryonic DTB", "CELL", 153, 166], ["otd", "DNA", 50, 53], ["Otx", "DNA", 54, 57], ["unpg", "DNA", 62, 66], ["Gbx", "DNA", 67, 70], ["FGF8", "PROTEIN", 113, 117], ["unpg/Gbx", "TREATMENT", 62, 70], ["these data", "TEST", 78, 88], ["FGF8-mediated organizer activity", "PROBLEM", 113, 145], ["the embryonic DTB", "PROBLEM", 149, 166], ["organizer activity", "OBSERVATION", 127, 145], ["embryonic DTB", "OBSERVATION", 153, 166]]], ["We conclude that FGF8-like signalling is required for the maintenance of the embryonic DTB, but contrary to what is seen in vertebrate MHB development appears not to organize the DTB region in Drosophila.RESULTSTo identify the adult brain structures and functional modalities that arise from the embryonic DTB, we used genetic tracing of neural lineages (38, 39) .", [["embryonic DTB", "ANATOMY", 77, 90], ["MHB", "ANATOMY", 135, 138], ["DTB region", "ANATOMY", 179, 189], ["brain structures", "ANATOMY", 233, 249], ["embryonic DTB", "ANATOMY", 296, 309], ["neural", "ANATOMY", 338, 344], ["FGF8", "GENE_OR_GENE_PRODUCT", 17, 21], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 77, 86], ["DTB", "GENE_OR_GENE_PRODUCT", 87, 90], ["MHB", "CELL", 135, 138], ["DTB", "GENE_OR_GENE_PRODUCT", 179, 182], ["brain structures", "MULTI-TISSUE_STRUCTURE", 233, 249], ["embryonic DTB", "MULTI-TISSUE_STRUCTURE", 296, 309], ["neural lineages", "CELL", 338, 353], ["FGF8", "PROTEIN", 17, 21], ["embryonic DTB", "DNA", 77, 90], ["DTB region", "DNA", 179, 189], ["embryonic DTB", "CELL_TYPE", 296, 309], ["neural lineages", "CELL_TYPE", 338, 353], ["Drosophila", "SPECIES", 193, 203], ["Drosophila", "SPECIES", 193, 203], ["FGF8", "TEST", 17, 21], ["the embryonic DTB", "TREATMENT", 73, 90], ["the embryonic DTB", "TEST", 292, 309], ["genetic tracing", "TEST", 319, 334], ["appears not to", "UNCERTAINTY", 151, 165], ["DTB", "OBSERVATION", 179, 182], ["Drosophila", "ANATOMY_MODIFIER", 193, 203], ["neural lineages", "ANATOMY", 338, 353]]], ["We traced engrailed expressing lineages of the embryonic neuroectodermal DTB (SI Appendix Fig. S4A -C) and identified neurons and projections of the antennal mechanosensory and motor centre (AMMC) and select antennal glomeruli in the adult brain (Fig. 1D, E and SI Appendix Fig. S4D-F) .", [["embryonic neuroectodermal DTB", "ANATOMY", 47, 76], ["neurons", "ANATOMY", 118, 125], ["antennal mechanosensory", "ANATOMY", 149, 172], ["motor centre", "ANATOMY", 177, 189], ["AMMC", "ANATOMY", 191, 195], ["antennal glomeruli", "ANATOMY", 208, 226], ["brain", "ANATOMY", 240, 245], ["embryonic neuroectodermal DTB", "CELL", 47, 76], ["S4A -C", "GENE_OR_GENE_PRODUCT", 95, 101], ["neurons", "CELL", 118, 125], ["antennal mechanosensory", "MULTI-TISSUE_STRUCTURE", 149, 172], ["motor centre", "MULTI-TISSUE_STRUCTURE", 177, 189], ["AMMC", "CANCER", 191, 195], ["antennal glomeruli", "TISSUE", 208, 226], ["brain", "ORGAN", 240, 245], ["S4D-F", "GENE_OR_GENE_PRODUCT", 279, 284], ["engrailed expressing lineages", "CELL_TYPE", 10, 39], ["S4A", "PROTEIN", 95, 98], ["S4D", "PROTEIN", 279, 282], ["the embryonic neuroectodermal DTB", "PROBLEM", 43, 76], ["embryonic", "OBSERVATION_MODIFIER", 47, 56], ["neuroectodermal DTB", "OBSERVATION", 57, 76], ["Fig", "OBSERVATION_MODIFIER", 90, 93], ["adult brain", "ANATOMY", 234, 245], ["Appendix", "ANATOMY", 265, 273]]], ["We also determined the fate of Poxn expressing cells which in the embryonic brain are located next to DTB-specific engrailed lineages (Fig. 3A-H) , and in the Wedge of the adult brain where, similar to En+ cells, they express the neurotransmitter GABA ( Fig. 3I-P) .", [["cells", "ANATOMY", 47, 52], ["embryonic brain", "ANATOMY", 66, 81], ["brain", "ANATOMY", 178, 183], ["En+ cells", "ANATOMY", 202, 211], ["GABA", "CHEMICAL", 247, 251], ["GABA", "CHEMICAL", 247, 251], ["3I-P", "CHEMICAL", 259, 263], ["Poxn", "GENE_OR_GENE_PRODUCT", 31, 35], ["cells", "CELL", 47, 52], ["embryonic", "ORGAN", 66, 75], ["brain", "ORGAN", 76, 81], ["Fig. 3A-H", "CELL", 135, 144], ["brain", "ORGAN", 178, 183], ["En+ cells", "CELL", 202, 211], ["GABA", "SIMPLE_CHEMICAL", 247, 251], ["Poxn expressing cells", "CELL_LINE", 31, 52], ["DTB", "PROTEIN", 102, 105], ["engrailed lineages", "CELL_TYPE", 115, 133], ["En+ cells", "CELL_TYPE", 202, 211], ["P", "DNA", 262, 263], ["Poxn expressing cells", "PROBLEM", 31, 52], ["DTB", "TEST", 102, 105], ["embryonic", "ANATOMY_MODIFIER", 66, 75], ["brain", "ANATOMY", 76, 81], ["Wedge", "ANATOMY_MODIFIER", 159, 164], ["adult brain", "ANATOMY", 172, 183]]], ["Genetic tracing revealed that Poxn-expressing AMMC/Wedge neurons derive from DTB lineages, with their region-specific projection patterns resembling the mechanosensory pathway architecture of local interneurons and projection neurons ( Fig. 3Q-T) previously identified for the AMMC and the Wedge (40) (41) (42) (43) .RESULTSThe Drosophila AMMC and Wedge neuropils comprise neurons that mediate auditory, vestibular, mechanosensory and somatosensory information processing in pathways with similarities to the mammalian auditory and vestibular pathways (40) (41) (42) (43) .", [["AMMC/Wedge neurons", "ANATOMY", 46, 64], ["DTB lineages", "ANATOMY", 77, 89], ["interneurons", "ANATOMY", 198, 210], ["projection neurons", "ANATOMY", 215, 233], ["AMMC", "ANATOMY", 339, 343], ["Wedge neuropils", "ANATOMY", 348, 363], ["neurons", "ANATOMY", 373, 380], ["vestibular", "ANATOMY", 404, 414], ["vestibular", "ANATOMY", 532, 542], ["Poxn-", "GENE_OR_GENE_PRODUCT", 30, 35], ["AMMC", "GENE_OR_GENE_PRODUCT", 46, 50], ["Wedge neurons", "CELL", 51, 64], ["DTB lineages", "CELL", 77, 89], ["interneurons", "CELL", 198, 210], ["projection neurons", "CELL", 215, 233], ["3Q-T", "GENE_OR_GENE_PRODUCT", 241, 245], ["Drosophila AMMC", "CELL", 328, 343], ["Wedge neuropils", "CELL", 348, 363], ["neurons", "CELL", 373, 380], ["vestibular", "ORGAN", 532, 542], ["Poxn-expressing AMMC/Wedge neurons", "CELL_LINE", 30, 64], ["DTB lineages", "CELL_TYPE", 77, 89], ["projection neurons", "CELL_TYPE", 215, 233], ["Drosophila AMMC", "DNA", 328, 343], ["Drosophila", "SPECIES", 328, 338], ["Drosophila", "SPECIES", 328, 338], ["Genetic tracing", "TEST", 0, 15], ["Poxn-expressing AMMC/Wedge neurons", "PROBLEM", 30, 64], ["DTB lineages", "PROBLEM", 77, 89], ["the AMMC", "TEST", 273, 281], ["the Wedge", "TEST", 286, 295], ["RESULTSThe Drosophila AMMC", "TEST", 317, 343], ["Wedge neuropils comprise neurons", "PROBLEM", 348, 380], ["Wedge neurons", "OBSERVATION", 51, 64], ["local interneurons", "OBSERVATION", 192, 210], ["Wedge", "ANATOMY_MODIFIER", 290, 295], ["Wedge neuropils", "OBSERVATION", 348, 363], ["vestibular", "ANATOMY", 404, 414], ["vestibular", "ANATOMY", 532, 542]]], ["In vertebrates, auditory, vestibular, somatosensory and motor information, are processed by neural populations of the tectum and cerebellum, adult brain structures derived from the MHB region (36, 44) .", [["vestibular", "ANATOMY", 26, 36], ["somatosensory", "ANATOMY", 38, 51], ["neural populations", "ANATOMY", 92, 110], ["tectum", "ANATOMY", 118, 124], ["cerebellum", "ANATOMY", 129, 139], ["adult brain structures", "ANATOMY", 141, 163], ["MHB region", "ANATOMY", 181, 191], ["vestibular", "MULTI-TISSUE_STRUCTURE", 26, 36], ["tectum", "MULTI-TISSUE_STRUCTURE", 118, 124], ["cerebellum", "ORGAN", 129, 139], ["adult brain structures", "TISSUE", 141, 163], ["MHB region", "DNA", 181, 191], ["vertebrates", "ANATOMY_MODIFIER", 3, 14], ["auditory", "ANATOMY_MODIFIER", 16, 24], ["vestibular", "ANATOMY", 26, 36], ["neural populations", "OBSERVATION", 92, 110], ["tectum", "ANATOMY", 118, 124], ["cerebellum", "ANATOMY", 129, 139], ["brain", "ANATOMY", 147, 152], ["MHB", "ANATOMY_MODIFIER", 181, 184], ["region", "ANATOMY_MODIFIER", 185, 191]]], ["The tectum and cerebellum receive auditory and vestibular, as well as motor information and, among other functions, are important for balance, body posture, sensorimotor integration and motor coordination (1, 4, 45) .RESULTSTo test whether DTB-derived circuits in Drosophila might exert similar functions, the GAL4-UAS system was used to express Tetanus-Toxin-Light-Chain (TNT) and inhibit synaptic transmission (46) in subsets of AMMC neurons (41) .", [["tectum", "ANATOMY", 4, 10], ["cerebellum", "ANATOMY", 15, 25], ["vestibular", "ANATOMY", 47, 57], ["body", "ANATOMY", 143, 147], ["synaptic", "ANATOMY", 390, 398], ["AMMC neurons", "ANATOMY", 431, 443], ["tectum", "MULTI-TISSUE_STRUCTURE", 4, 10], ["cerebellum", "ORGAN", 15, 25], ["vestibular", "MULTI-TISSUE_STRUCTURE", 47, 57], ["body", "ORGANISM_SUBDIVISION", 143, 147], ["DTB", "GENE_OR_GENE_PRODUCT", 240, 243], ["Drosophila", "ORGANISM", 264, 274], ["GAL4", "GENE_OR_GENE_PRODUCT", 310, 314], ["UAS", "GENE_OR_GENE_PRODUCT", 315, 318], ["TNT", "GENE_OR_GENE_PRODUCT", 373, 376], ["AMMC neurons", "CELL", 431, 443], ["DTB", "PROTEIN", 240, 243], ["GAL4", "PROTEIN", 310, 314], ["UAS", "PROTEIN", 315, 318], ["Tetanus-Toxin-Light-Chain", "PROTEIN", 346, 371], ["AMMC neurons", "CELL_TYPE", 431, 443], ["Drosophila", "SPECIES", 264, 274], ["Drosophila", "SPECIES", 264, 274], ["RESULTSTo test", "TEST", 217, 231], ["DTB", "TEST", 240, 243], ["the GAL4-UAS system", "TEST", 306, 325], ["Tetanus", "TEST", 346, 353], ["tectum", "ANATOMY", 4, 10], ["cerebellum", "ANATOMY", 15, 25], ["vestibular", "ANATOMY", 47, 57]]], ["Flies were tested for their startle-induced negative geotaxis (SING) response, which after being shaken to the bottom in a test tube quantifies their ability to right themselves and climb upwards (47) .", [["tube", "TISSUE", 128, 132], ["their startle", "TEST", 22, 35], ["a test tube", "TREATMENT", 121, 132], ["right", "ANATOMY_MODIFIER", 161, 166]]], ["Except R19E09>TNT, all of the tested genotypes showed significantly impaired SING behaviour ( Fig. 4A and SI Appendix Table S1 ), including R79D08, R45D07 and R30A07 that target AMMC neurons and co-express engrailed, or encompass Poxn and engrailed expression domains ( Fig. 4C-I) .", [["AMMC neurons", "ANATOMY", 178, 190], ["SI Appendix Table S1", "GENE_OR_GENE_PRODUCT", 106, 126], ["AMMC neurons", "CELL", 178, 190], ["Poxn", "GENE_OR_GENE_PRODUCT", 230, 234], ["R19E09", "PROTEIN", 7, 13], ["SING", "PROTEIN", 77, 81], ["R79D08", "PROTEIN", 140, 146], ["R45D07", "PROTEIN", 148, 154], ["R30A07", "PROTEIN", 159, 165], ["AMMC neurons", "CELL_TYPE", 178, 190], ["Poxn", "PROTEIN", 230, 234], ["engrailed expression domains", "PROTEIN", 239, 267], ["Fig. 4C-I", "PROTEIN", 270, 279], ["the tested genotypes", "TEST", 26, 46], ["significantly impaired SING behaviour", "PROBLEM", 54, 91], ["R79D08", "TEST", 140, 146], ["significantly", "OBSERVATION_MODIFIER", 54, 67], ["impaired", "OBSERVATION", 68, 76]]], ["Of note, several of the tested genotypes showed difficulties with balance and to right themselves, as exemplified for R52F05>TNT compared to control (SI Appendix Movies S1 and S2).RESULTSTo further analyze AMMC-mediated motor coordination, we employed video-assisted motion tracking and recorded freely moving flies (Fig. 4B) .", [["TNT", "CHEMICAL", 125, 128], ["AMMC", "GENE_OR_GENE_PRODUCT", 206, 210], ["AMMC", "PROTEIN", 206, 210], ["the tested genotypes", "TEST", 20, 40], ["difficulties with balance", "PROBLEM", 48, 73], ["R52F05", "TEST", 118, 124], ["further analyze", "TEST", 190, 205], ["AMMC", "TEST", 206, 210], ["right", "ANATOMY_MODIFIER", 81, 86], ["S2", "ANATOMY", 176, 178]]], ["During 135-minute recordings, activity bouts and movement trajectories were analyzed to quantify locomotion parameters: frequency of episodic movements, how often they were initiated, their length and average velocity, as well as the duration and frequency of pauses.", [["activity bouts", "PROBLEM", 30, 44], ["movement trajectories", "TEST", 49, 70], ["locomotion parameters", "TEST", 97, 118], ["episodic movements", "PROBLEM", 133, 151], ["pauses", "PROBLEM", 260, 266]]], ["Response to sensory stimulation triggered by repeated mechanical shock were also recorded.", [["shock", "DISEASE", 65, 70], ["sensory stimulation", "TEST", 12, 31], ["repeated mechanical shock", "TREATMENT", 45, 70], ["sensory stimulation", "OBSERVATION", 12, 31], ["mechanical shock", "OBSERVATION", 54, 70]]], ["UAS-TNT expression by R79D08 (CG9650/dZic-B)-Gal4, which targets zone B (40-42) of the AMMC (Fig. 4C , arrows), significantly impaired overall activity and duration, with fewer actions initiated, shorter episodes of activity and their intervals, reduced velocity and distances travelled ( Fig. 4D and SI Appendix Fig. S5A ).", [["impaired overall activity", "DISEASE", 126, 151], ["UAS-TNT", "GENE_OR_GENE_PRODUCT", 0, 7], ["Zic-B)-Gal4", "GENE_OR_GENE_PRODUCT", 38, 49], ["UAS", "DNA", 0, 3], ["R79D08", "PROTEIN", 22, 28], ["CG9650", "PROTEIN", 30, 36], ["Zic", "PROTEIN", 38, 41], ["Gal4", "PROTEIN", 45, 49], ["UAS", "TEST", 0, 3], ["R79D08", "TEST", 22, 28], ["Zic", "TEST", 38, 41], ["the AMMC", "TEST", 83, 91], ["reduced velocity and distances", "PROBLEM", 246, 276], ["Gal4", "ANATOMY", 45, 49], ["impaired", "OBSERVATION_MODIFIER", 126, 134], ["overall activity", "OBSERVATION", 135, 151], ["velocity", "OBSERVATION_MODIFIER", 254, 262]]], ["UAS-TNT expression by R88B12 (en/inv)-Gal4 targeting zone A (40-42) of the AMMC (Fig. 4E , arrows) significantly impaired average and pre-stimulus speed, with shorter bouts of activity, together resulting in less distance travelled ( Fig. 4F and SI Appendix Fig. S5B ).", [["AMMC", "ANATOMY", 75, 79], ["UAS-TNT", "GENE_OR_GENE_PRODUCT", 0, 7], ["R88B12", "GENE_OR_GENE_PRODUCT", 22, 28], ["Gal4", "GENE_OR_GENE_PRODUCT", 38, 42], ["UAS", "DNA", 0, 3], ["R88B12", "PROTEIN", 22, 28], ["Gal4", "PROTEIN", 38, 42], ["UAS", "TEST", 0, 3], ["R88B12", "TEST", 22, 28], ["the AMMC", "TEST", 71, 79], ["pre-stimulus speed", "TEST", 134, 152], ["impaired", "OBSERVATION_MODIFIER", 113, 121], ["average", "OBSERVATION_MODIFIER", 122, 129]]], ["Comparable motor phenotypes were seen with R30A07 (NetA)-Gal4, which targets AMMC neurons that co-express engrailed (Fig. 4G , arrowheads; Fig. 4H and Fig. S5C ), but not with R45D07 (hth) Gal4 targeting parts of the AMMC-specific giant fiber system (Fig. 4I , J and SI Appendix Fig. S5D ).", [["AMMC neurons", "ANATOMY", 77, 89], ["R30A07 (NetA)-Gal4", "GENE_OR_GENE_PRODUCT", 43, 61], ["AMMC neurons", "CELL", 77, 89], ["Fig. 4H", "GENE_OR_GENE_PRODUCT", 139, 146], ["S5C", "GENE_OR_GENE_PRODUCT", 156, 159], ["Gal4", "GENE_OR_GENE_PRODUCT", 189, 193], ["AMMC", "GENE_OR_GENE_PRODUCT", 217, 221], ["R30A07", "PROTEIN", 43, 49], ["NetA", "PROTEIN", 51, 55], ["Gal4", "PROTEIN", 57, 61], ["AMMC neurons", "CELL_TYPE", 77, 89], ["S5C", "PROTEIN", 156, 159], ["R45D07", "PROTEIN", 176, 182], ["hth", "PROTEIN", 184, 187], ["Gal4", "PROTEIN", 189, 193], ["AMMC", "PROTEIN", 217, 221], ["S5D", "PROTEIN", 284, 287], ["the AMMC", "TEST", 213, 221]]], ["Together, with SING data, our behavioural observations establish essential functions of the AMMC for sensorimotor integration (40, 41, 43) , balance, righting reflex and motor coordination in Drosophila, behavioural manifestations similar to MHB region-derived circuits and their ancestral functions.RESULTSOur findings thus far establish correspondences between Drosophila DTB and vertebrate MHB at multiple levels including adult brain circuits and the behaviours they regulate.", [["sensorimotor", "ANATOMY", 101, 113], ["brain", "ANATOMY", 432, 437], ["AMMC", "GENE_OR_GENE_PRODUCT", 92, 96], ["Drosophila", "ORGANISM", 363, 373], ["DTB", "GENE_OR_GENE_PRODUCT", 374, 377], ["MHB", "GENE_OR_GENE_PRODUCT", 393, 396], ["brain", "ORGAN", 432, 437], ["SING", "PROTEIN", 15, 19], ["AMMC", "DNA", 92, 96], ["MHB region", "DNA", 242, 252], ["Drosophila DTB", "PROTEIN", 363, 377], ["Drosophila", "SPECIES", 192, 202], ["Drosophila", "SPECIES", 363, 373], ["Drosophila", "SPECIES", 192, 202], ["Drosophila", "SPECIES", 363, 373], ["SING data", "TEST", 15, 24], ["our behavioural observations", "TEST", 26, 54], ["sensorimotor integration", "TEST", 101, 125], ["righting reflex", "TEST", 150, 165], ["motor coordination in Drosophila", "PROBLEM", 170, 202], ["behavioural manifestations", "PROBLEM", 204, 230], ["MHB region", "TREATMENT", 242, 252], ["Drosophila DTB", "TEST", 363, 377], ["vertebrate MHB at multiple levels", "PROBLEM", 382, 415], ["adult brain circuits", "TREATMENT", 426, 446], ["brain circuits", "ANATOMY", 432, 446]]], ["We hypothesized that this will be reflected in commonalities among character identity networks of DTB and MHB that are mediated by homologous gene regulatory networks (27, 28) .", [["DTB", "GENE_OR_GENE_PRODUCT", 98, 101], ["DTB", "PROTEIN", 98, 101], ["MHB", "PROTEIN", 106, 109], ["homologous gene regulatory networks", "DNA", 131, 166]]], ["To test this hypothesis, we screened the Janelia Gal4 collection (48) for cis- Figure 2 .", [["Gal4", "GENE_OR_GENE_PRODUCT", 49, 53], ["Janelia Gal4", "DNA", 41, 53]]], ["FGF8 signalling is required for the formation and maintenance of the embryonic DTB.", [["embryonic DTB", "ANATOMY", 69, 82], ["FGF8", "GENE_OR_GENE_PRODUCT", 0, 4], ["embryonic DTB", "CELL", 69, 82], ["FGF8", "PROTEIN", 0, 4], ["embryonic DTB", "CELL_TYPE", 69, 82], ["FGF8 signalling", "TEST", 0, 15], ["the embryonic DTB", "PROBLEM", 65, 82], ["embryonic DTB", "OBSERVATION", 69, 82]]], ["Confocal images of stage 13/14 embryonic brains, in (A) immunolabelled for HRP (red) and anti-Engrailed (green/yellow), in (B) immunolabelled for HRP (red), anti-Ems (blue) and anti-\uf062-galactosidase (green/yellow), lateral views; brackets and arrows indicate deutocerebral-tritocerebral boundary (DTB).", [["embryonic brains", "ANATOMY", 31, 47], ["deutocerebral", "ANATOMY", 258, 271], ["embryonic brains", "MULTI-TISSUE_STRUCTURE", 31, 47], ["HRP", "GENE_OR_GENE_PRODUCT", 75, 78], ["HRP", "GENE_OR_GENE_PRODUCT", 146, 149], ["anti-Ems (blue)", "GENE_OR_GENE_PRODUCT", 157, 172], ["anti-\uf062-galactosidase", "SIMPLE_CHEMICAL", 177, 197], ["HRP", "PROTEIN", 75, 78], ["HRP", "PROTEIN", 146, 149], ["anti-\uf062-galactosidase", "PROTEIN", 177, 197], ["Confocal images", "TEST", 0, 15], ["stage 13/14 embryonic brains", "PROBLEM", 19, 47], ["HRP", "TEST", 75, 78], ["anti-Engrailed (green/yellow", "PROBLEM", 89, 117], ["HRP", "TEST", 146, 149], ["anti-Ems (blue", "TREATMENT", 157, 171], ["anti-\uf062-galactosidase (green/yellow)", "TREATMENT", 177, 212], ["lateral views", "TEST", 214, 227], ["brackets", "TREATMENT", 229, 237], ["arrows", "PROBLEM", 242, 248], ["deutocerebral-tritocerebral boundary", "TREATMENT", 258, 294], ["embryonic brains", "OBSERVATION", 31, 47]]], ["(A) in wildtype, the DTB is characterized by a stripe-like engrailed expression pattern, that is affected in Df(2R)BSC25, a deficiency deleting both FGF8-like1 and FGF8-like2 genomic loci, as well as in htl null mutant.", [["DTB", "CANCER", 21, 24], ["Df(2R)BSC25", "GENE_OR_GENE_PRODUCT", 109, 120], ["FGF8", "GENE_OR_GENE_PRODUCT", 149, 153], ["like1", "GENE_OR_GENE_PRODUCT", 154, 159], ["FGF8", "GENE_OR_GENE_PRODUCT", 164, 168], ["htl", "GENE_OR_GENE_PRODUCT", 203, 206], ["DTB", "DNA", 21, 24], ["FGF8-like1 and FGF8-like2 genomic loci", "DNA", 149, 187], ["htl null mutant", "PROTEIN", 203, 218], ["a stripe-like engrailed expression pattern", "PROBLEM", 45, 87], ["a deficiency", "PROBLEM", 122, 134], ["FGF8", "TEST", 149, 153], ["FGF8", "TEST", 164, 168], ["genomic loci", "PROBLEM", 175, 187], ["genomic loci", "OBSERVATION", 175, 187]]], ["Note morphological defects, especially for longitudinal connectives of deutocerebral-tritocerebral neuromeres (arrowhead) (B), transgenic unpg-lacZ control brains at embryonic stages E12, E14 and E16, respectively.", [["connectives", "ANATOMY", 56, 67], ["deutocerebral-tritocerebral neuromeres", "ANATOMY", 71, 109], ["brains", "ANATOMY", 156, 162], ["embryonic stages E12", "ANATOMY", 166, 186], ["E14", "ANATOMY", 188, 191], ["arrowhead) (B)", "GENE_OR_GENE_PRODUCT", 111, 125], ["unpg-lacZ", "GENE_OR_GENE_PRODUCT", 138, 147], ["E14", "CELL", 188, 191], ["deutocerebral-tritocerebral neuromeres", "CELL_TYPE", 71, 109], ["morphological defects", "PROBLEM", 5, 26], ["transgenic unpg", "TREATMENT", 127, 142], ["defects", "OBSERVATION", 19, 26]]], ["Progressive unpg-lacZ and ems expression patterns reveal successive formation of the DTB.", [["DTB", "DISEASE", 85, 88], ["unpg-lacZ", "GENE_OR_GENE_PRODUCT", 12, 21], ["DTB", "CANCER", 85, 88], ["Progressive unpg-lacZ", "PROBLEM", 0, 21], ["the DTB", "PROBLEM", 81, 88], ["successive", "OBSERVATION_MODIFIER", 57, 67], ["formation", "OBSERVATION_MODIFIER", 68, 77]]], ["However, in htl null mutant embryos (unpg-lacZ; htl AB42-/-), unpg and ems expression are initially visible but subsequently lost by embryonic stage 16). regulatory elements (CREs) mediating the spatio-temporal expression of developmental genes controlling DTB formation in Drosophila.", [["embryos", "ANATOMY", 28, 35], ["embryonic", "ANATOMY", 133, 142], ["DTB", "ANATOMY", 257, 260], ["htl", "GENE_OR_GENE_PRODUCT", 12, 15], ["unpg-lacZ", "GENE_OR_GENE_PRODUCT", 37, 46], ["htl AB42", "GENE_OR_GENE_PRODUCT", 48, 56], ["unpg", "GENE_OR_GENE_PRODUCT", 62, 66], ["ems", "GENE_OR_GENE_PRODUCT", 71, 74], ["DTB", "GENE_OR_GENE_PRODUCT", 257, 260], ["htl", "PROTEIN", 12, 15], ["lacZ", "DNA", 42, 46], ["AB42", "PROTEIN", 52, 56], ["unpg", "DNA", 62, 66], ["ems", "DNA", 71, 74], ["regulatory elements", "DNA", 154, 173], ["CREs", "DNA", 175, 179], ["developmental genes", "DNA", 225, 244], ["DTB", "DNA", 257, 260], ["Drosophila", "SPECIES", 274, 284], ["Drosophila", "SPECIES", 274, 284], ["htl null mutant embryos", "PROBLEM", 12, 35], ["htl AB42", "TEST", 48, 56], ["developmental genes", "PROBLEM", 225, 244], ["mutant embryos", "OBSERVATION", 21, 35], ["temporal", "OBSERVATION_MODIFIER", 202, 210], ["developmental genes", "OBSERVATION", 225, 244], ["Drosophila", "ANATOMY_MODIFIER", 274, 284]]], ["We identified CREs for msh, vnd, ems, and for thisbe/FGF8-like1 (SI Appendix Fig. S6A-E) , genes that are essential for the formation and/or maintenance of the embryonic DTB ( Fig. 2 and SI Appendix Fig. S1 and ref.", [["embryonic DTB", "ANATOMY", 160, 173], ["msh", "GENE_OR_GENE_PRODUCT", 23, 26], ["vnd", "GENE_OR_GENE_PRODUCT", 28, 31], ["ems", "GENE_OR_GENE_PRODUCT", 33, 36], ["thisbe", "GENE_OR_GENE_PRODUCT", 46, 52], ["FGF8", "GENE_OR_GENE_PRODUCT", 53, 57], ["S6A-E", "GENE_OR_GENE_PRODUCT", 82, 87], ["S1", "GENE_OR_GENE_PRODUCT", 204, 206], ["CREs", "DNA", 14, 18], ["msh", "DNA", 23, 26], ["vnd", "DNA", 28, 31], ["ems", "DNA", 33, 36], ["thisbe", "DNA", 46, 52], ["FGF8", "DNA", 53, 57], ["like1", "DNA", 58, 63], ["S6A", "PROTEIN", 82, 85], ["E", "DNA", 86, 87], ["S1", "PROTEIN", 204, 206], ["msh", "PROBLEM", 23, 26], ["thisbe", "TEST", 46, 52], ["FGF8", "TEST", 53, 57], ["the embryonic DTB", "PROBLEM", 156, 173], ["Appendix", "ANATOMY", 190, 198], ["ref", "OBSERVATION", 211, 214]]], ["In addition, we identified CREs for Wnt10, Sex combs reduced/Hox5; the Drosophila homologs of zinc finger of the cerebellum (ZIC), oddpaired (opa/dZic-A) and CG9650/dZic-B; of Purkinje cell protein 4 (PCP4), igloo (igl/dPCP4); of Ptf1a, Fer1/dPtf1a, and of Lim1 (SI Appendix Fig. S6F-J) .", [["cerebellum", "ANATOMY", 113, 123], ["Purkinje cell", "ANATOMY", 176, 189], ["zinc", "CHEMICAL", 94, 98], ["Wnt10", "GENE_OR_GENE_PRODUCT", 36, 41], ["Sex", "GENE_OR_GENE_PRODUCT", 43, 46], ["Hox5", "GENE_OR_GENE_PRODUCT", 61, 65], ["zinc finger of the", "GENE_OR_GENE_PRODUCT", 94, 112], ["cerebellum", "ORGAN", 113, 123], ["ZIC", "GENE_OR_GENE_PRODUCT", 125, 128], ["oddpaired", "GENE_OR_GENE_PRODUCT", 131, 140], ["opa", "GENE_OR_GENE_PRODUCT", 142, 145], ["dZic-A", "GENE_OR_GENE_PRODUCT", 146, 152], ["Zic-B", "GENE_OR_GENE_PRODUCT", 166, 171], ["Purkinje cell protein 4", "GENE_OR_GENE_PRODUCT", 176, 199], ["PCP4", "GENE_OR_GENE_PRODUCT", 201, 205], ["igloo", "GENE_OR_GENE_PRODUCT", 208, 213], ["igl", "GENE_OR_GENE_PRODUCT", 215, 218], ["dPCP4", "GENE_OR_GENE_PRODUCT", 219, 224], ["Ptf1a", "GENE_OR_GENE_PRODUCT", 230, 235], ["Fer1", "GENE_OR_GENE_PRODUCT", 237, 241], ["dPtf1a", "GENE_OR_GENE_PRODUCT", 242, 248], ["Lim1", "GENE_OR_GENE_PRODUCT", 257, 261], ["S6F-J", "GENE_OR_GENE_PRODUCT", 280, 285], ["CREs", "DNA", 27, 31], ["Wnt10", "DNA", 36, 41], ["Sex combs", "DNA", 43, 52], ["Hox5", "DNA", 61, 65], ["Drosophila homologs", "DNA", 71, 90], ["zinc finger", "PROTEIN", 94, 105], ["ZIC", "PROTEIN", 125, 128], ["oddpaired", "PROTEIN", 131, 140], ["opa", "PROTEIN", 142, 145], ["dZic", "PROTEIN", 146, 150], ["A", "PROTEIN", 151, 152], ["CG9650", "PROTEIN", 158, 164], ["Zic", "PROTEIN", 166, 169], ["B", "PROTEIN", 170, 171], ["Purkinje cell protein 4", "PROTEIN", 176, 199], ["PCP4", "PROTEIN", 201, 205], ["igloo", "PROTEIN", 208, 213], ["igl", "PROTEIN", 215, 218], ["dPCP4", "PROTEIN", 219, 224], ["Ptf1a", "PROTEIN", 230, 235], ["Fer1", "PROTEIN", 237, 241], ["dPtf1a", "PROTEIN", 242, 248], ["Lim1", "PROTEIN", 257, 261], ["SI Appendix Fig.", "PROTEIN", 263, 279], ["S6F", "PROTEIN", 280, 283], ["Drosophila", "SPECIES", 71, 81], ["Wnt", "TEST", 36, 39], ["Sex combs", "TEST", 43, 52], ["opa", "TEST", 142, 145], ["dZic", "TEST", 146, 150], ["Zic", "TEST", 166, 169], ["Purkinje cell protein", "TEST", 176, 197], ["PCP4", "TEST", 201, 205], ["igloo", "TEST", 208, 213], ["Ptf1a", "TEST", 230, 235], ["Fer1", "TEST", 237, 241], ["dPtf1a", "TEST", 242, 248], ["zinc finger", "ANATOMY", 94, 105], ["cerebellum", "ANATOMY", 113, 123]]], ["All mammalian homologs of these genes have been implicated in vertebrate MHB formation and the specification of midbrain-cerebellar circuitry (30) (31) (32) (33) (34) 49) as shown in SI Appendix Table S2 .RESULTSWe also identified CREs for dachshund (dac) and the Pax2 homologue shaven (sv/dPax2).", [["MHB", "ANATOMY", 73, 76], ["midbrain-cerebellar", "ANATOMY", 112, 131], ["MHB", "GENE_OR_GENE_PRODUCT", 73, 76], ["cerebellar", "MULTI-TISSUE_STRUCTURE", 121, 131], ["dachshund (dac)", "GENE_OR_GENE_PRODUCT", 240, 255], ["Pax2", "GENE_OR_GENE_PRODUCT", 264, 268], ["sv/dPax2", "GENE_OR_GENE_PRODUCT", 287, 295], ["CREs", "DNA", 231, 235], ["dachshund", "DNA", 240, 249], ["dac", "DNA", 251, 254], ["Pax2 homologue shaven", "DNA", 264, 285], ["sv", "DNA", 287, 289], ["dPax2", "DNA", 290, 295], ["cerebellar circuitry", "TEST", 121, 141], ["dachshund (dac)", "TREATMENT", 240, 255], ["the Pax2 homologue shaven", "TREATMENT", 260, 285], ["sv/dPax2", "TREATMENT", 287, 295], ["vertebrate MHB", "OBSERVATION", 62, 76], ["midbrain", "ANATOMY", 112, 120], ["cerebellar circuitry", "ANATOMY", 121, 141], ["SI Appendix", "ANATOMY", 183, 194]]], ["Consistent with engrailed/invected and Poxn-related genetic tracing of DTB-AMMC lineages, dac-specific CRE R65A11-Gal4 targeted UAS-mCD8::GFP expression to the procephalic DTB region, in derived lineages of the embryonic brain and to the AMMC in a pattern encompassed by DTB-specific engrailed and Poxn expression domains (Fig. 5A-C) .", [["procephalic DTB region", "ANATOMY", 160, 182], ["embryonic brain", "ANATOMY", 211, 226], ["AMMC", "ANATOMY", 238, 242], ["DTB-AMMC lineages", "CELL", 71, 88], ["R65A11-Gal4", "GENE_OR_GENE_PRODUCT", 107, 118], ["UAS-mCD8", "GENE_OR_GENE_PRODUCT", 128, 136], ["GFP", "GENE_OR_GENE_PRODUCT", 138, 141], ["embryonic", "ORGAN", 211, 220], ["brain", "ORGAN", 221, 226], ["AMMC", "CANCER", 238, 242], ["DTB", "GENE_OR_GENE_PRODUCT", 271, 274], ["Poxn", "GENE_OR_GENE_PRODUCT", 298, 302], ["DTB-AMMC lineages", "CELL_LINE", 71, 88], ["dac-specific CRE R65A11", "DNA", 90, 113], ["Gal4", "DNA", 114, 118], ["UAS", "DNA", 128, 131], ["mCD8", "DNA", 132, 136], ["procephalic DTB region", "DNA", 160, 182], ["DTB", "PROTEIN", 271, 274], ["engrailed and Poxn expression domains", "DNA", 284, 321], ["DTB", "TEST", 71, 74], ["AMMC lineages", "PROBLEM", 75, 88], ["CRE", "TEST", 103, 106], ["Gal4 targeted UAS", "TEST", 114, 131], ["GFP expression", "PROBLEM", 138, 152], ["DTB", "TEST", 271, 274], ["lineages", "ANATOMY_MODIFIER", 195, 203], ["embryonic brain", "ANATOMY", 211, 226]]], ["The regulatory element VT51937 (50) located within an intronic region of the sv/dPax2 locus targets Gal4 expression in a segment-specific pattern similar to endogenous sv/dPax2, including DTB expression domains (SI Appendix Fig. S7A-F) .", [["VT51937", "GENE_OR_GENE_PRODUCT", 23, 30], ["sv", "GENE_OR_GENE_PRODUCT", 77, 79], ["dPax2", "GENE_OR_GENE_PRODUCT", 80, 85], ["Gal4", "GENE_OR_GENE_PRODUCT", 100, 104], ["sv", "GENE_OR_GENE_PRODUCT", 168, 170], ["dPax2", "GENE_OR_GENE_PRODUCT", 171, 176], ["DTB", "GENE_OR_GENE_PRODUCT", 188, 191], ["S7A-F", "GENE_OR_GENE_PRODUCT", 229, 234], ["regulatory element", "DNA", 4, 22], ["VT51937", "DNA", 23, 30], ["intronic region", "DNA", 54, 69], ["sv/dPax2 locus", "DNA", 77, 91], ["Gal4", "PROTEIN", 100, 104], ["sv", "PROTEIN", 168, 170], ["dPax2", "PROTEIN", 171, 176], ["DTB expression domains", "PROTEIN", 188, 210], ["S7A", "PROTEIN", 229, 232], ["endogenous sv/dPax2", "PROBLEM", 157, 176], ["DTB expression domains", "PROBLEM", 188, 210], ["element", "OBSERVATION_MODIFIER", 15, 22], ["intronic", "OBSERVATION", 54, 62], ["sv", "ANATOMY", 77, 79], ["Gal4 expression", "OBSERVATION", 100, 115], ["endogenous sv", "OBSERVATION", 157, 170], ["Fig", "OBSERVATION_MODIFIER", 224, 227]]], ["VT51937-Gal4 mediated genetic tracing also identified cells and projections in the AMMC (SI Appendix Fig. S7G ).", [["cells", "ANATOMY", 54, 59], ["AMMC", "ANATOMY", 83, 87], ["VT51937", "CHEMICAL", 0, 7], ["Gal4", "GENE_OR_GENE_PRODUCT", 8, 12], ["cells", "CELL", 54, 59], ["VT51937", "PROTEIN", 0, 7], ["Gal4", "PROTEIN", 8, 12]]], ["Together these data identify CREs of the DTB-AMMC character identity network in Drosophila that mediate the spatio-temporal expression patterns of genes that are homologous to genes involved in the formation and specification of the vertebrate MHB and derived midbrain-cerebellar circuitry (30) (31) (32) (33) (34) 49) .RESULTSComparable to the observed genealogy of DTB-AMMC lineages in Drosophila, studies on murine brain development showed that tectum, tegmentum and cerebellar Purkinje and granule cells in the adult brain derive from the embryonic MHB (36, 44) .", [["MHB", "ANATOMY", 244, 247], ["midbrain-cerebellar", "ANATOMY", 260, 279], ["brain", "ANATOMY", 418, 423], ["tectum", "ANATOMY", 448, 454], ["tegmentum", "ANATOMY", 456, 465], ["cerebellar Purkinje", "ANATOMY", 470, 489], ["granule cells", "ANATOMY", 494, 507], ["adult brain", "ANATOMY", 515, 526], ["embryonic MHB", "ANATOMY", 543, 556], ["DTB", "GENE_OR_GENE_PRODUCT", 41, 44], ["MHB", "GENE_OR_GENE_PRODUCT", 244, 247], ["DTB-AMMC lineages", "CELL", 367, 384], ["Drosophila", "ORGANISM", 388, 398], ["murine", "ORGANISM", 411, 417], ["brain", "ORGAN", 418, 423], ["tectum", "MULTI-TISSUE_STRUCTURE", 448, 454], ["tegmentum", "CELLULAR_COMPONENT", 456, 465], ["cerebellar Purkinje", "CELL", 470, 489], ["granule cells", "CELL", 494, 507], ["adult", "ORGAN", 515, 520], ["brain", "ORGAN", 521, 526], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 543, 552], ["CREs", "DNA", 29, 33], ["DTB", "DNA", 41, 44], ["vertebrate MHB", "DNA", 233, 247], ["DTB-AMMC lineages", "CELL_LINE", 367, 384], ["cerebellar Purkinje and granule cells", "CELL_TYPE", 470, 507], ["Drosophila", "SPECIES", 80, 90], ["Drosophila", "SPECIES", 388, 398], ["murine", "SPECIES", 411, 417], ["Drosophila", "SPECIES", 80, 90], ["Drosophila", "SPECIES", 388, 398], ["the DTB", "TEST", 37, 44], ["cerebellar circuitry", "TEST", 269, 289], ["DTB", "TEST", 367, 370], ["AMMC lineages in Drosophila", "PROBLEM", 371, 398], ["murine brain development", "TEST", 411, 435], ["tectum, tegmentum and cerebellar Purkinje and granule cells", "PROBLEM", 448, 507], ["temporal", "ANATOMY_MODIFIER", 115, 123], ["midbrain", "ANATOMY", 260, 268], ["cerebellar circuitry", "ANATOMY", 269, 289], ["tectum", "ANATOMY", 448, 454], ["tegmentum", "ANATOMY", 456, 465], ["cerebellar Purkinje", "ANATOMY", 470, 489], ["granule cells", "OBSERVATION", 494, 507], ["adult brain", "ANATOMY", 515, 526], ["embryonic", "OBSERVATION_MODIFIER", 543, 552], ["MHB", "OBSERVATION_MODIFIER", 553, 556]]], ["Given the correspondences between the Drosophila DTB and vertebrate MHB gene regulatory and character identity networks, we asked whether cis-regulatory elements are conserved.", [["DTB", "GENE_OR_GENE_PRODUCT", 49, 52], ["MHB", "GENE_OR_GENE_PRODUCT", 68, 71], ["Drosophila DTB", "DNA", 38, 52], ["vertebrate MHB gene regulatory", "DNA", 57, 87], ["cis-regulatory elements", "DNA", 138, 161], ["Drosophila", "SPECIES", 38, 48], ["Drosophila", "SPECIES", 38, 48], ["the Drosophila DTB", "TEST", 34, 52]]], ["To determine potential cross-phylum CRE conservation, we utilized DTB-AMMC specific regulatory sequences and applied bioinformatics tools (51) including VISTA (52), MLAGAN (53) and EMBOSS MATCHER (54) to screen for corresponding CREs in mouse and human genomes (55) .", [["mouse", "ORGANISM", 237, 242], ["human", "ORGANISM", 247, 252], ["CRE", "DNA", 36, 39], ["DTB-AMMC specific regulatory sequences", "DNA", 66, 104], ["EMBOSS MATCHER", "DNA", 181, 195], ["CREs", "DNA", 229, 233], ["mouse and human genomes", "DNA", 237, 260], ["mouse", "SPECIES", 237, 242], ["human", "SPECIES", 247, 252], ["mouse", "SPECIES", 237, 242], ["human", "SPECIES", 247, 252], ["DTB", "TEST", 66, 69], ["bioinformatics tools", "TEST", 117, 137]]], ["Stringent selection criteria (56) were applied to identify CRE sequences that are (i) linked to the same homologous genes in the different species; (ii) there is a minimum of 62% sequence identity over at least 55 base pairs with minimum 1e -1 confidence level; (iii) the CREs are not unannotated protein sequences; and (iv) the CREs are not repetitive elements.RESULTSWe first analyzed the DTB-AMMC-specific CRE of sv/dPax2 (= VT51937 sequence) and identified non-coding CREs for mouse Pax2 and human PAX2 with extensive sequence similarities (SI Appendix Fig. S7H and data set S1), and comparable intragenic location (SI Appendix Fig. S7I) .", [["sv", "GENE_OR_GENE_PRODUCT", 416, 418], ["dPax2", "GENE_OR_GENE_PRODUCT", 419, 424], ["mouse", "ORGANISM", 481, 486], ["Pax2", "GENE_OR_GENE_PRODUCT", 487, 491], ["human", "ORGANISM", 496, 501], ["PAX2", "GENE_OR_GENE_PRODUCT", 502, 506], ["S7I", "GENE_OR_GENE_PRODUCT", 637, 640], ["CRE sequences", "DNA", 59, 72], ["homologous genes", "DNA", 105, 121], ["CREs", "DNA", 272, 276], ["protein sequences", "DNA", 297, 314], ["CREs", "DNA", 329, 333], ["repetitive elements", "DNA", 342, 361], ["DTB", "DNA", 391, 394], ["AMMC", "DNA", 395, 399], ["CRE", "DNA", 409, 412], ["sv", "DNA", 416, 418], ["dPax2", "DNA", 419, 424], ["VT51937 sequence", "DNA", 428, 444], ["non-coding CREs", "DNA", 461, 476], ["Pax2", "PROTEIN", 487, 491], ["human PAX2", "PROTEIN", 496, 506], ["S7H", "PROTEIN", 562, 565], ["S7I", "PROTEIN", 637, 640], ["mouse", "SPECIES", 481, 486], ["human", "SPECIES", 496, 501], ["mouse", "SPECIES", 481, 486], ["human", "SPECIES", 496, 501], ["Stringent selection criteria", "TEST", 0, 28], ["CRE sequences", "TEST", 59, 72], ["unannotated protein sequences", "TEST", 285, 314], ["the DTB", "TEST", 387, 394], ["AMMC", "TEST", 395, 399], ["specific CRE", "TEST", 400, 412], ["sv", "TEST", 416, 418], ["VT", "TEST", 428, 430], ["non-coding CREs", "PROBLEM", 461, 476], ["mouse Pax2", "TREATMENT", 481, 491], ["human PAX2", "TREATMENT", 496, 506], ["extensive sequence similarities", "TEST", 512, 543], ["not", "UNCERTAINTY", 338, 341], ["repetitive elements", "OBSERVATION", 342, 361], ["Appendix Fig", "OBSERVATION", 623, 635]]], ["Following this strategy, we used DTB-AMMC-specific CRE sequences for dachshund and engrailed/invected and identified corresponding human CREs conserved among vertebrates that direct MHB-specific expression in mouse for the dachshund homologs Dach1/DACH1 (Fig. 5D-F) and for the engrailed/invected homologs Engrailed2/EN2 (SI Appendix Fig. S8) .", [["human", "ORGANISM", 131, 136], ["MHB", "GENE_OR_GENE_PRODUCT", 182, 185], ["mouse", "ORGANISM", 209, 214], ["dachshund", "GENE_OR_GENE_PRODUCT", 223, 232], ["Dach1", "GENE_OR_GENE_PRODUCT", 242, 247], ["DACH1", "GENE_OR_GENE_PRODUCT", 248, 253], ["S8", "GENE_OR_GENE_PRODUCT", 339, 341], ["DTB-AMMC-specific CRE sequences", "DNA", 33, 64], ["human CREs", "DNA", 131, 141], ["MHB", "DNA", 182, 185], ["dachshund homologs", "PROTEIN", 223, 241], ["Dach1", "PROTEIN", 242, 247], ["DACH1", "PROTEIN", 248, 253], ["engrailed", "DNA", 278, 287], ["Engrailed2", "PROTEIN", 306, 316], ["EN2", "DNA", 317, 320], ["S8", "PROTEIN", 339, 341], ["human", "SPECIES", 131, 136], ["mouse", "SPECIES", 209, 214], ["human", "SPECIES", 131, 136], ["mouse", "SPECIES", 209, 214], ["DTB", "TEST", 33, 36], ["AMMC", "TEST", 37, 41], ["specific CRE sequences", "TEST", 42, 64], ["dachshund", "PROBLEM", 69, 78], ["corresponding human CREs", "PROBLEM", 117, 141]]], ["Further bioinformatics analysis identified core CRE sequences associated with dac and DACH1, en/inv and EN2 and sv and PAX2 in Drosophilidae and vertebrate genomes (SI Appendix data sets S1-S3), suggesting ancestral non-coding regulatory sequences and their function predate the radiation of insect-specific DTB and vertebrate-specific MHB circuits and morphologies.DISCUSSIONWe have identified gene regulatory and character-identity networks that underlie the formation of the deutocerebraltritocerebral boundary in Drosophila.", [["dac", "GENE_OR_GENE_PRODUCT", 78, 81], ["DACH1", "GENE_OR_GENE_PRODUCT", 86, 91], ["inv", "GENE_OR_GENE_PRODUCT", 96, 99], ["EN2", "GENE_OR_GENE_PRODUCT", 104, 107], ["sv", "GENE_OR_GENE_PRODUCT", 112, 114], ["PAX2", "GENE_OR_GENE_PRODUCT", 119, 123], ["S1-S3", "GENE_OR_GENE_PRODUCT", 187, 192], ["DTB", "GENE_OR_GENE_PRODUCT", 308, 311], ["CRE sequences", "DNA", 48, 61], ["dac", "DNA", 78, 81], ["DACH1", "DNA", 86, 91], ["inv", "DNA", 96, 99], ["EN2", "DNA", 104, 107], ["sv", "DNA", 112, 114], ["PAX2", "DNA", 119, 123], ["Drosophilidae and vertebrate genomes", "DNA", 127, 163], ["S1", "DNA", 187, 189], ["S3", "DNA", 190, 192], ["ancestral non-coding regulatory sequences", "DNA", 206, 247], ["Drosophila", "SPECIES", 517, 527], ["Drosophila", "SPECIES", 517, 527], ["Further bioinformatics analysis", "TEST", 0, 31], ["core CRE sequences", "TEST", 43, 61], ["dac", "TEST", 78, 81], ["DACH1", "TEST", 86, 91], ["EN2", "TEST", 104, 107], ["sv", "TEST", 112, 114], ["PAX2 in Drosophilidae", "TREATMENT", 119, 140], ["ancestral non-coding regulatory sequences", "PROBLEM", 206, 247], ["insect-specific DTB", "TEST", 292, 311], ["gene regulatory and character-identity networks", "PROBLEM", 395, 442], ["sv", "ANATOMY", 112, 114], ["PAX2", "OBSERVATION", 119, 123], ["vertebrate genomes", "OBSERVATION", 145, 163], ["deutocerebraltritocerebral", "ANATOMY_MODIFIER", 478, 504], ["boundary", "ANATOMY_MODIFIER", 505, 513], ["Drosophila", "ANATOMY", 517, 527]]], ["Mutant analyses reveal that otd + wg and msh + vnd, acting along the AP and DV body axes, respectively, are required for the formation of the embryonic DTB, and that FGF8-like signaling is necessary for its developmental maintenance.", [["body", "ANATOMY", 79, 83], ["embryonic DTB", "ANATOMY", 142, 155], ["otd + wg", "GENE_OR_GENE_PRODUCT", 28, 36], ["msh + vnd", "GENE_OR_GENE_PRODUCT", 41, 50], ["AP", "GENE_OR_GENE_PRODUCT", 69, 71], ["DTB", "GENE_OR_GENE_PRODUCT", 152, 155], ["FGF8", "GENE_OR_GENE_PRODUCT", 166, 170], ["otd", "PROTEIN", 28, 31], ["wg", "PROTEIN", 34, 36], ["msh", "PROTEIN", 41, 44], ["vnd", "PROTEIN", 47, 50], ["FGF8", "PROTEIN", 166, 170], ["Mutant analyses", "TEST", 0, 15], ["wg", "TEST", 34, 36], ["msh", "TEST", 41, 44], ["the embryonic DTB", "PROBLEM", 138, 155], ["FGF8", "TEST", 166, 170], ["DV body", "ANATOMY", 76, 83]]], ["Genetic tracing experiments, together with the analysis of cis-regulatory elements for engrailed/invected, dachshund and shaven/dPax2, as well as behavioral analysis after synaptic inactivation show that embryonic DTB lineages give rise to neural circuits in the AMMC/Wedge complex of the adult brain that mediate balance and motor coordination in Drosophila.", [["synaptic", "ANATOMY", 172, 180], ["embryonic DTB lineages", "ANATOMY", 204, 226], ["neural", "ANATOMY", 240, 246], ["brain", "ANATOMY", 295, 300], ["dachshund", "GENE_OR_GENE_PRODUCT", 107, 116], ["shaven", "GENE_OR_GENE_PRODUCT", 121, 127], ["dPax2", "GENE_OR_GENE_PRODUCT", 128, 133], ["embryonic DTB lineages", "CELL", 204, 226], ["AMMC", "GENE_OR_GENE_PRODUCT", 263, 267], ["Wedge", "GENE_OR_GENE_PRODUCT", 268, 273], ["brain", "ORGAN", 295, 300], ["Drosophila", "ORGANISM", 348, 358], ["cis-regulatory elements", "DNA", 59, 82], ["dachshund", "DNA", 107, 116], ["shaven", "DNA", 121, 127], ["dPax2", "DNA", 128, 133], ["embryonic DTB lineages", "CELL_TYPE", 204, 226], ["AMMC/Wedge complex", "PROTEIN", 263, 281], ["Drosophila", "SPECIES", 348, 358], ["Drosophila", "SPECIES", 348, 358], ["Genetic tracing experiments", "TEST", 0, 27], ["dachshund and shaven/dPax2", "TREATMENT", 107, 133], ["behavioral analysis", "TEST", 146, 165], ["synaptic inactivation", "TREATMENT", 172, 193], ["embryonic DTB lineages", "PROBLEM", 204, 226], ["neural circuits", "TREATMENT", 240, 255], ["neural circuits", "OBSERVATION", 240, 255], ["Wedge", "OBSERVATION", 268, 273], ["adult brain", "ANATOMY", 289, 300], ["motor coordination", "OBSERVATION", 326, 344]]], ["Together these findings establish a ground pattern of DTB formation and derived circuit function in Drosophila that corresponds to the ground pattern, gene regulatory and character identity networks of the vertebrate MHB and derived midbrain-cerebellar circuits (SI Appendix Fig. S9) .DISCUSSIONThese data imply that caudal domains of the arthropod deutocerebrum and its circuits in Drosophila correspond to the vertebrate MHB and its derived principle proprioceptive circuits (see SI Appendix Fig. S9 ).", [["DTB", "ANATOMY", 54, 57], ["MHB", "ANATOMY", 217, 220], ["midbrain-cerebellar", "ANATOMY", 233, 252], ["caudal domains", "ANATOMY", 317, 331], ["deutocerebrum", "ANATOMY", 349, 362], ["DTB", "GENE_OR_GENE_PRODUCT", 54, 57], ["Drosophila", "ORGANISM", 100, 110], ["MHB", "CELL", 217, 220], ["cerebellar circuits", "MULTI-TISSUE_STRUCTURE", 242, 261], ["S9", "GENE_OR_GENE_PRODUCT", 280, 282], ["deutocerebrum", "CANCER", 349, 362], ["Drosophila", "ORGANISM", 383, 393], ["S9", "GENE_OR_GENE_PRODUCT", 499, 501], ["vertebrate MHB", "DNA", 206, 220], ["S9", "PROTEIN", 280, 282], ["vertebrate MHB", "DNA", 412, 426], ["S9", "PROTEIN", 499, 501], ["Drosophila", "SPECIES", 100, 110], ["Drosophila", "SPECIES", 383, 393], ["Drosophila", "SPECIES", 100, 110], ["Drosophila", "SPECIES", 383, 393], ["DTB formation", "PROBLEM", 54, 67], ["caudal domains of the arthropod deutocerebrum", "PROBLEM", 317, 362], ["the vertebrate MHB", "PROBLEM", 408, 426], ["ground pattern", "OBSERVATION_MODIFIER", 36, 50], ["ground pattern", "OBSERVATION", 135, 149], ["midbrain", "ANATOMY", 233, 241], ["cerebellar circuits", "ANATOMY", 242, 261], ["Appendix Fig", "OBSERVATION", 266, 278], ["vertebrate MHB", "OBSERVATION", 412, 426]]], ["It must be emphasized here that these are not ascribed to the cerebellum, the anlage of which forms as an asegmental volume within Gbx2 and non-Hox expression domains of the developing MHB (30) (31) (32) (33) 36, 57) .", [["cerebellum", "ANATOMY", 62, 72], ["cerebellum", "ORGAN", 62, 72], ["Gbx2", "GENE_OR_GENE_PRODUCT", 131, 135], ["Gbx2", "PROTEIN", 131, 135], ["Hox expression domains", "PROTEIN", 144, 166], ["an asegmental volume", "TEST", 103, 123], ["cerebellum", "ANATOMY", 62, 72], ["non-Hox", "OBSERVATION_MODIFIER", 140, 147]]], ["In vertebrates, FGF8 signalling acts as a secondary organizer in boundary development of the MHB and by promoting growth essential for the formation of tectum and cerebellum (30) (31) (32) (33) (34) 36, 57) .", [["tectum", "ANATOMY", 152, 158], ["FGF8", "GENE_OR_GENE_PRODUCT", 16, 20], ["tectum", "MULTI-TISSUE_STRUCTURE", 152, 158], ["FGF8", "PROTEIN", 16, 20], ["MHB", "PROTEIN", 93, 96], ["tectum", "ANATOMY", 152, 158], ["cerebellum", "ANATOMY", 163, 173]]], ["We did not observe FGF8-like organizer activity in flies but a role in the maintenance of the DTB boundary, suggesting an ancestral boundary-related function for FGF8 (57) .", [["DTB", "ANATOMY", 94, 97], ["FGF8", "GENE_OR_GENE_PRODUCT", 19, 23], ["DTB", "GENE_OR_GENE_PRODUCT", 94, 97], ["FGF8", "GENE_OR_GENE_PRODUCT", 162, 166], ["FGF8", "PROTEIN", 19, 23], ["DTB boundary", "DNA", 94, 106], ["FGF8", "PROTEIN", 162, 166], ["FGF8", "TEST", 19, 23], ["the DTB boundary", "TREATMENT", 90, 106], ["FGF8", "TEST", 162, 166], ["organizer activity", "OBSERVATION", 29, 47], ["ancestral boundary", "OBSERVATION", 122, 140]]], ["Yet the absence of extended proliferative activity in Drosophila (34 and this paper) suggests that growth-related organizer activity of FGF8 is a vertebrate innovation, whereas the boundary region is defined by expression patterns of genes homologous to those observed at the Embryos and bar diagrams are oriented anterior to the left, dorsal up; brown colouring indicates boundary region.", [["Embryos", "ANATOMY", 276, 283], ["left", "ANATOMY", 330, 334], ["dorsal", "ANATOMY", 336, 342], ["FGF8", "GENE_OR_GENE_PRODUCT", 136, 140], ["anterior", "MULTI-TISSUE_STRUCTURE", 314, 322], ["FGF8", "PROTEIN", 136, 140], ["Drosophila", "SPECIES", 54, 64], ["Drosophila", "SPECIES", 54, 64], ["extended proliferative activity in Drosophila", "PROBLEM", 19, 64], ["growth-related organizer activity of FGF8", "PROBLEM", 99, 140], ["a vertebrate innovation", "PROBLEM", 144, 167], ["extended", "OBSERVATION_MODIFIER", 19, 27], ["proliferative", "OBSERVATION_MODIFIER", 28, 41], ["activity", "OBSERVATION_MODIFIER", 42, 50], ["growth", "OBSERVATION_MODIFIER", 99, 105], ["organizer activity", "OBSERVATION", 114, 132], ["vertebrate innovation", "OBSERVATION", 146, 167], ["anterior", "ANATOMY_MODIFIER", 314, 322], ["left", "ANATOMY_MODIFIER", 330, 334], ["dorsal", "ANATOMY_MODIFIER", 336, 342], ["brown colouring", "OBSERVATION", 347, 362], ["boundary region", "OBSERVATION", 373, 388]]], ["Multi-level correspondences of arthropod DTB and vertebrate MHB ground pattern organization suggest ancestral origin of gene regulatory networks (GRNs) for cephalic nervous systems >520 million years ago (Mya) that predate the radiation into protostomes and deuterostomes, and a suggested origin of the MHB-specific isthmic organizer (IsO) in the vertebrate lineage.", [["cephalic nervous systems", "ANATOMY", 156, 180], ["isthmic organizer", "ANATOMY", 316, 333], ["cephalic nervous", "ANATOMICAL_SYSTEM", 156, 172], ["IsO", "GENE_OR_GENE_PRODUCT", 335, 338], ["gene regulatory networks", "DNA", 120, 144], ["GRNs", "DNA", 146, 150], ["MHB-specific isthmic organizer", "DNA", 303, 333], ["IsO", "DNA", 335, 338], ["vertebrate lineage", "CELL_TYPE", 347, 365], ["arthropod DTB", "TEST", 31, 44], ["cephalic nervous systems", "PROBLEM", 156, 180], ["the MHB", "PROBLEM", 299, 306], ["arthropod DTB", "OBSERVATION", 31, 44], ["ancestral origin", "OBSERVATION", 100, 116], ["cephalic nervous", "ANATOMY", 156, 172], ["isthmic", "OBSERVATION_MODIFIER", 316, 323], ["vertebrate lineage", "OBSERVATION", 347, 365]]], ["Abbreviations: cg, cerebral ganglion; col, collar; dc, deutocerebrum; di, diencephalon; hb, hindbrain; mb, midbrain; Mes, Mesencephalon; Met, Metencephalon; Mye, Myelencephalon; n, neck; nc, nerve cord; pc, protocerebrum; pr, proboscis; sg, segmental ganglia; SOG, Subesophageal ganglion;sv, sensory vesicle; tc, tritocerebrum; tel, telencephalon; tr, trunk.", [["cerebral ganglion", "ANATOMY", 19, 36], ["diencephalon", "ANATOMY", 74, 86], ["hindbrain", "ANATOMY", 92, 101], ["midbrain", "ANATOMY", 107, 115], ["neck", "ANATOMY", 181, 185], ["nerve cord", "ANATOMY", 191, 201], ["protocerebrum", "ANATOMY", 207, 220], ["proboscis", "ANATOMY", 226, 235], ["sg", "ANATOMY", 237, 239], ["segmental ganglia", "ANATOMY", 241, 258], ["SOG", "ANATOMY", 260, 263], ["Subesophageal ganglion", "ANATOMY", 265, 287], ["sensory vesicle", "ANATOMY", 292, 307], ["tritocerebrum", "ANATOMY", 313, 326], ["tel", "ANATOMY", 328, 331], ["telencephalon", "ANATOMY", 333, 346], ["trunk", "ANATOMY", 352, 357], ["cerebral ganglion", "MULTI-TISSUE_STRUCTURE", 19, 36], ["diencephalon", "MULTI-TISSUE_STRUCTURE", 74, 86], ["hb", "GENE_OR_GENE_PRODUCT", 88, 90], ["hindbrain; mb", "GENE_OR_GENE_PRODUCT", 92, 105], ["midbrain", "MULTI-TISSUE_STRUCTURE", 107, 115], ["Met", "GENE_OR_GENE_PRODUCT", 137, 140], ["neck", "ORGAN", 181, 185], ["nerve cord", "TISSUE", 191, 201], ["protocerebrum", "MULTI-TISSUE_STRUCTURE", 207, 220], ["proboscis", "ORGANISM_SUBDIVISION", 226, 235], ["sg", "GENE_OR_GENE_PRODUCT", 237, 239], ["Subesophageal ganglion", "TISSUE", 265, 287], ["trunk", "ORGANISM_SUBDIVISION", 352, 357], ["deutocerebrum", "PROBLEM", 55, 68], ["di, diencephalon; hb, hindbrain; mb, midbrain", "PROBLEM", 70, 115], ["Mesencephalon", "PROBLEM", 122, 135], ["Metencephalon", "TEST", 142, 155], ["Mye", "TEST", 157, 160], ["Myelencephalon", "PROBLEM", 162, 176], ["neck; nc, nerve cord", "PROBLEM", 181, 201], ["pc, protocerebrum", "PROBLEM", 203, 220], ["proboscis", "PROBLEM", 226, 235], ["sg, segmental ganglia", "PROBLEM", 237, 258], ["Subesophageal ganglion", "PROBLEM", 265, 287], ["sensory vesicle", "PROBLEM", 292, 307], ["tc, tritocerebrum", "PROBLEM", 309, 326], ["cerebral ganglion", "ANATOMY", 19, 36], ["collar", "ANATOMY", 43, 49], ["diencephalon", "ANATOMY", 74, 86], ["hb", "ANATOMY", 88, 90], ["hindbrain", "ANATOMY", 92, 101], ["mb", "ANATOMY", 103, 105], ["midbrain", "ANATOMY", 107, 115], ["Mesencephalon", "ANATOMY", 122, 135], ["neck", "ANATOMY", 181, 185], ["nc", "ANATOMY", 187, 189], ["nerve cord", "ANATOMY", 191, 201], ["protocerebrum", "ANATOMY", 207, 220], ["sg", "ANATOMY", 237, 239], ["segmental ganglia", "ANATOMY", 241, 258], ["SOG", "ANATOMY", 260, 263], ["Subesophageal ganglion", "ANATOMY", 265, 287], ["sv", "ANATOMY", 288, 290], ["sensory vesicle", "ANATOMY", 292, 307], ["tritocerebrum", "ANATOMY", 313, 326], ["telencephalon", "ANATOMY", 333, 346], ["trunk", "ANATOMY", 352, 357]]], ["DTB/MHB (Fig. 6) .", [["DTB", "PROTEIN", 0, 3], ["MHB", "ANATOMY", 4, 7]]], ["Indeed, in spite of comparable expression domains (11, 12, 58, 59) , no phenotypic cerebellum is found in ascidians, hemichordates and cephalochordates; none of which can be assumed as proxies for ancestral vertebrates, but all of which may as likely represent highly derived and evolutionary simplified crown species.", [["cerebellum", "ANATOMY", 83, 93], ["ascidians", "ANATOMY", 106, 115], ["hemichordates", "ANATOMY", 117, 130], ["cerebellum", "ORGAN", 83, 93], ["phenotypic cerebellum", "PROBLEM", 72, 93], ["hemichordates and cephalochordates", "PROBLEM", 117, 151], ["ancestral vertebrates", "PROBLEM", 197, 218], ["evolutionary simplified crown species", "PROBLEM", 280, 317], ["no", "UNCERTAINTY", 69, 71], ["cerebellum", "ANATOMY", 83, 93], ["crown species", "OBSERVATION", 304, 317]]], ["However, ancestral circuits mediating vestibular and motor (balance) coordination, which are specified by genes and regulatory networks homologous to those described in this paper, can be found in the persisting ancient lineages of early vertebrates, lampreys and hagfish (2) .DISCUSSIONThe observed correspondences in circuit formation extend to behaviours they regulate.", [["vestibular", "ANATOMY", 38, 48], ["vestibular", "MULTI-TISSUE_STRUCTURE", 38, 48]]], ["UAS-TNT expression mediating synaptic inactivation, for example in R88B12-Gal4 and R30A07-Gal4 targeting DTB-derived sub-circuits of the AMMC/Wedge complex, results in flies with impaired balance, defective action initiation and maintenance, and compromised sequences of motor actions.", [["synaptic", "ANATOMY", 29, 37], ["UAS-TNT", "GENE_OR_GENE_PRODUCT", 0, 7], ["R88B12-Gal4", "GENE_OR_GENE_PRODUCT", 67, 78], ["R30A07-Gal4", "GENE_OR_GENE_PRODUCT", 83, 94], ["DTB", "GENE_OR_GENE_PRODUCT", 105, 108], ["AMMC", "GENE_OR_GENE_PRODUCT", 137, 141], ["Wedge", "GENE_OR_GENE_PRODUCT", 142, 147], ["UAS", "DNA", 0, 3], ["R88B12", "PROTEIN", 67, 73], ["Gal4", "PROTEIN", 74, 78], ["R30A07", "PROTEIN", 83, 89], ["Gal4", "PROTEIN", 90, 94], ["DTB", "PROTEIN", 105, 108], ["AMMC", "PROTEIN", 137, 141], ["Wedge complex", "PROTEIN", 142, 155], ["UAS", "TEST", 0, 3], ["synaptic inactivation", "PROBLEM", 29, 50], ["R88B12", "TEST", 67, 73], ["Gal4", "TEST", 74, 78], ["the AMMC/Wedge complex", "PROBLEM", 133, 155], ["impaired balance", "PROBLEM", 179, 195], ["defective action initiation", "TREATMENT", 197, 224], ["synaptic inactivation", "OBSERVATION", 29, 50], ["Wedge complex", "OBSERVATION", 142, 155], ["impaired balance", "OBSERVATION", 179, 195]]], ["These AMMC circuits have been shown to mediate auditory and vestibular information processing and coordination (40, 41) , suggesting the DTB-derived AMMC/Wedge circuits integrate mechanosensory submodalities for motor homeostasis.", [["vestibular", "ANATOMY", 60, 70], ["mechanosensory submodalities", "ANATOMY", 179, 207], ["AMMC", "GENE_OR_GENE_PRODUCT", 6, 10], ["DTB", "GENE_OR_GENE_PRODUCT", 137, 140], ["AMMC", "CELL", 149, 153], ["Wedge", "GENE_OR_GENE_PRODUCT", 154, 159], ["DTB", "PROTEIN", 137, 140], ["AMMC", "PROTEIN", 149, 153], ["These AMMC circuits", "TREATMENT", 0, 19], ["the DTB", "TEST", 133, 140], ["AMMC/Wedge circuits", "TREATMENT", 149, 168], ["motor homeostasis", "PROBLEM", 212, 229], ["Wedge circuits", "OBSERVATION", 154, 168], ["motor homeostasis", "OBSERVATION", 212, 229]]], ["These functions correspond to activity of MHB-derived acoustic and vestibular receptor pathways in vertebrates (40, 43) which, when impaired in inherited disorders, affects both auditory and vestibular functions such as seen in ataxic patients (60) .", [["vestibular", "ANATOMY", 67, 77], ["vestibular", "ANATOMY", 191, 201], ["inherited disorders", "DISEASE", 144, 163], ["ataxic", "DISEASE", 228, 234], ["vestibular receptor", "GENE_OR_GENE_PRODUCT", 67, 86], ["vestibular", "ORGAN", 191, 201], ["patients", "ORGANISM", 235, 243], ["MHB", "PROTEIN", 42, 45], ["patients", "SPECIES", 235, 243], ["impaired in inherited disorders", "PROBLEM", 132, 163], ["vestibular", "ANATOMY", 191, 201]]], ["The observed correspondences therefore suggest that similar to MHBderived circuits and their ancestral functions, the DTB-derived AMMC/Wedge circuits in Arthropoda are required for sensorimotor integration, body posture and motor coordination.", [["sensorimotor", "ANATOMY", 181, 193], ["body", "ANATOMY", 207, 211], ["DTB", "GENE_OR_GENE_PRODUCT", 118, 121], ["AMMC", "GENE_OR_GENE_PRODUCT", 130, 134], ["Wedge", "GENE_OR_GENE_PRODUCT", 135, 140], ["Arthropoda", "GENE_OR_GENE_PRODUCT", 153, 163], ["body", "ORGANISM_SUBDIVISION", 207, 211], ["MHBderived circuits", "DNA", 63, 82], ["DTB", "DNA", 118, 121], ["AMMC", "DNA", 130, 134], ["MHBderived circuits", "TREATMENT", 63, 82], ["the DTB", "TEST", 114, 121], ["AMMC/Wedge circuits in Arthropoda", "TREATMENT", 130, 163], ["sensorimotor integration", "TREATMENT", 181, 205], ["body posture", "TEST", 207, 219], ["Wedge circuits", "OBSERVATION", 135, 149]]], ["These findings identify correspondences between ground patterns of the insect DTB and vertebrate MHB that extend beyond homologous genes and their spatio-temporal expression patterns and functions, to neural circuits and behavior.DISCUSSIONThe present results identify CREs with extensive sequence similarities associated with highly conserved developmental control genes regulating boundary formation between the rostral brain and its genetically distinct caudal nervous system in insects and vertebrates.", [["neural", "ANATOMY", 201, 207], ["rostral brain", "ANATOMY", 414, 427], ["caudal nervous system", "ANATOMY", 457, 478], ["DTB", "GENE_OR_GENE_PRODUCT", 78, 81], ["MHB", "GENE_OR_GENE_PRODUCT", 97, 100], ["brain", "ORGAN", 422, 427], ["caudal nervous system", "ANATOMICAL_SYSTEM", 457, 478], ["insect DTB and vertebrate MHB", "DNA", 71, 100], ["homologous genes", "DNA", 120, 136], ["CREs", "DNA", 269, 273], ["the insect DTB and vertebrate MHB", "PROBLEM", 67, 100], ["temporal expression", "OBSERVATION", 154, 173], ["rostral", "ANATOMY_MODIFIER", 414, 421], ["brain", "ANATOMY", 422, 427], ["caudal", "ANATOMY_MODIFIER", 457, 463], ["nervous", "ANATOMY", 464, 471]]], ["Core elements of the identified CREs are conserved and are employed for the formation of corresponding circuits and roles in neuronal processing.", [["neuronal", "ANATOMY", 125, 133], ["neuronal", "CELL", 125, 133], ["Core elements", "DNA", 0, 13], ["CREs", "DNA", 32, 36]]], ["In conclusion, the corresponding ground patterns of insect DTB and vertebrate MHB suggest the early appearance in bilaterian evolution of a cephalic nervous system that evolved predictive motor homeostasis before the divergence of the protostome lineages and before the origin of deuterostomes.", [["cephalic nervous system", "ANATOMY", 140, 163], ["DTB", "GENE_OR_GENE_PRODUCT", 59, 62], ["MHB", "GENE_OR_GENE_PRODUCT", 78, 81], ["cephalic nervous system", "ANATOMICAL_SYSTEM", 140, 163], ["insect DTB", "PROTEIN", 52, 62], ["protostome lineages", "CELL_TYPE", 235, 254], ["insect DTB and vertebrate MHB", "PROBLEM", 52, 81], ["a cephalic nervous system", "PROBLEM", 138, 163], ["predictive motor homeostasis", "PROBLEM", 177, 205], ["early", "OBSERVATION_MODIFIER", 94, 99], ["bilaterian", "ANATOMY_MODIFIER", 114, 124], ["cephalic nervous", "ANATOMY", 140, 156], ["motor homeostasis", "OBSERVATION", 188, 205], ["origin", "ANATOMY_MODIFIER", 270, 276]]], ["The observed correspondences therefore hypothesize the retention across phyla of conserved regulatory mechanisms (61-64) necessary and sufficient for the formation and function of neural networks for adaptive behaviors (22) common to all animals that possess a brain.MATERIALS AND METHODSFly Strains and Genetics.", [["neural networks", "ANATOMY", 180, 195], ["brain", "ANATOMY", 261, 266], ["neural networks", "MULTI-TISSUE_STRUCTURE", 180, 195], ["brain", "ORGAN", 261, 266], ["the retention", "PROBLEM", 51, 64], ["brain", "ANATOMY", 261, 266]]], ["The wild-type strain used was Oregon R. The following mutant alleles and characterization constructs were used to investigate expression and function: P{en2.4-Gal4}e16E, UAS-mCD8::GFP LL5 and poxn brain -Gal4 as well as UAS-mCD8::GFP, tub-FRT-CD2-FRT-Gal4, UAS-FLP/CyO GMR Dfd YFP (65) ; otd JA101 (14) ; P{lacZ}unpg f85 (an unpg-lacZ reporter gene that expresses cytoplasmic \u03b2-galactosidase in the same pattern as endogenous unpg) (34) ; P{lacZ}Pax2 \u0394122 (a Pax2-lacZ reporter gene that expresses \u03b2-galactosidase in the same pattern as endogenous Pax2) (34) ; P{3\u2032lacZ}unpg r37 (unpg null allele with a unpg-lacZ reporter gene that expresses nuclear \u03b2galactosidase in the same pattern as endogenous unpg) (34) ; wg CX4 and wg-lacZ (Bloomington); msh \u039468 (66); vnd 6 (67) ; the deficiency Df (2R) BSC25 that removes the FGF8-like 1 and FGF8-like 2 loci together with adjacent regions and htl AB42 (37) UAS-FGF8-like 1 (37) ; and ems2.6 (72.5)-Gal4 (S.G. Sprecher, unpublished) .MATERIALS AND METHODSTo generate Poxn brain -Gal4 flies, the Poxn brain enhancer (68) was amplified by PCR from genomic DNA.", [["cytoplasmic", "ANATOMY", 364, 375], ["nuclear", "ANATOMY", 643, 650], ["brain", "ANATOMY", 1016, 1021], ["Poxn brain", "ANATOMY", 1039, 1049], ["P{en2.4-Gal4}e16E", "GENE_OR_GENE_PRODUCT", 151, 168], ["UAS-mCD8", "GENE_OR_GENE_PRODUCT", 170, 178], ["GFP LL5", "GENE_OR_GENE_PRODUCT", 180, 187], ["poxn brain -Gal4", "GENE_OR_GENE_PRODUCT", 192, 208], ["UAS-mCD8", "GENE_OR_GENE_PRODUCT", 220, 228], ["GFP", "GENE_OR_GENE_PRODUCT", 230, 233], ["tub-FRT-CD2-FRT-Gal4", "GENE_OR_GENE_PRODUCT", 235, 255], ["UAS-FLP", "GENE_OR_GENE_PRODUCT", 257, 264], ["CyO GMR Dfd YFP (65)", "GENE_OR_GENE_PRODUCT", 265, 285], ["otd JA101 (14)", "GENE_OR_GENE_PRODUCT", 288, 302], ["P{lacZ}unpg f85", "GENE_OR_GENE_PRODUCT", 305, 320], ["unpg-lacZ reporter gene", "GENE_OR_GENE_PRODUCT", 325, 348], ["cytoplasmic \u03b2-galactosidase", "GENE_OR_GENE_PRODUCT", 364, 391], ["unpg) (34)", "GENE_OR_GENE_PRODUCT", 426, 436], ["P{lacZ}Pax2 \u0394122", "GENE_OR_GENE_PRODUCT", 439, 455], ["Pax2", "GENE_OR_GENE_PRODUCT", 459, 463], ["lacZ reporter gene", "GENE_OR_GENE_PRODUCT", 464, 482], ["\u03b2-galactosidase", "GENE_OR_GENE_PRODUCT", 498, 513], ["Pax2", "GENE_OR_GENE_PRODUCT", 548, 552], ["P{3\u2032lacZ}unpg r37", "GENE_OR_GENE_PRODUCT", 561, 578], ["unpg null", "GENE_OR_GENE_PRODUCT", 580, 589], ["unpg-lacZ reporter gene", "GENE_OR_GENE_PRODUCT", 604, 627], ["nuclear \u03b2galactosidase", "GENE_OR_GENE_PRODUCT", 643, 665], ["unpg) (34)", "GENE_OR_GENE_PRODUCT", 700, 710], ["wg CX4", "GENE_OR_GENE_PRODUCT", 713, 719], ["wg-lacZ (Bloomington)", "GENE_OR_GENE_PRODUCT", 724, 745], ["msh \u039468 (66)", "GENE_OR_GENE_PRODUCT", 747, 759], ["Df (2R) BSC25", "GENE_OR_GENE_PRODUCT", 789, 802], ["FGF8-like 1", "GENE_OR_GENE_PRODUCT", 820, 831], ["FGF8-like 2", "GENE_OR_GENE_PRODUCT", 836, 847], ["UAS-FGF8-like 1", "GENE_OR_GENE_PRODUCT", 902, 917], ["Gal4", "GENE_OR_GENE_PRODUCT", 1023, 1027], ["Poxn", "GENE_OR_GENE_PRODUCT", 1039, 1043], ["brain", "ORGAN", 1044, 1049], ["DNA", "CELLULAR_COMPONENT", 1098, 1101], ["mutant alleles", "DNA", 54, 68], ["P{en2.4", "PROTEIN", 151, 158], ["e16E", "DNA", 164, 168], ["UAS", "DNA", 170, 173], ["mCD8", "DNA", 174, 178], ["GFP LL5", "DNA", 180, 187], ["poxn brain", "DNA", 192, 202], ["Gal4", "DNA", 204, 208], ["UAS", "DNA", 220, 223], ["mCD8", "DNA", 224, 228], ["GFP", "DNA", 230, 233], ["tub", "DNA", 235, 238], ["FRT", "DNA", 239, 242], ["CD2", "DNA", 243, 246], ["FRT", "DNA", 247, 250], ["Gal4", "DNA", 251, 255], ["UAS", "DNA", 257, 260], ["FLP", "DNA", 261, 264], ["CyO GMR", "DNA", 265, 272], ["YFP", "DNA", 277, 280], ["65", "DNA", 282, 284], ["otd JA101", "DNA", 288, 297], ["P{lacZ}unpg f85", "DNA", 305, 320], ["unpg", "DNA", 325, 329], ["lacZ reporter gene", "DNA", 330, 348], ["cytoplasmic \u03b2-galactosidase", "PROTEIN", 364, 391], ["Pax2 \u0394122", "DNA", 446, 455], ["Pax2-lacZ reporter gene", "DNA", 459, 482], ["\u03b2-galactosidase", "PROTEIN", 498, 513], ["Pax2", "PROTEIN", 548, 552], ["P{3\u2032lacZ}unpg r37", "DNA", 561, 578], ["unpg null allele", "DNA", 580, 596], ["unpg-lacZ reporter gene", "DNA", 604, 627], ["nuclear \u03b2galactosidase", "PROTEIN", 643, 665], ["wg CX4", "DNA", 713, 719], ["wg", "DNA", 724, 726], ["lacZ", "DNA", 727, 731], ["Bloomington", "DNA", 733, 744], ["msh \u039468", "DNA", 747, 754], ["vnd 6", "DNA", 761, 766], ["deficiency Df (2R) BSC25", "DNA", 778, 802], ["FGF8", "DNA", 820, 824], ["FGF8", "DNA", 836, 840], ["like 2 loci", "DNA", 841, 852], ["htl AB42 (37) UAS", "DNA", 888, 905], ["FGF8", "DNA", 906, 910], ["Gal4", "DNA", 943, 947], ["Poxn brain -Gal4 flies", "DNA", 1011, 1033], ["Poxn brain enhancer", "DNA", 1039, 1058], ["68", "DNA", 1060, 1062], ["genomic DNA", "DNA", 1090, 1101], ["type strain", "PROBLEM", 9, 20], ["characterization constructs", "TEST", 73, 100], ["function", "TEST", 141, 149], ["UAS", "TEST", 170, 173], ["GFP", "TEST", 180, 183], ["UAS", "TEST", 220, 223], ["mCD8", "TEST", 224, 228], ["GFP", "TEST", 230, 233], ["tub", "TEST", 235, 238], ["FRT", "TEST", 239, 242], ["CD2", "TEST", 243, 246], ["FRT", "TEST", 247, 250], ["Gal4", "TEST", 251, 255], ["UAS", "TEST", 257, 260], ["FLP", "TEST", 261, 264], ["CyO", "TEST", 265, 268], ["GMR", "TEST", 269, 272], ["Dfd YFP", "TEST", 273, 280], ["JA101", "TEST", 292, 297], ["an unpg-lacZ reporter gene", "TREATMENT", 322, 348], ["cytoplasmic \u03b2-galactosidase", "TEST", 364, 391], ["P{lacZ", "TEST", 439, 445], ["a Pax2-lacZ reporter gene", "TREATMENT", 457, 482], ["a unpg-lacZ reporter gene", "TREATMENT", 602, 627], ["nuclear \u03b2galactosidase", "TEST", 643, 665], ["wg CX4", "TEST", 713, 719], ["wg", "TEST", 724, 726], ["msh", "TEST", 747, 750], ["vnd", "TEST", 761, 764], ["the deficiency Df", "PROBLEM", 774, 791], ["the FGF8", "TEST", 816, 824], ["FGF8", "TEST", 836, 840], ["htl AB42", "TEST", 888, 896], ["UAS", "TEST", 902, 905], ["FGF8", "TEST", 906, 910], ["ems2.6", "TEST", 929, 935], ["Gal4 (S.G. Sprecher", "TEST", 943, 962], ["the Poxn brain enhancer", "TEST", 1035, 1058], ["Gal4", "ANATOMY", 251, 255]]], ["The PCR product was subcloned into pPTGal vector using XbaI and NotI sites, followed by sequencing; the genomic region 2R:11723830 to 11725559 was inserted into pPTGal.", [["pPTGal", "GENE_OR_GENE_PRODUCT", 35, 41], ["XbaI", "GENE_OR_GENE_PRODUCT", 55, 59], ["NotI", "GENE_OR_GENE_PRODUCT", 64, 68], ["pPTGal", "GENE_OR_GENE_PRODUCT", 161, 167], ["pPTGal vector", "DNA", 35, 48], ["XbaI and NotI sites", "DNA", 55, 74], ["genomic region 2R:11723830 to 11725559", "DNA", 104, 142], ["pPTGal", "DNA", 161, 167], ["The PCR product", "TREATMENT", 0, 15], ["XbaI and NotI sites", "TREATMENT", 55, 74]]], ["Primer sequences are:MATERIALS AND METHODSTransgenesis was performed by BestGene Inc (CA, USA).MATERIALS AND METHODSFor lineage tracing, the following strains were used: w 1118 (control), P{en2.4-Gal4}e16E, UAS-mCD8::GFP LL5 , or poxn brain -Gal4 were crossed to UAS-mCD8::GFP, tub-FRT-CD2-FRT-Gal4, UAS-FLP/CyO GMR Dfd YFP.", [["brain", "ANATOMY", 235, 240], ["P{en2.4-Gal4}e16E", "GENE_OR_GENE_PRODUCT", 188, 205], ["UAS-mCD8", "GENE_OR_GENE_PRODUCT", 207, 215], ["GFP", "GENE_OR_GENE_PRODUCT", 217, 220], ["LL5", "GENE_OR_GENE_PRODUCT", 221, 224], ["poxn brain -Gal4", "GENE_OR_GENE_PRODUCT", 230, 246], ["UAS", "GENE_OR_GENE_PRODUCT", 263, 266], ["mCD8", "GENE_OR_GENE_PRODUCT", 267, 271], ["GFP", "GENE_OR_GENE_PRODUCT", 273, 276], ["Gal4", "GENE_OR_GENE_PRODUCT", 294, 298], ["UAS-FLP", "GENE_OR_GENE_PRODUCT", 300, 307], ["YFP", "GENE_OR_GENE_PRODUCT", 320, 323], ["Primer sequences", "DNA", 0, 16], ["UAS", "DNA", 207, 210], ["mCD8", "DNA", 211, 215], ["GFP LL5", "DNA", 217, 224], ["poxn brain -Gal4", "DNA", 230, 246], ["UAS", "DNA", 263, 266], ["mCD8", "DNA", 267, 271], ["GFP", "DNA", 273, 276], ["tub", "DNA", 278, 281], ["FRT", "DNA", 282, 285], ["CD2", "DNA", 286, 289], ["FRT", "DNA", 290, 293], ["Gal4", "DNA", 294, 298], ["UAS", "DNA", 300, 303], ["FLP", "DNA", 304, 307], ["CyO GMR Dfd YFP", "DNA", 308, 323], ["METHODSTransgenesis", "TEST", 35, 54], ["lineage tracing", "TEST", 120, 135], ["UAS", "TEST", 207, 210], ["GFP LL5", "TEST", 217, 224], ["UAS", "TEST", 263, 266], ["mCD8", "TEST", 267, 271], ["GFP", "TEST", 273, 276], ["tub", "TEST", 278, 281], ["FRT", "TEST", 282, 285], ["CD2", "TEST", 286, 289], ["FRT", "TEST", 290, 293], ["Gal4", "TEST", 294, 298], ["UAS", "TEST", 300, 303], ["FLP", "TEST", 304, 307], ["Gal4", "ANATOMY", 294, 298]]], ["Offspring were raised at 18\u00b0C to suppress random leaky FLP activity.MATERIALS AND METHODSFor behavioural experiments, we used UAS-TNT-E (46) crossed to AMMC-specific Gal4 lines.", [["Gal4 lines", "ANATOMY", 166, 176], ["FLP", "GENE_OR_GENE_PRODUCT", 55, 58], ["AMMC", "CELL", 152, 156], ["Gal4 lines", "CELL", 166, 176], ["FLP", "PROTEIN", 55, 58], ["UAS", "DNA", 126, 129], ["E (46)", "DNA", 134, 140], ["AMMC-specific Gal4 lines", "CELL_LINE", 152, 176], ["random leaky FLP activity", "PROBLEM", 42, 67], ["UAS", "TEST", 126, 129], ["AMMC", "TEST", 152, 156], ["leaky FLP", "OBSERVATION", 49, 58], ["Gal4 lines", "OBSERVATION", 166, 176]]], ["Corresponding controls for Gal4 driver and for UAS responder line, were generated by backcrossing to w 1118 .", [["Gal4", "GENE_OR_GENE_PRODUCT", 27, 31], ["Gal4 driver", "DNA", 27, 38], ["UAS responder line", "CELL_LINE", 47, 65], ["UAS responder line", "TREATMENT", 47, 65]]], ["All behavioural experiments were carried out in a temperature-controlled chamber at 25\u00b0C.MATERIALS AND METHODSIn situ Hybridization, Immunocytochemistry and Image Analysis.", [["Immunocytochemistry", "TEST", 133, 152], ["Image Analysis", "TEST", 157, 171]]], ["For in situ hybridization experiments, digoxigeninlabelled sense and antisense RNA probes were generated in vitro with a DIG labelling kit (Roche diagnostics) and hybridized to Drosophila whole-mount embryos, following standard procedures (69) .MATERIALS AND METHODSWhole-mount immunocytochemistry was performed as previously described (70, 71) .", [["embryos", "ANATOMY", 200, 207], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 200, 207], ["digoxigeninlabelled sense and antisense RNA probes", "RNA", 39, 89], ["Drosophila", "SPECIES", 177, 187], ["Drosophila", "SPECIES", 177, 187], ["antisense RNA probes", "TREATMENT", 69, 89], ["Drosophila whole-mount embryos", "TREATMENT", 177, 207], ["METHODSWhole-mount immunocytochemistry", "TEST", 259, 297]]], ["Primary antibodies were rabbit anti-Otd Fluorescence samples were scanned and recorded with a Leica TCS SP5 confocal microscope.", [["samples", "ANATOMY", 53, 60], ["rabbit", "ORGANISM", 24, 30], ["rabbit", "SPECIES", 24, 30], ["rabbit", "SPECIES", 24, 30], ["Primary antibodies", "TEST", 0, 18], ["a Leica TCS", "TEST", 92, 103]]], ["Images were processed using Adobe Photoshop and figures constructed in Adobe Illustrator.MATERIALS AND METHODSStartle Induced Negative Geotaxis Assay (SING).", [["Images", "TEST", 0, 6], ["Geotaxis Assay", "TEST", 135, 149]]], ["Groups of 10 flies with shortened wings of the same age, sex and genotype were placed in a vertical column (19 cm long, 2cm diameter).", [["flies", "ORGANISM", 13, 18], ["vertical column", "OBSERVATION_MODIFIER", 91, 106], ["19 cm", "OBSERVATION_MODIFIER", 108, 113]]], ["The wings were clipped under sedation (with CO2) at least 24 hours prior to testing.", [["CO2", "CHEMICAL", 44, 47], ["CO2", "CHEMICAL", 44, 47], ["CO2", "SIMPLE_CHEMICAL", 44, 47], ["sedation", "TREATMENT", 29, 37], ["CO2", "TEST", 44, 47], ["testing", "TEST", 76, 83], ["wings", "OBSERVATION_MODIFIER", 4, 9]]], ["They were suddenly startled by gently tapping them down, to which Drosophila responds by climbing up.", [["Drosophila", "SPECIES", 66, 76], ["Drosophila", "SPECIES", 66, 76]]], ["After 10 seconds, it was counted how many flies were above the 2cm mark and the trial was repeated 15 times for each tube and the average was calculated.", [["flies", "ORGANISM", 42, 47], ["tube", "TISSUE", 117, 121], ["each tube", "TREATMENT", 112, 121], ["tube", "OBSERVATION", 117, 121]]], ["For each genotype 10 groups of females and 10 groups of males were tested.", [["males", "ORGANISM", 56, 61]]], ["Flies were reared at 25\u00b0C and were maintained under 12hr light/dark cycle.", [["C", "GENE_OR_GENE_PRODUCT", 24, 25]]], ["All assays were performed at the same time of day.MATERIALS AND METHODSMotor Behavior Analysis.", [["All assays", "TEST", 0, 10], ["METHODSMotor Behavior Analysis", "TEST", 64, 94]]], ["Control and experimental flies were reared at 18\u00b0C and adult mated females up to 5 days post-eclosion were transferred to 25\u00b0C for behavioural analyses.", [["C", "GENE_OR_GENE_PRODUCT", 49, 50], ["C", "GENE_OR_GENE_PRODUCT", 125, 126], ["behavioural analyses", "TEST", 131, 151]]], ["Mechanical stimuli trains consisted of 5 pulses of 200ms each, spaced by 800ms.", [["Mechanical stimuli trains", "TREATMENT", 0, 25], ["5 pulses", "TEST", 39, 47]]], ["Motor behaviour parameters were determined as previously described (38, 75, 76) .Bioinformatics Analyses and Identification of Cis-Regulatory Elements(CREs).", [["Cis-Regulatory Elements", "DNA", 127, 150], ["CREs", "DNA", 151, 155], ["Motor behaviour parameters", "TEST", 0, 26], ["Bioinformatics Analyses", "TEST", 81, 104], ["Cis-Regulatory Elements", "OBSERVATION", 127, 150]]], ["The Janelia Gal4 collection (http://flweb.janelia.org/cgi-bin/flew.cgi) (48) was screened for AMMC-specific GFP expression patterns.", [["Gal4", "GENE_OR_GENE_PRODUCT", 12, 16], ["AMMC", "GENE_OR_GENE_PRODUCT", 94, 98], ["GFP", "GENE_OR_GENE_PRODUCT", 108, 111], ["AMMC", "PROTEIN", 94, 98], ["The Janelia Gal4 collection", "PROBLEM", 0, 27], ["AMMC", "TEST", 94, 98], ["Janelia", "ANATOMY", 4, 11], ["Gal4 collection", "OBSERVATION", 12, 27], ["GFP expression", "OBSERVATION", 108, 122]]], ["All hits were cross checked to be verified/excluded from the Janelia/Bloomington list (see https://bdsc.indiana.edu/stocks/gal4/gal4_janelia_info.html).", [["Janelia/Bloomington list", "DNA", 61, 85], ["All hits", "TEST", 0, 8]]], ["For each hit, annotated left and right primers were used to BLAST the Drosophila genome annotated at the Ensembl genome browser (http://www.ensembl.org/index.html) to determine the position and sequence within genome version BDGP6, or where known the sequence was extracted from the respective gene map annotation in JBrowse (http://flybase.org/).", [["left", "ANATOMY", 24, 28], ["left and right primers", "DNA", 24, 46], ["Drosophila genome", "DNA", 70, 87], ["Ensembl genome browser", "DNA", 105, 127], ["http://www.ensembl.org/index.html", "DNA", 129, 162], ["BDGP6", "DNA", 225, 230], ["Drosophila", "SPECIES", 70, 80], ["Drosophila", "SPECIES", 70, 80], ["annotated left and right primers", "TREATMENT", 14, 46], ["left", "ANATOMY_MODIFIER", 24, 28], ["right", "ANATOMY_MODIFIER", 33, 38], ["Drosophila genome", "OBSERVATION", 70, 87]]], ["The resulting sequence was compared against available VT enhancer sequences and their annotated expression pattern determined for DTB expression patterns (http://enhancers.starklab.org/) (50) .", [["DTB", "GENE_OR_GENE_PRODUCT", 130, 133], ["VT enhancer sequences", "DNA", 54, 75], ["DTB", "PROTEIN", 130, 133], ["The resulting sequence", "TEST", 0, 22], ["available VT enhancer sequences", "TEST", 44, 75], ["DTB expression patterns", "PROBLEM", 130, 153]]], ["Drosophila-specific, non-coding regulatory sequences were then used to BLAST the mouse (GRCm38.p5) and human (GRCh38.p7) genome annotated at Ensemble (https://www.ensembl.org/index.html) to identify any potential corresponding sequences.", [["mouse", "ORGANISM", 81, 86], ["GRCm38.p5", "GENE_OR_GENE_PRODUCT", 88, 97], ["human", "ORGANISM", 103, 108], ["non-coding regulatory sequences", "DNA", 21, 52], ["mouse (GRCm38.p5", "DNA", 81, 97], ["human (GRCh38.p7) genome", "DNA", 103, 127], ["Drosophila", "SPECIES", 0, 10], ["mouse", "SPECIES", 81, 86], ["human", "SPECIES", 103, 108], ["Drosophila", "SPECIES", 0, 10], ["mouse", "SPECIES", 81, 86], ["human", "SPECIES", 103, 108], ["Drosophila", "TEST", 0, 10], ["non-coding regulatory sequences", "PROBLEM", 21, 52], ["human (GRCh38.p7)", "TREATMENT", 103, 120]]], ["Any matching sequences were scrutinized for further analysis on the basis of criteria that have been used previously to identify transphyletic cis-regulatory DNA sequences (56) .", [["DNA", "CELLULAR_COMPONENT", 158, 161], ["transphyletic cis-regulatory DNA sequences", "DNA", 129, 171], ["Any matching sequences", "TEST", 0, 22], ["further analysis", "TEST", 44, 60], ["transphyletic cis-regulatory DNA sequences", "TEST", 129, 171]]], ["These criteria were:Bioinformatics Analyses and Identification of Cis-Regulatory Elements(i) the sequences are linked to the same homologous genes in the different species;Bioinformatics Analyses and Identification of Cis-Regulatory Elements(ii) there is a minimum of 62% sequence identity over at least 55 bp with minimum 1e -1 confidence level;Bioinformatics Analyses and Identification of Cis-Regulatory Elements(iii) the CREs are not un-annotated protein sequences; and (iv) the CREs are not repetitive elements.Bioinformatics Analyses and Identification of Cis-Regulatory ElementsThe resulting sequences were then used for refined comparisons using pair-wise and multiple sequence alignment algorithms including EMBOSS Matcher and t-coffee (http://www.ebi.ac.uk/services).", [["Cis-Regulatory Elements", "DNA", 66, 89], ["homologous genes", "DNA", 130, 146], ["Cis-Regulatory Elements", "DNA", 218, 241], ["Cis-Regulatory Elements", "DNA", 392, 415], ["CREs", "DNA", 425, 429], ["un-annotated protein sequences", "DNA", 438, 468], ["CREs", "DNA", 483, 487], ["repetitive elements", "DNA", 496, 515], ["Cis-Regulatory Elements", "DNA", 562, 585], ["EMBOSS Matcher", "DNA", 717, 731], ["Bioinformatics Analyses", "TEST", 20, 43], ["Bioinformatics Analyses", "TEST", 172, 195], ["bp", "TEST", 307, 309], ["Bioinformatics Analyses", "TEST", 346, 369], ["Bioinformatics Analyses", "TEST", 516, 539], ["The resulting sequences", "TEST", 585, 608], ["multiple sequence alignment algorithms", "TEST", 668, 706]]], ["To carry out sequence alignments, which automatically indicated whether any CNS regulatory elements might be covered by the input sequences, we used the MLAGAN algorithm (http://genome.lbl.gov/vista/lagan/submit.shtml).", [["CNS", "ANATOMY", 76, 79], ["CNS regulatory elements", "DNA", 76, 99], ["MLAGAN algorithm", "DNA", 153, 169], ["sequence alignments", "TEST", 13, 32], ["any CNS regulatory elements", "PROBLEM", 72, 99], ["the input sequences", "TEST", 120, 139], ["the MLAGAN algorithm", "TREATMENT", 149, 169]]], ["Detected CNS CREs were then further scrutinized using the VISTA enhancer browser (https://enhancer.lbl.gov/frnt_page_n.shtml), which provides human and mouse regulatory sequences and their expression pattern at embryonic stage E11.5 in transgenic mouse embryos expressing LacZ under the control of the respective regulatory sequence (52, 55) .", [["CNS", "ANATOMY", 9, 12], ["embryonic", "ANATOMY", 211, 220], ["embryos", "ANATOMY", 253, 260], ["human", "ORGANISM", 142, 147], ["mouse", "ORGANISM", 152, 157], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 211, 220], ["E11.5", "DEVELOPING_ANATOMICAL_STRUCTURE", 227, 232], ["mouse", "ORGANISM", 247, 252], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 253, 260], ["LacZ", "GENE_OR_GENE_PRODUCT", 272, 276], ["CNS CREs", "DNA", 9, 17], ["VISTA enhancer browser", "DNA", 58, 80], ["https://enhancer.lbl.gov/frnt_page_n.shtml", "DNA", 82, 124], ["human and mouse regulatory sequences", "DNA", 142, 178], ["LacZ", "PROTEIN", 272, 276], ["regulatory sequence", "DNA", 313, 332], ["human", "SPECIES", 142, 147], ["mouse", "SPECIES", 152, 157], ["mouse", "SPECIES", 247, 252], ["human", "SPECIES", 142, 147], ["mouse", "SPECIES", 152, 157], ["mouse", "SPECIES", 247, 252], ["human and mouse regulatory sequences", "TREATMENT", 142, 178], ["embryonic stage", "PROBLEM", 211, 226], ["transgenic mouse embryos", "TREATMENT", 236, 260]]], ["The relevant images of LacZ expression were extracted and reproduced with permission by Dr. Len Pennacchio, Lawrence Berkeley National Laboratory.", [["LacZ", "GENE_OR_GENE_PRODUCT", 23, 27], ["LacZ", "DNA", 23, 27]]], ["Finally, identified MHB-specific regulatory sequences were utilized to perform multiple sequence alignment with the respective DTB->AMMC-specific regulatory elements; any matches were re-confirmed and quantified using the EMBOSS Matcher and CLUSTAL Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/) algorithms.Bioinformatics Analyses and Identification of Cis-Regulatory ElementsStatistical Analysis.", [["DTB", "GENE_OR_GENE_PRODUCT", 127, 130], ["MHB-specific regulatory sequences", "DNA", 20, 53], ["DTB->AMMC-specific regulatory elements", "DNA", 127, 165], ["EMBOSS Matcher", "DNA", 222, 236], ["CLUSTAL Omega", "DNA", 241, 254], ["MHB", "TEST", 20, 23], ["multiple sequence alignment", "TEST", 79, 106], ["the respective DTB", "TEST", 112, 130], ["the EMBOSS Matcher", "TREATMENT", 218, 236], ["CLUSTAL Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/) algorithms", "TREATMENT", 241, 308], ["Statistical Analysis", "TEST", 378, 398]]], ["If every data set under comparison was normal and the variances were similar (Hartley's fmax was calculated in each case and used as a cut-off for variance ratio), then a one-way ANOVA test was used to determine whether any differences existed between groups.", [["Hartley's fmax", "TEST", 78, 92], ["a one-way ANOVA test", "TEST", 169, 189]]], ["If significance was found for ANOVA with \uf061 = 0.05, then pair-wise comparisons were made using a post hoc Tukey-Kramer test, again with \uf061 = 0.05.", [["ANOVA", "TEST", 30, 35]]], ["If any of the data sets was found not to be normally distributed, then a Kruskal-Wallis test was used to determine any overall differences between the groups with \uf061 = 0.05.", [["the data sets", "TEST", 10, 23], ["a Kruskal-Wallis test", "TEST", 71, 92]]], ["If significance was achieved, a post hoc pairwise Mann-Whitney U test with Dunn-Sidak correction was used to compare groups with \uf061 = 0.05.", [["Whitney U test", "TEST", 55, 69], ["Dunn-Sidak correction", "TREATMENT", 75, 96]]], ["For each test group, two controls were used corresponding to the two genetic elements that were altered in the group under analysis.", [["each test group", "TEST", 4, 19]]], ["For example, R11A07>TNT would be tested against TNT control and R11A07>w1118.", [["R11A07", "CHEMICAL", 13, 19], ["TNT", "CHEMICAL", 20, 23], ["TNT", "CHEMICAL", 20, 23], ["R11A07", "SIMPLE_CHEMICAL", 13, 19], ["TNT", "SIMPLE_CHEMICAL", 20, 23], ["R11A07", "TEST", 13, 19]]], ["All calculations were performed using MATLAB.SUPPLEMENTARY INFORMATIONSupplementary Information includes supplementary Figs.", [["SUPPLEMENTARY", "DISEASE", 45, 58], ["All calculations", "TEST", 0, 16]]], ["S1 to S9, Tables S1 to S2; captions for movies S1 to S2; captions for databases S1 to S3 and references for SI reference citations.", [["S9", "PROTEIN", 6, 8], ["S2", "PROTEIN", 23, 25], ["S2", "PROTEIN", 53, 55], ["S3", "PROTEIN", 86, 88], ["S9", "ANATOMY", 6, 8], ["S2", "ANATOMY", 23, 25]]]], "c5146cd6dfaa0cb4e0250023fba50c758508212e": [["IntroductionViral mucosal infections such as influenza cause considerable morbidity, and even mortality in very young and geriatric patients (1).", [["mucosal", "ANATOMY", 18, 25], ["mucosal infections", "DISEASE", 18, 36], ["influenza", "DISEASE", 45, 54], ["patients", "ORGANISM", 132, 140], ["patients", "SPECIES", 132, 140], ["IntroductionViral mucosal infections", "PROBLEM", 0, 36], ["influenza", "PROBLEM", 45, 54], ["considerable morbidity", "PROBLEM", 61, 83], ["mucosal", "ANATOMY", 18, 25], ["infections", "OBSERVATION", 26, 36]]], ["Protection afforded against influenza A virus (IAV) by antibodies is typically virus type/subtype specific; however, T cells are believed to provide broad heterosubtypic immunity (2) (3) (4) (5) .", [["T cells", "ANATOMY", 117, 124], ["influenza A virus", "DISEASE", 28, 45], ["influenza A virus", "ORGANISM", 28, 45], ["IAV", "ORGANISM", 47, 50], ["T cells", "CELL", 117, 124], ["antibodies", "PROTEIN", 55, 65], ["T cells", "CELL_TYPE", 117, 124], ["influenza A virus", "SPECIES", 28, 45], ["influenza A virus", "SPECIES", 28, 45], ["IAV", "SPECIES", 47, 50], ["Protection", "TREATMENT", 0, 10], ["influenza A virus", "PROBLEM", 28, 45], ["typically virus type/subtype specific", "PROBLEM", 69, 106], ["T cells", "PROBLEM", 117, 124]]], ["IAV infection elicits strong effector CD8 and CD4 T-cell responses in the lungs leading to the development of protective lung and airway-resident memory T cells (3, 6) .", [["CD8", "ANATOMY", 38, 41], ["CD4 T-cell", "ANATOMY", 46, 56], ["lungs", "ANATOMY", 74, 79], ["lung", "ANATOMY", 121, 125], ["airway-resident memory T cells", "ANATOMY", 130, 160], ["infection", "DISEASE", 4, 13], ["IAV", "ORGANISM", 0, 3], ["CD8", "GENE_OR_GENE_PRODUCT", 38, 41], ["CD4", "GENE_OR_GENE_PRODUCT", 46, 49], ["lungs", "ORGAN", 74, 79], ["lung", "ORGAN", 121, 125], ["airway-resident memory T cells", "CELL", 130, 160], ["CD8", "PROTEIN", 38, 41], ["airway-resident memory T cells", "CELL_TYPE", 130, 160], ["IAV", "SPECIES", 0, 3], ["IAV infection", "PROBLEM", 0, 13], ["infection", "OBSERVATION", 4, 13], ["strong", "OBSERVATION_MODIFIER", 22, 28], ["effector CD8", "OBSERVATION", 29, 41], ["lungs", "ANATOMY", 74, 79], ["protective", "OBSERVATION_MODIFIER", 110, 120], ["lung", "ANATOMY", 121, 125], ["airway", "ANATOMY", 130, 136]]], ["However, influenza-specific mucosal memory T cells exhibit attrition and T-cell-based protection wanes in a span of 3-6 months (7, 8) .", [["mucosal memory T cells", "ANATOMY", 28, 50], ["T-cell", "ANATOMY", 73, 79], ["mucosal memory T cells", "CELL", 28, 50], ["T-cell", "CELL", 73, 79], ["mucosal memory T cells", "CELL_TYPE", 28, 50], ["influenza", "PROBLEM", 9, 18], ["attrition", "TEST", 59, 68]]], ["Therefore, unlike systemic viral infections that typically engender enduring immunity (9, 10) , mucosal viral infections fail to program durable T-cell immunity in the respiratory tract (RT).", [["mucosal", "ANATOMY", 96, 103], ["T-cell", "ANATOMY", 145, 151], ["respiratory tract", "ANATOMY", 168, 185], ["viral infections", "DISEASE", 27, 43], ["viral infections", "DISEASE", 104, 120], ["mucosal viral", "ORGANISM", 96, 109], ["T-cell", "CELL", 145, 151], ["respiratory tract", "ORGANISM_SUBDIVISION", 168, 185], ["systemic viral infections", "PROBLEM", 18, 43], ["mucosal viral infections", "PROBLEM", 96, 120], ["systemic", "OBSERVATION_MODIFIER", 18, 26], ["viral infections", "OBSERVATION", 27, 43], ["mucosal", "ANATOMY", 96, 103], ["viral infections", "OBSERVATION", 104, 120], ["cell immunity", "OBSERVATION", 147, 160], ["respiratory tract", "ANATOMY", 168, 185]]], ["While engagement of multiple innate receptors early in the response might be key to long-lived immunological memory following systemic infections (11, 12) , there is a lack of understanding of why mucosal infections lead to shorter duration of cellular immunity.", [["mucosal", "ANATOMY", 197, 204], ["cellular", "ANATOMY", 244, 252], ["systemic infections", "DISEASE", 126, 145], ["mucosal infections", "DISEASE", 197, 215], ["mucosal", "ORGANISM_SUBDIVISION", 197, 204], ["cellular", "CELL", 244, 252], ["multiple innate receptors", "PROTEIN", 20, 45], ["systemic infections", "PROBLEM", 126, 145], ["mucosal infections", "PROBLEM", 197, 215], ["infections", "OBSERVATION", 205, 215], ["cellular immunity", "OBSERVATION", 244, 261]]], ["There is a general paucity of adjuvants that induce strong T-cell responses, and we have limited knowledge of mucosal T-cell responses to adjuvanted subunit vaccines, especially in the RT.", [["T-cell", "ANATOMY", 59, 65], ["mucosal T-cell", "ANATOMY", 110, 124], ["T-cell", "CELL", 59, 65], ["mucosal T-cell", "CELL", 110, 124], ["a general paucity of adjuvants", "PROBLEM", 9, 39], ["adjuvanted subunit vaccines", "TREATMENT", 138, 165]]], ["These knowledge gaps pose daunting constraints in the development of immunization strategies targeted at the establishment of durable protective T-cell immunity in the RT (13) (14) (15) (16) .IntroductionAdjuplex\uf0e2 (ADJ) is a polyacrylic acid-based (carbomer) adjuvant that is a component of some current veterinary vaccines and also known to induce neutralizing antibodies against HIV and malaria (17) (18) (19) (20) .", [["T-cell", "ANATOMY", 145, 151], ["Adjuplex\uf0e2", "CHEMICAL", 204, 213], ["ADJ", "CHEMICAL", 215, 218], ["polyacrylic acid", "CHEMICAL", 225, 241], ["carbomer", "CHEMICAL", 249, 257], ["HIV and malaria", "DISEASE", 381, 396], ["RT (13) (14) (15)", "CHEMICAL", 168, 185], ["polyacrylic acid", "CHEMICAL", 225, 241], ["T-cell", "CELL", 145, 151], ["Adjuplex\uf0e2", "SIMPLE_CHEMICAL", 204, 213], ["ADJ", "SIMPLE_CHEMICAL", 215, 218], ["polyacrylic acid", "SIMPLE_CHEMICAL", 225, 241], ["carbomer", "SIMPLE_CHEMICAL", 249, 257], ["HIV", "ORGANISM", 381, 384], ["neutralizing antibodies", "PROTEIN", 349, 372], ["HIV", "SPECIES", 381, 384], ["HIV", "SPECIES", 381, 384], ["immunization strategies", "TREATMENT", 69, 92], ["IntroductionAdjuplex\uf0e2 (ADJ)", "TREATMENT", 192, 219], ["a polyacrylic acid-based (carbomer) adjuvant", "TREATMENT", 223, 267], ["some current veterinary vaccines", "TREATMENT", 291, 323], ["neutralizing antibodies", "PROBLEM", 349, 372], ["HIV", "PROBLEM", 381, 384], ["malaria", "PROBLEM", 389, 396]]], ["Here, we report that ADJ, in combination with Toll-like receptor (TLR) 4/9Introductionagonists, elicits unexpectedly potent and functionally diverse CD8 and CD4 T-cell responses to a subunit viral protein in the RT.", [["CD8", "ANATOMY", 149, 152], ["CD4 T-cell", "ANATOMY", 157, 167], ["ADJ", "CHEMICAL", 21, 24], ["ADJ", "SIMPLE_CHEMICAL", 21, 24], ["Toll-like receptor", "GENE_OR_GENE_PRODUCT", 46, 64], ["TLR", "GENE_OR_GENE_PRODUCT", 66, 69], ["CD8", "GENE_OR_GENE_PRODUCT", 149, 152], ["CD4", "GENE_OR_GENE_PRODUCT", 157, 160], ["Toll-like receptor", "PROTEIN", 46, 64], ["TLR", "PROTEIN", 66, 69], ["CD8", "PROTEIN", 149, 152], ["subunit viral protein", "PROTEIN", 183, 204], ["Toll-like receptor (TLR)", "TREATMENT", 46, 70], ["a subunit viral protein in the RT", "PROBLEM", 181, 214], ["viral protein", "OBSERVATION", 191, 204], ["RT", "ANATOMY", 212, 214]]], ["Studies with this adjuvant system provided the means to differentially program distinct patterns of effector and memory T-cell differentiation in the RT.IntroductionFurther, these studies provided the first glimpse of the evolution of T-cell responses to adjuvanted vaccines in the lungs to define the quantitative, phenotypic and functional attributes of mucosal effector/memory CD8 and CD4 T cells that are associated with effective viral control in the lungs, and protection against H1N1 and H5N1 influenza infections.", [["memory T-cell", "ANATOMY", 113, 126], ["T-cell", "ANATOMY", 235, 241], ["lungs", "ANATOMY", 282, 287], ["mucosal", "ANATOMY", 356, 363], ["memory CD8", "ANATOMY", 373, 383], ["CD4 T cells", "ANATOMY", 388, 399], ["lungs", "ANATOMY", 456, 461], ["H1N1", "DISEASE", 486, 490], ["influenza infections", "DISEASE", 500, 520], ["memory T-cell", "CELL", 113, 126], ["T-cell", "CELL", 235, 241], ["lungs", "ORGAN", 282, 287], ["mucosal effector", "CELL", 356, 372], ["CD8", "GENE_OR_GENE_PRODUCT", 380, 383], ["CD4", "GENE_OR_GENE_PRODUCT", 388, 391], ["lungs", "ORGAN", 456, 461], ["H5N1 influenza", "ORGANISM", 495, 509], ["mucosal effector/memory CD8 and CD4 T cells", "CELL_TYPE", 356, 399], ["H5N1 influenza", "SPECIES", 495, 509], ["Studies", "TEST", 0, 7], ["this adjuvant system", "TREATMENT", 13, 33], ["these studies", "TEST", 174, 187], ["adjuvanted vaccines", "TREATMENT", 255, 274], ["mucosal effector", "PROBLEM", 356, 372], ["CD4 T cells", "PROBLEM", 388, 399], ["effective viral control in the lungs", "PROBLEM", 425, 461], ["protection", "TREATMENT", 467, 477], ["H1N1", "PROBLEM", 486, 490], ["H5N1 influenza infections", "PROBLEM", 495, 520], ["RT", "ANATOMY_MODIFIER", 150, 152], ["lungs", "ANATOMY", 282, 287], ["mucosal effector", "OBSERVATION", 356, 372], ["effective", "OBSERVATION_MODIFIER", 425, 434], ["viral", "OBSERVATION", 435, 440], ["lungs", "ANATOMY", 456, 461]]], ["Collectively, these findings provide novel insights into the immunological apparatus underlying the generation and establishment of protective and durable T-cell immunity in the RT in response to adjuvanted subunit vaccines.Introduction(P<0.05) than in the GLA group.", [["T-cell", "ANATOMY", 155, 161], ["GLA", "CHEMICAL", 257, 260], ["T-cell", "CELL", 155, 161], ["GLA", "SIMPLE_CHEMICAL", 257, 260], ["durable T-cell immunity", "TREATMENT", 147, 170], ["adjuvanted subunit vaccines", "TREATMENT", 196, 223], ["Introduction(P<", "TREATMENT", 224, 239]]], ["Interestingly, comparison of ADJ, GLA and ADJ+GLA groups suggested that GLA limited the development of CX3CR1 HI CD8 T cells.IntroductionAs another surrogate marker for effector differentiation, we quantified granzyme B levels in CD8 T cells directly ex vivo (Fig. 1C) .", [["CD8 T cells", "ANATOMY", 113, 124], ["CD8 T cells", "ANATOMY", 230, 241], ["GLA", "CHEMICAL", 72, 75], ["GLA", "CHEMICAL", 72, 75], ["ADJ", "GENE_OR_GENE_PRODUCT", 29, 32], ["GLA", "SIMPLE_CHEMICAL", 34, 37], ["ADJ+GLA", "GENE_OR_GENE_PRODUCT", 42, 49], ["GLA", "SIMPLE_CHEMICAL", 72, 75], ["CX3CR1", "GENE_OR_GENE_PRODUCT", 103, 109], ["granzyme B", "GENE_OR_GENE_PRODUCT", 209, 219], ["CD8 T cells", "CELL", 230, 241], ["ADJ", "PROTEIN", 42, 45], ["CX3CR1", "PROTEIN", 103, 109], ["CD8 T cells", "CELL_TYPE", 113, 124], ["granzyme B", "PROTEIN", 209, 219], ["CD8 T cells", "CELL_TYPE", 230, 241], ["comparison of ADJ, GLA and ADJ+GLA groups", "TEST", 15, 56], ["granzyme B levels", "TEST", 209, 226], ["CD8 T cells", "OBSERVATION", 113, 124]]], ["The percentages of granzyme B HI CD8 T cells among NP366specific CD8 T cells in ADJ, CpG and ADJ+CpG groups were significantly (P<0.05) higher than in GLA or ADJ+GLA groups.", [["CD8 T cells", "ANATOMY", 33, 44], ["NP366specific CD8 T cells", "ANATOMY", 51, 76], ["ADJ", "ANATOMY", 80, 83], ["CpG", "CHEMICAL", 85, 88], ["CpG", "CHEMICAL", 97, 100], ["granzyme B", "GENE_OR_GENE_PRODUCT", 19, 29], ["ADJ", "CELL", 80, 83], ["GLA", "SIMPLE_CHEMICAL", 151, 154], ["granzyme B HI CD8 T cells", "CELL_TYPE", 19, 44], ["NP366specific CD8 T cells", "CELL_TYPE", 51, 76], ["The percentages", "TEST", 0, 15], ["granzyme", "TEST", 19, 27], ["T cells", "TEST", 37, 44], ["NP366specific", "TEST", 51, 64], ["ADJ", "TEST", 80, 83], ["CpG", "TEST", 85, 88], ["ADJ+CpG groups", "TREATMENT", 93, 107]]], ["Clearly, ADJ and CpG promoted granzyme B expression, but GLA antagonized the granzyme B-enhancing effects of ADJ.IntroductionStudies to determine the transcriptional basis for the disparate differentiation of effector CD8 T cells in different adjuvant groups showed that the expressions of T-bet, IRF-4 and BATF were substantially greater in ADJ and ADJ+CpG groups, compared to GLA and ADJ+GLA groups ( Fig. 1D) .", [["effector CD8 T cells", "ANATOMY", 209, 229], ["ADJ", "ANATOMY", 342, 345], ["CpG", "CHEMICAL", 17, 20], ["GLA", "CHEMICAL", 57, 60], ["ADJ", "CHEMICAL", 109, 112], ["ADJ", "CHEMICAL", 9, 12], ["CpG", "CHEMICAL", 17, 20], ["GLA", "CHEMICAL", 57, 60], ["CpG", "CHEMICAL", 354, 357], ["ADJ", "SIMPLE_CHEMICAL", 9, 12], ["CpG", "SIMPLE_CHEMICAL", 17, 20], ["granzyme B", "GENE_OR_GENE_PRODUCT", 30, 40], ["GLA", "SIMPLE_CHEMICAL", 57, 60], ["granzyme B", "GENE_OR_GENE_PRODUCT", 77, 87], ["ADJ", "SIMPLE_CHEMICAL", 109, 112], ["CD8 T cells", "CELL", 218, 229], ["T-bet", "GENE_OR_GENE_PRODUCT", 290, 295], ["IRF-4", "GENE_OR_GENE_PRODUCT", 297, 302], ["BATF", "GENE_OR_GENE_PRODUCT", 307, 311], ["ADJ", "CANCER", 342, 345], ["GLA", "SIMPLE_CHEMICAL", 378, 381], ["ADJ", "PROTEIN", 9, 12], ["granzyme B", "PROTEIN", 30, 40], ["granzyme B", "PROTEIN", 77, 87], ["effector CD8 T cells", "CELL_TYPE", 209, 229], ["IRF-4", "PROTEIN", 297, 302], ["BATF", "PROTEIN", 307, 311], ["CpG", "TREATMENT", 17, 20], ["IntroductionStudies", "TREATMENT", 113, 132], ["T-bet", "TEST", 290, 295], ["IRF", "TEST", 297, 300], ["BATF", "TEST", 307, 311], ["ADJ+CpG groups", "TREATMENT", 350, 364], ["GLA", "TEST", 378, 381], ["greater", "OBSERVATION_MODIFIER", 331, 338]]], ["While ADJ appeared to be the primary driver of T-bet, IRF-4 and BATF expression, GLA effectively negated this effect in ADJ+GLA mice (Fig. 1D) .", [["ADJ", "GENE_OR_GENE_PRODUCT", 6, 9], ["T-bet", "GENE_OR_GENE_PRODUCT", 47, 52], ["IRF-4", "GENE_OR_GENE_PRODUCT", 54, 59], ["BATF", "GENE_OR_GENE_PRODUCT", 64, 68], ["GLA", "SIMPLE_CHEMICAL", 81, 84], ["ADJ", "PROTEIN", 6, 9], ["IRF-4", "PROTEIN", 54, 59], ["BATF", "PROTEIN", 64, 68], ["GLA", "PROTEIN", 81, 84], ["mice", "SPECIES", 128, 132], ["IRF", "TEST", 54, 57]]], ["The levels of EOMES did not differ between adjuvants, but analysis of T-bet and EOMES co-expression showed that a higher percentage of CD8 T cells co-expressed T-bet and EOMES (T-bet HI EOMES HI ) in the CpG and ADJ+CpG groups (Fig. S1C) .", [["CD8 T cells", "ANATOMY", 135, 146], ["CpG", "CHEMICAL", 204, 207], ["CpG", "CHEMICAL", 216, 219], ["T-bet", "GENE_OR_GENE_PRODUCT", 70, 75], ["EOMES", "GENE_OR_GENE_PRODUCT", 80, 85], ["CD8 T", "GENE_OR_GENE_PRODUCT", 135, 140], ["T-bet", "GENE_OR_GENE_PRODUCT", 160, 165], ["EOMES", "PROTEIN", 80, 85], ["CD8 T cells", "CELL_TYPE", 135, 146], ["T-bet", "PROTEIN", 160, 165], ["EOMES", "PROTEIN", 170, 175], ["adjuvants", "TREATMENT", 43, 52], ["analysis", "TEST", 58, 66], ["T-bet", "TEST", 70, 75], ["EOMES co-expression", "TEST", 80, 99], ["EOMES", "TEST", 170, 175], ["T", "TEST", 177, 178], ["the CpG", "TREATMENT", 200, 207], ["ADJ+CpG groups", "TREATMENT", 212, 226]]], ["By contrast, a greater proportion of CD8 T cells in GLA and ADJ+GLA groups expressed EOMES, but not T-bet (T-bet LO EOMES HI ) (Fig. S1C) .", [["CD8 T cells", "ANATOMY", 37, 48], ["CD8", "GENE_OR_GENE_PRODUCT", 37, 40], ["GLA", "SIMPLE_CHEMICAL", 52, 55], ["T-bet", "GENE_OR_GENE_PRODUCT", 100, 105], ["CD8 T cells", "CELL_TYPE", 37, 48], ["EOMES", "PROTEIN", 85, 90], ["T-bet", "PROTEIN", 100, 105], ["bet", "PROTEIN", 109, 112], ["GLA", "TEST", 52, 55], ["EOMES", "TEST", 85, 90], ["T", "TEST", 100, 101], ["CD8 T cells", "OBSERVATION", 37, 48]]], ["Taken together, terminal differentiation of effector CD8 T cells in ADJ and/or CpG was linked to high levels of T-bet, IRF-4 and BATF.IntroductionNext, we assessed expression of CD103 and CD69 to ask whether adjuvants affected mucosal imprinting of CD8 T cells in the RT.", [["effector CD8 T cells", "ANATOMY", 44, 64], ["ADJ", "ANATOMY", 68, 71], ["mucosal", "ANATOMY", 227, 234], ["CD8 T cells", "ANATOMY", 249, 260], ["CpG", "CHEMICAL", 79, 82], ["CD8 T", "GENE_OR_GENE_PRODUCT", 53, 58], ["ADJ", "GENE_OR_GENE_PRODUCT", 68, 71], ["T-bet", "GENE_OR_GENE_PRODUCT", 112, 117], ["IRF-4", "GENE_OR_GENE_PRODUCT", 119, 124], ["BATF", "GENE_OR_GENE_PRODUCT", 129, 133], ["CD103", "GENE_OR_GENE_PRODUCT", 178, 183], ["CD69", "GENE_OR_GENE_PRODUCT", 188, 192], ["mucosal", "PATHOLOGICAL_FORMATION", 227, 234], ["CD8 T cells", "CELL", 249, 260], ["effector CD8 T cells", "CELL_TYPE", 44, 64], ["ADJ and/or CpG", "DNA", 68, 82], ["T-bet", "PROTEIN", 112, 117], ["IRF-4", "PROTEIN", 119, 124], ["BATF", "PROTEIN", 129, 133], ["CD103", "PROTEIN", 178, 183], ["CD69", "PROTEIN", 188, 192], ["CD8 T cells", "CELL_TYPE", 249, 260], ["ADJ", "TEST", 68, 71], ["CpG", "PROBLEM", 79, 82], ["IRF", "TEST", 119, 122], ["BATF", "TREATMENT", 129, 133], ["CD103", "PROBLEM", 178, 183], ["adjuvants", "TREATMENT", 208, 217], ["terminal", "OBSERVATION_MODIFIER", 16, 24], ["differentiation", "OBSERVATION_MODIFIER", 25, 40], ["effector CD8", "OBSERVATION", 44, 56]]], ["The majority of NP366-specific CD8 T cells in lungs and BAL expressed CD69 but not CD103 in all groups.", [["CD8 T cells", "ANATOMY", 31, 42], ["lungs", "ANATOMY", 46, 51], ["BAL", "ANATOMY", 56, 59], ["NP366", "GENE_OR_GENE_PRODUCT", 16, 21], ["CD8", "GENE_OR_GENE_PRODUCT", 31, 34], ["lungs", "ORGAN", 46, 51], ["BAL", "CELL", 56, 59], ["CD69", "GENE_OR_GENE_PRODUCT", 70, 74], ["CD103", "GENE_OR_GENE_PRODUCT", 83, 88], ["NP366", "PROTEIN", 16, 21], ["CD8 T cells", "CELL_TYPE", 31, 42], ["CD69", "PROTEIN", 70, 74], ["CD103", "PROTEIN", 83, 88], ["NP366", "TEST", 16, 21], ["BAL", "TEST", 56, 59], ["CD69", "TEST", 70, 74], ["CD8 T cells", "OBSERVATION", 31, 42], ["lungs", "ANATOMY", 46, 51], ["BAL", "ANATOMY", 56, 59], ["not", "UNCERTAINTY", 79, 82], ["CD103", "OBSERVATION", 83, 88]]], ["The percentages of CD103 HI CD69 HI CD8 T cells in ADJ, ADJ+CpG and ADJ+GLA groups were higher than in CpG and GLA groups, which suggested that ADJ was a potent inducer of CD103 (Fig. 1E) .", [["CD8 T cells", "ANATOMY", 36, 47], ["ADJ", "ANATOMY", 51, 54], ["ADJ", "ANATOMY", 56, 59], ["ADJ", "CHEMICAL", 144, 147], ["CpG", "CHEMICAL", 60, 63], ["CpG", "CHEMICAL", 103, 106], ["CD103", "GENE_OR_GENE_PRODUCT", 19, 24], ["CD69", "GENE_OR_GENE_PRODUCT", 28, 32], ["GLA", "SIMPLE_CHEMICAL", 111, 114], ["ADJ", "SIMPLE_CHEMICAL", 144, 147], ["CD103", "GENE_OR_GENE_PRODUCT", 172, 177], ["CD103", "PROTEIN", 19, 24], ["CD69", "PROTEIN", 28, 32], ["CD8 T cells", "CELL_TYPE", 36, 47], ["CD103", "PROTEIN", 172, 177], ["The percentages", "TEST", 0, 15], ["CD103", "TEST", 19, 24], ["CD69", "TEST", 28, 32], ["T cells", "TEST", 40, 47], ["ADJ", "TEST", 51, 54], ["ADJ", "TEST", 56, 59], ["CpG", "TEST", 60, 63], ["ADJ", "TEST", 68, 71], ["GLA groups", "TEST", 72, 82], ["percentages", "OBSERVATION_MODIFIER", 4, 15], ["CD103", "ANATOMY", 19, 24]]], ["Altogether, Fig. 1 shows that ADJ and/or CpG promoted different facets of CD8 T-cell terminal differentiation.IntroductionRemarkably however, when combined with ADJ, GLA selectively antagonized ADJ-driven terminal differentiation program without affecting mucosal imprinting of CD8 T cells.", [["CD8 T-cell", "ANATOMY", 74, 84], ["mucosal", "ANATOMY", 256, 263], ["CD8 T cells", "ANATOMY", 278, 289], ["CpG", "CHEMICAL", 41, 44], ["GLA", "CHEMICAL", 166, 169], ["ADJ", "CHEMICAL", 194, 197], ["CpG", "CHEMICAL", 41, 44], ["GLA", "CHEMICAL", 166, 169], ["ADJ", "GENE_OR_GENE_PRODUCT", 30, 33], ["CpG", "CELLULAR_COMPONENT", 41, 44], ["CD8", "GENE_OR_GENE_PRODUCT", 74, 77], ["ADJ", "SIMPLE_CHEMICAL", 161, 164], ["GLA", "SIMPLE_CHEMICAL", 166, 169], ["ADJ", "SIMPLE_CHEMICAL", 194, 197], ["mucosal", "MULTI-TISSUE_STRUCTURE", 256, 263], ["CD8 T", "GENE_OR_GENE_PRODUCT", 278, 283], ["ADJ and/or CpG", "DNA", 30, 44], ["CD8", "PROTEIN", 74, 77], ["ADJ", "PROTEIN", 194, 197], ["CD8 T cells", "CELL_TYPE", 278, 289], ["ADJ", "TEST", 30, 33], ["CpG", "TREATMENT", 41, 44], ["GLA selectively antagonized ADJ", "TREATMENT", 166, 197], ["terminal differentiation program", "TREATMENT", 205, 237], ["cell", "OBSERVATION", 80, 84], ["terminal differentiation", "OBSERVATION", 85, 109], ["CD8 T cells", "OBSERVATION", 278, 289]]], ["Thus, ADJ-driven CD8 T-cell differentiation program can be augmented or antagonized by TLR agonists CpG and GLA respectively.Adjuvants Regulate Differentiation and Mucosal Imprinting of Effector CD4 T Cells in the RTNext, we characterized NP-specific CD4 T-cell responses to various adjuvants following mucosal immunization.", [["CD8 T-cell", "ANATOMY", 17, 27], ["Mucosal", "ANATOMY", 164, 171], ["Effector CD4 T Cells", "ANATOMY", 186, 206], ["CD4 T-cell", "ANATOMY", 251, 261], ["mucosal", "ANATOMY", 303, 310], ["CpG", "CHEMICAL", 100, 103], ["ADJ", "GENE_OR_GENE_PRODUCT", 6, 9], ["CD8", "GENE_OR_GENE_PRODUCT", 17, 20], ["TLR", "GENE_OR_GENE_PRODUCT", 87, 90], ["GLA", "SIMPLE_CHEMICAL", 108, 111], ["Effector CD4 T Cells", "CELL", 186, 206], ["NP", "CELL", 239, 241], ["CD4 T-cell", "CELL", 251, 261], ["mucosal", "MULTI-TISSUE_STRUCTURE", 303, 310], ["ADJ", "PROTEIN", 6, 9], ["TLR", "PROTEIN", 87, 90], ["Effector CD4 T Cells", "CELL_TYPE", 186, 206], ["CD4", "PROTEIN", 251, 254], ["ADJ", "TEST", 6, 9], ["CD8 T-cell differentiation program", "TREATMENT", 17, 51], ["Adjuvants Regulate Differentiation", "TREATMENT", 125, 159], ["NP", "TEST", 239, 241], ["various adjuvants", "TREATMENT", 275, 292], ["mucosal immunization", "TREATMENT", 303, 323], ["GLA", "ANATOMY", 108, 111], ["Mucosal", "ANATOMY", 164, 171], ["Effector CD4", "OBSERVATION", 186, 198]]], ["At day 8 PV, high perecentages of NP311-specific CD4 T cells were detected in lungs and airways of all groups of mice ( Fig. 2A) .", [["CD4 T cells", "ANATOMY", 49, 60], ["lungs", "ANATOMY", 78, 83], ["airways", "ANATOMY", 88, 95], ["NP311", "GENE_OR_GENE_PRODUCT", 34, 39], ["CD4 T", "GENE_OR_GENE_PRODUCT", 49, 54], ["lungs", "ORGAN", 78, 83], ["airways", "MULTI-TISSUE_STRUCTURE", 88, 95], ["mice", "ORGANISM", 113, 117], ["NP311", "PROTEIN", 34, 39], ["CD4 T cells", "CELL_TYPE", 49, 60], ["mice", "SPECIES", 113, 117], ["mice", "SPECIES", 113, 117], ["PV", "TEST", 9, 11], ["NP311", "TEST", 34, 39], ["specific CD4 T cells", "TEST", 40, 60], ["lungs", "ANATOMY", 78, 83], ["airways", "ANATOMY", 88, 95]]], ["The percentages and total numbers of NP311-specific CD4 T cells in lungs and airways were comparable between ADJ, CpG, GLA and ADJ+CpG groups.", [["CD4 T cells", "ANATOMY", 52, 63], ["lungs", "ANATOMY", 67, 72], ["airways", "ANATOMY", 77, 84], ["ADJ", "ANATOMY", 109, 112], ["CpG", "CHEMICAL", 114, 117], ["CpG", "CHEMICAL", 131, 134], ["NP311", "GENE_OR_GENE_PRODUCT", 37, 42], ["CD4 T", "GENE_OR_GENE_PRODUCT", 52, 57], ["lungs", "ORGAN", 67, 72], ["airways", "MULTI-TISSUE_STRUCTURE", 77, 84], ["GLA", "SIMPLE_CHEMICAL", 119, 122], ["NP311", "PROTEIN", 37, 42], ["CD4 T cells", "CELL_TYPE", 52, 63], ["The percentages", "TEST", 0, 15], ["total numbers", "TEST", 20, 33], ["NP311", "TEST", 37, 42], ["ADJ, CpG", "TREATMENT", 109, 117], ["ADJ+CpG groups", "TREATMENT", 127, 141], ["percentages", "OBSERVATION_MODIFIER", 4, 15], ["total", "OBSERVATION_MODIFIER", 20, 25], ["lungs", "ANATOMY", 67, 72], ["airways", "ANATOMY", 77, 84]]], ["However, the total numbers of NP311-specific CD4 T cells in the lungs and airways of ADJ+GLA group were significantly higher than in other groups ( Fig. 2A) .Adjuvants Regulate Differentiation and Mucosal Imprinting of Effector CD4 T Cells in the RTPhenotypically, ADJ and CpG promoted the expression of terminal differentiation markers CX3CR1 and KLRG-1, respectively (Fig. 2B) .", [["CD4 T cells", "ANATOMY", 45, 56], ["lungs", "ANATOMY", 64, 69], ["airways", "ANATOMY", 74, 81], ["Mucosal", "ANATOMY", 197, 204], ["Effector CD4 T Cells", "ANATOMY", 219, 239], ["CpG", "CHEMICAL", 273, 276], ["NP311", "GENE_OR_GENE_PRODUCT", 30, 35], ["CD4 T", "GENE_OR_GENE_PRODUCT", 45, 50], ["lungs", "ORGAN", 64, 69], ["airways", "MULTI-TISSUE_STRUCTURE", 74, 81], ["CX3CR1", "GENE_OR_GENE_PRODUCT", 337, 343], ["KLRG-1", "GENE_OR_GENE_PRODUCT", 348, 354], ["NP311", "PROTEIN", 30, 35], ["CD4 T cells", "CELL_TYPE", 45, 56], ["Effector CD4 T Cells", "CELL_TYPE", 219, 239], ["terminal differentiation markers", "PROTEIN", 304, 336], ["CX3CR1", "PROTEIN", 337, 343], ["KLRG", "PROTEIN", 348, 352], ["the total numbers", "TEST", 9, 26], ["NP311", "TEST", 30, 35], ["GLA group", "TEST", 89, 98], ["Adjuvants Regulate Differentiation", "TREATMENT", 158, 192], ["Effector CD4 T Cells", "TREATMENT", 219, 239], ["ADJ and CpG", "TREATMENT", 265, 276], ["CX3CR1", "TEST", 337, 343], ["KLRG", "TEST", 348, 352], ["lungs", "ANATOMY", 64, 69], ["airways", "ANATOMY", 74, 81], ["higher", "OBSERVATION_MODIFIER", 118, 124], ["Mucosal", "ANATOMY", 197, 204], ["Effector CD4", "OBSERVATION", 219, 231], ["terminal", "OBSERVATION_MODIFIER", 304, 312], ["differentiation", "OBSERVATION_MODIFIER", 313, 328]]], ["By contrast, expressions of CX3CR1 and KLRG-1 were lowest in the GLA group (Fig. 2B) and GLA tempered ADJ-induced expression of CX3CR1 in ADJ+GLA group.", [["ADJ", "ANATOMY", 138, 141], ["ADJ", "CHEMICAL", 102, 105], ["CX3CR1", "GENE_OR_GENE_PRODUCT", 28, 34], ["KLRG-1", "GENE_OR_GENE_PRODUCT", 39, 45], ["GLA", "SIMPLE_CHEMICAL", 65, 68], ["GLA", "SIMPLE_CHEMICAL", 89, 92], ["ADJ", "SIMPLE_CHEMICAL", 102, 105], ["CX3CR1", "GENE_OR_GENE_PRODUCT", 128, 134], ["ADJ+GLA", "SIMPLE_CHEMICAL", 138, 145], ["CX3CR1", "PROTEIN", 28, 34], ["KLRG-1", "PROTEIN", 39, 45], ["CX3CR1", "PROTEIN", 128, 134], ["CX3CR1", "TEST", 28, 34], ["KLRG", "TEST", 39, 43], ["GLA tempered ADJ", "TEST", 89, 105], ["CX3CR1", "TEST", 128, 134], ["CX3CR1", "OBSERVATION", 128, 134]]], ["NP311-specific CD4 T cells from ADJ and/or CpG groups contained greater levels of T-bet, as compared to other groups (Fig. 2C) , but EOMES levels were not different between groups.", [["CD4 T cells", "ANATOMY", 15, 26], ["ADJ", "ANATOMY", 32, 35], ["CpG", "CHEMICAL", 43, 46], ["NP311", "GENE_OR_GENE_PRODUCT", 0, 5], ["CD4", "GENE_OR_GENE_PRODUCT", 15, 18], ["ADJ", "CANCER", 32, 35], ["T-bet", "GENE_OR_GENE_PRODUCT", 82, 87], ["EOMES", "SIMPLE_CHEMICAL", 133, 138], ["NP311", "PROTEIN", 0, 5], ["CD4 T cells", "CELL_TYPE", 15, 26], ["EOMES", "PROTEIN", 133, 138], ["ADJ", "TEST", 32, 35], ["CpG groups", "TEST", 43, 53], ["EOMES levels", "TEST", 133, 145], ["greater", "OBSERVATION_MODIFIER", 64, 71]]], ["GLA with or without ADJ induced the lowest levels of T-bet, which resulted in greater percentages of T-bet LO EOMES HI CD4 T cells in GLA and ADJ+GLA groups (Fig. 2D) .", [["CD4 T cells", "ANATOMY", 119, 130], ["GLA", "CHEMICAL", 0, 3], ["ADJ", "CHEMICAL", 20, 23], ["ADJ", "CHEMICAL", 20, 23], ["GLA", "SIMPLE_CHEMICAL", 0, 3], ["ADJ", "SIMPLE_CHEMICAL", 20, 23], ["T-bet", "GENE_OR_GENE_PRODUCT", 53, 58], ["GLA", "SIMPLE_CHEMICAL", 134, 137], ["T-bet", "PROTEIN", 53, 58], ["LO", "PROTEIN", 107, 109], ["CD4 T cells", "CELL_TYPE", 119, 130], ["GLA", "TEST", 134, 137], ["greater", "OBSERVATION_MODIFIER", 78, 85], ["GLA", "ANATOMY", 134, 137]]], ["Thus, ADJ and CpG promoted terminal differentiation of CD4 T cells byAdjuvants Regulate Differentiation and Mucosal Imprinting of Effector CD4 T Cells in the RTinducing T-bet expression, as compared to GLA or ADJ+GLA groups.", [["CD4 T cells", "ANATOMY", 55, 66], ["Mucosal", "ANATOMY", 108, 115], ["Effector CD4 T Cells", "ANATOMY", 130, 150], ["ADJ", "CHEMICAL", 6, 9], ["CpG", "CHEMICAL", 14, 17], ["ADJ", "CHEMICAL", 6, 9], ["CpG", "CHEMICAL", 14, 17], ["ADJ", "SIMPLE_CHEMICAL", 6, 9], ["CpG", "SIMPLE_CHEMICAL", 14, 17], ["CD4 T", "GENE_OR_GENE_PRODUCT", 55, 60], ["Mucosal", "ORGAN", 108, 115], ["T-bet", "GENE_OR_GENE_PRODUCT", 169, 174], ["GLA", "SIMPLE_CHEMICAL", 202, 205], ["ADJ+GLA", "SIMPLE_CHEMICAL", 209, 216], ["CD4 T cells", "CELL_TYPE", 55, 66], ["Effector CD4 T Cells", "CELL_TYPE", 130, 150], ["ADJ and CpG", "TREATMENT", 6, 17], ["CD4 T cells byAdjuvants", "TREATMENT", 55, 78], ["GLA", "TEST", 202, 205], ["Mucosal", "ANATOMY", 108, 115], ["Effector CD4", "OBSERVATION", 130, 142]]], ["Analysis of mucosal imprinting markers CD103 and CD69 showed that ADJ-containing adjuvants elicited higher percentages of CD103 HI and CD103 HI CD69 HI CD4 T cells in lungs (Fig. 2E) .", [["mucosal", "ANATOMY", 12, 19], ["CD4 T cells", "ANATOMY", 152, 163], ["lungs", "ANATOMY", 167, 172], ["ADJ", "CHEMICAL", 66, 69], ["mucosal", "MULTI-TISSUE_STRUCTURE", 12, 19], ["CD103", "GENE_OR_GENE_PRODUCT", 39, 44], ["CD69", "GENE_OR_GENE_PRODUCT", 49, 53], ["ADJ", "SIMPLE_CHEMICAL", 66, 69], ["CD103", "GENE_OR_GENE_PRODUCT", 122, 127], ["CD103", "GENE_OR_GENE_PRODUCT", 135, 140], ["CD69", "GENE_OR_GENE_PRODUCT", 144, 148], ["lungs", "ORGAN", 167, 172], ["mucosal imprinting markers", "PROTEIN", 12, 38], ["CD103", "PROTEIN", 39, 44], ["CD69", "PROTEIN", 49, 53], ["ADJ", "PROTEIN", 66, 69], ["CD103", "PROTEIN", 122, 127], ["CD103", "PROTEIN", 135, 140], ["CD69", "PROTEIN", 144, 148], ["CD4 T cells", "CELL_TYPE", 152, 163], ["mucosal imprinting markers CD103", "TEST", 12, 44], ["CD69", "TEST", 49, 53], ["ADJ", "TEST", 66, 69], ["adjuvants", "TREATMENT", 81, 90], ["CD103 HI", "TEST", 122, 130], ["CD103", "TEST", 135, 140], ["CD69", "TEST", 144, 148], ["mucosal", "ANATOMY", 12, 19], ["CD103", "ANATOMY", 122, 127], ["lungs", "ANATOMY", 167, 172]]], ["Thus, in contrast to ADJ and CpG, combining ADJ with GLA promoted the development of less differentiated mucosally-imprinted CD4 T cells in the lungs and airways.AdjuvantsWe then asked whether adjuvants regulated functional programming of effector CD8 and CD4 T cells into TC1/TC17 or TH1/TH17 subsets respectively, in lungs.", [["mucosally", "ANATOMY", 105, 114], ["CD4 T cells", "ANATOMY", 125, 136], ["lungs", "ANATOMY", 144, 149], ["airways", "ANATOMY", 154, 161], ["CD8", "ANATOMY", 248, 251], ["CD4 T cells", "ANATOMY", 256, 267], ["TC1/TC17", "ANATOMY", 273, 281], ["lungs", "ANATOMY", 319, 324], ["ADJ", "CHEMICAL", 44, 47], ["GLA", "CHEMICAL", 53, 56], ["ADJ", "CHEMICAL", 21, 24], ["CpG", "CHEMICAL", 29, 32], ["GLA", "CHEMICAL", 53, 56], ["ADJ", "GENE_OR_GENE_PRODUCT", 21, 24], ["ADJ", "SIMPLE_CHEMICAL", 44, 47], ["GLA", "SIMPLE_CHEMICAL", 53, 56], ["mucosally", "CELL", 105, 114], ["CD4 T cells", "CELL", 125, 136], ["lungs", "ORGAN", 144, 149], ["airways", "MULTI-TISSUE_STRUCTURE", 154, 161], ["CD8", "GENE_OR_GENE_PRODUCT", 248, 251], ["CD4", "GENE_OR_GENE_PRODUCT", 256, 259], ["TC1", "GENE_OR_GENE_PRODUCT", 273, 276], ["TC17", "GENE_OR_GENE_PRODUCT", 277, 281], ["TH1", "GENE_OR_GENE_PRODUCT", 285, 288], ["lungs", "ORGAN", 319, 324], ["ADJ", "DNA", 21, 24], ["GLA", "PROTEIN", 53, 56], ["CD4 T cells", "CELL_TYPE", 125, 136], ["effector CD8 and CD4 T cells", "CELL_TYPE", 239, 267], ["TC1/TC17 or TH1/TH17 subsets", "CELL_LINE", 273, 301], ["CpG", "TREATMENT", 29, 32], ["GLA", "TREATMENT", 53, 56], ["adjuvants", "TREATMENT", 193, 202], ["TC1", "TEST", 273, 276], ["less", "OBSERVATION_MODIFIER", 85, 89], ["lungs", "ANATOMY", 144, 149], ["airways", "ANATOMY", 154, 161], ["TC17", "ANATOMY", 277, 281], ["TH17 subsets", "OBSERVATION", 289, 301], ["lungs", "ANATOMY", 319, 324]]], ["NP366-specific IFN-\uf067-producing TC1 CD8 T cells were induced in all groups and the percentages of such cells among CD8 T cells were generally higher in the ADJ+GLA group (Fig. 3A) .", [["TC1 CD8", "ANATOMY", 31, 38], ["T cells", "ANATOMY", 39, 46], ["cells", "ANATOMY", 102, 107], ["CD8", "ANATOMY", 114, 117], ["T cells", "ANATOMY", 118, 125], ["ADJ", "ANATOMY", 155, 158], ["NP366", "CHEMICAL", 0, 5], ["NP366", "GENE_OR_GENE_PRODUCT", 0, 5], ["IFN", "GENE_OR_GENE_PRODUCT", 15, 18], ["TC1 CD8", "GENE_OR_GENE_PRODUCT", 31, 38], ["T cells", "CELL", 39, 46], ["cells", "CELL", 102, 107], ["CD8", "GENE_OR_GENE_PRODUCT", 114, 117], ["T cells", "CELL", 118, 125], ["NP366", "PROTEIN", 0, 5], ["IFN", "PROTEIN", 15, 18], ["TC1 CD8", "CELL_LINE", 31, 38], ["T cells", "CELL_TYPE", 39, 46], ["CD8", "CELL_TYPE", 114, 117], ["T cells", "CELL_TYPE", 118, 125], ["T cells", "PROBLEM", 39, 46], ["such cells", "PROBLEM", 97, 107], ["T cells", "TEST", 118, 125], ["higher", "OBSERVATION_MODIFIER", 141, 147]]], ["Interestingly however, IL-17-producing NP366-specific TC17 CD8 T cells were strongly induced only in the GLA and ADJ+GLA groups.", [["TC17 CD8", "ANATOMY", 54, 62], ["T cells", "ANATOMY", 63, 70], ["IL-17", "GENE_OR_GENE_PRODUCT", 23, 28], ["NP366", "GENE_OR_GENE_PRODUCT", 39, 44], ["TC17 CD8", "GENE_OR_GENE_PRODUCT", 54, 62], ["T cells", "CELL", 63, 70], ["GLA", "SIMPLE_CHEMICAL", 105, 108], ["ADJ", "SIMPLE_CHEMICAL", 113, 116], ["IL-17", "PROTEIN", 23, 28], ["NP366", "PROTEIN", 39, 44], ["TC17 CD8", "CELL_LINE", 54, 62], ["T cells", "CELL_TYPE", 63, 70], ["IL", "TEST", 23, 25], ["T cells", "TEST", 63, 70], ["GLA", "ANATOMY", 105, 108]]], ["To further elucidate the relative dominance of TC1 versus TC17 in different adjuvant groups, we calculated the relative proportions of these cells among total cytokine-producing (IL-17+IFN-\uf067 producing cells) peptide-stimulated NP366-specific CD8 T cells (Fig. 3B) ; ~80-88% of NP366-specific cytokine-producing CD8 T cells produced IFN-\uf067 in the CpG and ADJ+CpG groups, and only 65%, 56% and 36% of such cells produced IFN-\uf067 in ADJ, GLA and ADJ+GLA groups, respectively.", [["cells", "ANATOMY", 141, 146], ["cells", "ANATOMY", 201, 206], ["NP366", "ANATOMY", 227, 232], ["CD8 T cells", "ANATOMY", 242, 253], ["CD8 T cells", "ANATOMY", 311, 322], ["cells", "ANATOMY", 403, 408], ["ADJ", "ANATOMY", 427, 430], ["CpG", "CHEMICAL", 345, 348], ["CpG", "CHEMICAL", 357, 360], ["TC1", "GENE_OR_GENE_PRODUCT", 47, 50], ["TC17", "GENE_OR_GENE_PRODUCT", 58, 62], ["cells", "CELL", 141, 146], ["IL-17", "GENE_OR_GENE_PRODUCT", 179, 184], ["cells", "CELL", 201, 206], ["NP366", "SIMPLE_CHEMICAL", 227, 232], ["CD8 T cells", "CELL", 242, 253], ["Fig. 3B", "CELL", 255, 262], ["NP366", "GENE_OR_GENE_PRODUCT", 277, 282], ["CD8 T cells", "CELL", 311, 322], ["IFN-\uf067", "GENE_OR_GENE_PRODUCT", 332, 337], ["cells", "CELL", 403, 408], ["IFN-\uf067", "GENE_OR_GENE_PRODUCT", 418, 423], ["ADJ", "SIMPLE_CHEMICAL", 427, 430], ["GLA", "SIMPLE_CHEMICAL", 432, 435], ["ADJ", "SIMPLE_CHEMICAL", 440, 443], ["GLA", "SIMPLE_CHEMICAL", 444, 447], ["TC1", "PROTEIN", 47, 50], ["TC17", "PROTEIN", 58, 62], ["cytokine-producing (IL-17+IFN-\uf067 producing cells", "CELL_LINE", 159, 206], ["NP366", "PROTEIN", 227, 232], ["CD8 T cells", "CELL_TYPE", 242, 253], ["NP366", "PROTEIN", 277, 282], ["cytokine", "PROTEIN", 292, 300], ["CD8 T cells", "CELL_TYPE", 311, 322], ["IFN", "PROTEIN", 332, 335], ["IFN", "PROTEIN", 418, 421], ["TC17 in different adjuvant groups", "TREATMENT", 58, 91], ["these cells", "PROBLEM", 135, 146], ["total cytokine", "TEST", 153, 167], ["IL", "TEST", 179, 181], ["IFN", "TEST", 185, 188], ["peptide", "TEST", 208, 215], ["NP366", "TEST", 277, 282], ["specific cytokine", "TEST", 283, 300], ["IFN", "TEST", 332, 335], ["the CpG", "TEST", 341, 348], ["CpG groups", "TEST", 357, 367], ["such cells", "TEST", 398, 408], ["IFN", "TEST", 418, 421], ["GLA", "TEST", 432, 435], ["GLA", "ANATOMY", 432, 435]]], ["Reciprocally, while only a relatively small fraction (12-20%) of NP366specific cytokine-producing CD8 T cells produced IL-17 or IL-17+IFN-\uf067 in CpG and ADJ+CpG groups, 40-57% of NP366-specific CD8 T cells produced IL-17 or IL-17+IFN-\uf067 in GLA and ADJ+GLA groups.", [["CD8 T cells", "ANATOMY", 98, 109], ["CD8 T cells", "ANATOMY", 192, 203], ["CpG", "CHEMICAL", 143, 146], ["CpG", "CHEMICAL", 155, 158], ["cytokine", "GENE_OR_GENE_PRODUCT", 79, 87], ["CD8", "GENE_OR_GENE_PRODUCT", 98, 101], ["IL-17", "GENE_OR_GENE_PRODUCT", 119, 124], ["IL-17", "GENE_OR_GENE_PRODUCT", 128, 133], ["IFN-\uf067", "GENE_OR_GENE_PRODUCT", 134, 139], ["CpG", "SIMPLE_CHEMICAL", 143, 146], ["ADJ", "SIMPLE_CHEMICAL", 151, 154], ["NP366", "GENE_OR_GENE_PRODUCT", 177, 182], ["CD8 T cells", "CELL", 192, 203], ["IL-17", "GENE_OR_GENE_PRODUCT", 213, 218], ["IL-17", "GENE_OR_GENE_PRODUCT", 222, 227], ["IFN-\uf067", "GENE_OR_GENE_PRODUCT", 228, 233], ["GLA", "SIMPLE_CHEMICAL", 237, 240], ["ADJ+GLA", "SIMPLE_CHEMICAL", 245, 252], ["NP366specific cytokine", "PROTEIN", 65, 87], ["CD8 T cells", "CELL_TYPE", 98, 109], ["IL", "PROTEIN", 119, 121], ["IL", "PROTEIN", 128, 130], ["IFN", "PROTEIN", 134, 137], ["NP366", "PROTEIN", 177, 182], ["CD8 T cells", "CELL_TYPE", 192, 203], ["IL", "PROTEIN", 222, 224], ["IFN", "PROTEIN", 228, 231], ["NP366specific cytokine", "TEST", 65, 87], ["IL", "TEST", 119, 121], ["IL", "TEST", 128, 130], ["IFN", "TEST", 134, 137], ["CpG", "TEST", 143, 146], ["ADJ", "TEST", 151, 154], ["CpG groups", "TEST", 155, 165], ["NP366", "TEST", 177, 182], ["IL", "TEST", 213, 215], ["IL", "TEST", 222, 224], ["IFN", "TEST", 228, 231], ["GLA", "TEST", 237, 240], ["small", "OBSERVATION_MODIFIER", 38, 43], ["fraction", "OBSERVATION", 44, 52], ["GLA", "ANATOMY", 237, 240]]], ["Thus, CpG and ADJ+CpG promoted functional polarization of TC1 cells, and ADJ, GLA and ADJ+GLA drove a balanced differentiation of TC1 and TC17 cells.", [["TC1 cells", "ANATOMY", 58, 67], ["TC1", "ANATOMY", 130, 133], ["TC17 cells", "ANATOMY", 138, 148], ["CpG", "CHEMICAL", 6, 9], ["CpG", "CHEMICAL", 18, 21], ["GLA", "CHEMICAL", 90, 93], ["CpG", "CHEMICAL", 6, 9], ["ADJ", "CHEMICAL", 14, 17], ["CpG", "CHEMICAL", 18, 21], ["CpG", "SIMPLE_CHEMICAL", 6, 9], ["TC1 cells", "CELL", 58, 67], ["ADJ", "SIMPLE_CHEMICAL", 73, 76], ["GLA", "SIMPLE_CHEMICAL", 78, 81], ["ADJ+GLA", "SIMPLE_CHEMICAL", 86, 93], ["TC1", "CELL", 130, 133], ["TC17 cells", "CELL", 138, 148], ["ADJ", "PROTEIN", 14, 17], ["TC1 cells", "CELL_LINE", 58, 67], ["ADJ", "PROTEIN", 86, 89], ["GLA", "PROTEIN", 90, 93], ["TC1", "CELL_LINE", 130, 133], ["TC17 cells", "CELL_LINE", 138, 148], ["CpG and ADJ+CpG", "TREATMENT", 6, 21], ["ADJ", "TEST", 73, 76], ["GLA", "TEST", 78, 81], ["ADJ+GLA", "TREATMENT", 86, 93], ["TC1 cells", "OBSERVATION", 58, 67], ["GLA", "ANATOMY", 78, 81], ["TC17 cells", "OBSERVATION", 138, 148]]], ["Evaluation of the ability of NP366-specific CD8 T cells to co-produce IFN-\uf067, TNF-\uf061 and IL-2 ( Fig. 3C) showed that all adjuvants induced polyfunctional CD8 T cells, but a significantly higher percentages of NP366-specific CD8 T cells in the GLA group were polyfunctional, as compared to other groups (Fig. 3C) .AdjuvantsNP311-specific TH1 and TH17 CD4 T cells were induced to varying levels by different adjuvants (Fig. 3D) .", [["CD8 T cells", "ANATOMY", 44, 55], ["CD8 T cells", "ANATOMY", 152, 163], ["CD8 T cells", "ANATOMY", 222, 233], ["TH17 CD4 T cells", "ANATOMY", 343, 359], ["AdjuvantsNP311", "CHEMICAL", 311, 325], ["NP366", "SIMPLE_CHEMICAL", 29, 34], ["CD8", "GENE_OR_GENE_PRODUCT", 44, 47], ["IFN-\uf067", "GENE_OR_GENE_PRODUCT", 70, 75], ["TNF-\uf061", "GENE_OR_GENE_PRODUCT", 77, 82], ["IL-2", "GENE_OR_GENE_PRODUCT", 87, 91], ["CD8 T cells", "CELL", 152, 163], ["NP366", "GENE_OR_GENE_PRODUCT", 207, 212], ["CD8", "GENE_OR_GENE_PRODUCT", 222, 225], ["GLA", "SIMPLE_CHEMICAL", 241, 244], ["AdjuvantsNP311", "SIMPLE_CHEMICAL", 311, 325], ["TH1", "GENE_OR_GENE_PRODUCT", 335, 338], ["NP366", "PROTEIN", 29, 34], ["CD8 T cells", "CELL_TYPE", 44, 55], ["IFN", "PROTEIN", 70, 73], ["TNF", "PROTEIN", 77, 80], ["IL", "PROTEIN", 87, 89], ["polyfunctional CD8 T cells", "CELL_TYPE", 137, 163], ["NP366", "PROTEIN", 207, 212], ["CD8 T cells", "CELL_TYPE", 222, 233], ["AdjuvantsNP311", "PROTEIN", 311, 325], ["TH1 and TH17 CD4 T cells", "CELL_TYPE", 335, 359], ["Evaluation", "TEST", 0, 10], ["NP366", "TEST", 29, 34], ["co-produce", "TEST", 59, 69], ["IFN", "TEST", 70, 73], ["\uf067", "TEST", 74, 75], ["TNF", "TEST", 77, 80], ["IL", "TEST", 87, 89], ["all adjuvants", "TREATMENT", 115, 128], ["polyfunctional CD8 T cells", "PROBLEM", 137, 163], ["NP366", "TEST", 207, 212], ["AdjuvantsNP311", "TEST", 311, 325], ["TH17 CD4 T cells", "TREATMENT", 343, 359], ["different adjuvants", "TREATMENT", 394, 413], ["polyfunctional CD8 T cells", "OBSERVATION", 137, 163]]], ["ADJ promoted TH17 polarization of effector CD4 T cells but CpG promoted TH1 differentiation and negated the TH17 skewing effects of ADJ in the ADJ+CpG group.", [["CD4 T cells", "ANATOMY", 43, 54], ["ADJ", "ANATOMY", 143, 146], ["ADJ", "CHEMICAL", 0, 3], ["ADJ", "CHEMICAL", 132, 135], ["CpG", "CHEMICAL", 147, 150], ["CpG", "CHEMICAL", 59, 62], ["CpG", "CHEMICAL", 147, 150], ["ADJ", "SIMPLE_CHEMICAL", 0, 3], ["TH17", "CELL", 13, 17], ["CD4 T", "GENE_OR_GENE_PRODUCT", 43, 48], ["TH1", "GENE_OR_GENE_PRODUCT", 72, 75], ["ADJ", "SIMPLE_CHEMICAL", 132, 135], ["effector CD4 T cells", "CELL_TYPE", 34, 54], ["effector CD4 T cells", "TREATMENT", 34, 54], ["CpG", "PROBLEM", 59, 62], ["ADJ in the ADJ+CpG group", "TREATMENT", 132, 156], ["TH17 polarization", "OBSERVATION", 13, 30], ["effector CD4", "OBSERVATION", 34, 46]]], ["TH17 differentiation dominated over the TH1 development in GLA and ADJ+GLA groups (Fig. 3E) .", [["TH1", "GENE_OR_GENE_PRODUCT", 40, 43], ["GLA", "SIMPLE_CHEMICAL", 59, 62], ["TH17 differentiation", "PROBLEM", 0, 20], ["GLA", "ANATOMY", 59, 62]]], ["In summary, while CpG and ADJ+CpG promoted the development of TH1 effector cells, ADJ, GLA and ADJ+GLA favored the differentiation of TH17 cells (Fig. 3E) .", [["TH1 effector cells", "ANATOMY", 62, 80], ["ADJ", "ANATOMY", 82, 85], ["TH17 cells", "ANATOMY", 134, 144], ["CpG", "CHEMICAL", 30, 33], ["ADJ", "CHEMICAL", 95, 98], ["GLA", "CHEMICAL", 99, 102], ["CpG", "CHEMICAL", 18, 21], ["ADJ", "CHEMICAL", 26, 29], ["CpG", "CHEMICAL", 30, 33], ["ADJ+CpG", "GENE_OR_GENE_PRODUCT", 26, 33], ["TH1 effector cells", "CELL", 62, 80], ["ADJ", "SIMPLE_CHEMICAL", 82, 85], ["GLA", "SIMPLE_CHEMICAL", 87, 90], ["ADJ+GLA", "SIMPLE_CHEMICAL", 95, 102], ["TH17 cells", "CELL", 134, 144], ["ADJ", "DNA", 26, 29], ["TH1 effector cells", "CELL_TYPE", 62, 80], ["ADJ", "PROTEIN", 95, 98], ["TH17 cells", "CELL_TYPE", 134, 144], ["ADJ+CpG", "TREATMENT", 26, 33], ["TH1 effector cells", "PROBLEM", 62, 80], ["GLA and ADJ+GLA", "TREATMENT", 87, 102], ["TH1 effector cells", "OBSERVATION", 62, 80], ["GLA", "ANATOMY", 87, 90], ["TH17 cells", "OBSERVATION", 134, 144]]], ["Polyfunctionality among NP311-specific CD4 T cells was largely comparable between groups (Fig. 3F) .Elicited Effector T CellsAntigenic stimulation and the inflammatory milieu govern effector differentiation during infections (25) (26) (27) .", [["CD4 T cells", "ANATOMY", 39, 50], ["infections", "DISEASE", 214, 224], ["NP311", "GENE_OR_GENE_PRODUCT", 24, 29], ["Effector T CellsAntigenic", "GENE_OR_GENE_PRODUCT", 109, 134], ["NP311-specific CD4 T cells", "CELL_LINE", 24, 50], ["Polyfunctionality", "TEST", 0, 17], ["Effector T CellsAntigenic stimulation", "TREATMENT", 109, 146], ["inflammatory", "OBSERVATION_MODIFIER", 155, 167]]], ["In order to determine whether adjuvants differed in terms of antigenic stimulation in draining lymph nodes (DLNs) and lungs, early after vaccination (day 2 and 5), we adoptively transferred 5x10 4 TCR transgenic OT-I CD8 T cells that express GFP under the control of Nur77 promoter; Nur77 expression faithfully reports specific TCR signaling in T cells (28) .", [["draining lymph nodes", "ANATOMY", 86, 106], ["DLNs", "ANATOMY", 108, 112], ["lungs", "ANATOMY", 118, 123], ["OT-I CD8 T cells", "ANATOMY", 212, 228], ["T cells", "ANATOMY", 345, 352], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 95, 106], ["DLNs", "MULTI-TISSUE_STRUCTURE", 108, 112], ["lungs", "ORGAN", 118, 123], ["TCR", "GENE_OR_GENE_PRODUCT", 197, 200], ["OT-I CD8 T cells", "CELL", 212, 228], ["GFP", "GENE_OR_GENE_PRODUCT", 242, 245], ["Nur77", "GENE_OR_GENE_PRODUCT", 267, 272], ["Nur77", "GENE_OR_GENE_PRODUCT", 283, 288], ["TCR", "GENE_OR_GENE_PRODUCT", 328, 331], ["T cells", "CELL", 345, 352], ["5x10 4 TCR transgenic OT-I CD8 T cells", "CELL_LINE", 190, 228], ["GFP", "PROTEIN", 242, 245], ["Nur77 promoter", "DNA", 267, 281], ["Nur77", "PROTEIN", 283, 288], ["TCR", "PROTEIN", 328, 331], ["T cells", "CELL_TYPE", 345, 352], ["adjuvants", "TREATMENT", 30, 39], ["antigenic stimulation", "TREATMENT", 61, 82], ["draining lymph nodes", "PROBLEM", 86, 106], ["Nur77 promoter", "TREATMENT", 267, 281], ["draining", "OBSERVATION_MODIFIER", 86, 94], ["lymph nodes", "OBSERVATION", 95, 106], ["lungs", "ANATOMY", 118, 123]]], ["Subsequently, mice were vaccinated with chicken ovalbumin (OVA) mixed with different adjuvants, and GFP expression by OT-I CD8 T cells was assessed at days 2 and 5 PV.", [["OT-I CD8 T cells", "ANATOMY", 118, 134], ["mice", "ORGANISM", 14, 18], ["chicken", "ORGANISM", 40, 47], ["OVA", "SIMPLE_CHEMICAL", 59, 62], ["GFP", "GENE_OR_GENE_PRODUCT", 100, 103], ["OT-I CD8", "GENE_OR_GENE_PRODUCT", 118, 126], ["GFP", "PROTEIN", 100, 103], ["I CD8 T cells", "CELL_TYPE", 121, 134], ["mice", "SPECIES", 14, 18], ["chicken", "SPECIES", 40, 47], ["mice", "SPECIES", 14, 18], ["chicken", "SPECIES", 40, 47], ["chicken ovalbumin (OVA)", "TREATMENT", 40, 63], ["different adjuvants", "TREATMENT", 75, 94], ["GFP expression", "TEST", 100, 114], ["OT", "TEST", 118, 120]]], ["OT-I CD8 T cells expressed readily detectable levels of GFP in DLNs and lungs at different days PV (Fig. 4A) .", [["OT-I CD8 T cells", "ANATOMY", 0, 16], ["DLNs", "ANATOMY", 63, 67], ["lungs", "ANATOMY", 72, 77], ["OT-I CD8", "GENE_OR_GENE_PRODUCT", 0, 8], ["GFP", "GENE_OR_GENE_PRODUCT", 56, 59], ["DLNs", "CELL", 63, 67], ["lungs", "ORGAN", 72, 77], ["OT-I CD8 T cells", "CELL_LINE", 0, 16], ["GFP", "PROTEIN", 56, 59], ["DLNs", "CELL_TYPE", 63, 67], ["GFP", "TEST", 56, 59], ["lungs", "ANATOMY", 72, 77]]], ["Overall, GFP levels were not significantly different for OT-I CD8 T cells (P<0.05) in DLNs between various groups (except between GLA and ADJ+GLA) at day 5 PV (Fig. 4A) .", [["OT-I CD8 T cells", "ANATOMY", 57, 73], ["DLNs", "ANATOMY", 86, 90], ["GFP", "GENE_OR_GENE_PRODUCT", 9, 12], ["OT-I CD8", "GENE_OR_GENE_PRODUCT", 57, 65], ["DLNs", "PATHOLOGICAL_FORMATION", 86, 90], ["GLA", "SIMPLE_CHEMICAL", 130, 133], ["GFP", "PROTEIN", 9, 12], ["CD8 T cells", "CELL_TYPE", 62, 73], ["GFP levels", "TEST", 9, 19], ["OT", "TEST", 57, 59], ["P", "TEST", 75, 76], ["GLA", "TEST", 130, 133]]], ["OT-I CD8 T cells were not detectable in lungs until day 5 PV; at day 5 PV, significantly (P<0.05) higher levels of GFP were detected in OT-I CD8 T cells from the lungs of ADJ mice, compared to CpG, GLA and ADJ+GLA groups (Fig. 4A) .", [["OT-I CD8 T cells", "ANATOMY", 0, 16], ["lungs", "ANATOMY", 40, 45], ["OT-I CD8 T cells", "ANATOMY", 136, 152], ["lungs", "ANATOMY", 162, 167], ["CpG", "CHEMICAL", 193, 196], ["OT-I CD8", "GENE_OR_GENE_PRODUCT", 0, 8], ["lungs", "ORGAN", 40, 45], ["GFP", "GENE_OR_GENE_PRODUCT", 115, 118], ["OT-I CD8 T cells", "CELL", 136, 152], ["lungs", "ORGAN", 162, 167], ["ADJ mice", "ORGANISM", 171, 179], ["GLA", "SIMPLE_CHEMICAL", 198, 201], ["ADJ+GLA", "SIMPLE_CHEMICAL", 206, 213], ["OT-I CD8 T cells", "CELL_LINE", 0, 16], ["GFP", "PROTEIN", 115, 118], ["OT-I CD8 T cells", "CELL_LINE", 136, 152], ["mice", "SPECIES", 175, 179], ["mice", "SPECIES", 175, 179], ["CD8 T cells", "TEST", 5, 16], ["PV", "TEST", 71, 73], ["higher levels of GFP", "PROBLEM", 98, 118], ["OT", "TEST", 136, 138], ["CpG", "TEST", 193, 196], ["GLA", "TEST", 198, 201], ["lungs", "ANATOMY", 40, 45], ["lungs", "ANATOMY", 162, 167], ["GLA", "ANATOMY", 198, 201]]], ["Adoptive transfer of 5x10 4 TCR transgenic CD8 T cells was technically essential to assess T-cell signaling early after vaccination (Fig. 4A ), but transfer of such unphysiologically high numbers of T cells might affect their differentiation (29) .Elicited Effector T CellsTherefore, for assessment of TCR signaling at day 8 PV, we adoptively transferred 10 3 Nur77-GFP OT-I TCR transgenic CD8 T cells prior to vaccination.", [["CD8 T cells", "ANATOMY", 43, 54], ["T-cell", "ANATOMY", 91, 97], ["T cells", "ANATOMY", 199, 206], ["Effector T Cells", "ANATOMY", 257, 273], ["CD8 T cells", "ANATOMY", 390, 401], ["TCR", "GENE_OR_GENE_PRODUCT", 28, 31], ["CD8", "GENE_OR_GENE_PRODUCT", 43, 46], ["T-cell", "CELL", 91, 97], ["T cells", "CELL", 199, 206], ["Effector T Cells", "CELL", 257, 273], ["TCR", "GENE_OR_GENE_PRODUCT", 302, 305], ["Nur77", "GENE_OR_GENE_PRODUCT", 360, 365], ["OT-I TCR", "GENE_OR_GENE_PRODUCT", 370, 378], ["CD8", "GENE_OR_GENE_PRODUCT", 390, 393], ["5x10 4 TCR transgenic CD8 T cells", "CELL_LINE", 21, 54], ["T cells", "CELL_TYPE", 199, 206], ["TCR", "PROTEIN", 302, 305], ["Nur77", "PROTEIN", 360, 365], ["TCR", "PROTEIN", 375, 378], ["CD8 T cells", "CELL_TYPE", 390, 401], ["Effector T Cells", "PROBLEM", 257, 273], ["assessment", "TEST", 288, 298], ["TCR signaling", "PROBLEM", 302, 315], ["Nur77", "TEST", 360, 365], ["OT", "TEST", 370, 372], ["vaccination", "TREATMENT", 411, 422], ["Effector T Cells", "OBSERVATION", 257, 273]]], ["The pattern of GFP fluorescence in donor OT-I CD8 T cells in DLNs and lungs of vaccinated mice at day 8 PV, is shown in Fig. S2 .Elicited Effector T CellsOn the 8 th day PV, OT-I CD8 T cells in the DLNs of ADJ mice expressed higher levels of GFP, compared to other groups, but the differences did not reach statistical significance.", [["OT-I CD8 T cells", "ANATOMY", 41, 57], ["DLNs", "ANATOMY", 61, 65], ["lungs", "ANATOMY", 70, 75], ["OT-I CD8 T cells", "ANATOMY", 174, 190], ["DLNs", "ANATOMY", 198, 202], ["GFP", "GENE_OR_GENE_PRODUCT", 15, 18], ["OT-I CD8 T cells", "CELL", 41, 57], ["DLNs", "CANCER", 61, 65], ["lungs", "ORGAN", 70, 75], ["mice", "ORGANISM", 90, 94], ["S2", "GENE_OR_GENE_PRODUCT", 125, 127], ["Effector T CellsOn", "CELL", 138, 156], ["OT-I CD8", "GENE_OR_GENE_PRODUCT", 174, 182], ["DLNs", "CANCER", 198, 202], ["ADJ mice", "ORGANISM", 206, 214], ["GFP", "GENE_OR_GENE_PRODUCT", 242, 245], ["donor OT-I CD8 T cells", "CELL_TYPE", 35, 57], ["DLNs", "CELL_TYPE", 61, 65], ["S2", "PROTEIN", 125, 127], ["OT-I CD8 T cells", "CELL_TYPE", 174, 190], ["DLNs", "CELL_TYPE", 198, 202], ["GFP", "PROTEIN", 242, 245], ["mice", "SPECIES", 90, 94], ["mice", "SPECIES", 210, 214], ["mice", "SPECIES", 90, 94], ["mice", "SPECIES", 210, 214], ["GFP fluorescence", "TEST", 15, 31], ["donor OT", "TEST", 35, 43], ["DLNs", "TEST", 61, 65], ["OT", "TEST", 174, 176], ["GFP", "PROBLEM", 242, 245], ["GFP fluorescence", "OBSERVATION", 15, 31], ["lungs", "ANATOMY", 70, 75]]], ["By contrast, on day 8 PV, GFP levels in OT-I CD8 T cells from lungs of ADJ mice were significantly higher (P<0.05) than in OT-I CD8 T cells from lungs of CpG, GLA and ADJ+GLA mice (Fig. 4A) .Elicited Effector T CellsCollectively, a greater percentage of OT-I CD8 T cells in the lungs of ADJ group showed evidence of active TCR signaling in the lungs at days 5 and 8 after vaccination, and, notably, this effect of ADJ was dampened by GLA but not CpG.", [["OT-I CD8 T cells", "ANATOMY", 40, 56], ["lungs", "ANATOMY", 62, 67], ["OT-I CD8 T cells", "ANATOMY", 123, 139], ["lungs", "ANATOMY", 145, 150], ["OT-I CD8 T cells", "ANATOMY", 254, 270], ["lungs", "ANATOMY", 278, 283], ["ADJ", "ANATOMY", 287, 290], ["lungs", "ANATOMY", 344, 349], ["TCR", "CHEMICAL", 323, 326], ["ADJ", "CHEMICAL", 414, 417], ["GLA", "CHEMICAL", 434, 437], ["GLA", "CHEMICAL", 434, 437], ["GFP", "GENE_OR_GENE_PRODUCT", 26, 29], ["OT-I CD8 T", "GENE_OR_GENE_PRODUCT", 40, 50], ["lungs", "ORGAN", 62, 67], ["ADJ mice", "ORGANISM", 71, 79], ["OT-I CD8 T cells", "CELL", 123, 139], ["lungs", "ORGAN", 145, 150], ["Effector T", "CELL", 200, 210], ["OT-I CD8 T cells", "CELL", 254, 270], ["lungs", "ORGAN", 278, 283], ["ADJ", "CANCER", 287, 290], ["TCR", "GENE_OR_GENE_PRODUCT", 323, 326], ["lungs", "ORGAN", 344, 349], ["ADJ", "SIMPLE_CHEMICAL", 414, 417], ["GLA", "SIMPLE_CHEMICAL", 434, 437], ["GFP", "PROTEIN", 26, 29], ["I CD8 T cells", "CELL_TYPE", 43, 56], ["CD8 T cells", "CELL_TYPE", 128, 139], ["OT-I CD8 T cells", "CELL_TYPE", 254, 270], ["TCR", "PROTEIN", 323, 326], ["mice", "SPECIES", 75, 79], ["mice", "SPECIES", 175, 179], ["mice", "SPECIES", 75, 79], ["PV", "TEST", 22, 24], ["GFP levels", "TEST", 26, 36], ["OT", "TEST", 40, 42], ["ADJ mice", "TEST", 71, 79], ["OT", "TEST", 123, 125], ["CpG", "TEST", 154, 157], ["GLA", "TEST", 159, 162], ["ADJ", "TEST", 167, 170], ["OT", "TEST", 254, 256], ["active TCR signaling in the lungs", "PROBLEM", 316, 349], ["vaccination", "TREATMENT", 372, 383], ["lungs", "ANATOMY", 62, 67], ["lungs", "ANATOMY", 145, 150], ["lungs", "ANATOMY", 278, 283], ["evidence of", "UNCERTAINTY", 304, 315], ["active", "OBSERVATION_MODIFIER", 316, 322], ["TCR", "OBSERVATION", 323, 326], ["lungs", "ANATOMY", 344, 349]]], ["Enhanced TCR signaling in ADJ group (and to a lesser extent in CpG group) was consistent with elevation of IRF-4 and BATF (Fig. 1D) , whose expressions are known to be driven by TCR signaling (30) .Elicited Effector T CellsTranscription factor KLF2 plays a key role in regulating T-cell trafficking, and TCR signaling downregulates KLF2 expression (31, 32) .", [["ADJ", "ANATOMY", 26, 29], ["T-cell", "ANATOMY", 280, 286], ["TCR", "CHEMICAL", 9, 12], ["CpG", "CHEMICAL", 63, 66], ["TCR", "GENE_OR_GENE_PRODUCT", 9, 12], ["ADJ", "CANCER", 26, 29], ["IRF-4", "GENE_OR_GENE_PRODUCT", 107, 112], ["BATF", "GENE_OR_GENE_PRODUCT", 117, 121], ["Fig. 1D", "GENE_OR_GENE_PRODUCT", 123, 130], ["TCR", "GENE_OR_GENE_PRODUCT", 178, 181], ["Effector T CellsTranscription factor", "GENE_OR_GENE_PRODUCT", 207, 243], ["KLF2", "GENE_OR_GENE_PRODUCT", 244, 248], ["T-cell", "CELL", 280, 286], ["TCR", "GENE_OR_GENE_PRODUCT", 304, 307], ["KLF2", "GENE_OR_GENE_PRODUCT", 332, 336], ["TCR", "PROTEIN", 9, 12], ["IRF-4", "PROTEIN", 107, 112], ["BATF", "PROTEIN", 117, 121], ["TCR", "PROTEIN", 178, 181], ["Effector T CellsTranscription factor", "PROTEIN", 207, 243], ["KLF2", "PROTEIN", 244, 248], ["TCR", "PROTEIN", 304, 307], ["KLF2", "PROTEIN", 332, 336], ["Enhanced TCR signaling in ADJ group", "PROBLEM", 0, 35], ["elevation of IRF", "PROBLEM", 94, 110], ["Effector T CellsTranscription factor KLF2", "TREATMENT", 207, 248], ["KLF2 expression", "TEST", 332, 347], ["TCR signaling", "OBSERVATION", 9, 22], ["consistent with", "UNCERTAINTY", 78, 93], ["elevation", "OBSERVATION_MODIFIER", 94, 103], ["IRF", "OBSERVATION", 107, 110]]], ["Using KLF2-GFP reporter mice (32), we assessed whether high TCR signaling in ADJ-vaccinated mice led to KLF2 downregulation in polyclonal NP366-specific CD8 T cells in the DLNs and lungs, at day 8 PV.", [["NP366", "ANATOMY", 138, 143], ["CD8 T cells", "ANATOMY", 153, 164], ["DLNs", "ANATOMY", 172, 176], ["lungs", "ANATOMY", 181, 186], ["TCR", "CHEMICAL", 60, 63], ["KLF2", "GENE_OR_GENE_PRODUCT", 6, 10], ["GFP", "GENE_OR_GENE_PRODUCT", 11, 14], ["TCR", "GENE_OR_GENE_PRODUCT", 60, 63], ["ADJ", "GENE_OR_GENE_PRODUCT", 77, 80], ["mice", "ORGANISM", 92, 96], ["KLF2", "GENE_OR_GENE_PRODUCT", 104, 108], ["NP366", "GENE_OR_GENE_PRODUCT", 138, 143], ["CD8 T cells", "CELL", 153, 164], ["DLNs", "CANCER", 172, 176], ["lungs", "ORGAN", 181, 186], ["KLF2", "PROTEIN", 6, 10], ["TCR", "PROTEIN", 60, 63], ["KLF2", "PROTEIN", 104, 108], ["polyclonal NP366-specific CD8 T cells", "CELL_LINE", 127, 164], ["DLNs", "CELL_TYPE", 172, 176], ["mice", "SPECIES", 24, 28], ["mice", "SPECIES", 92, 96], ["mice", "SPECIES", 92, 96], ["high TCR signaling", "PROBLEM", 55, 73], ["ADJ", "TEST", 77, 80], ["KLF2 downregulation", "PROBLEM", 104, 123], ["polyclonal NP366", "TEST", 127, 143], ["KLF2", "ANATOMY", 104, 108], ["CD8 T cells", "OBSERVATION", 153, 164], ["lungs", "ANATOMY", 181, 186]]], ["In all groups, NP366-specific CD8 T cells downregulated KLF2 expression in lungs, relative to KLF2 levels in their respective lymph nodes (Fig. 4B) .", [["CD8 T cells", "ANATOMY", 30, 41], ["lungs", "ANATOMY", 75, 80], ["lymph nodes", "ANATOMY", 126, 137], ["NP366", "SIMPLE_CHEMICAL", 15, 20], ["CD8 T cells", "CELL", 30, 41], ["KLF2", "GENE_OR_GENE_PRODUCT", 56, 60], ["lungs", "ORGAN", 75, 80], ["KLF2", "GENE_OR_GENE_PRODUCT", 94, 98], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 126, 137], ["NP366", "PROTEIN", 15, 20], ["CD8 T cells", "CELL_TYPE", 30, 41], ["KLF2", "PROTEIN", 56, 60], ["KLF2", "PROTEIN", 94, 98], ["NP366", "TEST", 15, 20], ["KLF2 expression in lungs", "PROBLEM", 56, 80], ["KLF2 levels", "TEST", 94, 105], ["KLF2 expression", "OBSERVATION", 56, 71], ["lungs", "ANATOMY", 75, 80], ["KLF2", "ANATOMY", 94, 98], ["lymph nodes", "OBSERVATION", 126, 137]]], ["In lungs of ADJ, CpG and ADJ+CpG groups, NP366-specific CD8 T cells expressed lower levels of KLF2 than in CD8 T cells from GLA and ADJ+GLA groups ( Fig. 4B) .", [["lungs", "ANATOMY", 3, 8], ["ADJ", "ANATOMY", 12, 15], ["CD8 T cells", "ANATOMY", 56, 67], ["CD8 T cells", "ANATOMY", 107, 118], ["CpG", "CHEMICAL", 17, 20], ["CpG", "CHEMICAL", 29, 32], ["lungs", "ORGAN", 3, 8], ["ADJ", "CANCER", 12, 15], ["NP366", "SIMPLE_CHEMICAL", 41, 46], ["CD8", "GENE_OR_GENE_PRODUCT", 56, 59], ["KLF2", "GENE_OR_GENE_PRODUCT", 94, 98], ["CD8 T cells", "CELL", 107, 118], ["GLA", "SIMPLE_CHEMICAL", 124, 127], ["NP366", "PROTEIN", 41, 46], ["CD8 T cells", "CELL_TYPE", 56, 67], ["KLF2", "PROTEIN", 94, 98], ["CD8 T cells", "CELL_TYPE", 107, 118], ["CpG", "TEST", 17, 20], ["ADJ+CpG groups", "TREATMENT", 25, 39], ["NP366", "TEST", 41, 46], ["KLF2", "TEST", 94, 98], ["CD8 T cells", "TEST", 107, 118], ["GLA", "TEST", 124, 127], ["ADJ", "TEST", 132, 135], ["lungs", "ANATOMY", 3, 8], ["KLF2", "ANATOMY", 94, 98], ["GLA", "ANATOMY", 124, 127]]], ["These data suggested that ADJ and/or CpG might enhance TCR signaling-induced KLF2 downregulation in lungs, as compared to ADJ+GLA.Elicited Effector T CellsDuring influenza virus infection in mice, TCR signaling drives PD-1 expression in lungs (33) .", [["lungs", "ANATOMY", 100, 105], ["lungs", "ANATOMY", 237, 242], ["CpG", "CHEMICAL", 37, 40], ["TCR", "CHEMICAL", 55, 58], ["ADJ", "CHEMICAL", 122, 125], ["influenza virus infection", "DISEASE", 162, 187], ["TCR", "CHEMICAL", 197, 200], ["CpG", "CHEMICAL", 37, 40], ["ADJ", "GENE_OR_GENE_PRODUCT", 26, 29], ["TCR", "GENE_OR_GENE_PRODUCT", 55, 58], ["KLF2", "GENE_OR_GENE_PRODUCT", 77, 81], ["lungs", "ORGAN", 100, 105], ["ADJ+GLA", "SIMPLE_CHEMICAL", 122, 129], ["Effector T CellsDuring influenza virus", "ORGANISM", 139, 177], ["mice", "ORGANISM", 191, 195], ["TCR", "GENE_OR_GENE_PRODUCT", 197, 200], ["PD-1", "GENE_OR_GENE_PRODUCT", 218, 222], ["lungs", "ORGAN", 237, 242], ["TCR", "PROTEIN", 55, 58], ["KLF2", "PROTEIN", 77, 81], ["TCR", "PROTEIN", 197, 200], ["T CellsDuring influenza virus", "SPECIES", 148, 177], ["mice", "SPECIES", 191, 195], ["T CellsDuring influenza virus", "SPECIES", 148, 177], ["mice", "SPECIES", 191, 195], ["ADJ and/or CpG", "TREATMENT", 26, 40], ["TCR signaling", "PROBLEM", 55, 68], ["KLF2 downregulation in lungs", "PROBLEM", 77, 105], ["Effector T CellsDuring influenza virus infection", "PROBLEM", 139, 187], ["PD", "TEST", 218, 220], ["KLF2 downregulation", "OBSERVATION", 77, 96], ["lungs", "ANATOMY", 100, 105], ["GLA", "ANATOMY", 126, 129], ["lungs", "ANATOMY", 237, 242]]], ["Therefore, we investigated whether PD-1 expression was linked to varying levels of TCR signaling induced by different adjuvants.", [["TCR", "CHEMICAL", 83, 86], ["PD-1", "GENE_OR_GENE_PRODUCT", 35, 39], ["TCR", "GENE_OR_GENE_PRODUCT", 83, 86], ["TCR", "PROTEIN", 83, 86], ["PD", "TEST", 35, 37], ["TCR signaling", "PROBLEM", 83, 96], ["different adjuvants", "TREATMENT", 108, 127]]], ["At day 8 PV, higher percentages of NP366-specific CD8 T cells in ADJ mice expressed PD-1, as compared to those in CpG and GLA mice (Fig. 4C) .", [["CD8 T cells", "ANATOMY", 50, 61], ["CpG", "CHEMICAL", 114, 117], ["NP366", "GENE_OR_GENE_PRODUCT", 35, 40], ["CD8", "GENE_OR_GENE_PRODUCT", 50, 53], ["ADJ mice", "ORGANISM", 65, 73], ["PD-1", "GENE_OR_GENE_PRODUCT", 84, 88], ["GLA mice", "ORGANISM", 122, 130], ["NP366", "PROTEIN", 35, 40], ["CD8 T cells", "CELL_TYPE", 50, 61], ["mice", "SPECIES", 69, 73], ["mice", "SPECIES", 126, 130], ["mice", "SPECIES", 69, 73], ["mice", "SPECIES", 126, 130], ["PV", "TEST", 9, 11], ["NP366", "TEST", 35, 40]]], ["Interestingly, addition of GLA but not CpG to ADJ significantly reduced ADJ-driven PD-1 expression on NP366-specific CD8 T cells (Fig. 4C) .", [["NP366", "ANATOMY", 102, 107], ["CD8 T cells", "ANATOMY", 117, 128], ["GLA", "CHEMICAL", 27, 30], ["CpG", "CHEMICAL", 39, 42], ["ADJ", "CHEMICAL", 46, 49], ["GLA", "CHEMICAL", 27, 30], ["CpG", "CHEMICAL", 39, 42], ["ADJ", "CHEMICAL", 46, 49], ["GLA", "SIMPLE_CHEMICAL", 27, 30], ["ADJ", "SIMPLE_CHEMICAL", 46, 49], ["ADJ", "SIMPLE_CHEMICAL", 72, 75], ["PD-1", "GENE_OR_GENE_PRODUCT", 83, 87], ["NP366", "SIMPLE_CHEMICAL", 102, 107], ["CD8", "GENE_OR_GENE_PRODUCT", 117, 120], ["GLA", "PROTEIN", 27, 30], ["ADJ", "PROTEIN", 72, 75], ["NP366", "PROTEIN", 102, 107], ["CD8 T cells", "CELL_TYPE", 117, 128], ["GLA", "TREATMENT", 27, 30], ["PD", "TEST", 83, 85], ["NP366", "TEST", 102, 107]]], ["To elucidate the possible relationship between the frequency of NP366-specific CD8 T cells and their PD-1 expression levels in the lungs, we calculated correlation co-efficient between the two parameters (Fig. 4D) .", [["CD8 T cells", "ANATOMY", 79, 90], ["lungs", "ANATOMY", 131, 136], ["NP366", "GENE_OR_GENE_PRODUCT", 64, 69], ["CD8", "GENE_OR_GENE_PRODUCT", 79, 82], ["PD-1", "GENE_OR_GENE_PRODUCT", 101, 105], ["lungs", "ORGAN", 131, 136], ["NP366", "PROTEIN", 64, 69], ["CD8 T cells", "CELL_TYPE", 79, 90], ["NP366", "TEST", 64, 69], ["their PD", "TEST", 95, 103], ["lungs", "ANATOMY", 131, 136]]], ["Strikingly, there was a significant linear inverse correlation between PD-1 expression and the frequency of NP366-specific CD8 T cells in lungs of mice vaccinated with ADJ, CpG and GLA adjuvants.Elicited Effector T CellsThese findings suggested that TCR signaling-induced PD-1 expression might limit the accumulation of CD8 T cells (clonal burst size) in the lungs.", [["CD8 T cells", "ANATOMY", 123, 134], ["lungs", "ANATOMY", 138, 143], ["CD8 T cells", "ANATOMY", 320, 331], ["lungs", "ANATOMY", 359, 364], ["ADJ", "CHEMICAL", 168, 171], ["TCR", "CHEMICAL", 250, 253], ["ADJ", "CHEMICAL", 168, 171], ["CpG", "CHEMICAL", 173, 176], ["PD-1", "GENE_OR_GENE_PRODUCT", 71, 75], ["NP366", "GENE_OR_GENE_PRODUCT", 108, 113], ["CD8", "GENE_OR_GENE_PRODUCT", 123, 126], ["lungs", "ORGAN", 138, 143], ["mice", "ORGANISM", 147, 151], ["ADJ", "SIMPLE_CHEMICAL", 168, 171], ["CpG", "SIMPLE_CHEMICAL", 173, 176], ["GLA", "SIMPLE_CHEMICAL", 181, 184], ["Effector T CellsThese", "GENE_OR_GENE_PRODUCT", 204, 225], ["TCR", "GENE_OR_GENE_PRODUCT", 250, 253], ["PD-1", "GENE_OR_GENE_PRODUCT", 272, 276], ["CD8 T cells", "CELL", 320, 331], ["lungs", "ORGAN", 359, 364], ["NP366", "PROTEIN", 108, 113], ["CD8 T cells", "CELL_TYPE", 123, 134], ["TCR", "PROTEIN", 250, 253], ["CD8 T cells", "CELL_TYPE", 320, 331], ["mice", "SPECIES", 147, 151], ["mice", "SPECIES", 147, 151], ["PD", "TEST", 71, 73], ["NP366", "TEST", 108, 113], ["ADJ", "TREATMENT", 168, 171], ["CpG and GLA adjuvants", "TREATMENT", 173, 194], ["TCR signaling", "PROBLEM", 250, 263], ["induced PD", "PROBLEM", 264, 274], ["CD8 T cells", "PROBLEM", 320, 331], ["clonal burst size) in the lungs", "PROBLEM", 333, 364], ["significant", "OBSERVATION_MODIFIER", 24, 35], ["linear", "OBSERVATION_MODIFIER", 36, 42], ["lungs", "ANATOMY", 138, 143], ["CD8 T cells", "OBSERVATION", 320, 331], ["burst", "OBSERVATION_MODIFIER", 340, 345], ["size", "OBSERVATION_MODIFIER", 346, 350], ["lungs", "ANATOMY", 359, 364]]], ["In summary ( Fig. 1 and 4) ,Elicited Effector T Cellsterminal differentiation of effector CD8 T cells in ADJ and ADJ+CpG groups was associated with enhanced TCR signaling in the lungs.", [["effector CD8 T cells", "ANATOMY", 81, 101], ["ADJ", "ANATOMY", 105, 108], ["lungs", "ANATOMY", 178, 183], ["TCR", "CHEMICAL", 157, 160], ["CpG", "CHEMICAL", 117, 120], ["CD8", "GENE_OR_GENE_PRODUCT", 90, 93], ["ADJ", "CELL", 105, 108], ["TCR", "GENE_OR_GENE_PRODUCT", 157, 160], ["lungs", "ORGAN", 178, 183], ["effector CD8 T cells", "CELL_TYPE", 81, 101], ["TCR", "PROTEIN", 157, 160], ["ADJ", "TEST", 105, 108], ["ADJ+CpG groups", "TREATMENT", 113, 127], ["enhanced TCR signaling in the lungs", "PROBLEM", 148, 183], ["effector CD8", "OBSERVATION", 81, 93], ["TCR signaling", "OBSERVATION", 157, 170], ["lungs", "ANATOMY", 178, 183]]], ["Reciprocally, GLA might protect effector CD8 T cells from ADJ-driven terminal differentiation, by limiting TCR signaling in the lungs.Elicited Effector T CellsTo explore whether TCR signaling in CD8 T cells in ADJ+GLA mice is governed by the abundance of antigen-presenting cells in lungs, first we quantified innate immune cells including DCs in lungs at day 5 and 8 PV (Fig. S3A) .", [["effector CD8 T cells", "ANATOMY", 32, 52], ["lungs", "ANATOMY", 128, 133], ["CD8 T cells", "ANATOMY", 195, 206], ["antigen-presenting cells", "ANATOMY", 255, 279], ["lungs", "ANATOMY", 283, 288], ["immune cells", "ANATOMY", 317, 329], ["DCs", "ANATOMY", 340, 343], ["lungs", "ANATOMY", 347, 352], ["GLA", "CHEMICAL", 14, 17], ["GLA", "SIMPLE_CHEMICAL", 14, 17], ["CD8 T cells", "CELL", 41, 52], ["ADJ", "GENE_OR_GENE_PRODUCT", 58, 61], ["TCR", "GENE_OR_GENE_PRODUCT", 107, 110], ["lungs", "ORGAN", 128, 133], ["Effector T CellsTo", "GENE_OR_GENE_PRODUCT", 143, 161], ["TCR", "GENE_OR_GENE_PRODUCT", 178, 181], ["CD8 T", "GENE_OR_GENE_PRODUCT", 195, 200], ["ADJ+GLA mice", "ORGANISM", 210, 222], ["antigen", "GENE_OR_GENE_PRODUCT", 255, 262], ["cells", "CELL", 274, 279], ["lungs", "ORGAN", 283, 288], ["innate immune cells", "CELL", 310, 329], ["DCs", "CELL", 340, 343], ["lungs", "ORGAN", 347, 352], ["S3A", "GENE_OR_GENE_PRODUCT", 377, 380], ["GLA", "PROTEIN", 14, 17], ["effector CD8 T cells", "CELL_TYPE", 32, 52], ["TCR", "PROTEIN", 107, 110], ["TCR", "PROTEIN", 178, 181], ["CD8 T cells", "CELL_TYPE", 195, 206], ["antigen-presenting cells", "CELL_TYPE", 255, 279], ["innate immune cells", "CELL_TYPE", 310, 329], ["DCs", "CELL_TYPE", 340, 343], ["S3A", "PROTEIN", 377, 380], ["mice", "SPECIES", 218, 222], ["mice", "SPECIES", 218, 222], ["PV", "SPECIES", 368, 370], ["ADJ", "TEST", 58, 61], ["TCR signaling", "PROBLEM", 178, 191], ["CD8 T cells", "TEST", 195, 206], ["ADJ", "TEST", 210, 213], ["GLA mice", "PROBLEM", 214, 222], ["presenting cells in lungs", "PROBLEM", 263, 288], ["DCs in lungs", "TREATMENT", 340, 352], ["terminal differentiation", "OBSERVATION", 69, 93], ["TCR signaling", "OBSERVATION", 107, 120], ["lungs", "ANATOMY", 128, 133], ["lungs", "ANATOMY", 283, 288], ["immune cells", "OBSERVATION", 317, 329], ["lungs", "ANATOMY", 347, 352]]], ["ADJ+GLA and ADJ+CpG increased the infiltration of neutrophils in lungs at day 5 and 8 respectively.", [["neutrophils", "ANATOMY", 50, 61], ["lungs", "ANATOMY", 65, 70], ["ADJ", "SIMPLE_CHEMICAL", 0, 3], ["GLA", "SIMPLE_CHEMICAL", 4, 7], ["ADJ+CpG", "SIMPLE_CHEMICAL", 12, 19], ["neutrophils", "CELL", 50, 61], ["lungs", "ORGAN", 65, 70], ["ADJ", "PROTEIN", 0, 3], ["neutrophils", "CELL_TYPE", 50, 61], ["GLA", "TREATMENT", 4, 7], ["ADJ+CpG", "TREATMENT", 12, 19], ["the infiltration of neutrophils in lungs", "PROBLEM", 30, 70], ["GLA", "OBSERVATION", 4, 7], ["infiltration", "OBSERVATION", 34, 46], ["neutrophils", "OBSERVATION", 50, 61], ["lungs", "ANATOMY", 65, 70]]], ["Only at day 5 but not at day 8 PV, lungs of ADJ, ADJ+CpG and ADJ+GLA contained higher numbers of monocytes and monocyte-derived DCs, than in CpG and GLA mice.", [["lungs", "ANATOMY", 35, 40], ["ADJ", "ANATOMY", 44, 47], ["monocytes", "ANATOMY", 97, 106], ["monocyte", "ANATOMY", 111, 119], ["DCs", "ANATOMY", 128, 131], ["CpG", "CHEMICAL", 53, 56], ["CpG", "CHEMICAL", 141, 144], ["lungs", "ORGAN", 35, 40], ["ADJ+GLA", "SIMPLE_CHEMICAL", 61, 68], ["monocytes", "CELL", 97, 106], ["monocyte", "CELL", 111, 119], ["DCs", "CELL", 128, 131], ["GLA mice", "ORGANISM", 149, 157], ["monocytes", "CELL_TYPE", 97, 106], ["monocyte", "CELL_TYPE", 111, 119], ["DCs", "CELL_TYPE", 128, 131], ["mice", "SPECIES", 153, 157], ["mice", "SPECIES", 153, 157], ["ADJ+CpG", "TREATMENT", 49, 56], ["ADJ+GLA", "TREATMENT", 61, 68], ["monocytes", "TEST", 97, 106], ["monocyte", "TREATMENT", 111, 119], ["lungs", "ANATOMY", 35, 40], ["monocytes", "ANATOMY", 97, 106]]], ["There were no differences between the groups in the numbers of CD103 +ve DCs or alveolar macrophages on either days after vaccination.", [["CD103 +ve DCs", "ANATOMY", 63, 76], ["alveolar macrophages", "ANATOMY", 80, 100], ["CD103", "GENE_OR_GENE_PRODUCT", 63, 68], ["alveolar macrophages", "CELL", 80, 100], ["CD103", "PROTEIN", 63, 68], ["DCs", "CELL_TYPE", 73, 76], ["alveolar macrophages", "CELL_TYPE", 80, 100], ["alveolar macrophages", "PROBLEM", 80, 100], ["vaccination", "TREATMENT", 122, 133], ["no", "UNCERTAINTY", 11, 13], ["alveolar", "ANATOMY", 80, 88], ["macrophages", "OBSERVATION", 89, 100]]], ["We deterimined the abundance and type of antigen-processing cells in lungs by vaccinating mice with DQ-OVA, which emits green/red fluorescence upon degradation by proteases (Fig. S3B) .", [["cells", "ANATOMY", 60, 65], ["lungs", "ANATOMY", 69, 74], ["DQ-OVA", "CHEMICAL", 100, 106], ["antigen", "GENE_OR_GENE_PRODUCT", 41, 48], ["cells", "CELL", 60, 65], ["lungs", "ORGAN", 69, 74], ["mice", "ORGANISM", 90, 94], ["DQ-OVA", "SIMPLE_CHEMICAL", 100, 106], ["antigen-processing cells", "CELL_TYPE", 41, 65], ["proteases", "PROTEIN", 163, 172], ["S3B", "PROTEIN", 179, 182], ["mice", "SPECIES", 90, 94], ["mice", "SPECIES", 90, 94], ["processing cells in lungs", "PROBLEM", 49, 74], ["OVA", "PROBLEM", 103, 106], ["green/red fluorescence", "PROBLEM", 120, 142], ["lungs", "ANATOMY", 69, 74]]], ["As compared to CpG and GLA groups, lungs of ADJ and ADJ+CpG (and ADJ+GLA to a slightly lesser degree) contained significantly higher numbers of DQ-OVA-bearing monocyte-derived DCs, monocytes and CD103 +ve DCs at day 5 PV, but not at day 8 PV.", [["lungs", "ANATOMY", 35, 40], ["ADJ", "ANATOMY", 44, 47], ["monocyte", "ANATOMY", 159, 167], ["DCs", "ANATOMY", 176, 179], ["monocytes", "ANATOMY", 181, 190], ["CD103 +ve DCs", "ANATOMY", 195, 208], ["CpG", "CHEMICAL", 15, 18], ["GLA", "CHEMICAL", 23, 26], ["CpG", "CHEMICAL", 56, 59], ["GLA", "SIMPLE_CHEMICAL", 23, 26], ["lungs", "ORGAN", 35, 40], ["DQ-OVA", "GENE_OR_GENE_PRODUCT", 144, 150], ["monocyte", "CELL", 159, 167], ["DCs", "CELL", 176, 179], ["monocytes", "CELL", 181, 190], ["CD103", "GENE_OR_GENE_PRODUCT", 195, 200], ["DQ-OVA-bearing monocyte", "CELL_TYPE", 144, 167], ["DCs", "CELL_TYPE", 176, 179], ["monocytes", "CELL_TYPE", 181, 190], ["CD103", "PROTEIN", 195, 200], ["DCs", "CELL_TYPE", 205, 208], ["CpG and GLA groups", "TEST", 15, 33], ["ADJ and ADJ+CpG", "TREATMENT", 44, 59], ["ADJ+GLA", "TREATMENT", 65, 72], ["DQ", "TEST", 144, 146], ["monocyte", "TEST", 159, 167], ["DCs", "TEST", 176, 179], ["monocytes", "TEST", 181, 190], ["CD103", "TEST", 195, 200], ["DCs", "TEST", 205, 208], ["PV", "TEST", 218, 220], ["lungs", "ANATOMY", 35, 40]]], ["These data suggested that dampened TCR signaling in ADJ+GLA group, as compared to augmented signaling in ADJ and ADJ+CpG groups ( Fig. 4A -D) cannot be simply explained by reduced abundance of specific antigenbearing cells in the lungs.Elicited Effector T CellsTo determine whether early inflammatory response influenced the phenotypic and functional differentiation of effector T cells, we quantified cytokine expression in the lungs.", [["ADJ", "ANATOMY", 105, 108], ["antigenbearing cells", "ANATOMY", 202, 222], ["lungs", "ANATOMY", 230, 235], ["Effector T Cells", "ANATOMY", 245, 261], ["effector T cells", "ANATOMY", 370, 386], ["lungs", "ANATOMY", 429, 434], ["TCR", "CHEMICAL", 35, 38], ["CpG", "CHEMICAL", 117, 120], ["TCR", "GENE_OR_GENE_PRODUCT", 35, 38], ["ADJ+GLA", "GENE_OR_GENE_PRODUCT", 52, 59], ["ADJ", "CELL", 105, 108], ["antigenbearing cells", "CELL", 202, 222], ["lungs", "ORGAN", 230, 235], ["Effector T Cells", "CELL", 245, 261], ["effector T cells", "CELL", 370, 386], ["lungs", "ORGAN", 429, 434], ["TCR", "PROTEIN", 35, 38], ["antigenbearing cells", "CELL_TYPE", 202, 222], ["Effector T Cells", "CELL_TYPE", 245, 261], ["effector T cells", "CELL_TYPE", 370, 386], ["cytokine", "PROTEIN", 402, 410], ["These data", "TEST", 0, 10], ["dampened TCR signaling", "PROBLEM", 26, 48], ["augmented signaling in ADJ", "PROBLEM", 82, 108], ["ADJ+CpG groups", "TREATMENT", 113, 127], ["reduced abundance of specific antigenbearing cells in the lungs", "PROBLEM", 172, 235], ["Effector T Cells", "PROBLEM", 245, 261], ["early inflammatory response", "PROBLEM", 282, 309], ["effector T cells", "PROBLEM", 370, 386], ["quantified cytokine expression in the lungs", "PROBLEM", 391, 434], ["dampened", "OBSERVATION_MODIFIER", 26, 34], ["TCR", "OBSERVATION", 35, 38], ["reduced", "OBSERVATION_MODIFIER", 172, 179], ["abundance", "OBSERVATION", 180, 189], ["antigenbearing cells", "OBSERVATION", 202, 222], ["lungs", "ANATOMY", 230, 235], ["Effector T Cells", "OBSERVATION", 245, 261], ["early", "OBSERVATION_MODIFIER", 282, 287], ["inflammatory", "OBSERVATION", 288, 300], ["cytokine expression", "OBSERVATION", 402, 421], ["lungs", "ANATOMY", 429, 434]]], ["At 24 ( Fig. S4A ) and 48 hours (Fig. S4B ) PV, the levels of cytokines/chemokines IL-1\uf061, IL-1\uf062, IL-6, KC, RANTES, G-CSF and GM-CSF were higher in lungs of GLA and/or ADJ+GLA mice.", [["lungs", "ANATOMY", 147, 152], ["IL-1\uf061", "GENE_OR_GENE_PRODUCT", 83, 88], ["IL-1\uf062", "GENE_OR_GENE_PRODUCT", 90, 95], ["IL-6", "GENE_OR_GENE_PRODUCT", 97, 101], ["KC", "GENE_OR_GENE_PRODUCT", 103, 105], ["RANTES", "GENE_OR_GENE_PRODUCT", 107, 113], ["G-CSF", "GENE_OR_GENE_PRODUCT", 115, 120], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 125, 131], ["lungs", "ORGAN", 147, 152], ["GLA", "SIMPLE_CHEMICAL", 156, 159], ["ADJ", "GENE_OR_GENE_PRODUCT", 167, 170], ["cytokines", "PROTEIN", 62, 71], ["chemokines", "PROTEIN", 72, 82], ["IL", "PROTEIN", 90, 92], ["IL-6", "PROTEIN", 97, 101], ["KC", "PROTEIN", 103, 105], ["RANTES", "PROTEIN", 107, 113], ["CSF", "PROTEIN", 117, 120], ["GM", "PROTEIN", 125, 127], ["CSF", "PROTEIN", 128, 131], ["mice", "SPECIES", 175, 179], ["mice", "SPECIES", 175, 179], ["PV", "TEST", 44, 46], ["the levels", "TEST", 48, 58], ["cytokines", "TEST", 62, 71], ["chemokines IL", "TEST", 72, 85], ["IL", "TEST", 90, 92], ["IL", "TEST", 97, 99], ["KC", "TEST", 103, 105], ["RANTES", "TEST", 107, 113], ["G", "TEST", 115, 116], ["CSF", "TEST", 117, 120], ["GM", "TEST", 125, 127], ["CSF", "TEST", 128, 131], ["GLA", "TEST", 156, 159], ["lungs", "ANATOMY", 147, 152]]], ["However, the levels of IFN-\uf062, IFN-\uf06c, IL-10, IL-12p40, IL-12p70, MIP1\uf061, MIP1\uf062, MCP, TGF-\uf0621 and TNF\uf061 in lungs were largely comparable between groups, except for the ADJ group (Fig. S4) .Elicited Effector T CellsThus, terminal differentiation of effector CD8 T cells in ADJ, CpG and ADJ+CpG mice was not associated with excessive inflammation in the lungs, relative to other groups.", [["lungs", "ANATOMY", 102, 107], ["ADJ", "ANATOMY", 163, 166], ["Effector T CellsThus", "ANATOMY", 193, 213], ["effector CD8 T cells", "ANATOMY", 243, 263], ["ADJ", "ANATOMY", 267, 270], ["lungs", "ANATOMY", 347, 352], ["inflammation", "DISEASE", 327, 339], ["CpG", "CHEMICAL", 272, 275], ["CpG", "CHEMICAL", 284, 287], ["IFN-\uf062", "GENE_OR_GENE_PRODUCT", 23, 28], ["IFN-\uf06c", "GENE_OR_GENE_PRODUCT", 30, 35], ["IL-10", "GENE_OR_GENE_PRODUCT", 37, 42], ["IL-12p40", "GENE_OR_GENE_PRODUCT", 44, 52], ["IL-12p70", "GENE_OR_GENE_PRODUCT", 54, 62], ["MIP1\uf061", "GENE_OR_GENE_PRODUCT", 64, 69], ["MIP1\uf062", "GENE_OR_GENE_PRODUCT", 71, 76], ["MCP", "GENE_OR_GENE_PRODUCT", 78, 81], ["TGF-\uf0621", "GENE_OR_GENE_PRODUCT", 83, 89], ["TNF\uf061", "GENE_OR_GENE_PRODUCT", 94, 98], ["lungs", "ORGAN", 102, 107], ["Effector T CellsThus", "CELL", 193, 213], ["CD8 T", "GENE_OR_GENE_PRODUCT", 252, 257], ["ADJ", "CELL", 267, 270], ["CpG", "CELLULAR_COMPONENT", 272, 275], ["ADJ", "GENE_OR_GENE_PRODUCT", 280, 283], ["lungs", "ORGAN", 347, 352], ["IFN", "PROTEIN", 23, 26], ["IFN", "PROTEIN", 30, 33], ["MIP1\uf061", "PROTEIN", 64, 69], ["MIP1\uf062", "PROTEIN", 71, 76], ["MCP", "PROTEIN", 78, 81], ["TGF-\uf0621", "PROTEIN", 83, 89], ["TNF", "PROTEIN", 94, 97], ["effector CD8 T cells", "CELL_TYPE", 243, 263], ["mice", "SPECIES", 288, 292], ["mice", "SPECIES", 288, 292], ["the levels", "TEST", 9, 19], ["IFN", "TEST", 23, 26], ["IFN", "TEST", 30, 33], ["IL", "TEST", 37, 39], ["IL", "TEST", 44, 46], ["IL", "TEST", 54, 56], ["MIP1\uf061", "TEST", 64, 69], ["MIP1\uf062", "TEST", 71, 76], ["MCP", "TEST", 78, 81], ["TGF", "TEST", 83, 86], ["TNF", "TEST", 94, 97], ["Effector T CellsThus", "PROBLEM", 193, 213], ["effector CD8 T cells in ADJ", "TREATMENT", 243, 270], ["CpG and ADJ+CpG mice", "TREATMENT", 272, 292], ["excessive inflammation in the lungs", "PROBLEM", 317, 352], ["lungs", "ANATOMY", 102, 107], ["Effector T CellsThus", "OBSERVATION", 193, 213], ["effector CD8", "OBSERVATION", 243, 255], ["not associated with", "UNCERTAINTY", 297, 316], ["excessive", "OBSERVATION_MODIFIER", 317, 326], ["inflammation", "OBSERVATION", 327, 339], ["lungs", "ANATOMY", 347, 352]]], ["Notably however, TC17 and TH17 cell development in GLA and ADJ+GLA groups was associated with elevated IL-1\uf061 in the lungs.", [["TH17 cell", "ANATOMY", 26, 35], ["lungs", "ANATOMY", 116, 121], ["TC17", "CELL", 17, 21], ["TH17 cell", "CELL", 26, 35], ["GLA", "SIMPLE_CHEMICAL", 51, 54], ["IL-1\uf061", "GENE_OR_GENE_PRODUCT", 103, 108], ["lungs", "ORGAN", 116, 121], ["IL", "PROTEIN", 103, 105], ["TC17", "TEST", 17, 21], ["GLA", "TEST", 51, 54], ["elevated IL", "PROBLEM", 94, 105], ["TH17 cell", "OBSERVATION", 26, 35], ["GLA", "ANATOMY", 51, 54], ["elevated", "OBSERVATION_MODIFIER", 94, 102], ["IL", "OBSERVATION", 103, 105], ["lungs", "ANATOMY", 116, 121]]], ["Further, development of TH1 effectors and enhanced T-bet induction ( Fig. 1 and Fig. 2 ) in CpG and ADJ+CpG groups was not associated with elevated levels of IL-12p70 in the lungs.", [["lungs", "ANATOMY", 174, 179], ["CpG", "CHEMICAL", 92, 95], ["CpG", "CHEMICAL", 104, 107], ["TH1", "GENE_OR_GENE_PRODUCT", 24, 27], ["T-bet", "GENE_OR_GENE_PRODUCT", 51, 56], ["CpG", "CELLULAR_COMPONENT", 92, 95], ["IL-12p70", "GENE_OR_GENE_PRODUCT", 158, 166], ["lungs", "ORGAN", 174, 179], ["TH1 effectors", "PROTEIN", 24, 37], ["IL-12p70", "PROTEIN", 158, 166], ["TH1 effectors", "PROBLEM", 24, 37], ["enhanced T-bet induction", "TREATMENT", 42, 66], ["CpG and ADJ+CpG groups", "TREATMENT", 92, 114], ["elevated levels of IL", "PROBLEM", 139, 160], ["TH1 effectors", "OBSERVATION", 24, 37], ["lungs", "ANATOMY", 174, 179]]], ["Thus, the differences in accumulation and terminal differentiation of effector T cells in the lungs of vaccinated mice cannot be explained by the degree of early inflammation.Mucosal CD8 and CD4 T-Cell Memory in Vaccinated MiceAt 100 days PV, we quantified NP366-specific memory CD8 T cells in lungs, airways and spleen.", [["effector T cells", "ANATOMY", 70, 86], ["lungs", "ANATOMY", 94, 99], ["Mucosal", "ANATOMY", 175, 182], ["CD4 T-Cell", "ANATOMY", 191, 201], ["memory CD8 T cells", "ANATOMY", 272, 290], ["lungs", "ANATOMY", 294, 299], ["airways", "ANATOMY", 301, 308], ["spleen", "ANATOMY", 313, 319], ["inflammation", "DISEASE", 162, 174], ["effector T cells", "CELL", 70, 86], ["lungs", "ORGAN", 94, 99], ["mice", "ORGANISM", 114, 118], ["Mucosal CD8", "CELL", 175, 186], ["CD4", "GENE_OR_GENE_PRODUCT", 191, 194], ["NP366", "GENE_OR_GENE_PRODUCT", 257, 262], ["CD8 T cells", "CELL", 279, 290], ["lungs", "ORGAN", 294, 299], ["airways", "MULTI-TISSUE_STRUCTURE", 301, 308], ["spleen", "ORGAN", 313, 319], ["effector T cells", "CELL_TYPE", 70, 86], ["CD8", "PROTEIN", 183, 186], ["NP366", "PROTEIN", 257, 262], ["memory CD8 T cells", "CELL_TYPE", 272, 290], ["mice", "SPECIES", 114, 118], ["mice", "SPECIES", 114, 118], ["PV", "SPECIES", 239, 241], ["the differences in accumulation", "PROBLEM", 6, 37], ["early inflammation", "PROBLEM", 156, 174], ["Mucosal CD8", "TEST", 175, 186], ["CD4 T", "TEST", 191, 196], ["PV", "TEST", 239, 241], ["NP366", "TEST", 257, 262], ["accumulation", "OBSERVATION_MODIFIER", 25, 37], ["terminal", "OBSERVATION_MODIFIER", 42, 50], ["differentiation", "OBSERVATION_MODIFIER", 51, 66], ["effector T cells", "OBSERVATION", 70, 86], ["lungs", "ANATOMY", 94, 99], ["cannot be explained", "UNCERTAINTY", 119, 138], ["degree", "OBSERVATION_MODIFIER", 146, 152], ["early", "OBSERVATION_MODIFIER", 156, 161], ["inflammation", "OBSERVATION", 162, 174], ["CD8", "OBSERVATION", 183, 186], ["lungs", "ANATOMY", 294, 299], ["airways", "ANATOMY", 301, 308], ["spleen", "ANATOMY", 313, 319]]], ["All adjuvants elicited robust CD8 T-cell memory in the RT (Fig. 5) .", [["CD8 T-cell", "ANATOMY", 30, 40], ["CD8 T-cell", "CELL", 30, 40], ["CD8", "PROTEIN", 30, 33], ["All adjuvants", "TREATMENT", 0, 13], ["cell memory", "OBSERVATION", 36, 47], ["RT", "ANATOMY", 55, 57]]], ["Notably, both frequencies and total numbers of NP366-specific memory CD8 T cells in lungs, airways and spleen of ADJ+GLA group were significantly (P<0.05) higher than in other groups (Fig. 5A) .Mucosal CD8 and CD4 T-Cell Memory in Vaccinated MiceIntravascular staining showed that 60-80% of NP366-specific memory CD8 T cells in the lungs localized to the non-vascular compartment in ADJ, CpG, GLA and ADJ+GLA groups; the percentages of non-vascular memory CD8 T cells were slightly reduced in the ADJ+CpG group ( Fig. 5B) .", [["memory CD8 T cells", "ANATOMY", 62, 80], ["lungs", "ANATOMY", 84, 89], ["airways", "ANATOMY", 91, 98], ["spleen", "ANATOMY", 103, 109], ["Mucosal", "ANATOMY", 194, 201], ["CD4 T-Cell", "ANATOMY", 210, 220], ["memory CD8 T cells", "ANATOMY", 306, 324], ["lungs", "ANATOMY", 332, 337], ["non-vascular compartment", "ANATOMY", 355, 379], ["ADJ", "ANATOMY", 383, 386], ["non-vascular memory CD8 T cells", "ANATOMY", 436, 467], ["ADJ", "ANATOMY", 497, 500], ["CpG", "CHEMICAL", 501, 504], ["CpG", "CHEMICAL", 388, 391], ["CpG", "CHEMICAL", 501, 504], ["NP366", "GENE_OR_GENE_PRODUCT", 47, 52], ["lungs", "ORGAN", 84, 89], ["airways", "MULTI-TISSUE_STRUCTURE", 91, 98], ["spleen", "ORGAN", 103, 109], ["CD8", "GENE_OR_GENE_PRODUCT", 202, 205], ["CD4", "GENE_OR_GENE_PRODUCT", 210, 213], ["NP366", "GENE_OR_GENE_PRODUCT", 291, 296], ["memory CD8 T cells", "CELL", 306, 324], ["lungs", "ORGAN", 332, 337], ["non-vascular compartment", "MULTI-TISSUE_STRUCTURE", 355, 379], ["ADJ", "CELL", 383, 386], ["GLA", "GENE_OR_GENE_PRODUCT", 393, 396], ["ADJ", "GENE_OR_GENE_PRODUCT", 401, 404], ["non-vascular memory CD8 T cells", "CELL", 436, 467], ["NP366", "PROTEIN", 47, 52], ["memory CD8 T cells", "CELL_TYPE", 62, 80], ["CD8", "PROTEIN", 202, 205], ["NP366", "PROTEIN", 291, 296], ["memory CD8 T cells", "CELL_TYPE", 306, 324], ["non-vascular memory CD8 T cells", "CELL_TYPE", 436, 467], ["total numbers", "TEST", 30, 43], ["NP366", "TEST", 47, 52], ["GLA group", "TEST", 117, 126], ["Mucosal CD8", "TEST", 194, 205], ["CD4 T", "TEST", 210, 215], ["Vaccinated MiceIntravascular staining", "TEST", 231, 268], ["NP366", "TEST", 291, 296], ["CpG", "TEST", 388, 391], ["GLA", "TEST", 393, 396], ["slightly reduced", "PROBLEM", 473, 489], ["lungs", "ANATOMY", 84, 89], ["airways", "ANATOMY", 91, 98], ["spleen", "ANATOMY", 103, 109], ["CD8", "OBSERVATION", 202, 205], ["memory CD8 T cells", "OBSERVATION", 306, 324], ["lungs", "ANATOMY", 332, 337], ["non-vascular compartment", "ANATOMY", 355, 379], ["GLA", "ANATOMY", 393, 396], ["non-vascular", "ANATOMY", 436, 448]]], ["The percentages of CD103 +ve CD69 +ve lung resident memory (TRM) cells among NP366-specific CD8 T cells were comparable for various adjuvants (Fig. 5C) .", [["CD103 +ve CD69 +ve lung resident memory (TRM) cells", "ANATOMY", 19, 70], ["NP366", "ANATOMY", 77, 82], ["CD8 T cells", "ANATOMY", 92, 103], ["CD103", "GENE_OR_GENE_PRODUCT", 19, 24], ["CD69", "GENE_OR_GENE_PRODUCT", 29, 33], ["NP366", "CELL", 77, 82], ["CD8 T cells", "CELL", 92, 103], ["CD103", "PROTEIN", 19, 24], ["CD69", "PROTEIN", 29, 33], ["lung resident memory (TRM) cells", "CELL_TYPE", 38, 70], ["NP366-specific CD8 T cells", "CELL_LINE", 77, 103], ["The percentages", "TEST", 0, 15], ["CD103", "TEST", 19, 24], ["CD69", "TEST", 29, 33], ["cells", "TEST", 65, 70], ["NP366", "TEST", 77, 82], ["various adjuvants", "TREATMENT", 124, 141], ["CD103", "OBSERVATION", 19, 24], ["lung", "ANATOMY", 38, 42]]], ["However, lungs of ADJ+GLA group contained significantly (P<0.05) greater numbers of both non-vascular and vascular CD103 +ve NP366-specific CD8 T cells, as compared to other groups (Fig. 5D) .", [["lungs", "ANATOMY", 9, 14], ["non-vascular", "ANATOMY", 89, 101], ["vascular CD103 +ve NP366", "ANATOMY", 106, 130], ["CD8 T cells", "ANATOMY", 140, 151], ["lungs", "ORGAN", 9, 14], ["non-vascular", "CELL", 89, 101], ["vascular", "MULTI-TISSUE_STRUCTURE", 106, 114], ["CD103", "GENE_OR_GENE_PRODUCT", 115, 120], ["NP366", "GENE_OR_GENE_PRODUCT", 125, 130], ["CD8 T", "GENE_OR_GENE_PRODUCT", 140, 145], ["CD103", "PROTEIN", 115, 120], ["NP366", "PROTEIN", 125, 130], ["CD8 T cells", "CELL_TYPE", 140, 151], ["GLA group", "TEST", 22, 31], ["vascular CD103", "TEST", 106, 120], ["NP366", "TEST", 125, 130], ["lungs", "ANATOMY", 9, 14], ["both", "ANATOMY_MODIFIER", 84, 88], ["non-vascular", "ANATOMY", 89, 101], ["vascular", "ANATOMY", 106, 114], ["CD103", "OBSERVATION", 115, 120], ["CD8 T cells", "OBSERVATION", 140, 151]]], ["Thus, ADJ+GLA was the most effective adjuvant that elicited high numbers of CD103 +ve TRM CD8 T cells in the airways and the non-vascular compartment of the lungs.Mucosal CD8 and CD4 T-Cell Memory in Vaccinated MiceAt 100 days after vaccination, all adjuvants induced strong CD4 T-cell memory and the percentages of NP311-specific memory CD4 T cells ranged from 1.5-4% in the lungs (Fig. 5E) .Mucosal CD8 and CD4 T-Cell Memory in Vaccinated MiceThe percentages of memory CD4 T cells in lungs of ADJ+GLA group were consistently higher than in other groups (Fig. 5E) .", [["T cells", "ANATOMY", 94, 101], ["airways", "ANATOMY", 109, 116], ["non-vascular compartment", "ANATOMY", 125, 149], ["lungs", "ANATOMY", 157, 162], ["Mucosal", "ANATOMY", 163, 170], ["CD4 T-Cell", "ANATOMY", 179, 189], ["CD4 T-cell", "ANATOMY", 275, 285], ["memory CD4 T cells", "ANATOMY", 331, 349], ["lungs", "ANATOMY", 376, 381], ["Mucosal", "ANATOMY", 393, 400], ["CD4 T-Cell", "ANATOMY", 409, 419], ["memory CD4 T cells", "ANATOMY", 464, 482], ["lungs", "ANATOMY", 486, 491], ["ADJ", "ANATOMY", 495, 498], ["ADJ", "CHEMICAL", 6, 9], ["GLA", "CHEMICAL", 10, 13], ["ADJ", "CHEMICAL", 6, 9], ["GLA", "CHEMICAL", 10, 13], ["ADJ+GLA", "SIMPLE_CHEMICAL", 6, 13], ["CD103", "GENE_OR_GENE_PRODUCT", 76, 81], ["CD8", "GENE_OR_GENE_PRODUCT", 90, 93], ["T cells", "CELL", 94, 101], ["airways", "MULTI-TISSUE_STRUCTURE", 109, 116], ["non-vascular compartment", "MULTI-TISSUE_STRUCTURE", 125, 149], ["lungs", "ORGAN", 157, 162], ["Mucosal", "CELL", 163, 170], ["CD8", "GENE_OR_GENE_PRODUCT", 171, 174], ["CD4", "GENE_OR_GENE_PRODUCT", 179, 182], ["NP311", "GENE_OR_GENE_PRODUCT", 316, 321], ["lungs", "ORGAN", 376, 381], ["Mucosal", "CELL", 393, 400], ["CD8", "GENE_OR_GENE_PRODUCT", 401, 404], ["CD4", "GENE_OR_GENE_PRODUCT", 409, 412], ["Mice", "ORGANISM", 441, 445], ["lungs", "ORGAN", 486, 491], ["CD103", "PROTEIN", 76, 81], ["CD8", "PROTEIN", 90, 93], ["T cells", "CELL_TYPE", 94, 101], ["CD8", "PROTEIN", 171, 174], ["CD4", "PROTEIN", 275, 278], ["NP311", "PROTEIN", 316, 321], ["memory CD4 T cells", "CELL_TYPE", 331, 349], ["CD8", "PROTEIN", 401, 404], ["CD4", "PROTEIN", 409, 412], ["memory CD4 T cells", "CELL_TYPE", 464, 482], ["Mice", "SPECIES", 441, 445], ["ADJ+GLA", "TREATMENT", 6, 13], ["CD103", "TEST", 76, 81], ["Mucosal CD8", "TEST", 163, 174], ["CD4 T", "TEST", 179, 184], ["Vaccinated MiceAt", "TREATMENT", 200, 217], ["vaccination", "TREATMENT", 233, 244], ["all adjuvants", "TREATMENT", 246, 259], ["the percentages", "TEST", 297, 312], ["NP311", "TEST", 316, 321], ["Mucosal CD8", "TEST", 393, 404], ["CD4 T", "TEST", 409, 414], ["GLA group", "TEST", 499, 508], ["airways", "ANATOMY", 109, 116], ["non-vascular", "ANATOMY_MODIFIER", 125, 137], ["compartment", "ANATOMY_MODIFIER", 138, 149], ["lungs", "ANATOMY", 157, 162], ["CD8", "OBSERVATION", 171, 174], ["lungs", "ANATOMY", 376, 381], ["CD8", "OBSERVATION", 401, 404], ["percentages", "OBSERVATION_MODIFIER", 449, 460], ["memory CD4 T cells", "OBSERVATION", 464, 482], ["lungs", "ANATOMY", 486, 491], ["higher", "OBSERVATION_MODIFIER", 527, 533]]], ["Regardless of adjuvants 60-80% of memory CD4 T cells localized to the non-vascular compartment in the lungs (Fig. 5F) .", [["memory CD4 T cells", "ANATOMY", 34, 52], ["non-vascular compartment", "ANATOMY", 70, 94], ["lungs", "ANATOMY", 102, 107], ["memory CD4 T cells", "CELL", 34, 52], ["non-vascular compartment", "MULTI-TISSUE_STRUCTURE", 70, 94], ["lungs", "ORGAN", 102, 107], ["memory CD4 T cells", "CELL_TYPE", 34, 52], ["adjuvants", "TREATMENT", 14, 23], ["memory CD4 T cells", "TEST", 34, 52], ["non-vascular", "ANATOMY_MODIFIER", 70, 82], ["compartment", "ANATOMY_MODIFIER", 83, 94], ["lungs", "ANATOMY", 102, 107]]], ["Likewise, the percentages (15-20%) of lung CD69 +ve TRM-like CD4 T cells were comparable for various adjuvants.Mucosal CD8 and CD4 T-Cell Memory in Vaccinated MiceWe determined whether polarization of TH1 versus TH17 was maintained in memory CD4 T cells of vaccinated mice.", [["lung CD69 +ve TRM-like CD4 T cells", "ANATOMY", 38, 72], ["Mucosal", "ANATOMY", 111, 118], ["CD4 T-Cell", "ANATOMY", 127, 137], ["memory CD4 T cells", "ANATOMY", 235, 253], ["lung", "ORGAN", 38, 42], ["CD69", "GENE_OR_GENE_PRODUCT", 43, 47], ["Mucosal", "CELL", 111, 118], ["CD8", "GENE_OR_GENE_PRODUCT", 119, 122], ["CD4", "GENE_OR_GENE_PRODUCT", 127, 130], ["TH1", "GENE_OR_GENE_PRODUCT", 201, 204], ["TH17", "GENE_OR_GENE_PRODUCT", 212, 216], ["memory CD4 T cells", "CELL", 235, 253], ["mice", "ORGANISM", 268, 272], ["CD69", "PROTEIN", 43, 47], ["CD4 T cells", "CELL_TYPE", 61, 72], ["CD8", "PROTEIN", 119, 122], ["Vaccinated MiceWe", "CELL_LINE", 148, 165], ["TH1", "PROTEIN", 201, 204], ["TH17", "PROTEIN", 212, 216], ["memory CD4 T cells", "CELL_TYPE", 235, 253], ["mice", "SPECIES", 268, 272], ["mice", "SPECIES", 268, 272], ["the percentages", "TEST", 10, 25], ["lung CD69", "TEST", 38, 47], ["TRM", "TEST", 52, 55], ["CD4 T cells", "PROBLEM", 61, 72], ["various adjuvants", "TREATMENT", 93, 110], ["Mucosal CD8", "TEST", 111, 122], ["CD4 T", "TEST", 127, 132], ["percentages", "OBSERVATION_MODIFIER", 14, 25], ["lung", "ANATOMY", 38, 42], ["CD69", "OBSERVATION", 43, 47], ["CD4 T cells", "OBSERVATION", 61, 72], ["CD8", "OBSERVATION", 119, 122], ["memory CD4", "OBSERVATION", 235, 245]]], ["At 100 days after vaccination, IFN-\uf067 and/or IL-17-producing NP-specific memory CD4 T cells were detectable in the lungs of vaccinated mice (Fig. 5G) .", [["memory CD4 T cells", "ANATOMY", 72, 90], ["lungs", "ANATOMY", 114, 119], ["IFN-\uf067", "GENE_OR_GENE_PRODUCT", 31, 36], ["IL-17", "GENE_OR_GENE_PRODUCT", 44, 49], ["NP", "CELL", 60, 62], ["memory CD4 T cells", "CELL", 72, 90], ["lungs", "ORGAN", 114, 119], ["mice", "ORGANISM", 134, 138], ["IFN", "PROTEIN", 31, 34], ["memory CD4 T cells", "CELL_TYPE", 72, 90], ["mice", "SPECIES", 134, 138], ["mice", "SPECIES", 134, 138], ["vaccination", "TREATMENT", 18, 29], ["IFN", "TEST", 31, 34], ["IL", "TEST", 44, 46], ["lungs", "ANATOMY", 114, 119]]], ["Fig. 5H illustrates that the percentages of NP-specific cytokine-producing CD4 T cells that produce IFN-\uf067 and/or IL-17 differed amongst various groups.", [["CD4 T cells", "ANATOMY", 75, 86], ["NP", "GENE_OR_GENE_PRODUCT", 44, 46], ["CD4", "GENE_OR_GENE_PRODUCT", 75, 78], ["IFN-\uf067", "GENE_OR_GENE_PRODUCT", 100, 105], ["IL-17", "GENE_OR_GENE_PRODUCT", 113, 118], ["cytokine", "PROTEIN", 56, 64], ["CD4 T cells", "CELL_TYPE", 75, 86], ["IFN", "PROTEIN", 100, 103], ["IL", "PROTEIN", 113, 115], ["NP", "TEST", 44, 46], ["specific cytokine", "TEST", 47, 64], ["CD4 T cells", "PROBLEM", 75, 86], ["IFN", "TEST", 100, 103], ["IL", "TEST", 113, 115]]], ["IFN-\uf067-producing CD4 T cells were only dominant (~60%) in the CpG group, but IL-17-producing CD4 T cells formed the dominant subset (~75%) in the GLA and ADJ+GLA groups.", [["CD4 T cells", "ANATOMY", 16, 27], ["IL-17-producing CD4 T cells", "ANATOMY", 76, 103], ["CpG", "CHEMICAL", 61, 64], ["IFN", "GENE_OR_GENE_PRODUCT", 0, 3], ["IL-17", "GENE_OR_GENE_PRODUCT", 76, 81], ["CD4 T cells", "CELL", 92, 103], ["GLA", "SIMPLE_CHEMICAL", 145, 148], ["ADJ", "SIMPLE_CHEMICAL", 153, 156], ["IFN-\uf067-producing CD4 T cells", "CELL_LINE", 0, 27], ["IL-17", "PROTEIN", 76, 81], ["CD4 T cells", "CELL_TYPE", 92, 103], ["IFN", "TEST", 0, 3], ["CD4 T cells", "TEST", 16, 27], ["IL", "TEST", 76, 78], ["CD4 T cells", "TEST", 92, 103], ["dominant", "OBSERVATION_MODIFIER", 38, 46], ["dominant", "OBSERVATION_MODIFIER", 115, 123], ["subset", "OBSERVATION_MODIFIER", 124, 130], ["GLA", "ANATOMY", 145, 148]]], ["About 50-60% of NP-specific memory CD4Mucosal CD8 and CD4 T-Cell Memory in Vaccinated MiceT cells produced IL-17 in the ADJ and ADJ+CpG groups.", [["memory CD4Mucosal CD8", "ANATOMY", 28, 49], ["CD4 T-Cell", "ANATOMY", 54, 64], ["MiceT cells", "ANATOMY", 86, 97], ["ADJ", "ANATOMY", 120, 123], ["CpG", "CHEMICAL", 132, 135], ["NP", "CELL", 16, 18], ["CD8", "GENE_OR_GENE_PRODUCT", 46, 49], ["CD4", "GENE_OR_GENE_PRODUCT", 54, 57], ["MiceT cells", "CELL", 86, 97], ["IL-17", "GENE_OR_GENE_PRODUCT", 107, 112], ["ADJ", "CANCER", 120, 123], ["memory CD4Mucosal CD8", "CELL_TYPE", 28, 49], ["Vaccinated MiceT cells", "CELL_LINE", 75, 97], ["IL-17", "PROTEIN", 107, 112], ["NP", "TEST", 16, 18], ["CD4 T", "TEST", 54, 59], ["Vaccinated MiceT cells", "TEST", 75, 97], ["IL", "TEST", 107, 109], ["ADJ+CpG groups", "TREATMENT", 128, 142]]], ["Therefore, functional programming in effector cells is largely preserved in memory T cells.Adjuvants Regulate Recall T-Cell Responses and Protective Heterosubtypic Immunity to Influenza A Virus in MiceMice were vaccinated twice with NP protein formulated in various adjuvants.", [["effector cells", "ANATOMY", 37, 51], ["memory T cells", "ANATOMY", 76, 90], ["Cell", "ANATOMY", 119, 123], ["effector cells", "CELL", 37, 51], ["memory T cells", "CELL", 76, 90], ["T-Cell", "CELL", 117, 123], ["Influenza A Virus", "ORGANISM", 176, 193], ["MiceMice", "ORGANISM", 197, 205], ["effector cells", "CELL_TYPE", 37, 51], ["memory T cells", "CELL_TYPE", 76, 90], ["NP protein", "PROTEIN", 233, 243], ["Influenza A Virus", "SPECIES", 176, 193], ["Influenza A Virus", "SPECIES", 176, 193], ["MiceMice", "SPECIES", 197, 205], ["functional programming in effector cells", "PROBLEM", 11, 51], ["Adjuvants Regulate", "TREATMENT", 91, 109], ["Protective Heterosubtypic Immunity", "TREATMENT", 138, 172], ["Influenza A Virus in MiceMice", "TREATMENT", 176, 205], ["NP protein", "TREATMENT", 233, 243], ["various adjuvants", "TREATMENT", 258, 275], ["effector cells", "OBSERVATION", 37, 51], ["memory T cells", "OBSERVATION", 76, 90]]], ["At day 100 after the booster vaccination, we investigated whether NP-specific T-cell memory protected against respiratory challenge with the virulent PR8/H1N1 influenza A virus (IAV).", [["T-cell", "ANATOMY", 78, 84], ["respiratory", "ANATOMY", 110, 121], ["influenza A", "DISEASE", 159, 170], ["T-cell", "CELL", 78, 84], ["PR8/H1N1 influenza A virus", "ORGANISM", 150, 176], ["IAV", "ORGANISM", 178, 181], ["H1N1 influenza A virus", "SPECIES", 154, 176], ["PR8/H1N1 influenza A virus", "SPECIES", 150, 176], ["IAV", "SPECIES", 178, 181], ["the booster vaccination", "TREATMENT", 17, 40], ["NP", "TEST", 66, 68], ["respiratory challenge", "TREATMENT", 110, 131], ["the virulent PR8/H1N1 influenza A virus", "PROBLEM", 137, 176]]], ["On the 6 th day after challenge, viral burden was high in lungs of mice that were unvaccinated or vaccinated with NP alone (without adjuvants) (Fig. 6A) .", [["lungs", "ANATOMY", 58, 63], ["NP", "CHEMICAL", 114, 116], ["lungs", "ORGAN", 58, 63], ["mice", "ORGANISM", 67, 71], ["mice", "SPECIES", 67, 71], ["mice", "SPECIES", 67, 71], ["viral burden", "PROBLEM", 33, 45], ["NP", "TREATMENT", 114, 116], ["adjuvants", "TREATMENT", 132, 141], ["lungs", "ANATOMY", 58, 63]]], ["Compared to the unvaccinated and NP-only groups, other groups exhibited varying degrees of protection.", [["NP", "TEST", 33, 35], ["varying degrees", "OBSERVATION_MODIFIER", 72, 87]]], ["The ADJ+GLA vaccine provided the most effective protection, followed by GLA and ADJ+CpG vaccines ( Fig. 6A and S5A ).", [["ADJ", "CHEMICAL", 4, 7], ["GLA", "CHEMICAL", 8, 11], ["GLA", "CHEMICAL", 72, 75], ["ADJ", "CHEMICAL", 80, 83], ["CpG", "CHEMICAL", 84, 87], ["ADJ+GLA", "SIMPLE_CHEMICAL", 4, 11], ["GLA", "SIMPLE_CHEMICAL", 72, 75], ["ADJ", "SIMPLE_CHEMICAL", 80, 83], ["S5A", "GENE_OR_GENE_PRODUCT", 111, 114], ["The ADJ+GLA vaccine", "TREATMENT", 0, 19], ["GLA and ADJ+CpG vaccines", "TREATMENT", 72, 96]]], ["Although relatively less effective, ADJ and CpG vaccines still reduced viral titers by >90%.", [["ADJ", "CHEMICAL", 36, 39], ["CpG", "CHEMICAL", 44, 47], ["ADJ", "CHEMICAL", 36, 39], ["CpG", "CHEMICAL", 44, 47], ["ADJ", "SIMPLE_CHEMICAL", 36, 39], ["ADJ and CpG vaccines", "TREATMENT", 36, 56], ["viral titers", "TEST", 71, 83], ["less", "OBSERVATION_MODIFIER", 20, 24], ["effective", "OBSERVATION_MODIFIER", 25, 34]]], ["Kinetically, at 100 days PV, viral burden was reduced in the lungs of all vaccinated mice within 2-4 days after PR8/H1N1 challenge (Fig. S5B) , but clear differences in viral control among adjuvants emerged beween days 4 and 6 postchallenge ( Fig. 6A and Fig. S5B ).", [["lungs", "ANATOMY", 61, 66], ["lungs", "ORGAN", 61, 66], ["mice", "ORGANISM", 85, 89], ["PR8/H1N1", "ORGANISM", 112, 120], ["mice", "SPECIES", 85, 89], ["PV", "SPECIES", 25, 27], ["mice", "SPECIES", 85, 89], ["viral burden", "PROBLEM", 29, 41], ["PR8/H1N1 challenge", "TREATMENT", 112, 130], ["viral control among adjuvants", "TREATMENT", 169, 198], ["viral burden", "OBSERVATION", 29, 41], ["reduced", "OBSERVATION_MODIFIER", 46, 53], ["lungs", "ANATOMY", 61, 66]]], ["Protection against IAV afforded by various adjuvant groups was durable and was maintained for at least until day 180 PV (Fig. S5C ).Adjuvants Regulate Recall T-Cell Responses and Protective Heterosubtypic Immunity to Influenza A Virus in MiceTo elucidate correlates of protection afforded by various adjuvanted vaccines, we quantified recall CD8 and CD4 T-cell responses in the lungs at day 6 after PR8/H1N1 challenge.Adjuvants Regulate Recall T-Cell Responses and Protective Heterosubtypic Immunity to Influenza A Virus in MiceInterestingly, despite varying levels of protection afforded by various vaccines (Fig. 6A) , the numbers and extra-vascular localization of NP366-specific CD8 T cells and NP311-specific CD4 T cells in the lungs were comparable between the groups (Fig. S5D) .", [["Cell", "ANATOMY", 160, 164], ["CD8", "ANATOMY", 342, 345], ["CD4 T-cell", "ANATOMY", 350, 360], ["lungs", "ANATOMY", 378, 383], ["Cell", "ANATOMY", 446, 450], ["extra-vascular", "ANATOMY", 637, 651], ["CD8 T cells", "ANATOMY", 683, 694], ["CD4 T cells", "ANATOMY", 714, 725], ["lungs", "ANATOMY", 733, 738], ["Influenza A Virus", "DISEASE", 217, 234], ["Influenza A Virus", "DISEASE", 503, 520], ["IAV", "ORGANISM", 19, 22], ["T-Cell", "CELL", 158, 164], ["Influenza A Virus", "ORGANISM", 217, 234], ["CD8", "GENE_OR_GENE_PRODUCT", 342, 345], ["CD4", "GENE_OR_GENE_PRODUCT", 350, 353], ["lungs", "ORGAN", 378, 383], ["PR8", "ORGANISM", 399, 402], ["T-Cell", "CELL", 444, 450], ["Influenza A Virus", "ORGANISM", 503, 520], ["NP366", "GENE_OR_GENE_PRODUCT", 668, 673], ["CD8", "GENE_OR_GENE_PRODUCT", 683, 686], ["NP311", "GENE_OR_GENE_PRODUCT", 699, 704], ["lungs", "ORGAN", 733, 738], ["CD8", "PROTEIN", 342, 345], ["NP366", "PROTEIN", 668, 673], ["CD8 T cells", "CELL_TYPE", 683, 694], ["NP311", "PROTEIN", 699, 704], ["CD4 T cells", "CELL_TYPE", 714, 725], ["Influenza A Virus", "SPECIES", 217, 234], ["Influenza A Virus", "SPECIES", 503, 520], ["IAV", "SPECIES", 19, 22], ["Influenza A Virus", "SPECIES", 217, 234], ["Influenza A Virus", "SPECIES", 503, 520], ["Protection", "TREATMENT", 0, 10], ["IAV", "PROBLEM", 19, 22], ["various adjuvant groups", "TREATMENT", 35, 58], ["Adjuvants Regulate", "TREATMENT", 132, 150], ["Influenza", "PROBLEM", 217, 226], ["various adjuvanted vaccines", "TREATMENT", 292, 319], ["CD8", "TEST", 342, 345], ["PR8/H1N1 challenge", "TREATMENT", 399, 417], ["Adjuvants", "TREATMENT", 418, 427], ["Influenza", "PROBLEM", 503, 512], ["protection afforded", "TREATMENT", 569, 588], ["the numbers", "TEST", 621, 632], ["extra-vascular localization", "TEST", 637, 664], ["NP366", "TEST", 668, 673], ["NP311", "TEST", 699, 704], ["lungs", "ANATOMY", 378, 383], ["CD4 T cells", "OBSERVATION", 714, 725], ["lungs", "ANATOMY", 733, 738]]], ["The percentages of NP366specific IFN-\uf067-producing CD8 T cells were also comparable for all groups of mice (Fig. 6B) .", [["CD8 T cells", "ANATOMY", 49, 60], ["IFN", "GENE_OR_GENE_PRODUCT", 33, 36], ["CD8", "GENE_OR_GENE_PRODUCT", 49, 52], ["mice", "ORGANISM", 100, 104], ["NP366specific IFN-\uf067-producing CD8 T cells", "CELL_TYPE", 19, 60], ["mice", "SPECIES", 100, 104], ["mice", "SPECIES", 100, 104], ["The percentages", "TEST", 0, 15], ["NP366specific IFN", "TEST", 19, 36], ["CD8 T cells", "PROBLEM", 49, 60]]], ["In striking contrast, percentages of NP366-specific IL-17-producing TC17 cells were considerably higher in the lungs of ADJ+GLA and GLA groups (Fig. 6B) .", [["IL-17-producing TC17 cells", "ANATOMY", 52, 78], ["lungs", "ANATOMY", 111, 116], ["ADJ", "ANATOMY", 120, 123], ["NP366", "GENE_OR_GENE_PRODUCT", 37, 42], ["IL-17", "GENE_OR_GENE_PRODUCT", 52, 57], ["TC17 cells", "CELL", 68, 78], ["lungs", "ORGAN", 111, 116], ["NP366", "PROTEIN", 37, 42], ["IL-17", "PROTEIN", 52, 57], ["TC17 cells", "CELL_LINE", 68, 78], ["percentages", "TEST", 22, 33], ["NP366", "TEST", 37, 42], ["specific IL", "TEST", 43, 54], ["TC17 cells", "PROBLEM", 68, 78], ["TC17 cells", "OBSERVATION", 68, 78], ["higher", "OBSERVATION_MODIFIER", 97, 103], ["lungs", "ANATOMY", 111, 116], ["GLA", "ANATOMY", 124, 127]]], ["The percentages of NP311-specific IFN-\uf067-producing CD4 T cells in the CpG and ADJ+CpG groups were significantly higher than in other groups (Fig. 6C) .", [["CD4 T cells", "ANATOMY", 50, 61], ["CpG", "CHEMICAL", 69, 72], ["CpG", "CHEMICAL", 81, 84], ["NP311", "GENE_OR_GENE_PRODUCT", 19, 24], ["IFN", "GENE_OR_GENE_PRODUCT", 34, 37], ["NP311", "PROTEIN", 19, 24], ["IFN", "PROTEIN", 34, 37], ["CD4 T cells", "CELL_TYPE", 50, 61], ["The percentages", "TEST", 0, 15], ["NP311", "TEST", 19, 24], ["specific IFN", "TEST", 25, 37], ["CD4 T cells", "PROBLEM", 50, 61], ["the CpG", "TREATMENT", 65, 72], ["ADJ+CpG groups", "TREATMENT", 77, 91], ["higher", "OBSERVATION_MODIFIER", 111, 117]]], ["In addition, lungs of GLA and ADJ+GLA mice contained higher percentages of IL-17-producing NP311-specific TH17 CD4 T cells, than in other groups.", [["lungs", "ANATOMY", 13, 18], ["TH17 CD4 T cells", "ANATOMY", 106, 122], ["lungs", "ORGAN", 13, 18], ["GLA", "GENE_OR_GENE_PRODUCT", 22, 25], ["ADJ", "GENE_OR_GENE_PRODUCT", 30, 33], ["IL-17", "GENE_OR_GENE_PRODUCT", 75, 80], ["NP311", "GENE_OR_GENE_PRODUCT", 91, 96], ["TH17 CD4 T cells", "CELL", 106, 122], ["IL-17", "PROTEIN", 75, 80], ["NP311", "PROTEIN", 91, 96], ["TH17 CD4 T cells", "CELL_TYPE", 106, 122], ["mice", "SPECIES", 38, 42], ["mice", "SPECIES", 38, 42], ["lungs of GLA", "TEST", 13, 25], ["ADJ", "TEST", 30, 33], ["GLA mice", "TEST", 34, 42], ["IL", "TEST", 75, 77], ["lungs", "ANATOMY", 13, 18], ["GLA", "ANATOMY", 22, 25]]], ["In this adjuvant system, all adjuvants afforded considerable protection.", [["this adjuvant system", "TREATMENT", 3, 23], ["all adjuvants", "TREATMENT", 25, 38], ["considerable protection", "TREATMENT", 48, 71]]], ["However, differences in viral control between groups appeared to associate with disparate levels of TC17 and/or TH17 cells, but not TC1 or TH1 cells.", [["TH17 cells", "ANATOMY", 112, 122], ["TC1", "ANATOMY", 132, 135], ["TH1 cells", "ANATOMY", 139, 148], ["TC17", "GENE_OR_GENE_PRODUCT", 100, 104], ["TH17 cells", "CELL", 112, 122], ["TC1", "CELL", 132, 135], ["TH1 cells", "CELL", 139, 148], ["TC17 and/or TH17 cells", "CELL_LINE", 100, 122], ["TC1", "CELL_LINE", 132, 135], ["TH1 cells", "CELL_LINE", 139, 148], ["disparate levels of TC17 and/or TH17 cells", "PROBLEM", 80, 122], ["TC1 or TH1 cells", "PROBLEM", 132, 148], ["TH17 cells", "OBSERVATION", 112, 122], ["TH1 cells", "OBSERVATION", 139, 148]]], ["For example, better viral control by GLA and ADJ+GLA groups was associated with increased percentages of IL-17-producing NP366-specific TC17 and NP311specific TH17 cells ( Fig. 6B and 6C ).", [["TC17", "ANATOMY", 136, 140], ["NP311specific TH17 cells", "ANATOMY", 145, 169], ["ADJ", "CHEMICAL", 45, 48], ["GLA", "CHEMICAL", 37, 40], ["GLA", "SIMPLE_CHEMICAL", 37, 40], ["ADJ", "SIMPLE_CHEMICAL", 45, 48], ["IL-17", "GENE_OR_GENE_PRODUCT", 105, 110], ["NP366", "GENE_OR_GENE_PRODUCT", 121, 126], ["TC17", "CELL", 136, 140], ["NP311specific TH17 cells", "CELL", 145, 169], ["IL-17", "PROTEIN", 105, 110], ["NP366", "PROTEIN", 121, 126], ["TC17 and NP311specific TH17 cells", "CELL_LINE", 136, 169], ["GLA and ADJ+GLA groups", "TEST", 37, 59], ["IL", "TEST", 105, 107]]], ["CpG and ADJ+CpG groups also differed in the percentages of NP311-specific TH17 cells but not TH1 or TC1 cells.", [["TH17 cells", "ANATOMY", 74, 84], ["TC1 cells", "ANATOMY", 100, 109], ["CpG", "CHEMICAL", 0, 3], ["CpG", "CHEMICAL", 12, 15], ["NP311", "GENE_OR_GENE_PRODUCT", 59, 64], ["TH17 cells", "CELL", 74, 84], ["TH1", "CELL", 93, 96], ["TC1 cells", "CELL", 100, 109], ["NP311", "PROTEIN", 59, 64], ["TH17 cells", "CELL_LINE", 74, 84], ["TH1 or TC1 cells", "CELL_LINE", 93, 109], ["CpG", "TREATMENT", 0, 3], ["ADJ+CpG groups", "TREATMENT", 8, 22], ["NP311", "TEST", 59, 64], ["TH17 cells", "OBSERVATION", 74, 84]]], ["These data suggest that stimulation of TC17/TH17 cells in parallel with TC1/TH1 cells might constitute a correlate of enhanced immunity conferred by ADJ and GLA, as compared to ADJ and CpG groups.", [["TC17/TH17 cells", "ANATOMY", 39, 54], ["TC1/TH1 cells", "ANATOMY", 72, 85], ["ADJ", "ANATOMY", 177, 180], ["ADJ", "CHEMICAL", 177, 180], ["CpG", "CHEMICAL", 185, 188], ["TC17", "GENE_OR_GENE_PRODUCT", 39, 43], ["TH17 cells", "CELL", 44, 54], ["TC1", "GENE_OR_GENE_PRODUCT", 72, 75], ["TH1 cells", "CELL", 76, 85], ["ADJ", "SIMPLE_CHEMICAL", 149, 152], ["GLA", "SIMPLE_CHEMICAL", 157, 160], ["ADJ", "CANCER", 177, 180], ["TC17/TH17 cells", "CELL_LINE", 39, 54], ["TC1/TH1 cells", "CELL_LINE", 72, 85], ["These data", "TEST", 0, 10], ["stimulation of TC17/TH17 cells", "TEST", 24, 54], ["TC1/TH1 cells", "TREATMENT", 72, 85], ["ADJ and CpG groups", "TREATMENT", 177, 195], ["TH17 cells", "OBSERVATION", 44, 54], ["TH1 cells", "OBSERVATION", 76, 85]]], ["To test this inference, we assessed the importance of IL-17A in mediating protective immunity to IAV in mice vaccinated with NP formulated in ADJ+GLA.", [["ADJ", "CHEMICAL", 142, 145], ["GLA", "CHEMICAL", 146, 149], ["IL-17A", "GENE_OR_GENE_PRODUCT", 54, 60], ["IAV", "ORGANISM", 97, 100], ["mice", "ORGANISM", 104, 108], ["ADJ+GLA", "SIMPLE_CHEMICAL", 142, 149], ["IL-17A", "PROTEIN", 54, 60], ["mice", "SPECIES", 104, 108], ["IAV", "SPECIES", 97, 100], ["mice", "SPECIES", 104, 108], ["IAV in mice vaccinated", "TREATMENT", 97, 119], ["GLA", "ANATOMY", 146, 149]]], ["At 180 days after vaccination, ADJ+GLAvaccinated mice were treated with isotype control antibodies or anti-IL-17A antibodies, just prior to viral challenge.", [["ADJ", "SIMPLE_CHEMICAL", 31, 34], ["mice", "ORGANISM", 49, 53], ["anti-IL-17A", "GENE_OR_GENE_PRODUCT", 102, 113], ["isotype control antibodies", "PROTEIN", 72, 98], ["anti-IL-17A antibodies", "PROTEIN", 102, 124], ["mice", "SPECIES", 49, 53], ["mice", "SPECIES", 49, 53], ["vaccination", "TREATMENT", 18, 29], ["ADJ+GLAvaccinated mice", "TREATMENT", 31, 53], ["isotype control antibodies", "TREATMENT", 72, 98], ["anti-IL", "TREATMENT", 102, 109], ["viral challenge", "TREATMENT", 140, 155]]], ["Data in Fig. 6D show that treatment with anti-IL-17A antibodies did not affect the accumulation of NP366-specific CD8 T cells or NP311-specific CD4 T cells in lungs following viral challenge.", [["CD8 T cells", "ANATOMY", 114, 125], ["CD4 T cells", "ANATOMY", 144, 155], ["lungs", "ANATOMY", 159, 164], ["anti-IL-17A", "GENE_OR_GENE_PRODUCT", 41, 52], ["NP366", "GENE_OR_GENE_PRODUCT", 99, 104], ["CD8", "GENE_OR_GENE_PRODUCT", 114, 117], ["NP311", "GENE_OR_GENE_PRODUCT", 129, 134], ["CD4", "GENE_OR_GENE_PRODUCT", 144, 147], ["lungs", "ORGAN", 159, 164], ["anti-IL-17A antibodies", "PROTEIN", 41, 63], ["NP366", "PROTEIN", 99, 104], ["CD8 T cells", "CELL_TYPE", 114, 125], ["NP311", "PROTEIN", 129, 134], ["CD4 T cells", "CELL_TYPE", 144, 155], ["anti-IL-17A antibodies", "TEST", 41, 63], ["NP366", "TEST", 99, 104], ["NP311", "TEST", 129, 134], ["viral challenge", "TREATMENT", 175, 190], ["lungs", "ANATOMY", 159, 164], ["viral challenge", "OBSERVATION", 175, 190]]], ["In mice treated with isotype control antibodies but not in anti-IL-17Atreated mice, lung viral titers were significantly lower than in unvaccinated control mice (Fig. 6D ).", [["lung", "ANATOMY", 84, 88], ["mice", "ORGANISM", 3, 7], ["anti-IL-17Atreated", "ORGANISM", 59, 77], ["mice", "ORGANISM", 78, 82], ["lung", "ORGAN", 84, 88], ["mice", "ORGANISM", 156, 160], ["isotype control antibodies", "PROTEIN", 21, 47], ["mice", "SPECIES", 3, 7], ["mice", "SPECIES", 78, 82], ["mice", "SPECIES", 156, 160], ["mice", "SPECIES", 3, 7], ["mice", "SPECIES", 78, 82], ["mice", "SPECIES", 156, 160], ["isotype control antibodies", "TREATMENT", 21, 47], ["anti-IL", "TEST", 59, 66], ["lung viral titers", "TEST", 84, 101], ["lung", "ANATOMY", 84, 88], ["viral titers", "OBSERVATION", 89, 101]]], ["These data suggested that IL-17A might have contributed to viral control in lungs in mice vaccinated with ADJ+GLA.", [["lungs", "ANATOMY", 76, 81], ["ADJ", "CHEMICAL", 106, 109], ["IL-17A", "GENE_OR_GENE_PRODUCT", 26, 32], ["lungs", "ORGAN", 76, 81], ["mice", "ORGANISM", 85, 89], ["ADJ+GLA", "SIMPLE_CHEMICAL", 106, 113], ["IL-17A", "PROTEIN", 26, 32], ["mice", "SPECIES", 85, 89], ["mice", "SPECIES", 85, 89], ["viral control in lungs", "PROBLEM", 59, 81], ["lungs", "ANATOMY", 76, 81], ["GLA", "ANATOMY", 110, 113]]], ["Although IL-17 production is known to be protective against certain fungal and bacterial infections, it is also linked to immune pathology (34, 35) .", [["fungal and bacterial infections", "DISEASE", 68, 99], ["IL-17", "GENE_OR_GENE_PRODUCT", 9, 14], ["IL", "PROTEIN", 9, 11], ["IL", "TEST", 9, 11], ["certain fungal and bacterial infections", "PROBLEM", 60, 99], ["immune pathology", "TEST", 122, 138], ["bacterial", "OBSERVATION_MODIFIER", 79, 88], ["infections", "OBSERVATION", 89, 99]]], ["In order to evaluate whether vaccine-induced protective immunity in ADJ+GLA mice was associated with lung pathology, we analyzed histopathological changes in lungs after viral challenge (Fig. S6) .Adjuvants Regulate Recall T-Cell Responses and Protective Heterosubtypic Immunity to Influenza A Virus in MiceWith the exception of the ADJ group, moderate necrotizing bronchiolitis was present in all mice, and was most severe in the CPG where it progressed to early-stage bronchiolitis obliterans and organizing pneumonia.", [["lung", "ANATOMY", 101, 105], ["lungs", "ANATOMY", 158, 163], ["Cell", "ANATOMY", 225, 229], ["ADJ", "ANATOMY", 333, 336], ["Influenza A Virus", "DISEASE", 282, 299], ["bronchiolitis", "DISEASE", 365, 378], ["bronchiolitis obliterans", "DISEASE", 470, 494], ["pneumonia", "DISEASE", 510, 519], ["ADJ+GLA mice", "ORGANISM", 68, 80], ["lung", "ORGAN", 101, 105], ["lungs", "ORGAN", 158, 163], ["T-Cell", "CELL", 223, 229], ["Influenza A Virus", "ORGANISM", 282, 299], ["ADJ", "CANCER", 333, 336], ["mice", "ORGANISM", 398, 402], ["mice", "SPECIES", 76, 80], ["Influenza A Virus", "SPECIES", 282, 299], ["mice", "SPECIES", 398, 402], ["mice", "SPECIES", 76, 80], ["Influenza A Virus", "SPECIES", 282, 299], ["mice", "SPECIES", 398, 402], ["vaccine", "TREATMENT", 29, 36], ["GLA mice", "PROBLEM", 72, 80], ["lung pathology", "PROBLEM", 101, 115], ["histopathological changes in lungs", "PROBLEM", 129, 163], ["viral challenge", "TREATMENT", 170, 185], ["Adjuvants", "TREATMENT", 197, 206], ["Influenza A Virus", "PROBLEM", 282, 299], ["moderate necrotizing bronchiolitis", "PROBLEM", 344, 378], ["early-stage bronchiolitis obliterans", "PROBLEM", 458, 494], ["organizing pneumonia", "PROBLEM", 499, 519], ["lung", "ANATOMY", 101, 105], ["pathology", "OBSERVATION", 106, 115], ["lungs", "ANATOMY", 158, 163], ["moderate", "OBSERVATION_MODIFIER", 344, 352], ["necrotizing", "OBSERVATION_MODIFIER", 353, 364], ["bronchiolitis", "OBSERVATION", 365, 378], ["most severe", "OBSERVATION_MODIFIER", 412, 423], ["early", "OBSERVATION_MODIFIER", 458, 463], ["-stage", "OBSERVATION_MODIFIER", 463, 469], ["bronchiolitis obliterans", "OBSERVATION", 470, 494], ["organizing", "OBSERVATION_MODIFIER", 499, 509], ["pneumonia", "OBSERVATION", 510, 519]]], ["Very mild extension to the surrounding alveoli was present in the GLA and AJ GLA group.", [["alveoli", "ANATOMY", 39, 46], ["AJ", "ANATOMY", 74, 76], ["alveoli", "MULTI-TISSUE_STRUCTURE", 39, 46], ["GLA", "SIMPLE_CHEMICAL", 66, 69], ["Very mild extension to the surrounding alveoli", "PROBLEM", 0, 46], ["mild", "OBSERVATION_MODIFIER", 5, 9], ["surrounding", "ANATOMY_MODIFIER", 27, 38], ["alveoli", "ANATOMY", 39, 46], ["GLA", "ANATOMY", 66, 69], ["AJ GLA", "ANATOMY", 74, 80]]], ["Thus, we did not find any evidence of augmented lung pathology in ADJ+GLA mice following viral challenge.Adjuvants Regulate Recall T-Cell Responses and Protective Heterosubtypic Immunity to Influenza A Virus in MiceNext we assessed whether NP-based adjuvanted vaccines conferred heterosubtypic immunity against a highly lethal infection with H5N1 avian influenza virus at 50 days PV.", [["lung", "ANATOMY", 48, 52], ["Cell", "ANATOMY", 133, 137], ["Influenza A Virus", "DISEASE", 190, 207], ["NP", "CHEMICAL", 240, 242], ["infection", "DISEASE", 327, 336], ["H5N1 avian influenza virus", "DISEASE", 342, 368], ["lung", "ORGAN", 48, 52], ["ADJ+GLA mice", "ORGANISM", 66, 78], ["T-Cell", "CELL", 131, 137], ["Influenza A Virus", "ORGANISM", 190, 207], ["H5N1", "ORGANISM", 342, 346], ["avian influenza virus", "ORGANISM", 347, 368], ["mice", "SPECIES", 74, 78], ["Influenza A Virus", "SPECIES", 190, 207], ["H5N1 avian influenza virus", "SPECIES", 342, 368], ["mice", "SPECIES", 74, 78], ["Influenza A Virus", "SPECIES", 190, 207], ["H5N1 avian influenza virus", "SPECIES", 342, 368], ["PV", "SPECIES", 380, 382], ["augmented lung pathology", "PROBLEM", 38, 62], ["viral challenge", "TREATMENT", 89, 104], ["Adjuvants", "TREATMENT", 105, 114], ["Influenza", "PROBLEM", 190, 199], ["NP-based adjuvanted vaccines", "TREATMENT", 240, 268], ["heterosubtypic immunity", "TREATMENT", 279, 302], ["a highly lethal infection", "PROBLEM", 311, 336], ["H5N1 avian influenza virus", "TREATMENT", 342, 368], ["lung", "ANATOMY", 48, 52], ["pathology", "OBSERVATION", 53, 62]]], ["In the unvaccinated and NP-vaccinated group, 100% of mice lost significant weight and succumbed to H5N1 infection (Fig. 6E) .", [["H5N1 infection", "DISEASE", 99, 113], ["mice", "ORGANISM", 53, 57], ["mice", "SPECIES", 53, 57], ["mice", "SPECIES", 53, 57], ["NP-vaccinated group", "TREATMENT", 24, 43], ["H5N1 infection", "PROBLEM", 99, 113], ["H5N1", "OBSERVATION_MODIFIER", 99, 103], ["infection", "OBSERVATION", 104, 113]]], ["By contrast, 100% of ADJ+GLA and ADJ+CpG mice lost little weight and survived H5N1 challenge, while other groups showed excellent protection ranging from 70-90% (Fig. 6E) .Protective Immunity to InfluenzaIn order to determine whether CD4 T cells regulate the quality of CD8 T-cell memory and protective immunity induced by the ADJ+GLA vaccine, we depleted CD4 T cells, only at the time of prime and boost vaccination.", [["CD4 T cells", "ANATOMY", 234, 245], ["CD8 T-cell", "ANATOMY", 270, 280], ["CD4 T cells", "ANATOMY", 356, 367], ["H5N1", "DISEASE", 78, 82], ["ADJ", "CHEMICAL", 327, 330], ["CpG", "CHEMICAL", 37, 40], ["ADJ", "GENE_OR_GENE_PRODUCT", 21, 24], ["GLA", "GENE_OR_GENE_PRODUCT", 25, 28], ["ADJ", "GENE_OR_GENE_PRODUCT", 33, 36], ["mice", "ORGANISM", 41, 45], ["CD4 T cells", "CELL", 234, 245], ["CD8", "GENE_OR_GENE_PRODUCT", 270, 273], ["ADJ", "SIMPLE_CHEMICAL", 327, 330], ["GLA", "SIMPLE_CHEMICAL", 331, 334], ["CD4 T cells", "CELL", 356, 367], ["CD4 T cells", "CELL_TYPE", 234, 245], ["CD4 T cells", "CELL_TYPE", 356, 367], ["mice", "SPECIES", 41, 45], ["mice", "SPECIES", 41, 45], ["ADJ+GLA", "TREATMENT", 21, 28], ["ADJ+CpG mice", "TREATMENT", 33, 45], ["H5N1 challenge", "TREATMENT", 78, 92], ["CD4 T cells", "PROBLEM", 234, 245], ["the ADJ+GLA vaccine", "TREATMENT", 323, 342], ["CD4 T cells", "PROBLEM", 356, 367], ["boost vaccination", "TREATMENT", 399, 416]]], ["At 80 days PV, we examined CD4 and CD8 T-cell memory in the RT (Fig. 7) .", [["CD4", "ANATOMY", 27, 30], ["CD8 T-cell", "ANATOMY", 35, 45], ["CD4", "GENE_OR_GENE_PRODUCT", 27, 30], ["CD8", "GENE_OR_GENE_PRODUCT", 35, 38], ["CD4", "PROTEIN", 27, 30], ["CD8", "PROTEIN", 35, 38], ["CD4", "TEST", 27, 30]]], ["NP311-specific memory CD4 T cells were only detected in lungs and airways of non-depleted mice (Fig. 7A) .", [["memory CD4 T cells", "ANATOMY", 15, 33], ["lungs", "ANATOMY", 56, 61], ["airways", "ANATOMY", 66, 73], ["NP311", "GENE_OR_GENE_PRODUCT", 0, 5], ["lungs", "ORGAN", 56, 61], ["airways", "MULTI-TISSUE_STRUCTURE", 66, 73], ["mice", "ORGANISM", 90, 94], ["NP311", "PROTEIN", 0, 5], ["memory CD4 T cells", "CELL_TYPE", 15, 33], ["mice", "SPECIES", 90, 94], ["mice", "SPECIES", 90, 94], ["lungs", "ANATOMY", 56, 61], ["airways", "ANATOMY", 66, 73]]], ["CD4 T-cell depletion had no adverse effect on the numbers of NP366-specific memory CD8 T cells in the RT (Fig. 7B) .", [["CD4 T-cell", "ANATOMY", 0, 10], ["memory CD8 T cells", "ANATOMY", 76, 94], ["CD4", "GENE_OR_GENE_PRODUCT", 0, 3], ["NP366", "GENE_OR_GENE_PRODUCT", 61, 66], ["CD8 T cells", "CELL", 83, 94], ["CD4", "PROTEIN", 0, 3], ["NP366", "PROTEIN", 61, 66], ["memory CD8 T cells", "CELL_TYPE", 76, 94], ["CD4 T-cell depletion", "PROBLEM", 0, 20], ["adverse effect", "PROBLEM", 28, 42], ["the numbers", "TEST", 46, 57], ["NP366", "TEST", 61, 66], ["cell depletion", "OBSERVATION", 6, 20], ["no", "UNCERTAINTY", 25, 27], ["adverse effect", "OBSERVATION_MODIFIER", 28, 42]]], ["Among TRM markers, only the expression of CD103, but not CD69 or CD49a was significantly reduced by CD4 T-cell depletion (Fig. 7C) .", [["CD4 T-cell", "ANATOMY", 100, 110], ["CD103", "GENE_OR_GENE_PRODUCT", 42, 47], ["CD69", "GENE_OR_GENE_PRODUCT", 57, 61], ["CD49a", "GENE_OR_GENE_PRODUCT", 65, 70], ["TRM markers", "PROTEIN", 6, 17], ["CD103", "PROTEIN", 42, 47], ["CD69", "PROTEIN", 57, 61], ["CD49a", "PROTEIN", 65, 70], ["CD4", "PROTEIN", 100, 103], ["TRM markers", "TEST", 6, 17], ["CD103", "TEST", 42, 47], ["CD69", "TEST", 57, 61], ["CD49a", "TEST", 65, 70], ["CD103", "OBSERVATION", 42, 47], ["cell depletion", "OBSERVATION", 106, 120]]], ["Coincident with impaired CD103 expression, memory CD8 T cells in CD4 T-cell-depleted mice poorly localized to the lung parenchyma (Fig. 7D) .", [["memory CD8 T cells", "ANATOMY", 43, 61], ["CD4 T-cell", "ANATOMY", 65, 75], ["lung parenchyma", "ANATOMY", 114, 129], ["CD103", "GENE_OR_GENE_PRODUCT", 25, 30], ["CD8", "GENE_OR_GENE_PRODUCT", 50, 53], ["CD4", "GENE_OR_GENE_PRODUCT", 65, 68], ["mice", "ORGANISM", 85, 89], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 114, 129], ["CD103", "PROTEIN", 25, 30], ["memory CD8 T cells", "CELL_TYPE", 43, 61], ["CD4 T-cell", "CELL_TYPE", 65, 75], ["mice", "SPECIES", 85, 89], ["mice", "SPECIES", 85, 89], ["impaired CD103 expression", "PROBLEM", 16, 41], ["CD4 T", "TEST", 65, 70], ["cell", "TEST", 71, 75], ["impaired", "OBSERVATION_MODIFIER", 16, 24], ["CD103 expression", "OBSERVATION", 25, 41], ["lung", "ANATOMY", 114, 118], ["parenchyma", "ANATOMY_MODIFIER", 119, 129]]], ["Functionally, the percentages of NP366-specific IFN-\uf067-producing CD8 T cells were significantly (P<0.05) increased in the lungs of CD4 T cell-depleted mice, with no effect on IL-17-producing CD8 T cells ( Fig. 7E and 7F) .", [["CD8 T cells", "ANATOMY", 64, 75], ["lungs", "ANATOMY", 121, 126], ["CD4 T cell", "ANATOMY", 130, 140], ["CD8 T cells", "ANATOMY", 190, 201], ["NP366", "GENE_OR_GENE_PRODUCT", 33, 38], ["IFN", "GENE_OR_GENE_PRODUCT", 48, 51], ["CD8", "GENE_OR_GENE_PRODUCT", 64, 67], ["lungs", "ORGAN", 121, 126], ["CD4 T cell", "CELL", 130, 140], ["mice", "ORGANISM", 150, 154], ["IL-17", "GENE_OR_GENE_PRODUCT", 174, 179], ["CD8", "GENE_OR_GENE_PRODUCT", 190, 193], ["NP366", "PROTEIN", 33, 38], ["IFN", "PROTEIN", 48, 51], ["CD8 T cells", "CELL_TYPE", 64, 75], ["CD4 T cell", "CELL_TYPE", 130, 140], ["IL-17", "PROTEIN", 174, 179], ["CD8 T cells", "CELL_TYPE", 190, 201], ["mice", "SPECIES", 150, 154], ["mice", "SPECIES", 150, 154], ["the percentages", "TEST", 14, 29], ["NP366", "TEST", 33, 38], ["specific IFN", "TEST", 39, 51], ["CD8 T cells", "TEST", 64, 75], ["IL", "TEST", 174, 176], ["lungs", "ANATOMY", 121, 126], ["CD4 T cell", "OBSERVATION", 130, 140], ["no", "UNCERTAINTY", 161, 163]]], ["In summary, loss of CD4 T cells impaired CD103 expression and extravascular localization of memory CD8 T cells but increased the percentages of NP366-specific memory TC1 cells in the lungs.Protective Immunity to InfluenzaTo assess whether depletion of CD4 T cells affected protective immunity, we challenged undepleted and CD4 T-cell-depleted vaccinated mice with the PR8/H1N1 virus.", [["CD4 T cells", "ANATOMY", 20, 31], ["extravascular", "ANATOMY", 62, 75], ["memory CD8 T cells", "ANATOMY", 92, 110], ["memory TC1 cells", "ANATOMY", 159, 175], ["lungs", "ANATOMY", 183, 188], ["CD4 T cells", "ANATOMY", 252, 263], ["CD4 T-cell", "ANATOMY", 323, 333], ["CD4 T", "GENE_OR_GENE_PRODUCT", 20, 25], ["CD103", "GENE_OR_GENE_PRODUCT", 41, 46], ["extravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 62, 75], ["CD8 T cells", "CELL", 99, 110], ["NP366", "GENE_OR_GENE_PRODUCT", 144, 149], ["memory TC1 cells", "CELL", 159, 175], ["lungs", "ORGAN", 183, 188], ["CD4", "GENE_OR_GENE_PRODUCT", 252, 255], ["CD4 T-cell", "CELL", 323, 333], ["mice", "ORGANISM", 354, 358], ["PR8/H1N1 virus", "ORGANISM", 368, 382], ["CD4 T cells", "CELL_TYPE", 20, 31], ["CD103", "PROTEIN", 41, 46], ["memory CD8 T cells", "CELL_TYPE", 92, 110], ["NP366", "PROTEIN", 144, 149], ["memory TC1 cells", "CELL_TYPE", 159, 175], ["CD4 T cells", "CELL_TYPE", 252, 263], ["CD4 T-cell", "CELL_TYPE", 323, 333], ["mice", "SPECIES", 354, 358], ["H1N1 virus", "SPECIES", 372, 382], ["mice", "SPECIES", 354, 358], ["PR8/H1N1 virus", "SPECIES", 368, 382], ["loss of CD4 T cells", "PROBLEM", 12, 31], ["impaired CD103 expression", "PROBLEM", 32, 57], ["memory CD8 T cells", "PROBLEM", 92, 110], ["NP366", "TEST", 144, 149], ["CD4 T cells", "PROBLEM", 252, 263], ["the PR8/H1N1 virus", "TREATMENT", 364, 382], ["CD103 expression", "OBSERVATION", 41, 57], ["extravascular", "OBSERVATION_MODIFIER", 62, 75], ["memory CD8", "OBSERVATION", 92, 102], ["increased", "OBSERVATION_MODIFIER", 115, 124], ["memory TC1 cells", "OBSERVATION", 159, 175], ["lungs", "ANATOMY", 183, 188]]], ["On the 6 th day after challenge, we assessed recall CD8 T-cell responses and viral control in the lungs.", [["CD8 T-cell", "ANATOMY", 52, 62], ["lungs", "ANATOMY", 98, 103], ["CD8 T-cell", "CELL", 52, 62], ["lungs", "ORGAN", 98, 103], ["CD8", "PROTEIN", 52, 55], ["viral control in the lungs", "PROBLEM", 77, 103], ["viral control", "OBSERVATION", 77, 90], ["lungs", "ANATOMY", 98, 103]]], ["The percentages of NP366-specific CD8 T cells in lungs of CD4 T-cell-depleted mice were higher than in un-depleted mice (Fig. 7G) , and the majority of these effector cells localized to the nonvascular compartment (Fig. 7H) .", [["CD8 T cells", "ANATOMY", 34, 45], ["lungs", "ANATOMY", 49, 54], ["CD4 T-cell", "ANATOMY", 58, 68], ["cells", "ANATOMY", 167, 172], ["nonvascular compartment", "ANATOMY", 190, 213], ["NP366", "GENE_OR_GENE_PRODUCT", 19, 24], ["CD8", "GENE_OR_GENE_PRODUCT", 34, 37], ["lungs", "ORGAN", 49, 54], ["CD4", "GENE_OR_GENE_PRODUCT", 58, 61], ["mice", "ORGANISM", 78, 82], ["mice", "ORGANISM", 115, 119], ["effector cells", "CELL", 158, 172], ["nonvascular compartment", "MULTI-TISSUE_STRUCTURE", 190, 213], ["NP366", "PROTEIN", 19, 24], ["CD8 T cells", "CELL_TYPE", 34, 45], ["CD4 T-cell", "CELL_TYPE", 58, 68], ["effector cells", "CELL_TYPE", 158, 172], ["mice", "SPECIES", 78, 82], ["mice", "SPECIES", 115, 119], ["mice", "SPECIES", 78, 82], ["mice", "SPECIES", 115, 119], ["The percentages", "TEST", 0, 15], ["NP366", "TEST", 19, 24], ["CD4 T", "TEST", 58, 63], ["these effector cells", "PROBLEM", 152, 172], ["lungs", "ANATOMY", 49, 54], ["higher", "OBSERVATION_MODIFIER", 88, 94], ["effector cells", "OBSERVATION", 158, 172], ["nonvascular compartment", "ANATOMY", 190, 213]]], ["NP311-specific CD4 T cells were only detected in the lungs of un-depleted mice (Fig. 7I) .", [["T cells", "ANATOMY", 19, 26], ["lungs", "ANATOMY", 53, 58], ["NP311", "GENE_OR_GENE_PRODUCT", 0, 5], ["CD4", "GENE_OR_GENE_PRODUCT", 15, 18], ["T cells", "CELL", 19, 26], ["lungs", "ORGAN", 53, 58], ["mice", "ORGANISM", 74, 78], ["NP311", "PROTEIN", 0, 5], ["CD4", "PROTEIN", 15, 18], ["T cells", "CELL_TYPE", 19, 26], ["mice", "SPECIES", 74, 78], ["T cells", "TEST", 19, 26], ["lungs", "ANATOMY", 53, 58], ["depleted mice", "OBSERVATION", 65, 78]]], ["CD4 T-cell depletion had no effect on the percentages of CD69 +ve CD8 T cells, but the percentages of CD49a +ve cells were significantly (P<0.05) increased in CD4 T-cell-depleted mice.", [["CD4 T-cell", "ANATOMY", 0, 10], ["CD69 +ve CD8 T cells", "ANATOMY", 57, 77], ["CD49a +ve cells", "ANATOMY", 102, 117], ["CD4 T-cell", "ANATOMY", 159, 169], ["CD4", "GENE_OR_GENE_PRODUCT", 0, 3], ["CD69", "GENE_OR_GENE_PRODUCT", 57, 61], ["CD49a", "GENE_OR_GENE_PRODUCT", 102, 107], ["CD4 T-cell", "CELL", 159, 169], ["mice", "ORGANISM", 179, 183], ["CD4", "PROTEIN", 0, 3], ["CD69", "PROTEIN", 57, 61], ["CD8 T cells", "CELL_TYPE", 66, 77], ["CD49a", "PROTEIN", 102, 107], ["CD4 T-cell", "CELL_TYPE", 159, 169], ["mice", "SPECIES", 179, 183], ["CD4 T-cell depletion", "TEST", 0, 20], ["CD69", "TEST", 57, 61], ["CD8 T cells", "PROBLEM", 66, 77], ["the percentages", "TEST", 83, 98], ["CD49a", "TEST", 102, 107], ["ve cells", "PROBLEM", 109, 117], ["cell depletion", "OBSERVATION", 6, 20], ["no", "UNCERTAINTY", 25, 27], ["depleted mice", "OBSERVATION", 170, 183]]], ["A small percentage of NP366-specific CD8 T cells in the lungs of undepleted mice expressed CD103, and this fraction was significantly (P<0.05) reduced by CD4 T-cell depletion (Fig. 7J) .", [["CD8 T cells", "ANATOMY", 37, 48], ["lungs", "ANATOMY", 56, 61], ["CD4 T-cell", "ANATOMY", 154, 164], ["NP366", "GENE_OR_GENE_PRODUCT", 22, 27], ["CD8 T", "GENE_OR_GENE_PRODUCT", 37, 42], ["lungs", "ORGAN", 56, 61], ["mice", "ORGANISM", 76, 80], ["CD103", "GENE_OR_GENE_PRODUCT", 91, 96], ["NP366-specific CD8 T cells", "CELL_LINE", 22, 48], ["CD103", "PROTEIN", 91, 96], ["CD4", "PROTEIN", 154, 157], ["mice", "SPECIES", 76, 80], ["mice", "SPECIES", 76, 80], ["NP366", "TEST", 22, 27], ["this fraction", "TEST", 102, 115], ["CD4 T-cell depletion", "TREATMENT", 154, 174], ["small", "OBSERVATION_MODIFIER", 2, 7], ["percentage", "OBSERVATION_MODIFIER", 8, 18], ["CD8 T cells", "OBSERVATION", 37, 48], ["lungs", "ANATOMY", 56, 61], ["CD103", "OBSERVATION", 91, 96], ["cell depletion", "OBSERVATION", 160, 174]]], ["In the CD4 T-cell-depleted group, the percentages of CXCR3 +ve NP366-specific CD8 T cells were significantly reduced, but the percentages of NP366-specific CD8 T cells that expressed elevated levels of CX3CR1, T-bet and EOMES were higher in CD4 T-cell-depleted group than in undepleted group (Fig. 7K) .", [["CD4 T-cell", "ANATOMY", 7, 17], ["CD8 T cells", "ANATOMY", 78, 89], ["CD8 T cells", "ANATOMY", 156, 167], ["CD4 T-cell", "ANATOMY", 241, 251], ["CD4 T-cell", "CELL", 7, 17], ["CXCR3", "GENE_OR_GENE_PRODUCT", 53, 58], ["NP366", "GENE_OR_GENE_PRODUCT", 63, 68], ["CD8", "GENE_OR_GENE_PRODUCT", 78, 81], ["NP366", "GENE_OR_GENE_PRODUCT", 141, 146], ["CD8", "GENE_OR_GENE_PRODUCT", 156, 159], ["CX3CR1", "GENE_OR_GENE_PRODUCT", 202, 208], ["T-bet", "GENE_OR_GENE_PRODUCT", 210, 215], ["EOMES", "GENE_OR_GENE_PRODUCT", 220, 225], ["CD4 T-cell", "CELL", 241, 251], ["CD4 T-cell-depleted group", "CELL_LINE", 7, 32], ["CXCR3", "PROTEIN", 53, 58], ["NP366", "PROTEIN", 63, 68], ["CD8 T cells", "CELL_TYPE", 78, 89], ["NP366", "PROTEIN", 141, 146], ["CD8 T cells", "CELL_TYPE", 156, 167], ["CX3CR1", "PROTEIN", 202, 208], ["T-bet", "PROTEIN", 210, 215], ["EOMES", "PROTEIN", 220, 225], ["CD4 T-cell", "CELL_TYPE", 241, 251], ["the percentages", "TEST", 34, 49], ["CXCR3", "TEST", 53, 58], ["NP366", "TEST", 63, 68], ["specific CD8 T cells", "TEST", 69, 89], ["the percentages", "TEST", 122, 137], ["NP366", "TEST", 141, 146], ["elevated levels", "PROBLEM", 183, 198], ["CX3CR1", "TEST", 202, 208], ["T", "TEST", 210, 211], ["EOMES", "TEST", 220, 225], ["elevated", "OBSERVATION_MODIFIER", 183, 191], ["higher", "OBSERVATION_MODIFIER", 231, 237]]], ["Increased accumulation of CX3CR1 Hi cells and reduced expression of CXCR3 on CD8 T cells in CD4 T-cell-depleted mice is consistent with elevated expression of T-bet (23, 36) .", [["Hi cells", "ANATOMY", 33, 41], ["CD8 T cells", "ANATOMY", 77, 88], ["CD4 T-cell", "ANATOMY", 92, 102], ["CX3CR1", "GENE_OR_GENE_PRODUCT", 26, 32], ["Hi cells", "CELL", 33, 41], ["CXCR3", "GENE_OR_GENE_PRODUCT", 68, 73], ["CD8", "GENE_OR_GENE_PRODUCT", 77, 80], ["CD4", "GENE_OR_GENE_PRODUCT", 92, 95], ["mice", "ORGANISM", 112, 116], ["T-bet", "GENE_OR_GENE_PRODUCT", 159, 164], ["CX3CR1", "PROTEIN", 26, 32], ["Hi cells", "CELL_TYPE", 33, 41], ["CXCR3", "PROTEIN", 68, 73], ["CD8 T cells", "CELL_TYPE", 77, 88], ["CD4 T-cell", "CELL_TYPE", 92, 102], ["mice", "SPECIES", 112, 116], ["Increased accumulation of CX3CR", "PROBLEM", 0, 31], ["Hi cells", "PROBLEM", 33, 41], ["CXCR3", "TEST", 68, 73], ["CD8 T cells", "TEST", 77, 88], ["CD4 T", "TEST", 92, 97], ["elevated expression of T-bet", "PROBLEM", 136, 164], ["accumulation", "OBSERVATION_MODIFIER", 10, 22], ["reduced", "OBSERVATION_MODIFIER", 46, 53], ["consistent with", "UNCERTAINTY", 120, 135], ["elevated", "OBSERVATION_MODIFIER", 136, 144], ["expression", "OBSERVATION_MODIFIER", 145, 155]]], ["Significantly, the percentages of IFN-\uf067producing and granzyme B +ve CD8 T cells were higher, but there was a concurrent reduction in IL-17-producing CD8 T cells in the lungs of CD4 T-cell-depleted mice (Fig. 7L-M) .", [["granzyme B +ve CD8 T cells", "ANATOMY", 53, 79], ["CD8 T cells", "ANATOMY", 149, 160], ["lungs", "ANATOMY", 168, 173], ["CD4 T-cell", "ANATOMY", 177, 187], ["IFN", "GENE_OR_GENE_PRODUCT", 34, 37], ["granzyme B", "GENE_OR_GENE_PRODUCT", 53, 63], ["IL-17", "GENE_OR_GENE_PRODUCT", 133, 138], ["CD8", "GENE_OR_GENE_PRODUCT", 149, 152], ["lungs", "ORGAN", 168, 173], ["CD4 T-cell", "CELL", 177, 187], ["mice", "ORGANISM", 197, 201], ["IFN", "PROTEIN", 34, 37], ["granzyme B +ve CD8 T cells", "CELL_TYPE", 53, 79], ["IL-17", "PROTEIN", 133, 138], ["CD8 T cells", "CELL_TYPE", 149, 160], ["CD4 T-cell", "CELL_TYPE", 177, 187], ["mice", "SPECIES", 197, 201], ["IFN", "TEST", 34, 37], ["granzyme B", "TEST", 53, 63], ["CD8 T cells", "TEST", 68, 79], ["IL", "TEST", 133, 135], ["reduction", "OBSERVATION_MODIFIER", 120, 129], ["CD8 T cells", "OBSERVATION", 149, 160], ["lungs", "ANATOMY", 168, 173], ["CD4", "ANATOMY", 177, 180]]], ["Strikingly, >90% of NP366-specific CD8 T cells produced IFN-\uf067 in the CD4 T-cell-depleted group as opposed to ~56% in undepleted mice (Fig. 7N) .", [["CD8 T cells", "ANATOMY", 35, 46], ["CD4 T-cell", "ANATOMY", 69, 79], ["NP366", "GENE_OR_GENE_PRODUCT", 20, 25], ["CD8", "GENE_OR_GENE_PRODUCT", 35, 38], ["IFN-\uf067", "GENE_OR_GENE_PRODUCT", 56, 61], ["CD4 T-cell", "CELL", 69, 79], ["mice", "ORGANISM", 128, 132], ["NP366", "PROTEIN", 20, 25], ["CD8 T cells", "CELL_TYPE", 35, 46], ["IFN", "PROTEIN", 56, 59], ["CD4 T-cell-depleted group", "CELL_LINE", 69, 94], ["mice", "SPECIES", 128, 132], ["mice", "SPECIES", 128, 132], ["NP366", "TEST", 20, 25], ["IFN", "TEST", 56, 59]]], ["Undepleted mice effectively controlled viral replication in the lungs (Fig. 7O ; >99% reduction in lung viral titers).", [["lungs", "ANATOMY", 64, 69], ["lung", "ANATOMY", 99, 103], ["mice", "ORGANISM", 11, 15], ["lungs", "ORGAN", 64, 69], ["lung", "ORGAN", 99, 103], ["mice", "SPECIES", 11, 15], ["mice", "SPECIES", 11, 15], ["lung viral titers", "TEST", 99, 116], ["viral replication", "OBSERVATION", 39, 56], ["lungs", "ANATOMY", 64, 69], ["lung", "ANATOMY", 99, 103], ["viral titers", "OBSERVATION", 104, 116]]], ["Thus, surprisingly, despite markedly increased development of IFN-\uf067-producing granzyme B +ve TC1 CD8 T cells, CD4 Tcell-depleted mice showed poor control of influenza virus in the lungs (Fig. 7O) and also exhibited exaggerated weight loss (Fig. 7P) .", [["granzyme B +ve TC1 CD8 T cells", "ANATOMY", 78, 108], ["lungs", "ANATOMY", 180, 185], ["influenza virus", "DISEASE", 157, 172], ["weight loss", "DISEASE", 227, 238], ["IFN", "GENE_OR_GENE_PRODUCT", 62, 65], ["granzyme B", "GENE_OR_GENE_PRODUCT", 78, 88], ["CD4", "GENE_OR_GENE_PRODUCT", 110, 113], ["mice", "ORGANISM", 129, 133], ["influenza virus", "ORGANISM", 157, 172], ["lungs", "ORGAN", 180, 185], ["IFN", "PROTEIN", 62, 65], ["granzyme B", "PROTEIN", 78, 88], ["TC1 CD8 T cells", "CELL_TYPE", 93, 108], ["CD4", "PROTEIN", 110, 113], ["mice", "SPECIES", 129, 133], ["influenza virus", "SPECIES", 157, 172], ["mice", "SPECIES", 129, 133], ["influenza virus", "SPECIES", 157, 172], ["IFN", "TEST", 62, 65], ["granzyme B", "TEST", 78, 88], ["CD4 Tcell", "TEST", 110, 119], ["influenza virus in the lungs", "PROBLEM", 157, 185], ["exaggerated weight loss", "PROBLEM", 215, 238], ["markedly", "OBSERVATION_MODIFIER", 28, 36], ["increased", "OBSERVATION_MODIFIER", 37, 46], ["influenza virus", "OBSERVATION", 157, 172], ["lungs", "ANATOMY", 180, 185], ["exaggerated", "OBSERVATION_MODIFIER", 215, 226], ["weight loss", "OBSERVATION", 227, 238]]], ["Taken together data in In order to dissect whether impaired viral control in CD4 T cell-depleted mice was due to defective programming of CD8 T cells and/or due to loss of CD4 T cell-dependent viral control, we depleted CD4 or CD8 T cells just prior to influenza virus challenge (Fig. S7) .", [["CD4 T cell", "ANATOMY", 77, 87], ["CD8 T cells", "ANATOMY", 138, 149], ["CD4 T cell", "ANATOMY", 172, 182], ["CD4", "ANATOMY", 220, 223], ["CD8 T cells", "ANATOMY", 227, 238], ["CD4 T cell", "CELL", 77, 87], ["mice", "ORGANISM", 97, 101], ["CD8 T cells", "CELL", 138, 149], ["CD4", "GENE_OR_GENE_PRODUCT", 172, 175], ["CD4", "GENE_OR_GENE_PRODUCT", 220, 223], ["CD8", "GENE_OR_GENE_PRODUCT", 227, 230], ["influenza virus", "ORGANISM", 253, 268], ["S7", "GENE_OR_GENE_PRODUCT", 285, 287], ["CD4 T cell", "CELL_TYPE", 77, 87], ["CD8 T cells", "CELL_TYPE", 138, 149], ["CD4", "PROTEIN", 172, 175], ["CD4", "PROTEIN", 220, 223], ["CD8 T cells", "CELL_TYPE", 227, 238], ["S7", "PROTEIN", 285, 287], ["mice", "SPECIES", 97, 101], ["mice", "SPECIES", 97, 101], ["impaired viral control", "PROBLEM", 51, 73], ["defective programming", "PROBLEM", 113, 134], ["CD8 T cells", "PROBLEM", 138, 149], ["CD4 T cell", "PROBLEM", 172, 182], ["dependent viral control", "TREATMENT", 183, 206], ["CD8 T cells", "PROBLEM", 227, 238], ["influenza virus challenge", "TREATMENT", 253, 278], ["impaired", "OBSERVATION_MODIFIER", 51, 59], ["viral", "OBSERVATION", 60, 65]]], ["As shown inDiscussionMucosal viral infections such as influenza fail to induce durable T-cell immunity and therefore, studies of T-cell responses to IAV have failed to provide clues about how to induce durable Tcell immunity in the RT (7, 37) .", [["T-cell", "ANATOMY", 87, 93], ["T-cell", "ANATOMY", 129, 135], ["Tcell", "ANATOMY", 210, 215], ["viral infections", "DISEASE", 29, 45], ["influenza", "DISEASE", 54, 63], ["T-cell", "CELL", 87, 93], ["T-cell", "CELL", 129, 135], ["IAV", "ORGANISM", 149, 152], ["Tcell", "CANCER", 210, 215], ["Mucosal viral infections", "PROBLEM", 21, 45], ["influenza fail", "PROBLEM", 54, 68], ["IAV", "PROBLEM", 149, 152], ["viral infections", "OBSERVATION", 29, 45]]], ["Here, we report an adjuvant system comprised of a polyacrylic acid-based adjuvant ADJ and TLR agonists that elicits surprisingly potent, durable and functionally diverse mucosal T-cell immunity to disparate strains of IAV.DiscussionAs a mucosal adjuvant, ADJ afforded protection against IAV in mice (21) .", [["mucosal T-cell", "ANATOMY", 170, 184], ["mucosal", "ANATOMY", 237, 244], ["polyacrylic acid", "CHEMICAL", 50, 66], ["ADJ", "CHEMICAL", 82, 85], ["ADJ", "CHEMICAL", 255, 258], ["polyacrylic acid", "CHEMICAL", 50, 66], ["polyacrylic acid", "SIMPLE_CHEMICAL", 50, 66], ["ADJ", "SIMPLE_CHEMICAL", 82, 85], ["TLR", "GENE_OR_GENE_PRODUCT", 90, 93], ["mucosal T-cell", "CELL", 170, 184], ["IAV", "ORGANISM", 218, 221], ["mucosal", "ORGANISM_SUBDIVISION", 237, 244], ["ADJ", "SIMPLE_CHEMICAL", 255, 258], ["IAV", "ORGANISM", 287, 290], ["mice", "ORGANISM", 294, 298], ["mice", "SPECIES", 294, 298], ["IAV", "SPECIES", 218, 221], ["IAV", "SPECIES", 287, 290], ["mice", "SPECIES", 294, 298], ["an adjuvant system", "TREATMENT", 16, 34], ["a polyacrylic acid-based adjuvant ADJ", "TREATMENT", 48, 85], ["TLR agonists", "TREATMENT", 90, 102], ["IAV", "PROBLEM", 218, 221], ["a mucosal adjuvant", "TREATMENT", 235, 253], ["ADJ afforded protection", "TREATMENT", 255, 278], ["IAV", "OBSERVATION_MODIFIER", 218, 221], ["mucosal", "ANATOMY", 237, 244]]], ["Here, we define ways to broaden T-cell immunity and enhance the protective efficacy of ADJ by combining with TLR4 and TLR9 agonists, GLA and CpG respectively.", [["T-cell", "ANATOMY", 32, 38], ["ADJ", "CHEMICAL", 87, 90], ["CpG", "CHEMICAL", 141, 144], ["T-cell", "CELL", 32, 38], ["ADJ", "SIMPLE_CHEMICAL", 87, 90], ["TLR4", "GENE_OR_GENE_PRODUCT", 109, 113], ["TLR9", "GENE_OR_GENE_PRODUCT", 118, 122], ["GLA", "SIMPLE_CHEMICAL", 133, 136], ["TLR4", "PROTEIN", 109, 113], ["TLR9", "PROTEIN", 118, 122], ["T-cell immunity", "TREATMENT", 32, 47], ["TLR4 and TLR9 agonists", "TREATMENT", 109, 131], ["GLA and CpG", "TREATMENT", 133, 144]]], ["This adjuvant system's ability to elicit impressive numbers of antigen-specific CD8 and CD4 T cells enabled us to perform in-depth characterization of vaccine-elicited effector and memory T cells directly ex vivo, without the need for tetramer enrichment.", [["CD8", "ANATOMY", 80, 83], ["CD4 T cells", "ANATOMY", 88, 99], ["effector", "ANATOMY", 168, 176], ["memory T cells", "ANATOMY", 181, 195], ["antigen", "GENE_OR_GENE_PRODUCT", 63, 70], ["CD8", "GENE_OR_GENE_PRODUCT", 80, 83], ["CD4", "GENE_OR_GENE_PRODUCT", 88, 91], ["effector", "CELL", 168, 176], ["memory T cells", "CELL", 181, 195], ["CD8 and CD4 T cells", "CELL_TYPE", 80, 99], ["vaccine-elicited effector and memory T cells", "CELL_TYPE", 151, 195], ["This adjuvant system", "TREATMENT", 0, 20], ["antigen", "TEST", 63, 70], ["vaccine", "TREATMENT", 151, 158], ["tetramer enrichment", "TREATMENT", 235, 254]]], ["Following IAV infection, activated CD8 T cells migrate from DLNs to the lungs, undergo another round of antigenic stimulation and differentiate into effector cells (6) .", [["CD8 T cells", "ANATOMY", 35, 46], ["DLNs", "ANATOMY", 60, 64], ["lungs", "ANATOMY", 72, 77], ["cells", "ANATOMY", 158, 163], ["IAV infection", "DISEASE", 10, 23], ["CD8 T cells", "CELL", 35, 46], ["DLNs", "GENE_OR_GENE_PRODUCT", 60, 64], ["lungs", "ORGAN", 72, 77], ["cells", "CELL", 158, 163], ["CD8 T cells", "CELL_TYPE", 35, 46], ["DLNs", "CELL_TYPE", 60, 64], ["effector cells", "CELL_TYPE", 149, 163], ["IAV", "SPECIES", 10, 13], ["IAV infection", "PROBLEM", 10, 23], ["activated CD8 T cells", "TREATMENT", 25, 46], ["antigenic stimulation", "TREATMENT", 104, 125], ["IAV", "OBSERVATION_MODIFIER", 10, 13], ["infection", "OBSERVATION", 14, 23], ["lungs", "ANATOMY", 72, 77], ["effector cells", "OBSERVATION", 149, 163]]], ["Likewise, antigen-specific CD8 T cells in all adjuvant groups experienced varying levels of TCR signaling in the lungs.", [["CD8 T cells", "ANATOMY", 27, 38], ["lungs", "ANATOMY", 113, 118], ["TCR", "CHEMICAL", 92, 95], ["antigen", "GENE_OR_GENE_PRODUCT", 10, 17], ["CD8", "GENE_OR_GENE_PRODUCT", 27, 30], ["TCR", "GENE_OR_GENE_PRODUCT", 92, 95], ["lungs", "ORGAN", 113, 118], ["CD8 T cells", "CELL_TYPE", 27, 38], ["TCR", "PROTEIN", 92, 95], ["antigen", "TEST", 10, 17], ["TCR signaling in the lungs", "PROBLEM", 92, 118], ["TCR signaling", "OBSERVATION", 92, 105], ["lungs", "ANATOMY", 113, 118]]], ["Significantly, adjuvants differed in terms of the degree of effector differentiation, for both CD8 and CD4 T cells.", [["CD8", "ANATOMY", 95, 98], ["CD4 T cells", "ANATOMY", 103, 114], ["CD8", "GENE_OR_GENE_PRODUCT", 95, 98], ["CD4", "GENE_OR_GENE_PRODUCT", 103, 106], ["CD8 and CD4 T cells", "CELL_TYPE", 95, 114], ["adjuvants", "TREATMENT", 15, 24], ["effector differentiation", "OBSERVATION", 60, 84]]], ["ADJ and/or CpG-adjuvanted vaccines drove terminal differentiation into CX3CR1 HI KLRG-1 HI effector cells; as in IAV-infected mice (3, 38) , the pathway to terminal differentiation is attributed at least in part to higher TCR signaling in the lungs, leading to induction of transcription factors T-bet, IRF-4 and BATF (30, 39, 40) .", [["cells", "ANATOMY", 100, 105], ["lungs", "ANATOMY", 243, 248], ["CpG", "CHEMICAL", 11, 14], ["IAV-infected", "DISEASE", 113, 125], ["TCR", "CHEMICAL", 222, 225], ["CpG", "CHEMICAL", 11, 14], ["ADJ", "GENE_OR_GENE_PRODUCT", 0, 3], ["CX3CR1", "GENE_OR_GENE_PRODUCT", 71, 77], ["KLRG-1", "GENE_OR_GENE_PRODUCT", 81, 87], ["IAV-infected", "ORGANISM", 113, 125], ["mice", "ORGANISM", 126, 130], ["TCR", "GENE_OR_GENE_PRODUCT", 222, 225], ["lungs", "ORGAN", 243, 248], ["T-bet", "GENE_OR_GENE_PRODUCT", 296, 301], ["IRF-4", "GENE_OR_GENE_PRODUCT", 303, 308], ["BATF", "GENE_OR_GENE_PRODUCT", 313, 317], ["CX3CR1 HI KLRG-1 HI effector cells", "CELL_LINE", 71, 105], ["TCR", "PROTEIN", 222, 225], ["transcription factors", "PROTEIN", 274, 295], ["T-bet", "PROTEIN", 296, 301], ["IRF-4", "PROTEIN", 303, 308], ["BATF", "PROTEIN", 313, 317], ["mice", "SPECIES", 126, 130], ["mice", "SPECIES", 126, 130], ["ADJ", "TREATMENT", 0, 3], ["CpG", "TREATMENT", 11, 14], ["adjuvanted vaccines", "TREATMENT", 15, 34], ["HI KLRG", "TEST", 78, 85], ["HI effector cells", "PROBLEM", 88, 105], ["higher TCR signaling in the lungs", "PROBLEM", 215, 248], ["transcription factors", "PROBLEM", 274, 295], ["IRF", "TEST", 303, 306], ["BATF", "TEST", 313, 317], ["effector cells", "OBSERVATION", 91, 105], ["infected mice", "OBSERVATION", 117, 130], ["higher TCR signaling", "OBSERVATION", 215, 235], ["lungs", "ANATOMY", 243, 248]]], ["Notably, high TCR signaling also induced PD-1 expression in ADJ, CpG and ADJ+CpG groups, and likely limited the accumulation of CD8 T cells in lungs.", [["ADJ", "ANATOMY", 60, 63], ["CD8 T cells", "ANATOMY", 128, 139], ["lungs", "ANATOMY", 143, 148], ["TCR", "CHEMICAL", 14, 17], ["CpG", "CHEMICAL", 65, 68], ["CpG", "CHEMICAL", 77, 80], ["TCR", "GENE_OR_GENE_PRODUCT", 14, 17], ["PD-1", "GENE_OR_GENE_PRODUCT", 41, 45], ["ADJ", "CANCER", 60, 63], ["CD8 T", "GENE_OR_GENE_PRODUCT", 128, 133], ["lungs", "ORGAN", 143, 148], ["TCR", "PROTEIN", 14, 17], ["CD8 T cells", "CELL_TYPE", 128, 139], ["high TCR signaling", "PROBLEM", 9, 27], ["induced PD", "PROBLEM", 33, 43], ["CpG and ADJ+CpG groups", "TREATMENT", 65, 87], ["CD8 T cells in lungs", "PROBLEM", 128, 148], ["high TCR", "OBSERVATION", 9, 17], ["CD8 T cells", "OBSERVATION", 128, 139], ["lungs", "ANATOMY", 143, 148]]], ["PD-1 might restrain RT inflammation (33) , but it would be worthwhile determining whether PD-1 limits vaccine-induced memory and protective immunity.", [["inflammation", "DISEASE", 23, 35], ["PD-1", "GENE_OR_GENE_PRODUCT", 0, 4], ["PD-1", "GENE_OR_GENE_PRODUCT", 90, 94], ["PD", "TREATMENT", 0, 2], ["restrain RT inflammation", "PROBLEM", 11, 35], ["PD", "TEST", 90, 92], ["inflammation", "OBSERVATION", 23, 35]]], ["It is noteworthy that despite the presence of similar numbers of antigen-bearing cells in lungs of ADJ, ADJ+CpG and ADJ+GLA mice, effector CD8 T cells in ADJ+GLA mice displayed substantially lower levels of TCR signaling in lungs.", [["cells", "ANATOMY", 81, 86], ["lungs", "ANATOMY", 90, 95], ["ADJ", "ANATOMY", 99, 102], ["CD8 T cells", "ANATOMY", 139, 150], ["lungs", "ANATOMY", 224, 229], ["CpG", "CHEMICAL", 108, 111], ["antigen", "GENE_OR_GENE_PRODUCT", 65, 72], ["cells", "CELL", 81, 86], ["lungs", "ORGAN", 90, 95], ["ADJ", "CELL", 99, 102], ["ADJ", "GENE_OR_GENE_PRODUCT", 104, 107], ["ADJ", "GENE_OR_GENE_PRODUCT", 116, 119], ["CD8", "GENE_OR_GENE_PRODUCT", 139, 142], ["ADJ", "GENE_OR_GENE_PRODUCT", 154, 157], ["TCR", "GENE_OR_GENE_PRODUCT", 207, 210], ["lungs", "ORGAN", 224, 229], ["antigen-bearing cells", "CELL_TYPE", 65, 86], ["effector CD8 T cells", "CELL_TYPE", 130, 150], ["TCR", "PROTEIN", 207, 210], ["mice", "SPECIES", 124, 128], ["mice", "SPECIES", 162, 166], ["mice", "SPECIES", 124, 128], ["mice", "SPECIES", 162, 166], ["ADJ", "TEST", 99, 102], ["ADJ", "TEST", 104, 107], ["CpG", "TEST", 108, 111], ["ADJ", "TEST", 116, 119], ["GLA mice", "TEST", 120, 128], ["effector CD8 T cells", "TEST", 130, 150], ["ADJ", "TEST", 154, 157], ["GLA mice", "TEST", 158, 166], ["TCR signaling in lungs", "PROBLEM", 207, 229], ["bearing cells", "OBSERVATION", 73, 86], ["lungs", "ANATOMY", 90, 95], ["TCR signaling", "OBSERVATION", 207, 220], ["lungs", "ANATOMY", 224, 229]]], ["It is possible that GLA-induced TLR4 stimulation antagonized antigen-triggered TCR signaling in ADJ+GLA mice (41) .", [["GLA", "CHEMICAL", 20, 23], ["TCR", "CHEMICAL", 79, 82], ["GLA", "CHEMICAL", 20, 23], ["GLA", "SIMPLE_CHEMICAL", 20, 23], ["TLR4", "GENE_OR_GENE_PRODUCT", 32, 36], ["antigen", "GENE_OR_GENE_PRODUCT", 61, 68], ["TCR", "GENE_OR_GENE_PRODUCT", 79, 82], ["ADJ", "GENE_OR_GENE_PRODUCT", 96, 99], ["TLR4", "PROTEIN", 32, 36], ["TCR", "PROTEIN", 79, 82], ["mice", "SPECIES", 104, 108], ["GLA", "TEST", 20, 23], ["TLR4 stimulation antagonized antigen", "TEST", 32, 68]]], ["By dampening TCR signaling, GLA might have mitigated terminal differentiation of effectors and promoted the development of TRMs in ADJ+GLA mice.", [["TRMs", "ANATOMY", 123, 127], ["GLA", "CHEMICAL", 28, 31], ["TRMs", "DISEASE", 123, 127], ["TCR", "GENE_OR_GENE_PRODUCT", 13, 16], ["GLA", "SIMPLE_CHEMICAL", 28, 31], ["TRMs", "GENE_OR_GENE_PRODUCT", 123, 127], ["ADJ", "GENE_OR_GENE_PRODUCT", 131, 134], ["TCR", "PROTEIN", 13, 16], ["GLA", "PROTEIN", 28, 31], ["mice", "SPECIES", 139, 143], ["mice", "SPECIES", 139, 143], ["terminal differentiation of effectors", "PROBLEM", 53, 90], ["TRMs", "PROBLEM", 123, 127]]], ["High levels of inflammation and IL-12 early in the response have been linked to T-bet induction and terminal differentiation of CD8 T cells in spleen (25, 27) , but the rules that govern T cell differentiation in lungs versus spleen are likely different and worthy of further exploration.DiscussionWe find that ADJ enhances CD103 expression in responding CD4 and CD8 T cells.", [["CD8 T cells", "ANATOMY", 128, 139], ["spleen", "ANATOMY", 143, 149], ["T cell", "ANATOMY", 187, 193], ["lungs", "ANATOMY", 213, 218], ["spleen", "ANATOMY", 226, 232], ["CD4", "ANATOMY", 355, 358], ["CD8 T cells", "ANATOMY", 363, 374], ["inflammation", "DISEASE", 15, 27], ["IL-12", "GENE_OR_GENE_PRODUCT", 32, 37], ["T-bet", "GENE_OR_GENE_PRODUCT", 80, 85], ["CD8 T", "GENE_OR_GENE_PRODUCT", 128, 133], ["spleen", "ORGAN", 143, 149], ["T cell", "CELL", 187, 193], ["lungs", "ORGAN", 213, 218], ["spleen", "ORGAN", 226, 232], ["ADJ", "SIMPLE_CHEMICAL", 311, 314], ["CD103", "GENE_OR_GENE_PRODUCT", 324, 329], ["CD4", "GENE_OR_GENE_PRODUCT", 355, 358], ["CD8", "GENE_OR_GENE_PRODUCT", 363, 366], ["CD8 T cells", "CELL_TYPE", 128, 139], ["ADJ", "PROTEIN", 311, 314], ["CD103", "PROTEIN", 324, 329], ["CD4 and CD8 T cells", "CELL_TYPE", 355, 374], ["High levels of inflammation", "PROBLEM", 0, 27], ["IL", "TREATMENT", 32, 34], ["T-bet induction", "TREATMENT", 80, 95], ["further exploration", "TEST", 268, 287], ["inflammation", "OBSERVATION", 15, 27], ["CD8 T cells", "OBSERVATION", 128, 139], ["spleen", "ANATOMY", 143, 149], ["T cell differentiation", "OBSERVATION", 187, 209], ["lungs", "ANATOMY", 213, 218], ["spleen", "ANATOMY", 226, 232], ["CD8 T cells", "OBSERVATION", 363, 374]]], ["TCR signaling, IL-10 and exposure to TGF-\uf062 promote CD103 expression and mucosal imprinting in T cells (3, 42) .", [["mucosal", "ANATOMY", 72, 79], ["T cells", "ANATOMY", 94, 101], ["TCR", "CHEMICAL", 0, 3], ["TCR", "GENE_OR_GENE_PRODUCT", 0, 3], ["IL-10", "GENE_OR_GENE_PRODUCT", 15, 20], ["TGF-\uf062", "GENE_OR_GENE_PRODUCT", 37, 42], ["CD103", "GENE_OR_GENE_PRODUCT", 51, 56], ["mucosal", "PATHOLOGICAL_FORMATION", 72, 79], ["T cells", "CELL", 94, 101], ["TCR", "PROTEIN", 0, 3], ["IL-10", "PROTEIN", 15, 20], ["TGF", "PROTEIN", 37, 40], ["CD103", "PROTEIN", 51, 56], ["T cells", "CELL_TYPE", 94, 101], ["TCR signaling", "TEST", 0, 13], ["IL", "TEST", 15, 17], ["TGF", "TEST", 37, 40], ["mucosal imprinting in T cells", "PROBLEM", 72, 101], ["CD103 expression", "OBSERVATION", 51, 67], ["mucosal", "ANATOMY", 72, 79]]], ["However, we find that at 24 and 48 hours after vaccination, the levels of TGF\uf0621 or IL-10 in lungs did not explain differences in CD103 expression.", [["lungs", "ANATOMY", 92, 97], ["TGF\uf0621", "GENE_OR_GENE_PRODUCT", 74, 79], ["IL-10", "GENE_OR_GENE_PRODUCT", 83, 88], ["lungs", "ORGAN", 92, 97], ["CD103", "GENE_OR_GENE_PRODUCT", 129, 134], ["TGF\uf0621", "PROTEIN", 74, 79], ["IL-10", "PROTEIN", 83, 88], ["CD103", "PROTEIN", 129, 134], ["vaccination", "TREATMENT", 47, 58], ["the levels", "TEST", 60, 70], ["TGF", "TEST", 74, 77], ["IL", "TEST", 83, 85], ["lungs", "ANATOMY", 92, 97], ["CD103 expression", "OBSERVATION", 129, 145]]], ["ADJ promotes crosspresentation of antigen to CD8 T cells (21) and hence, ADJ-induced increase in the number of antigen-bearing cells in lungs likely enhances TCR signaling and CD103 expression on effector CD8 T cells.", [["CD8 T cells", "ANATOMY", 45, 56], ["cells", "ANATOMY", 127, 132], ["lungs", "ANATOMY", 136, 141], ["CD8 T cells", "ANATOMY", 205, 216], ["ADJ", "CHEMICAL", 0, 3], ["ADJ", "CHEMICAL", 73, 76], ["ADJ", "SIMPLE_CHEMICAL", 0, 3], ["CD8", "GENE_OR_GENE_PRODUCT", 45, 48], ["ADJ", "SIMPLE_CHEMICAL", 73, 76], ["antigen", "GENE_OR_GENE_PRODUCT", 111, 118], ["cells", "CELL", 127, 132], ["lungs", "ORGAN", 136, 141], ["TCR", "GENE_OR_GENE_PRODUCT", 158, 161], ["CD103", "GENE_OR_GENE_PRODUCT", 176, 181], ["CD8", "GENE_OR_GENE_PRODUCT", 205, 208], ["ADJ", "PROTEIN", 0, 3], ["CD8 T cells", "CELL_TYPE", 45, 56], ["ADJ", "PROTEIN", 73, 76], ["antigen-bearing cells", "CELL_TYPE", 111, 132], ["TCR", "PROTEIN", 158, 161], ["CD103", "PROTEIN", 176, 181], ["effector CD8 T cells", "CELL_TYPE", 196, 216], ["CD8 T cells", "TEST", 45, 56], ["ADJ", "TEST", 73, 76], ["increase", "OBSERVATION_MODIFIER", 85, 93], ["bearing cells", "OBSERVATION", 119, 132], ["lungs", "ANATOMY", 136, 141], ["likely", "UNCERTAINTY", 142, 148], ["enhances TCR", "OBSERVATION", 149, 161], ["CD8 T cells", "OBSERVATION", 205, 216]]], ["Interestingly, GLA inhibited TCR signaling in ADJ+GLA mice without abrogating the CD103-inducing effects of ADJ.", [["GLA", "CHEMICAL", 15, 18], ["TCR", "CHEMICAL", 29, 32], ["ADJ", "CHEMICAL", 108, 111], ["GLA", "CHEMICAL", 15, 18], ["GLA", "SIMPLE_CHEMICAL", 15, 18], ["TCR", "GENE_OR_GENE_PRODUCT", 29, 32], ["ADJ", "GENE_OR_GENE_PRODUCT", 46, 49], ["CD103", "GENE_OR_GENE_PRODUCT", 82, 87], ["ADJ", "SIMPLE_CHEMICAL", 108, 111], ["TCR", "PROTEIN", 29, 32], ["CD103", "PROTEIN", 82, 87], ["mice", "SPECIES", 54, 58], ["mice", "SPECIES", 54, 58], ["CD103", "OBSERVATION", 82, 87]]], ["It is possible that the residual TCR signaling in ADJ+GLA mice is sufficient to induce CD103 or other mechanisms including IFN\uf067 production by CD4 T cells might have contributed to CD103 expression on CD8 T cells (43) .", [["CD4 T cells", "ANATOMY", 142, 153], ["CD8 T cells", "ANATOMY", 200, 211], ["TCR", "CHEMICAL", 33, 36], ["TCR", "GENE_OR_GENE_PRODUCT", 33, 36], ["ADJ", "GENE_OR_GENE_PRODUCT", 50, 53], ["CD103", "GENE_OR_GENE_PRODUCT", 87, 92], ["IFN\uf067", "GENE_OR_GENE_PRODUCT", 123, 127], ["CD4 T cells", "CELL", 142, 153], ["CD103", "GENE_OR_GENE_PRODUCT", 180, 185], ["CD8", "GENE_OR_GENE_PRODUCT", 200, 203], ["TCR", "PROTEIN", 33, 36], ["CD103", "PROTEIN", 87, 92], ["IFN", "PROTEIN", 123, 126], ["CD4 T cells", "CELL_TYPE", 142, 153], ["CD103", "PROTEIN", 180, 185], ["CD8 T cells", "CELL_TYPE", 200, 211], ["mice", "SPECIES", 58, 62], ["the residual TCR signaling", "PROBLEM", 20, 46], ["GLA mice", "PROBLEM", 54, 62], ["CD103", "PROBLEM", 87, 92], ["other mechanisms", "PROBLEM", 96, 112], ["IFN\uf067 production", "PROBLEM", 123, 138], ["CD4 T cells", "PROBLEM", 142, 153], ["CD8 T cells", "TEST", 200, 211], ["residual TCR", "OBSERVATION", 24, 36]]], ["In summary, we infer that the magnitude of TCR signaling in lungs is a key factor that controls accumulation, mucosal imprinting and effector/memory differentiation.DiscussionA salient feature of ADJ-based adjuvants is the diverse functional programming of effector and memory T cells.", [["lungs", "ANATOMY", 60, 65], ["mucosal", "ANATOMY", 110, 117], ["effector", "ANATOMY", 257, 265], ["memory T cells", "ANATOMY", 270, 284], ["TCR", "CHEMICAL", 43, 46], ["ADJ", "CHEMICAL", 196, 199], ["TCR", "GENE_OR_GENE_PRODUCT", 43, 46], ["lungs", "ORGAN", 60, 65], ["mucosal", "MULTI-TISSUE_STRUCTURE", 110, 117], ["ADJ", "SIMPLE_CHEMICAL", 196, 199], ["effector", "CELL", 257, 265], ["memory T cells", "CELL", 270, 284], ["TCR", "PROTEIN", 43, 46], ["effector and memory T cells", "CELL_TYPE", 257, 284], ["TCR signaling in lungs", "PROBLEM", 43, 65], ["controls accumulation", "PROBLEM", 87, 108], ["mucosal imprinting and effector/memory differentiation", "PROBLEM", 110, 164], ["ADJ-based adjuvants", "TREATMENT", 196, 215], ["lungs", "ANATOMY", 60, 65]]], ["For CD8 T cells, all adjuvants induced comparable levels of IL-12 and elicited a strong TC1 response.", [["CD8 T cells", "ANATOMY", 4, 15], ["CD8 T cells", "CELL", 4, 15], ["IL-12", "GENE_OR_GENE_PRODUCT", 60, 65], ["TC1", "GENE_OR_GENE_PRODUCT", 88, 91], ["CD8 T cells", "CELL_TYPE", 4, 15], ["IL-12", "PROTEIN", 60, 65], ["TC1", "PROTEIN", 88, 91], ["CD8 T cells", "PROBLEM", 4, 15], ["all adjuvants", "TREATMENT", 17, 30], ["IL", "TEST", 60, 62]]], ["However, GLA, by virtue of its ability to induce IL-1 and IL-6, also enabled a significant TC17/TH17 response, and induction of TH17 cells by GLA is consistent with published work (44) .", [["TH17 cells", "ANATOMY", 128, 138], ["GLA", "CHEMICAL", 9, 12], ["GLA", "SIMPLE_CHEMICAL", 9, 12], ["IL-1", "GENE_OR_GENE_PRODUCT", 49, 53], ["IL-6", "GENE_OR_GENE_PRODUCT", 58, 62], ["TC17", "GENE_OR_GENE_PRODUCT", 91, 95], ["TH17", "CELL", 96, 100], ["TH17 cells", "CELL", 128, 138], ["GLA", "SIMPLE_CHEMICAL", 142, 145], ["IL", "PROTEIN", 49, 51], ["IL-6", "PROTEIN", 58, 62], ["TH17 cells", "CELL_TYPE", 128, 138], ["IL", "TEST", 49, 51], ["GLA", "ANATOMY", 9, 12]]], ["Importantly, from a vaccination perspective, we have discovered the means to tailor an adjuvant based on pathogen-specific correlates of protection.", [["an adjuvant", "TREATMENT", 84, 95], ["pathogen", "PROBLEM", 105, 113]]], ["For example, ADJ formulated with CpG elicits strong TC1/TH1 memory, which protects against viruses and protozoan pathogens (e.g. leishmania).", [["ADJ", "CHEMICAL", 13, 16], ["CpG", "CHEMICAL", 33, 36], ["protozoan pathogens", "DISEASE", 103, 122], ["ADJ", "CHEMICAL", 13, 16], ["CpG", "CHEMICAL", 33, 36], ["ADJ", "SIMPLE_CHEMICAL", 13, 16], ["CpG", "SIMPLE_CHEMICAL", 33, 36], ["TC1", "GENE_OR_GENE_PRODUCT", 52, 55], ["TH1", "GENE_OR_GENE_PRODUCT", 56, 59], ["ADJ", "PROTEIN", 13, 16], ["TC1", "PROTEIN", 52, 55], ["viruses", "PROBLEM", 91, 98], ["protozoan pathogens", "PROBLEM", 103, 122], ["leishmania", "PROBLEM", 129, 139], ["protozoan", "OBSERVATION_MODIFIER", 103, 112]]], ["Alternatively, ADJ formulated with GLA stimulates balanced differentiation of TC1/TH1 and TH17 cells, which is protective against fungi, tuberculosis and other bacterial pathogens (45, 46) .DiscussionThe hallmark of effective adjuvants is their ability to elicit protective immunity.", [["TC1/TH1", "ANATOMY", 78, 85], ["TH17 cells", "ANATOMY", 90, 100], ["ADJ", "CHEMICAL", 15, 18], ["GLA", "CHEMICAL", 35, 38], ["tuberculosis", "DISEASE", 137, 149], ["GLA", "CHEMICAL", 35, 38], ["ADJ", "SIMPLE_CHEMICAL", 15, 18], ["GLA", "SIMPLE_CHEMICAL", 35, 38], ["TC1/TH1", "CELL", 78, 85], ["TH17 cells", "CELL", 90, 100], ["TC1/TH1 and TH17 cells", "CELL_LINE", 78, 100], ["GLA stimulates", "TREATMENT", 35, 49], ["TH17 cells", "PROBLEM", 90, 100], ["fungi", "PROBLEM", 130, 135], ["tuberculosis", "PROBLEM", 137, 149], ["other bacterial pathogens", "PROBLEM", 154, 179], ["effective adjuvants", "TREATMENT", 216, 235], ["TH1", "ANATOMY", 82, 85], ["TH17 cells", "OBSERVATION", 90, 100], ["tuberculosis", "OBSERVATION", 137, 149], ["bacterial", "OBSERVATION_MODIFIER", 160, 169]]], ["Effective T-cellbased protection against IAV requires a critical number of TRMs in the airways and the lung parenchyma (3, 36) .", [["airways", "ANATOMY", 87, 94], ["lung parenchyma", "ANATOMY", 103, 118], ["T-cellbased", "CELL", 10, 21], ["IAV", "ORGANISM", 41, 44], ["TRMs", "CANCER", 75, 79], ["airways", "MULTI-TISSUE_STRUCTURE", 87, 94], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 103, 118], ["IAV", "SPECIES", 41, 44], ["Effective T-cellbased protection", "TREATMENT", 0, 32], ["IAV", "PROBLEM", 41, 44], ["airways", "ANATOMY", 87, 94], ["lung", "ANATOMY", 103, 107], ["parenchyma", "ANATOMY_MODIFIER", 108, 118]]], ["In this study, all adjuvants elicited readily detectable CD8 and CD4 TRMs in the RT.", [["CD8", "GENE_OR_GENE_PRODUCT", 57, 60], ["CD4", "GENE_OR_GENE_PRODUCT", 65, 68], ["CD8", "PROTEIN", 57, 60], ["CD4", "PROTEIN", 65, 68], ["this study", "TEST", 3, 13], ["all adjuvants", "TREATMENT", 15, 28], ["CD4 TRMs", "TEST", 65, 73], ["CD4 TRMs", "OBSERVATION", 65, 73], ["RT", "ANATOMY_MODIFIER", 81, 83]]], ["ADJ+GLA induced the largest number of TRMs and vascular memory CD8/CD4 T cells in the lungs, which is likely a sequel to less terminal differentiation and larger clonal burst size during the effector phase (47) .", [["TRMs", "ANATOMY", 38, 42], ["vascular memory CD8/CD4 T cells", "ANATOMY", 47, 78], ["lungs", "ANATOMY", 86, 91], ["ADJ", "CHEMICAL", 0, 3], ["GLA", "CHEMICAL", 4, 7], ["GLA", "CHEMICAL", 4, 7], ["ADJ", "SIMPLE_CHEMICAL", 0, 3], ["GLA", "SIMPLE_CHEMICAL", 4, 7], ["TRMs", "CELL", 38, 42], ["vascular memory", "CELL", 47, 62], ["CD8", "GENE_OR_GENE_PRODUCT", 63, 66], ["CD4", "GENE_OR_GENE_PRODUCT", 67, 70], ["lungs", "ORGAN", 86, 91], ["TRMs", "CELL_TYPE", 38, 42], ["vascular memory CD8/CD4 T cells", "CELL_TYPE", 47, 78], ["TRMs", "TEST", 38, 42], ["vascular memory CD8", "TEST", 47, 66], ["a sequel to less terminal differentiation", "PROBLEM", 109, 150], ["larger clonal burst size", "PROBLEM", 155, 179], ["GLA", "OBSERVATION", 4, 7], ["largest", "OBSERVATION_MODIFIER", 20, 27], ["number", "OBSERVATION_MODIFIER", 28, 34], ["vascular", "ANATOMY", 47, 55], ["memory CD8", "OBSERVATION", 56, 66], ["CD4 T cells", "OBSERVATION", 67, 78], ["lungs", "ANATOMY", 86, 91], ["less terminal", "OBSERVATION_MODIFIER", 121, 134], ["differentiation", "OBSERVATION_MODIFIER", 135, 150], ["larger", "OBSERVATION_MODIFIER", 155, 161], ["clonal", "OBSERVATION_MODIFIER", 162, 168], ["burst", "OBSERVATION_MODIFIER", 169, 174], ["size", "OBSERVATION_MODIFIER", 175, 179], ["effector phase", "OBSERVATION_MODIFIER", 191, 205]]], ["TRMs are known to reside primarily in the tissue parenchyma and in the DLNs, but not as circulating cells (48) .", [["tissue parenchyma", "ANATOMY", 42, 59], ["DLNs", "ANATOMY", 71, 75], ["cells", "ANATOMY", 100, 105], ["TRMs", "GENE_OR_GENE_PRODUCT", 0, 4], ["tissue parenchyma", "TISSUE", 42, 59], ["DLNs", "CANCER", 71, 75], ["cells", "CELL", 100, 105], ["TRMs", "PROTEIN", 0, 4], ["DLNs", "CELL_TYPE", 71, 75], ["circulating cells", "CELL_TYPE", 88, 105], ["tissue", "ANATOMY", 42, 48], ["parenchyma", "ANATOMY_MODIFIER", 49, 59], ["not as", "UNCERTAINTY", 81, 87], ["circulating cells", "OBSERVATION", 88, 105]]], ["We find that lungs of ADJ+GLA mice contained CD103 +ve memory CD8 T cells in the vasculature, which are likely similar to circulating skinresident CD103 +ve memory T cells in humans (49) .", [["lungs", "ANATOMY", 13, 18], ["CD103 +ve memory CD8 T cells", "ANATOMY", 45, 73], ["vasculature", "ANATOMY", 81, 92], ["skinresident CD103 +ve memory T cells", "ANATOMY", 134, 171], ["lungs", "ORGAN", 13, 18], ["ADJ", "GENE_OR_GENE_PRODUCT", 22, 25], ["CD103", "GENE_OR_GENE_PRODUCT", 45, 50], ["vasculature", "MULTI-TISSUE_STRUCTURE", 81, 92], ["CD103", "GENE_OR_GENE_PRODUCT", 147, 152], ["humans", "ORGANISM", 175, 181], ["CD103", "PROTEIN", 45, 50], ["memory CD8 T cells", "CELL_TYPE", 55, 73], ["CD103", "PROTEIN", 147, 152], ["memory T cells", "CELL_TYPE", 157, 171], ["mice", "SPECIES", 30, 34], ["humans", "SPECIES", 175, 181], ["mice", "SPECIES", 30, 34], ["humans", "SPECIES", 175, 181], ["ADJ", "TEST", 22, 25], ["GLA mice", "TEST", 26, 34], ["CD103", "TEST", 45, 50], ["circulating skinresident CD103", "TEST", 122, 152], ["lungs", "ANATOMY", 13, 18], ["memory CD8 T cells", "OBSERVATION", 55, 73], ["vasculature", "ANATOMY", 81, 92], ["likely similar to", "UNCERTAINTY", 104, 121]]], ["Parabiosis studies are needed to elucidate whether vascular CD103 +ve memory CD8 T cells in ADJ+GLA mice are circulating cells or lung vasculature-resident memory T cells.", [["vascular CD103 +ve memory CD8 T cells", "ANATOMY", 51, 88], ["cells", "ANATOMY", 121, 126], ["lung vasculature", "ANATOMY", 130, 146], ["memory T cells", "ANATOMY", 156, 170], ["vascular", "MULTI-TISSUE_STRUCTURE", 51, 59], ["CD103", "GENE_OR_GENE_PRODUCT", 60, 65], ["ADJ", "GENE_OR_GENE_PRODUCT", 92, 95], ["cells", "CELL", 121, 126], ["lung vasculature-resident memory T cells", "CELL", 130, 170], ["CD103", "PROTEIN", 60, 65], ["memory CD8 T cells", "CELL_TYPE", 70, 88], ["circulating cells", "CELL_TYPE", 109, 126], ["lung vasculature-resident memory T cells", "CELL_TYPE", 130, 170], ["mice", "SPECIES", 100, 104], ["mice", "SPECIES", 100, 104], ["Parabiosis studies", "TEST", 0, 18], ["vascular CD103", "TEST", 51, 65], ["ADJ", "TEST", 92, 95], ["GLA mice", "TEST", 96, 104], ["circulating cells", "PROBLEM", 109, 126], ["lung vasculature", "PROBLEM", 130, 146], ["vascular", "ANATOMY", 51, 59], ["CD103", "OBSERVATION", 60, 65], ["lung", "ANATOMY", 130, 134], ["vasculature", "ANATOMY", 135, 146]]], ["The numbers of memory T cells in lungs of other adjuvant groups were comparable, but the differential polarity (TH1 vs. TH17) programmed by each during the effector phase was preserved in memory T cells; CpG and ADJ+CpG displayed TH1 dominance and ADJ, GLA and ADJ+GLA showed skewed TH17 differentiation.", [["memory T cells", "ANATOMY", 15, 29], ["lungs", "ANATOMY", 33, 38], ["memory T cells", "ANATOMY", 188, 202], ["CpG", "CHEMICAL", 204, 207], ["CpG", "CHEMICAL", 216, 219], ["memory T cells", "CELL", 15, 29], ["lungs", "ORGAN", 33, 38], ["TH1", "GENE_OR_GENE_PRODUCT", 112, 115], ["memory T cells", "CELL", 188, 202], ["CpG", "CELL", 204, 207], ["ADJ", "GENE_OR_GENE_PRODUCT", 212, 215], ["TH1", "GENE_OR_GENE_PRODUCT", 230, 233], ["ADJ", "GENE_OR_GENE_PRODUCT", 248, 251], ["GLA", "SIMPLE_CHEMICAL", 253, 256], ["ADJ+GLA", "SIMPLE_CHEMICAL", 261, 268], ["memory T cells", "CELL_TYPE", 15, 29], ["TH1", "CELL_LINE", 112, 115], ["TH17", "CELL_LINE", 120, 124], ["memory T cells", "CELL_TYPE", 188, 202], ["ADJ", "PROTEIN", 212, 215], ["ADJ", "PROTEIN", 261, 264], ["the differential polarity", "TEST", 85, 110], ["CpG", "TEST", 204, 207], ["ADJ+CpG", "TREATMENT", 212, 219], ["TH1 dominance", "TEST", 230, 243], ["ADJ", "TEST", 248, 251], ["GLA and ADJ+GLA", "TEST", 253, 268], ["skewed TH17 differentiation", "PROBLEM", 276, 303], ["numbers", "OBSERVATION_MODIFIER", 4, 11], ["memory T cells", "OBSERVATION", 15, 29], ["lungs", "ANATOMY", 33, 38], ["GLA", "ANATOMY", 253, 256]]], ["Upon challenge with the PR8/H1N1 IAV, all vaccinated groups afforded significant protection in the lungs.DiscussionInterestingly, the extent of protection varied between the groups; ADJ+GLA provided the most effective protection, and the descending order of adjuvants in terms of protection is GLA \u2265 ADJ+CpG > CpG \u2265 ADJ.", [["lungs", "ANATOMY", 99, 104], ["ADJ", "CHEMICAL", 182, 185], ["GLA", "CHEMICAL", 186, 189], ["ADJ", "CHEMICAL", 182, 185], ["GLA", "CHEMICAL", 186, 189], ["CpG", "CHEMICAL", 310, 313], ["PR8/H1N1 IAV", "ORGANISM", 24, 36], ["lungs", "ORGAN", 99, 104], ["ADJ+GLA", "SIMPLE_CHEMICAL", 182, 189], ["GLA", "SIMPLE_CHEMICAL", 294, 297], ["PR8/H1N1 IAV", "SPECIES", 24, 36], ["the PR8/H1N1 IAV", "TREATMENT", 20, 36], ["all vaccinated groups", "TREATMENT", 38, 59], ["significant protection in the lungs", "PROBLEM", 69, 104], ["ADJ+GLA", "TREATMENT", 182, 189], ["adjuvants", "TREATMENT", 258, 267], ["significant", "OBSERVATION_MODIFIER", 69, 80], ["protection", "OBSERVATION", 81, 91], ["lungs", "ANATOMY", 99, 104], ["descending", "ANATOMY", 238, 248]]], ["Upon challenge, all vaccinated groups mounted a strong recall response, and the accumulations of NP366-specific CD8 T cells and NP311-specific CD4 T cells in lungs were comparable.", [["CD8 T cells", "ANATOMY", 112, 123], ["CD4 T cells", "ANATOMY", 143, 154], ["lungs", "ANATOMY", 158, 163], ["NP366", "GENE_OR_GENE_PRODUCT", 97, 102], ["CD8", "GENE_OR_GENE_PRODUCT", 112, 115], ["NP311", "GENE_OR_GENE_PRODUCT", 128, 133], ["lungs", "ORGAN", 158, 163], ["NP366", "PROTEIN", 97, 102], ["CD8 T cells", "CELL_TYPE", 112, 123], ["NP311", "PROTEIN", 128, 133], ["CD4 T cells", "CELL_TYPE", 143, 154], ["the accumulations", "TEST", 76, 93], ["NP366", "TEST", 97, 102], ["NP311", "TEST", 128, 133], ["lungs", "ANATOMY", 158, 163]]], ["The percentages of IFN\uf067-producing NP366-specific CD8 T cells were similar between the groups and the percentages of IFN\uf067-producing NP311-specific CD4 T cells showed no correlation with viral control.", [["CD8 T cells", "ANATOMY", 49, 60], ["CD4 T cells", "ANATOMY", 146, 157], ["IFN\uf067-", "GENE_OR_GENE_PRODUCT", 19, 24], ["NP366", "GENE_OR_GENE_PRODUCT", 34, 39], ["CD8", "GENE_OR_GENE_PRODUCT", 49, 52], ["IFN\uf067-", "GENE_OR_GENE_PRODUCT", 116, 121], ["NP311", "GENE_OR_GENE_PRODUCT", 131, 136], ["CD4 T cells", "CELL", 146, 157], ["IFN", "PROTEIN", 19, 22], ["NP366", "PROTEIN", 34, 39], ["CD8 T cells", "CELL_TYPE", 49, 60], ["IFN", "PROTEIN", 116, 119], ["NP311", "PROTEIN", 131, 136], ["CD4 T cells", "CELL_TYPE", 146, 157], ["IFN", "TEST", 19, 22], ["NP366", "TEST", 34, 39], ["IFN", "TEST", 116, 119], ["viral control", "TREATMENT", 185, 198]]], ["However, interestingly, differences in viral control tend to associate with the combined percentages of IL-17-producing CD8 and CD4 T cells.", [["CD8", "ANATOMY", 120, 123], ["CD4 T cells", "ANATOMY", 128, 139], ["IL-17", "GENE_OR_GENE_PRODUCT", 104, 109], ["CD8", "GENE_OR_GENE_PRODUCT", 120, 123], ["CD4 T", "GENE_OR_GENE_PRODUCT", 128, 133], ["IL-17", "PROTEIN", 104, 109], ["CD8 and CD4 T cells", "CELL_TYPE", 120, 139], ["viral control", "TREATMENT", 39, 52], ["IL", "TEST", 104, 106], ["CD8 and CD4 T cells", "PROBLEM", 120, 139], ["CD4 T cells", "OBSERVATION", 128, 139]]], ["Further, blocking IL-17A modestly affected IAV control in mice vaccinated with ADJ+GLA.", [["ADJ", "CHEMICAL", 79, 82], ["GLA", "CHEMICAL", 83, 86], ["IL-17A", "GENE_OR_GENE_PRODUCT", 18, 24], ["IAV", "ORGANISM", 43, 46], ["mice", "ORGANISM", 58, 62], ["ADJ+GLA", "SIMPLE_CHEMICAL", 79, 86], ["IL-17A", "PROTEIN", 18, 24], ["mice", "SPECIES", 58, 62], ["IAV", "SPECIES", 43, 46], ["mice", "SPECIES", 58, 62], ["blocking IL", "TREATMENT", 9, 20], ["IAV control", "TREATMENT", 43, 54], ["GLA", "ANATOMY", 83, 86]]], ["These data are consistent with a report that TH17 cells can provide some degree of protection against IAV (50) .", [["TH17 cells", "ANATOMY", 45, 55], ["TH17 cells", "CELL", 45, 55], ["TH17 cells", "CELL_LINE", 45, 55], ["IAV", "SPECIES", 102, 105], ["TH17 cells", "PROBLEM", 45, 55], ["IAV", "PROBLEM", 102, 105], ["consistent with", "UNCERTAINTY", 15, 30]]], ["In addition to IL-17A, TC17/TH17 cells also produce cytokines such as IL-17F, IL-22 and GM-CSF, whose role in IAV control is unknown.", [["TC17/TH17 cells", "ANATOMY", 23, 38], ["IL-17A", "GENE_OR_GENE_PRODUCT", 15, 21], ["TC17", "GENE_OR_GENE_PRODUCT", 23, 27], ["TH17 cells", "CELL", 28, 38], ["IL-17F", "GENE_OR_GENE_PRODUCT", 70, 76], ["IL-22", "GENE_OR_GENE_PRODUCT", 78, 83], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 88, 94], ["IAV", "ORGANISM", 110, 113], ["IL-17A", "PROTEIN", 15, 21], ["TC17/TH17 cells", "CELL_LINE", 23, 38], ["cytokines", "PROTEIN", 52, 61], ["IL-17F, IL-22", "PROTEIN", 70, 83], ["GM", "PROTEIN", 88, 90], ["CSF", "PROTEIN", 91, 94], ["IAV", "SPECIES", 110, 113], ["IL", "TEST", 15, 17], ["TC17", "TEST", 23, 27], ["cytokines", "TEST", 52, 61], ["IL", "TEST", 70, 72], ["IL", "TEST", 78, 80], ["IAV control", "TREATMENT", 110, 121]]], ["We postulate that adjuvants (ADJ+GLA) that stimulate TC17/TH17 memory provide an additional layer of immune defense, that augments other mechanisms of CD8/CD4 T cell immunity, leading to enhanced protection.", [["CD8/CD4 T cell", "ANATOMY", 151, 165], ["ADJ", "CHEMICAL", 29, 32], ["GLA", "CHEMICAL", 33, 36], ["ADJ+GLA", "SIMPLE_CHEMICAL", 29, 36], ["TC17", "GENE_OR_GENE_PRODUCT", 53, 57], ["CD8", "GENE_OR_GENE_PRODUCT", 151, 154], ["CD4", "GENE_OR_GENE_PRODUCT", 155, 158], ["TC17", "PROTEIN", 53, 57], ["CD8", "PROTEIN", 151, 154], ["CD4", "PROTEIN", 155, 158], ["adjuvants (ADJ+GLA)", "TREATMENT", 18, 37], ["TC17/TH17 memory", "TREATMENT", 53, 69], ["immune defense", "PROBLEM", 101, 115], ["CD8", "TEST", 151, 154], ["CD4 T cell immunity", "PROBLEM", 155, 174], ["immune defense", "OBSERVATION", 101, 115]]], ["It is also possible that TC17/TH17 programming, and not IL-17-mediated antiviral functions per se, might be important in engendering protective immunity, because TH17 programming is associated with stem cell-like functionally plastic memory T cells (51) .", [["stem cell", "ANATOMY", 198, 207], ["plastic memory T cells", "ANATOMY", 226, 248], ["TC17", "GENE_OR_GENE_PRODUCT", 25, 29], ["IL-17", "GENE_OR_GENE_PRODUCT", 56, 61], ["stem cell", "CELL", 198, 207], ["memory T cells", "CELL", 234, 248], ["IL-17", "PROTEIN", 56, 61], ["stem cell", "CELL_TYPE", 198, 207], ["memory T cells", "CELL_TYPE", 234, 248], ["TC17/TH17 programming", "TREATMENT", 25, 46], ["IL", "TEST", 56, 58], ["TH17 programming", "PROBLEM", 162, 178], ["stem cell", "PROBLEM", 198, 207], ["also possible", "UNCERTAINTY", 6, 19], ["associated with", "UNCERTAINTY", 182, 197], ["stem cell", "OBSERVATION", 198, 207], ["plastic memory", "OBSERVATION", 226, 240]]], ["It is likely that a battery of redundant mechanisms including but limited to IL-17, IFN-\uf067 and MHC I/MHC II-restricted cytotoxicity orchestrate vaccine-induced protective immunity to influenza A virus (52) (53) (54) (55) .DiscussionOur investigations into the CD4 T cells' role in programming vaccinal immunity to IAV provided further insights into the mechanisms of protection in ADJ+GLA-vaccinated mice.DiscussionDepletion of CD4 T cells during vaccination precluded priming of NP311-specific CD4 T cells, but had no adverse effect on IFN\uf067-or IL-17-producing NP366-specific memory CD8 T cells in lungs.", [["CD4 T cells", "ANATOMY", 259, 270], ["CD4 T cells", "ANATOMY", 427, 438], ["CD4 T cells", "ANATOMY", 494, 505], ["memory CD8 T cells", "ANATOMY", 575, 593], ["lungs", "ANATOMY", 597, 602], ["ADJ", "CHEMICAL", 380, 383], ["GLA", "CHEMICAL", 384, 387], ["IL-17", "GENE_OR_GENE_PRODUCT", 77, 82], ["IFN-\uf067", "GENE_OR_GENE_PRODUCT", 84, 89], ["MHC I", "GENE_OR_GENE_PRODUCT", 94, 99], ["MHC II", "GENE_OR_GENE_PRODUCT", 100, 106], ["influenza A virus", "ORGANISM", 182, 199], ["CD4 T cells", "CELL", 259, 270], ["IAV", "ORGANISM", 313, 316], ["ADJ", "SIMPLE_CHEMICAL", 380, 383], ["GLA", "SIMPLE_CHEMICAL", 384, 387], ["mice", "ORGANISM", 399, 403], ["CD4 T cells", "CELL", 427, 438], ["NP311", "GENE_OR_GENE_PRODUCT", 479, 484], ["CD4 T cells", "CELL", 494, 505], ["IFN\uf067-", "GENE_OR_GENE_PRODUCT", 536, 541], ["IL-17", "GENE_OR_GENE_PRODUCT", 544, 549], ["NP366", "GENE_OR_GENE_PRODUCT", 560, 565], ["CD8 T cells", "CELL", 582, 593], ["lungs", "ORGAN", 597, 602], ["IL", "PROTEIN", 77, 79], ["IFN", "PROTEIN", 84, 87], ["MHC I", "PROTEIN", 94, 99], ["MHC II", "PROTEIN", 100, 106], ["CD4 T cells", "CELL_TYPE", 259, 270], ["CD4 T cells", "CELL_TYPE", 427, 438], ["NP311", "PROTEIN", 479, 484], ["CD4 T cells", "CELL_TYPE", 494, 505], ["IFN", "PROTEIN", 536, 539], ["NP366", "PROTEIN", 560, 565], ["memory CD8 T cells", "CELL_TYPE", 575, 593], ["influenza A virus", "SPECIES", 182, 199], ["mice", "SPECIES", 399, 403], ["influenza A virus", "SPECIES", 182, 199], ["IAV", "SPECIES", 313, 316], ["mice", "SPECIES", 399, 403], ["redundant mechanisms", "PROBLEM", 31, 51], ["IL", "TEST", 77, 79], ["IFN", "TEST", 84, 87], ["restricted cytotoxicity orchestrate vaccine", "TREATMENT", 107, 150], ["influenza A virus", "PROBLEM", 182, 199], ["DiscussionOur investigations", "TEST", 221, 249], ["the CD4 T cells", "TREATMENT", 255, 270], ["vaccinal immunity", "TREATMENT", 292, 309], ["CD4 T cells", "TREATMENT", 427, 438], ["vaccination", "TREATMENT", 446, 457], ["NP311", "TEST", 479, 484], ["adverse effect", "PROBLEM", 518, 532], ["IFN", "TEST", 536, 539], ["IL", "TEST", 544, 546], ["lungs", "ANATOMY", 597, 602]]], ["Importantly, however, CD4 T cell depletion reduced CD103 expression and the number of non-vascular CD8 TRMs in the lungs, as reported before (43) .", [["CD4 T cell", "ANATOMY", 22, 32], ["non-vascular CD8 TRMs", "ANATOMY", 86, 107], ["lungs", "ANATOMY", 115, 120], ["CD4 T", "GENE_OR_GENE_PRODUCT", 22, 27], ["CD103", "GENE_OR_GENE_PRODUCT", 51, 56], ["CD8", "GENE_OR_GENE_PRODUCT", 99, 102], ["lungs", "ORGAN", 115, 120], ["CD4", "PROTEIN", 22, 25], ["CD103", "PROTEIN", 51, 56], ["non-vascular CD8 TRMs", "CELL_TYPE", 86, 107], ["CD4 T cell depletion", "PROBLEM", 22, 42], ["non-vascular CD8 TRMs in the lungs", "PROBLEM", 86, 120], ["CD4 T cell depletion", "OBSERVATION", 22, 42], ["reduced", "OBSERVATION_MODIFIER", 43, 50], ["CD103 expression", "OBSERVATION", 51, 67], ["number", "OBSERVATION_MODIFIER", 76, 82], ["non-vascular CD8 TRMs", "OBSERVATION", 86, 107], ["lungs", "ANATOMY", 115, 120]]], ["Suresh (sureshm@vetmed.wisc.edu).Materials AvailabilityNo unique or new materials or reagents were developed in this study.", [["reagents", "TREATMENT", 85, 93], ["this study", "TEST", 112, 122]]], ["All materials or reagents used in this manuscript are available commercially or were obtained from other researchers.Data and Code AvailabilityAll data generated in this study are presented in Figures For intracellular cytokine staining, 1x10 6 cells were stimulated for 5 hours at 37C in the presence of human recombinant IL-2 (10 U/well), and brefeldin A (1 \u03bcl/ml, GolgiPlug, BD Biosciences), with one of the following peptides: SIINFEKL, NP366 or NP311 (thinkpeptides \u00ae , ProImmune Ltd.", [["intracellular", "ANATOMY", 205, 218], ["1x10 6 cells", "ANATOMY", 238, 250], ["brefeldin A", "CHEMICAL", 345, 356], ["brefeldin A", "CHEMICAL", 345, 356], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 205, 218], ["1x10 6 cells", "CELL", 238, 250], ["human", "ORGANISM", 305, 310], ["IL-2", "GENE_OR_GENE_PRODUCT", 323, 327], ["brefeldin A", "SIMPLE_CHEMICAL", 345, 356], ["NP366", "SIMPLE_CHEMICAL", 441, 446], ["NP311", "SIMPLE_CHEMICAL", 450, 455], ["thinkpeptides \u00ae", "SIMPLE_CHEMICAL", 457, 472], ["1x10 6 cells", "CELL_LINE", 238, 250], ["human recombinant IL-2", "PROTEIN", 305, 327], ["human", "SPECIES", 305, 310], ["human", "SPECIES", 305, 310], ["All materials", "TREATMENT", 0, 13], ["reagents", "TREATMENT", 17, 25], ["All data", "TEST", 143, 151], ["this study", "TEST", 165, 175], ["intracellular cytokine staining", "PROBLEM", 205, 236], ["human recombinant IL", "TREATMENT", 305, 325], ["thinkpeptides", "TREATMENT", 457, 470], ["ProImmune Ltd", "TREATMENT", 475, 488]]], ["Oxford, UK) at 0.1ug/ml.", [["UK", "GENE_OR_GENE_PRODUCT", 8, 10]]], ["After stimulation, cells were stained for surface markers, and then processed with Cytofix/Cytoperm kit (BD Biosciences, Franklin Lakes, NJ).", [["cells", "ANATOMY", 19, 24], ["surface", "ANATOMY", 42, 49], ["cells", "CELL", 19, 24], ["surface markers", "PROTEIN", 42, 57], ["cells", "PROBLEM", 19, 24], ["surface markers", "TEST", 42, 57], ["Cytofix/Cytoperm kit", "TREATMENT", 83, 103]]], ["To stain for transcription factors, cells were first stained for cell surface molecules, fixed, permeabilized and subsequently stained for transcription factors using the transcription factors staining kit (eBioscience).", [["cells", "ANATOMY", 36, 41], ["cell surface molecules", "ANATOMY", 65, 87], ["cells", "CELL", 36, 41], ["cell", "CELL", 65, 69], ["transcription factors", "PROTEIN", 13, 34], ["cell surface molecules", "PROTEIN", 65, 87], ["transcription factors", "PROTEIN", 139, 160], ["transcription factors", "PROTEIN", 171, 192], ["eBioscience", "PROTEIN", 207, 218], ["transcription factors", "PROBLEM", 13, 34], ["cell surface molecules", "PROBLEM", 65, 87], ["transcription factors", "PROBLEM", 139, 160]]], ["All samples were acquired on a LSRFortessa (BD Biosciences) flow cytometer.Data and Code AvailabilityData were analyzed with FlowJo software (TreeStar, Ashland, OR).Statistical analysesStatistical analyses were performed using GraphPad software (La Jolla, CA).", [["samples", "ANATOMY", 4, 11], ["All samples", "TEST", 0, 11], ["flow cytometer", "TEST", 60, 74], ["Statistical analysesStatistical analyses", "TEST", 165, 205], ["GraphPad software", "TEST", 227, 244]]], ["All comparisons were made using an one-way ANOVA test with Tukey corrected multiple comparisons or Students t test where p<0.05 = were considered significantly different among groups.", [["Students t test", "TEST", 99, 114]]], ["In some experiments (Fig. 4) , we used two-way ANOVA, Students t test and simple regression analysis.", [["Students t test", "TEST", 54, 69], ["simple regression analysis", "TEST", 74, 100]]], ["In Fig. 6 , we used non-linear regression for analyzing weight loss data.", [["weight loss", "DISEASE", 56, 67], ["analyzing weight loss data", "PROBLEM", 46, 72]]], ["Viral titers were log transformed prior to analysis.", [["Viral", "ORGANISM", 0, 5], ["Viral titers", "TEST", 0, 12], ["analysis", "TEST", 43, 51]]], ["No data or outliers were excluded from analyses.Statistical analysesFunding: This study was supported by a PHS grant from the National Institutes of Health (grant# U01AI124299 and R21 AI149793 ) and funds from the John E. Butler Professorship to M. Suresh.", [["This study", "TEST", 77, 87]]], ["Woojong Lee was supported by a pre-doctoral fellowship from the American Heart Association.", [["Heart", "ANATOMY", 73, 78]]]], "PMC2650502": [["Old pathogens, new patternsIn 1999, an outbreak of WNV was identified in New York City, the first time this well-characterized mosquito-borne flavivirus had been found in the Western hemisphere.", [["WNV", "DISEASE", 51, 54], ["flavivirus", "DISEASE", 142, 152], ["WNV", "ORGANISM", 51, 54], ["mosquito", "ORGANISM", 127, 135], ["flavivirus", "ORGANISM", 142, 152], ["WNV", "SPECIES", 51, 54], ["Old pathogens", "PROBLEM", 0, 13], ["WNV", "PROBLEM", 51, 54], ["mosquito-borne flavivirus", "PROBLEM", 127, 152], ["pathogens", "OBSERVATION", 4, 13], ["new", "OBSERVATION_MODIFIER", 15, 18], ["patterns", "OBSERVATION_MODIFIER", 19, 27], ["WNV", "OBSERVATION", 51, 54], ["Western hemisphere", "ANATOMY", 175, 193]]], ["Originally isolated from a human in Uganda in 1937, WNV later was shown to be maintained in bird reservoirs through mosquito vectors [9].", [["human", "ORGANISM", 27, 32], ["WNV", "ORGANISM", 52, 55], ["human", "SPECIES", 27, 32], ["human", "SPECIES", 27, 32], ["WNV", "SPECIES", 52, 55]]], ["Since 1999, the virus has spread throughout the United States, causing more than 27,000 human cases of WNV illness [10].", [["WNV illness", "DISEASE", 103, 114], ["human", "ORGANISM", 88, 93], ["human", "SPECIES", 88, 93], ["human", "SPECIES", 88, 93], ["WNV", "SPECIES", 103, 106], ["the virus", "PROBLEM", 12, 21], ["WNV illness", "PROBLEM", 103, 114], ["virus", "OBSERVATION", 16, 21]]], ["WNV may be less likely to cause disease in women than in men, as suggested by a study reporting a higher incidence of WNV neuroinvasive disease in men and two others that demonstrated higher rates of mortality in infected men [11], [12].", [["WNV", "DISEASE", 0, 3], ["WNV neuroinvasive disease", "DISEASE", 118, 143], ["WNV", "ORGANISM", 0, 3], ["women", "ORGANISM", 43, 48], ["men", "ORGANISM", 57, 60], ["men", "ORGANISM", 147, 150], ["men", "ORGANISM", 222, 225], ["women", "SPECIES", 43, 48], ["men", "SPECIES", 57, 60], ["men", "SPECIES", 147, 150], ["men", "SPECIES", 222, 225], ["WNV", "SPECIES", 0, 3], ["WNV", "SPECIES", 118, 121], ["WNV", "PROBLEM", 0, 3], ["disease", "PROBLEM", 32, 39], ["a study", "TEST", 78, 85], ["WNV neuroinvasive disease", "PROBLEM", 118, 143], ["may be less likely", "UNCERTAINTY", 4, 22], ["WNV", "OBSERVATION", 118, 121]]], ["How much of the apparent difference is due to biology is unclear, as behavioral factors resulting in disproportionate exposure of men to the infected mosquito vector may have important roles.Old pathogens, new patternsIn 2002, a case of intrauterine transmission of WNV was reported in Syracuse, New York.", [["intrauterine", "ANATOMY", 237, 249], ["intrauterine transmission", "DISEASE", 237, 262], ["WNV", "DISEASE", 266, 269], ["men", "ORGANISM", 130, 133], ["mosquito", "ORGANISM", 150, 158], ["intrauterine", "IMMATERIAL_ANATOMICAL_ENTITY", 237, 249], ["WNV", "ORGANISM", 266, 269], ["men", "SPECIES", 130, 133], ["WNV", "SPECIES", 266, 269], ["behavioral factors", "PROBLEM", 69, 87], ["the infected mosquito vector", "TREATMENT", 137, 165], ["Old pathogens", "PROBLEM", 191, 204], ["pathogens", "OBSERVATION", 195, 204], ["new", "OBSERVATION_MODIFIER", 206, 209], ["patterns", "OBSERVATION_MODIFIER", 210, 218]]], ["In this case, a pregnant woman suffered WNV encephalitis at 27 weeks' gestational age and subsequently delivered at 38 weeks.", [["WNV encephalitis", "DISEASE", 40, 56], ["woman", "ORGANISM", 25, 30], ["WNV", "ORGANISM", 40, 43], ["woman", "SPECIES", 25, 30], ["WNV encephalitis", "PROBLEM", 40, 56], ["WNV", "OBSERVATION_MODIFIER", 40, 43], ["encephalitis", "OBSERVATION", 44, 56]]], ["The neonate had neurologic sequelae, including severe bilateral loss of white matter, a cystic lesion with focal cerebral destruction in one temporal lobe, lissencephaly, and chorioretinal scarring [13].", [["neurologic", "ANATOMY", 16, 26], ["white matter", "ANATOMY", 72, 84], ["cystic lesion", "ANATOMY", 88, 101], ["cerebral", "ANATOMY", 113, 121], ["temporal lobe", "ANATOMY", 141, 154], ["lissencephaly", "ANATOMY", 156, 169], ["chorioretinal", "ANATOMY", 175, 188], ["neurologic sequelae", "DISEASE", 16, 35], ["loss of white matter", "DISEASE", 64, 84], ["cerebral destruction", "DISEASE", 113, 133], ["lissencephaly", "DISEASE", 156, 169], ["chorioretinal scarring", "DISEASE", 175, 197], ["neonate", "ORGANISM", 4, 11], ["cystic lesion", "PATHOLOGICAL_FORMATION", 88, 101], ["cerebral", "ORGAN", 113, 121], ["temporal lobe", "MULTI-TISSUE_STRUCTURE", 141, 154], ["neurologic sequelae", "PROBLEM", 16, 35], ["severe bilateral loss of white matter", "PROBLEM", 47, 84], ["a cystic lesion", "PROBLEM", 86, 101], ["focal cerebral destruction in one temporal lobe", "PROBLEM", 107, 154], ["lissencephaly", "PROBLEM", 156, 169], ["chorioretinal scarring", "PROBLEM", 175, 197], ["neurologic", "OBSERVATION_MODIFIER", 16, 26], ["sequelae", "OBSERVATION", 27, 35], ["severe", "OBSERVATION_MODIFIER", 47, 53], ["bilateral", "ANATOMY_MODIFIER", 54, 63], ["loss", "OBSERVATION_MODIFIER", 64, 68], ["white matter", "OBSERVATION_MODIFIER", 72, 84], ["cystic", "OBSERVATION_MODIFIER", 88, 94], ["lesion", "OBSERVATION", 95, 101], ["focal", "OBSERVATION_MODIFIER", 107, 112], ["cerebral", "ANATOMY", 113, 121], ["destruction", "OBSERVATION", 122, 133], ["one temporal lobe", "ANATOMY", 137, 154], ["lissencephaly", "OBSERVATION", 156, 169], ["chorioretinal", "OBSERVATION_MODIFIER", 175, 188], ["scarring", "OBSERVATION", 189, 197]]], ["Cord blood from delivery and blood from heel-stick specimens tested positive for WNV-specific IgM, which is consistent with intrauterine infection.", [["Cord blood", "ANATOMY", 0, 10], ["blood", "ANATOMY", 29, 34], ["heel-stick specimens", "ANATOMY", 40, 60], ["intrauterine", "ANATOMY", 124, 136], ["intrauterine infection", "DISEASE", 124, 146], ["Cord blood", "ORGANISM_SUBSTANCE", 0, 10], ["blood", "ORGANISM_SUBSTANCE", 29, 34], ["heel", "ORGANISM_SUBDIVISION", 40, 44], ["WNV", "ORGANISM", 81, 84], ["IgM", "GENE_OR_GENE_PRODUCT", 94, 97], ["IgM", "PROTEIN", 94, 97], ["WNV", "SPECIES", 81, 84], ["Cord blood", "TEST", 0, 10], ["delivery", "TREATMENT", 16, 24], ["blood from heel-stick specimens", "TEST", 29, 60], ["WNV", "PROBLEM", 81, 84], ["specific IgM", "TEST", 85, 97], ["intrauterine infection", "PROBLEM", 124, 146], ["heel", "ANATOMY", 40, 44], ["consistent with", "UNCERTAINTY", 108, 123], ["intrauterine", "OBSERVATION_MODIFIER", 124, 136], ["infection", "OBSERVATION", 137, 146]]], ["The placenta also tested positive for WNV RNA by reverse transcriptase\u2013polymerase chain reaction (RT-PCR) in one of two tests [14], [15].", [["placenta", "ANATOMY", 4, 12], ["placenta", "ORGAN", 4, 12], ["WNV", "ORGANISM", 38, 41], ["WNV RNA", "RNA", 38, 45], ["WNV", "SPECIES", 38, 41], ["WNV RNA", "PROBLEM", 38, 45], ["reverse transcriptase\u2013polymerase chain reaction", "PROBLEM", 49, 96], ["RT-PCR", "TEST", 98, 104], ["placenta", "ANATOMY", 4, 12]]], ["This initial case of congenital WNV infection prompted the Centers for Disease Control and Prevention (CDC) and state health departments to establish a WNV surveillance system for pregnant women.", [["congenital WNV infection", "DISEASE", 21, 45], ["women", "ORGANISM", 189, 194], ["women", "SPECIES", 189, 194], ["WNV", "SPECIES", 32, 35], ["WNV", "SPECIES", 152, 155], ["congenital WNV infection", "PROBLEM", 21, 45], ["Disease Control", "TREATMENT", 71, 86], ["congenital", "OBSERVATION_MODIFIER", 21, 31], ["WNV", "OBSERVATION", 32, 35]]], ["In 2003\u20132004, 83 pregnant women who had WNV illness were identified through surveillance, and clinical information was available on 77.", [["WNV illness", "DISEASE", 40, 51], ["women", "ORGANISM", 26, 31], ["WNV", "ORGANISM", 40, 43], ["women", "SPECIES", 26, 31], ["WNV", "SPECIES", 40, 43], ["WNV illness", "PROBLEM", 40, 51]]], ["Although three cases of possible congenital infection were found, intrauterine transmission was not confirmed.", [["intrauterine", "ANATOMY", 66, 78], ["congenital infection", "DISEASE", 33, 53], ["intrauterine", "IMMATERIAL_ANATOMICAL_ENTITY", 66, 78], ["congenital infection", "PROBLEM", 33, 53], ["intrauterine transmission", "PROBLEM", 66, 91], ["possible", "UNCERTAINTY", 24, 32], ["congenital", "OBSERVATION_MODIFIER", 33, 43], ["infection", "OBSERVATION", 44, 53]]], ["All three mothers had acute WNV illness within 3 weeks of delivery, allowing for the possibility of intrapartum or immediate postpartum transmission of infection.", [["WNV illness", "DISEASE", 28, 39], ["infection", "DISEASE", 152, 161], ["mothers", "ORGANISM", 10, 17], ["WNV", "SPECIES", 28, 31], ["acute WNV illness", "PROBLEM", 22, 39], ["delivery", "TREATMENT", 58, 66], ["infection", "PROBLEM", 152, 161], ["acute", "OBSERVATION_MODIFIER", 22, 27], ["WNV", "OBSERVATION", 28, 31], ["infection", "OBSERVATION", 152, 161]]], ["Cord blood specimens were not available in two of these cases, and testing for WNV-specific IgM and WNV RNA was negative in the third.", [["Cord blood specimens", "ANATOMY", 0, 20], ["Cord blood specimens", "ORGANISM_SUBSTANCE", 0, 20], ["WNV", "ORGANISM", 79, 82], ["IgM", "GENE_OR_GENE_PRODUCT", 92, 95], ["WNV", "ORGANISM", 100, 103], ["IgM", "PROTEIN", 92, 95], ["WNV RNA", "RNA", 100, 107], ["WNV", "SPECIES", 79, 82], ["WNV", "SPECIES", 100, 103], ["Cord blood specimens", "TEST", 0, 20], ["these cases", "TEST", 50, 61], ["testing", "TEST", 67, 74], ["WNV", "TEST", 79, 82], ["specific IgM", "TEST", 83, 95], ["WNV RNA", "TEST", 100, 107]]], ["One of the infected infants died at 7 weeks of age [16].Old pathogens, new patternsDuring the surveillance efforts, 42 specimens of breast milk from infected women were tested for WNV RNA, and two of these tested positive.", [["specimens", "ANATOMY", 119, 128], ["breast milk", "ANATOMY", 132, 143], ["breast milk", "DISEASE", 132, 143], ["infants", "ORGANISM", 20, 27], ["breast milk", "ORGANISM_SUBSTANCE", 132, 143], ["women", "ORGANISM", 158, 163], ["WNV", "ORGANISM", 180, 183], ["WNV RNA", "RNA", 180, 187], ["infants", "SPECIES", 20, 27], ["milk", "SPECIES", 139, 143], ["women", "SPECIES", 158, 163], ["WNV", "SPECIES", 180, 183], ["Old pathogens", "PROBLEM", 56, 69], ["breast milk", "PROBLEM", 132, 143], ["WNV RNA", "TEST", 180, 187], ["infected", "OBSERVATION_MODIFIER", 11, 19], ["pathogens", "OBSERVATION", 60, 69], ["new", "OBSERVATION_MODIFIER", 71, 74], ["patterns", "OBSERVATION_MODIFIER", 75, 83], ["breast", "ANATOMY", 132, 138]]], ["One of the infants fed WNV positive breast milk had negative serology at age 7 months, and the other was not available for testing [16].", [["breast milk", "ANATOMY", 36, 47], ["infants", "ORGANISM", 11, 18], ["WNV", "ORGANISM", 23, 26], ["breast milk", "ORGANISM_SUBSTANCE", 36, 47], ["infants", "SPECIES", 11, 18], ["WNV", "SPECIES", 23, 26], ["testing", "TEST", 123, 130], ["breast", "ANATOMY", 36, 42]]], ["Shortly after delivery, a woman received two units of blood from a WNV-infected donor and subsequently developed documented WNV meningoencephalitis.", [["blood", "ANATOMY", 54, 59], ["WNV-infected", "DISEASE", 67, 79], ["WNV meningoencephalitis", "DISEASE", 124, 147], ["woman", "ORGANISM", 26, 31], ["blood", "ORGANISM_SUBSTANCE", 54, 59], ["WNV", "ORGANISM", 67, 70], ["woman", "SPECIES", 26, 31], ["WNV", "SPECIES", 67, 70], ["WNV", "SPECIES", 124, 127], ["blood", "TREATMENT", 54, 59], ["a WNV", "PROBLEM", 65, 70], ["infected donor", "TREATMENT", 71, 85], ["documented WNV meningoencephalitis", "PROBLEM", 113, 147], ["infected", "OBSERVATION", 71, 79], ["WNV", "OBSERVATION_MODIFIER", 124, 127], ["meningoencephalitis", "OBSERVATION", 128, 147]]], ["WNV also was isolated from her breast milk, and her breastfed neonate developed WNV-specific IgM antibody but did not become ill.", [["breast milk", "ANATOMY", 31, 42], ["WNV", "ORGANISM", 0, 3], ["breast milk", "ORGANISM_SUBSTANCE", 31, 42], ["neonate", "ORGANISM", 62, 69], ["WNV", "ORGANISM", 80, 83], ["IgM antibody", "PROTEIN", 93, 105], ["milk", "SPECIES", 38, 42], ["WNV", "SPECIES", 0, 3], ["WNV", "SPECIES", 80, 83], ["WNV", "PROBLEM", 0, 3], ["her breastfed neonate", "PROBLEM", 48, 69], ["WNV", "PROBLEM", 80, 83], ["specific IgM antibody", "TEST", 84, 105], ["breast", "ANATOMY", 31, 37]]], ["From the limited information available, it seems that WNV is rarely transmitted transplacentally, but that congenital WNV infection may result in severe neurologic sequelae and even death.", [["neurologic", "ANATOMY", 153, 163], ["WNV", "DISEASE", 54, 57], ["congenital WNV infection", "DISEASE", 107, 131], ["neurologic sequelae", "DISEASE", 153, 172], ["death", "DISEASE", 182, 187], ["WNV", "ORGANISM", 54, 57], ["WNV", "ORGANISM", 118, 121], ["WNV", "SPECIES", 54, 57], ["WNV", "SPECIES", 118, 121], ["WNV", "PROBLEM", 54, 57], ["congenital WNV infection", "PROBLEM", 107, 131], ["severe neurologic sequelae", "PROBLEM", 146, 172], ["even death", "PROBLEM", 177, 187], ["WNV", "OBSERVATION", 54, 57], ["congenital", "OBSERVATION_MODIFIER", 107, 117], ["WNV", "OBSERVATION", 118, 121], ["severe", "OBSERVATION_MODIFIER", 146, 152]]], ["Mothers who have febrile illnesses suspicious for WNV infection should be counseled regarding the possible risk for transmission during pregnancy and via breast milk [18].Old pathogens, new patternsAnother previously studied but clinically rare pathogen has re-emerged recently as a cause of disease in the United States.", [["breast milk", "ANATOMY", 154, 165], ["febrile illnesses", "DISEASE", 17, 34], ["WNV infection", "DISEASE", 50, 63], ["Mothers", "ORGANISM", 0, 7], ["WNV", "ORGANISM", 50, 53], ["breast milk", "ORGANISM_SUBSTANCE", 154, 165], ["WNV", "SPECIES", 50, 53], ["febrile illnesses", "PROBLEM", 17, 34], ["WNV infection", "PROBLEM", 50, 63], ["transmission during pregnancy and via breast milk", "TREATMENT", 116, 165], ["Old pathogens", "PROBLEM", 171, 184], ["clinically rare pathogen", "PROBLEM", 229, 253], ["disease", "PROBLEM", 292, 299], ["pathogens", "OBSERVATION", 175, 184], ["new", "OBSERVATION_MODIFIER", 186, 189], ["pathogen", "OBSERVATION", 245, 253], ["disease", "OBSERVATION", 292, 299]]], ["LCMV, an arenavirus carried by house mice and other small rodents, appeared in several recipients of transplanted organs in 2003 and again in 2005.", [["organs", "ANATOMY", 114, 120], ["LCMV", "ORGANISM", 0, 4], ["house mice", "ORGANISM", 31, 41], ["recipients", "ORGANISM", 87, 97], ["organs", "ORGAN", 114, 120], ["mice", "SPECIES", 37, 41], ["LCMV", "SPECIES", 0, 4], ["mice", "SPECIES", 37, 41], ["LCMV", "PROBLEM", 0, 4], ["an arenavirus", "PROBLEM", 6, 19], ["arenavirus", "OBSERVATION", 9, 19], ["small", "OBSERVATION_MODIFIER", 52, 57], ["rodents", "OBSERVATION", 58, 65], ["transplanted organs", "ANATOMY", 101, 120]]], ["All had received their organs from one of two donors, and the resulting infections were fatal in seven of the eight recipients.", [["organs", "ANATOMY", 23, 29], ["infections", "DISEASE", 72, 82], ["organs", "ORGAN", 23, 29], ["donors", "ORGANISM", 46, 52], ["recipients", "ORGANISM", 116, 126], ["the resulting infections", "PROBLEM", 58, 82], ["infections", "OBSERVATION", 72, 82]]], ["The second donor had a history of exposure to a pet hamster with LCMV infection, but the initial donor could not be linked to any rodent exposure and his tissues tested negative for LCMV infection.", [["tissues", "ANATOMY", 154, 161], ["LCMV infection", "DISEASE", 65, 79], ["LCMV infection", "DISEASE", 182, 196], ["hamster", "ORGANISM", 52, 59], ["LCMV", "ORGANISM", 65, 69], ["tissues", "TISSUE", 154, 161], ["LCMV", "ORGANISM", 182, 186], ["hamster", "SPECIES", 52, 59], ["pet hamster", "SPECIES", 48, 59], ["LCMV", "SPECIES", 65, 69], ["LCMV", "SPECIES", 182, 186], ["a pet hamster", "TREATMENT", 46, 59], ["LCMV infection", "PROBLEM", 65, 79], ["his tissues", "TEST", 150, 161], ["LCMV infection", "PROBLEM", 182, 196], ["LCMV", "OBSERVATION_MODIFIER", 65, 69], ["infection", "OBSERVATION", 70, 79], ["infection", "OBSERVATION", 187, 196]]], ["The sole surviving recipient was treated with ribavirin, shown in vitro to control replication of LCMV, and he improved clinically with therapy.", [["ribavirin", "CHEMICAL", 46, 55], ["ribavirin", "CHEMICAL", 46, 55], ["recipient", "ORGANISM", 19, 28], ["ribavirin", "SIMPLE_CHEMICAL", 46, 55], ["LCMV", "ORGANISM", 98, 102], ["LCMV", "SPECIES", 98, 102], ["ribavirin", "TREATMENT", 46, 55], ["vitro", "TREATMENT", 66, 71], ["LCMV", "PROBLEM", 98, 102], ["therapy", "TREATMENT", 136, 143], ["LCMV", "OBSERVATION", 98, 102]]], ["Only one of the recipients was a woman, and she died on post-liver transplantation day 17 with multiorgan LCMV involvement demonstrated immunologically at autopsy [3].", [["post-liver", "ANATOMY", 56, 66], ["multiorgan", "ANATOMY", 95, 105], ["recipients", "ORGANISM", 16, 26], ["woman", "ORGANISM", 33, 38], ["LCMV", "ORGANISM", 106, 110], ["woman", "SPECIES", 33, 38], ["post-liver transplantation", "TREATMENT", 56, 82], ["multiorgan LCMV involvement", "PROBLEM", 95, 122], ["LCMV", "OBSERVATION", 106, 110]]], ["In 2005, the clusters of LCMV infection in transplant recipients prompted the CDC to issue interim guidelines on exposure to LCMV, recommending that immunosuppressed persons and pregnant women or women who may become pregnant avoid exposure to all rodents, including pet hamsters [19].", [["LCMV infection", "DISEASE", 25, 39], ["LCMV", "DISEASE", 125, 129], ["LCMV", "ORGANISM", 25, 29], ["LCMV", "ORGANISM", 125, 129], ["persons", "ORGANISM", 166, 173], ["women", "ORGANISM", 187, 192], ["women", "ORGANISM", 196, 201], ["persons", "SPECIES", 166, 173], ["women", "SPECIES", 187, 192], ["women", "SPECIES", 196, 201], ["LCMV", "SPECIES", 25, 29], ["LCMV", "SPECIES", 125, 129], ["LCMV infection", "PROBLEM", 25, 39], ["transplant recipients", "TREATMENT", 43, 64], ["LCMV", "TREATMENT", 125, 129], ["LCMV", "OBSERVATION_MODIFIER", 25, 29], ["infection", "OBSERVATION", 30, 39]]], ["LCMV is known to infect pregnant women, causing fetal wastage, hydrocephalus, and chorioretinitis in affected offspring [20], [21].", [["fetal", "ANATOMY", 48, 53], ["fetal wastage", "DISEASE", 48, 61], ["hydrocephalus", "DISEASE", 63, 76], ["chorioretinitis", "DISEASE", 82, 97], ["LCMV", "ORGANISM", 0, 4], ["women", "ORGANISM", 33, 38], ["fetal", "ANATOMICAL_SYSTEM", 48, 53], ["women", "SPECIES", 33, 38], ["LCMV", "SPECIES", 0, 4], ["LCMV", "PROBLEM", 0, 4], ["fetal wastage", "PROBLEM", 48, 61], ["hydrocephalus", "PROBLEM", 63, 76], ["chorioretinitis", "PROBLEM", 82, 97], ["known to", "UNCERTAINTY", 8, 16], ["fetal wastage", "OBSERVATION", 48, 61], ["hydrocephalus", "OBSERVATION", 63, 76], ["chorioretinitis", "OBSERVATION", 82, 97]]], ["Ribavirin, the only therapeutic option for LCMV disease, generally is not recommended in pregnancy because of findings of teratogenicity in animal models [22].The viral hemorrhagic feversThe viral hemorrhagic fevers (VHFs) originate from multiple virus families, including the flaviruses (dengue hemorrhagic fever [DHF] and yellow fever), arenaviruses (Lassa fever and Argentine, Bolivian, and Venezuelan hemorrhagic fevers), bunyaviruses (RVF, hantaviruses, and Crimean-Congo hemorrhagic fever), and filoviruses (Ebola and Marburg hemorrhagic fevers).", [["Ribavirin", "CHEMICAL", 0, 9], ["LCMV disease", "DISEASE", 43, 55], ["viral hemorrhagic fevers", "DISEASE", 163, 187], ["viral hemorrhagic fevers", "DISEASE", 191, 215], ["VHFs", "DISEASE", 217, 221], ["dengue hemorrhagic fever", "DISEASE", 289, 313], ["DHF", "DISEASE", 315, 318], ["yellow fever", "DISEASE", 324, 336], ["arenaviruses", "DISEASE", 339, 351], ["Lassa fever", "DISEASE", 353, 364], ["Venezuelan hemorrhagic fevers", "DISEASE", 394, 423], ["bunyaviruses", "DISEASE", 426, 438], ["RVF, hantaviruses", "DISEASE", 440, 457], ["Crimean-Congo hemorrhagic fever", "DISEASE", 463, 494], ["filoviruses", "DISEASE", 501, 512], ["Ebola", "DISEASE", 514, 519], ["Marburg hemorrhagic fevers", "DISEASE", 524, 550], ["Ribavirin", "CHEMICAL", 0, 9], ["Ribavirin", "SIMPLE_CHEMICAL", 0, 9], ["LCMV", "ORGANISM", 43, 47], ["VHFs", "CANCER", 217, 221], ["dengue hemorrhagic fever", "ORGANISM", 289, 313], ["yellow fever", "ORGANISM", 324, 336], ["Lassa fever", "ORGANISM", 353, 364], ["Crimean-Congo hemorrhagic fever", "ORGANISM", 463, 494], ["Ebola", "ORGANISM", 514, 519], ["Marburg hemorrhagic fevers", "ORGANISM", 524, 550], ["dengue hemorrhagic fever", "SPECIES", 289, 313], ["yellow fever", "SPECIES", 324, 336], ["Lassa fever", "SPECIES", 353, 364], ["Venezuelan hemorrhagic fevers", "SPECIES", 394, 423], ["Congo hemorrhagic fever", "SPECIES", 471, 494], ["Ebola", "SPECIES", 514, 519], ["LCMV", "SPECIES", 43, 47], ["RVF", "SPECIES", 440, 443], ["Crimean-Congo hemorrhagic fever)", "SPECIES", 463, 495], ["Ribavirin", "TREATMENT", 0, 9], ["LCMV disease", "PROBLEM", 43, 55], ["teratogenicity in animal models", "PROBLEM", 122, 153], ["The viral hemorrhagic fevers", "PROBLEM", 159, 187], ["The viral hemorrhagic fevers", "PROBLEM", 187, 215], ["VHFs)", "PROBLEM", 217, 222], ["multiple virus families", "PROBLEM", 238, 261], ["the flaviruses (dengue hemorrhagic fever", "PROBLEM", 273, 313], ["DHF", "PROBLEM", 315, 318], ["yellow fever", "PROBLEM", 324, 336], ["arenaviruses (Lassa fever", "PROBLEM", 339, 364], ["Bolivian", "TREATMENT", 380, 388], ["Venezuelan hemorrhagic fevers", "PROBLEM", 394, 423], ["bunyaviruses", "PROBLEM", 426, 438], ["RVF", "PROBLEM", 440, 443], ["hantaviruses", "PROBLEM", 445, 457], ["Crimean", "TEST", 463, 470], ["Congo hemorrhagic fever)", "PROBLEM", 471, 495], ["filoviruses", "PROBLEM", 501, 512], ["Ebola", "PROBLEM", 514, 519], ["Marburg hemorrhagic fevers", "PROBLEM", 524, 550], ["LCMV", "OBSERVATION", 43, 47], ["viral", "OBSERVATION_MODIFIER", 163, 168], ["hemorrhagic", "OBSERVATION_MODIFIER", 169, 180], ["fevers", "OBSERVATION", 181, 187], ["viral", "OBSERVATION_MODIFIER", 191, 196], ["hemorrhagic", "OBSERVATION_MODIFIER", 197, 208], ["fevers", "OBSERVATION", 209, 215], ["multiple", "OBSERVATION_MODIFIER", 238, 246], ["virus", "OBSERVATION", 247, 252], ["hemorrhagic", "OBSERVATION_MODIFIER", 296, 307], ["hantaviruses", "OBSERVATION", 445, 457]]], ["Although evolutionarily divergent, these viruses have in common natural animal reservoirs and rapidly mutating RNA genomes, with humans as incidental victims in the viral life cycle.", [["humans", "ORGANISM", 129, 135], ["humans", "SPECIES", 129, 135], ["humans", "SPECIES", 129, 135], ["these viruses", "PROBLEM", 35, 48], ["rapidly mutating RNA genomes", "PROBLEM", 94, 122], ["divergent", "OBSERVATION_MODIFIER", 24, 33], ["viruses", "OBSERVATION", 41, 48], ["reservoirs", "OBSERVATION_MODIFIER", 79, 89], ["RNA genomes", "OBSERVATION", 111, 122]]], ["The possible exception is the flaviviruses, which are believed to survive via arthropod-human-arthropod infectious cycles, the isolation of yellow fever and dengue fever viruses from non-human primates notwithstanding [9].", [["yellow fever", "DISEASE", 140, 152], ["dengue fever", "DISEASE", 157, 169], ["human", "ORGANISM", 88, 93], ["yellow fever", "ORGANISM", 140, 152], ["dengue fever viruses", "ORGANISM", 157, 177], ["non-human primates", "ORGANISM", 183, 201], ["human", "SPECIES", 88, 93], ["yellow fever", "SPECIES", 140, 152], ["dengue fever", "SPECIES", 157, 169], ["human", "SPECIES", 88, 93], ["yellow fever and dengue fever viruses", "SPECIES", 140, 177], ["the flaviviruses", "PROBLEM", 26, 42], ["arthropod infectious cycles", "TREATMENT", 94, 121], ["yellow fever", "PROBLEM", 140, 152], ["dengue fever viruses", "PROBLEM", 157, 177], ["possible", "UNCERTAINTY", 4, 12], ["flaviviruses", "OBSERVATION", 30, 42]]], ["The sporadic nature of VHF outbreaks\u2014and their often remote locations\u2014makes systematic epidemiologic study difficult.", [["VHF", "PROBLEM", 23, 26], ["systematic epidemiologic study", "TEST", 76, 106], ["VHF", "OBSERVATION", 23, 26]]], ["The limited existing data, however, suggest a pattern of increased severity of disease in women and increased mortality in pregnant compared with nonpregnant patients across a range of viruses.", [["women", "ORGANISM", 90, 95], ["patients", "ORGANISM", 158, 166], ["women", "SPECIES", 90, 95], ["patients", "SPECIES", 158, 166], ["increased severity of disease", "PROBLEM", 57, 86], ["increased mortality in pregnant", "PROBLEM", 100, 131], ["increased", "OBSERVATION_MODIFIER", 57, 66], ["severity", "OBSERVATION_MODIFIER", 67, 75], ["disease", "OBSERVATION", 79, 86], ["increased", "OBSERVATION_MODIFIER", 100, 109], ["mortality", "OBSERVATION_MODIFIER", 110, 119]]], ["Fetal pathology and pregnancy wastage also are documented as sequelae of some VHF infections.The viral hemorrhagic feversYellow fever virus, an important tropical mosquito-borne pathogen, remains an important cause of disease.", [["Fetal", "ANATOMY", 0, 5], ["infections", "DISEASE", 82, 92], ["viral hemorrhagic fevers", "DISEASE", 97, 121], ["Yellow fever", "DISEASE", 121, 133], ["Yellow fever virus", "ORGANISM", 121, 139], ["Yellow fever virus", "SPECIES", 121, 139], ["Yellow fever virus", "SPECIES", 121, 139], ["Fetal pathology", "PROBLEM", 0, 15], ["pregnancy wastage", "PROBLEM", 20, 37], ["some VHF infections", "PROBLEM", 73, 92], ["The viral hemorrhagic fevers", "PROBLEM", 93, 121], ["Yellow fever virus", "PROBLEM", 121, 139], ["an important tropical mosquito-borne pathogen", "PROBLEM", 141, 186], ["disease", "PROBLEM", 218, 225], ["pathology", "OBSERVATION", 6, 15], ["VHF", "OBSERVATION_MODIFIER", 78, 81], ["infections", "OBSERVATION", 82, 92], ["viral", "OBSERVATION_MODIFIER", 97, 102], ["hemorrhagic", "OBSERVATION_MODIFIER", 103, 114], ["fevers", "OBSERVATION", 115, 121], ["fever virus", "OBSERVATION", 128, 139], ["disease", "OBSERVATION", 218, 225]]], ["Despite the effectiveness of the available vaccine, the World Health Organization (WHO) [23] estimates that 200,000 cases and 30,000 deaths from yellow fever occur annually worldwide, and these numbers have been increasing since the 1980s.", [["deaths", "DISEASE", 133, 139], ["yellow fever", "DISEASE", 145, 157], ["the available vaccine", "TREATMENT", 29, 50], ["yellow fever", "PROBLEM", 145, 157], ["increasing", "OBSERVATION_MODIFIER", 212, 222]]], ["Endemic to South America, the Caribbean, and Africa, yellow fever case fatality rates are estimated at 10% to 20%.", [["yellow fever", "DISEASE", 53, 65], ["yellow fever", "PROBLEM", 53, 65], ["fatality rates", "TEST", 71, 85]]], ["Max Theiler received the 1951 Nobel prize in medicine for development of the vaccine, which in concert with mosquito control measures dramatically decreased the incidence of yellow fever worldwide.", [["yellow fever", "DISEASE", 174, 186], ["Max Theiler", "ORGANISM", 0, 11], ["Theiler", "SPECIES", 4, 11], ["the vaccine", "TREATMENT", 73, 84], ["mosquito control measures", "TREATMENT", 108, 133], ["yellow fever worldwide", "PROBLEM", 174, 196], ["yellow fever", "OBSERVATION", 174, 186]]], ["Some controversy exists regarding the safety of yellow fever vaccination during pregnancy, because early studies suggested increased risk for miscarriage among women receiving the live attenuated vaccine during the first trimester of pregnancy.", [["yellow fever", "DISEASE", 48, 60], ["miscarriage", "DISEASE", 142, 153], ["yellow fever", "ORGANISM", 48, 60], ["women", "ORGANISM", 160, 165], ["women", "SPECIES", 160, 165], ["yellow fever vaccination", "PROBLEM", 48, 72], ["early studies", "TEST", 99, 112], ["miscarriage", "PROBLEM", 142, 153], ["the live attenuated vaccine", "TREATMENT", 176, 203], ["pregnancy", "PROBLEM", 234, 243]]], ["For this reason, the WHO recommends vaccinating pregnant women against yellow fever only during an epidemic [23].", [["yellow fever", "DISEASE", 71, 83], ["women", "ORGANISM", 57, 62], ["women", "SPECIES", 57, 62], ["yellow fever", "PROBLEM", 71, 83]]], ["Recent data from 480 women who were vaccinated early in pregnancy, however, demonstrate no increase in adverse pregnancy outcomes, including miscarriage, malformations, and preterm delivery.", [["miscarriage", "DISEASE", 141, 152], ["malformations", "DISEASE", 154, 167], ["women", "ORGANISM", 21, 26], ["women", "SPECIES", 21, 26], ["increase in adverse pregnancy outcomes", "PROBLEM", 91, 129], ["miscarriage", "PROBLEM", 141, 152], ["malformations", "PROBLEM", 154, 167], ["preterm delivery", "TREATMENT", 173, 189], ["no", "UNCERTAINTY", 88, 90], ["increase", "OBSERVATION_MODIFIER", 91, 99], ["malformations", "OBSERVATION", 154, 167]]], ["This study also documented 98% seroconversion among the women studied, suggesting that the vaccine is safe and effective in pregnancy [24].The viral hemorrhagic feversDengue virus infection manifests clinically as several different entities, including dengue fever, DHF, and dengue shock syndrome (DSS).", [["viral hemorrhagic fevers", "DISEASE", 143, 167], ["Dengue virus infection", "DISEASE", 167, 189], ["dengue fever", "DISEASE", 252, 264], ["DHF", "DISEASE", 266, 269], ["dengue shock syndrome", "DISEASE", 275, 296], ["DSS", "DISEASE", 298, 301], ["women", "ORGANISM", 56, 61], ["Dengue virus", "ORGANISM", 167, 179], ["women", "SPECIES", 56, 61], ["Dengue virus", "SPECIES", 167, 179], ["Dengue virus", "SPECIES", 167, 179], ["This study", "TEST", 0, 10], ["98% seroconversion", "TREATMENT", 27, 45], ["the vaccine", "TREATMENT", 87, 98], ["The viral hemorrhagic feversDengue virus infection", "PROBLEM", 139, 189], ["several different entities", "PROBLEM", 214, 240], ["dengue fever", "PROBLEM", 252, 264], ["DHF", "PROBLEM", 266, 269], ["dengue shock syndrome", "PROBLEM", 275, 296], ["viral", "OBSERVATION_MODIFIER", 143, 148], ["hemorrhagic", "OBSERVATION_MODIFIER", 149, 160], ["fevers", "OBSERVATION", 161, 167], ["dengue", "OBSERVATION_MODIFIER", 252, 258], ["fever", "OBSERVATION", 259, 264], ["DHF", "OBSERVATION", 266, 269], ["dengue", "OBSERVATION_MODIFIER", 275, 281], ["shock syndrome", "OBSERVATION", 282, 296]]], ["Four dengue virus serotypes are characterized, and primary infection with any of them generally causes a self-limited mild febrile illness.", [["dengue", "DISEASE", 5, 11], ["primary infection", "DISEASE", 51, 68], ["febrile illness", "DISEASE", 123, 138], ["dengue virus", "SPECIES", 5, 17], ["Four dengue virus serotypes", "PROBLEM", 0, 27], ["primary infection", "PROBLEM", 51, 68], ["a self-limited mild febrile illness", "PROBLEM", 103, 138], ["dengue", "OBSERVATION_MODIFIER", 5, 11], ["virus serotypes", "OBSERVATION", 12, 27], ["primary", "OBSERVATION_MODIFIER", 51, 58], ["infection", "OBSERVATION", 59, 68], ["mild", "OBSERVATION_MODIFIER", 118, 122], ["febrile", "OBSERVATION_MODIFIER", 123, 130], ["illness", "OBSERVATION", 131, 138]]], ["A history of dengue infection, however, is a risk factor for developing the more severe DHF or DSS on secondary infection with another serotype.", [["dengue infection", "DISEASE", 13, 29], ["DHF", "DISEASE", 88, 91], ["DSS", "DISEASE", 95, 98], ["infection", "DISEASE", 112, 121], ["dengue", "SPECIES", 13, 19], ["dengue infection", "PROBLEM", 13, 29], ["a risk factor", "PROBLEM", 43, 56], ["the more severe DHF", "PROBLEM", 72, 91], ["DSS", "PROBLEM", 95, 98], ["secondary infection", "PROBLEM", 102, 121], ["another serotype", "PROBLEM", 127, 143], ["dengue", "OBSERVATION_MODIFIER", 13, 19], ["infection", "OBSERVATION", 20, 29], ["severe", "OBSERVATION_MODIFIER", 81, 87], ["DHF", "OBSERVATION", 88, 91], ["secondary", "OBSERVATION_MODIFIER", 102, 111], ["infection", "OBSERVATION", 112, 121]]], ["This antibody enhancement effect is believed mediated by IgG and has significant implications for pregnant women contracting secondary dengue infection.", [["dengue infection", "DISEASE", 135, 151], ["IgG", "GENE_OR_GENE_PRODUCT", 57, 60], ["women", "ORGANISM", 107, 112], ["IgG", "PROTEIN", 57, 60], ["women", "SPECIES", 107, 112], ["dengue", "SPECIES", 135, 141], ["This antibody enhancement effect", "PROBLEM", 0, 32], ["dengue infection", "PROBLEM", 135, 151], ["infection", "OBSERVATION", 142, 151]]], ["A disease of the urban tropics, dengue is transmitted from person to person by Aedes mosquitoes, with no obligate vertebrate intermediate.", [["dengue", "DISEASE", 32, 38], ["Aedes mosquitoes", "ORGANISM", 79, 95], ["person", "SPECIES", 59, 65], ["person", "SPECIES", 69, 75], ["dengue", "SPECIES", 32, 38], ["Aedes mosquitoes", "SPECIES", 79, 95], ["A disease of the urban tropics", "PROBLEM", 0, 30], ["obligate vertebrate intermediate", "PROBLEM", 105, 137], ["disease", "OBSERVATION", 2, 9]]], ["Serologic surveys indicate no difference in the prevalence of dengue antibodies between women and men in endemic areas, with seropositivity approaching 100% in adult populations in hyperendemic parts of the world [25], [26].", [["dengue", "DISEASE", 62, 68], ["women", "ORGANISM", 88, 93], ["men", "ORGANISM", 98, 101], ["dengue antibodies", "PROTEIN", 62, 79], ["women", "SPECIES", 88, 93], ["men", "SPECIES", 98, 101], ["dengue", "SPECIES", 62, 68], ["Serologic surveys", "TEST", 0, 17], ["dengue antibodies", "PROBLEM", 62, 79], ["seropositivity", "PROBLEM", 125, 139], ["no", "UNCERTAINTY", 27, 29]]], ["Dengue infection during pregnancy can result in complications for mothers and infants, especially if a mother has been previously infected with another serotype.", [["Dengue infection", "DISEASE", 0, 16], ["Dengue", "ORGANISM", 0, 6], ["infants", "ORGANISM", 78, 85], ["infants", "SPECIES", 78, 85], ["Dengue infection", "PROBLEM", 0, 16], ["infection", "OBSERVATION", 7, 16]]], ["Dengue infection with manifestations of maternal thrombocytopenia and elevated transaminases may present similarly to HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome, differentiated in the early stages only by the lack of hypertension and the presence of fever.", [["liver", "ANATOMY", 145, 150], ["platelets", "ANATOMY", 168, 177], ["Dengue infection", "DISEASE", 0, 16], ["thrombocytopenia", "DISEASE", 49, 65], ["HELLP", "DISEASE", 118, 123], ["hemolysis", "DISEASE", 125, 134], ["low platelets) syndrome", "DISEASE", 164, 187], ["hypertension", "DISEASE", 244, 256], ["fever", "DISEASE", 277, 282], ["Dengue", "ORGANISM", 0, 6], ["liver", "ORGAN", 145, 150], ["platelets", "CELL", 168, 177], ["liver enzymes", "PROTEIN", 145, 158], ["platelets", "CELL_TYPE", 168, 177], ["Dengue infection", "PROBLEM", 0, 16], ["maternal thrombocytopenia", "PROBLEM", 40, 65], ["elevated transaminases", "PROBLEM", 70, 92], ["HELLP (hemolysis", "PROBLEM", 118, 134], ["elevated liver enzymes", "PROBLEM", 136, 158], ["low platelets) syndrome", "PROBLEM", 164, 187], ["hypertension", "PROBLEM", 244, 256], ["fever", "PROBLEM", 277, 282], ["infection", "OBSERVATION", 7, 16], ["thrombocytopenia", "OBSERVATION", 49, 65], ["elevated", "OBSERVATION_MODIFIER", 70, 78], ["transaminases", "OBSERVATION", 79, 92], ["liver", "ANATOMY", 145, 150], ["low platelets", "OBSERVATION_MODIFIER", 164, 177], ["early stages", "OBSERVATION_MODIFIER", 211, 223], ["hypertension", "OBSERVATION", 244, 256], ["fever", "OBSERVATION", 277, 282]]], ["Peripartum DHF can result in life-threatening coagulopathies leading to post partum or intraoperative hemorrhage.", [["DHF", "DISEASE", 11, 14], ["coagulopathies", "DISEASE", 46, 60], ["hemorrhage", "DISEASE", 102, 112], ["Peripartum DHF", "PROBLEM", 0, 14], ["life-threatening coagulopathies", "PROBLEM", 29, 60], ["intraoperative hemorrhage", "PROBLEM", 87, 112], ["DHF", "OBSERVATION", 11, 14], ["hemorrhage", "OBSERVATION", 102, 112]]], ["The presence of maternal IgG specific to another serotype in the neonatal blood can lead to DHF or DSS during vertically acquired primary dengue infection, with one reported case resulting in death of the infant from intracranial hemorrhage [27].", [["neonatal blood", "ANATOMY", 65, 79], ["intracranial", "ANATOMY", 217, 229], ["DHF", "DISEASE", 92, 95], ["DSS", "DISEASE", 99, 102], ["primary dengue infection", "DISEASE", 130, 154], ["death", "DISEASE", 192, 197], ["intracranial hemorrhage", "DISEASE", 217, 240], ["IgG", "GENE_OR_GENE_PRODUCT", 25, 28], ["blood", "ORGANISM_SUBSTANCE", 74, 79], ["maternal IgG", "PROTEIN", 16, 28], ["infant", "SPECIES", 205, 211], ["dengue", "SPECIES", 138, 144], ["maternal IgG", "PROBLEM", 16, 28], ["DHF", "PROBLEM", 92, 95], ["DSS", "PROBLEM", 99, 102], ["vertically acquired primary dengue infection", "PROBLEM", 110, 154], ["death", "PROBLEM", 192, 197], ["intracranial hemorrhage", "PROBLEM", 217, 240], ["intracranial", "ANATOMY", 217, 229], ["hemorrhage", "OBSERVATION", 230, 240]]], ["The mechanism of vertical dengue transmission is unclear, but at least 17 cases are documented in the English-language literature [28].", [["dengue", "DISEASE", 26, 32], ["vertical dengue transmission", "PROBLEM", 17, 45], ["vertical", "OBSERVATION_MODIFIER", 17, 25], ["dengue", "OBSERVATION", 26, 32]]], ["Transplacental infection has been hypothesized after reports of increased rates of stillbirth in pregnant women who had dengue fever, but fetal and placental dengue virus infections were not documented [29].", [["fetal", "ANATOMY", 138, 143], ["placental", "ANATOMY", 148, 157], ["Transplacental infection", "DISEASE", 0, 24], ["stillbirth", "DISEASE", 83, 93], ["dengue fever", "DISEASE", 120, 132], ["fetal and placental dengue virus infections", "DISEASE", 138, 181], ["women", "ORGANISM", 106, 111], ["fetal", "ORGANISM_SUBDIVISION", 138, 143], ["placental dengue virus", "ORGANISM", 148, 170], ["women", "SPECIES", 106, 111], ["dengue virus", "SPECIES", 158, 170], ["Transplacental infection", "PROBLEM", 0, 24], ["dengue fever", "PROBLEM", 120, 132], ["fetal and placental dengue virus infections", "PROBLEM", 138, 181], ["infection", "OBSERVATION", 15, 24], ["increased", "OBSERVATION_MODIFIER", 64, 73], ["rates", "OBSERVATION_MODIFIER", 74, 79], ["placental", "ANATOMY", 148, 157]]], ["One congenitally infected term infant did have dengue virus RNA detected in cord blood by RT-PCR, suggesting fetal viremia and transplacental infection [30].", [["cord blood", "ANATOMY", 76, 86], ["fetal", "ANATOMY", 109, 114], ["congenitally infected", "DISEASE", 4, 25], ["dengue", "DISEASE", 47, 53], ["viremia", "DISEASE", 115, 122], ["transplacental infection", "DISEASE", 127, 151], ["infant", "ORGANISM", 31, 37], ["cord blood", "ORGANISM_SUBSTANCE", 76, 86], ["fetal", "DEVELOPING_ANATOMICAL_STRUCTURE", 109, 114], ["dengue virus RNA", "RNA", 47, 63], ["infant", "SPECIES", 31, 37], ["dengue virus", "SPECIES", 47, 59], ["One congenitally infected term infant", "PROBLEM", 0, 37], ["dengue virus RNA", "PROBLEM", 47, 63], ["cord blood", "TEST", 76, 86], ["RT-PCR", "TEST", 90, 96], ["fetal viremia", "PROBLEM", 109, 122], ["transplacental infection", "PROBLEM", 127, 151], ["infected", "OBSERVATION", 17, 25], ["cord", "ANATOMY", 76, 80], ["fetal", "ANATOMY", 109, 114], ["viremia", "OBSERVATION", 115, 122], ["infection", "OBSERVATION", 142, 151]]], ["Most reported cases of vertical transmission have occurred with maternal infection around the time of delivery, also raising the possibility of transmission to the infant during the intrapartum period or through breastfeeding.The viral hemorrhagic feversEndemic to West Africa, Lassa fever is caused by a zoonotic arenavirus carried by common rodents of the Mastomys genus.", [["infection", "DISEASE", 73, 82], ["viral hemorrhagic fevers", "DISEASE", 230, 254], ["Lassa fever", "DISEASE", 278, 289], ["zoonotic arenavirus", "DISEASE", 305, 324], ["infant", "ORGANISM", 164, 170], ["Lassa", "ORGANISM", 278, 283], ["Mastomys genus", "ORGANISM", 358, 372], ["infant", "SPECIES", 164, 170], ["Lassa fever", "SPECIES", 278, 289], ["vertical transmission", "PROBLEM", 23, 44], ["maternal infection", "PROBLEM", 64, 82], ["delivery", "TREATMENT", 102, 110], ["The viral hemorrhagic fevers", "PROBLEM", 226, 254], ["Lassa fever", "PROBLEM", 278, 289], ["a zoonotic arenavirus", "PROBLEM", 303, 324], ["infection", "OBSERVATION", 73, 82], ["viral", "OBSERVATION_MODIFIER", 230, 235], ["hemorrhagic", "OBSERVATION_MODIFIER", 236, 247], ["Mastomys genus", "OBSERVATION", 358, 372]]], ["Data demonstrate the increased severity of Lassa fever in pregnancy and the postpartum period, but nonpregnant women infected with the virus fare as well as men in most studies.", [["Lassa fever", "DISEASE", 43, 54], ["Lassa", "ORGANISM", 43, 48], ["women", "ORGANISM", 111, 116], ["men", "ORGANISM", 157, 160], ["women", "SPECIES", 111, 116], ["men", "SPECIES", 157, 160], ["Lassa fever in pregnancy", "PROBLEM", 43, 67], ["the virus fare", "TREATMENT", 131, 145], ["increased", "OBSERVATION_MODIFIER", 21, 30], ["severity", "OBSERVATION_MODIFIER", 31, 39], ["Lassa", "OBSERVATION", 43, 48]]], ["Case fatality rates in pregnancy and the puerperium are as high as 40%, with the worst prognosis for women in the final trimester [31].", [["women", "ORGANISM", 101, 106], ["women", "SPECIES", 101, 106], ["Case fatality rates in pregnancy", "PROBLEM", 0, 32]]], ["Fetal outcome is even more bleak: first- and second-trimester Lassa infections result in spontaneous abortion in approximately 80% of cases.", [["Fetal", "ANATOMY", 0, 5], ["Lassa infections", "DISEASE", 62, 78], ["Fetal", "ORGAN", 0, 5], ["Lassa", "ORGANISM", 62, 67], ["second-trimester Lassa infections", "PROBLEM", 45, 78], ["spontaneous abortion", "PROBLEM", 89, 109], ["Lassa", "OBSERVATION_MODIFIER", 62, 67], ["infections", "OBSERVATION", 68, 78], ["spontaneous", "OBSERVATION_MODIFIER", 89, 100], ["abortion", "OBSERVATION", 101, 109]]], ["In the third trimester, stillbirth and neonatal deaths approach 75% [32].", [["stillbirth", "DISEASE", 24, 34], ["deaths", "DISEASE", 48, 54]]], ["Placental and fetal infection with high-titer Lassa virus has been demonstrated in such cases, suggesting that the virus directly infects and causes disease in the fetus [31], [33].", [["Placental", "ANATOMY", 0, 9], ["fetal", "ANATOMY", 14, 19], ["fetus", "ANATOMY", 164, 169], ["infection", "DISEASE", 20, 29], ["Placental", "MULTI-TISSUE_STRUCTURE", 0, 9], ["fetal", "ANATOMICAL_SYSTEM", 14, 19], ["Lassa virus", "ORGANISM", 46, 57], ["Lassa virus", "SPECIES", 46, 57], ["Lassa virus", "SPECIES", 46, 57], ["Placental and fetal infection", "PROBLEM", 0, 29], ["high-titer Lassa virus", "PROBLEM", 35, 57], ["the virus directly infects", "PROBLEM", 111, 137], ["disease in the fetus", "PROBLEM", 149, 169], ["fetal", "ANATOMY", 14, 19], ["infection", "OBSERVATION", 20, 29], ["high", "OBSERVATION_MODIFIER", 35, 39], ["virus", "OBSERVATION", 115, 120]]], ["Virus also is shed in the milk of infected mothers, and vertical transmission through breastfeeding is suspected to occur [33].", [["milk", "ANATOMY", 26, 30], ["Virus", "ORGANISM", 0, 5], ["milk", "ORGANISM_SUBSTANCE", 26, 30], ["mothers", "ORGANISM", 43, 50], ["Virus", "PROBLEM", 0, 5], ["infected", "OBSERVATION", 34, 42]]], ["It is suggested that uterine evacuation improves maternal prognosis at every gestational age, with the highest mortality occurring in those women who have a fetus remaining in utero [32].The viral hemorrhagic feversAlthough fewer reports are published about Ebola infection during pregnancy, available evidence suggests that it also can present devastating consequences for mother and fetus.", [["uterine", "ANATOMY", 21, 28], ["fetus", "ANATOMY", 157, 162], ["fetus", "ANATOMY", 385, 390], ["viral hemorrhagic fevers", "DISEASE", 191, 215], ["Ebola infection", "DISEASE", 258, 273], ["uterine", "ORGAN", 21, 28], ["women", "ORGANISM", 140, 145], ["fetus", "ORGAN", 157, 162], ["Ebola", "ORGANISM", 258, 263], ["fetus", "ORGAN", 385, 390], ["women", "SPECIES", 140, 145], ["Ebola", "SPECIES", 258, 263], ["uterine evacuation", "TREATMENT", 21, 39], ["The viral hemorrhagic fevers", "PROBLEM", 187, 215], ["Ebola infection", "PROBLEM", 258, 273], ["uterine", "ANATOMY", 21, 28], ["viral", "OBSERVATION_MODIFIER", 191, 196], ["hemorrhagic", "OBSERVATION_MODIFIER", 197, 208], ["fevers", "OBSERVATION", 209, 215]]], ["Most of the available data were gathered by retrospective review of 15 Ebola cases in pregnant patients during the 1995 Ebola outbreak in the Democratic Republic of the Congo [34].", [["Ebola", "DISEASE", 71, 76], ["Ebola", "DISEASE", 120, 125], ["Ebola", "ORGANISM", 71, 76], ["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103]]], ["Of the 15 pregnant patients, only one survived, for a case fatality rate of 93%.", [["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["a case fatality rate", "TEST", 52, 72]]], ["Fetal outcomes were worse than maternal outcomes, however, with only one live birth of a neonate who died of a febrile illness 3 days later.", [["Fetal", "ANATOMY", 0, 5], ["febrile illness", "DISEASE", 111, 126], ["Fetal", "ORGAN", 0, 5], ["Fetal outcomes", "PROBLEM", 0, 14], ["a febrile illness", "PROBLEM", 109, 126]]], ["The mother in this case died from postpartum hemorrhage.", [["hemorrhage", "DISEASE", 45, 55], ["postpartum hemorrhage", "PROBLEM", 34, 55], ["hemorrhage", "OBSERVATION", 45, 55]]], ["Four other infected women died during the third trimester.", [["women", "ORGANISM", 20, 25], ["women", "SPECIES", 20, 25], ["infected", "OBSERVATION_MODIFIER", 11, 19], ["women", "OBSERVATION", 20, 25]]], ["One woman gave birth to a stillborn infant at 32 weeks' estimated gestational age and died herself during the postpartum period.", [["woman", "ORGANISM", 4, 9], ["woman", "SPECIES", 4, 9], ["infant", "SPECIES", 36, 42]]], ["Fetal viral infection was not documented in these cases, but it seems clear that maternal Ebola virus infection results in devastating outcomes for the fetus.", [["fetus", "ANATOMY", 152, 157], ["Fetal viral infection", "DISEASE", 0, 21], ["Ebola virus infection", "DISEASE", 90, 111], ["Fetal viral", "ORGANISM", 0, 11], ["maternal", "ORGANISM", 81, 89], ["Ebola virus", "ORGANISM", 90, 101], ["fetus", "ORGAN", 152, 157], ["Ebola virus", "SPECIES", 90, 101], ["Ebola virus", "SPECIES", 90, 101], ["Fetal viral infection", "PROBLEM", 0, 21], ["maternal Ebola virus infection", "PROBLEM", 81, 111], ["the fetus", "PROBLEM", 148, 157], ["viral", "OBSERVATION_MODIFIER", 6, 11], ["infection", "OBSERVATION", 12, 21]]], ["As for the effects on nonpregnant women versus men, no survival advantage has been demonstrated for either group.", [["women", "ORGANISM", 34, 39], ["men", "ORGANISM", 47, 50], ["women", "SPECIES", 34, 39], ["men", "SPECIES", 47, 50], ["survival advantage", "TREATMENT", 55, 73]]], ["One analysis suggested an increased risk of death for infected men, but this finding was not statistically significant [35].", [["death", "DISEASE", 44, 49], ["men", "ORGANISM", 63, 66], ["men", "SPECIES", 63, 66], ["One analysis", "TEST", 0, 12], ["death", "PROBLEM", 44, 49], ["increased", "OBSERVATION_MODIFIER", 26, 35]]], ["Ebola virus has been found in semen and vaginal secretions of infected patients even after clinical recovery, suggesting risk for transmission via sexual or occupational exposure to these fluids [36].The viral hemorrhagic feversFor many of the VHFs, few data exist regarding disease in women in general or during pregnancy in particular.", [["semen", "ANATOMY", 30, 35], ["vaginal secretions", "ANATOMY", 40, 58], ["Ebola virus", "DISEASE", 0, 11], ["viral hemorrhagic fevers", "DISEASE", 204, 228], ["VHFs", "DISEASE", 244, 248], ["Ebola virus", "ORGANISM", 0, 11], ["semen", "ORGANISM_SUBSTANCE", 30, 35], ["vaginal secretions", "ORGANISM_SUBSTANCE", 40, 58], ["patients", "ORGANISM", 71, 79], ["VHFs", "PATHOLOGICAL_FORMATION", 244, 248], ["women", "ORGANISM", 286, 291], ["Ebola virus", "SPECIES", 0, 11], ["patients", "SPECIES", 71, 79], ["women", "SPECIES", 286, 291], ["Ebola virus", "SPECIES", 0, 11], ["Ebola virus", "PROBLEM", 0, 11], ["semen and vaginal secretions", "PROBLEM", 30, 58], ["The viral hemorrhagic fevers", "PROBLEM", 200, 228], ["the VHFs", "TEST", 240, 248], ["disease", "PROBLEM", 275, 282], ["vaginal", "ANATOMY", 40, 47], ["secretions", "OBSERVATION", 48, 58], ["infected", "OBSERVATION_MODIFIER", 62, 70], ["viral", "OBSERVATION_MODIFIER", 204, 209], ["hemorrhagic", "OBSERVATION_MODIFIER", 210, 221], ["fevers", "OBSERVATION", 222, 228]]], ["Case reports suggest that hantavirus infection during pregnancy runs essentially the same course as in nonpregnant patients, and fetal infection has not been diagnosed [37].", [["fetal", "ANATOMY", 129, 134], ["hantavirus infection", "DISEASE", 26, 46], ["fetal infection", "DISEASE", 129, 144], ["hantavirus", "ORGANISM", 26, 36], ["patients", "ORGANISM", 115, 123], ["fetal", "ANATOMICAL_SYSTEM", 129, 134], ["patients", "SPECIES", 115, 123], ["hantavirus infection", "PROBLEM", 26, 46], ["pregnancy runs", "PROBLEM", 54, 68], ["fetal infection", "PROBLEM", 129, 144], ["hantavirus", "OBSERVATION_MODIFIER", 26, 36], ["infection", "OBSERVATION", 37, 46], ["infection", "OBSERVATION", 135, 144]]], ["One case of fetal hypoxic brain injury occurred after maternal hantavirus pulmonary syndrome with acute respiratory distress syndrome (ARDS), but serologic testing of the infant was negative [38].", [["fetal", "ANATOMY", 12, 17], ["brain", "ANATOMY", 26, 31], ["pulmonary", "ANATOMY", 74, 83], ["respiratory", "ANATOMY", 104, 115], ["brain injury", "DISEASE", 26, 38], ["hantavirus pulmonary syndrome", "DISEASE", 63, 92], ["acute respiratory distress syndrome", "DISEASE", 98, 133], ["ARDS", "DISEASE", 135, 139], ["fetal", "ANATOMICAL_SYSTEM", 12, 17], ["brain", "ORGAN", 26, 31], ["pulmonary", "ORGAN", 74, 83], ["infant", "ORGANISM", 171, 177], ["infant", "SPECIES", 171, 177], ["fetal hypoxic brain injury", "PROBLEM", 12, 38], ["maternal hantavirus pulmonary syndrome", "PROBLEM", 54, 92], ["acute respiratory distress syndrome", "PROBLEM", 98, 133], ["ARDS", "PROBLEM", 135, 139], ["serologic testing", "TEST", 146, 163], ["fetal", "ANATOMY", 12, 17], ["hypoxic brain injury", "OBSERVATION", 18, 38], ["hantavirus pulmonary syndrome", "OBSERVATION", 63, 92], ["acute", "OBSERVATION_MODIFIER", 98, 103], ["respiratory distress syndrome", "OBSERVATION", 104, 133]]], ["A case of intrauterine fetal death was reported with hantavirus hemorrhagic renal syndrome, but the fetus was not tested for evidence of infection [39].", [["intrauterine fetal", "ANATOMY", 10, 28], ["renal", "ANATOMY", 76, 81], ["fetus", "ANATOMY", 100, 105], ["intrauterine fetal death", "DISEASE", 10, 34], ["hantavirus hemorrhagic renal syndrome", "DISEASE", 53, 90], ["infection", "DISEASE", 137, 146], ["fetal", "ORGAN", 23, 28], ["renal", "ORGAN", 76, 81], ["fetus", "ORGANISM", 100, 105], ["intrauterine fetal death", "PROBLEM", 10, 34], ["hantavirus hemorrhagic renal syndrome", "PROBLEM", 53, 90], ["infection", "PROBLEM", 137, 146], ["renal", "ANATOMY", 76, 81], ["syndrome", "OBSERVATION", 82, 90], ["infection", "OBSERVATION", 137, 146]]], ["One case of congenital RVF has been reported, and women who have RVF infection are believed to have increased rates of spontaneous abortion [40], [41].", [["congenital RVF", "DISEASE", 12, 26], ["RVF infection", "DISEASE", 65, 78], ["women", "ORGANISM", 50, 55], ["women", "SPECIES", 50, 55], ["congenital RVF", "PROBLEM", 12, 26], ["RVF infection", "PROBLEM", 65, 78], ["spontaneous abortion", "PROBLEM", 119, 139], ["congenital", "OBSERVATION_MODIFIER", 12, 22], ["RVF", "OBSERVATION", 23, 26], ["infection", "OBSERVATION", 69, 78], ["increased", "OBSERVATION_MODIFIER", 100, 109]]], ["Little is known about the effect of Marburg hemorrhagic fever on pregnancy outcome.", [["Marburg hemorrhagic fever", "DISEASE", 36, 61], ["Marburg hemorrhagic fever", "ORGANISM", 36, 61], ["Marburg hemorrhagic fever", "PROBLEM", 36, 61], ["pregnancy outcome", "PROBLEM", 65, 82], ["hemorrhagic", "OBSERVATION_MODIFIER", 44, 55], ["fever", "OBSERVATION", 56, 61]]], ["The lessons of Lassa, Ebola, and dengue can be applied to clinical manifestations of other VHFs in pregnancy, however, as all conditions predisposing to hypotension, coagulopathy, and hemorrhage bring compounded risk to the pregnant patient and her fetus.Avian influenza A virusThe highly pathogenic H5N1 virus has received much attention in recent years because of its widespread infection of bird populations in many countries and its high mortality rate among humans, raising concern for an approaching influenza pandemic.", [["fetus", "ANATOMY", 249, 254], ["Lassa, Ebola", "DISEASE", 15, 27], ["dengue", "DISEASE", 33, 39], ["VHFs", "DISEASE", 91, 95], ["hypotension", "DISEASE", 153, 164], ["coagulopathy", "DISEASE", 166, 178], ["hemorrhage", "DISEASE", 184, 194], ["influenza A virus", "DISEASE", 261, 278], ["H5N1 virus", "DISEASE", 300, 310], ["infection", "DISEASE", 381, 390], ["influenza", "DISEASE", 506, 515], ["Lassa", "ORGANISM", 15, 20], ["Ebola", "ORGANISM", 22, 27], ["VHFs", "CANCER", 91, 95], ["patient", "ORGANISM", 233, 240], ["Avian influenza A virus", "ORGANISM", 255, 278], ["H5N1 virus", "ORGANISM", 300, 310], ["humans", "ORGANISM", 463, 469], ["patient", "SPECIES", 233, 240], ["Avian influenza A virus", "SPECIES", 255, 278], ["H5N1 virus", "SPECIES", 300, 310], ["humans", "SPECIES", 463, 469], ["Avian influenza A virus", "SPECIES", 255, 278], ["H5N1 virus", "SPECIES", 300, 310], ["humans", "SPECIES", 463, 469], ["Lassa", "TREATMENT", 15, 20], ["dengue", "PROBLEM", 33, 39], ["other VHFs in pregnancy", "PROBLEM", 85, 108], ["hypotension", "PROBLEM", 153, 164], ["coagulopathy", "PROBLEM", 166, 178], ["hemorrhage", "PROBLEM", 184, 194], ["Avian influenza A virus", "PROBLEM", 255, 278], ["The highly pathogenic H5N1 virus", "PROBLEM", 278, 310], ["bird populations", "PROBLEM", 394, 410], ["an approaching influenza pandemic", "PROBLEM", 491, 524], ["Lassa", "OBSERVATION_MODIFIER", 15, 20], ["hypotension", "OBSERVATION", 153, 164], ["coagulopathy", "OBSERVATION", 166, 178], ["hemorrhage", "OBSERVATION", 184, 194], ["highly", "OBSERVATION_MODIFIER", 282, 288], ["pathogenic", "OBSERVATION_MODIFIER", 289, 299], ["H5N1 virus", "OBSERVATION", 300, 310], ["widespread", "OBSERVATION_MODIFIER", 370, 380], ["infection", "OBSERVATION", 381, 390], ["bird populations", "OBSERVATION", 394, 410], ["influenza", "OBSERVATION", 506, 515]]], ["Wild birds are the natural reservoir for influenza A viruses and when infected usually are asymptomatic, but they can infect other birds (eg, domestic poultry) that may develop disease.", [["influenza A viruses", "DISEASE", 41, 60], ["Wild birds", "ORGANISM", 0, 10], ["influenza A viruses", "ORGANISM", 41, 60], ["birds", "ORGANISM", 131, 136], ["influenza A viruses", "SPECIES", 41, 60], ["influenza A viruses", "SPECIES", 41, 60], ["the natural reservoir", "TREATMENT", 15, 36], ["influenza A viruses", "PROBLEM", 41, 60], ["asymptomatic", "PROBLEM", 91, 103], ["disease", "PROBLEM", 177, 184]]], ["Subtypes of influenza A virus are identified by two surface proteins (hemagglutinin and neuraminidase), with 16 known hemagglutinin and nine known neuraminidase subtypes.", [["surface", "ANATOMY", 52, 59], ["influenza A virus", "DISEASE", 12, 29], ["influenza A virus", "ORGANISM", 12, 29], ["hemagglutinin", "GENE_OR_GENE_PRODUCT", 70, 83], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 88, 101], ["surface proteins", "PROTEIN", 52, 68], ["hemagglutinin", "PROTEIN", 70, 83], ["neuraminidase", "PROTEIN", 88, 101], ["hemagglutinin", "PROTEIN", 118, 131], ["neuraminidase subtypes", "PROTEIN", 147, 169], ["influenza A virus", "SPECIES", 12, 29], ["influenza A virus", "SPECIES", 12, 29], ["influenza A virus", "PROBLEM", 12, 29], ["two surface proteins", "TEST", 48, 68], ["hemagglutinin", "TEST", 70, 83], ["neuraminidase", "TEST", 88, 101], ["16 known hemagglutinin", "PROBLEM", 109, 131], ["nine known neuraminidase subtypes", "PROBLEM", 136, 169], ["influenza", "OBSERVATION", 12, 21], ["neuraminidase subtypes", "OBSERVATION", 147, 169]]], ["Many combinations of hemagglutinin and neuraminidase proteins are possible, and all known combinations can be found in avian influenza viruses that infect birds.", [["influenza viruses", "DISEASE", 125, 142], ["hemagglutinin", "GENE_OR_GENE_PRODUCT", 21, 34], ["neuraminidase proteins", "GENE_OR_GENE_PRODUCT", 39, 61], ["avian influenza viruses", "ORGANISM", 119, 142], ["birds", "ORGANISM", 155, 160], ["hemagglutinin", "PROTEIN", 21, 34], ["neuraminidase proteins", "PROTEIN", 39, 61], ["avian influenza", "SPECIES", 119, 134], ["hemagglutinin and neuraminidase proteins", "TREATMENT", 21, 61], ["avian influenza viruses", "PROBLEM", 119, 142], ["hemagglutinin", "OBSERVATION", 21, 34]]], ["Although avian influenza A viruses primarily affect birds, mutations in genes that produce surface proteins or gene reassortment with human viruses can result in a novel human influenza A subtype virus that can infect humans.", [["surface", "ANATOMY", 91, 98], ["influenza A viruses", "DISEASE", 15, 34], ["influenza A subtype", "DISEASE", 176, 195], ["avian influenza A viruses", "ORGANISM", 9, 34], ["birds", "ORGANISM", 52, 57], ["human", "ORGANISM", 134, 139], ["human", "ORGANISM", 170, 175], ["influenza A subtype virus", "ORGANISM", 176, 201], ["humans", "ORGANISM", 218, 224], ["surface proteins", "PROTEIN", 91, 107], ["avian influenza A", "SPECIES", 9, 26], ["human", "SPECIES", 134, 139], ["human", "SPECIES", 170, 175], ["influenza A subtype virus", "SPECIES", 176, 201], ["humans", "SPECIES", 218, 224], ["human viruses", "SPECIES", 134, 147], ["human influenza A subtype virus", "SPECIES", 170, 201], ["humans", "SPECIES", 218, 224], ["avian influenza A viruses", "PROBLEM", 9, 34], ["mutations in genes", "PROBLEM", 59, 77], ["surface proteins", "PROBLEM", 91, 107], ["gene reassortment", "TREATMENT", 111, 128], ["human viruses", "PROBLEM", 134, 147], ["a novel human influenza A subtype virus", "PROBLEM", 162, 201], ["influenza", "OBSERVATION", 15, 24]]], ["If a novel subtype virus to which the human population lacks immunity develops the ability for efficient and sustained transmission among humans, an influenza pandemic could occur [42], [43].Avian influenza A virusThe highly pathogenic H5N1 virus first appeared in humans in Hong Kong in 1997, infecting 18 people, six of whom died.", [["influenza pandemic", "DISEASE", 149, 167], ["influenza A virus", "DISEASE", 197, 214], ["human", "ORGANISM", 38, 43], ["humans", "ORGANISM", 138, 144], ["Avian influenza A virus", "ORGANISM", 191, 214], ["H5N1 virus", "ORGANISM", 236, 246], ["humans", "ORGANISM", 265, 271], ["people", "ORGANISM", 307, 313], ["human", "SPECIES", 38, 43], ["humans", "SPECIES", 138, 144], ["Avian influenza A virus", "SPECIES", 191, 214], ["H5N1 virus", "SPECIES", 236, 246], ["humans", "SPECIES", 265, 271], ["people", "SPECIES", 307, 313], ["human", "SPECIES", 38, 43], ["humans", "SPECIES", 138, 144], ["Avian influenza A virus", "SPECIES", 191, 214], ["H5N1 virus", "SPECIES", 236, 246], ["humans", "SPECIES", 265, 271], ["a novel subtype virus", "PROBLEM", 3, 24], ["an influenza pandemic", "PROBLEM", 146, 167], ["Avian influenza A virus", "PROBLEM", 191, 214], ["The highly pathogenic H5N1 virus", "PROBLEM", 214, 246], ["highly", "OBSERVATION_MODIFIER", 218, 224], ["pathogenic", "OBSERVATION_MODIFIER", 225, 235], ["H5N1 virus", "OBSERVATION", 236, 246]]], ["Studies of these initial cases demonstrated that exposure to live poultry during the week before the onset of illness was a major risk factor for infection [44].", [["illness", "DISEASE", 110, 117], ["infection", "DISEASE", 146, 155], ["illness", "PROBLEM", 110, 117], ["infection", "PROBLEM", 146, 155]]], ["Culling of poultry in Hong Kong and implementation of other measures contributed to control of the outbreak.", [["other measures", "TREATMENT", 54, 68], ["the outbreak", "PROBLEM", 95, 107], ["poultry", "OBSERVATION_MODIFIER", 11, 18]]], ["Beginning in 2003, however, human cases again were observed [42], and as of January 24, 2008, 353 confirmed human cases of H5N1 from 14 countries with 221 deaths had been reported to the WHO [45].", [["H5N1", "DISEASE", 123, 127], ["deaths", "DISEASE", 155, 161], ["human", "ORGANISM", 28, 33], ["human", "ORGANISM", 108, 113], ["human", "SPECIES", 28, 33], ["human", "SPECIES", 108, 113], ["human", "SPECIES", 28, 33], ["human", "SPECIES", 108, 113], ["H5N1", "PROBLEM", 123, 127]]], ["Cases of probable human-to-human transmission of H5N1 recently have been reported [46], further raising the threat of an influenza pandemic.", [["H5N1", "DISEASE", 49, 53], ["influenza", "DISEASE", 121, 130], ["human", "ORGANISM", 18, 23], ["human", "ORGANISM", 27, 32], ["H5N1", "ORGANISM", 49, 53], ["human", "SPECIES", 18, 23], ["human", "SPECIES", 27, 32], ["human", "SPECIES", 18, 23], ["human", "SPECIES", 27, 32], ["H5N1", "PROBLEM", 49, 53], ["an influenza pandemic", "PROBLEM", 118, 139], ["probable", "UNCERTAINTY", 9, 17], ["influenza", "OBSERVATION", 121, 130]]], ["Although H5N1 virus currently represents the highest threat for a future pandemic, other avian influenza A viruses that have infected humans also have pandemic potential.Avian influenza A virusThe incubation period for H5N1 seems to be 7 days or less after exposure to infected poultry, and 2 to 5 days in many cases [47].", [["H5N1 virus", "DISEASE", 9, 19], ["influenza A viruses", "DISEASE", 95, 114], ["influenza A virus", "DISEASE", 176, 193], ["H5N1", "DISEASE", 219, 223], ["H5N1 virus", "ORGANISM", 9, 19], ["avian influenza A viruses", "ORGANISM", 89, 114], ["humans", "ORGANISM", 134, 140], ["Avian influenza A virus", "ORGANISM", 170, 193], ["H5N1", "ORGANISM", 219, 223], ["H5N1 virus", "SPECIES", 9, 19], ["avian influenza A", "SPECIES", 89, 106], ["humans", "SPECIES", 134, 140], ["Avian influenza A virus", "SPECIES", 170, 193], ["H5N1 virus", "SPECIES", 9, 19], ["A viruses", "SPECIES", 105, 114], ["humans", "SPECIES", 134, 140], ["Avian influenza A virus", "SPECIES", 170, 193], ["H5N1", "SPECIES", 219, 223], ["H5N1 virus", "PROBLEM", 9, 19], ["other avian influenza A viruses", "PROBLEM", 83, 114], ["Avian influenza A virus", "PROBLEM", 170, 193], ["H5N1", "PROBLEM", 219, 223], ["H5N1", "OBSERVATION", 9, 13]]], ["Patients who have H5N1 virus often develop severe pulmonary disease with rapid clinical deterioration, even previously healthy individuals.", [["pulmonary", "ANATOMY", 50, 59], ["pulmonary disease", "DISEASE", 50, 67], ["Patients", "ORGANISM", 0, 8], ["H5N1 virus", "ORGANISM", 18, 28], ["pulmonary", "ORGAN", 50, 59], ["Patients", "SPECIES", 0, 8], ["H5N1 virus", "SPECIES", 18, 28], ["H5N1 virus", "SPECIES", 18, 28], ["H5N1 virus", "PROBLEM", 18, 28], ["severe pulmonary disease", "PROBLEM", 43, 67], ["rapid clinical deterioration", "PROBLEM", 73, 101], ["H5N1", "OBSERVATION", 18, 22], ["severe", "OBSERVATION_MODIFIER", 43, 49], ["pulmonary", "ANATOMY", 50, 59], ["disease", "OBSERVATION", 60, 67], ["rapid", "OBSERVATION_MODIFIER", 73, 78]]], ["They often present with a fever and other symptoms typical of influenza, but manifestations often can extend beyond the lungs to other organ systems (eg, the gastrointestinal tract) [42], and recent pathologic evidence has suggested dissemination to other organs, including the brain [48].Avian influenza A virusLimited information is available on the effects of H5N1 virus infection specifically on women.", [["lungs", "ANATOMY", 120, 125], ["organ", "ANATOMY", 135, 140], ["gastrointestinal tract", "ANATOMY", 158, 180], ["organs", "ANATOMY", 256, 262], ["brain", "ANATOMY", 278, 283], ["fever", "DISEASE", 26, 31], ["influenza", "DISEASE", 62, 71], ["H5N1 virus infection", "DISEASE", 363, 383], ["lungs", "ORGAN", 120, 125], ["organ", "ORGAN", 135, 140], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 158, 180], ["organs", "ORGAN", 256, 262], ["brain", "ORGAN", 278, 283], ["Avian influenza A", "ORGANISM", 289, 306], ["H5N1 virus", "ORGANISM", 363, 373], ["women", "ORGANISM", 400, 405], ["Avian influenza", "SPECIES", 289, 304], ["H5N1 virus", "SPECIES", 363, 373], ["women", "SPECIES", 400, 405], ["H5N1 virus", "SPECIES", 363, 373], ["a fever", "PROBLEM", 24, 31], ["other symptoms", "PROBLEM", 36, 50], ["influenza", "PROBLEM", 62, 71], ["dissemination to other organs", "PROBLEM", 233, 262], ["H5N1 virus infection", "PROBLEM", 363, 383], ["influenza", "OBSERVATION", 62, 71], ["lungs", "ANATOMY", 120, 125], ["gastrointestinal tract", "ANATOMY", 158, 180], ["pathologic", "OBSERVATION", 199, 209], ["brain", "ANATOMY", 278, 283]]], ["A survey of cases reported by the WHO [49] showed a relatively even distribution between men and women, except in two age groups; men were affected more often in the 4- to 6-year-old age group, whereas girls were affected more often in the 25- to 30-year-age group.", [["men", "ORGANISM", 89, 92], ["women", "ORGANISM", 97, 102], ["men", "ORGANISM", 130, 133], ["men", "SPECIES", 89, 92], ["women", "SPECIES", 97, 102], ["men", "SPECIES", 130, 133], ["girls", "SPECIES", 202, 207]]], ["The investigators hypothesized that the increased risk for exposure in boys aged 4 to 6 was due to their being more active outdoors, whereas in women aged 25 to 30, the increased risk was due to their roles related to feeding, purchasing, or handling sick poultry in the affected countries.Avian influenza A virusInformation on the effects of H5N1 virus infection on pregnant women is limited, but there are several reasons for concern.", [["influenza A virusInformation", "DISEASE", 296, 324], ["H5N1 virus infection", "DISEASE", 343, 363], ["women", "ORGANISM", 144, 149], ["Avian influenza A virusInformation", "ORGANISM", 290, 324], ["H5N1 virus", "ORGANISM", 343, 353], ["women", "ORGANISM", 376, 381], ["boys", "SPECIES", 71, 75], ["women", "SPECIES", 144, 149], ["Avian influenza", "SPECIES", 290, 305], ["H5N1 virus", "SPECIES", 343, 353], ["women", "SPECIES", 376, 381], ["H5N1 virus", "SPECIES", 343, 353], ["the increased risk", "PROBLEM", 165, 183], ["Avian influenza", "PROBLEM", 290, 305], ["H5N1 virus infection", "PROBLEM", 343, 363], ["increased", "OBSERVATION_MODIFIER", 40, 49]]], ["Pregnant women are shown to be at increased risk for severe complications from seasonal influenza [50], [51], [52].", [["influenza", "DISEASE", 88, 97], ["women", "ORGANISM", 9, 14], ["women", "SPECIES", 9, 14], ["severe complications", "PROBLEM", 53, 73], ["seasonal influenza", "PROBLEM", 79, 97]]], ["Several reports also suggest that pregnant women were at high risk of severe illness and death during the pandemics of 1918 and 1957 [53], [54], [55].", [["illness", "DISEASE", 77, 84], ["death", "DISEASE", 89, 94], ["women", "ORGANISM", 43, 48], ["women", "SPECIES", 43, 48], ["severe illness", "PROBLEM", 70, 84], ["death", "PROBLEM", 89, 94], ["severe", "OBSERVATION_MODIFIER", 70, 76], ["illness", "OBSERVATION", 77, 84]]], ["The WHO recently noted that four of the six pregnant women infected with H5N1 virus have died [47], [56].", [["H5N1 virus", "DISEASE", 73, 83], ["women", "ORGANISM", 53, 58], ["H5N1 virus", "ORGANISM", 73, 83], ["women", "SPECIES", 53, 58], ["H5N1 virus", "SPECIES", 73, 83], ["H5N1 virus", "SPECIES", 73, 83], ["H5N1 virus", "PROBLEM", 73, 83]]], ["A detailed clinical report of one of these women documents rapid progression to multiorgan failure and death, despite intensive supportive care [57].Avian influenza A virusThe potential for effects of H5N1 virus infection on the fetus also needs to be considered.", [["multiorgan", "ANATOMY", 80, 90], ["fetus", "ANATOMY", 229, 234], ["multiorgan failure", "DISEASE", 80, 98], ["death", "DISEASE", 103, 108], ["influenza A virus", "DISEASE", 155, 172], ["H5N1 virus infection", "DISEASE", 201, 221], ["women", "ORGANISM", 43, 48], ["multiorgan", "ORGAN", 80, 90], ["Avian influenza A virus", "ORGANISM", 149, 172], ["H5N1 virus", "ORGANISM", 201, 211], ["fetus", "ORGAN", 229, 234], ["women", "SPECIES", 43, 48], ["Avian influenza A virus", "SPECIES", 149, 172], ["H5N1 virus", "SPECIES", 201, 211], ["Avian influenza A virus", "SPECIES", 149, 172], ["H5N1 virus", "SPECIES", 201, 211], ["multiorgan failure", "PROBLEM", 80, 98], ["death", "PROBLEM", 103, 108], ["intensive supportive care", "TREATMENT", 118, 143], ["Avian influenza A virus", "PROBLEM", 149, 172], ["H5N1 virus infection", "PROBLEM", 201, 221], ["multiorgan failure", "OBSERVATION", 80, 98], ["potential for", "UNCERTAINTY", 176, 189], ["H5N1", "OBSERVATION", 201, 205]]], ["An increased risk for some birth defects after seasonal influenza infection or its associated fever has been observed in some studies [58], [59].", [["birth defects", "DISEASE", 27, 40], ["influenza infection", "DISEASE", 56, 75], ["fever", "DISEASE", 94, 99], ["An increased risk", "PROBLEM", 0, 17], ["some birth defects", "PROBLEM", 22, 40], ["seasonal influenza infection", "PROBLEM", 47, 75], ["its associated fever", "PROBLEM", 79, 99], ["increased", "OBSERVATION_MODIFIER", 3, 12], ["defects", "OBSERVATION", 33, 40], ["seasonal", "OBSERVATION_MODIFIER", 47, 55], ["influenza", "OBSERVATION", 56, 65]]], ["High rates of spontaneous pregnancy loss and preterm birth were reported during the influenza pandemic of 1918 [54], [55], and possible increases in defects of the nervous system, spontaneous pregnancy loss, fetal death, and preterm delivery were reported after the pandemic of 1957 [60], [61].", [["nervous system", "ANATOMY", 164, 178], ["fetal", "ANATOMY", 208, 213], ["pregnancy loss", "DISEASE", 26, 40], ["preterm birth", "DISEASE", 45, 58], ["influenza", "DISEASE", 84, 93], ["defects of the nervous system", "DISEASE", 149, 178], ["pregnancy loss", "DISEASE", 192, 206], ["fetal death", "DISEASE", 208, 219], ["nervous system", "ANATOMICAL_SYSTEM", 164, 178], ["fetal", "ANATOMICAL_SYSTEM", 208, 213], ["spontaneous pregnancy loss", "PROBLEM", 14, 40], ["preterm birth", "PROBLEM", 45, 58], ["the influenza pandemic", "TEST", 80, 102], ["increases in defects of the nervous system", "PROBLEM", 136, 178], ["spontaneous pregnancy loss", "PROBLEM", 180, 206], ["fetal death", "PROBLEM", 208, 219], ["preterm delivery", "PROBLEM", 225, 241], ["spontaneous pregnancy loss", "OBSERVATION", 14, 40], ["possible", "UNCERTAINTY", 127, 135], ["increases", "OBSERVATION_MODIFIER", 136, 145], ["defects", "OBSERVATION", 149, 156], ["nervous system", "ANATOMY", 164, 178], ["pregnancy loss", "OBSERVATION", 192, 206]]], ["The effects of H5N1 virus on the fetus are unknown; however, in the two pregnant women who had H5N1 virus who survived, both had spontaneous abortions [47].", [["fetus", "ANATOMY", 33, 38], ["abortions", "DISEASE", 141, 150], ["H5N1 virus", "ORGANISM", 15, 25], ["fetus", "ORGAN", 33, 38], ["women", "ORGANISM", 81, 86], ["H5N1 virus", "ORGANISM", 95, 105], ["H5N1 virus", "SPECIES", 15, 25], ["women", "SPECIES", 81, 86], ["H5N1 virus", "SPECIES", 95, 105], ["H5N1 virus", "SPECIES", 15, 25], ["H5N1 virus", "SPECIES", 95, 105], ["H5N1 virus", "PROBLEM", 15, 25], ["H5N1 virus", "PROBLEM", 95, 105], ["spontaneous abortions", "PROBLEM", 129, 150], ["H5N1 virus", "OBSERVATION", 15, 25]]], ["In addition, transmission of H5N1 virus from mother to fetus recently has been documented in one case [48].", [["fetus", "ANATOMY", 55, 60], ["H5N1 virus", "DISEASE", 29, 39], ["H5N1 virus", "ORGANISM", 29, 39], ["fetus", "ORGAN", 55, 60], ["H5N1 virus", "SPECIES", 29, 39], ["H5N1 virus", "SPECIES", 29, 39], ["H5N1 virus", "PROBLEM", 29, 39]]], ["During infection with other influenza viruses, viremia and placental transmission seem to occur infrequently [62], [63], so the finding of vertical transmission of H5N1 virus infection might suggest a higher risk for adverse fetal effects with H5N1 virus compared with other influenza viruses [63].Severe acute respiratory syndrome coronavirusThe 2003 epidemic of SARS started in China and spread rapidly throughout the world, affecting more than 8000 people and claiming at least 750 lives.", [["placental", "ANATOMY", 59, 68], ["fetal", "ANATOMY", 225, 230], ["infection", "DISEASE", 7, 16], ["influenza viruses", "DISEASE", 28, 45], ["viremia", "DISEASE", 47, 54], ["placental transmission", "DISEASE", 59, 81], ["H5N1 virus infection", "DISEASE", 164, 184], ["influenza viruses", "DISEASE", 275, 292], ["acute respiratory syndrome coronavirus", "DISEASE", 305, 343], ["SARS", "DISEASE", 364, 368], ["placental", "ORGAN", 59, 68], ["H5N1 virus", "ORGANISM", 164, 174], ["fetal", "ANATOMICAL_SYSTEM", 225, 230], ["H5N1 virus", "ORGANISM", 244, 254], ["influenza viruses", "ORGANISM", 275, 292], ["people", "ORGANISM", 452, 458], ["H5N1 virus", "SPECIES", 164, 174], ["H5N1 virus", "SPECIES", 244, 254], ["people", "SPECIES", 452, 458], ["H5N1 virus", "SPECIES", 164, 174], ["H5N1 virus", "SPECIES", 244, 254], ["Severe acute respiratory syndrome coronavirus", "SPECIES", 298, 343], ["infection", "PROBLEM", 7, 16], ["other influenza viruses", "PROBLEM", 22, 45], ["viremia", "PROBLEM", 47, 54], ["placental transmission", "TEST", 59, 81], ["vertical transmission", "PROBLEM", 139, 160], ["H5N1 virus infection", "PROBLEM", 164, 184], ["adverse fetal effects", "PROBLEM", 217, 238], ["H5N1 virus", "PROBLEM", 244, 254], ["other influenza viruses", "PROBLEM", 269, 292], ["Severe acute respiratory syndrome coronavirus", "PROBLEM", 298, 343], ["SARS", "PROBLEM", 364, 368], ["infection", "OBSERVATION", 7, 16], ["influenza viruses", "OBSERVATION", 28, 45], ["H5N1", "OBSERVATION", 164, 168], ["acute", "OBSERVATION_MODIFIER", 305, 310], ["respiratory syndrome", "OBSERVATION", 311, 331]]], ["A novel coronavirus, SARS, was isolated from patients and identified as the causative agent in the epidemic.", [["SARS", "DISEASE", 21, 25], ["coronavirus", "ORGANISM", 8, 19], ["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["A novel coronavirus", "PROBLEM", 0, 19], ["SARS", "PROBLEM", 21, 25], ["coronavirus", "OBSERVATION", 8, 19]]], ["This virus is believed originally transmitted to humans from the palm civet, a feline found in food markets in China [64].", [["humans", "ORGANISM", 49, 55], ["palm", "ORGANISM_SUBDIVISION", 65, 69], ["feline", "ORGANISM", 79, 85], ["humans", "SPECIES", 49, 55], ["humans", "SPECIES", 49, 55], ["This virus", "PROBLEM", 0, 10]]], ["The epidemic in Hong Kong involved 1755 patients diagnosed with SARS, resulting in 302 deaths.", [["SARS", "DISEASE", 64, 68], ["deaths", "DISEASE", 87, 93], ["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["SARS", "PROBLEM", 64, 68], ["epidemic", "OBSERVATION_MODIFIER", 4, 12]]], ["In this cohort, the rates of ARDS and overall case mortality among women were significantly lower than those in men after adjustment for multiple variables, including age [65].", [["ARDS", "DISEASE", 29, 33], ["women", "ORGANISM", 67, 72], ["men", "ORGANISM", 112, 115], ["women", "SPECIES", 67, 72], ["men", "SPECIES", 112, 115], ["ARDS", "PROBLEM", 29, 33], ["ARDS", "OBSERVATION", 29, 33]]], ["The basis for the more benign course in female SARS patients is not known.Severe acute respiratory syndrome coronavirusTwelve pregnant women were known to be infected with SARS in Hong Kong, and most information regarding the course of SARS in pregnancy comes from this cohort.", [["SARS", "DISEASE", 47, 51], ["acute respiratory syndrome coronavirus", "DISEASE", 81, 119], ["SARS", "DISEASE", 172, 176], ["SARS", "DISEASE", 236, 240], ["patients", "ORGANISM", 52, 60], ["women", "ORGANISM", 135, 140], ["patients", "SPECIES", 52, 60], ["coronavirus", "SPECIES", 108, 119], ["women", "SPECIES", 135, 140], ["Severe acute respiratory syndrome coronavirus", "SPECIES", 74, 119], ["Severe acute respiratory syndrome coronavirus", "PROBLEM", 74, 119], ["SARS in pregnancy", "PROBLEM", 236, 253], ["benign", "OBSERVATION_MODIFIER", 23, 29], ["acute", "OBSERVATION_MODIFIER", 81, 86], ["respiratory syndrome", "OBSERVATION", 87, 107], ["coronavirus", "OBSERVATION", 108, 119]]], ["When compared with matched nonpregnant SARS patients, the pregnant women who were studied demonstrated more severe pulmonary disease and higher case fatality rates and were more likely to develop renal failure and disseminated intravascular coagulopathy [66].", [["pulmonary", "ANATOMY", 115, 124], ["renal", "ANATOMY", 196, 201], ["intravascular", "ANATOMY", 227, 240], ["SARS", "DISEASE", 39, 43], ["pulmonary disease", "DISEASE", 115, 132], ["renal failure", "DISEASE", 196, 209], ["intravascular coagulopathy", "DISEASE", 227, 253], ["patients", "ORGANISM", 44, 52], ["women", "ORGANISM", 67, 72], ["pulmonary", "ORGAN", 115, 124], ["renal", "ORGAN", 196, 201], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 227, 240], ["patients", "SPECIES", 44, 52], ["women", "SPECIES", 67, 72], ["more severe pulmonary disease", "PROBLEM", 103, 132], ["renal failure", "PROBLEM", 196, 209], ["disseminated intravascular coagulopathy", "PROBLEM", 214, 253], ["severe", "OBSERVATION_MODIFIER", 108, 114], ["pulmonary", "ANATOMY", 115, 124], ["disease", "OBSERVATION", 125, 132], ["renal", "ANATOMY", 196, 201], ["failure", "OBSERVATION", 202, 209], ["disseminated", "OBSERVATION_MODIFIER", 214, 226], ["intravascular coagulopathy", "OBSERVATION", 227, 253]]], ["Perinatal outcomes in these women were dismal, with four of seven early trimester patients spontaneously aborting and four of five whose pregnancy continued beyond 24 weeks gestation delivering preterm.", [["women", "ORGANISM", 28, 33], ["patients", "ORGANISM", 82, 90], ["women", "SPECIES", 28, 33], ["patients", "SPECIES", 82, 90]]], ["Two infants who were born to mothers who had acute illness showed intrauterine growth restriction but no evidence of vertical transmission.", [["acute illness", "DISEASE", 45, 58], ["intrauterine growth restriction", "DISEASE", 66, 97], ["infants", "ORGANISM", 4, 11], ["mothers", "ORGANISM", 29, 36], ["infants", "SPECIES", 4, 11], ["acute illness", "PROBLEM", 45, 58], ["intrauterine growth restriction", "PROBLEM", 66, 97], ["vertical transmission", "PROBLEM", 117, 138], ["growth restriction", "OBSERVATION", 79, 97], ["no evidence of", "UNCERTAINTY", 102, 116], ["vertical transmission", "OBSERVATION", 117, 138]]], ["Systematic evaluation failed to detect any evidence of neonatal or placental infection, even in babies born during acute maternal SARS infection with demonstrable viral shedding [67].", [["placental", "ANATOMY", 67, 76], ["placental infection", "DISEASE", 67, 86], ["SARS infection", "DISEASE", 130, 144], ["placental", "ORGAN", 67, 76], ["babies", "ORGANISM", 96, 102], ["Systematic evaluation", "TEST", 0, 21], ["neonatal or placental infection", "PROBLEM", 55, 86], ["acute maternal SARS infection", "PROBLEM", 115, 144], ["placental", "ANATOMY", 67, 76], ["infection", "OBSERVATION", 77, 86]]], ["Two women who had pregnancy-associated SARS in the United States and one in Canada recovered from their acute illness and went on to deliver healthy, uninfected neonates [68], [69], [70].", [["SARS", "DISEASE", 39, 43], ["acute illness", "DISEASE", 104, 117], ["women", "ORGANISM", 4, 9], ["neonates", "ORGANISM", 161, 169], ["women", "SPECIES", 4, 9], ["pregnancy", "PROBLEM", 18, 27], ["their acute illness", "PROBLEM", 98, 117]]], ["Eleven of the 12 pregnant patients in Hong Kong received intravenous ribavirin therapy versus none of the three North American patients, leaving the possibility that the difference in perinatal outcomes is related to the drug rather than the virus.", [["intravenous", "ANATOMY", 57, 68], ["ribavirin", "CHEMICAL", 69, 78], ["ribavirin", "CHEMICAL", 69, 78], ["patients", "ORGANISM", 26, 34], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 57, 68], ["ribavirin", "SIMPLE_CHEMICAL", 69, 78], ["patients", "ORGANISM", 127, 135], ["patients", "SPECIES", 26, 34], ["patients", "SPECIES", 127, 135], ["intravenous ribavirin therapy", "TREATMENT", 57, 86], ["the difference in perinatal outcomes", "PROBLEM", 166, 202], ["the virus", "PROBLEM", 238, 247]]], ["The differences in outcome noted for pregnant women (in a comparison with nonpregnant women), however, in the Hong Kong case-control study were independent of ribavirin, as it was used equally in the two groups [66].", [["ribavirin", "CHEMICAL", 159, 168], ["ribavirin", "CHEMICAL", 159, 168], ["women", "ORGANISM", 46, 51], ["women", "ORGANISM", 86, 91], ["ribavirin", "SIMPLE_CHEMICAL", 159, 168], ["women", "SPECIES", 46, 51], ["women", "SPECIES", 86, 91], ["ribavirin", "TREATMENT", 159, 168]]], ["Ribavirin is a known teratogen in animals, and toxicity has not been systematically evaluated in human pregnancy because of its category X status as designated by the Food and Drug Administration [22].SpirochetesLess commonly categorized as emerging infections, nonviral pathogens nonetheless are described as the source of newly discovered or newly expanding diseases.", [["Ribavirin", "CHEMICAL", 0, 9], ["toxicity", "DISEASE", 47, 55], ["infections", "DISEASE", 250, 260], ["Ribavirin", "CHEMICAL", 0, 9], ["Ribavirin", "SIMPLE_CHEMICAL", 0, 9], ["human", "ORGANISM", 97, 102], ["human", "SPECIES", 97, 102], ["human", "SPECIES", 97, 102], ["Ribavirin", "TREATMENT", 0, 9], ["a known teratogen in animals", "PROBLEM", 13, 41], ["toxicity", "PROBLEM", 47, 55], ["emerging infections", "PROBLEM", 241, 260], ["nonviral pathogens", "PROBLEM", 262, 280], ["newly expanding diseases", "PROBLEM", 344, 368], ["infections", "OBSERVATION", 250, 260], ["newly", "OBSERVATION_MODIFIER", 344, 349], ["expanding", "OBSERVATION_MODIFIER", 350, 359], ["diseases", "OBSERVATION", 360, 368]]], ["The spirochetes comprise a group of bacterial pathogens with a particular tendency for perinatal transmission; the best known of this group, Treponema pallidum, is the causative agent of syphilis.", [["Treponema pallidum", "DISEASE", 141, 159], ["syphilis", "DISEASE", 187, 195], ["Treponema pallidum", "ORGANISM", 141, 159], ["Treponema pallidum", "SPECIES", 141, 159], ["Treponema pallidum", "SPECIES", 141, 159], ["bacterial pathogens", "PROBLEM", 36, 55], ["perinatal transmission", "PROBLEM", 87, 109], ["Treponema pallidum", "PROBLEM", 141, 159], ["syphilis", "PROBLEM", 187, 195]]], ["The impact of syphilis on women historically has been substantial because of its sexual transmission and association with stillbirth and other adverse pregnancy outcomes.", [["syphilis", "DISEASE", 14, 22], ["stillbirth", "DISEASE", 122, 132], ["women", "ORGANISM", 26, 31], ["women", "SPECIES", 26, 31], ["syphilis", "PROBLEM", 14, 22], ["stillbirth and other adverse pregnancy outcomes", "PROBLEM", 122, 169], ["syphilis", "OBSERVATION", 14, 22], ["substantial", "OBSERVATION_MODIFIER", 54, 65]]], ["Since the advent of penicillin in the twentieth century, however, this disease largely has been brought under control.", [["penicillin", "CHEMICAL", 20, 30], ["penicillin", "CHEMICAL", 20, 30], ["penicillin", "SIMPLE_CHEMICAL", 20, 30], ["penicillin", "TREATMENT", 20, 30], ["this disease", "PROBLEM", 66, 78], ["disease", "OBSERVATION", 71, 78]]], ["Other spirochetal illnesses, however, still fall into the category of emerging infectious diseases.", [["infectious diseases", "DISEASE", 79, 98], ["Other spirochetal illnesses", "PROBLEM", 0, 27], ["emerging infectious diseases", "PROBLEM", 70, 98], ["spirochetal", "OBSERVATION_MODIFIER", 6, 17], ["illnesses", "OBSERVATION", 18, 27], ["infectious", "OBSERVATION", 79, 89]]], ["During the 1970s, Borrelia burgdorferi was identified as the cause of a chronic, relapsing febrile illness, named Lyme disease, after the Connecticut town where it was discovered.", [["Borrelia burgdorferi", "DISEASE", 18, 38], ["febrile illness", "DISEASE", 91, 106], ["Lyme disease", "DISEASE", 114, 126], ["Borrelia burgdorferi", "ORGANISM", 18, 38], ["Borrelia burgdorferi", "SPECIES", 18, 38], ["Borrelia burgdorferi", "SPECIES", 18, 38], ["Borrelia burgdorferi", "PROBLEM", 18, 38], ["a chronic, relapsing febrile illness", "PROBLEM", 70, 106], ["Lyme disease", "PROBLEM", 114, 126], ["chronic", "OBSERVATION_MODIFIER", 72, 79], ["relapsing", "OBSERVATION_MODIFIER", 81, 90], ["Lyme disease", "OBSERVATION", 114, 126]]], ["The Lyme spirochete was found to be disseminated through bites from species of deer tick found throughout North America.", [["Lyme spirochete", "DISEASE", 4, 19], ["spirochete", "ORGANISM", 9, 19], ["deer", "ORGANISM", 79, 83], ["The Lyme spirochete", "PROBLEM", 0, 19], ["deer tick", "PROBLEM", 79, 88], ["disseminated", "OBSERVATION", 36, 48], ["deer tick", "OBSERVATION", 79, 88]]], ["During the subsequent epidemiologic characterization of Lyme disease, it was shown to cause transplacental infection of the fetus and was associated with stillbirth [71], [72].", [["fetus", "ANATOMY", 124, 129], ["Lyme disease", "DISEASE", 56, 68], ["transplacental infection of the fetus", "DISEASE", 92, 129], ["stillbirth", "DISEASE", 154, 164], ["fetus", "ORGAN", 124, 129], ["Lyme disease", "PROBLEM", 56, 68], ["transplacental infection of the fetus", "PROBLEM", 92, 129], ["Lyme disease", "OBSERVATION", 56, 68], ["infection", "OBSERVATION", 107, 116], ["fetus", "ANATOMY", 124, 129]]], ["Multiple reports of congenital Lyme disease prompted large serosurveys of pregnant women; these studies also suggested a link with pregnancy wastage and congenital defects.", [["congenital Lyme disease", "DISEASE", 20, 43], ["pregnancy wastage", "DISEASE", 131, 148], ["congenital defects", "DISEASE", 153, 171], ["women", "ORGANISM", 83, 88], ["women", "SPECIES", 83, 88], ["congenital Lyme disease", "PROBLEM", 20, 43], ["these studies", "TEST", 90, 103], ["pregnancy wastage", "PROBLEM", 131, 148], ["congenital defects", "PROBLEM", 153, 171], ["congenital", "OBSERVATION_MODIFIER", 20, 30], ["Lyme disease", "OBSERVATION", 31, 43], ["large", "OBSERVATION_MODIFIER", 53, 58], ["congenital defects", "OBSERVATION", 153, 171]]], ["Subsequent systematic inquiries, however, have failed to show any significant relationship between Lyme serostatus and adverse pregnancy outcomes [73].", [["Lyme", "DISEASE", 99, 103], ["Lyme serostatus", "PROBLEM", 99, 114], ["adverse pregnancy outcomes", "PROBLEM", 119, 145]]], ["Thus, although B burgdorferi has been shown to cause fetal infection, the combination of low disease prevalence and poor sensitivity of diagnostic tests has left doubt as to the clinical significance of these findings.", [["fetal", "ANATOMY", 53, 58], ["B burgdorferi", "DISEASE", 15, 28], ["fetal infection", "DISEASE", 53, 68], ["B burgdorferi", "ORGANISM", 15, 28], ["fetal", "ANATOMICAL_SYSTEM", 53, 58], ["B burgdorferi", "SPECIES", 15, 28], ["B burgdorferi", "SPECIES", 15, 28], ["B burgdorferi", "PROBLEM", 15, 28], ["fetal infection", "PROBLEM", 53, 68], ["low disease prevalence", "PROBLEM", 89, 111], ["diagnostic tests", "TEST", 136, 152], ["infection", "OBSERVATION", 59, 68], ["low", "OBSERVATION_MODIFIER", 89, 92], ["disease", "OBSERVATION", 93, 100]]], ["Current recommendations suggest symptom-based antibiotic treatment of pregnant women who have suspected Lyme disease before serologic results are available.SpirochetesTick-borne relapsing fever (TBRF), endemic worldwide as a cause of severe intermittent febrile illness, is caused by multiple spirochete species of the Borrelia genus.", [["Lyme disease", "DISEASE", 104, 116], ["SpirochetesTick", "CHEMICAL", 156, 171], ["relapsing fever", "DISEASE", 178, 193], ["TBRF", "DISEASE", 195, 199], ["intermittent febrile illness", "DISEASE", 241, 269], ["women", "ORGANISM", 79, 84], ["Borrelia genus", "ORGANISM", 319, 333], ["women", "SPECIES", 79, 84], ["SpirochetesTick-borne relapsing fever (TBRF)", "SPECIES", 156, 200], ["symptom", "PROBLEM", 32, 39], ["based antibiotic treatment", "TREATMENT", 40, 66], ["Lyme disease", "PROBLEM", 104, 116], ["serologic results", "TEST", 124, 141], ["SpirochetesTick", "TEST", 156, 171], ["borne relapsing fever (TBRF)", "PROBLEM", 172, 200], ["severe intermittent febrile illness", "PROBLEM", 234, 269], ["multiple spirochete species of the Borrelia genus", "PROBLEM", 284, 333], ["severe", "OBSERVATION_MODIFIER", 234, 240], ["intermittent", "OBSERVATION_MODIFIER", 241, 253], ["febrile", "OBSERVATION_MODIFIER", 254, 261], ["illness", "OBSERVATION", 262, 269], ["multiple", "OBSERVATION_MODIFIER", 284, 292], ["spirochete species", "OBSERVATION", 293, 311], ["Borrelia genus", "ANATOMY", 319, 333]]], ["There is now believed a rodent reservoir of Borrelia infection, making TBRF another zoonotic disease [74].", [["Borrelia infection", "DISEASE", 44, 62], ["TBRF", "CHEMICAL", 71, 75], ["zoonotic disease", "DISEASE", 84, 100], ["Borrelia", "ORGANISM", 44, 52], ["Borrelia infection", "PROBLEM", 44, 62], ["TBRF another zoonotic disease", "PROBLEM", 71, 100], ["rodent", "OBSERVATION_MODIFIER", 24, 30], ["reservoir", "OBSERVATION_MODIFIER", 31, 40], ["Borrelia", "OBSERVATION_MODIFIER", 44, 52], ["infection", "OBSERVATION", 53, 62], ["zoonotic", "OBSERVATION_MODIFIER", 84, 92]]], ["The tick vector thrives in poor housing conditions, often causing outbreaks of TBRF in villages with tick-infested huts.", [["TBRF", "DISEASE", 79, 83], ["The tick vector", "TREATMENT", 0, 15], ["TBRF", "PROBLEM", 79, 83]]], ["That phenomenon makes epidemic TBRF more common in economically disadvantaged areas, such as sub-Saharan Africa, but recent cases also are reported in women throughout the western United States [75], [76].", [["TBRF", "DISEASE", 31, 35], ["women", "ORGANISM", 151, 156], ["women", "SPECIES", 151, 156], ["epidemic TBRF", "PROBLEM", 22, 35], ["epidemic", "OBSERVATION_MODIFIER", 22, 30], ["more common", "OBSERVATION_MODIFIER", 36, 47], ["economically", "OBSERVATION_MODIFIER", 51, 63], ["disadvantaged", "OBSERVATION", 64, 77]]], ["In endemic areas, the incidence of TBRF can be as great as 11 cases per 100 person-years\u2014the highest of any known bacterial pathogen in Africa\u2014making it a major public health concern [74].", [["TBRF", "DISEASE", 35, 39], ["TBRF", "CANCER", 35, 39], ["any known bacterial pathogen", "PROBLEM", 104, 132], ["endemic", "OBSERVATION_MODIFIER", 3, 10], ["areas", "OBSERVATION_MODIFIER", 11, 16], ["bacterial pathogen", "OBSERVATION", 114, 132]]], ["Borrelia infection has for years been known to cause severe disease in pregnant women, manifesting as stillbirth, preterm birth, neonatal death, and maternal death [77], [78].", [["Borrelia infection", "DISEASE", 0, 18], ["stillbirth", "DISEASE", 102, 112], ["preterm birth", "DISEASE", 114, 127], ["neonatal death", "DISEASE", 129, 143], ["death", "DISEASE", 158, 163], ["Borrelia", "ORGANISM", 0, 8], ["women", "ORGANISM", 80, 85], ["women", "SPECIES", 80, 85], ["Borrelia infection", "PROBLEM", 0, 18], ["severe disease in pregnant women", "PROBLEM", 53, 85], ["neonatal death", "PROBLEM", 129, 143], ["maternal death", "PROBLEM", 149, 163], ["infection", "OBSERVATION", 9, 18], ["severe", "OBSERVATION_MODIFIER", 53, 59], ["disease", "OBSERVATION", 60, 67]]], ["Adverse pregnancy outcomes occur in as many as 50% of patients, and the prevalence of TBRF among pregnant hospitalized patients at a hospital in southern Zaire was estimated at 6% [79].", [["TBRF", "DISEASE", 86, 90], ["patients", "ORGANISM", 54, 62], ["patients", "ORGANISM", 119, 127], ["patients", "SPECIES", 54, 62], ["patients", "SPECIES", 119, 127], ["Adverse pregnancy outcomes", "PROBLEM", 0, 26]]], ["Diagnosis can be made on clinical grounds in areas of high prevalence, but demonstration of spirochetemia on peripheral blood smear is the diagnostic criterion of choice.", [["peripheral blood", "ANATOMY", 109, 125], ["spirochetemia", "DISEASE", 92, 105], ["spirochetemia", "CANCER", 92, 105], ["peripheral blood", "ORGANISM_SUBSTANCE", 109, 125], ["spirochetemia", "PROBLEM", 92, 105], ["peripheral blood smear", "TEST", 109, 131], ["high prevalence", "OBSERVATION_MODIFIER", 54, 69]]], ["Treatment is with penicillin, doxycycline (contraindicated in the pregnant woman), or erythromycin.", [["penicillin", "CHEMICAL", 18, 28], ["doxycycline", "CHEMICAL", 30, 41], ["erythromycin", "CHEMICAL", 86, 98], ["penicillin", "CHEMICAL", 18, 28], ["doxycycline", "CHEMICAL", 30, 41], ["erythromycin", "CHEMICAL", 86, 98], ["penicillin", "SIMPLE_CHEMICAL", 18, 28], ["doxycycline", "SIMPLE_CHEMICAL", 30, 41], ["woman", "ORGANISM", 75, 80], ["erythromycin", "SIMPLE_CHEMICAL", 86, 98], ["woman", "SPECIES", 75, 80], ["penicillin", "TREATMENT", 18, 28], ["doxycycline", "TREATMENT", 30, 41], ["erythromycin", "TREATMENT", 86, 98]]], ["Especially during spirochetemia, treatment can be associated with Jarisch-Herxheimer reactions; thus, intensive monitoring is recommended [75].", [["spirochetemia", "DISEASE", 18, 31], ["treatment", "TREATMENT", 33, 42], ["Herxheimer reactions", "PROBLEM", 74, 94], ["intensive monitoring", "TEST", 102, 122]]], ["It is not clear that antibiotic therapy improves short-term maternal or fetal outcomes [78].SpirochetesAnother zoonotic spirochetal illness, leptospirosis, has been strongly associated with spontaneous abortion.", [["fetal", "ANATOMY", 72, 77], ["zoonotic spirochetal illness", "DISEASE", 111, 139], ["leptospirosis", "DISEASE", 141, 154], ["fetal", "ANATOMICAL_SYSTEM", 72, 77], ["antibiotic therapy", "TREATMENT", 21, 39], ["Another zoonotic spirochetal illness", "PROBLEM", 103, 139], ["leptospirosis", "PROBLEM", 141, 154], ["spontaneous abortion", "PROBLEM", 190, 210], ["not", "UNCERTAINTY", 6, 9], ["clear", "OBSERVATION_MODIFIER", 10, 15], ["zoonotic", "OBSERVATION_MODIFIER", 111, 119], ["leptospirosis", "OBSERVATION", 141, 154]]], ["Leptospirosa species generally are transmitted through ingestion of water contaminated with infected animal urine or feces, and transmission may be associated with farm animals during outbreaks.", [["urine", "ANATOMY", 108, 113], ["feces", "ANATOMY", 117, 122], ["infected animal urine or feces", "DISEASE", 92, 122], ["Leptospirosa species", "ORGANISM", 0, 20], ["urine", "ORGANISM_SUBSTANCE", 108, 113], ["feces", "ORGANISM_SUBSTANCE", 117, 122], ["Leptospirosa species", "PROBLEM", 0, 20], ["infected animal urine or feces", "PROBLEM", 92, 122], ["feces", "OBSERVATION", 117, 122], ["may be associated", "UNCERTAINTY", 141, 158]]], ["Infection results in jaundice, malaise, fever, and myalgias but usually is self-limiting.", [["Infection", "DISEASE", 0, 9], ["jaundice", "DISEASE", 21, 29], ["fever", "DISEASE", 40, 45], ["myalgias", "DISEASE", 51, 59], ["Infection", "PROBLEM", 0, 9], ["jaundice", "PROBLEM", 21, 29], ["malaise", "PROBLEM", 31, 38], ["fever", "PROBLEM", 40, 45], ["myalgias", "PROBLEM", 51, 59], ["jaundice", "OBSERVATION", 21, 29], ["malaise", "OBSERVATION", 31, 38], ["myalgias", "OBSERVATION", 51, 59]]], ["The organism is endemic to Latin America; however, it is found sporadically worldwide.", [["The organism", "PROBLEM", 0, 12], ["endemic", "OBSERVATION_MODIFIER", 16, 23]]], ["As early as the 1960s, leptospires were observed in aborted fetal tissues from infected women, and the infection was believed to cause pregnancy wastage [80].", [["fetal tissues", "ANATOMY", 60, 73], ["infection", "DISEASE", 103, 112], ["fetal tissues", "TISSUE", 60, 73], ["women", "ORGANISM", 88, 93], ["women", "SPECIES", 88, 93], ["leptospires", "PROBLEM", 23, 34], ["aborted fetal tissues", "PROBLEM", 52, 73], ["the infection", "PROBLEM", 99, 112], ["pregnancy wastage", "PROBLEM", 135, 152], ["fetal tissues", "ANATOMY", 60, 73], ["infected", "OBSERVATION_MODIFIER", 79, 87], ["infection", "OBSERVATION", 103, 112]]], ["Multiple case reports have confirmed this association, but large studies have not been performed to further characterize the phenomenon.", [["large studies", "TEST", 59, 72]]], ["From case reports, it seems that first- and second-trimester maternal infection is associated more strongly with poor pregnancy outcome (50% or greater loss rate) than third-trimester infection [81].", [["infection", "DISEASE", 70, 79], ["infection", "DISEASE", 184, 193], ["second-trimester maternal infection", "PROBLEM", 44, 79], ["poor pregnancy outcome", "PROBLEM", 113, 135], ["greater loss rate)", "PROBLEM", 144, 162], ["third-trimester infection", "PROBLEM", 168, 193], ["infection", "OBSERVATION", 70, 79]]], ["Congenital transmission to live-born infants has been documented after third-trimester maternal infection [81].", [["infection", "DISEASE", 96, 105], ["infants", "ORGANISM", 37, 44], ["infants", "SPECIES", 37, 44], ["Congenital transmission", "PROBLEM", 0, 23], ["third-trimester maternal infection", "PROBLEM", 71, 105], ["infection", "OBSERVATION", 96, 105]]], ["It is not known whether or not early treatment of maternal leptospirosis can prevent spontaneous abortion, but antimicrobial therapy is recommended to decrease the duration and severity of the illness.Chagas' diseaseChagas' disease, endemic to South America, Central America, and Mexico, recently has become a concern in the United States because of the large immigrant population [82].", [["leptospirosis", "DISEASE", 59, 72], ["Chagas' diseaseChagas' disease", "DISEASE", 201, 231], ["maternal leptospirosis", "PROBLEM", 50, 72], ["spontaneous abortion", "PROBLEM", 85, 105], ["antimicrobial therapy", "TREATMENT", 111, 132], ["the illness", "PROBLEM", 189, 200], ["Chagas' diseaseChagas' disease", "PROBLEM", 201, 231], ["not known", "UNCERTAINTY", 6, 15], ["illness", "OBSERVATION", 193, 200], ["Central", "ANATOMY_MODIFIER", 259, 266], ["large", "OBSERVATION_MODIFIER", 354, 359]]], ["The disease is caused by infection with Trypanosoma cruzi, a blood-borne protozoan parasite transmitted most commonly to humans from vertebrate intermediates via the reduviid bug vector.", [["blood", "ANATOMY", 61, 66], ["infection", "DISEASE", 25, 34], ["Trypanosoma cruzi", "DISEASE", 40, 57], ["protozoan parasite", "DISEASE", 73, 91], ["Trypanosoma cruzi", "ORGANISM", 40, 57], ["blood", "ORGANISM_SUBSTANCE", 61, 66], ["humans", "ORGANISM", 121, 127], ["Trypanosoma cruzi", "SPECIES", 40, 57], ["humans", "SPECIES", 121, 127], ["Trypanosoma cruzi", "SPECIES", 40, 57], ["humans", "SPECIES", 121, 127], ["The disease", "PROBLEM", 0, 11], ["infection", "PROBLEM", 25, 34], ["Trypanosoma cruzi", "PROBLEM", 40, 57], ["a blood-borne protozoan parasite", "PROBLEM", 59, 91], ["the reduviid bug vector", "TREATMENT", 162, 185], ["disease", "OBSERVATION", 4, 11], ["caused by", "UNCERTAINTY", 15, 24], ["infection", "OBSERVATION", 25, 34], ["Trypanosoma cruzi", "OBSERVATION", 40, 57]]], ["The vector is found throughout the endemic areas, and infected insects also have been identified across the southern United States [82].", [["The vector", "TREATMENT", 0, 10], ["vector", "ANATOMY", 4, 10], ["endemic", "OBSERVATION_MODIFIER", 35, 42], ["areas", "OBSERVATION_MODIFIER", 43, 48], ["infected", "OBSERVATION", 54, 62]]], ["Asymptomatic, seropositive women can transmit the parasite transplacentally, with a congenital transmission rate of 1% to 10% [83].", [["women", "ORGANISM", 27, 32], ["women", "SPECIES", 27, 32], ["Asymptomatic", "PROBLEM", 0, 12], ["a congenital transmission rate", "TEST", 82, 112], ["seropositive", "OBSERVATION", 14, 26], ["congenital", "OBSERVATION", 84, 94]]], ["Clinical manifestations in the infected neonate range from asymptomatic infection in the majority to hepatosplenomegaly, hydrops, and neonatal death in some cases.", [["infection", "DISEASE", 72, 81], ["hepatosplenomegaly", "DISEASE", 101, 119], ["hydrops", "DISEASE", 121, 128], ["neonatal death", "DISEASE", 134, 148], ["neonate", "ORGANISM", 40, 47], ["Clinical manifestations", "PROBLEM", 0, 23], ["the infected neonate range", "PROBLEM", 27, 53], ["asymptomatic infection", "PROBLEM", 59, 81], ["hepatosplenomegaly", "PROBLEM", 101, 119], ["hydrops", "PROBLEM", 121, 128], ["neonatal death", "PROBLEM", 134, 148], ["infected", "OBSERVATION_MODIFIER", 31, 39], ["neonate range", "OBSERVATION_MODIFIER", 40, 53], ["asymptomatic", "OBSERVATION_MODIFIER", 59, 71], ["infection", "OBSERVATION", 72, 81], ["hepatosplenomegaly", "OBSERVATION", 101, 119], ["hydrops", "OBSERVATION", 121, 128]]], ["In recent years, cases of adult Chagas' disease increasingly have been diagnosed in the United States, even appearing in recipients of transplants from an infected donor [84].", [["Chagas' disease", "DISEASE", 32, 47], ["recipients", "ORGANISM", 121, 131], ["adult Chagas' disease", "PROBLEM", 26, 47], ["transplants", "TREATMENT", 135, 146], ["infected", "OBSERVATION", 155, 163]]], ["Concern now exists regarding the safety of the United States blood supply, as newly approved screening tests yielded more than 300 positive results in selected donors in 2007 [84], [85], [86].", [["blood", "ANATOMY", 61, 66], ["blood", "ORGANISM_SUBSTANCE", 61, 66], ["donors", "ORGANISM", 160, 166], ["newly approved screening tests", "TEST", 78, 108]]], ["One recent study found a 0.3% seroprevalence among the asymptomatic maternal population in Houston, Texas, suggesting that many cases of congenital Chagas' disease are undiagnosed each year in the United States [87].", [["congenital", "DISEASE", 137, 147], ["Chagas' disease", "DISEASE", 148, 163], ["One recent study", "TEST", 0, 16], ["congenital Chagas' disease", "PROBLEM", 137, 163], ["congenital", "OBSERVATION_MODIFIER", 137, 147], ["Chagas", "OBSERVATION", 148, 154]]], ["Neonatal cure rates as high as 90% are achieved when appropriate antimicrobial therapy is initiated during the first year of life, so early diagnosis is imperative [88].", [["Neonatal cure rates", "TEST", 0, 19], ["appropriate antimicrobial therapy", "TREATMENT", 53, 86]]], ["Maternal implications of chronic infection also must be considered, as T cruzi chronically infects the myocardium and can lead to cardiomyopathy, a particularly dangerous condition in pregnancy.", [["myocardium", "ANATOMY", 103, 113], ["chronic infection", "DISEASE", 25, 42], ["cardiomyopathy", "DISEASE", 130, 144], ["T cruzi", "ORGANISM", 71, 78], ["myocardium", "ORGAN", 103, 113], ["T cruzi", "SPECIES", 71, 78], ["T cruzi", "SPECIES", 71, 78], ["chronic infection", "PROBLEM", 25, 42], ["T cruzi chronically infects the myocardium", "PROBLEM", 71, 113], ["cardiomyopathy", "PROBLEM", 130, 144], ["a particularly dangerous condition in pregnancy", "PROBLEM", 146, 193], ["chronic", "OBSERVATION_MODIFIER", 25, 32], ["infection", "OBSERVATION", 33, 42], ["myocardium", "ANATOMY", 103, 113]]], ["Cardiomyopathy or cardiac conduction defects of unknown etiology in a pregnant woman from an endemic area should prompt testing for T cruzi antibodies, followed by testing and, if necessary, treatment of the neonate with benznidazole or nifurtimox [88].", [["cardiac", "ANATOMY", 18, 25], ["Cardiomyopathy", "DISEASE", 0, 14], ["cardiac conduction defects", "DISEASE", 18, 44], ["benznidazole", "CHEMICAL", 221, 233], ["nifurtimox", "CHEMICAL", 237, 247], ["benznidazole", "CHEMICAL", 221, 233], ["nifurtimox", "CHEMICAL", 237, 247], ["cardiac", "ORGAN", 18, 25], ["woman", "ORGANISM", 79, 84], ["T cruzi", "GENE_OR_GENE_PRODUCT", 132, 139], ["benznidazole", "SIMPLE_CHEMICAL", 221, 233], ["nifurtimox", "SIMPLE_CHEMICAL", 237, 247], ["T cruzi antibodies", "PROTEIN", 132, 150], ["woman", "SPECIES", 79, 84], ["T cruzi", "SPECIES", 132, 139], ["T cruzi", "SPECIES", 132, 139], ["Cardiomyopathy", "PROBLEM", 0, 14], ["cardiac conduction defects", "PROBLEM", 18, 44], ["an endemic area", "PROBLEM", 90, 105], ["prompt testing", "TEST", 113, 127], ["T cruzi antibodies", "TEST", 132, 150], ["testing", "TEST", 164, 171], ["benznidazole", "TREATMENT", 221, 233], ["nifurtimox", "TREATMENT", 237, 247], ["cardiac", "ANATOMY", 18, 25], ["conduction defects", "OBSERVATION", 26, 44]]], ["In the United States, benznidazole and nifurtimox are not approved by the Food and Drug Administration but can be obtained under investigational new drug protocols through the CDC Drug Service (telephone number: 404-639-3670) [88], [89].BioterrorismMost potential biologic weapons agents also are emerging or zoonotic diseases that can be found regularly under natural conditions.", [["benznidazole", "CHEMICAL", 22, 34], ["nifurtimox", "CHEMICAL", 39, 49], ["zoonotic diseases", "DISEASE", 309, 326], ["benznidazole", "CHEMICAL", 22, 34], ["nifurtimox", "CHEMICAL", 39, 49], ["benznidazole", "SIMPLE_CHEMICAL", 22, 34], ["nifurtimox", "SIMPLE_CHEMICAL", 39, 49], ["benznidazole", "TREATMENT", 22, 34], ["nifurtimox", "TREATMENT", 39, 49], ["Drug Administration", "TREATMENT", 83, 102], ["BioterrorismMost potential biologic weapons agents", "TREATMENT", 237, 287], ["zoonotic diseases", "PROBLEM", 309, 326]]], ["The CDC has compiled a list of select agents [90] whose propagation and possession are regulated by federal law based on their lethality and potential for use as biologic weapons [91].", [["select agents", "TREATMENT", 31, 44]]], ["Possession, use, and transfer of select agents and toxins that pose a severe threat to public health and safety are regulated by federal law to protect the public and laboratory workers.", [["select agents", "TREATMENT", 33, 46], ["toxins", "TREATMENT", 51, 57]]], ["Many zoonotic diseases appear on the overlapping select agent list, meaning they are regulated by the CDC, under the Department of Health and Human Services or the Department of Agriculture, based on human or agricultural risk, respectively.", [["zoonotic diseases", "DISEASE", 5, 22], ["Human", "ORGANISM", 142, 147], ["human", "ORGANISM", 200, 205], ["Human", "SPECIES", 142, 147], ["human", "SPECIES", 200, 205], ["human", "SPECIES", 200, 205], ["Many zoonotic diseases", "PROBLEM", 0, 22], ["zoonotic", "OBSERVATION_MODIFIER", 5, 13], ["diseases", "OBSERVATION", 14, 22]]], ["The agents that cause VHFs and 1918 pandemic influenza virus are included, along with many bacterial pathogens that offer better environmental stability for weaponization.", [["VHFs", "DISEASE", 22, 26], ["influenza virus", "DISEASE", 45, 60], ["influenza virus", "ORGANISM", 45, 60], ["pandemic influenza virus", "SPECIES", 36, 60], ["1918 pandemic influenza virus", "SPECIES", 31, 60], ["The agents", "TREATMENT", 0, 10], ["VHFs", "PROBLEM", 22, 26], ["1918 pandemic influenza virus", "PROBLEM", 31, 60], ["many bacterial pathogens", "PROBLEM", 86, 110], ["weaponization", "TREATMENT", 157, 170]]], ["The ideal weapons agents offer a low infectious dose, high case fatality rate, environmental stability, and efficient human-to-human transmission, allowing a small inoculum to infect a large population.BioterrorismSmallpox has been widely discussed as a biologic weapons agent, having been actually weaponized by the former Soviet Union.", [["BioterrorismSmallpox", "CHEMICAL", 202, 222], ["human", "ORGANISM", 118, 123], ["human", "ORGANISM", 127, 132], ["human", "SPECIES", 118, 123], ["human", "SPECIES", 127, 132], ["human", "SPECIES", 118, 123], ["human", "SPECIES", 127, 132], ["a low infectious dose", "TREATMENT", 31, 52], ["a small inoculum", "PROBLEM", 156, 172], ["a large population", "PROBLEM", 183, 201], ["BioterrorismSmallpox", "TREATMENT", 202, 222], ["stability", "OBSERVATION_MODIFIER", 93, 102], ["small inoculum", "OBSERVATION_MODIFIER", 158, 172], ["large", "OBSERVATION_MODIFIER", 185, 190], ["population", "OBSERVATION", 191, 201]]], ["After the worldwide eradication of smallpox in 1950, the need to vaccinate the population was deemed outweighed by the adverse effects of the vaccine.", [["smallpox", "DISEASE", 35, 43], ["smallpox", "TREATMENT", 35, 43], ["the vaccine", "TREATMENT", 138, 149]]], ["Thus, since the 1970s, people no longer are routinely immunized against smallpox.", [["smallpox", "DISEASE", 72, 80], ["people", "ORGANISM", 23, 29], ["people", "SPECIES", 23, 29], ["smallpox", "PROBLEM", 72, 80]]], ["After the 2001 anthrax attacks in the United States, the military once again started vaccinating its personnel with the live attenuated vaccinia virus vaccine (a closely related virus), which provides 95% protection against smallpox infection for at least 5 years.", [["anthrax attacks", "DISEASE", 15, 30], ["smallpox infection", "DISEASE", 224, 242], ["vaccinia virus", "ORGANISM", 136, 150], ["vaccinia virus vaccine", "SPECIES", 136, 158], ["vaccinia virus", "SPECIES", 136, 150], ["smallpox", "SPECIES", 224, 232], ["the live attenuated vaccinia virus vaccine", "TREATMENT", 116, 158], ["smallpox infection", "PROBLEM", 224, 242]]], ["Adverse effects include myocarditis, pericarditis, and occasional dilated cardiomyopathy [92].", [["myocarditis", "DISEASE", 24, 35], ["pericarditis", "DISEASE", 37, 49], ["dilated cardiomyopathy", "DISEASE", 66, 88], ["Adverse effects", "PROBLEM", 0, 15], ["myocarditis", "PROBLEM", 24, 35], ["pericarditis", "PROBLEM", 37, 49], ["occasional dilated cardiomyopathy", "PROBLEM", 55, 88], ["myocarditis", "OBSERVATION", 24, 35], ["pericarditis", "OBSERVATION", 37, 49], ["occasional", "OBSERVATION_MODIFIER", 55, 65], ["dilated", "OBSERVATION_MODIFIER", 66, 73], ["cardiomyopathy", "OBSERVATION", 74, 88]]], ["Because this is a live attenuated vaccine, its routine prophylactic use is contraindicated in pregnancy.", [["a live attenuated vaccine", "TREATMENT", 16, 41], ["its routine prophylactic use", "TREATMENT", 43, 71]]], ["Rarely, the vaccination of pregnant women causes fetal vaccinia infection, which can cause pregnancy loss or neonatal death.", [["fetal", "ANATOMY", 49, 54], ["fetal vaccinia infection", "DISEASE", 49, 73], ["pregnancy loss", "DISEASE", 91, 105], ["neonatal death", "DISEASE", 109, 123], ["women", "ORGANISM", 36, 41], ["fetal vaccinia", "ORGANISM", 49, 63], ["women", "SPECIES", 36, 41], ["vaccinia", "SPECIES", 55, 63], ["fetal vaccinia infection", "PROBLEM", 49, 73], ["pregnancy loss", "PROBLEM", 91, 105], ["neonatal death", "PROBLEM", 109, 123], ["vaccinia infection", "OBSERVATION", 55, 73]]], ["During times of known exposure or outbreak, however, the vaccine should be administered to all exposed persons because the risk for smallpox in pregnancy far outweighs that for fetal vaccinia [93].", [["fetal", "ANATOMY", 177, 182], ["smallpox", "DISEASE", 132, 140], ["persons", "ORGANISM", 103, 110], ["fetal vaccinia", "ORGANISM", 177, 191], ["persons", "SPECIES", 103, 110], ["outbreak", "PROBLEM", 34, 42], ["the vaccine", "TREATMENT", 53, 64], ["smallpox in pregnancy", "PROBLEM", 132, 153], ["fetal vaccinia", "PROBLEM", 177, 191]]], ["From limited historical data it is clear that smallpox infection in pregnancy results in case fatality rates as high as 50% and at least a 50% rate of pregnancy loss regardless of gestational age [94].", [["infection", "DISEASE", 55, 64], ["pregnancy loss", "DISEASE", 151, 165], ["smallpox infection", "PROBLEM", 46, 64], ["fatality rates", "TEST", 94, 108], ["pregnancy loss", "PROBLEM", 151, 165], ["smallpox", "OBSERVATION_MODIFIER", 46, 54], ["infection", "OBSERVATION", 55, 64]]], ["Pregnant women also are significantly more likely to develop a fatal form of smallpox, known as hemorrhagic smallpox, than their nonpregnant counterparts [93].", [["smallpox", "DISEASE", 77, 85], ["hemorrhagic smallpox", "DISEASE", 96, 116], ["women", "ORGANISM", 9, 14], ["women", "SPECIES", 9, 14], ["smallpox", "PROBLEM", 77, 85], ["hemorrhagic smallpox", "PROBLEM", 96, 116], ["hemorrhagic", "OBSERVATION_MODIFIER", 96, 107], ["smallpox", "OBSERVATION", 108, 116]]], ["Given the severity of disease, when planning for a possible smallpox attack, authorities must prioritize early vaccination strategies for pregnant women.BioterrorismAnother biologic warfare agent of concern, C burnetii, poses a disproportionate threat to women.", [["women", "ORGANISM", 147, 152], ["C burnetii", "ORGANISM", 208, 218], ["women", "ORGANISM", 255, 260], ["women", "SPECIES", 147, 152], ["C burnetii", "SPECIES", 208, 218], ["women", "SPECIES", 255, 260], ["C burnetii", "SPECIES", 208, 218], ["disease", "PROBLEM", 22, 29], ["smallpox attack", "PROBLEM", 60, 75], ["early vaccination strategies", "TREATMENT", 105, 133], ["C burnetii", "PROBLEM", 208, 218], ["disease", "OBSERVATION", 22, 29]]], ["C burnetii is the causative agent of Q fever, a zoonotic disease generally acquired by handling or inhaling contaminated material from infected cattle or sheep [95].", [["Q fever", "DISEASE", 37, 44], ["zoonotic disease", "DISEASE", 48, 64], ["C burnetii", "ORGANISM", 0, 10], ["cattle", "ORGANISM", 144, 150], ["sheep", "ORGANISM", 154, 159], ["C burnetii", "SPECIES", 0, 10], ["cattle", "SPECIES", 144, 150], ["sheep", "SPECIES", 154, 159], ["C burnetii", "SPECIES", 0, 10], ["cattle", "SPECIES", 144, 150], ["sheep", "SPECIES", 154, 159], ["C burnetii", "PROBLEM", 0, 10], ["Q fever", "PROBLEM", 37, 44], ["a zoonotic disease", "PROBLEM", 46, 64], ["burnetii", "OBSERVATION", 2, 10], ["zoonotic", "OBSERVATION_MODIFIER", 48, 56], ["disease", "OBSERVATION", 57, 64]]], ["The economic impact of endemic Q fever results from recurrent abortion in animal herds, with large numbers of bacteria demonstrable in the products of conception.", [["Q fever", "DISEASE", 31, 38], ["endemic Q fever", "PROBLEM", 23, 38], ["recurrent abortion in animal herds", "PROBLEM", 52, 86], ["large numbers of bacteria", "PROBLEM", 93, 118], ["endemic", "OBSERVATION_MODIFIER", 23, 30], ["large", "OBSERVATION_MODIFIER", 93, 98], ["numbers", "OBSERVATION_MODIFIER", 99, 106], ["bacteria", "OBSERVATION", 110, 118]]], ["Contact with infected sheep placenta historically has been the greatest risk factor for acute Q fever in humans [95].", [["placenta", "ANATOMY", 28, 36], ["acute Q fever", "DISEASE", 88, 101], ["sheep", "ORGANISM", 22, 27], ["placenta", "ORGAN", 28, 36], ["humans", "ORGANISM", 105, 111], ["sheep", "SPECIES", 22, 27], ["humans", "SPECIES", 105, 111], ["sheep", "SPECIES", 22, 27], ["humans", "SPECIES", 105, 111], ["acute Q fever in humans", "PROBLEM", 88, 111], ["infected", "OBSERVATION", 13, 21]]], ["Q fever is attractive as a bioterror agent because the bacterium forms environmentally stable spores with a low inhalational infectious dose [96].", [["spores", "ANATOMY", 94, 100], ["fever", "DISEASE", 2, 7], ["fever", "PROBLEM", 2, 7], ["a bioterror agent", "TREATMENT", 25, 42], ["the bacterium forms environmentally stable spores", "PROBLEM", 51, 100], ["a low inhalational infectious dose", "TREATMENT", 106, 140], ["fever", "OBSERVATION", 2, 7]]], ["The disease generally is not fatal but causes pneumonia with weeks of disability during the acute phase and can cause chronic infection associated with treatment-resistant bacterial endocarditis.", [["pneumonia", "DISEASE", 46, 55], ["disability", "DISEASE", 70, 80], ["infection", "DISEASE", 126, 135], ["bacterial endocarditis", "DISEASE", 172, 194], ["The disease", "PROBLEM", 0, 11], ["pneumonia", "PROBLEM", 46, 55], ["disability", "PROBLEM", 70, 80], ["chronic infection", "PROBLEM", 118, 135], ["treatment", "TREATMENT", 152, 161], ["resistant bacterial endocarditis", "PROBLEM", 162, 194], ["disease", "OBSERVATION", 4, 11], ["pneumonia", "OBSERVATION", 46, 55], ["chronic", "OBSERVATION_MODIFIER", 118, 125], ["infection", "OBSERVATION", 126, 135], ["resistant", "OBSERVATION_MODIFIER", 162, 171], ["bacterial", "OBSERVATION_MODIFIER", 172, 181], ["endocarditis", "OBSERVATION", 182, 194]]], ["Human-to-human transmission of Q fever is rare.", [["Q fever", "DISEASE", 31, 38], ["Human", "ORGANISM", 0, 5], ["human", "ORGANISM", 9, 14], ["Human", "SPECIES", 0, 5], ["human", "SPECIES", 9, 14], ["human", "SPECIES", 9, 14], ["Q fever", "PROBLEM", 31, 38]]], ["After zoonotic acquisition, male-to-female sexual transmission of C burnetii has been documented, with bacterial DNA found in semen months after the acute infection [97].", [["semen", "ANATOMY", 126, 131], ["acute infection", "DISEASE", 149, 164], ["C burnetii", "ORGANISM", 66, 76], ["DNA", "CELLULAR_COMPONENT", 113, 116], ["semen", "ORGANISM_SUBSTANCE", 126, 131], ["C burnetii", "SPECIES", 66, 76], ["C burnetii", "SPECIES", 66, 76], ["C burnetii", "PROBLEM", 66, 76], ["bacterial DNA", "PROBLEM", 103, 116], ["the acute infection", "PROBLEM", 145, 164], ["acute", "OBSERVATION_MODIFIER", 149, 154], ["infection", "OBSERVATION", 155, 164]]], ["Infection of the female genital tract can be chronic but it rarely has been associated with fetal infection and pregnancy loss in humans [98].", [["genital tract", "ANATOMY", 24, 37], ["fetal", "ANATOMY", 92, 97], ["Infection of the female genital tract", "DISEASE", 0, 37], ["fetal infection", "DISEASE", 92, 107], ["pregnancy loss", "DISEASE", 112, 126], ["female", "ORGAN", 17, 23], ["genital tract", "ORGAN", 24, 37], ["fetal", "ORGANISM_SUBDIVISION", 92, 97], ["humans", "ORGANISM", 130, 136], ["humans", "SPECIES", 130, 136], ["humans", "SPECIES", 130, 136], ["Infection of the female genital tract", "PROBLEM", 0, 37], ["fetal infection", "PROBLEM", 92, 107], ["pregnancy loss in humans", "PROBLEM", 112, 136], ["genital tract", "ANATOMY", 24, 37], ["chronic", "OBSERVATION_MODIFIER", 45, 52], ["associated with", "UNCERTAINTY", 76, 91], ["fetal", "OBSERVATION_MODIFIER", 92, 97], ["infection", "OBSERVATION", 98, 107]]], ["C burnetii\u2013infected women are less likely than infected men to manifest the symptoms of acute Q fever, and pregnancy reduces the rates even more [99].", [["acute Q fever", "DISEASE", 88, 101], ["women", "ORGANISM", 20, 25], ["men", "ORGANISM", 56, 59], ["women", "SPECIES", 20, 25], ["men", "SPECIES", 56, 59], ["C burnetii\u2013infected women", "PROBLEM", 0, 25], ["the symptoms", "PROBLEM", 72, 84], ["acute Q fever", "PROBLEM", 88, 101], ["pregnancy", "PROBLEM", 107, 116], ["the rates", "TEST", 125, 134], ["less likely", "UNCERTAINTY", 30, 41], ["acute", "OBSERVATION_MODIFIER", 88, 93]]], ["Pregnant women, however, are more likely to develop chronic Q fever with endocarditis than are infected nonpregnant women [99].", [["chronic Q fever", "DISEASE", 52, 67], ["endocarditis", "DISEASE", 73, 85], ["women", "ORGANISM", 9, 14], ["women", "ORGANISM", 116, 121], ["women", "SPECIES", 9, 14], ["women", "SPECIES", 116, 121], ["chronic Q fever", "PROBLEM", 52, 67], ["endocarditis", "PROBLEM", 73, 85], ["chronic", "OBSERVATION_MODIFIER", 52, 59], ["fever", "OBSERVATION", 62, 67], ["endocarditis", "OBSERVATION", 73, 85]]], ["Chronic infection is believed to result from a diminished cell-mediated immune response to the intracellular bacteria, helping to explain the predisposition to chronic rather than acute disease during pregnancy [4], [96].", [["cell", "ANATOMY", 58, 62], ["intracellular", "ANATOMY", 95, 108], ["Chronic infection", "DISEASE", 0, 17], ["cell", "CELL", 58, 62], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 95, 108], ["Chronic infection", "PROBLEM", 0, 17], ["a diminished cell-mediated immune response", "PROBLEM", 45, 87], ["the intracellular bacteria", "PROBLEM", 91, 117], ["acute disease during pregnancy", "PROBLEM", 180, 210], ["infection", "OBSERVATION", 8, 17], ["diminished", "OBSERVATION_MODIFIER", 47, 57], ["cell", "OBSERVATION", 58, 62], ["chronic", "OBSERVATION_MODIFIER", 160, 167], ["acute", "OBSERVATION_MODIFIER", 180, 185], ["disease", "OBSERVATION", 186, 193]]], ["Although no prospective data are available, it has been recommended that pregnant women and immunosuppressed people receive prophylactic antibiotic therapy in the case of a bioterror attack [96].", [["women", "ORGANISM", 82, 87], ["people", "ORGANISM", 109, 115], ["women", "SPECIES", 82, 87], ["people", "SPECIES", 109, 115], ["prospective data", "TEST", 12, 28], ["immunosuppressed people", "TREATMENT", 92, 115], ["prophylactic antibiotic therapy", "TREATMENT", 124, 155], ["a bioterror attack", "PROBLEM", 171, 189]]], ["Trimethoprim-sulfamethoxazole is recommended as first-line prophylaxis and treatment of Q fever in pregnancy, but chronic infection may require long-term treatment with doxycycline and rifampin after delivery [96].", [["Trimethoprim-sulfamethoxazole", "CHEMICAL", 0, 29], ["fever", "DISEASE", 90, 95], ["chronic infection", "DISEASE", 114, 131], ["doxycycline", "CHEMICAL", 169, 180], ["rifampin", "CHEMICAL", 185, 193], ["Trimethoprim-sulfamethoxazole", "CHEMICAL", 0, 29], ["doxycycline", "CHEMICAL", 169, 180], ["rifampin", "CHEMICAL", 185, 193], ["Trimethoprim-sulfamethoxazole", "SIMPLE_CHEMICAL", 0, 29], ["doxycycline", "SIMPLE_CHEMICAL", 169, 180], ["rifampin", "SIMPLE_CHEMICAL", 185, 193], ["Trimethoprim", "TREATMENT", 0, 12], ["sulfamethoxazole", "TREATMENT", 13, 29], ["first-line prophylaxis", "TREATMENT", 48, 70], ["treatment", "TREATMENT", 75, 84], ["Q fever in pregnancy", "PROBLEM", 88, 108], ["chronic infection", "PROBLEM", 114, 131], ["long-term treatment", "TREATMENT", 144, 163], ["doxycycline", "TREATMENT", 169, 180], ["rifampin", "TREATMENT", 185, 193], ["delivery", "TREATMENT", 200, 208], ["chronic", "OBSERVATION_MODIFIER", 114, 121], ["infection", "OBSERVATION", 122, 131], ["long-term", "OBSERVATION_MODIFIER", 144, 153]]], ["No vaccine for Q fever is available in the United States.BioterrorismOther high-profile biologic weapons agents include tularemia, plague, and anthrax.", [["Q fever", "DISEASE", 15, 22], ["tularemia", "DISEASE", 120, 129], ["plague", "DISEASE", 131, 137], ["anthrax", "DISEASE", 143, 150], ["vaccine", "TREATMENT", 3, 10], ["Q fever", "PROBLEM", 15, 22], ["BioterrorismOther", "TREATMENT", 57, 74], ["tularemia", "PROBLEM", 120, 129], ["plague", "PROBLEM", 131, 137], ["anthrax", "PROBLEM", 143, 150], ["tularemia", "OBSERVATION", 120, 129]]], ["Treatment of pregnant women in the event of an attack with these agents recently has been reviewed [100], and the clinical manifestations in pregnancy generally do not differ from those in the general population.", [["women", "ORGANISM", 22, 27], ["women", "SPECIES", 22, 27], ["these agents", "TREATMENT", 59, 71]]], ["Several principles guide the treatment of pregnant women in the event of a biologic weapons attack.", [["women", "ORGANISM", 51, 56], ["women", "SPECIES", 51, 56], ["the treatment of pregnant women", "TREATMENT", 25, 56]]], ["Second, live attenuated vaccines are to be avoided except in the case of smallpox exposure.", [["smallpox", "DISEASE", 73, 81], ["live attenuated vaccines", "TREATMENT", 8, 32], ["smallpox exposure", "PROBLEM", 73, 90]]], ["Finally, quinolones, tetracyclines, and ribavirin are associated with fetal toxicity and alternative drugs should be used when available.", [["fetal", "ANATOMY", 70, 75], ["quinolones", "CHEMICAL", 9, 19], ["tetracyclines", "CHEMICAL", 21, 34], ["ribavirin", "CHEMICAL", 40, 49], ["fetal toxicity", "DISEASE", 70, 84], ["quinolones", "CHEMICAL", 9, 19], ["tetracyclines", "CHEMICAL", 21, 34], ["ribavirin", "CHEMICAL", 40, 49], ["quinolones", "SIMPLE_CHEMICAL", 9, 19], ["tetracyclines", "SIMPLE_CHEMICAL", 21, 34], ["ribavirin", "SIMPLE_CHEMICAL", 40, 49], ["fetal", "ANATOMICAL_SYSTEM", 70, 75], ["quinolones", "TREATMENT", 9, 19], ["tetracyclines", "TREATMENT", 21, 34], ["ribavirin", "TREATMENT", 40, 49], ["fetal toxicity", "PROBLEM", 70, 84], ["alternative drugs", "TREATMENT", 89, 106]]], ["In the case of maternal exposure to life-threatening infectious agents, however, prophylaxis or treatment with these drugs may be indicated [100].SummaryAs recently recognized by the American Medical Association and the American Veterinary Medical Association, the majority of emerging threats to humans are zoonotic infections [2].", [["zoonotic infections", "DISEASE", 308, 327], ["humans", "ORGANISM", 297, 303], ["humans", "SPECIES", 297, 303], ["humans", "SPECIES", 297, 303], ["life-threatening infectious agents", "TREATMENT", 36, 70], ["prophylaxis", "TREATMENT", 81, 92], ["treatment", "TREATMENT", 96, 105], ["these drugs", "TREATMENT", 111, 122], ["zoonotic infections", "PROBLEM", 308, 327]]], ["Others pose no danger for reservoir animals but when transmitted to humans they cause devastating disease.", [["humans", "ORGANISM", 68, 74], ["humans", "SPECIES", 68, 74], ["humans", "SPECIES", 68, 74], ["reservoir animals", "TREATMENT", 26, 43], ["devastating disease", "PROBLEM", 86, 105], ["no", "UNCERTAINTY", 12, 14], ["devastating", "OBSERVATION_MODIFIER", 86, 97], ["disease", "OBSERVATION", 98, 105]]], ["Because animals serve as the main natural reservoirs for emerging infections, the organisms can be maintained in nature for long periods in-between human outbreaks.", [["infections", "DISEASE", 66, 76], ["human", "ORGANISM", 148, 153], ["human", "SPECIES", 148, 153], ["human", "SPECIES", 148, 153], ["emerging infections", "PROBLEM", 57, 76], ["the organisms", "PROBLEM", 78, 91], ["infections", "OBSERVATION", 66, 76]]], ["Thus, when outbreaks occur, they confront health care workers with clusters of severe disease they likely have never before encountered and may have difficulty diagnosing.", [["severe disease", "PROBLEM", 79, 93], ["severe", "OBSERVATION_MODIFIER", 79, 85], ["disease", "OBSERVATION", 86, 93]]], ["In the case of a bioterrorist attack, the mass casualties could be abrupt and catastrophic.", [["a bioterrorist attack", "PROBLEM", 15, 36], ["the mass casualties", "PROBLEM", 38, 57], ["catastrophic", "PROBLEM", 78, 90], ["mass", "OBSERVATION", 42, 46], ["abrupt", "OBSERVATION_MODIFIER", 67, 73], ["catastrophic", "OBSERVATION_MODIFIER", 78, 90]]], ["Physicians must recognize the atypical manifestations of emerging infectious threats in female patients and accord special emphasis to the unique immunologic state of pregnancy as it relates to fetal and maternal risk.", [["fetal", "ANATOMY", 194, 199], ["patients", "ORGANISM", 95, 103], ["fetal", "DEVELOPING_ANATOMICAL_STRUCTURE", 194, 199], ["patients", "SPECIES", 95, 103], ["fetal and maternal risk", "PROBLEM", 194, 217], ["infectious", "OBSERVATION", 66, 76]]], ["When outbreaks occur, systematic and prospective collection of data, including patient gender, pregnancy status, and complications, must accompany epidemiologic characterization of disease [101].", [["patient", "ORGANISM", 79, 86], ["patient", "SPECIES", 79, 86], ["prospective collection of data", "TEST", 37, 67], ["pregnancy status", "PROBLEM", 95, 111], ["complications", "PROBLEM", 117, 130], ["disease", "PROBLEM", 181, 188]]]], "d5278c7bb04a653544473a3a38c2272b334537ac": [["2020a), which has to date killed around 150,000 people.", [["people", "ORGANISM", 48, 54], ["people", "SPECIES", 48, 54]]], ["The Middle East region has previously experienced one type of coronavirus in 2012, called Middle East respiratory syndrome (MERS) or MERS coronavirus (MERS-Cov) .", [["coronavirus", "DISEASE", 62, 73], ["Middle East respiratory syndrome (MERS) or MERS coronavirus", "DISEASE", 90, 149], ["coronavirus", "ORGANISM", 62, 73], ["MERS coronavirus", "ORGANISM", 133, 149], ["Middle East respiratory syndrome (MERS) or MERS coronavirus", "SPECIES", 90, 149], ["coronavirus", "PROBLEM", 62, 73], ["Middle East respiratory syndrome", "PROBLEM", 90, 122], ["MERS coronavirus", "PROBLEM", 133, 149], ["Middle", "ANATOMY_MODIFIER", 4, 10], ["coronavirus", "OBSERVATION", 62, 73], ["Middle", "ANATOMY_MODIFIER", 90, 96], ["respiratory syndrome", "OBSERVATION", 102, 122]]], ["From 2012 to 2020, 23 cases were reported from Qatar as diseases transmitted from animals to humans (WHO 2020b).", [["humans", "ORGANISM", 93, 99], ["humans", "SPECIES", 93, 99], ["humans", "SPECIES", 93, 99], ["diseases", "OBSERVATION", 56, 64]]], ["Nevertheless, MERS-Cov was not considered a pandemic because of the low rates of reported cases.", [["a pandemic", "PROBLEM", 42, 52]]], ["A new member of this large family of coronaviruses is the novel coronavirus called COVID-19, which has not previously been identified in humans.", [["coronaviruses", "ORGANISM", 37, 50], ["coronavirus", "ORGANISM", 64, 75], ["COVID-19", "CELL", 83, 91], ["humans", "ORGANISM", 137, 143], ["coronavirus", "SPECIES", 64, 75], ["humans", "SPECIES", 137, 143], ["humans", "SPECIES", 137, 143], ["coronaviruses", "PROBLEM", 37, 50], ["new", "OBSERVATION_MODIFIER", 2, 5]]]], "c4acc1b7e388efa08d475e703513fd380fae271a": [["IntroductionDisease severity during viral infections is a function of direct virus-induced cytopathology and of the non-specific inflammatory and antigen-specific immune responses of the host.", [["viral infections", "DISEASE", 36, 52], ["IntroductionDisease severity", "PROBLEM", 0, 28], ["viral infections", "PROBLEM", 36, 52], ["direct virus", "PROBLEM", 70, 82], ["the non-specific inflammatory and antigen", "PROBLEM", 112, 153], ["viral infections", "OBSERVATION", 36, 52], ["non-specific", "OBSERVATION_MODIFIER", 116, 128], ["inflammatory", "OBSERVATION_MODIFIER", 129, 141]]], ["An immune host encountering a virus for a second time usually resists any disease associated with re-infection, as the expanded pools of virus-specific memory B and T cells effectively restrict the replication of the pathogen.", [["memory B", "ANATOMY", 152, 160], ["T cells", "ANATOMY", 165, 172], ["memory B", "CELL", 152, 160], ["T cells", "CELL", 165, 172], ["memory B and T cells", "CELL_TYPE", 152, 172], ["a virus", "PROBLEM", 28, 35], ["any disease", "PROBLEM", 70, 81], ["re-infection", "PROBLEM", 98, 110], ["the expanded pools of virus", "PROBLEM", 115, 142], ["T cells", "PROBLEM", 165, 172], ["the pathogen", "PROBLEM", 213, 225], ["re-infection", "OBSERVATION", 98, 110]]], ["Individuals exposed to a virus for the first time, however, can vary dramatically in their symptoms and viral load.", [["a virus", "PROBLEM", 23, 30], ["their symptoms", "PROBLEM", 85, 99], ["viral load", "PROBLEM", 104, 114], ["viral load", "OBSERVATION", 104, 114]]], ["This variation is sometimes attributed to the initial viral dose or to the genetics or physiological state of the host, but we suggest here that another major factor lead-ing to this variation is the contribution of the pools of memory cells specific to previously encountered and sometimes completely unrelated pathogens.IntroductionIt has been recognized for some time that B cell responses generated by prior viral infections will influence both the production of virus-specific antibodies and the replication of virus during future infections with antigenically related but not identical viruses through phenomena such as 'original antigenic sin' (Francis, 1953; Fazekas de St and Webster, 1966) and antibody-dependent immune enhancement (Tirado and Yoon, 2003) .", [["memory cells", "ANATOMY", 229, 241], ["B cell", "ANATOMY", 376, 382], ["viral infections", "DISEASE", 412, 428], ["infections", "DISEASE", 536, 546], ["memory cells", "CELL", 229, 241], ["B cell", "CELL", 376, 382], ["memory cells", "CELL_TYPE", 229, 241], ["virus-specific antibodies", "PROTEIN", 467, 492], ["memory cells", "PROBLEM", 229, 241], ["completely unrelated pathogens", "PROBLEM", 291, 321], ["B cell responses", "PROBLEM", 376, 392], ["prior viral infections", "PROBLEM", 406, 428], ["virus", "PROBLEM", 467, 472], ["specific antibodies", "PROBLEM", 473, 492], ["virus", "PROBLEM", 516, 521], ["future infections", "PROBLEM", 529, 546], ["identical viruses through phenomena", "PROBLEM", 582, 617], ["antibody", "TEST", 704, 712], ["viruses", "OBSERVATION", 592, 599], ["immune enhancement", "OBSERVATION", 723, 741]]], ["Because of the profound involvement of CD8 T cells in viral immunity and immunopathology and of their propensity for crossreactivity against a diverse array of epitopes, we have explored and documented their potential for being even more effective than cross-reactive antibody in altering the pathogenesis of virus infections in sequence.", [["CD8 T cells", "ANATOMY", 39, 50], ["infections", "DISEASE", 315, 325], ["CD8 T cells", "CELL", 39, 50], ["CD8 T cells", "CELL_TYPE", 39, 50], ["epitopes", "PROTEIN", 160, 168], ["cross-reactive antibody", "PROTEIN", 253, 276], ["CD8 T cells", "PROBLEM", 39, 50], ["immunopathology", "PROBLEM", 73, 88], ["crossreactivity", "PROBLEM", 117, 132], ["epitopes", "PROBLEM", 160, 168], ["cross-reactive antibody", "PROBLEM", 253, 276], ["virus infections in sequence", "PROBLEM", 309, 337], ["profound", "OBSERVATION_MODIFIER", 15, 23], ["CD8 T cells", "OBSERVATION", 39, 50], ["viral immunity", "OBSERVATION", 54, 68], ["virus infections", "OBSERVATION", 309, 325]]], ["Here we will describe the properties of CD8 T cells and examine their modulation and function under conditions of infections with heterologous viral pathogens in sequence (Fig. 1) .Degeneracy in antigen recognition and cross-reactivityCD8 T cells recognize short, 8-11 amino acid residue peptide epitopes presented in the context of self-MHC class I molecules (Townsend et al ., 1986) .", [["CD8 T cells", "ANATOMY", 40, 51], ["T cells", "ANATOMY", 239, 246], ["infections", "DISEASE", 114, 124], ["amino acid", "CHEMICAL", 269, 279], ["amino acid", "CHEMICAL", 269, 279], ["CD8 T cells", "CELL", 40, 51], ["antigen", "GENE_OR_GENE_PRODUCT", 195, 202], ["T cells", "CELL", 239, 246], ["amino acid", "AMINO_ACID", 269, 279], ["CD8 T cells", "CELL_TYPE", 40, 51], ["T cells", "CELL_TYPE", 239, 246], ["MHC class I molecules", "PROTEIN", 338, 359], ["CD8 T cells", "PROBLEM", 40, 51], ["infections", "PROBLEM", 114, 124], ["heterologous viral pathogens", "PROBLEM", 130, 158], ["T cells", "TEST", 239, 246], ["amino acid residue peptide epitopes", "PROBLEM", 269, 304]]], ["The recognition of this peptide/MHC complex is mediated by the T cell receptor (TCR), which is a heterodimeric structure comprised of an a and b chain (Davis et al ., 1998) .", [["T cell", "ANATOMY", 63, 69], ["T cell receptor", "GENE_OR_GENE_PRODUCT", 63, 78], ["TCR", "GENE_OR_GENE_PRODUCT", 80, 83], ["MHC complex", "PROTEIN", 32, 43], ["T cell receptor", "PROTEIN", 63, 78], ["TCR", "PROTEIN", 80, 83], ["heterodimeric structure", "PROTEIN", 97, 120], ["this peptide/MHC complex", "TREATMENT", 19, 43], ["a heterodimeric structure", "PROBLEM", 95, 120], ["heterodimeric structure", "OBSERVATION", 97, 120], ["chain", "OBSERVATION_MODIFIER", 145, 150]]], ["Within each chain of the TCR are three variable sites, known as complementarity determining regions (CDRs) (van der Merwe and Davis, 2003) , which protrude as loops from the TCR and directly contact sites on the peptide and the MHC molecule (Stewart-Jones et al ., 2003) .Degeneracy in antigen recognition and cross-reactivityTheoretical considerations have suggested that the number of peptide-MHC complexes that could be generated by environmental antigens exceeds the number of mature T cells within an individual (Regner, 2001) .", [["T cells", "ANATOMY", 488, 495], ["TCR", "CHEMICAL", 174, 177], ["TCR", "GENE_OR_GENE_PRODUCT", 25, 28], ["TCR", "GENE_OR_GENE_PRODUCT", 174, 177], ["antigen", "GENE_OR_GENE_PRODUCT", 286, 293], ["T cells", "CELL", 488, 495], ["TCR", "PROTEIN", 25, 28], ["complementarity determining regions", "PROTEIN", 64, 99], ["CDRs", "DNA", 101, 105], ["TCR", "PROTEIN", 174, 177], ["MHC molecule", "PROTEIN", 228, 240], ["MHC complexes", "PROTEIN", 395, 408], ["environmental antigens", "PROTEIN", 436, 458], ["mature T cells", "CELL_TYPE", 481, 495], ["three variable sites", "PROBLEM", 33, 53], ["peptide-MHC complexes", "PROBLEM", 387, 408], ["chain", "OBSERVATION_MODIFIER", 12, 17], ["TCR", "OBSERVATION", 25, 28], ["variable", "OBSERVATION_MODIFIER", 39, 47], ["loops", "ANATOMY_MODIFIER", 159, 164], ["mature", "OBSERVATION_MODIFIER", 481, 487], ["T cells", "OBSERVATION", 488, 495]]], ["Thus, the breadth of the T cell repertoire would not be sufficient unless T cells had the capacity to recognize more than one antigen.", [["T cell", "ANATOMY", 25, 31], ["T cells", "ANATOMY", 74, 81], ["T cell", "CELL", 25, 31], ["T cells", "CELL", 74, 81], ["T cells", "CELL_TYPE", 74, 81], ["the T cell repertoire", "TREATMENT", 21, 42], ["T cells", "PROBLEM", 74, 81], ["the capacity", "PROBLEM", 86, 98]]], ["Otherwise, non-immunogenic pathogens would easily evolve to escape detection by T cells.", [["T cells", "ANATOMY", 80, 87], ["T cells", "CELL", 80, 87], ["T cells", "CELL_TYPE", 80, 87], ["non-immunogenic pathogens", "PROBLEM", 11, 36]]], ["T cells are, however, cross-reactive against numerous epitopes, and a mathematical modelling analysis predicted that a single TCR may be able to interact with over one million different peptides (Mason, 1998) .", [["T cells", "ANATOMY", 0, 7], ["TCR", "CHEMICAL", 126, 129], ["T cells", "CELL", 0, 7], ["TCR", "GENE_OR_GENE_PRODUCT", 126, 129], ["T cells", "CELL_TYPE", 0, 7], ["epitopes", "PROTEIN", 54, 62], ["TCR", "PROTEIN", 126, 129], ["numerous epitopes", "PROBLEM", 45, 62], ["a mathematical modelling analysis", "TEST", 68, 101]]], ["The CDR3 loops of the TCR undergo significant conformational changes in order to accommodate the 3-dimensional structure of the peptide-MHC surface (Garcia et al ., 1998; Reiser et al ., 2002; Wu et al ., 2002; Kjer-Nielsen et al ., 2003) .", [["TCR", "CHEMICAL", 22, 25], ["TCR", "GENE_OR_GENE_PRODUCT", 22, 25], ["CDR3 loops", "PROTEIN", 4, 14], ["TCR", "PROTEIN", 22, 25], ["MHC", "PROTEIN", 136, 139], ["significant conformational changes", "PROBLEM", 34, 68], ["significant", "OBSERVATION_MODIFIER", 34, 45], ["conformational", "OBSERVATION", 46, 60]]], ["This flexibility imparted to the TCR may allow a single TCR to be promiscuous in the recognition of peptides and thereby be inherently cross-reactive.", [["TCR", "CHEMICAL", 33, 36], ["TCR", "GENE_OR_GENE_PRODUCT", 33, 36], ["TCR", "GENE_OR_GENE_PRODUCT", 56, 59], ["TCR", "PROTEIN", 33, 36], ["TCR", "PROTEIN", 56, 59], ["cross-reactive", "OBSERVATION", 135, 149]]], ["This cross-reactive nature of T cells may allow memory CD8 T cells generated by prior viral infections to play roles in subsequent infections with unrelated viruses.Degeneracy in antigen recognition and cross-reactivityCross-reactivity between virus-specific CD8 T cells has been identified in a variety of different forms in both human and murine models.", [["T cells", "ANATOMY", 30, 37], ["memory CD8 T cells", "ANATOMY", 48, 66], ["CD8 T cells", "ANATOMY", 259, 270], ["viral infections", "DISEASE", 86, 102], ["infections", "DISEASE", 131, 141], ["T cells", "CELL", 30, 37], ["memory CD8 T cells", "CELL", 48, 66], ["antigen", "GENE_OR_GENE_PRODUCT", 179, 186], ["CD8 T cells", "CELL", 259, 270], ["human", "ORGANISM", 331, 336], ["murine", "ORGANISM", 341, 347], ["T cells", "CELL_TYPE", 30, 37], ["memory CD8 T cells", "CELL_TYPE", 48, 66], ["CD8 T cells", "CELL_TYPE", 259, 270], ["human", "SPECIES", 331, 336], ["murine", "SPECIES", 341, 347], ["human", "SPECIES", 331, 336], ["T cells", "PROBLEM", 30, 37], ["prior viral infections", "PROBLEM", 80, 102], ["subsequent infections", "PROBLEM", 120, 141], ["unrelated viruses", "PROBLEM", 147, 164], ["Cross-reactivity", "TEST", 219, 235], ["virus", "TEST", 244, 249], ["viral infections", "OBSERVATION", 86, 102], ["infections", "OBSERVATION", 131, 141], ["viruses", "OBSERVATION", 157, 164], ["CD8 T cells", "OBSERVATION", 259, 270], ["variety", "OBSERVATION_MODIFIER", 296, 303], ["both human", "ANATOMY_MODIFIER", 326, 336], ["murine models", "OBSERVATION", 341, 354]]], ["An expected form of crossreactivity would be against evolutionarily conserved sequences between very closely related viruses, where epitopes would either be identical or differ only slightly.Degeneracy in antigen recognition and cross-reactivitySuch cross-reactivity has been observed in T cell responses between influenza virus A subtypes (Haanen et al ., 1999; Belz et al ., 2001) , members of the Old World arenavirus family , the four serotypes of dengue virus (Spaulding et al ., 1999; Mongkolsapaya et al ., 2003) , very closely related hantaviruses (including Hantaan and Seoul) (Van Epps et al ., 1999) , and serotypes of vesicular stomatitis virus (VSV-Indiana and New Jersey) (Puddington et al ., 1986; Yewdell et al ., 1986) .", [["T cell", "ANATOMY", 288, 294], ["dengue virus", "DISEASE", 452, 464], ["hantaviruses", "DISEASE", 543, 555], ["vesicular stomatitis", "DISEASE", 630, 650], ["antigen", "GENE_OR_GENE_PRODUCT", 205, 212], ["T cell", "CELL", 288, 294], ["influenza virus A", "ORGANISM", 313, 330], ["Old World arenavirus", "ORGANISM", 400, 420], ["dengue virus", "ORGANISM", 452, 464], ["hantaviruses", "ORGANISM", 543, 555], ["Hantaan", "ORGANISM", 567, 574], ["vesicular stomatitis virus", "ORGANISM", 630, 656], ["VSV", "ORGANISM", 658, 661], ["epitopes", "PROTEIN", 132, 140], ["influenza virus", "SPECIES", 313, 328], ["dengue virus", "SPECIES", 452, 464], ["vesicular stomatitis virus", "SPECIES", 630, 656], ["Old World arenavirus", "SPECIES", 400, 420], ["dengue virus", "SPECIES", 452, 464], ["vesicular stomatitis virus", "SPECIES", 630, 656], ["VSV", "SPECIES", 658, 661], ["very closely related viruses", "PROBLEM", 96, 124], ["dengue virus", "PROBLEM", 452, 464], ["vesicular stomatitis virus", "PROBLEM", 630, 656], ["viruses", "OBSERVATION", 117, 124], ["hantaviruses", "OBSERVATION", 543, 555], ["vesicular stomatitis", "ANATOMY", 630, 650]]], ["While mapping immunodominant epitopes cross-reactivity was occasionally found between two different and nonhomologous sequences on the same protein or between different proteins derived from the same virus.", [["mapping immunodominant epitopes cross-reactivity", "TEST", 6, 54], ["different proteins", "PROBLEM", 159, 177], ["the same virus", "PROBLEM", 191, 205], ["immunodominant", "OBSERVATION_MODIFIER", 14, 28], ["epitopes cross-reactivity", "OBSERVATION", 29, 54]]], ["Such cross-reactivity has been reported for T cells specific for peptides derived from influenza virus (Kuwano et al ., 1991; Anderson et al ., 1992; Haanen et al ., 1999) , poly- Response of both non-cross-reactive and cross-reactive virus-specific memory CD8 T cells to heterologous virus infections.", [["T cells", "ANATOMY", 44, 51], ["memory CD8 T cells", "ANATOMY", 250, 268], ["influenza virus", "DISEASE", 87, 102], ["infections", "DISEASE", 291, 301], ["T cells", "CELL", 44, 51], ["influenza virus", "ORGANISM", 87, 102], ["CD8 T cells", "CELL", 257, 268], ["heterologous virus", "ORGANISM", 272, 290], ["T cells", "CELL_TYPE", 44, 51], ["non-cross-reactive and cross-reactive virus-specific memory CD8 T cells", "CELL_TYPE", 197, 268], ["influenza virus", "SPECIES", 87, 102], ["T cells", "PROBLEM", 44, 51], ["peptides", "PROBLEM", 65, 73], ["influenza virus", "PROBLEM", 87, 102], ["poly", "TEST", 174, 178], ["cross-reactive virus", "PROBLEM", 220, 240], ["heterologous virus infections", "PROBLEM", 272, 301], ["reactive", "OBSERVATION_MODIFIER", 207, 215], ["cross-reactive virus", "OBSERVATION", 220, 240]]], ["This figure depicts the events occurring after a secondary infection of a virus-immune mouse with a heterologous but cross-reactive virus such as PV.", [["infection", "DISEASE", 59, 68], ["mouse", "ORGANISM", 87, 92], ["mouse", "SPECIES", 87, 92], ["mouse", "SPECIES", 87, 92], ["PV", "SPECIES", 146, 148], ["a secondary infection", "PROBLEM", 47, 68], ["a virus", "PROBLEM", 72, 79], ["immune mouse", "PROBLEM", 80, 92], ["a heterologous", "PROBLEM", 98, 112], ["cross-reactive virus", "PROBLEM", 117, 137], ["secondary", "OBSERVATION_MODIFIER", 49, 58], ["infection", "OBSERVATION", 59, 68], ["cross-reactive virus", "OBSERVATION", 117, 137]]], ["Shown on the figure is the stability of memory CD8 T cells before re-challenge, the virus-induced lymphopenia, the peak of type 1 IFN, the peak of virus load, the expansion of T cells, the apoptotic decline, and the return to an immune state.", [["memory CD8 T cells", "ANATOMY", 40, 58], ["T cells", "ANATOMY", 176, 183], ["lymphopenia", "DISEASE", 98, 109], ["CD8 T cells", "CELL", 47, 58], ["type 1 IFN", "GENE_OR_GENE_PRODUCT", 123, 133], ["T cells", "CELL", 176, 183], ["memory CD8 T cells", "CELL_TYPE", 40, 58], ["type 1 IFN", "PROTEIN", 123, 133], ["T cells", "CELL_TYPE", 176, 183], ["the virus", "PROBLEM", 80, 89], ["lymphopenia", "PROBLEM", 98, 109], ["type 1 IFN", "PROBLEM", 123, 133], ["virus load", "PROBLEM", 147, 157], ["the expansion of T cells", "PROBLEM", 159, 183], ["the apoptotic decline", "PROBLEM", 185, 206], ["lymphopenia", "OBSERVATION", 98, 109], ["virus load", "OBSERVATION", 147, 157], ["expansion", "OBSERVATION_MODIFIER", 163, 172], ["apoptotic decline", "OBSERVATION", 189, 206]]], ["It shows the loss of non-cross-reactive memory CD8 T cells and the maintenance of cross-reactive memory. oma virus (Wilson et al ., 1999) , and respiratory syncytial virus (RSV) (Kulkarni et al ., 1993) .Degeneracy in antigen recognition and cross-reactivityOf significance is that virus-specific CD8 T cells have also been shown to recognize epitopes derived from heterologous or more distantly related viruses.", [["non-cross-reactive memory CD8 T cells", "ANATOMY", 21, 58], ["CD8 T cells", "ANATOMY", 297, 308], ["respiratory syncytial virus", "DISEASE", 144, 171], ["CD8 T cells", "CELL", 47, 58], ["oma virus", "ORGANISM", 105, 114], ["respiratory syncytial virus", "ORGANISM", 144, 171], ["RSV", "ORGANISM", 173, 176], ["antigen", "GENE_OR_GENE_PRODUCT", 218, 225], ["CD8", "GENE_OR_GENE_PRODUCT", 297, 300], ["non-cross-reactive memory CD8 T cells", "CELL_TYPE", 21, 58], ["CD8 T cells", "CELL_TYPE", 297, 308], ["epitopes", "PROTEIN", 343, 351], ["oma virus", "SPECIES", 105, 114], ["respiratory syncytial virus", "SPECIES", 144, 171], ["oma virus", "SPECIES", 105, 114], ["respiratory syncytial virus", "SPECIES", 144, 171], ["RSV", "SPECIES", 173, 176], ["the loss of non-cross", "PROBLEM", 9, 30], ["oma virus", "PROBLEM", 105, 114], ["respiratory syncytial virus", "PROBLEM", 144, 171], ["virus", "PROBLEM", 282, 287], ["specific CD8 T cells", "PROBLEM", 288, 308], ["loss", "OBSERVATION_MODIFIER", 13, 17], ["reactive", "OBSERVATION_MODIFIER", 31, 39], ["memory CD8 T cells", "OBSERVATION", 40, 58], ["cross-reactive memory", "OBSERVATION", 82, 103], ["respiratory syncytial", "ANATOMY", 144, 165], ["virus", "OBSERVATION", 282, 287]]], ["CD8 T cell cross-reactivity amongst heterologous viruses has been defined between the two distantly related Arenaviruses (lymphocytic choriomeningitis virus (LCMV) and Pichinde virus (PV)) , between different flaviviruses (Murray Valley encephalitis virus, yellow fever virus, West Nile virus, and dengue virus) , between influenza virus and EBV , between influenza virus and hepatitis-C virus (Wedemeyer et al ., 2001) , between influenza virus and rotavirus (Shimojo et al ., 1989) , between human papillomavirus-16 and a human coronavirus (Nilges et al ., 2003) , and between LCMV and vaccinia virus (VV) .", [["CD8 T cell", "ANATOMY", 0, 10], ["lymphocytic choriomeningitis virus", "DISEASE", 122, 156], ["Murray Valley encephalitis", "DISEASE", 223, 249], ["yellow fever", "DISEASE", 257, 269], ["dengue", "DISEASE", 298, 304], ["influenza virus", "DISEASE", 322, 337], ["influenza virus and hepatitis-C virus", "DISEASE", 356, 393], ["influenza virus and rotavirus", "DISEASE", 430, 459], ["human papillomavirus-16", "DISEASE", 494, 517], ["human coronavirus", "DISEASE", 524, 541], ["LCMV and vaccinia virus", "DISEASE", 579, 602], ["CD8", "GENE_OR_GENE_PRODUCT", 0, 3], ["Arenaviruses (lymphocytic choriomeningitis virus", "ORGANISM", 108, 156], ["LCMV", "ORGANISM", 158, 162], ["Pichinde virus", "ORGANISM", 168, 182], ["Murray Valley encephalitis virus", "ORGANISM", 223, 255], ["yellow fever virus", "ORGANISM", 257, 275], ["West Nile virus", "ORGANISM", 277, 292], ["dengue virus", "ORGANISM", 298, 310], ["influenza virus", "ORGANISM", 322, 337], ["EBV", "ORGANISM", 342, 345], ["influenza virus", "ORGANISM", 356, 371], ["hepatitis-C virus", "ORGANISM", 376, 393], ["influenza virus", "ORGANISM", 430, 445], ["rotavirus", "ORGANISM", 450, 459], ["human", "ORGANISM", 494, 499], ["papillomavirus-16", "ORGANISM", 500, 517], ["human", "ORGANISM", 524, 529], ["coronavirus", "ORGANISM", 530, 541], ["LCMV", "ORGANISM", 579, 583], ["vaccinia virus", "ORGANISM", 588, 602], ["CD8", "PROTEIN", 0, 3], ["lymphocytic choriomeningitis virus", "SPECIES", 122, 156], ["Pichinde virus", "SPECIES", 168, 182], ["Valley encephalitis virus", "SPECIES", 230, 255], ["yellow fever virus", "SPECIES", 257, 275], ["West Nile virus", "SPECIES", 277, 292], ["dengue virus", "SPECIES", 298, 310], ["influenza virus", "SPECIES", 322, 337], ["influenza virus", "SPECIES", 356, 371], ["hepatitis-C virus", "SPECIES", 376, 393], ["influenza virus", "SPECIES", 430, 445], ["human", "SPECIES", 494, 499], ["papillomavirus", "SPECIES", 500, 514], ["human", "SPECIES", 524, 529], ["coronavirus", "SPECIES", 530, 541], ["vaccinia virus", "SPECIES", 588, 602], ["lymphocytic choriomeningitis virus", "SPECIES", 122, 156], ["LCMV", "SPECIES", 158, 162], ["Pichinde virus", "SPECIES", 168, 182], ["PV", "SPECIES", 184, 186], ["Murray Valley encephalitis virus", "SPECIES", 223, 255], ["yellow fever virus", "SPECIES", 257, 275], ["West Nile virus", "SPECIES", 277, 292], ["dengue virus", "SPECIES", 298, 310], ["influenza virus", "SPECIES", 322, 337], ["EBV", "SPECIES", 342, 345], ["influenza virus", "SPECIES", 356, 371], ["hepatitis-C virus", "SPECIES", 376, 393], ["influenza virus", "SPECIES", 430, 445], ["human papillomavirus-16", "SPECIES", 494, 517], ["human coronavirus", "SPECIES", 524, 541], ["LCMV", "SPECIES", 579, 583], ["vaccinia virus", "SPECIES", 588, 602], ["VV", "SPECIES", 604, 606], ["CD8 T cell cross", "TEST", 0, 16], ["heterologous viruses", "PROBLEM", 36, 56], ["Arenaviruses (lymphocytic choriomeningitis virus", "PROBLEM", 108, 156], ["Pichinde virus", "PROBLEM", 168, 182], ["different flaviviruses (Murray Valley encephalitis virus", "PROBLEM", 199, 255], ["yellow fever virus", "PROBLEM", 257, 275], ["West Nile virus", "PROBLEM", 277, 292], ["dengue virus", "PROBLEM", 298, 310], ["influenza virus", "PROBLEM", 322, 337], ["EBV", "PROBLEM", 342, 345], ["influenza virus", "PROBLEM", 356, 371], ["hepatitis-C virus", "PROBLEM", 376, 393], ["influenza virus", "PROBLEM", 430, 445], ["rotavirus", "PROBLEM", 450, 459], ["human papillomavirus", "TREATMENT", 494, 514], ["a human coronavirus", "TREATMENT", 522, 541], ["LCMV", "TREATMENT", 579, 583], ["vaccinia virus", "TREATMENT", 588, 602], ["viruses", "OBSERVATION", 49, 56], ["Arenaviruses", "OBSERVATION", 108, 120], ["lymphocytic choriomeningitis virus", "OBSERVATION", 122, 156]]], ["Cumulatively, these findings demonstrate the highly cross-reactive nature of virus-specific T cell responses, and it seems likely that with further investigation more examples will be discovered.Impact of viral infections on memory T cellsThe T cell repertoire of a host that has been previously infected with a virus will be significantly altered relative to a na\u00efve individual because a robust and stable population of memory T cells will have been established.", [["T cell", "ANATOMY", 92, 98], ["memory T cells", "ANATOMY", 225, 239], ["T cell", "ANATOMY", 243, 249], ["memory T cells", "ANATOMY", 421, 435], ["viral infections", "DISEASE", 205, 221], ["T cell", "CELL", 92, 98], ["memory T cells", "CELL", 225, 239], ["T cell", "CELL", 243, 249], ["memory T cells", "CELL", 421, 435], ["memory T cells", "CELL_TYPE", 225, 239], ["memory T cells", "CELL_TYPE", 421, 435], ["virus", "PROBLEM", 77, 82], ["further investigation", "TEST", 140, 161], ["viral infections", "PROBLEM", 205, 221], ["a virus", "PROBLEM", 310, 317], ["memory T cells", "PROBLEM", 421, 435], ["virus", "OBSERVATION", 77, 82], ["seems likely", "UNCERTAINTY", 117, 129], ["viral infections", "OBSERVATION", 205, 221], ["cells", "OBSERVATION", 234, 239], ["infected", "OBSERVATION", 296, 304], ["stable", "OBSERVATION_MODIFIER", 400, 406]]], ["New viral infections can have a profound impact on these preexisting pools of memory cells as a consequence of inflammatory cytokines and chemokines and of antigendependent TCR stimulation (Fig. 1 ).Memory T cell apoptosis and compensatory divisionInitial stages of infection often involve a profound depletion of memory CD8 T cells throughout the body in both lymphoid and peripheral tissue (Fig. 1 ).", [["memory cells", "ANATOMY", 78, 90], ["Memory T cell", "ANATOMY", 199, 212], ["memory CD8 T cells", "ANATOMY", 314, 332], ["body", "ANATOMY", 348, 352], ["lymphoid", "ANATOMY", 361, 369], ["peripheral tissue", "ANATOMY", 374, 391], ["viral infections", "DISEASE", 4, 20], ["infection", "DISEASE", 266, 275], ["memory cells", "CELL", 78, 90], ["TCR", "GENE_OR_GENE_PRODUCT", 173, 176], ["Memory T cell", "CELL", 199, 212], ["CD8 T cells", "CELL", 321, 332], ["body", "ORGANISM_SUBDIVISION", 348, 352], ["lymphoid", "TISSUE", 361, 369], ["peripheral tissue", "TISSUE", 374, 391], ["memory cells", "CELL_TYPE", 78, 90], ["inflammatory cytokines", "PROTEIN", 111, 133], ["chemokines", "PROTEIN", 138, 148], ["TCR", "PROTEIN", 173, 176], ["memory CD8 T cells", "CELL_TYPE", 314, 332], ["New viral infections", "PROBLEM", 0, 20], ["memory cells", "PROBLEM", 78, 90], ["inflammatory cytokines", "PROBLEM", 111, 133], ["chemokines", "TREATMENT", 138, 148], ["antigendependent TCR stimulation", "TREATMENT", 156, 188], ["Memory T cell apoptosis", "PROBLEM", 199, 222], ["compensatory divisionInitial stages of infection", "PROBLEM", 227, 275], ["memory CD8 T cells", "PROBLEM", 314, 332], ["viral", "OBSERVATION_MODIFIER", 4, 9], ["infections", "OBSERVATION", 10, 20], ["profound", "OBSERVATION_MODIFIER", 32, 40], ["impact", "OBSERVATION_MODIFIER", 41, 47], ["memory cells", "OBSERVATION", 78, 90], ["inflammatory", "OBSERVATION_MODIFIER", 111, 123], ["T cell apoptosis", "OBSERVATION", 206, 222], ["compensatory", "OBSERVATION_MODIFIER", 227, 239], ["divisionInitial stages", "OBSERVATION_MODIFIER", 240, 262], ["infection", "OBSERVATION", 266, 275], ["profound", "OBSERVATION_MODIFIER", 292, 300], ["depletion", "OBSERVATION_MODIFIER", 301, 310], ["memory CD8 T cells", "OBSERVATION", 314, 332], ["body", "ANATOMY_MODIFIER", 348, 352], ["both", "ANATOMY_MODIFIER", 356, 360], ["lymphoid", "ANATOMY", 361, 369], ["peripheral tissue", "ANATOMY", 374, 391]]], ["This is a manifestation of a global virus-induced lymphopenia that occurs with many viral infections and that affects many cell types (Peacock et al ., 2003) .", [["cell", "ANATOMY", 123, 127], ["lymphopenia", "DISEASE", 50, 61], ["viral infections", "DISEASE", 84, 100], ["cell", "CELL", 123, 127], ["a global virus", "PROBLEM", 27, 41], ["lymphopenia", "PROBLEM", 50, 61], ["many viral infections", "PROBLEM", 79, 100], ["global", "OBSERVATION_MODIFIER", 29, 35], ["virus", "OBSERVATION", 36, 41], ["lymphopenia", "OBSERVATION", 50, 61], ["viral", "OBSERVATION_MODIFIER", 84, 89], ["infections", "OBSERVATION", 90, 100], ["cell types", "OBSERVATION", 123, 133]]], ["This lymphopenia is at least partially dependent on type 1 IFN, as it parallels the type 1 IFN response, can be induced by the IFN stimulator poly I:C, and does not occur in type 1 IFN receptor knock-out mice (Binder et al ., 1997; McNally et al ., 2001) .", [["lymphopenia", "DISEASE", 5, 16], ["type 1 IFN", "GENE_OR_GENE_PRODUCT", 52, 62], ["type 1 IFN", "GENE_OR_GENE_PRODUCT", 84, 94], ["poly I:C", "GENE_OR_GENE_PRODUCT", 142, 150], ["mice", "ORGANISM", 204, 208], ["type 1 IFN", "PROTEIN", 52, 62], ["IFN", "PROTEIN", 91, 94], ["IFN", "PROTEIN", 127, 130], ["IFN receptor", "PROTEIN", 181, 193], ["mice", "SPECIES", 204, 208], ["This lymphopenia", "PROBLEM", 0, 16], ["lymphopenia", "OBSERVATION", 5, 16], ["at least partially dependent", "OBSERVATION_MODIFIER", 20, 48]]], ["This cell loss is associated with high levels of apoptosis in the memory CD8 T cell subset and lower levels in the na\u00efve CD8 T cell subset (McNally et al ., 2001) .", [["cell", "ANATOMY", 5, 9], ["memory CD8", "ANATOMY", 66, 76], ["T cell", "ANATOMY", 77, 83], ["CD8 T cell", "ANATOMY", 121, 131], ["cell", "CELL", 5, 9], ["CD8", "GENE_OR_GENE_PRODUCT", 73, 76], ["T cell", "CELL", 77, 83], ["CD8 T cell", "CELL", 121, 131], ["memory CD8", "CELL_TYPE", 66, 76], ["T cell subset", "CELL_TYPE", 77, 90], ["na\u00efve CD8 T cell subset", "CELL_TYPE", 115, 138], ["This cell loss", "PROBLEM", 0, 14], ["high levels of apoptosis", "PROBLEM", 34, 58], ["T cell subset", "TEST", 77, 90], ["lower levels", "TEST", 95, 107], ["cell loss", "OBSERVATION", 5, 14], ["high levels", "OBSERVATION_MODIFIER", 34, 45], ["memory CD8", "OBSERVATION", 66, 76], ["cell subset", "OBSERVATION", 79, 90], ["lower levels", "OBSERVATION_MODIFIER", 95, 107]]], ["Whether IFN works alone or through another mechanism is not clear at present, but it should be noted that IFN can induce other pro-apoptotic proteins such as TRAIL (Barber, 2001; Chawla-Sarkar et al ., 2003) and that it can enhance the effects of other pro-apoptotic molecules such as TNFa (Binder et al ., 1997) .", [["IFN", "CHEMICAL", 8, 11], ["IFN", "CHEMICAL", 106, 109], ["IFN", "GENE_OR_GENE_PRODUCT", 8, 11], ["IFN", "GENE_OR_GENE_PRODUCT", 106, 109], ["TRAIL", "GENE_OR_GENE_PRODUCT", 158, 163], ["TNFa", "GENE_OR_GENE_PRODUCT", 285, 289], ["IFN", "PROTEIN", 8, 11], ["IFN", "PROTEIN", 106, 109], ["pro-apoptotic proteins", "PROTEIN", 127, 149], ["TRAIL", "PROTEIN", 158, 163], ["pro-apoptotic molecules", "PROTEIN", 253, 276], ["TNFa", "PROTEIN", 285, 289], ["other pro-apoptotic molecules", "TREATMENT", 247, 276]]], ["This early loss of T cells is followed by antigen-specific and non-specific homeostatic events to fill the available space.", [["T cells", "ANATOMY", 19, 26], ["T cells", "CELL", 19, 26], ["T cells", "CELL_TYPE", 19, 26], ["This early loss of T cells", "PROBLEM", 0, 26], ["antigen", "TEST", 42, 49], ["non-specific homeostatic events", "PROBLEM", 63, 94]]], ["Treatment with agents such as poly(I:C), IFNg , LPS, and IL-15 can stimulate CD44 hi memory-phenotype CD8 T cells to divide, as determined by uptake of bromodeoxyuridine (BrdU) into DNA (Tough et al ., 1996; Zhang et al ., 1998) .", [["CD44 hi memory-phenotype CD8 T cells", "ANATOMY", 77, 113], ["poly(I:C", "CHEMICAL", 30, 38], ["LPS", "CHEMICAL", 48, 51], ["bromodeoxyuridine", "CHEMICAL", 152, 169], ["BrdU", "CHEMICAL", 171, 175], ["bromodeoxyuridine", "CHEMICAL", 152, 169], ["BrdU", "CHEMICAL", 171, 175], ["poly(I:C", "SIMPLE_CHEMICAL", 30, 38], ["IFNg", "SIMPLE_CHEMICAL", 41, 45], ["LPS", "SIMPLE_CHEMICAL", 48, 51], ["IL-15", "GENE_OR_GENE_PRODUCT", 57, 62], ["CD44", "GENE_OR_GENE_PRODUCT", 77, 81], ["CD8", "GENE_OR_GENE_PRODUCT", 102, 105], ["bromodeoxyuridine", "SIMPLE_CHEMICAL", 152, 169], ["BrdU", "SIMPLE_CHEMICAL", 171, 175], ["DNA", "CELLULAR_COMPONENT", 182, 185], ["IL", "PROTEIN", 57, 59], ["CD44", "PROTEIN", 77, 81], ["CD8 T cells", "CELL_TYPE", 102, 113], ["agents", "TREATMENT", 15, 21], ["poly(I:C), IFNg , LPS", "TREATMENT", 30, 51], ["IL", "TREATMENT", 57, 59]]], ["However, this bystander division does not result in an overall increase in the number of T cells, suggesting that the division is balanced by cell death in order to maintain homeostasis (McNally et al ., 2001; Turner et al ., 2001) .", [["T cells", "ANATOMY", 89, 96], ["cell", "ANATOMY", 142, 146], ["death", "DISEASE", 147, 152], ["T cells", "CELL", 89, 96], ["cell", "CELL", 142, 146], ["T cells", "CELL_TYPE", 89, 96], ["cell death", "PROBLEM", 142, 152], ["overall", "OBSERVATION_MODIFIER", 55, 62], ["increase", "OBSERVATION_MODIFIER", 63, 71], ["cell death", "OBSERVATION", 142, 152]]], ["A careful examination of this division after poly(I:C) treatment shows first a profound apoptosis-driven loss of memory CD8 T cells (McNally et al ., 2001) , followed by an IL-15-dependent recovery to steady-state levels (Zhang et al ., 1998; Kim and Welsh, 2004) .", [["memory CD8 T cells", "ANATOMY", 113, 131], ["poly(I:C", "CHEMICAL", 45, 53], ["poly(I:C", "CHEMICAL", 45, 53], ["poly(I:C", "SIMPLE_CHEMICAL", 45, 53], ["CD8", "GENE_OR_GENE_PRODUCT", 120, 123], ["IL-15", "GENE_OR_GENE_PRODUCT", 173, 178], ["memory CD8 T cells", "CELL_TYPE", 113, 131], ["IL", "PROTEIN", 173, 175], ["A careful examination", "TEST", 0, 21], ["C) treatment", "TREATMENT", 52, 64], ["a profound apoptosis", "PROBLEM", 77, 97], ["an IL", "TEST", 170, 175], ["profound", "OBSERVATION_MODIFIER", 79, 87], ["apoptosis", "OBSERVATION", 88, 97], ["memory CD8", "OBSERVATION", 113, 123]]], ["Studies examining the recovery of memory cell populations after various forms of experimental lymphopenia showed that bona fide virus-specific memory CD8 T cells underwent fewer cell divisions than other homeostatically responding cells, such that there was a substantial permanent loss in virus-specific T cells under those conditions (McNally et al ., 2001; Peacock et al ., 2003) .Memory T cell apoptosis and compensatory divisionViral infections resemble poly I:C in their induction of memory cell loss, but they also provide antigenic peptide epitopes to stimulate T cells.", [["memory cell", "ANATOMY", 34, 45], ["T cells", "ANATOMY", 154, 161], ["cell", "ANATOMY", 178, 182], ["cells", "ANATOMY", 231, 236], ["T cells", "ANATOMY", 305, 312], ["T cell", "ANATOMY", 391, 397], ["memory cell", "ANATOMY", 490, 501], ["T cells", "ANATOMY", 570, 577], ["lymphopenia", "DISEASE", 94, 105], ["Viral infections", "DISEASE", 433, 449], ["memory cell loss", "DISEASE", 490, 506], ["memory cell populations", "CELL", 34, 57], ["CD8", "GENE_OR_GENE_PRODUCT", 150, 153], ["T cells", "CELL", 154, 161], ["cell", "CELL", 178, 182], ["cells", "CELL", 231, 236], ["T cells", "CELL", 305, 312], ["Memory T cell", "CELL", 384, 397], ["poly I:C", "GENE_OR_GENE_PRODUCT", 459, 467], ["memory cell", "CELL", 490, 501], ["T cells", "CELL", 570, 577], ["memory cell populations", "CELL_TYPE", 34, 57], ["memory CD8", "CELL_TYPE", 143, 153], ["T cells", "CELL_TYPE", 154, 161], ["homeostatically responding cells", "CELL_TYPE", 204, 236], ["T cells", "CELL_TYPE", 305, 312], ["poly I:C", "PROTEIN", 459, 467], ["T cells", "CELL_TYPE", 570, 577], ["Studies", "TEST", 0, 7], ["experimental lymphopenia", "PROBLEM", 81, 105], ["bona fide virus", "PROBLEM", 118, 133], ["T cells", "PROBLEM", 154, 161], ["fewer cell divisions", "TREATMENT", 172, 192], ["other homeostatically responding cells", "PROBLEM", 198, 236], ["a substantial permanent loss in virus", "PROBLEM", 258, 295], ["Memory T cell apoptosis", "PROBLEM", 384, 407], ["compensatory divisionViral infections", "PROBLEM", 412, 449], ["memory cell loss", "PROBLEM", 490, 506], ["antigenic peptide epitopes", "TREATMENT", 530, 556], ["lymphopenia", "OBSERVATION", 94, 105], ["fewer cell divisions", "OBSERVATION", 172, 192], ["substantial", "OBSERVATION_MODIFIER", 260, 271], ["permanent loss", "OBSERVATION", 272, 286], ["cell apoptosis", "OBSERVATION", 393, 407], ["compensatory", "OBSERVATION_MODIFIER", 412, 424], ["division", "OBSERVATION_MODIFIER", 425, 433], ["Viral infections", "OBSERVATION", 433, 449], ["memory cell loss", "OBSERVATION", 490, 506]]], ["T cells stimulated by their cognate ligands are induced into many cycles of division and far out-compete the homeostatically dividing T cells ( Fig. 2) (Kim et al ., 2002) .", [["T cells", "ANATOMY", 0, 7], ["T cells", "ANATOMY", 134, 141], ["T cells", "CELL", 0, 7], ["T cells", "CELL", 134, 141], ["T cells", "CELL_TYPE", 0, 7], ["homeostatically dividing T cells", "CELL_TYPE", 109, 141]]], ["Whether antigen ligation can prevent the initial apoptosis of memory T cells has been investigated.", [["memory T cells", "ANATOMY", 62, 76], ["antigen", "GENE_OR_GENE_PRODUCT", 8, 15], ["memory T cells", "CELL", 62, 76], ["memory T cells", "CELL_TYPE", 62, 76], ["antigen ligation", "TREATMENT", 8, 24], ["memory T cells", "PROBLEM", 62, 76], ["ligation", "OBSERVATION", 16, 24]]], ["Studies using an adoptive transfer model to examine the attrition of memory T cells demonstrated that LCMV-specific memory CD8 T cells were significantly reduced in number 2 days after infection with the heterologous but cross-reactive PV, and T cells specific for either the cross-reactive or non-cross-reactive peptides underwent similar levels of attrition (Peacock et al ., 2003; Kim and Welsh, 2004) .", [["memory T cells", "ANATOMY", 69, 83], ["memory CD8 T cells", "ANATOMY", 116, 134], ["T cells", "ANATOMY", 244, 251], ["infection", "DISEASE", 185, 194], ["memory T cells", "CELL", 69, 83], ["LCMV", "ORGANISM", 102, 106], ["CD8 T cells", "CELL", 123, 134], ["PV", "CELL", 236, 238], ["T cells", "CELL", 244, 251], ["memory T cells", "CELL_TYPE", 69, 83], ["memory CD8 T cells", "CELL_TYPE", 116, 134], ["T cells", "CELL_TYPE", 244, 251], ["LCMV", "SPECIES", 102, 106], ["PV", "SPECIES", 236, 238], ["LCMV", "TEST", 102, 106], ["infection", "PROBLEM", 185, 194], ["the heterologous", "TEST", 200, 216], ["cross-reactive PV", "TEST", 221, 238], ["the cross-reactive or non-cross-reactive peptides", "PROBLEM", 272, 321]]], ["This suggests that the attrition of memory is a generalized phenomenon affecting all memory T cell specificities independent of TCR signalling.", [["memory T cell", "ANATOMY", 85, 98], ["memory T cell", "CELL", 85, 98], ["TCR", "GENE_OR_GENE_PRODUCT", 128, 131], ["TCR", "PROTEIN", 128, 131], ["a generalized phenomenon", "PROBLEM", 46, 70], ["generalized", "OBSERVATION_MODIFIER", 48, 59]]], ["Crossreactive T cells, however, selectively and rapidly expand in number following the early attrition process ( Fig. 1 ) .", [["T cells", "ANATOMY", 14, 21], ["T cells", "CELL", 14, 21], ["Crossreactive T cells", "CELL_TYPE", 0, 21], ["Crossreactive T cells", "PROBLEM", 0, 21]]], ["A recent study examining the susceptibility of na\u00efve T cells to attrition concluded that infection with Listeria monocytogenes selectively depleted na\u00efve CD8 T cells that were not specific for antigens expressed by the bacteria by 3 days, while antigenspecific na\u00efve T cells were not lost (Jiang et al ., 2003) .Memory T cell apoptosis and compensatory divisionCytokine production.", [["T cells", "ANATOMY", 53, 60], ["CD8 T cells", "ANATOMY", 154, 165], ["T cells", "ANATOMY", 267, 274], ["Memory T cell", "ANATOMY", 312, 325], ["infection", "DISEASE", 89, 98], ["na\u00efve T cells", "CELL", 47, 60], ["Listeria monocytogenes", "ORGANISM", 104, 126], ["CD8 T cells", "CELL", 154, 165], ["T cells", "CELL", 267, 274], ["Memory T cell", "CELL", 312, 325], ["Cytokine", "GENE_OR_GENE_PRODUCT", 361, 369], ["na\u00efve T cells", "CELL_TYPE", 47, 60], ["na\u00efve CD8 T cells", "CELL_TYPE", 148, 165], ["antigens", "PROTEIN", 193, 201], ["antigenspecific na\u00efve T cells", "CELL_TYPE", 245, 274], ["Cytokine", "PROTEIN", 361, 369], ["Listeria monocytogenes", "SPECIES", 104, 126], ["Listeria monocytogenes", "SPECIES", 104, 126], ["A recent study", "TEST", 0, 14], ["na\u00efve T cells", "TREATMENT", 47, 60], ["infection", "PROBLEM", 89, 98], ["Listeria monocytogenes", "PROBLEM", 104, 126], ["CD8 T cells", "PROBLEM", 154, 165], ["antigens", "PROBLEM", 193, 201], ["the bacteria", "PROBLEM", 215, 227], ["Memory T cell apoptosis", "PROBLEM", 312, 335], ["compensatory divisionCytokine production", "PROBLEM", 340, 380], ["infection", "OBSERVATION", 89, 98], ["T cell apoptosis", "OBSERVATION", 319, 335], ["compensatory", "OBSERVATION_MODIFIER", 340, 352], ["division", "OBSERVATION_MODIFIER", 353, 361], ["Cytokine production", "OBSERVATION", 361, 380]]], ["Some viral and bacterial infections can induce a high proportion of memory CD8 T cells to synthesize IFNg early in infection Lertmemongkolchai et al ., 2001; Berg et al ., 2003) .", [["memory CD8 T cells", "ANATOMY", 68, 86], ["infections", "DISEASE", 25, 35], ["infection", "DISEASE", 115, 124], ["CD8 T cells", "CELL", 75, 86], ["IFNg", "GENE_OR_GENE_PRODUCT", 101, 105], ["memory CD8 T cells", "CELL_TYPE", 68, 86], ["Some viral and bacterial infections", "PROBLEM", 0, 35], ["viral", "OBSERVATION", 5, 10], ["bacterial infections", "OBSERVATION", 15, 35], ["memory CD8", "OBSERVATION", 68, 78]]], ["This is an important observation relating to heterologous immunity, as many pathogens are controlled by IFNg .", [["IFNg", "GENE_OR_GENE_PRODUCT", 104, 108], ["IFNg", "PROTEIN", 104, 108], ["heterologous immunity", "TREATMENT", 45, 66], ["many pathogens", "PROBLEM", 71, 85]]], ["Some work has suggested that cytokines alone may stimulate memory cells to produce IFNg (Berg et al ., 2002; Kambayashi et al ., 2003) .", [["memory cells", "ANATOMY", 59, 71], ["memory cells", "CELL", 59, 71], ["cytokines", "PROTEIN", 29, 38], ["memory cells", "CELL_TYPE", 59, 71], ["cytokines alone", "TREATMENT", 29, 44]]], ["However, the mechanisms mediating this early production of IFNg have not been satisfactorily elucidated, as viral and bacterial pathogens may encode numerous foreign epitopes having the capacity to trigger the TCR at low affinity, and the role of T cell crossreactivity in these studies was not excluded.", [["T cell", "ANATOMY", 247, 253], ["TCR", "CHEMICAL", 210, 213], ["IFNg", "GENE_OR_GENE_PRODUCT", 59, 63], ["TCR", "GENE_OR_GENE_PRODUCT", 210, 213], ["T cell", "CELL", 247, 253], ["IFNg", "PROTEIN", 59, 63], ["TCR", "PROTEIN", 210, 213], ["viral and bacterial pathogens", "PROBLEM", 108, 137], ["numerous foreign epitopes", "PROBLEM", 149, 174], ["the capacity", "PROBLEM", 182, 194], ["the TCR at low affinity", "PROBLEM", 206, 229], ["T cell crossreactivity", "PROBLEM", 247, 269], ["these studies", "TEST", 273, 286], ["numerous", "OBSERVATION_MODIFIER", 149, 157], ["foreign epitopes", "OBSERVATION", 158, 174], ["low affinity", "OBSERVATION_MODIFIER", 217, 229], ["not excluded", "UNCERTAINTY", 291, 303]]], ["Results from our laboratory highlight the difficulties in distinguishing between TCR-dependent and TCR-independent stimulations.", [["TCR", "CHEMICAL", 81, 84], ["TCR", "CHEMICAL", 99, 102], ["TCR", "GENE_OR_GENE_PRODUCT", 81, 84], ["TCR", "GENE_OR_GENE_PRODUCT", 99, 102], ["TCR", "PROTEIN", 81, 84], ["TCR", "PROTEIN", 99, 102], ["our laboratory", "TEST", 13, 27], ["TCR", "TEST", 81, 84]]], ["LCMV-immune CD8 T cells produced IFNg 3 days after vaccinia virus (VV) infection .", [["CD8 T cells", "ANATOMY", 12, 23], ["vaccinia virus (VV) infection", "DISEASE", 51, 80], ["LCMV", "ORGANISM", 0, 4], ["immune CD8 T cells", "CELL", 5, 23], ["vaccinia virus", "ORGANISM", 51, 65], ["VV", "ORGANISM", 67, 69], ["LCMV-immune CD8 T cells", "CELL_LINE", 0, 23], ["vaccinia virus", "SPECIES", 51, 65], ["LCMV", "SPECIES", 0, 4], ["vaccinia virus", "SPECIES", 51, 65], ["VV", "SPECIES", 67, 69], ["LCMV", "TEST", 0, 4], ["IFNg", "PROBLEM", 33, 37], ["vaccinia virus (VV) infection", "PROBLEM", 51, 80], ["immune CD8", "OBSERVATION", 5, 15], ["infection", "OBSERVATION", 71, 80]]], ["It could be argued that this was a non-specific phenomenon because T cells of multiple specificities were activated.", [["T cells", "ANATOMY", 67, 74], ["T cells", "CELL", 67, 74], ["T cells", "CELL_TYPE", 67, 74], ["a non-specific phenomenon", "PROBLEM", 33, 58], ["T cells of multiple specificities", "PROBLEM", 67, 100]]], ["However, IFNg was made by higher proportions of some LCMV epitope-specific T cells than other epitope-specific populations.", [["T cells", "ANATOMY", 75, 82], ["IFNg", "GENE_OR_GENE_PRODUCT", 9, 13], ["LCMV", "ORGANISM", 53, 57], ["T cells", "CELL", 75, 82], ["IFNg", "PROTEIN", 9, 13], ["LCMV epitope-specific T cells", "CELL_TYPE", 53, 82], ["epitope", "PROTEIN", 94, 101], ["LCMV", "SPECIES", 53, 57], ["some LCMV epitope", "PROBLEM", 48, 65], ["LCMV epitope", "OBSERVATION", 53, 65]]], ["This diversity in the proportions of epitopespecific populations producing IFNg suggested a level of selectivity that may be supported by the recent identification of some cross-reactive epitopes between VV and LCMV .", [["IFNg", "CHEMICAL", 75, 79], ["IFNg", "GENE_OR_GENE_PRODUCT", 75, 79], ["VV", "ORGANISM", 204, 206], ["LCMV", "ORGANISM", 211, 215], ["IFNg", "PROTEIN", 75, 79], ["cross-reactive epitopes", "PROTEIN", 172, 195], ["VV", "SPECIES", 204, 206], ["LCMV", "SPECIES", 211, 215], ["epitopespecific populations", "PROBLEM", 37, 64], ["some cross-reactive epitopes", "PROBLEM", 167, 195], ["cross-reactive", "OBSERVATION_MODIFIER", 172, 186], ["epitopes", "OBSERVATION", 187, 195], ["LCMV", "OBSERVATION", 211, 215]]], ["Regardless of the mechanism for IFNg production, the IFNg inhibited the replication of VV.Memory T cell apoptosis and compensatory divisionRecruitment to sites of inflammation.", [["Memory T cell", "ANATOMY", 90, 103], ["sites", "ANATOMY", 154, 159], ["IFNg", "CHEMICAL", 53, 57], ["inflammation", "DISEASE", 163, 175], ["IFNg", "CHEMICAL", 53, 57], ["IFNg", "GENE_OR_GENE_PRODUCT", 32, 36], ["IFNg", "SIMPLE_CHEMICAL", 53, 57], ["VV", "ORGANISM", 87, 89], ["Memory T cell", "CELL", 90, 103], ["IFNg", "PROTEIN", 32, 36], ["IFNg", "PROTEIN", 53, 57], ["VV", "SPECIES", 87, 89], ["IFNg production", "PROBLEM", 32, 47], ["Memory T cell apoptosis", "PROBLEM", 90, 113], ["compensatory divisionRecruitment", "PROBLEM", 118, 150], ["inflammation", "PROBLEM", 163, 175], ["T cell apoptosis", "OBSERVATION", 97, 113], ["inflammation", "OBSERVATION", 163, 175]]], ["Memory CD8 T cells, surviving the early attrition process, can be nonspecifically recruited to peripheral sites of infection early following a viral challenge (Zhang and Mak, 1986) .", [["T cells", "ANATOMY", 11, 18], ["peripheral sites", "ANATOMY", 95, 111], ["infection", "DISEASE", 115, 124], ["CD8", "GENE_OR_GENE_PRODUCT", 7, 10], ["T cells", "CELL", 11, 18], ["peripheral sites", "MULTI-TISSUE_STRUCTURE", 95, 111], ["Memory CD8", "CELL_TYPE", 0, 10], ["T cells", "CELL_TYPE", 11, 18], ["T cells", "PROBLEM", 11, 18], ["infection", "PROBLEM", 115, 124], ["a viral challenge", "TREATMENT", 141, 158], ["peripheral sites", "OBSERVATION_MODIFIER", 95, 111], ["infection", "OBSERVATION", 115, 124]]], ["This has been shown in transgenic and non-transgenic systems.", [["non-transgenic systems", "OBSERVATION", 38, 60]]], ["Memory TCR-transgenic CD8 T cells specific for OVA and the LCMV-epitope GP33 migrate to the lung following intranasal infection with the unrelated influenza virus and RSV, respectively (Topham et al ., 2001; Ostler et al ., 2003) .", [["T cells", "ANATOMY", 26, 33], ["lung", "ANATOMY", 92, 96], ["TCR", "CHEMICAL", 7, 10], ["infection", "DISEASE", 118, 127], ["TCR", "GENE_OR_GENE_PRODUCT", 7, 10], ["CD8", "GENE_OR_GENE_PRODUCT", 22, 25], ["T cells", "CELL", 26, 33], ["OVA", "GENE_OR_GENE_PRODUCT", 47, 50], ["LCMV", "ORGANISM", 59, 63], ["GP33", "GENE_OR_GENE_PRODUCT", 72, 76], ["lung", "ORGAN", 92, 96], ["influenza virus", "ORGANISM", 147, 162], ["RSV", "ORGANISM", 167, 170], ["TCR", "PROTEIN", 7, 10], ["transgenic CD8", "CELL_LINE", 11, 25], ["T cells", "CELL_TYPE", 26, 33], ["LCMV-epitope GP33", "PROTEIN", 59, 76], ["influenza virus", "SPECIES", 147, 162], ["RSV", "SPECIES", 167, 170], ["Memory TCR", "TEST", 0, 10], ["OVA", "PROBLEM", 47, 50], ["the LCMV-epitope GP33", "TREATMENT", 55, 76], ["intranasal infection", "PROBLEM", 107, 127], ["the unrelated influenza virus", "PROBLEM", 133, 162], ["RSV", "PROBLEM", 167, 170], ["LCMV", "OBSERVATION", 59, 63], ["lung", "ANATOMY", 92, 96], ["infection", "OBSERVATION", 118, 127], ["influenza virus", "OBSERVATION", 147, 162]]], ["Migration of MHC-tetramer-defined memory T cell populations to peripheral sites of infection was also shown in studies demonstrating that memory CD8 T cells Fig. 2 .", [["memory T cell", "ANATOMY", 34, 47], ["peripheral sites", "ANATOMY", 63, 79], ["memory CD8 T cells", "ANATOMY", 138, 156], ["infection", "DISEASE", 83, 92], ["memory T cell populations", "CELL", 34, 59], ["peripheral sites", "MULTI-TISSUE_STRUCTURE", 63, 79], ["MHC", "PROTEIN", 13, 16], ["memory T cell populations", "CELL_TYPE", 34, 59], ["memory CD8 T cells", "CELL_TYPE", 138, 156], ["memory T cell populations", "TREATMENT", 34, 59], ["peripheral sites of infection", "PROBLEM", 63, 92], ["memory T cell populations", "OBSERVATION", 34, 59], ["peripheral sites", "OBSERVATION_MODIFIER", 63, 79], ["infection", "OBSERVATION", 83, 92]]], ["CD8 T cells from LCMV-immune mice are stimulated to divide following infection with homologous and heterologous viruses.", [["CD8 T cells", "ANATOMY", 0, 11], ["infection", "DISEASE", 69, 78], ["CD8", "GENE_OR_GENE_PRODUCT", 0, 3], ["LCMV-immune mice", "ORGANISM", 17, 33], ["CD8 T cells", "CELL_TYPE", 0, 11], ["mice", "SPECIES", 29, 33], ["mice", "SPECIES", 29, 33], ["CD8 T cells", "TEST", 0, 11], ["LCMV", "TEST", 17, 21], ["immune mice", "TREATMENT", 22, 33], ["infection", "PROBLEM", 69, 78], ["homologous and heterologous viruses", "PROBLEM", 84, 119], ["infection", "OBSERVATION", 69, 78], ["heterologous viruses", "OBSERVATION", 99, 119]]], ["Splenocytes from LCMV-immune mice (Thy1.1) were labelled with CFSE and adoptively transferred into congenic na\u00efve mice (Thy1.2).", [["Splenocytes", "ANATOMY", 0, 11], ["CFSE", "CHEMICAL", 62, 66], ["CFSE", "CHEMICAL", 62, 66], ["Splenocytes", "CELL", 0, 11], ["LCMV-immune mice", "ORGANISM", 17, 33], ["Thy1.1", "CELL", 35, 41], ["CFSE", "SIMPLE_CHEMICAL", 62, 66], ["mice", "ORGANISM", 114, 118], ["Thy1.2", "CELL", 120, 126], ["Splenocytes", "CELL_TYPE", 0, 11], ["mice", "SPECIES", 29, 33], ["mice", "SPECIES", 114, 118], ["mice", "SPECIES", 29, 33], ["mice", "SPECIES", 114, 118], ["Splenocytes", "TEST", 0, 11], ["LCMV", "TEST", 17, 21], ["LCMV", "OBSERVATION", 17, 21]]], ["One day following transfer, recipient mice were left untreated, injected with poly(I:C), or infected with LCMV, PV, or VV.", [["poly(I:C", "CHEMICAL", 78, 86], ["mice", "ORGANISM", 38, 42], ["poly(I:C", "SIMPLE_CHEMICAL", 78, 86], ["LCMV", "ORGANISM", 106, 110], ["mice", "SPECIES", 38, 42], ["mice", "SPECIES", 38, 42], ["LCMV", "SPECIES", 106, 110], ["PV", "SPECIES", 112, 114], ["VV", "SPECIES", 119, 121], ["LCMV", "PROBLEM", 106, 110], ["left", "ANATOMY_MODIFIER", 48, 52], ["infected", "OBSERVATION", 92, 100], ["LCMV", "OBSERVATION", 106, 110]]], ["Six days later, splenocytes from recipient mice were stained with antibodies to CD8 and the congenic marker (Thy1.1) and then analysed by flow cytometry.", [["splenocytes", "ANATOMY", 16, 27], ["splenocytes", "CELL", 16, 27], ["mice", "ORGANISM", 43, 47], ["CD8", "GENE_OR_GENE_PRODUCT", 80, 83], ["splenocytes", "CELL_TYPE", 16, 27], ["antibodies", "PROTEIN", 66, 76], ["CD8", "PROTEIN", 80, 83], ["Thy1.1", "PROTEIN", 109, 115], ["mice", "SPECIES", 43, 47], ["mice", "SPECIES", 43, 47], ["antibodies", "TEST", 66, 76], ["CD8", "TEST", 80, 83], ["the congenic marker", "TEST", 88, 107], ["flow cytometry", "TEST", 138, 152], ["splenocytes", "ANATOMY", 16, 27], ["flow cytometry", "OBSERVATION", 138, 152]]], ["The histograms showing the loss of CFSE were analysed by gating on cells positive for the donor marker and CD8.", [["cells", "ANATOMY", 67, 72], ["CFSE", "CHEMICAL", 35, 39], ["CFSE", "SIMPLE_CHEMICAL", 35, 39], ["cells", "CELL", 67, 72], ["CD8", "GENE_OR_GENE_PRODUCT", 107, 110], ["CD8", "PROTEIN", 107, 110], ["The histograms", "TEST", 0, 14], ["the loss of CFSE", "PROBLEM", 23, 39], ["the donor marker", "TEST", 86, 102]]], ["This figure was courtesy of S.K. Kim and based on previous studies (Kim et al ., 2002) . specific to influenza virus, LCMV, murine g herpes virus 68, and Sendai virus were recruited into the lung following infection with heterologous viruses (Topham et al ., 2001; Ely et al ., 2003; Ostler et al ., 2003) .", [["lung", "ANATOMY", 191, 195], ["influenza virus", "DISEASE", 101, 116], ["infection", "DISEASE", 206, 215], ["influenza virus", "ORGANISM", 101, 116], ["LCMV", "ORGANISM", 118, 122], ["murine g herpes virus 68", "ORGANISM", 124, 148], ["Sendai virus", "ORGANISM", 154, 166], ["lung", "ORGAN", 191, 195], ["influenza virus", "SPECIES", 101, 116], ["murine", "SPECIES", 124, 130], ["g herpes virus", "SPECIES", 131, 145], ["Sendai virus", "SPECIES", 154, 166], ["influenza virus", "SPECIES", 101, 116], ["LCMV", "SPECIES", 118, 122], ["murine g herpes virus 68", "SPECIES", 124, 148], ["Sendai virus", "SPECIES", 154, 166], ["previous studies", "TEST", 50, 66], ["influenza virus", "PROBLEM", 101, 116], ["LCMV", "PROBLEM", 118, 122], ["murine g herpes virus", "PROBLEM", 124, 145], ["Sendai virus", "PROBLEM", 154, 166], ["infection", "PROBLEM", 206, 215], ["heterologous viruses", "PROBLEM", 221, 241], ["influenza virus", "OBSERVATION", 101, 116], ["lung", "ANATOMY", 191, 195], ["infection", "OBSERVATION", 206, 215]]], ["The mechanism mediating the recruitment of memory CD8 T cells to the lung following intranasal infection is not yet fully defined but would be consistent with a generalized migration to an inflammatory site driven by the production of chemokines (Stephens et al ., 2002) , as this influx of T cells is independent of cell division (Ely et al ., 2003; Ostler et al ., 2003) .", [["memory CD8 T cells", "ANATOMY", 43, 61], ["lung", "ANATOMY", 69, 73], ["T cells", "ANATOMY", 291, 298], ["cell", "ANATOMY", 317, 321], ["infection", "DISEASE", 95, 104], ["CD8 T cells", "CELL", 50, 61], ["lung", "ORGAN", 69, 73], ["T cells", "CELL", 291, 298], ["cell", "CELL", 317, 321], ["memory CD8 T cells", "CELL_TYPE", 43, 61], ["chemokines", "PROTEIN", 235, 245], ["T cells", "CELL_TYPE", 291, 298], ["intranasal infection", "PROBLEM", 84, 104], ["a generalized migration", "PROBLEM", 159, 182], ["an inflammatory site", "PROBLEM", 186, 206], ["recruitment", "OBSERVATION_MODIFIER", 28, 39], ["memory CD8", "OBSERVATION", 43, 53], ["lung", "ANATOMY", 69, 73], ["infection", "OBSERVATION", 95, 104], ["consistent with", "UNCERTAINTY", 143, 158], ["generalized", "OBSERVATION_MODIFIER", 161, 172], ["migration", "OBSERVATION", 173, 182], ["inflammatory", "OBSERVATION", 189, 201]]], ["The generalized recruitment of virus-specific CD8 T cells to the site of infection may be a normal characteristic of an inflammatory response that allows for efficient effector function in the periphery.Sequential infections with homologous and heterologous virusesMemory CD8 T cells generated by prior viral infections will be reactivated upon re-challenge with the originally encountered virus and will contribute to the overall immunity against the second infection.", [["CD8 T cells", "ANATOMY", 46, 57], ["site", "ANATOMY", 65, 69], ["Memory CD8 T cells", "ANATOMY", 265, 283], ["infection", "DISEASE", 73, 82], ["infections", "DISEASE", 214, 224], ["viral infections", "DISEASE", 303, 319], ["infection", "DISEASE", 459, 468], ["CD8 T cells", "CELL", 46, 57], ["CD8", "GENE_OR_GENE_PRODUCT", 272, 275], ["CD8 T cells", "CELL_TYPE", 46, 57], ["Memory CD8 T cells", "CELL_TYPE", 265, 283], ["The generalized recruitment of virus", "PROBLEM", 0, 36], ["infection", "PROBLEM", 73, 82], ["an inflammatory response", "PROBLEM", 117, 141], ["Sequential infections with homologous and heterologous viruses", "PROBLEM", 203, 265], ["prior viral infections", "PROBLEM", 297, 319], ["the originally encountered virus", "PROBLEM", 363, 395], ["the second infection", "PROBLEM", 448, 468], ["generalized", "OBSERVATION_MODIFIER", 4, 15], ["recruitment", "OBSERVATION_MODIFIER", 16, 27], ["virus", "OBSERVATION", 31, 36], ["infection", "OBSERVATION", 73, 82], ["inflammatory", "OBSERVATION", 120, 132], ["periphery", "ANATOMY_MODIFIER", 193, 202], ["infections", "OBSERVATION", 214, 224], ["heterologous viruses", "OBSERVATION", 245, 265], ["viral", "OBSERVATION_MODIFIER", 303, 308], ["infections", "OBSERVATION", 309, 319], ["infection", "OBSERVATION", 459, 468]]], ["Normally the presence of neutralizing antibody will mute a secondary T cell response by restricting viral replication and antigen presentation to T cells, but in the absence of neutralizing antibody sufficient antigen is expressed to induce an anamnestic T cell response.", [["T cell", "ANATOMY", 69, 75], ["T cells", "ANATOMY", 146, 153], ["T cell", "ANATOMY", 255, 261], ["T cell", "CELL", 69, 75], ["T cells", "CELL", 146, 153], ["T cell", "CELL", 255, 261], ["neutralizing antibody", "PROTEIN", 25, 46], ["T cells", "CELL_TYPE", 146, 153], ["neutralizing antibody", "PROTEIN", 177, 198], ["neutralizing antibody", "PROBLEM", 25, 46], ["a secondary T cell response", "PROBLEM", 57, 84], ["restricting viral replication", "PROBLEM", 88, 117], ["T cells", "PROBLEM", 146, 153], ["neutralizing antibody sufficient antigen", "PROBLEM", 177, 217], ["an anamnestic T cell response", "PROBLEM", 241, 270], ["neutralizing antibody", "OBSERVATION", 25, 46], ["cell response", "OBSERVATION", 71, 84], ["viral replication", "OBSERVATION", 100, 117], ["cell response", "OBSERVATION", 257, 270]]], ["A well documented example is in the influenza system, where antigenic shift produces subtypes of influenza A virus that are not recognized by neutralizing antibodies generated by previous infections with different influenza A subtypes (Wright and Webster, 2001) .", [["influenza", "DISEASE", 36, 45], ["influenza A virus", "DISEASE", 97, 114], ["infections", "DISEASE", 188, 198], ["influenza A virus", "ORGANISM", 97, 114], ["neutralizing antibodies", "PROTEIN", 142, 165], ["influenza A virus", "SPECIES", 97, 114], ["influenza A virus", "SPECIES", 97, 114], ["the influenza system", "PROBLEM", 32, 52], ["influenza A virus", "PROBLEM", 97, 114], ["neutralizing antibodies", "PROBLEM", 142, 165], ["previous infections", "PROBLEM", 179, 198], ["influenza", "OBSERVATION", 36, 45], ["influenza", "OBSERVATION", 97, 106], ["not recognized", "UNCERTAINTY", 124, 138]]], ["In the absence of those protective antibodies, prior infection with one influenza subtype generally still provides substantial protection against a challenge with a different subtype.", [["infection", "DISEASE", 53, 62], ["protective antibodies", "PROTEIN", 24, 45], ["prior infection", "PROBLEM", 47, 62], ["one influenza subtype", "PROBLEM", 68, 89], ["infection", "OBSERVATION", 53, 62]]], ["The protection afforded against subsequent infections with heterologous influenza virus subtypes has been attributed, in some studies, to the massive cross-reactive CD8 T cell response at the site of infection following rechallenge (Yewdell et al ., 1985; Townsend et al ., 1986; Belz et al ., 2001) .", [["CD8 T cell", "ANATOMY", 165, 175], ["infections", "DISEASE", 43, 53], ["influenza virus", "DISEASE", 72, 87], ["infection", "DISEASE", 200, 209], ["heterologous influenza virus", "ORGANISM", 59, 87], ["CD8 T cell", "CELL", 165, 175], ["CD8", "PROTEIN", 165, 168], ["heterologous influenza virus", "SPECIES", 59, 87], ["The protection", "TREATMENT", 0, 14], ["subsequent infections", "PROBLEM", 32, 53], ["heterologous influenza virus subtypes", "PROBLEM", 59, 96], ["the massive cross-reactive CD8 T cell response", "PROBLEM", 138, 184], ["infection", "PROBLEM", 200, 209], ["infections", "OBSERVATION", 43, 53], ["massive", "OBSERVATION_MODIFIER", 142, 149], ["cross-reactive CD8 T cell response", "OBSERVATION", 150, 184], ["infection", "OBSERVATION", 200, 209]]], ["Similar types of responses have been seen between the New Jersey and Indiana strains of VSV, which do not share neutralizing antibody epitopes but have cross-reactive T cell epitopes that differ in only two amino acids (Puddington et al ., 1986; Yewdell et al ., 1986) .", [["T cell", "ANATOMY", 167, 173], ["amino acids", "CHEMICAL", 207, 218], ["amino acids", "CHEMICAL", 207, 218], ["Indiana strains", "ORGANISM", 69, 84], ["VSV", "ORGANISM", 88, 91], ["T cell", "CELL", 167, 173], ["amino acids", "AMINO_ACID", 207, 218], ["neutralizing antibody epitopes", "PROTEIN", 112, 142], ["cross-reactive T cell epitopes", "PROTEIN", 152, 182], ["VSV", "SPECIES", 88, 91], ["neutralizing antibody epitopes", "PROBLEM", 112, 142], ["cross-reactive T cell epitopes", "PROBLEM", 152, 182], ["New", "OBSERVATION_MODIFIER", 54, 57], ["Jersey", "OBSERVATION_MODIFIER", 58, 64], ["cell epitopes", "OBSERVATION", 169, 182]]], ["All of these systems indicate that if virus replication is not restricted by neutralizing antibody, the response of epitope-stimulated T cells can be quite profound, and this feature could contribute to dramatic T cell responses under conditions of heterologous immunity.Sequential infections with homologous and heterologous virusesThe promiscuous nature of antigen recognition by the TCR allows memory CD8 T cells generated by prior viral infections to cross-react with heterologous viruses and to impact the generation of immune responses against subsequently encountered pathogens.", [["T cells", "ANATOMY", 135, 142], ["T cell", "ANATOMY", 212, 218], ["memory CD8 T cells", "ANATOMY", 397, 415], ["infections", "DISEASE", 282, 292], ["TCR", "CHEMICAL", 386, 389], ["viral infections", "DISEASE", 435, 451], ["T cells", "CELL", 135, 142], ["T cell", "CELL", 212, 218], ["antigen", "GENE_OR_GENE_PRODUCT", 359, 366], ["TCR", "GENE_OR_GENE_PRODUCT", 386, 389], ["CD8", "GENE_OR_GENE_PRODUCT", 404, 407], ["neutralizing antibody", "PROTEIN", 77, 98], ["epitope-stimulated T cells", "CELL_LINE", 116, 142], ["TCR", "PROTEIN", 386, 389], ["memory CD8 T cells", "CELL_TYPE", 397, 415], ["virus replication", "PROBLEM", 38, 55], ["neutralizing antibody", "TEST", 77, 98], ["epitope-stimulated T cells", "PROBLEM", 116, 142], ["dramatic T cell responses", "PROBLEM", 203, 228], ["heterologous immunity", "TREATMENT", 249, 270], ["Sequential infections with homologous and heterologous viruses", "PROBLEM", 271, 333], ["prior viral infections", "PROBLEM", 429, 451], ["heterologous viruses", "PROBLEM", 472, 492], ["immune responses", "TREATMENT", 525, 541], ["subsequently encountered pathogens", "PROBLEM", 550, 584], ["infections", "OBSERVATION", 282, 292], ["heterologous viruses", "OBSERVATION", 313, 333], ["promiscuous", "OBSERVATION_MODIFIER", 337, 348], ["viral infections", "OBSERVATION", 435, 451]]], ["To characterize the response of virus-specific memory CD8 T cells against subsequent infections with heterologous but cross-reactive viruses, the proliferation of these memory cells was examined after a viral challenge using an adoptive transfer model that allows the division of CD8 T cells to be directly quantified (Lyons and Parish, 1994) .", [["memory CD8 T cells", "ANATOMY", 47, 65], ["memory cells", "ANATOMY", 169, 181], ["CD8 T cells", "ANATOMY", 280, 291], ["infections", "DISEASE", 85, 95], ["memory CD8 T cells", "CELL", 47, 65], ["memory cells", "CELL", 169, 181], ["CD8 T cells", "CELL", 280, 291], ["memory CD8 T cells", "CELL_TYPE", 47, 65], ["memory cells", "CELL_TYPE", 169, 181], ["CD8 T cells", "CELL_TYPE", 280, 291], ["virus", "PROBLEM", 32, 37], ["subsequent infections", "PROBLEM", 74, 95], ["heterologous but cross-reactive viruses", "PROBLEM", 101, 140], ["a viral challenge", "TREATMENT", 201, 218], ["an adoptive transfer model", "TREATMENT", 225, 251], ["CD8 T cells", "TREATMENT", 280, 291], ["virus", "OBSERVATION", 32, 37], ["cross-reactive viruses", "OBSERVATION", 118, 140], ["proliferation", "OBSERVATION_MODIFIER", 146, 159], ["memory cells", "OBSERVATION", 169, 181]]], ["Splenocytes from LCMV-immune mice were labelled with a fluorescent dye, CFSE, which divides equally between daughter cells during division and then transferred into a naive host.", [["Splenocytes", "ANATOMY", 0, 11], ["cells", "ANATOMY", 117, 122], ["CFSE", "CHEMICAL", 72, 76], ["CFSE", "CHEMICAL", 72, 76], ["Splenocytes", "CELL", 0, 11], ["LCMV-immune mice", "ORGANISM", 17, 33], ["CFSE", "SIMPLE_CHEMICAL", 72, 76], ["daughter cells", "CELL", 108, 122], ["Splenocytes", "CELL_TYPE", 0, 11], ["daughter cells", "CELL_TYPE", 108, 122], ["mice", "SPECIES", 29, 33], ["LCMV", "SPECIES", 17, 21], ["mice", "SPECIES", 29, 33], ["Splenocytes", "TEST", 0, 11], ["LCMV", "TEST", 17, 21], ["a fluorescent dye", "TREATMENT", 53, 70]]], ["Infection of a recipient with the homologous virus, LCMV, induced substantial division and accumulation of the donor CD8 T cells (Fig. 2) , with virtually all detectable T cells specific for LCMV undergoing at least seven divisions, the limit of detection with CFSE (Kim et al ., 2002) .", [["CD8 T cells", "ANATOMY", 117, 128], ["T cells", "ANATOMY", 170, 177], ["CFSE", "CHEMICAL", 261, 265], ["LCMV", "ORGANISM", 52, 56], ["CD8", "GENE_OR_GENE_PRODUCT", 117, 120], ["T cells", "CELL", 170, 177], ["LCMV", "ORGANISM", 191, 195], ["CFSE", "SIMPLE_CHEMICAL", 261, 265], ["donor CD8 T cells", "CELL_TYPE", 111, 128], ["T cells", "CELL_TYPE", 170, 177], ["LCMV", "SPECIES", 52, 56], ["LCMV", "SPECIES", 191, 195], ["the homologous virus", "PROBLEM", 30, 50], ["LCMV", "PROBLEM", 52, 56], ["the donor CD8 T cells", "TEST", 107, 128], ["LCMV", "PROBLEM", 191, 195], ["LCMV", "OBSERVATION", 52, 56], ["substantial", "OBSERVATION_MODIFIER", 66, 77], ["division", "OBSERVATION_MODIFIER", 78, 86], ["accumulation", "OBSERVATION_MODIFIER", 91, 103], ["donor CD8 T cells", "OBSERVATION", 111, 128]]], ["In contrast, treatment of recipient mice with poly (I:C) induced no increase in cell number of donor cells and stimulated only limited cell division, again demonstrating the requirement for TCR engagement for sustained proliferation.", [["cell", "ANATOMY", 80, 84], ["cells", "ANATOMY", 101, 106], ["cell", "ANATOMY", 135, 139], ["poly (I:C", "CHEMICAL", 46, 55], ["TCR", "CHEMICAL", 190, 193], ["poly (I:C", "CHEMICAL", 46, 55], ["mice", "ORGANISM", 36, 40], ["poly (I:C", "SIMPLE_CHEMICAL", 46, 55], ["cell", "CELL", 80, 84], ["donor cells", "CELL", 95, 106], ["cell", "CELL", 135, 139], ["TCR", "GENE_OR_GENE_PRODUCT", 190, 193], ["donor cells", "CELL_TYPE", 95, 106], ["TCR", "PROTEIN", 190, 193], ["mice", "SPECIES", 36, 40], ["mice", "SPECIES", 36, 40], ["donor cells", "PROBLEM", 95, 106], ["TCR engagement", "TREATMENT", 190, 204], ["sustained proliferation", "PROBLEM", 209, 232], ["no", "UNCERTAINTY", 65, 67], ["increase", "OBSERVATION_MODIFIER", 68, 76], ["cell", "OBSERVATION", 80, 84], ["donor cells", "OBSERVATION", 95, 106], ["proliferation", "OBSERVATION", 219, 232]]], ["In this transfer model, infection with the heterologous but cross-reactive viruses PV and VV stimulated significant proliferation of a subset of the donor cells (Fig. 2) , which were presumably those cross-reactive between the viruses.", [["cells", "ANATOMY", 155, 160], ["infection", "DISEASE", 24, 33], ["cross-reactive viruses PV", "ORGANISM", 60, 85], ["VV", "ORGANISM", 90, 92], ["cells", "CELL", 155, 160], ["Fig. 2", "CELL", 162, 168], ["donor cells", "CELL_TYPE", 149, 160], ["PV", "SPECIES", 83, 85], ["VV", "SPECIES", 90, 92], ["infection", "PROBLEM", 24, 33], ["the heterologous", "PROBLEM", 39, 55], ["cross-reactive viruses PV", "PROBLEM", 60, 85], ["infection", "OBSERVATION", 24, 33], ["cross-reactive viruses", "OBSERVATION", 60, 82], ["significant", "OBSERVATION_MODIFIER", 104, 115], ["proliferation", "OBSERVATION_MODIFIER", 116, 129], ["donor cells", "OBSERVATION", 149, 160], ["viruses", "OBSERVATION", 227, 234]]], ["These findings show that cross-reactivity results in the proliferation of selected populations of virus-specific memory CD8 T cells and raises the question of what effect these expanded populations of memory T cells will have on the response against the current infection.Sequential infections with homologous and heterologous virusesThe stimulation of LCMV-specific CTL activity and proliferation of populations of virus-specific memory CD8 T cells by subsequent infections with heterologous viruses resemble the phenomenon of 'original antigenic sin' that has been described for B cell responses against influenza virus subtypes (Francis, 1953; Selin et al ., 1994; Kim et al ., 2002) .", [["memory CD8 T cells", "ANATOMY", 113, 131], ["memory T cells", "ANATOMY", 201, 215], ["memory CD8 T cells", "ANATOMY", 431, 449], ["B cell", "ANATOMY", 581, 587], ["infection", "DISEASE", 262, 271], ["infections", "DISEASE", 283, 293], ["infections", "DISEASE", 464, 474], ["influenza virus", "DISEASE", 606, 621], ["memory CD8 T cells", "CELL", 113, 131], ["memory T cells", "CELL", 201, 215], ["LCMV", "ORGANISM", 353, 357], ["CTL", "CELL", 367, 370], ["memory CD8 T cells", "CELL", 431, 449], ["B cell", "CELL", 581, 587], ["influenza virus", "ORGANISM", 606, 621], ["memory CD8 T cells", "CELL_TYPE", 113, 131], ["memory T cells", "CELL_TYPE", 201, 215], ["memory CD8 T cells", "CELL_TYPE", 431, 449], ["influenza virus", "SPECIES", 606, 621], ["LCMV", "SPECIES", 353, 357], ["virus", "PROBLEM", 98, 103], ["memory T cells", "PROBLEM", 201, 215], ["the current infection", "PROBLEM", 250, 271], ["Sequential infections with homologous and heterologous viruses", "PROBLEM", 272, 334], ["LCMV", "PROBLEM", 353, 357], ["virus", "PROBLEM", 416, 421], ["subsequent infections", "PROBLEM", 453, 474], ["heterologous viruses", "PROBLEM", 480, 500], ["B cell responses", "PROBLEM", 581, 597], ["influenza virus subtypes", "PROBLEM", 606, 630], ["proliferation", "OBSERVATION_MODIFIER", 57, 70], ["virus", "OBSERVATION_MODIFIER", 98, 103], ["memory CD8", "OBSERVATION", 113, 123], ["infection", "OBSERVATION", 262, 271], ["infections", "OBSERVATION", 283, 293], ["heterologous viruses", "OBSERVATION", 314, 334], ["LCMV", "OBSERVATION", 353, 357]]], ["In agreement, mice previously infected with a wild-type strain of LCMV and then challenged with variant strains of LCMV that encode altered T cell epitopes preferentially generated CD8 T cells that were specific for the epitope encoded for by the previously encountered wild-type virus (Klenerman and Zinkernagel, 1998) .", [["T cell", "ANATOMY", 140, 146], ["CD8 T cells", "ANATOMY", 181, 192], ["mice", "ORGANISM", 14, 18], ["LCMV", "ORGANISM", 66, 70], ["LCMV", "ORGANISM", 115, 119], ["T cell", "CELL", 140, 146], ["CD8 T cells", "CELL", 181, 192], ["wild-type virus", "ORGANISM", 270, 285], ["T cell epitopes", "PROTEIN", 140, 155], ["CD8 T cells", "CELL_TYPE", 181, 192], ["mice", "SPECIES", 14, 18], ["mice", "SPECIES", 14, 18], ["LCMV", "SPECIES", 66, 70], ["LCMV", "SPECIES", 115, 119], ["a wild-type strain of LCMV", "PROBLEM", 44, 70], ["LCMV", "PROBLEM", 115, 119], ["altered T cell epitopes", "PROBLEM", 132, 155], ["CD8 T cells", "PROBLEM", 181, 192], ["LCMV", "OBSERVATION", 66, 70], ["LCMV", "OBSERVATION", 115, 119]]], ["However, the recall T cell responses generated by secondary infection with the LCMV-variants did not efficiently recognize the variant epitopes encoded for by the second virus and resulted in the impaired clearance of the variant viruses.", [["T cell", "ANATOMY", 20, 26], ["infection", "DISEASE", 60, 69], ["T cell", "CELL", 20, 26], ["LCMV", "ORGANISM", 79, 83], ["secondary infection", "PROBLEM", 50, 69], ["the variant epitopes", "PROBLEM", 123, 143], ["the second virus", "PROBLEM", 159, 175], ["the impaired clearance of the variant viruses", "PROBLEM", 192, 237], ["secondary", "OBSERVATION_MODIFIER", 50, 59], ["infection", "OBSERVATION", 60, 69], ["impaired", "OBSERVATION", 196, 204], ["variant viruses", "OBSERVATION", 222, 237]]], ["This impairment in immunity during sequential infections suggests that in some instances memory T cells generated by prior infections can have detrimental consequences for a host's defence against pathogens.Sequential infections with homologous and heterologous virusesA similar phenomenon has been demonstrated for dengue virus-specific CD8 T cell responses in humans (Mongkolsapaya et al., 2003) .", [["memory T cells", "ANATOMY", 89, 103], ["CD8 T cell", "ANATOMY", 338, 348], ["infections", "DISEASE", 46, 56], ["infections", "DISEASE", 123, 133], ["infections", "DISEASE", 218, 228], ["dengue", "DISEASE", 316, 322], ["memory T cells", "CELL", 89, 103], ["dengue virus", "ORGANISM", 316, 328], ["CD8 T cell", "CELL", 338, 348], ["humans", "ORGANISM", 362, 368], ["memory T cells", "CELL_TYPE", 89, 103], ["humans", "SPECIES", 362, 368], ["dengue virus", "SPECIES", 316, 328], ["humans", "SPECIES", 362, 368], ["This impairment in immunity during sequential infections", "PROBLEM", 0, 56], ["prior infections", "PROBLEM", 117, 133], ["pathogens", "PROBLEM", 197, 206], ["Sequential infections", "PROBLEM", 207, 228], ["homologous and heterologous viruses", "PROBLEM", 234, 269], ["A similar phenomenon", "PROBLEM", 269, 289], ["dengue virus", "PROBLEM", 316, 328], ["infections", "OBSERVATION", 218, 228], ["heterologous viruses", "OBSERVATION", 249, 269]]], ["Dengue viruses are arthropod-borne flaviviruses occurring as four serotypes defined in part by neutralizing antibody .", [["Dengue viruses", "DISEASE", 0, 14], ["arthropod-borne flaviviruses", "DISEASE", 19, 47], ["Dengue viruses", "ORGANISM", 0, 14], ["neutralizing antibody", "PROTEIN", 95, 116], ["Dengue viruses", "SPECIES", 0, 14], ["Dengue viruses", "PROBLEM", 0, 14], ["arthropod-borne flaviviruses", "PROBLEM", 19, 47], ["four serotypes", "PROBLEM", 61, 75], ["viruses", "OBSERVATION", 7, 14], ["neutralizing antibody", "OBSERVATION", 95, 116]]], ["Initial infection with one dengue serotype provides protective immunity against re-infection with the identical virus, but subsequent infection with other serotypes can be associated with the development of lifethreatening disease such as dengue haemorrhagic fever and dengue shock syndrome.", [["infection", "DISEASE", 8, 17], ["dengue", "DISEASE", 27, 33], ["infection", "DISEASE", 134, 143], ["dengue haemorrhagic fever", "DISEASE", 239, 264], ["dengue shock syndrome", "DISEASE", 269, 290], ["dengue haemorrhagic fever", "SPECIES", 239, 264], ["dengue", "SPECIES", 27, 33], ["Initial infection", "PROBLEM", 0, 17], ["one dengue serotype", "TREATMENT", 23, 42], ["re-infection", "PROBLEM", 80, 92], ["the identical virus", "PROBLEM", 98, 117], ["subsequent infection", "PROBLEM", 123, 143], ["other serotypes", "PROBLEM", 149, 164], ["lifethreatening disease", "PROBLEM", 207, 230], ["dengue haemorrhagic fever", "PROBLEM", 239, 264], ["dengue shock syndrome", "PROBLEM", 269, 290], ["infection", "OBSERVATION", 8, 17], ["virus", "OBSERVATION", 112, 117], ["infection", "OBSERVATION", 134, 143], ["lifethreatening disease", "OBSERVATION", 207, 230], ["haemorrhagic", "OBSERVATION_MODIFIER", 246, 258], ["shock syndrome", "OBSERVATION", 276, 290]]], ["Interestingly, secondary infections with dengue virus elicited CD8 T cells with a higher affinity for different dengue serotypes than for the current infecting virus, suggesting the reactivation of memory CD8 T cells specific to previously encountered dengue virus serotypes.T cell immunodominance and sequential viral infectionsEpitope-specific CD8 T cells generated by viral infections have defined hierarchies, with some dominating the response and others being weak to barely detectable (Mylin et al., 1995) .", [["CD8 T cells", "ANATOMY", 63, 74], ["memory CD8 T cells", "ANATOMY", 198, 216], ["T cell", "ANATOMY", 275, 281], ["CD8 T cells", "ANATOMY", 346, 357], ["infections", "DISEASE", 25, 35], ["dengue", "DISEASE", 41, 47], ["dengue", "DISEASE", 112, 118], ["dengue", "DISEASE", 252, 258], ["viral infections", "DISEASE", 313, 329], ["viral infections", "DISEASE", 371, 387], ["dengue virus", "ORGANISM", 41, 53], ["CD8 T cells", "CELL", 63, 74], ["CD8 T cells", "CELL", 205, 216], ["dengue virus serotypes", "ORGANISM", 252, 274], ["T cell", "CELL", 275, 281], ["CD8", "GENE_OR_GENE_PRODUCT", 346, 349], ["CD8 T cells", "CELL_TYPE", 63, 74], ["memory CD8 T cells", "CELL_TYPE", 198, 216], ["CD8 T cells", "CELL_TYPE", 346, 357], ["dengue virus", "SPECIES", 41, 53], ["dengue", "SPECIES", 112, 118], ["dengue virus", "SPECIES", 252, 264], ["secondary infections", "PROBLEM", 15, 35], ["dengue virus", "PROBLEM", 41, 53], ["CD8 T cells", "PROBLEM", 63, 74], ["a higher affinity", "PROBLEM", 80, 97], ["different dengue serotypes", "PROBLEM", 102, 128], ["the current infecting virus", "PROBLEM", 138, 165], ["memory CD8 T cells", "PROBLEM", 198, 216], ["previously encountered dengue virus serotypes", "PROBLEM", 229, 274], ["T cell immunodominance", "PROBLEM", 275, 297], ["sequential viral infections", "PROBLEM", 302, 329], ["Epitope", "TEST", 329, 336], ["viral infections", "PROBLEM", 371, 387], ["secondary", "OBSERVATION_MODIFIER", 15, 24], ["infections", "OBSERVATION", 25, 35], ["cell immunodominance", "OBSERVATION", 277, 297], ["viral infections", "OBSERVATION", 313, 329], ["viral infections", "OBSERVATION", 371, 387]]], ["These immunodominance hierarchies are extremely reproducible between individual hosts of the same haplotype and are maintained in the memory population (Belz et al., 2000) .", [["immunodominance hierarchies", "OBSERVATION", 6, 33]]], ["Multiple parameters, including the efficiency of peptide processing and presentation, the affinity of the peptide for the presenting MHC molecule, the quantity of MHC-peptide complexes, the available TCR repertoire, and competition between T cells (immunodomination) are thought to contribute to these immunodominance profiles (Yewdell and Bennink, 1999) .T cell immunodominance and sequential viral infectionsThe activation of virus-specific memory CD8 T cells following infections with heterologous viruses is a newly described factor influencing the immunodominance of T cells specific for the challenge virus .", [["T cells", "ANATOMY", 240, 247], ["T cell", "ANATOMY", 356, 362], ["memory CD8 T cells", "ANATOMY", 443, 461], ["T cells", "ANATOMY", 572, 579], ["viral infections", "DISEASE", 394, 410], ["infections", "DISEASE", 472, 482], ["TCR", "GENE_OR_GENE_PRODUCT", 200, 203], ["T cells", "CELL", 240, 247], ["T cell", "CELL", 356, 362], ["CD8 T cells", "CELL", 450, 461], ["T cells", "CELL", 572, 579], ["MHC molecule", "PROTEIN", 133, 145], ["MHC", "PROTEIN", 163, 166], ["TCR repertoire", "PROTEIN", 200, 214], ["T cells", "CELL_TYPE", 240, 247], ["memory CD8 T cells", "CELL_TYPE", 443, 461], ["T cells", "CELL_TYPE", 572, 579], ["Multiple parameters", "TEST", 0, 19], ["peptide processing", "PROBLEM", 49, 67], ["peptide complexes", "PROBLEM", 167, 184], ["the available TCR repertoire", "TEST", 186, 214], ["competition between T cells", "PROBLEM", 220, 247], ["T cell immunodominance", "PROBLEM", 356, 378], ["sequential viral infections", "PROBLEM", 383, 410], ["The activation of virus", "PROBLEM", 410, 433], ["infections", "PROBLEM", 472, 482], ["heterologous viruses", "PROBLEM", 488, 508], ["T cells", "PROBLEM", 572, 579], ["the challenge virus", "PROBLEM", 593, 612], ["thought to contribute", "UNCERTAINTY", 271, 292], ["cell immunodominance", "OBSERVATION", 358, 378], ["viral infections", "OBSERVATION", 394, 410], ["virus", "OBSERVATION", 428, 433]]], ["Cross-reactive T cells are not always readily apparent following an infection with a single virus because the frequencies of cross-reactive cells may be very low.", [["T cells", "ANATOMY", 15, 22], ["cells", "ANATOMY", 140, 145], ["infection", "DISEASE", 68, 77], ["T cells", "CELL", 15, 22], ["cells", "CELL", 140, 145], ["Cross-reactive T cells", "CELL_TYPE", 0, 22], ["cross-reactive cells", "CELL_TYPE", 125, 145], ["Cross-reactive T cells", "PROBLEM", 0, 22], ["an infection", "PROBLEM", 65, 77], ["a single virus", "PROBLEM", 83, 97], ["cross-reactive cells", "PROBLEM", 125, 145], ["infection", "OBSERVATION", 68, 77], ["cross-reactive cells", "OBSERVATION", 125, 145]]], ["Cross-reactivity is more easily detectable following multiple infections, because it is those cross-reactive T cells that are selectively amplified after infection (Selin et al., 1994; Haanen et al., 1999) .", [["T cells", "ANATOMY", 109, 116], ["infections", "DISEASE", 62, 72], ["infection", "DISEASE", 154, 163], ["T cells", "CELL", 109, 116], ["cross-reactive T cells", "CELL_TYPE", 94, 116], ["multiple infections", "PROBLEM", 53, 72], ["those cross-reactive T cells", "PROBLEM", 88, 116], ["infection", "PROBLEM", 154, 163], ["multiple", "OBSERVATION_MODIFIER", 53, 61], ["infections", "OBSERVATION", 62, 72]]], ["The expansion of crossreactive CD8 T cell responses by sequential infection with natural variants of influenza virus has been elegantly demonstrated (Haanen et al., 1999) .", [["CD8 T cell", "ANATOMY", 31, 41], ["infection", "DISEASE", 66, 75], ["influenza virus", "DISEASE", 101, 116], ["CD8 T cell", "CELL", 31, 41], ["influenza virus", "ORGANISM", 101, 116], ["influenza virus", "SPECIES", 101, 116], ["influenza virus", "SPECIES", 101, 116], ["crossreactive CD8 T cell responses", "TREATMENT", 17, 51], ["sequential infection", "PROBLEM", 55, 75], ["natural variants", "PROBLEM", 81, 97], ["influenza virus", "PROBLEM", 101, 116], ["expansion", "OBSERVATION_MODIFIER", 4, 13], ["crossreactive CD8 T cell", "OBSERVATION", 17, 41], ["infection", "OBSERVATION", 66, 75], ["influenza virus", "OBSERVATION", 101, 116]]], ["The two influenza variants differ by two amino acid residues in the dominant epitope NP366.", [["amino acid", "CHEMICAL", 41, 51], ["amino acid", "CHEMICAL", 41, 51], ["amino acid", "AMINO_ACID", 41, 51], ["dominant epitope NP366", "PROTEIN", 68, 90], ["The two influenza variants", "PROBLEM", 0, 26], ["two amino acid residues", "TREATMENT", 37, 60], ["influenza variants", "OBSERVATION", 8, 26], ["dominant", "OBSERVATION_MODIFIER", 68, 76], ["epitope NP366", "OBSERVATION", 77, 90]]], ["Sequential infection with the two influenza variants preferentially stimulated the expansion of the cross-reactive CD8 T cells that represent only a minor population during infection with a single variant.", [["CD8 T cells", "ANATOMY", 115, 126], ["infection", "DISEASE", 11, 20], ["infection", "DISEASE", 173, 182], ["CD8 T cells", "CELL", 115, 126], ["cross-reactive CD8 T cells", "CELL_TYPE", 100, 126], ["Sequential infection", "PROBLEM", 0, 20], ["the two influenza variants", "PROBLEM", 26, 52], ["a minor population during infection", "PROBLEM", 147, 182], ["infection", "OBSERVATION", 11, 20], ["influenza", "OBSERVATION", 34, 43], ["expansion", "OBSERVATION_MODIFIER", 83, 92], ["cross-reactive CD8 T cells", "OBSERVATION", 100, 126], ["minor", "OBSERVATION_MODIFIER", 149, 154], ["population", "OBSERVATION", 155, 165], ["infection", "OBSERVATION", 173, 182]]], ["These findings show that the potential for cross-reactivity between heterologous viruses may be completely obscured unless the cross-reactive T cells are amplified by infections in sequence.T cell immunodominance and sequential viral infectionsThe immunodominance hierarchies for H-2 b -restricted CD8 T cells specific for LCMV are dramatically altered in mice previously infected with heterologous but cross-reac-tive viruses .", [["T cells", "ANATOMY", 142, 149], ["T cell", "ANATOMY", 190, 196], ["CD8 T cells", "ANATOMY", 298, 309], ["infections", "DISEASE", 167, 177], ["viral infections", "DISEASE", 228, 244], ["T cells", "CELL", 142, 149], ["T cell", "CELL", 190, 196], ["H-2", "GENE_OR_GENE_PRODUCT", 280, 283], ["CD8", "GENE_OR_GENE_PRODUCT", 298, 301], ["LCMV", "ORGANISM", 323, 327], ["mice", "ORGANISM", 356, 360], ["cross-reac-tive viruses", "ORGANISM", 403, 426], ["cross-reactive T cells", "CELL_TYPE", 127, 149], ["H-2 b -restricted CD8 T cells", "CELL_LINE", 280, 309], ["mice", "SPECIES", 356, 360], ["LCMV", "SPECIES", 323, 327], ["mice", "SPECIES", 356, 360], ["cross-reactivity between heterologous viruses", "PROBLEM", 43, 88], ["the cross-reactive T cells", "PROBLEM", 123, 149], ["infections in sequence", "PROBLEM", 167, 189], ["T cell immunodominance", "PROBLEM", 190, 212], ["sequential viral infections", "PROBLEM", 217, 244], ["The immunodominance hierarchies", "TEST", 244, 275], ["H", "TEST", 280, 281], ["LCMV", "PROBLEM", 323, 327], ["cross-reac", "TEST", 403, 413], ["cell immunodominance", "OBSERVATION", 192, 212], ["viral infections", "OBSERVATION", 228, 244]]], ["Following sequential infections with LCMV and PV in either order, CD8 T cells specific for the normally subdominant but cross-reactive NP205 epitope become dominant, while CD8 T cells specific for the normally dominant epitopes are reduced in frequency (Fig. 3) .", [["CD8 T cells", "ANATOMY", 66, 77], ["CD8 T cells", "ANATOMY", 172, 183], ["infections", "DISEASE", 21, 31], ["LCMV", "ORGANISM", 37, 41], ["CD8", "GENE_OR_GENE_PRODUCT", 66, 69], ["NP205", "GENE_OR_GENE_PRODUCT", 135, 140], ["CD8 T", "GENE_OR_GENE_PRODUCT", 172, 177], ["CD8 T cells", "CELL_TYPE", 66, 77], ["NP205 epitope", "PROTEIN", 135, 148], ["CD8 T cells", "CELL_TYPE", 172, 183], ["LCMV", "SPECIES", 37, 41], ["PV", "SPECIES", 46, 48], ["sequential infections", "PROBLEM", 10, 31], ["LCMV", "PROBLEM", 37, 41], ["PV", "TEST", 46, 48], ["CD8 T cells", "TEST", 66, 77], ["CD8 T cells", "TEST", 172, 183], ["the normally dominant epitopes", "PROBLEM", 197, 227], ["infections", "OBSERVATION", 21, 31], ["LCMV", "OBSERVATION", 37, 41], ["dominant", "OBSERVATION", 156, 164], ["dominant", "OBSERVATION_MODIFIER", 210, 218], ["epitopes", "OBSERVATION", 219, 227], ["reduced", "OBSERVATION_MODIFIER", 232, 239]]], ["Alterations in the immunodominance hierarchies of LCMV-specific memory CD8 T cells have also been observed following infection with VV Kim et al., 2002) .", [["memory CD8 T cells", "ANATOMY", 64, 82], ["infection", "DISEASE", 117, 126], ["LCMV", "ORGANISM", 50, 54], ["CD8", "GENE_OR_GENE_PRODUCT", 71, 74], ["LCMV-specific memory CD8 T cells", "CELL_TYPE", 50, 82], ["LCMV", "PROBLEM", 50, 54], ["infection", "PROBLEM", 117, 126]]], ["These findings all lead to the conclusion that the nature of CD8 T cell immunodominance in a 'real world' scenario where a host is continuously exposed to viral pathogens may be very different when compared to a naive host.Heterologous immunity and immunopathologyA host's history of viral infections may also influence how well the new infection is controlled, and this is a function of heterologous immunity.", [["CD8 T cell", "ANATOMY", 61, 71], ["viral infections", "DISEASE", 284, 300], ["infection", "DISEASE", 337, 346], ["CD8", "GENE_OR_GENE_PRODUCT", 61, 64], ["CD8", "PROTEIN", 61, 64], ["CD8 T cell immunodominance", "PROBLEM", 61, 87], ["viral pathogens", "PROBLEM", 155, 170], ["viral infections", "PROBLEM", 284, 300], ["the new infection", "PROBLEM", 329, 346], ["heterologous immunity", "TREATMENT", 388, 409], ["CD8 T cell immunodominance", "OBSERVATION", 61, 87], ["viral", "OBSERVATION_MODIFIER", 284, 289], ["infections", "OBSERVATION", 290, 300], ["new", "OBSERVATION_MODIFIER", 333, 336], ["infection", "OBSERVATION", 337, 346]]], ["Mice previously infected with a panel of heterologous viruses (LCMV, PV, MCMV and VV) were often protected against challenges with the unrelated viruses (Selin et al., 1998) .", [["Mice", "ORGANISM", 0, 4], ["LCMV", "ORGANISM", 63, 67], ["MCMV", "ORGANISM", 73, 77], ["VV", "ORGANISM", 82, 84], ["Mice", "SPECIES", 0, 4], ["Mice", "SPECIES", 0, 4], ["LCMV", "SPECIES", 63, 67], ["PV", "SPECIES", 69, 71], ["MCMV", "SPECIES", 73, 77], ["VV", "SPECIES", 82, 84], ["a panel", "TEST", 30, 37], ["heterologous viruses", "PROBLEM", 41, 61], ["LCMV", "TEST", 63, 67], ["infected", "OBSERVATION", 16, 24]]], ["For example, LCMVimmune, PV-immune and MCMV-immune mice were afforded a significant level of protection against challenge with VV (greater than a 100-fold decrease in titres relative to na\u00efve mice by four days post infection).", [["infection", "DISEASE", 215, 224], ["LCMVimmune", "SIMPLE_CHEMICAL", 13, 23], ["PV-immune", "ORGANISM", 25, 34], ["MCMV", "ORGANISM", 39, 43], ["-immune mice", "ORGANISM", 43, 55], ["VV", "ORGANISM", 127, 129], ["mice", "ORGANISM", 192, 196], ["mice", "SPECIES", 51, 55], ["mice", "SPECIES", 192, 196], ["PV", "SPECIES", 25, 27], ["MCMV", "SPECIES", 39, 43], ["mice", "SPECIES", 51, 55], ["VV", "SPECIES", 127, 129], ["mice", "SPECIES", 192, 196], ["LCMVimmune", "TEST", 13, 23], ["PV", "TEST", 25, 27], ["MCMV", "TEST", 39, 43], ["VV", "TREATMENT", 127, 129], ["infection", "PROBLEM", 215, 224], ["infection", "OBSERVATION", 215, 224]]], ["Both CD4 and CD8 T cells from LCMV-immune mice were necessary to provide protection against PV and VV, and immunity against VV was mediated at least in part by the production of IFN-g.", [["CD4", "ANATOMY", 5, 8], ["CD8 T cells", "ANATOMY", 13, 24], ["CD4", "GENE_OR_GENE_PRODUCT", 5, 8], ["CD8", "GENE_OR_GENE_PRODUCT", 13, 16], ["LCMV-immune mice", "ORGANISM", 30, 46], ["VV", "ORGANISM", 99, 101], ["VV", "ORGANISM", 124, 126], ["CD4 and CD8 T cells", "CELL_TYPE", 5, 24], ["IFN", "PROTEIN", 178, 181], ["mice", "SPECIES", 42, 46], ["mice", "SPECIES", 42, 46], ["PV", "SPECIES", 92, 94], ["VV", "SPECIES", 99, 101], ["VV", "SPECIES", 124, 126], ["Both CD4", "TEST", 0, 8], ["LCMV", "TEST", 30, 34], ["immune mice", "TREATMENT", 35, 46], ["PV", "TEST", 92, 94], ["VV", "PROBLEM", 124, 126], ["CD4", "OBSERVATION", 5, 8]]], ["Of note is that this immunity was not reciprocal, as VV-immune mice were not protected against infection with any of the heterologous viruses.", [["infection", "DISEASE", 95, 104], ["VV-immune mice", "ORGANISM", 53, 67], ["mice", "SPECIES", 63, 67], ["VV", "SPECIES", 53, 55], ["mice", "SPECIES", 63, 67], ["VV", "TEST", 53, 55], ["infection", "PROBLEM", 95, 104], ["the heterologous viruses", "PROBLEM", 117, 141]]], ["This lack of reciprocity for heterologous immunity in VV-immune mice correlated with the functional activity of T cells, as VV-specific memory T cells were not stimulated by LCMV infection to proliferate or to be cytolytic (Selin et al., 1994; Kim et al., 2002) .Heterologous immunity and immunopathologyHeterologous immunity has been studied extensively with respiratory viral infections .", [["T cells", "ANATOMY", 112, 119], ["memory T cells", "ANATOMY", 136, 150], ["infection", "DISEASE", 179, 188], ["respiratory viral infections", "DISEASE", 360, 388], ["VV-immune mice", "ORGANISM", 54, 68], ["T cells", "CELL", 112, 119], ["VV", "ORGANISM", 124, 126], ["memory T cells", "CELL", 136, 150], ["LCMV", "ORGANISM", 174, 178], ["T cells", "CELL_TYPE", 112, 119], ["VV-specific memory T cells", "CELL_TYPE", 124, 150], ["mice", "SPECIES", 64, 68], ["VV", "SPECIES", 54, 56], ["mice", "SPECIES", 64, 68], ["VV", "SPECIES", 124, 126], ["LCMV", "SPECIES", 174, 178], ["heterologous immunity", "TREATMENT", 29, 50], ["VV", "TEST", 124, 126], ["LCMV infection", "PROBLEM", 174, 188], ["Heterologous immunity", "TREATMENT", 263, 284], ["respiratory viral infections", "PROBLEM", 360, 388], ["viral infections", "OBSERVATION", 372, 388]]], ["LCMV-immune mice were protected against a lethal dose of VV delivered intranasally, with significant reductions in VV titres in the lung compared to na\u00efve mice.", [["intranasally", "ANATOMY", 70, 82], ["lung", "ANATOMY", 132, 136], ["LCMV-immune mice", "ORGANISM", 0, 16], ["VV", "ORGANISM", 57, 59], ["VV", "ORGANISM", 115, 117], ["lung", "ORGAN", 132, 136], ["mice", "ORGANISM", 155, 159], ["mice", "SPECIES", 12, 16], ["mice", "SPECIES", 155, 159], ["LCMV", "SPECIES", 0, 4], ["mice", "SPECIES", 12, 16], ["VV", "SPECIES", 57, 59], ["VV", "SPECIES", 115, 117], ["mice", "SPECIES", 155, 159], ["LCMV-immune mice", "TREATMENT", 0, 16], ["VV delivered intranasally", "TREATMENT", 57, 82], ["significant reductions in VV titres in the lung", "PROBLEM", 89, 136], ["significant", "OBSERVATION_MODIFIER", 89, 100], ["reductions", "OBSERVATION_MODIFIER", 101, 111], ["VV titres", "OBSERVATION", 115, 124], ["lung", "ANATOMY", 132, 136]]], ["Mice previously infected with MCMV or influenza also were protected against intranasal challenge with VV.", [["Mice", "ORGANISM", 0, 4], ["MCMV", "ORGANISM", 30, 34], ["influenza", "ORGANISM", 38, 47], ["Mice", "SPECIES", 0, 4], ["MCMV", "SPECIES", 30, 34], ["Mice", "SPECIES", 0, 4], ["MCMV", "SPECIES", 30, 34], ["VV", "SPECIES", 102, 104], ["MCMV", "PROBLEM", 30, 34], ["influenza", "PROBLEM", 38, 47], ["MCMV", "OBSERVATION", 30, 34]]], ["Following VV challenge of mice that were previously infected with either LCMV or influenza, a shift in cytokine production towards a Th1 phenotype (such as IFN-g production) was observed in the lungs 3 days after infection in comparison to the cytokines produced in VV-infected na\u00efve mice.", [["lungs", "ANATOMY", 194, 199], ["influenza", "DISEASE", 81, 90], ["infection", "DISEASE", 213, 222], ["VV", "ORGANISM", 10, 12], ["mice", "ORGANISM", 26, 30], ["LCMV", "ORGANISM", 73, 77], ["IFN-g", "GENE_OR_GENE_PRODUCT", 156, 161], ["lungs", "ORGAN", 194, 199], ["VV", "ORGANISM", 266, 268], ["mice", "ORGANISM", 284, 288], ["cytokine", "PROTEIN", 103, 111], ["IFN", "PROTEIN", 156, 159], ["cytokines", "PROTEIN", 244, 253], ["mice", "SPECIES", 26, 30], ["mice", "SPECIES", 284, 288], ["VV", "SPECIES", 10, 12], ["mice", "SPECIES", 26, 30], ["LCMV", "SPECIES", 73, 77], ["VV", "SPECIES", 266, 268], ["mice", "SPECIES", 284, 288], ["VV challenge of mice", "TREATMENT", 10, 30], ["LCMV", "PROBLEM", 73, 77], ["influenza", "PROBLEM", 81, 90], ["a shift in cytokine production", "PROBLEM", 92, 122], ["a Th1 phenotype", "PROBLEM", 131, 146], ["IFN-g production", "TREATMENT", 156, 172], ["infection", "PROBLEM", 213, 222], ["the cytokines", "TEST", 240, 253], ["LCMV", "OBSERVATION", 73, 77], ["influenza", "OBSERVATION", 81, 90], ["lungs", "ANATOMY", 194, 199], ["infection", "OBSERVATION", 213, 222], ["infected", "OBSERVATION", 269, 277]]], ["Heterologous immunity in the lung was not always protective, however, as clearance of LCMV and MCMV was impaired in influenza-immune mice, and a history of an LCMV infection impaired the ability of mice to clear RSV from the lung following an intranasal inoculation (Ostler et al., 2003) .", [["lung", "ANATOMY", 29, 33], ["lung", "ANATOMY", 225, 229], ["LCMV infection", "DISEASE", 159, 173], ["lung", "ORGAN", 29, 33], ["LCMV", "ORGANISM", 86, 90], ["MCMV", "ORGANISM", 95, 99], ["influenza-immune mice", "ORGANISM", 116, 137], ["LCMV", "ORGANISM", 159, 163], ["mice", "ORGANISM", 198, 202], ["RSV", "ORGANISM", 212, 215], ["lung", "ORGAN", 225, 229], ["mice", "SPECIES", 133, 137], ["mice", "SPECIES", 198, 202], ["LCMV", "SPECIES", 86, 90], ["MCMV", "SPECIES", 95, 99], ["mice", "SPECIES", 133, 137], ["LCMV", "SPECIES", 159, 163], ["mice", "SPECIES", 198, 202], ["RSV", "SPECIES", 212, 215], ["LCMV", "PROBLEM", 86, 90], ["MCMV", "PROBLEM", 95, 99], ["influenza", "PROBLEM", 116, 125], ["an LCMV infection", "PROBLEM", 156, 173], ["an intranasal inoculation", "TREATMENT", 240, 265], ["lung", "ANATOMY", 29, 33], ["LCMV", "OBSERVATION", 86, 90], ["LCMV", "OBSERVATION_MODIFIER", 159, 163], ["infection", "OBSERVATION", 164, 173], ["RSV", "OBSERVATION", 212, 215], ["lung", "ANATOMY", 225, 229]]], ["The mechanisms of diminished protective immunity in mice previously infected with heterologous virus are uncertain and may correlate with altered cytokine profiles.", [["mice", "ORGANISM", 52, 56], ["heterologous virus", "ORGANISM", 82, 100], ["cytokine", "PROTEIN", 146, 154], ["mice", "SPECIES", 52, 56], ["mice", "SPECIES", 52, 56], ["diminished protective immunity", "PROBLEM", 18, 48], ["heterologous virus", "PROBLEM", 82, 100], ["altered cytokine profiles", "PROBLEM", 138, 163], ["diminished", "OBSERVATION_MODIFIER", 18, 28]]], ["Alternatively, the reduced levels of protection may be attributed to the stimulation of memory T cells that are not effective at controlling the infection and to the suppressed development of T cells that would be effective, as shown in other studies on original antigenic sin (Klenerman and Zinkernagel, 1998; Mongkolsapaya et al., 2003) .", [["memory T cells", "ANATOMY", 88, 102], ["T cells", "ANATOMY", 192, 199], ["infection", "DISEASE", 145, 154], ["memory T cells", "CELL", 88, 102], ["T cells", "CELL", 192, 199], ["memory T cells", "CELL_TYPE", 88, 102], ["T cells", "CELL_TYPE", 192, 199], ["the reduced levels of protection", "PROBLEM", 15, 47], ["memory T cells", "PROBLEM", 88, 102], ["the infection", "PROBLEM", 141, 154], ["T cells", "PROBLEM", 192, 199], ["reduced", "OBSERVATION_MODIFIER", 19, 26], ["infection", "OBSERVATION", 145, 154]]], ["Overall these results indicate that prior viral infections can either augment or inhibit viral clearance during subsequent infections with unrelated viruses.Heterologous immunity and immunopathologyHeterologous immunity may also be associated with the development of severe immunopathology.", [["viral infections", "DISEASE", 42, 58], ["infections", "DISEASE", 123, 133], ["immunopathology", "DISEASE", 274, 289], ["prior viral infections", "PROBLEM", 36, 58], ["viral clearance", "PROBLEM", 89, 104], ["subsequent infections", "PROBLEM", 112, 133], ["unrelated viruses", "PROBLEM", 139, 156], ["Heterologous immunity", "TREATMENT", 157, 178], ["severe immunopathology", "PROBLEM", 267, 289], ["viral", "OBSERVATION_MODIFIER", 42, 47], ["infections", "OBSERVATION", 48, 58], ["severe", "OBSERVATION_MODIFIER", 267, 273], ["immunopathology", "OBSERVATION", 274, 289]]], ["LCMV-immune mice infected intraperitoneally with VV developed an IFNg-dependent acute fatty necrosis associated with a cellular infiltrate in the visceral fat pads (Selin et al., 1998) .", [["intraperitoneally", "ANATOMY", 26, 43], ["cellular", "ANATOMY", 119, 127], ["visceral fat pads", "ANATOMY", 146, 163], ["fatty necrosis", "DISEASE", 86, 100], ["LCMV-immune mice", "ORGANISM", 0, 16], ["IFNg", "GENE_OR_GENE_PRODUCT", 65, 69], ["cellular", "CELL", 119, 127], ["visceral fat pads", "TISSUE", 146, 163], ["mice", "SPECIES", 12, 16], ["LCMV", "SPECIES", 0, 4], ["mice", "SPECIES", 12, 16], ["VV", "SPECIES", 49, 51], ["LCMV", "TEST", 0, 4], ["VV", "PROBLEM", 49, 51], ["an IFNg-dependent acute fatty necrosis", "PROBLEM", 62, 100], ["a cellular infiltrate in the visceral fat pads", "PROBLEM", 117, 163], ["IFNg", "OBSERVATION", 65, 69], ["dependent", "OBSERVATION_MODIFIER", 70, 79], ["acute", "OBSERVATION_MODIFIER", 80, 85], ["fatty necrosis", "OBSERVATION", 86, 100], ["cellular", "OBSERVATION_MODIFIER", 119, 127], ["infiltrate", "OBSERVATION", 128, 138], ["visceral fat", "ANATOMY", 146, 158]]], ["In an intranasal model, LCMV-immune mice infected with VV developed a severe lung pathology that was characterized by a strong lymphocytic response, and the induction of bronchiolitis obliterans, which involves the obstruction of bronchioles by fibrin and inflammatory cells .", [["lung", "ANATOMY", 77, 81], ["lymphocytic", "ANATOMY", 127, 138], ["bronchioles", "ANATOMY", 230, 241], ["fibrin", "ANATOMY", 245, 251], ["inflammatory cells", "ANATOMY", 256, 274], ["bronchiolitis obliterans", "DISEASE", 170, 194], ["LCMV-immune mice", "ORGANISM", 24, 40], ["VV", "ORGANISM", 55, 57], ["lung", "ORGAN", 77, 81], ["bronchioles", "MULTI-TISSUE_STRUCTURE", 230, 241], ["fibrin", "GENE_OR_GENE_PRODUCT", 245, 251], ["inflammatory cells", "CELL", 256, 274], ["fibrin", "PROTEIN", 245, 251], ["inflammatory cells", "CELL_TYPE", 256, 274], ["mice", "SPECIES", 36, 40], ["LCMV", "SPECIES", 24, 28], ["mice", "SPECIES", 36, 40], ["VV", "SPECIES", 55, 57], ["an intranasal model", "TREATMENT", 3, 22], ["LCMV", "PROBLEM", 24, 28], ["VV", "PROBLEM", 55, 57], ["a severe lung pathology", "PROBLEM", 68, 91], ["a strong lymphocytic response", "PROBLEM", 118, 147], ["bronchiolitis obliterans", "PROBLEM", 170, 194], ["the obstruction of bronchioles", "PROBLEM", 211, 241], ["fibrin and inflammatory cells", "PROBLEM", 245, 274], ["LCMV", "OBSERVATION", 24, 28], ["severe", "OBSERVATION_MODIFIER", 70, 76], ["lung", "ANATOMY", 77, 81], ["pathology", "OBSERVATION", 82, 91], ["strong", "OBSERVATION_MODIFIER", 120, 126], ["lymphocytic response", "OBSERVATION", 127, 147], ["bronchiolitis obliterans", "OBSERVATION", 170, 194], ["obstruction", "OBSERVATION", 215, 226], ["bronchioles", "ANATOMY", 230, 241], ["fibrin", "OBSERVATION", 245, 251], ["inflammatory cells", "OBSERVATION", 256, 274]]], ["This development of immunopathology during sequential viral infections correlates with the activation of pre-existing memory LCMV-specific CD8 T cells, but additional factors may also contribute to the pathology, including altered cytokine profiles.", [["CD8 T cells", "ANATOMY", 139, 150], ["immunopathology", "DISEASE", 20, 35], ["viral infections", "DISEASE", 54, 70], ["LCMV", "ORGANISM", 125, 129], ["CD8 T cells", "CELL", 139, 150], ["memory LCMV-specific CD8 T cells", "CELL_TYPE", 118, 150], ["cytokine", "PROTEIN", 231, 239], ["immunopathology", "PROBLEM", 20, 35], ["sequential viral infections", "PROBLEM", 43, 70], ["pre-existing memory LCMV", "PROBLEM", 105, 129], ["the pathology", "TEST", 198, 211], ["altered cytokine profiles", "PROBLEM", 223, 248], ["immunopathology", "OBSERVATION", 20, 35], ["viral", "OBSERVATION_MODIFIER", 54, 59], ["infections", "OBSERVATION", 60, 70], ["memory LCMV", "OBSERVATION", 118, 129]]], ["Other studies have shown that prior infections with MCMV, influenza, and Sendai can dramatically alter the histopathology of the lung during subsequent infections with unrelated viruses (Jakab, 1990; Chen et al., 2003) .", [["lung", "ANATOMY", 129, 133], ["infections", "DISEASE", 36, 46], ["influenza", "DISEASE", 58, 67], ["infections", "DISEASE", 152, 162], ["MCMV", "ORGANISM", 52, 56], ["Sendai", "ORGANISM", 73, 79], ["lung", "ORGAN", 129, 133], ["MCMV", "SPECIES", 52, 56], ["Other studies", "TEST", 0, 13], ["prior infections", "PROBLEM", 30, 46], ["MCMV", "PROBLEM", 52, 56], ["influenza", "PROBLEM", 58, 67], ["Sendai", "PROBLEM", 73, 79], ["unrelated viruses", "PROBLEM", 168, 185], ["infections", "OBSERVATION", 36, 46], ["lung", "ANATOMY", 129, 133], ["infections", "OBSERVATION", 152, 162]]], ["Some of the immunopathologies developed following sequential viral infections resemble forms of immune-mediated human diseases of unknown aetiology, with acute fatty necrosis being similar to erythema nodosum, the most common form of human panniculitis, and the induction of bronchiolitis obliterans in humans being associated with viral and bacterial infections and transplant rejections (Bolognia and Braverman, 1992; Schlesinger et al., 1998) .Maintenance of T cell memory during sequential viral infectionsVirus-specific memory CD8 T cells generated by a single virus are maintained at relatively stable frequencies over time (Selin et al., 1996; Homann et al., 2001) .", [["erythema nodosum", "ANATOMY", 192, 208], ["panniculitis", "ANATOMY", 240, 252], ["T cell", "ANATOMY", 462, 468], ["memory CD8 T cells", "ANATOMY", 525, 543], ["viral infections", "DISEASE", 61, 77], ["fatty necrosis", "DISEASE", 160, 174], ["erythema nodosum", "DISEASE", 192, 208], ["panniculitis", "DISEASE", 240, 252], ["bronchiolitis obliterans", "DISEASE", 275, 299], ["viral and bacterial infections", "DISEASE", 332, 362], ["viral infections", "DISEASE", 494, 510], ["human", "ORGANISM", 112, 117], ["human", "ORGANISM", 234, 239], ["humans", "ORGANISM", 303, 309], ["T cell", "CELL", 462, 468], ["Virus", "ORGANISM", 510, 515], ["CD8 T cells", "CELL", 532, 543], ["memory CD8 T cells", "CELL_TYPE", 525, 543], ["human", "SPECIES", 112, 117], ["human", "SPECIES", 234, 239], ["humans", "SPECIES", 303, 309], ["human", "SPECIES", 112, 117], ["human", "SPECIES", 234, 239], ["humans", "SPECIES", 303, 309], ["the immunopathologies", "PROBLEM", 8, 29], ["sequential viral infections", "PROBLEM", 50, 77], ["immune-mediated human diseases", "PROBLEM", 96, 126], ["acute fatty necrosis", "PROBLEM", 154, 174], ["erythema nodosum", "PROBLEM", 192, 208], ["human panniculitis", "PROBLEM", 234, 252], ["bronchiolitis obliterans", "PROBLEM", 275, 299], ["viral and bacterial infections", "PROBLEM", 332, 362], ["transplant rejections", "PROBLEM", 367, 388], ["T cell memory", "PROBLEM", 462, 475], ["sequential viral infections", "PROBLEM", 483, 510], ["Virus", "PROBLEM", 510, 515], ["a single virus", "PROBLEM", 557, 571], ["viral infections", "OBSERVATION", 61, 77], ["human diseases", "OBSERVATION", 112, 126], ["acute", "OBSERVATION_MODIFIER", 154, 159], ["fatty necrosis", "OBSERVATION", 160, 174], ["erythema", "OBSERVATION_MODIFIER", 192, 200], ["nodosum", "OBSERVATION", 201, 208], ["most common", "OBSERVATION_MODIFIER", 214, 225], ["human", "OBSERVATION_MODIFIER", 234, 239], ["panniculitis", "OBSERVATION", 240, 252], ["bronchiolitis obliterans", "OBSERVATION", 275, 299], ["bacterial", "OBSERVATION_MODIFIER", 342, 351], ["infections", "OBSERVATION", 352, 362], ["transplant rejections", "OBSERVATION", 367, 388], ["T cell memory", "OBSERVATION", 462, 475], ["viral", "OBSERVATION_MODIFIER", 494, 499], ["infections", "OBSERVATION", 500, 510], ["stable", "OBSERVATION_MODIFIER", 601, 607]]], ["However, following a subsequent viral infection these populations of memory CD8 T cells are dramatically altered, with the Fig. 3 .", [["memory CD8 T cells", "ANATOMY", 69, 87], ["viral infection", "DISEASE", 32, 47], ["memory CD8 T cells", "CELL", 69, 87], ["memory CD8 T cells", "CELL_TYPE", 69, 87], ["a subsequent viral infection", "PROBLEM", 19, 47], ["viral", "OBSERVATION_MODIFIER", 32, 37], ["infection", "OBSERVATION", 38, 47], ["memory CD8", "OBSERVATION", 69, 79]]], ["The immunodominance hierarchies of virus-specific CD8 T cell responses are altered in mice that have been previously infected with a heterologous virus.", [["CD8 T cell", "ANATOMY", 50, 60], ["CD8", "GENE_OR_GENE_PRODUCT", 50, 53], ["mice", "ORGANISM", 86, 90], ["mice", "SPECIES", 86, 90], ["mice", "SPECIES", 86, 90], ["The immunodominance hierarchies of virus", "PROBLEM", 0, 40], ["a heterologous virus", "PROBLEM", 131, 151], ["immunodominance hierarchies", "OBSERVATION", 4, 31]]], ["The sections of the pie charts reflect the proportion of each epitope-specific response relative to the T cell repertoire shown.", [["sections", "ANATOMY", 4, 12], ["T cell", "ANATOMY", 104, 110], ["T cell", "CELL", 104, 110], ["epitope", "PROTEIN", 62, 69], ["T cell repertoire", "PROTEIN", 104, 121], ["the T cell repertoire", "TREATMENT", 100, 121]]], ["The LCMV-specific response is shown on the left and the PV-specific response is shown on the right.", [["left", "ANATOMY", 43, 47], ["LCMV", "ORGANISM", 4, 8], ["The LCMV", "TEST", 0, 8], ["LCMV", "OBSERVATION", 4, 8], ["specific", "OBSERVATION_MODIFIER", 9, 17], ["response", "OBSERVATION_MODIFIER", 18, 26], ["left", "ANATOMY_MODIFIER", 43, 47], ["PV", "ANATOMY", 56, 58], ["specific response", "OBSERVATION", 59, 76], ["right", "ANATOMY_MODIFIER", 93, 98]]], ["The cross-reactive T cells specific for the NP205 epitope are shown in red for both responses.", [["T cells", "ANATOMY", 19, 26], ["T cells", "CELL", 19, 26], ["NP205", "GENE_OR_GENE_PRODUCT", 44, 49], ["cross-reactive T cells", "CELL_TYPE", 4, 26], ["NP205 epitope", "PROTEIN", 44, 57], ["The cross-reactive T cells", "PROBLEM", 0, 26], ["the NP205 epitope", "TREATMENT", 40, 57], ["cross-reactive T cells", "OBSERVATION", 4, 26]]], ["The figure is based on previous studies . permanent loss of the non-cross-reactive T cells from the memory repertoire and an enrichment of T cells that are cross-reactive with the challenge virus ( Fig. 1) (Selin et al., 1996; Brehm et al., 2002) .", [["T cells", "ANATOMY", 83, 90], ["T cells", "ANATOMY", 139, 146], ["T cells", "CELL", 83, 90], ["T cells", "CELL", 139, 146], ["non-cross-reactive T cells", "CELL_TYPE", 64, 90], ["T cells", "CELL_TYPE", 139, 146], ["previous studies", "TEST", 23, 39], ["permanent loss of the non-cross-reactive T cells", "PROBLEM", 42, 90], ["an enrichment of T cells", "PROBLEM", 122, 146], ["the challenge virus", "TREATMENT", 176, 195], ["figure", "OBSERVATION", 4, 10], ["loss", "OBSERVATION_MODIFIER", 52, 56]]], ["Challenge of virusimmune mice with heterologous viruses that establish either acute sterilizing infections (LCMV strain Armstrong, PV, MCMV, and VV) or persistent infections (murine gherpes virus 68 and LCMV clone 13), can trigger the attrition of virus-specific CD8 T cells from the memory repertoire Kim and Welsh, 2004) .", [["CD8 T cells", "ANATOMY", 263, 274], ["infections", "DISEASE", 96, 106], ["infections", "DISEASE", 163, 173], ["virusimmune mice", "ORGANISM", 13, 29], ["LCMV", "ORGANISM", 108, 112], ["MCMV", "ORGANISM", 135, 139], ["murine gherpes virus 68", "ORGANISM", 175, 198], ["LCMV clone 13", "ORGANISM", 203, 216], ["CD8 T cells", "CELL", 263, 274], ["CD8 T cells", "CELL_TYPE", 263, 274], ["mice", "SPECIES", 25, 29], ["murine", "SPECIES", 175, 181], ["mice", "SPECIES", 25, 29], ["LCMV", "SPECIES", 108, 112], ["PV", "SPECIES", 131, 133], ["MCMV", "SPECIES", 135, 139], ["VV", "SPECIES", 145, 147], ["murine gherpes virus 68", "SPECIES", 175, 198], ["virusimmune mice", "TREATMENT", 13, 29], ["heterologous viruses", "PROBLEM", 35, 55], ["acute sterilizing infections", "PROBLEM", 78, 106], ["LCMV strain Armstrong", "PROBLEM", 108, 129], ["MCMV", "PROBLEM", 135, 139], ["persistent infections (murine gherpes virus", "PROBLEM", 152, 195], ["LCMV clone", "TEST", 203, 213], ["virus", "PROBLEM", 248, 253], ["acute", "OBSERVATION_MODIFIER", 78, 83], ["sterilizing", "OBSERVATION_MODIFIER", 84, 95], ["infections", "OBSERVATION", 96, 106], ["persistent", "OBSERVATION_MODIFIER", 152, 162], ["infections", "OBSERVATION", 163, 173]]], ["Infection with the clone 13 variant of LCMV is associated with the continuous production of cytokines and T cell activation and resulted in an even more dramatic attrition of memory CD8 T cells relative to LCMV strain Armstrong, with greater than 10-fold drops in CD8 memory T cell frequencies specific to VV, VSV, and PV-encoded antigens (Kim and Welsh, 2004) .Maintenance of T cell memory during sequential viral infectionsThis depletion of CD8 T cell memory could be a consequence of competition between newly generated memory T cells and previously formed memory cells for protective niches in lymphoid tissue.", [["T cell", "ANATOMY", 106, 112], ["memory CD8 T cells", "ANATOMY", 175, 193], ["CD8 memory T cell", "ANATOMY", 264, 281], ["T cell", "ANATOMY", 377, 383], ["CD8 T cell", "ANATOMY", 443, 453], ["memory T cells", "ANATOMY", 523, 537], ["memory cells", "ANATOMY", 560, 572], ["lymphoid tissue", "ANATOMY", 598, 613], ["LCMV", "DISEASE", 39, 43], ["viral infections", "DISEASE", 409, 425], ["LCMV", "ORGANISM", 39, 43], ["T cell", "CELL", 106, 112], ["CD8 T cells", "CELL", 182, 193], ["LCMV strain Armstrong", "ORGANISM", 206, 227], ["CD8", "GENE_OR_GENE_PRODUCT", 264, 267], ["T cell", "CELL", 275, 281], ["VV", "ORGANISM", 306, 308], ["VSV", "ORGANISM", 310, 313], ["T cell", "CELL", 377, 383], ["CD8", "GENE_OR_GENE_PRODUCT", 443, 446], ["memory T cells", "CELL", 523, 537], ["memory cells", "CELL", 560, 572], ["lymphoid tissue", "TISSUE", 598, 613], ["clone 13 variant", "CELL_LINE", 19, 35], ["cytokines", "PROTEIN", 92, 101], ["memory CD8 T cells", "CELL_TYPE", 175, 193], ["CD8", "PROTEIN", 264, 267], ["encoded antigens", "PROTEIN", 322, 338], ["CD8", "PROTEIN", 443, 446], ["memory T cells", "CELL_TYPE", 523, 537], ["memory cells", "CELL_TYPE", 560, 572], ["LCMV", "SPECIES", 39, 43], ["VV", "SPECIES", 306, 308], ["VSV", "SPECIES", 310, 313], ["PV", "SPECIES", 319, 321], ["Infection", "PROBLEM", 0, 9], ["the clone", "PROBLEM", 15, 24], ["LCMV", "PROBLEM", 39, 43], ["cytokines", "PROBLEM", 92, 101], ["T cell activation", "PROBLEM", 106, 123], ["memory CD8 T cells", "PROBLEM", 175, 193], ["LCMV strain Armstrong", "PROBLEM", 206, 227], ["VV", "TEST", 306, 308], ["VSV", "TEST", 310, 313], ["T cell memory", "PROBLEM", 377, 390], ["sequential viral infections", "PROBLEM", 398, 425], ["CD8 T cell memory", "PROBLEM", 443, 460], ["newly generated memory T cells", "PROBLEM", 507, 537], ["protective niches in lymphoid tissue", "PROBLEM", 577, 613], ["LCMV", "OBSERVATION", 39, 43], ["cell activation", "OBSERVATION", 108, 123], ["dramatic", "OBSERVATION_MODIFIER", 153, 161], ["memory CD8", "OBSERVATION", 175, 185], ["PV", "ANATOMY", 319, 321], ["T cell memory", "OBSERVATION", 377, 390], ["viral", "OBSERVATION_MODIFIER", 409, 414], ["infections", "OBSERVATION", 415, 425], ["CD8 T cell memory", "OBSERVATION", 443, 460], ["memory cells", "OBSERVATION", 560, 572], ["lymphoid tissue", "OBSERVATION", 598, 613]]], ["Alternatively it could be a byproduct of the virus-induced lymphopenia that leads to memory T cell apoptosis early in infection.", [["memory T cell", "ANATOMY", 85, 98], ["lymphopenia", "DISEASE", 59, 70], ["infection", "DISEASE", 118, 127], ["memory T cell", "CELL", 85, 98], ["the virus", "PROBLEM", 41, 50], ["lymphopenia", "PROBLEM", 59, 70], ["memory T cell apoptosis", "PROBLEM", 85, 108], ["infection", "PROBLEM", 118, 127], ["virus", "OBSERVATION", 45, 50], ["lymphopenia", "OBSERVATION", 59, 70], ["memory T cell apoptosis", "OBSERVATION", 85, 108], ["infection", "OBSERVATION", 118, 127]]], ["Recent kinetic studies indicate that once memory cells are lost early in infection, they never return to their original frequencies, arguing for the importance of the virus-induced lymphopenia in this process (Kim and Welsh, 2004) .", [["memory cells", "ANATOMY", 42, 54], ["infection", "DISEASE", 73, 82], ["lymphopenia", "DISEASE", 181, 192], ["memory cells", "CELL", 42, 54], ["memory cells", "CELL_TYPE", 42, 54], ["Recent kinetic studies", "TEST", 0, 22], ["memory cells", "PROBLEM", 42, 54], ["infection", "PROBLEM", 73, 82], ["the virus", "PROBLEM", 163, 172], ["lymphopenia", "PROBLEM", 181, 192], ["infection", "OBSERVATION", 73, 82], ["lymphopenia", "OBSERVATION", 181, 192]]], ["Thus, preexisting memory populations can play substantial roles in the host response to new virus infections, and those virus infections permanently alter the memory T cell pool that was present before infection.Sequential viral infections and transplantationVirus-specific CD8 T cells can cross-react with allogeneic MHC molecules presenting endogenous non-viral peptides (Braciale et al., 1981; Yang and Welsh, 1986; Nahill and Welsh, 1993; Burrows et al., 1994; Brehm et al., 2003) , and have the potential to hinder transplantation of allogeneic tissues.", [["memory T cell", "ANATOMY", 159, 172], ["CD8 T cells", "ANATOMY", 274, 285], ["tissues", "ANATOMY", 550, 557], ["infections", "DISEASE", 98, 108], ["infections", "DISEASE", 126, 136], ["infection", "DISEASE", 202, 211], ["viral infections", "DISEASE", 223, 239], ["memory populations", "CELL", 18, 36], ["memory T cell", "CELL", 159, 172], ["Virus", "ORGANISM", 259, 264], ["CD8", "GENE_OR_GENE_PRODUCT", 274, 277], ["tissues", "TISSUE", 550, 557], ["memory populations", "CELL_TYPE", 18, 36], ["memory T cell pool", "CELL_TYPE", 159, 177], ["CD8 T cells", "CELL_TYPE", 274, 285], ["allogeneic MHC molecules", "PROTEIN", 307, 331], ["preexisting memory populations", "PROBLEM", 6, 36], ["new virus infections", "PROBLEM", 88, 108], ["those virus infections", "PROBLEM", 114, 136], ["infection", "PROBLEM", 202, 211], ["Sequential viral infections", "PROBLEM", 212, 239], ["transplantation", "TREATMENT", 244, 259], ["Virus", "TEST", 259, 264], ["allogeneic MHC molecules", "PROBLEM", 307, 331], ["endogenous non-viral peptides", "PROBLEM", 343, 372], ["transplantation of allogeneic tissues", "TREATMENT", 520, 557], ["memory populations", "OBSERVATION", 18, 36], ["viral", "OBSERVATION_MODIFIER", 223, 228], ["infections", "OBSERVATION", 229, 239], ["transplantation", "OBSERVATION", 244, 259], ["transplantation", "OBSERVATION", 520, 535], ["allogeneic tissues", "OBSERVATION", 539, 557]]], ["Acute infections with viruses such as LCMV and PV interfere with the induction of tolerance using costimulatory blockade against allogeneic skin grafts (Welsh et al., 2000) .", [["skin grafts", "ANATOMY", 140, 151], ["infections", "DISEASE", 6, 16], ["LCMV", "ORGANISM", 38, 42], ["skin grafts", "TISSUE", 140, 151], ["LCMV", "SPECIES", 38, 42], ["PV", "SPECIES", 47, 49], ["Acute infections", "PROBLEM", 0, 16], ["viruses", "PROBLEM", 22, 29], ["LCMV", "PROBLEM", 38, 42], ["costimulatory blockade", "TREATMENT", 98, 120], ["allogeneic skin grafts", "TREATMENT", 129, 151], ["infections", "OBSERVATION", 6, 16], ["viruses", "OBSERVATION", 22, 29], ["LCMV", "OBSERVATION", 38, 42]]], ["Recent studies have also shown that LCMV-immune mice are refractory to the induction of tolerance against allogeneic skin resulting in graft rejection (Brehm et al., 2003) , and mice that have been sequentially infected with heterologous viruses become even more difficult to tolerise to allo-antigens (Adams et al., 2003) .", [["skin", "ANATOMY", 117, 121], ["graft", "ANATOMY", 135, 140], ["LCMV-immune mice", "ORGANISM", 36, 52], ["skin", "ORGAN", 117, 121], ["graft", "TISSUE", 135, 140], ["mice", "ORGANISM", 178, 182], ["mice", "SPECIES", 48, 52], ["mice", "SPECIES", 178, 182], ["mice", "SPECIES", 48, 52], ["mice", "SPECIES", 178, 182], ["Recent studies", "TEST", 0, 14], ["LCMV", "PROBLEM", 36, 40], ["allogeneic skin", "PROBLEM", 106, 121], ["graft rejection", "PROBLEM", 135, 150], ["heterologous viruses", "PROBLEM", 225, 245], ["LCMV", "OBSERVATION", 36, 40], ["graft rejection", "OBSERVATION", 135, 150], ["infected", "OBSERVATION", 211, 219]]], ["Sequential infections with heterologous viruses can increase the frequency of T cells specific for allo-antigens, and create a larger pool of memory cells to tolerize before engraftment.", [["T cells", "ANATOMY", 78, 85], ["allo-antigens", "ANATOMY", 99, 112], ["memory cells", "ANATOMY", 142, 154], ["infections", "DISEASE", 11, 21], ["T cells", "CELL", 78, 85], ["allo-antigens", "CELL", 99, 112], ["memory cells", "CELL", 142, 154], ["T cells", "CELL_TYPE", 78, 85], ["allo-antigens", "PROTEIN", 99, 112], ["memory cells", "CELL_TYPE", 142, 154], ["Sequential infections", "PROBLEM", 0, 21], ["heterologous viruses", "PROBLEM", 27, 47], ["T cells", "PROBLEM", 78, 85], ["allo-antigens", "PROBLEM", 99, 112], ["infections", "OBSERVATION", 11, 21], ["heterologous viruses", "OBSERVATION", 27, 47], ["memory cells", "OBSERVATION", 142, 154]]], ["In H-2 b mice that had previously been infected with PV and then infected with LCMV, the induction of allo-antigen-specific CD8 T cells was altered, with higher frequencies of T cells specific for H-2 k antigens and slightly reduced populations specific for H-2 d antigens in comparison to na\u00efve mice infected with LCMV (Brehm et al., 2003) .", [["CD8 T cells", "ANATOMY", 124, 135], ["T cells", "ANATOMY", 176, 183], ["H-2 b", "CELL", 3, 8], ["mice", "ORGANISM", 9, 13], ["LCMV", "ORGANISM", 79, 83], ["allo-antigen", "GENE_OR_GENE_PRODUCT", 102, 114], ["CD8", "GENE_OR_GENE_PRODUCT", 124, 127], ["T cells", "CELL", 176, 183], ["H-2 k antigens", "GENE_OR_GENE_PRODUCT", 197, 211], ["H-2 d antigens", "GENE_OR_GENE_PRODUCT", 258, 272], ["mice", "ORGANISM", 296, 300], ["LCMV", "ORGANISM", 315, 319], ["allo-antigen", "PROTEIN", 102, 114], ["CD8 T cells", "CELL_TYPE", 124, 135], ["T cells", "CELL_TYPE", 176, 183], ["H-2 k antigens", "PROTEIN", 197, 211], ["H-2 d antigens", "PROTEIN", 258, 272], ["mice", "SPECIES", 9, 13], ["mice", "SPECIES", 296, 300], ["mice", "SPECIES", 9, 13], ["PV", "SPECIES", 53, 55], ["LCMV", "SPECIES", 79, 83], ["mice", "SPECIES", 296, 300], ["LCMV", "SPECIES", 315, 319], ["PV", "PROBLEM", 53, 55], ["LCMV", "PROBLEM", 79, 83], ["allo-antigen", "TEST", 102, 114], ["T cells", "PROBLEM", 176, 183], ["H", "TEST", 197, 198], ["k antigens", "TEST", 201, 211], ["slightly reduced populations", "PROBLEM", 216, 244], ["infected", "OBSERVATION", 39, 47], ["LCMV", "OBSERVATION", 79, 83]]], ["The alterations in the alloantigen-specific T cell response generated in PV-immune mice infected with LCMV may reflect the changes in the hierarchies of the LCMV epitope-specific (Fig. 3 ) CD8 T cells, which cross-react with allo-antigens.", [["T cell", "ANATOMY", 44, 50], ["Fig. 3 ) CD8 T cells", "ANATOMY", 180, 200], ["alloantigen", "GENE_OR_GENE_PRODUCT", 23, 34], ["T cell", "CELL", 44, 50], ["PV-immune mice", "ORGANISM", 73, 87], ["LCMV", "ORGANISM", 102, 106], ["LCMV", "ORGANISM", 157, 161], ["CD8", "GENE_OR_GENE_PRODUCT", 189, 192], ["alloantigen", "PROTEIN", 23, 34], ["LCMV epitope", "PROTEIN", 157, 169], ["CD8 T cells", "CELL_TYPE", 189, 200], ["allo-antigens", "PROTEIN", 225, 238], ["mice", "SPECIES", 83, 87], ["PV", "SPECIES", 73, 75], ["mice", "SPECIES", 83, 87], ["LCMV", "SPECIES", 102, 106], ["The alterations", "PROBLEM", 0, 15], ["the alloantigen", "TEST", 19, 34], ["PV", "TEST", 73, 75], ["LCMV", "PROBLEM", 102, 106], ["the LCMV epitope", "TEST", 153, 169], ["CD8 T cells", "PROBLEM", 189, 200], ["LCMV", "OBSERVATION", 102, 106], ["LCMV epitope", "OBSERVATION", 157, 169]]], ["These findings suggest that the generation of allo-antigen-specific memory CD8 T cells by viral infections presents a unique impediment for transplantation.Concluding remarksWe demonstrated here that a host's history of viral infections, by changing the repertoire of the T cell memory pool, may influence T cell immunodominance, protective immunity, and immunopathology occurring in response to subsequent infections.", [["memory CD8 T cells", "ANATOMY", 68, 86], ["T cell", "ANATOMY", 272, 278], ["T cell", "ANATOMY", 306, 312], ["viral infections", "DISEASE", 90, 106], ["viral infections", "DISEASE", 220, 236], ["immunopathology", "DISEASE", 355, 370], ["infections", "DISEASE", 407, 417], ["allo-antigen", "GENE_OR_GENE_PRODUCT", 46, 58], ["CD8 T cells", "CELL", 75, 86], ["T cell", "CELL", 272, 278], ["T cell", "CELL", 306, 312], ["allo-antigen-specific memory CD8 T cells", "CELL_TYPE", 46, 86], ["allo-antigen", "TEST", 46, 58], ["viral infections", "PROBLEM", 90, 106], ["transplantation", "TREATMENT", 140, 155], ["viral infections", "PROBLEM", 220, 236], ["T cell immunodominance", "PROBLEM", 306, 328], ["immunopathology", "PROBLEM", 355, 370], ["subsequent infections", "PROBLEM", 396, 417], ["viral infections", "OBSERVATION", 90, 106], ["viral", "OBSERVATION_MODIFIER", 220, 225], ["infections", "OBSERVATION", 226, 236], ["infections", "OBSERVATION", 407, 417]]], ["Although parameters of this heterologous immunity have been studied most definitively in murine systems, the identification of T cells cross-reactive between many common human viruses suggests that the imprint left on the human immune system by previous viral infections may alter the course of human diseases.", [["T cells", "ANATOMY", 127, 134], ["immune system", "ANATOMY", 228, 241], ["viral infections", "DISEASE", 254, 270], ["murine", "ORGANISM", 89, 95], ["T cells", "CELL", 127, 134], ["human", "ORGANISM", 170, 175], ["human", "ORGANISM", 222, 227], ["immune system", "ANATOMICAL_SYSTEM", 228, 241], ["human", "ORGANISM", 295, 300], ["T cells", "CELL_TYPE", 127, 134], ["murine", "SPECIES", 89, 95], ["human", "SPECIES", 170, 175], ["human", "SPECIES", 222, 227], ["human", "SPECIES", 295, 300], ["human", "SPECIES", 170, 175], ["human", "SPECIES", 222, 227], ["human", "SPECIES", 295, 300], ["this heterologous immunity", "TREATMENT", 23, 49], ["T cells", "PROBLEM", 127, 134], ["many common human viruses", "PROBLEM", 158, 183], ["the human immune system", "TREATMENT", 218, 241], ["previous viral infections", "PROBLEM", 245, 270], ["human diseases", "PROBLEM", 295, 309], ["left", "ANATOMY_MODIFIER", 210, 214], ["viral infections", "OBSERVATION", 254, 270]]], ["Many viral infections present more severely in teenagers and young adults than in children (Weinstein and Meade, 1956; Simonsen et al., 1998) , and one questions whether prior infections encountered earlier in life have altered the immune responses to these pathogens.", [["viral infections", "DISEASE", 5, 21], ["infections", "DISEASE", 176, 186], ["children", "ORGANISM", 82, 90], ["children", "SPECIES", 82, 90], ["Many viral infections", "PROBLEM", 0, 21], ["prior infections", "PROBLEM", 170, 186], ["these pathogens", "PROBLEM", 252, 267], ["viral", "OBSERVATION_MODIFIER", 5, 10], ["infections", "OBSERVATION", 11, 21], ["more severely", "OBSERVATION_MODIFIER", 30, 43], ["infections", "OBSERVATION", 176, 186]]], ["Similarly, because of T cell cross-reactivity, vaccination might unexpectedly impact responses to pathogens unrelated to the vaccine.", [["T cell", "ANATOMY", 22, 28], ["T cell", "CELL", 22, 28], ["vaccination", "TREATMENT", 47, 58], ["pathogens", "PROBLEM", 98, 107], ["the vaccine", "TREATMENT", 121, 132]]], ["The full impact of heterologous T cell-dependent immunity in human infections should become clear as more is learned about the activation and fate of crossreactive T cells in human viral infections.", [["T cell", "ANATOMY", 32, 38], ["crossreactive T cells", "ANATOMY", 150, 171], ["infections", "DISEASE", 67, 77], ["viral infections", "DISEASE", 181, 197], ["T cell", "CELL", 32, 38], ["human", "ORGANISM", 61, 66], ["crossreactive T cells", "CELL", 150, 171], ["human", "ORGANISM", 175, 180], ["crossreactive T cells", "CELL_TYPE", 150, 171], ["human", "SPECIES", 61, 66], ["human", "SPECIES", 175, 180], ["human", "SPECIES", 61, 66], ["human", "SPECIES", 175, 180], ["heterologous T cell", "TREATMENT", 19, 38], ["human infections", "PROBLEM", 61, 77], ["crossreactive T cells", "PROBLEM", 150, 171], ["human viral infections", "PROBLEM", 175, 197], ["viral infections", "OBSERVATION", 181, 197]]]], "f1dfd42866922767be52a560b3c3ccde37ecb95d": [["disease has led many to abandon those principles.", [["disease", "PROBLEM", 0, 7]]], ["Some scientists have used the situation to publish substandard articles that would never get published in normal times as journals publish quickly (and gain citations), without proper review and level of criticism.", [["criticism", "PROBLEM", 204, 213]]], ["This situation has been used by medical equipment manufacturers and pharmaceutical industry as well, to promote publication of biased sponsored articles.", [["medical equipment manufacturers", "TREATMENT", 32, 63], ["pharmaceutical industry", "TREATMENT", 68, 91]]], ["It seems that anything related to COVID-19 goes during this pandemic.", [["COVID", "TEST", 34, 39]]], ["In the aftermath, months from now, the same authors and journals will probably publish corrections and retrospectives recognizing the mentioned issues and justifying them with the need for rapid spread of information that was necessary to fight the virus.", [["the virus", "PROBLEM", 245, 254]]]], "59a9b3d3d680bd014913bd96b9230b1ca89ee5bb": [["INTRODUCTIONIn mid-December the novel coronavirus disease (COVID- 19) was initially detected in Wuhan, China, and then it propagated quickly across the country as well as worldwide (Cucinotta and Vanelli, 2020) .", [["coronavirus disease", "DISEASE", 38, 57], ["coronavirus", "ORGANISM", 38, 49], ["coronavirus", "SPECIES", 38, 49], ["the novel coronavirus disease", "PROBLEM", 28, 57], ["COVID", "TEST", 59, 64], ["coronavirus disease", "OBSERVATION", 38, 57]]], ["Particularly, the Lombardy region in northern Italy was severely affected by this infection.", [["infection", "DISEASE", 82, 91], ["severely affected", "PROBLEM", 56, 73], ["this infection", "PROBLEM", 77, 91], ["Lombardy", "ANATOMY_MODIFIER", 18, 26], ["severely", "OBSERVATION_MODIFIER", 56, 64], ["affected", "OBSERVATION", 65, 73], ["infection", "OBSERVATION", 82, 91]]], ["As a consequence, on March 9 th , the government imposed a national quarantine, restricting the movement of the population except for necessity, work, and health reasons in order to reduce the spread of coronavirus.", [["coronavirus", "DISEASE", 203, 214], ["coronavirus", "ORGANISM", 203, 214], ["a national quarantine", "TREATMENT", 57, 78], ["coronavirus", "PROBLEM", 203, 214]]], ["Subsequently, on May 3 rd , Italian Government ended the so-called \"Phase 1\" of the lockdown period, gradually resuming economic activities, easing restrictions, and slowly allowing movements inside the Region.INTRODUCTIONFollowing the reorganization of the Healthcare system to manage COVID-19 emergency, Regional Health Authorities acknowledged mental health as a priority and authorized the continuation of psychiatry care services for general population (Percudani et al., 2020) .", [["COVID", "DISEASE", 286, 291]]], ["Particularly, some psychiatric wards were structurally modified for the purpose of admitting patients with COVID-19, many physicians and nurses were diverted to other clinical wards, consultations were restricted to the most severe cases, and most day hospital services and day-therapy programs for patients with psychiatric disorders were temporarily closed (Fagiolini et al., 2020) .", [["psychiatric", "DISEASE", 19, 30], ["psychiatric disorders", "DISEASE", 313, 334], ["patients", "ORGANISM", 93, 101], ["patients", "ORGANISM", 299, 307], ["patients", "SPECIES", 93, 101], ["patients", "SPECIES", 299, 307], ["COVID", "TREATMENT", 107, 112], ["therapy programs", "TREATMENT", 278, 294], ["psychiatric disorders", "PROBLEM", 313, 334]]], ["Nevertheless, patients living in psychiatric residential treatment facilities (PRTFs) had to be confined in these structures with important restrictions on the movement .", [["psychiatric", "DISEASE", 33, 44], ["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22]]], ["In addition to these changes affecting public health system and resulting in high stress levels both on general population and people with mental conditions, the fear associated with the coronavirus pandemic and the consequent lockdown had a relevant impact on psychological well-being (Naqvi, 2020) .", [["coronavirus pandemic", "DISEASE", 187, 207], ["people", "ORGANISM", 127, 133], ["coronavirus", "ORGANISM", 187, 198], ["people", "SPECIES", 127, 133], ["these changes affecting public health system", "PROBLEM", 15, 59], ["high stress levels", "PROBLEM", 77, 95], ["mental conditions", "PROBLEM", 139, 156], ["the coronavirus pandemic", "PROBLEM", 183, 207], ["high stress", "OBSERVATION", 77, 88]]], ["First of all, quarantine and lockdown were associated with boredom, anger, psychological unrest, uncertainty, frustration, irritability, suicidal ideation and sleep disorders, which are in turn related to poor mental health, including the occurrence of psychiatric disorders as well as the exacerbation of pre-existing conditions (Brooks et al., 2020; Courtet et al., 2020; Kelly, 2020) .", [["irritability", "DISEASE", 123, 135], ["suicidal ideation", "DISEASE", 137, 154], ["sleep disorders", "DISEASE", 159, 174], ["psychiatric disorders", "DISEASE", 253, 274], ["irritability", "PROBLEM", 123, 135], ["suicidal ideation", "PROBLEM", 137, 154], ["sleep disorders", "PROBLEM", 159, 174], ["poor mental health", "PROBLEM", 205, 223], ["psychiatric disorders", "PROBLEM", 253, 274], ["pre-existing conditions", "PROBLEM", 306, 329]]], ["Secondly, contamination fear may be accompanied by anxious and obsessional symptoms, as well as the recurrence of obsessive compulsive disorder (OCD) symptoms (Fiorillo and Gorwood, 2020; French and Lyne 2020).", [["contamination fear", "DISEASE", 10, 28], ["obsessive compulsive disorder", "DISEASE", 114, 143], ["OCD", "DISEASE", 145, 148], ["contamination fear", "PROBLEM", 10, 28], ["anxious and obsessional symptoms", "PROBLEM", 51, 83], ["obsessive compulsive disorder", "PROBLEM", 114, 143], ["OCD) symptoms", "PROBLEM", 145, 158]]], ["Finally, some studies cited the economic crisis associated with COVID-19 pandemic as potential factor of vulnerability for psychiatric disorders (Pfefferbaum and North, 2020) .", [["psychiatric disorders", "DISEASE", 123, 144], ["some studies", "TEST", 9, 21], ["the economic crisis", "PROBLEM", 28, 47], ["COVID", "TEST", 64, 69], ["psychiatric disorders", "PROBLEM", 123, 144]]], ["Despite the negative impact of pandemic on mental health, preliminary evidence showed a substantial decrease both of total number of psychiatric emergency consultations and psychiatric admission rates during lockdown Pignon et al., 2020) , if compared to the same period of 2019.", [["psychiatric", "DISEASE", 133, 144], ["psychiatric", "DISEASE", 173, 184], ["substantial", "OBSERVATION_MODIFIER", 88, 99], ["decrease", "OBSERVATION_MODIFIER", 100, 108]]], ["More precisely Pignon (2020) reported over 50 per cent of decrease of emergency psychiatry consultations in three psychiatric centers in Paris and its suburbs.", [["psychiatric", "DISEASE", 114, 125], ["decrease", "OBSERVATION_MODIFIER", 58, 66]]], ["The decrease was evident across all psychiatric disorders, although the rate of patients consulting for psychotic disorders was higher in 2020 than in 2019, as was the rate of compulsory hospitalizations.", [["psychiatric disorders", "DISEASE", 36, 57], ["psychotic disorders", "DISEASE", 104, 123], ["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["The decrease", "PROBLEM", 0, 12], ["all psychiatric disorders", "PROBLEM", 32, 57], ["psychotic disorders", "PROBLEM", 104, 123], ["decrease", "OBSERVATION_MODIFIER", 4, 12]]], ["On the other hand the study by and collaborators, carried out in four DMHAs in the Lombardy region, reported a marked reduction in psychiatric admission rates between 2020 and the same period of 2019, except for involuntary admissions.INTRODUCTIONIn our knowledge, no Italian studies were performed to explore the characteristics of emergency psychiatric consultations during the weeks of lockdown and comparing them to the same period in 2019.", [["psychiatric", "DISEASE", 131, 142], ["psychiatric", "DISEASE", 343, 354], ["the study", "TEST", 18, 27], ["a marked reduction", "PROBLEM", 109, 127], ["Italian studies", "TEST", 268, 283], ["Lombardy region", "ANATOMY", 83, 98], ["marked", "OBSERVATION_MODIFIER", 111, 117], ["reduction", "OBSERVATION_MODIFIER", 118, 127]]], ["Thus, we aimed to assess sociodemographic and clinical characteristics of patients receiving psychiatric consultations during the whole lockdown in two psychiatric emergency services of DMHA of ASST Monza (Lombardy region) and to compare them to the same period in 2019.", [["psychiatric", "DISEASE", 93, 104], ["psychiatric", "DISEASE", 152, 163], ["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["psychiatric consultations", "TREATMENT", 93, 118]]], ["We hope that findings of the present study might contribute to focus on the subjects who were deeply affected by COVID-19 pandemic in order to offer targeted assistance.METHODSThis study was drawn up following the Strengthening the Reporting of Observational studies in EpidemiologySetting and study designWe conducted a cross-sectional study including subjects consecutively admitted to two psychiatric emergency rooms of DMHA of Monza, one in Monza and the other in Desio.", [["psychiatric", "DISEASE", 392, 403], ["the present study", "TEST", 25, 42], ["METHODSThis study", "TEST", 169, 186], ["Observational studies", "TEST", 245, 266], ["a cross-sectional study", "TEST", 319, 342]]], ["Monza and Desio University hospitals cover the health demands of almost 850.000 inhabitants, offer psychiatric emergency care 24 hours a day and provide treatment for a range of psychiatric conditions.", [["psychiatric", "DISEASE", 99, 110], ["psychiatric", "DISEASE", 178, 189], ["psychiatric emergency care", "TREATMENT", 99, 125], ["treatment", "TREATMENT", 153, 162], ["psychiatric conditions", "TREATMENT", 178, 200]]], ["We compared consultation rates between the first confirmed case of COVID-19 in Italy and the end of \"Phase 1\" of the lockdown period.", [["COVID", "TEST", 67, 72]]], ["No subjects were excluded from the study.Data collectionThe data of the present study were extracted anonymously from hospital registers.", [["the study", "TEST", 31, 40], ["Data collection", "TEST", 41, 56], ["the present study", "TEST", 68, 85]]], ["Information included sociodemographic data, housing status (home or PRTF), current use of outpatient mental health services, ongoing psychopharmacological treatments, co-occurring alcohol and substance use disorders.", [["alcohol", "CHEMICAL", 180, 187], ["substance use disorders", "DISEASE", 192, 215], ["alcohol", "CHEMICAL", 180, 187], ["outpatient mental health services", "TREATMENT", 90, 123], ["ongoing psychopharmacological treatments", "TREATMENT", 125, 165], ["disorders", "PROBLEM", 206, 215]]], ["Data on both alcohol and substance use disorders were obtained using ICD-10 codes along with urine drug toxicology where available.", [["urine", "ANATOMY", 93, 98], ["alcohol", "CHEMICAL", 13, 20], ["alcohol", "CHEMICAL", 13, 20], ["urine", "ORGANISM_SUBSTANCE", 93, 98], ["ICD", "TREATMENT", 69, 72], ["urine drug toxicology", "TEST", 93, 114]]], ["We also extracted data concerning the presence of multiple consultations during the period A and period B. For each patient, referred psychiatric symptoms as well as clinical information on ICD-10 mental disorders were retrieved.", [["psychiatric", "DISEASE", 134, 145], ["patient", "ORGANISM", 116, 123], ["patient", "SPECIES", 116, 123], ["psychiatric symptoms", "PROBLEM", 134, 154], ["ICD", "TREATMENT", 190, 193], ["mental disorders", "PROBLEM", 197, 213]]], ["Finally, type of management after the emergency consultation was also taken into account: admission at inpatient clinic, compulsory hospitalization, hospital discharge with follow-up in outpatient clinics, only acute medication, prescription of a new pharmacotherapy to be taken at home.Data analysisDescriptive analyses of included variables was performed for period A and period B: mean and standard deviation (SD) for quantitative variables, and frequency and percentage for qualitative ones.", [["acute medication", "TREATMENT", 211, 227], ["a new pharmacotherapy", "TREATMENT", 245, 266], ["Data analysisDescriptive analyses", "TEST", 287, 320], ["standard deviation (SD)", "PROBLEM", 393, 416], ["quantitative variables", "PROBLEM", 421, 443]]], ["Then, we carried out univariate analysis in order to detect statistically significant differences in these two periods.", [["univariate analysis", "TEST", 21, 40]]], ["The normal distribution of quantitative variables was verified by using Shapiro-Wilk's test.", [["Shapiro-Wilk's test", "TEST", 72, 91], ["normal", "OBSERVATION", 4, 10], ["distribution", "OBSERVATION_MODIFIER", 11, 23]]], ["According to this assumption, Student's t test was used (adopting the Welch's variables were analysed via the chi-square or Fisher's Exact tests.", [["Student's t test", "TEST", 30, 46], ["the Welch's variables", "TEST", 66, 87], ["Fisher's Exact tests", "TEST", 124, 144]]], ["Finally, all variables from the univariate analysis with p < 0.05, together with age and gender, were entered as independent variables into a logistic regression model with period B as dependent variable.", [["the univariate analysis", "TEST", 28, 51]]], ["Adjusted odds ratios (aOR) together with their 95% confidence intervals (CI) were reported.Data analysisAnalysis were conducted using Stata Version 13.1 SE.RESULTSDuring the lockdown, 225 emergency psychiatric consultations were carried out, representing just over half (58%) of the corresponding period in 2019 (388 emergency room accesses) ( Table 1) .Table 1 about hereNo statistical differences were observed between the two periods with regard to sociodemographic variables.", [["SE", "DISEASE", 153, 155], ["psychiatric", "DISEASE", 198, 209], ["CI", "TEST", 73, 75], ["Data analysis", "TEST", 91, 104], ["Analysis", "TEST", 104, 112], ["Stata Version", "TEST", 134, 147], ["statistical differences", "PROBLEM", 375, 398]]], ["However, the number of consultations of subjects from PRTFs as well as of subjects with cannabis misuse was statistically higher in 2020 than in 2019.", [["PRTFs", "DISEASE", 54, 59], ["cannabis", "CHEMICAL", 88, 96]]], ["As regards as referred symptoms, mood disturbances were less reported during the lockdown than in the previous year, differently from self-harm or suicide attempts.", [["mood disturbances", "DISEASE", 33, 50], ["symptoms", "PROBLEM", 23, 31], ["mood disturbances", "PROBLEM", 33, 50]]], ["With regard to the diagnosis of discharge from emergency room, depressive and adjustment disorders were less identified in 2020 than in 2019, differently from OCD that was more diagnosed during the lockdown than in previous year.", [["depressive", "DISEASE", 63, 73], ["OCD", "DISEASE", 159, 162], ["depressive", "PROBLEM", 63, 73], ["adjustment disorders", "PROBLEM", 78, 98], ["OCD", "PROBLEM", 159, 162]]], ["The rate of hospitalizations after emergency consultation was higher during the lockdown than in the previous year.Table 1 about hereThe multivariate logistic regression (Table 2) , controlled for age and gender, showed that living in PRTFs (aOR=1.78, p=0.031), cannabis addiction (aOR=1.76, p=0.028) and diagnosis of OCD (aOR=10.94, p=0.003) were all statistically significant predictors of emergency psychiatric consultation during the quarantine.DISCUSSIONOur data, collected in a DMHA of Lombardy region, provide clear evidence of a decrease in the number of psychiatric emergency consultations during the lockdown period due the COVID-19 pandemic, compared to the same period of 2019.", [["cannabis addiction", "DISEASE", 262, 280], ["OCD", "DISEASE", 318, 321], ["psychiatric", "DISEASE", 402, 413], ["psychiatric", "DISEASE", 563, 574], ["The multivariate logistic regression", "PROBLEM", 133, 169], ["aOR", "TEST", 282, 285], ["OCD", "PROBLEM", 318, 321], ["aOR", "TEST", 323, 326], ["the COVID", "TEST", 630, 639], ["pandemic", "PROBLEM", 643, 651], ["decrease", "OBSERVATION_MODIFIER", 537, 545]]], ["This finding is consistent with what was recently reported in another paper (Pignon et al., 2020) , albeit other studies found that this decrease may not be merely specific of psychiatry (Thornton,2020) .", [["other studies", "TEST", 107, 120], ["consistent with", "UNCERTAINTY", 16, 31]]], ["In addition, three findings regarding patients' clinical features should be highlighted.", [["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["patients' clinical features", "PROBLEM", 38, 65]]], ["First of all, we observed that subjects living in PRTFs were more likely to seek emergency psychiatric care than individuals staying at home.", [["psychiatric", "DISEASE", 91, 102]]], ["As a consequence of COVID-19 pandemic, residential facilities faced unique challenges in controlling the spread of COVID-19.", [["COVID", "TEST", 115, 120]]], ["Patients with serious mental disorders, who were used to spending some hour a day outside of PRTFs, were forced to strict confinement (de Caution is required in interpreting our findings and some important methodological limitations should be acknowledged.DISCUSSIONFirst of all, as this study was a cross-sectional one, we cannot evaluate the changes over the time as regards the severity of symptoms.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["serious mental disorders", "PROBLEM", 14, 38], ["this study", "TEST", 283, 293], ["symptoms", "PROBLEM", 393, 401], ["serious", "OBSERVATION_MODIFIER", 14, 21]]], ["Furthermore, the analyzed data include the early phase of pandemic and it is likely that some findings may reflect short-term worsening related to COVID-19 outbreak.", [["pandemic", "PROBLEM", 58, 66], ["short-term worsening", "PROBLEM", 115, 135], ["COVID", "TEST", 147, 152], ["short-term", "OBSERVATION_MODIFIER", 115, 125]]], ["Second, our study could be affected by information bias.", [["our study", "TEST", 8, 17]]], ["The diagnosis of the different mental disorders was made by a team of different psychiatrists with a possible interviewer bias.", [["the different mental disorders", "PROBLEM", 17, 47], ["different", "OBSERVATION_MODIFIER", 21, 30], ["mental disorders", "OBSERVATION", 31, 47]]], ["Nevertheless, important information concerning age at illness onset, illness duration, time on treatment, frequency of substance abuse, severity of mental disorder, type of obsessions and comorbid psychiatric disorders are lacking.", [["illness", "DISEASE", 54, 61], ["illness", "DISEASE", 69, 76], ["substance abuse", "DISEASE", 119, 134], ["mental disorder", "DISEASE", 148, 163], ["obsessions", "DISEASE", 173, 183], ["psychiatric disorders", "DISEASE", 197, 218], ["treatment", "TREATMENT", 95, 104], ["mental disorder", "PROBLEM", 148, 163], ["type of obsessions", "PROBLEM", 165, 183], ["comorbid psychiatric disorders", "PROBLEM", 188, 218], ["mental disorder", "OBSERVATION", 148, 163]]], ["Third, our study was conducted in a single DMHA, which limits the generalization of our results to other institutions or other Italian regions.", [["our study", "TEST", 7, 16]]], ["Particularly, the district of Monza and Desio within Lombardy region were one of the most heavily affected areas by the epidemic in Europe.", [["most heavily", "OBSERVATION_MODIFIER", 85, 97], ["epidemic", "OBSERVATION_MODIFIER", 120, 128]]], ["Finally, the sample size of the present study may limit the generalizability of our results.DISCUSSIONIn sum, despite some limitations, the current study shows that the numbers of patients seeking emergency psychiatric consultations decreased during the lockdown.", [["psychiatric", "DISEASE", 207, 218], ["patients", "ORGANISM", 180, 188], ["patients", "SPECIES", 180, 188], ["the present study", "TEST", 28, 45], ["the current study", "TEST", 136, 153], ["size", "OBSERVATION_MODIFIER", 20, 24]]], ["However, individuals affected by OCD and resident in PRTFs were more likely to present to psychiatric emergency services during the phase 1 of COVID-19 lockdown, if compared with the same period of 2019.", [["OCD", "DISEASE", 33, 36], ["psychiatric", "DISEASE", 90, 101], ["PRTFs", "CANCER", 53, 58], ["COVID", "TEST", 143, 148]]], ["Thus, COVID-19 epidemic may have represented an important stressful live event, leading to poor mental health in some vulnerable subjects.", [["COVID", "TEST", 6, 11]]], ["Moreover, according to our findings, we cannot completely exclude that the most distressed patients may have taken refuge in addictive substances as cannabis, which is readily available to", [["cannabis", "CHEMICAL", 149, 157], ["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99]]]]}